(lp0
(dp1
S'line'
p2
S'Then the dissection of some CBG physiological roles in an animal model of genetic CBG deficiency is reported.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I28
sS'uniprot'
p8
VP08185
p9
sS'lengthInChars'
p10
I3
sS'name'
p11
VCBG
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I28
sg8
VP08185
p15
sg10
I3
sg11
VCBG
p16
sg13
I1
sasS'diseases'
p17
(lp18
(dp19
g7
I82
sS'cui'
p20
VC1852529
p21
sg10
I14
sg11
VCBG deficiency
p22
sg13
I2
sasa(dp23
g2
S'To the best of our knowledge, this case represents the first de novo mutation reported for corticosteroid-binding globulin deficiency, implicating a pathogenic role of variants of SERPINA6 in some cases of muscle fatigue.\n'
p24
sg4
(lp25
(dp26
g7
I91
sg8
VP08185
p27
sg10
I31
sg11
Vcorticosteroid-binding globulin
p28
sg13
I2
sa(dp29
g7
I180
sg8
VP08185
p30
sg10
I8
sg11
VSERPINA6
p31
sg13
I1
sasg17
(lp32
(dp33
g7
I61
sg20
VC2985439
p34
sg10
I16
sg11
Vde novo mutation
p35
sg13
I3
sa(dp36
g7
I91
sg20
VC1852529
p37
sg10
I42
sg11
Vcorticosteroid-binding globulin deficiency
p38
sg13
I3
sa(dp39
g7
I213
sg20
VC0015672
p40
sg10
I7
sg11
Vfatigue
p41
sg13
I1
sasa(dp42
g2
S'However little is known about the distribution of free cortisol in plasma where CBG is inactivated or in congenital CBG deficiency.\n'
p43
sg4
(lp44
(dp45
g7
I80
sg8
VP08185
p46
sg10
I3
sg11
VCBG
p47
sg13
I1
sa(dp48
g7
I80
sg8
VP08185
p49
sg10
I3
sg11
VCBG
p50
sg13
I1
sasg17
(lp51
(dp52
g7
I116
sg20
VC1852529
p53
sg10
I14
sg11
VCBG deficiency
p54
sg13
I2
sasa(dp55
g2
S'However, a decreased expression of the mitochondrial protein quality control proteases Lon and ClpP, both at the RNA and protein level, was demonstrated in SPG13 patient cells.\n'
p56
sg4
(lp57
(dp58
g7
I95
sg8
S''
p59
sg10
I4
sg11
VClpP
p60
sg13
I1
sa(dp61
g7
I39
sg8
VP36776
p62
sg10
I51
sg11
Vmitochondrial protein quality control proteases Lon
p63
sg13
I6
sasg17
(lp64
(dp65
g7
I156
sg20
VC1854467
p66
sg10
I5
sg11
VSPG13
p67
sg13
I1
sasa(dp68
g2
S'We performed a case-control study to evaluate the association between polymorphisms in CYP19A1 rs2899470, GSTM1, GSTT1, and GSTP1 rs1695 and the development of endometriosis in a Chinese population.\n'
p69
sg4
(lp70
(dp71
g7
I113
sg8
VP30711
p72
sg10
I5
sg11
VGSTT1
p73
sg13
I1
sa(dp74
g7
I124
sg8
VP09211
p75
sg10
I12
sg11
VGSTP1 rs1695
p76
sg13
I2
sa(dp77
g7
I87
sg8
VP11511
p78
sg10
I17
sg11
VCYP19A1 rs2899470
p79
sg13
I2
sa(dp80
g7
I106
sg8
VP09488
p81
sg10
I5
sg11
VGSTM1
p82
sg13
I1
sasg17
(lp83
(dp84
g7
I160
sg20
VC0014175
p85
sg10
I13
sg11
Vendometriosis
p86
sg13
I1
sasa(dp87
g2
S'However, GSTM1, GSTT1, and GSTP1 rs1695 polymorphisms did not affect the pathogenesis of endometriosis.\n'
p88
sg4
(lp89
(dp90
g7
I16
sg8
VP30711
p91
sg10
I5
sg11
VGSTT1
p92
sg13
I1
sa(dp93
g7
I9
sg8
VP09488
p94
sg10
I5
sg11
VGSTM1
p95
sg13
I1
sa(dp96
g7
I27
sg8
VP09211
p97
sg10
I12
sg11
VGSTP1 rs1695
p98
sg13
I2
sasg17
(lp99
(dp100
g7
I89
sg20
VC0014175
p101
sg10
I13
sg11
Vendometriosis
p102
sg13
I1
sa(dp103
g7
I73
sg20
VC0699748
p104
sg10
I12
sg11
Vpathogenesis
p105
sg13
I1
sasa(dp106
g2
S'We examined the associations of GSTM1 and GSTT1 null genotypes and GSTP1 313 A/G polymorphisms with endometriosis in an Iranian population.\n'
p107
sg4
(lp108
(dp109
g7
I67
sg8
VP09211
p110
sg10
I11
sg11
VGSTP1 313 A
p111
sg13
I3
sa(dp112
g7
I32
sg8
VP09488
p113
sg10
I5
sg11
VGSTM1
p114
sg13
I1
sa(dp115
g7
I42
sg8
VP30711
p116
sg10
I5
sg11
VGSTT1
p117
sg13
I1
sasg17
(lp118
(dp119
g7
I100
sg20
VC0014175
p120
sg10
I13
sg11
Vendometriosis
p121
sg13
I1
sasa(dp122
g2
S'Our results showed that GSTM1 and GSTP1 polymorphisms may be associated with susceptibility of endometriosis in Iranian women.\n'
p123
sg4
(lp124
(dp125
g7
I24
sg8
VP09488
p126
sg10
I5
sg11
VGSTM1
p127
sg13
I1
sa(dp128
g7
I34
sg8
VP09211
p129
sg10
I5
sg11
VGSTP1
p130
sg13
I1
sasg17
(lp131
(dp132
g7
I95
sg20
VC0014175
p133
sg10
I13
sg11
Vendometriosis
p134
sg13
I1
sasa(dp135
g2
S'In view of the controversies surrounding the association of glutathione S-transferases (GST) P1 with endometriosis, a meta-analysis of GSTP1 -313A/G polymorphism with endometriosis risk was performed.\n'
p136
sg4
(lp137
(dp138
g7
I88
sg8
g59
sg10
I3
sg11
VGST
p139
sg13
I1
sa(dp140
g7
I135
sg8
VP09211
p141
sg10
I5
sg11
VGSTP1
p142
sg13
I1
sa(dp143
g7
I60
sg8
VP09211
p144
sg10
I26
sg11
Vglutathione S-transferases
p145
sg13
I2
sasg17
(lp146
(dp147
g7
I101
sg20
VC0014175
p148
sg10
I13
sg11
Vendometriosis
p149
sg13
I1
sa(dp150
g7
I101
sg20
VC0014175
p151
sg10
I13
sg11
Vendometriosis
p152
sg13
I1
sasa(dp153
g2
S'The association between GSTP1 -313A/G polymorphism and endometriosis risk was pooled by odds ratios (ORs) together with their 95% confidence intervals (95% CIs).\n'
p154
sg4
(lp155
(dp156
g7
I24
sg8
VP09211
p157
sg10
I5
sg11
VGSTP1
p158
sg13
I1
sasg17
(lp159
(dp160
g7
I156
sg20
VC0007099
p161
sg10
I3
sg11
VCIs
p162
sg13
I1
sa(dp163
g7
I55
sg20
VC0014175
p164
sg10
I13
sg11
Vendometriosis
p165
sg13
I1
sasa(dp166
g2
S'We found that GSTP1-313A/G polymorphism was not associated with endometriosis risk in the overall population (A vs. G: OR=1.02, 95% CI=0.97-1.07, P=0.511; AA vs. GG: OR=1.02, 95% CI=0.98-1.06, P=0.359; GA vs. GG: OR=1.03, 95% CI=0.98-1.08, P=0.299; AA vs. OR=1.01, 95% CI=0.96-1.07, P=0.621; AA/GA vs. GG: OR=1.00, 95% CI=0.97-1.03, P=0.972).\n'
p167
sg4
(lp168
(dp169
g7
I14
sg8
VP09211
p170
sg10
I5
sg11
VGSTP1
p171
sg13
I1
sasg17
(lp172
(dp173
g7
I64
sg20
VC0014175
p174
sg10
I13
sg11
Vendometriosis
p175
sg13
I1
sasa(dp176
g2
S'GSTP1 -313A/G polymorphism may not be associated with endometriosis risk, while the observed increase in risk of endometriosis may be due to small-study bias.\n'
p177
sg4
(lp178
(dp179
g7
I0
sg8
VP09211
p180
sg10
I5
sg11
VGSTP1
p181
sg13
I1
sasg17
(lp182
(dp183
g7
I54
sg20
VC0014175
p184
sg10
I13
sg11
Vendometriosis
p185
sg13
I1
sa(dp186
g7
I54
sg20
VC0014175
p187
sg10
I13
sg11
Vendometriosis
p188
sg13
I1
sasa(dp189
g2
S'To investigate the association of polymorphisms of arylhydrocarbon receptor (AhR)-1661G/A with glutathione S-transferase pi (GSTP1) -313A/G and the susceptibility to endometriosis in southern Han Chinese.\n'
p190
sg4
(lp191
(dp192
g7
I95
sg8
VP09211
p193
sg10
I28
sg11
Vglutathione S-transferase pi
p194
sg13
I3
sa(dp195
g7
I77
sg8
VP35869
p196
sg10
I3
sg11
VAhR
p197
sg13
I1
sa(dp198
g7
I51
sg8
g59
sg10
I24
sg11
Varylhydrocarbon receptor
p199
sg13
I2
sa(dp200
g7
I125
sg8
VP09211
p201
sg10
I5
sg11
VGSTP1
p202
sg13
I1
sasg17
(lp203
(dp204
g7
I166
sg20
VC0014175
p205
sg10
I13
sg11
Vendometriosis
p206
sg13
I1
sasa(dp207
g2
S'The numbers of combined genotypes AhR -1661G/A and GSTP1 -313A/G were 120 patients with AG + AA, 64 patients with AG + AG, 8 patients with AG + GG, 109 patients with GG + AA, 84 patients with GG + AG, 4 patients with GG + GG, 31 patients with AA + AA, 10 patients with AA + AG, 1 patient with AA + GG at endometriosis group and 131 patients with AG + AA, 68 patients with AG + AG, 6 patients with AG + GG, 157 patients with GG + AA, 66 patients with GG + AG, 4 patients with GG + GG, 35 patients with AA + AA, 20 patients with AA + AG, 3 patients with AA + GG at endometriosis group.\n'
p208
sg4
(lp209
(dp210
g7
I51
sg8
VP09211
p211
sg10
I5
sg11
VGSTP1
p212
sg13
I1
sa(dp213
g7
I34
sg8
VP35869
p214
sg10
I12
sg11
VAhR -1661G/A
p215
sg13
I2
sasg17
(lp216
(dp217
g7
I304
sg20
VC0014175
p218
sg10
I13
sg11
Vendometriosis
p219
sg13
I1
sa(dp220
g7
I304
sg20
VC0014175
p221
sg10
I13
sg11
Vendometriosis
p222
sg13
I1
sasa(dp223
g2
S'The combined genotype GG + AG [from AhR -1661G/A (GG) and GSTP1 -313A/G (AG)] might be related with susceptibility to endometriosis.\n'
p224
sg4
(lp225
(dp226
g7
I36
sg8
VP35869
p227
sg10
I12
sg11
VAhR -1661G/A
p228
sg13
I2
sa(dp229
g7
I58
sg8
VP09211
p230
sg10
I11
sg11
VGSTP1 -313A
p231
sg13
I2
sasg17
(lp232
(dp233
g7
I118
sg20
VC0014175
p234
sg10
I13
sg11
Vendometriosis
p235
sg13
I1
sasa(dp236
g2
S'The GSTP1 wild-type genotype in the presence of medium-high blood levels of PCB153, total PCBs, or of high levels of PCB180 significantly increased the risk of endometriosis, suggesting a multiplicative interaction.\n'
p237
sg4
(lp238
(dp239
g7
I4
sg8
VP09211
p240
sg10
I5
sg11
VGSTP1
p241
sg13
I1
sasg17
(lp242
(dp243
g7
I160
sg20
VC0014175
p244
sg10
I13
sg11
Vendometriosis
p245
sg13
I1
sasa(dp246
g2
S'To investigate whether the glutathione-S-transferase P1 (GSTP1) exon 5 polymorphism is associated with susceptibility to advanced stage endometriosis in Korean women.\n'
p247
sg4
(lp248
(dp249
g7
I27
sg8
VP14222
p250
sg10
I28
sg11
Vglutathione-S-transferase P1
p251
sg13
I2
sa(dp252
g7
I57
sg8
VP09211
p253
sg10
I5
sg11
VGSTP1
p254
sg13
I1
sasg17
(lp255
(dp256
g7
I136
sg20
VC0014175
p257
sg10
I13
sg11
Vendometriosis
p258
sg13
I1
sasa(dp259
g2
S'The genotype distribution of the GSTP1 exon 5 polymorphism in the endometriosis group was not significantly different from that of the control group (AA/AG/GG rates were 64.2%/32.7%/3.1% and 65.2%/31.7%/3.0% for the endometriosis and control groups, respectively, P = 0.977).\n'
p260
sg4
(lp261
(dp262
g7
I33
sg8
VP09211
p263
sg10
I10
sg11
VGSTP1 exon
p264
sg13
I2
sasg17
(lp265
(dp266
g7
I66
sg20
VC0014175
p267
sg10
I13
sg11
Vendometriosis
p268
sg13
I1
sa(dp269
g7
I66
sg20
VC0014175
p270
sg10
I13
sg11
Vendometriosis
p271
sg13
I1
sasa(dp272
g2
S'These findings suggest that the GSTP1 exon 5 polymorphism is not a major determinant of the development of advanced stage endometriosis in the Korean population.\n'
p273
sg4
(lp274
(dp275
g7
I32
sg8
VP09211
p276
sg10
I12
sg11
VGSTP1 exon 5
p277
sg13
I3
sasg17
(lp278
(dp279
g7
I122
sg20
VC0014175
p280
sg10
I13
sg11
Vendometriosis
p281
sg13
I1
sasa(dp282
g2
S'With the evolvement of DNA sequencing, many genes have been associated with psoriasis vulgaris and psoriatic arthritis, which included MHC, TNF, LCE, IL23R, IL12B, TRAF3IP2 and TNFAIP3, though some, such as MHC, IL-13 and PTPN22, have been specifically associated with psoriatic arthritis.\n'
p283
sg4
(lp284
(dp285
g7
I222
sg8
g59
sg10
I6
sg11
VPTPN22
p286
sg13
I1
sa(dp287
g7
I135
sg8
VP13747
p288
sg10
I3
sg11
VMHC
p289
sg13
I1
sa(dp290
g7
I177
sg8
VP21580
p291
sg10
I7
sg11
VTNFAIP3
p292
sg13
I1
sa(dp293
g7
I135
sg8
VP13747
p294
sg10
I3
sg11
VMHC
p295
sg13
I1
sa(dp296
g7
I145
sg8
g59
sg10
I3
sg11
VLCE
p297
sg13
I1
sa(dp298
g7
I140
sg8
VP01375
p299
sg10
I3
sg11
VTNF
p300
sg13
I1
sa(dp301
g7
I157
sg8
VP29460
p302
sg10
I5
sg11
VIL12B
p303
sg13
I1
sa(dp304
g7
I212
sg8
VP35225
p305
sg10
I5
sg11
VIL-13
p306
sg13
I1
sa(dp307
g7
I164
sg8
g59
sg10
I8
sg11
VTRAF3IP2
p308
sg13
I1
sasg17
(lp309
(dp310
g7
I99
sg20
VC0003872
p311
sg10
I19
sg11
Vpsoriatic arthritis
p312
sg13
I2
sa(dp313
g7
I76
sg20
VC0263361
p314
sg10
I18
sg11
Vpsoriasis vulgaris
p315
sg13
I2
sa(dp316
g7
I99
sg20
VC0003872
p317
sg10
I19
sg11
Vpsoriatic arthritis
p318
sg13
I2
sasa(dp319
g2
S'We discovered three significant associations at rs6679677 on 1p13.2 (P=6.15x10-5 , OR=5.07), rs16861329 on 3q27.3 (P=2.02x10-4 , OR=0.87) and rs849135 on 7p15.1 (P=6.59x10-9 , OR=1.78), which suggested PTPN22, ST6GAL1 and JAZF1 as novel susceptibility genes for psoriasis in Chinese population.\n'
p320
sg4
(lp321
(dp322
g7
I202
sg8
g59
sg10
I6
sg11
VPTPN22
p323
sg13
I1
sa(dp324
g7
I210
sg8
VP15907
p325
sg10
I7
sg11
VST6GAL1
p326
sg13
I1
sa(dp327
g7
I222
sg8
g59
sg10
I5
sg11
VJAZF1
p328
sg13
I1
sasg17
(lp329
(dp330
g7
I262
sg20
VC0033860
p331
sg10
I9
sg11
Vpsoriasis
p332
sg13
I1
sasa(dp333
g2
S'We found genome-wide significant association to rs2476601, mapping to PTPN22 (p=1.49x10(-9), OR=1.32), but no evidence for association in the psoriasis cohort (p=0.34) and the effect estimates were significantly different between PsA and psoriasis (p=3.2x10(-4)).\n'
p334
sg4
(lp335
(dp336
g7
I230
sg8
VP55786
p337
sg10
I3
sg11
VPsA
p338
sg13
I1
sa(dp339
g7
I70
sg8
g59
sg10
I6
sg11
VPTPN22
p340
sg13
I1
sasg17
(lp341
(dp342
g7
I142
sg20
VC0033860
p343
sg10
I9
sg11
Vpsoriasis
p344
sg13
I1
sa(dp345
g7
I230
sg20
VC1519176
p346
sg10
I3
sg11
VPsA
p347
sg13
I1
sa(dp348
g7
I142
sg20
VC0033860
p349
sg10
I9
sg11
Vpsoriasis
p350
sg13
I1
sasa(dp351
g2
S'For the first time, we report genome-wide significant association of PTPN22 (rs2476601) to PsA susceptibility, but no evidence for association to psoriasis.\n'
p352
sg4
(lp353
(dp354
g7
I91
sg8
VP55786
p355
sg10
I18
sg11
VPsA susceptibility
p356
sg13
I2
sa(dp357
g7
I69
sg8
g59
sg10
I6
sg11
VPTPN22
p358
sg13
I1
sasg17
(lp359
(dp360
g7
I91
sg20
VC1519176
p361
sg10
I3
sg11
VPsA
p362
sg13
I1
sa(dp363
g7
I146
sg20
VC0033860
p364
sg10
I9
sg11
Vpsoriasis
p365
sg13
I1
sasa(dp366
g2
S'A polymorphism of the PTPN22 gene has been found to be associated with chronic urticaria (CU).\n'
p367
sg4
(lp368
(dp369
g7
I22
sg8
g59
sg10
I11
sg11
VPTPN22 gene
p370
sg13
I2
sasg17
(lp371
(dp372
g7
I71
sg20
VC0263338
p373
sg10
I17
sg11
Vchronic urticaria
p374
sg13
I2
sa(dp375
g7
I90
sg20
VC0263338
p376
sg10
I2
sg11
VCU
p377
sg13
I1
sasa(dp378
g2
S"By contrast, PTPN22 C1858T showed a negligible association with systemic sclerosis, celiac disease, multiple sclerosis, psoriasis, ankylosing spondylitis, pemphigus vulgaris, ulcerative colitis, primary sclerosing cholangitis, primary biliary cirrhosis, Crohn's disease and acute anterior uveitis.\n"
p379
sg4
(lp380
(dp381
g7
I13
sg8
g59
sg10
I13
sg11
VPTPN22 C1858T
p382
sg13
I2
sasg17
(lp383
(dp384
g7
I131
sg20
VC0038013
p385
sg10
I22
sg11
Vankylosing spondylitis
p386
sg13
I2
sa(dp387
g7
I195
sg20
VC0566602
p388
sg10
I30
sg11
Vprimary sclerosing cholangitis
p389
sg13
I3
sa(dp390
g7
I175
sg20
VC0009324
p391
sg10
I18
sg11
Vulcerative colitis
p392
sg13
I2
sa(dp393
g7
I254
sg20
VC0010346
p394
sg10
I15
sg11
VCrohn's disease
p395
sg13
I2
sa(dp396
g7
I120
sg20
VC0033860
p397
sg10
I9
sg11
Vpsoriasis
p398
sg13
I1
sa(dp399
g7
I155
sg20
VC0030809
p400
sg10
I18
sg11
Vpemphigus vulgaris
p401
sg13
I2
sa(dp402
g7
I100
sg20
VC0026769
p403
sg10
I18
sg11
Vmultiple sclerosis
p404
sg13
I2
sa(dp405
g7
I84
sg20
VC0007570
p406
sg10
I14
sg11
Vceliac disease
p407
sg13
I2
sa(dp408
g7
I227
sg20
VC0008312
p409
sg10
I25
sg11
Vprimary biliary cirrhosis
p410
sg13
I3
sa(dp411
g7
I274
sg20
VC0701807
p412
sg10
I22
sg11
Vacute anterior uveitis
p413
sg13
I3
sa(dp414
g7
I64
sg20
VC0036421
p415
sg10
I18
sg11
Vsystemic sclerosis
p416
sg13
I2
sasa(dp417
g2
S'Previous studies of the association between psoriasis and PTPN22 C1858T (rs2476601), a gain of function variant associated with a stronger inhibitory effect of T-lymphocytes, have produced inconsistent results.\n'
p418
sg4
(lp419
(dp420
g7
I58
sg8
g59
sg10
I13
sg11
VPTPN22 C1858T
p421
sg13
I2
sasg17
(lp422
(dp423
g7
I44
sg20
VC0033860
p424
sg10
I9
sg11
Vpsoriasis
p425
sg13
I1
sasa(dp426
g2
S'The purpose of the current study is to evaluate the association between PTPN22 C1858T and psoriasis using meta-analysis to: (1) have a sufficient sample size for detecting a weak association; and (2) to explore the heterogeneity between studies.\n'
p427
sg4
(lp428
(dp429
g7
I72
sg8
g59
sg10
I6
sg11
VPTPN22
p430
sg13
I1
sasg17
(lp431
(dp432
g7
I90
sg20
VC0033860
p433
sg10
I9
sg11
Vpsoriasis
p434
sg13
I1
sasa(dp435
g2
S'A non-significantly positive association between psoriasis and the PTPN22 T1858 was observed [summary allelic odds ratio (OR) = 1.15, 95 % confidence interval (CI): 1.00-1.33] and the association appears stronger among subjects with psoriatic arthritis (summary allelic OR = 1.23, 95 % CI: 1.00-1.52).\n'
p436
sg4
(lp437
(dp438
g7
I67
sg8
g59
sg10
I6
sg11
VPTPN22
p439
sg13
I1
sasg17
(lp440
(dp441
g7
I233
sg20
VC0003872
p442
sg10
I19
sg11
Vpsoriatic arthritis
p443
sg13
I2
sa(dp444
g7
I49
sg20
VC0033860
p445
sg10
I9
sg11
Vpsoriasis
p446
sg13
I1
sasa(dp447
g2
S'A null association between PTPN22 T1858 and early-onset psoriasis was observed (summary allelic OR = 1.08, 95 % CI: 0.92-1.28).\n'
p448
sg4
(lp449
(dp450
g7
I27
sg8
g59
sg10
I6
sg11
VPTPN22
p451
sg13
I1
sasg17
(lp452
(dp453
g7
I56
sg20
VC0033860
p454
sg10
I9
sg11
Vpsoriasis
p455
sg13
I1
sasa(dp456
g2
S'The current analysis showed a non-significantly positive association between psoriasis and the PTPN22 T1858 allele, and the association appeared stronger among subjects with psoriatic arthritis.\n'
p457
sg4
(lp458
(dp459
g7
I95
sg8
g59
sg10
I19
sg11
VPTPN22 T1858 allele
p460
sg13
I3
sasg17
(lp461
(dp462
g7
I77
sg20
VC0033860
p463
sg10
I9
sg11
Vpsoriasis
p464
sg13
I1
sa(dp465
g7
I174
sg20
VC0003872
p466
sg10
I19
sg11
Vpsoriatic arthritis
p467
sg13
I2
sasa(dp468
g2
S'Twenty-five patients (61%) had no to mild mitral regurgitation during anastomosis of the LCX territory (M-MR group) and 16 patients (39%) had moderate to severe mitral regurgitation during anastomosis of the LCX territory (S-MR group).\n'
p469
sg4
(lp470
sg17
(lp471
(dp472
g7
I42
sg20
VC0026266
p473
sg10
I20
sg11
Vmitral regurgitation
p474
sg13
I2
sa(dp475
g7
I42
sg20
VC0026266
p476
sg10
I20
sg11
Vmitral regurgitation
p477
sg13
I2
sa(dp478
g7
I70
sg20
VC0332853
p479
sg10
I11
sg11
Vanastomosis
p480
sg13
I1
sa(dp481
g7
I70
sg20
VC0332853
p482
sg10
I11
sg11
Vanastomosis
p483
sg13
I1
sasa(dp484
g2
S'We used immunohistochemistry to quantitate liver expression of RANKL, its receptor (RANK), and importantly the decoy receptor osteoprotegerin (OPG), including a total of 122 liver samples (PBC = 37, primary sclerosing cholangitis = 20, autoimmune hepatitis = 26, chronic hepatitis B = 32 and unaffected controls = 7).\n'
p485
sg4
(lp486
(dp487
g7
I63
sg8
g59
sg10
I5
sg11
VRANKL
p488
sg13
I1
sa(dp489
g7
I111
sg8
g59
sg10
I30
sg11
Vdecoy receptor osteoprotegerin
p490
sg13
I3
sa(dp491
g7
I143
sg8
g59
sg10
I3
sg11
VOPG
p492
sg13
I1
sasg17
(lp493
(dp494
g7
I263
sg20
VC0524909
p495
sg10
I19
sg11
Vchronic hepatitis B
p496
sg13
I3
sa(dp497
g7
I236
sg20
VC0241910
p498
sg10
I20
sg11
Vautoimmune hepatitis
p499
sg13
I2
sa(dp500
g7
I189
sg20
VC0008312
p501
sg10
I3
sg11
VPBC
p502
sg13
I1
sa(dp503
g7
I199
sg20
VC0566602
p504
sg10
I30
sg11
Vprimary sclerosing cholangitis
p505
sg13
I3
sasa(dp506
g2
S'Autoantibodies neutralising the effect of the bone regulatory cytokine osteoprotegerin (OPG) have been described in a patient with severe osteoporosis and coeliac disease.\n'
p507
sg4
(lp508
(dp509
g7
I46
sg8
VP13236
p510
sg10
I40
sg11
Vbone regulatory cytokine osteoprotegerin
p511
sg13
I4
sa(dp512
g7
I88
sg8
g59
sg10
I3
sg11
VOPG
p513
sg13
I1
sasg17
(lp514
(dp515
g7
I155
sg20
VC0007570
p516
sg10
I15
sg11
Vcoeliac disease
p517
sg13
I2
sa(dp518
g7
I138
sg20
VC0029456
p519
sg10
I12
sg11
Vosteoporosis
p520
sg13
I1
sasa(dp521
g2
S'To investigate risk factors for low bone mineral density (BMD) in celiac disease (CD) patients, focusing on circulating autoantibodies against osteoprotegerin (OPG).\n'
p522
sg4
(lp523
(dp524
g7
I143
sg8
g59
sg10
I15
sg11
Vosteoprotegerin
p525
sg13
I1
sa(dp526
g7
I160
sg8
g59
sg10
I3
sg11
VOPG
p527
sg13
I1
sasg17
(lp528
(dp529
g7
I36
sg20
VC0917713
p530
sg10
I20
sg11
Vbone mineral density
p531
sg13
I3
sa(dp532
g7
I66
sg20
VC0007570
p533
sg10
I14
sg11
Vceliac disease
p534
sg13
I2
sa(dp535
g7
I58
sg20
VC0917713
p536
sg10
I3
sg11
VBMD
p537
sg13
I1
sa(dp538
g7
I82
sg20
VC0007570
p539
sg10
I2
sg11
VCD
p540
sg13
I1
sasa(dp541
g2
S'Autoantibodies against osteoprotegerin, which block the inhibitory effect of osteoprotegerin on signaling by the receptor activator of nuclear factor (NF)-kappaB (RANK), were identified in a man with celiac disease who presented with severe osteoporosis and high bone turnover.\n'
p542
sg4
(lp543
(dp544
g7
I23
sg8
g59
sg10
I15
sg11
Vosteoprotegerin
p545
sg13
I1
sa(dp546
g7
I23
sg8
g59
sg10
I15
sg11
Vosteoprotegerin
p547
sg13
I1
sa(dp548
g7
I113
sg8
VP01160
p549
sg10
I48
sg11
Vreceptor activator of nuclear factor (NF)-kappaB
p550
sg13
I6
sasg17
(lp551
(dp552
g7
I241
sg20
VC0029456
p553
sg10
I12
sg11
Vosteoporosis
p554
sg13
I1
sa(dp555
g7
I200
sg20
VC0007570
p556
sg10
I14
sg11
Vceliac disease
p557
sg13
I2
sasa(dp558
g2
S'Autoantibodies against osteoprotegerin were detected in three additional patients with celiac disease.\n'
p559
sg4
(lp560
(dp561
g7
I23
sg8
g59
sg10
I15
sg11
Vosteoprotegerin
p562
sg13
I1
sasg17
(lp563
(dp564
g7
I87
sg20
VC0007570
p565
sg10
I14
sg11
Vceliac disease
p566
sg13
I2
sasa(dp567
g2
S'Such autoantibodies may be associated with the development of high-turnover osteoporosis, but whether autoantibodies against osteoprotegerin commonly contribute to the pathogenesis of osteoporosis in patients with celiac disease remains to be determined.\n'
p568
sg4
(lp569
(dp570
g7
I125
sg8
g59
sg10
I15
sg11
Vosteoprotegerin
p571
sg13
I1
sasg17
(lp572
(dp573
g7
I214
sg20
VC0007570
p574
sg10
I14
sg11
Vceliac disease
p575
sg13
I2
sa(dp576
g7
I76
sg20
VC0029456
p577
sg10
I12
sg11
Vosteoporosis
p578
sg13
I1
sa(dp579
g7
I76
sg20
VC0029456
p580
sg10
I12
sg11
Vosteoporosis
p581
sg13
I1
sa(dp582
g7
I168
sg20
VC0699748
p583
sg10
I12
sg11
Vpathogenesis
p584
sg13
I1
sasa(dp585
g2
S'Next, we combined Akti-1/2 with metformin, a widely-prescribed drug for treating type 2 diabetes, which was reported to down-regulate OCT4 expression.\n'
p586
sg4
(lp587
sg17
(lp588
(dp589
g7
I81
sg20
VC0011860
p590
sg10
I15
sg11
Vtype 2 diabetes
p591
sg13
I3
sasa(dp592
g2
S'This study applied the immunohistochemistry technique SP method In fibroadenoma, ductal carcinoma in situ and invasive ductal carcinoma of the breast 4 groups, the positive immunostaining rate of nm23, MMP-2 and TIMP-2 have significant difference among 4 groups (p &lt; 0.05).\n'
p593
sg4
(lp594
(dp595
g7
I202
sg8
VP08253
p596
sg10
I5
sg11
VMMP-2
p597
sg13
I1
sa(dp598
g7
I212
sg8
VP16035
p599
sg10
I6
sg11
VTIMP-2
p600
sg13
I1
sa(dp601
g7
I196
sg8
VP15531
p602
sg10
I4
sg11
Vnm23
p603
sg13
I1
sasg17
(lp604
(dp605
g7
I67
sg20
VC0206650
p606
sg10
I12
sg11
Vfibroadenoma
p607
sg13
I1
sa(dp608
g7
I110
sg20
VC1134719
p609
sg10
I39
sg11
Vinvasive ductal carcinoma of the breast
p610
sg13
I6
sa(dp611
g7
I81
sg20
VC0007124
p612
sg10
I24
sg11
Vductal carcinoma in situ
p613
sg13
I4
sasa(dp614
g2
S'MMP-2 in the breast ductal carcinoma in situ appears of high expression and this suggested that the positive expression of this onco-proteins was the early incident in the genetic course of the breast cancer The unite detection of nm23, MMP-2 and TIMP-2 expression would contribute to the early diagnosis and prognostic assessment of the carcinoma of the breast.\n'
p615
sg4
(lp616
(dp617
g7
I231
sg8
VP15531
p618
sg10
I4
sg11
Vnm23
p619
sg13
I1
sa(dp620
g7
I247
sg8
VP16035
p621
sg10
I6
sg11
VTIMP-2
p622
sg13
I1
sa(dp623
g7
I0
sg8
VP08253
p624
sg10
I5
sg11
VMMP-2
p625
sg13
I1
sa(dp626
g7
I0
sg8
VP08253
p627
sg10
I5
sg11
VMMP-2
p628
sg13
I1
sasg17
(lp629
(dp630
g7
I13
sg20
VC0007124
p631
sg10
I31
sg11
Vbreast ductal carcinoma in situ
p632
sg13
I5
sa(dp633
g7
I194
sg20
VC0678222
p634
sg10
I13
sg11
Vbreast cancer
p635
sg13
I2
sa(dp636
g7
I338
sg20
VC0678222
p637
sg10
I23
sg11
Vcarcinoma of the breast
p638
sg13
I4
sasa(dp639
g2
S'Expression of nm23-H1 was evident in 9/25 (36%) CIN I, 13/28 (46%) CIN II, 22/28 (78.5%) CIN III and 17/25 (68%) infiltrating carcinoma biopsies.\n'
p640
sg4
(lp641
(dp642
g7
I14
sg8
VP22392
p643
sg10
I7
sg11
Vnm23-H1
p644
sg13
I1
sasg17
(lp645
(dp646
g7
I89
sg20
VC0851140
p647
sg10
I7
sg11
VCIN III
p648
sg13
I2
sa(dp649
g7
I113
sg20
VC0332448
p650
sg10
I12
sg11
Vinfiltrating
p651
sg13
I1
sa(dp652
g7
I67
sg20
VC0349459
p653
sg10
I6
sg11
VCIN II
p654
sg13
I2
sa(dp655
g7
I48
sg20
VC0349458
p656
sg10
I5
sg11
VCIN I
p657
sg13
I2
sa(dp658
g7
I126
sg20
VC0007097
p659
sg10
I9
sg11
Vcarcinoma
p660
sg13
I1
sasa(dp661
g2
S'The cases that had low-grade squamous dysplasia of the cervix (CIN I-II) (N = 7; 100%) also displayed moderate to strong nm23-H1 immunoreactivity in the epithelium except for the basal layer (CIN I) or the lower two-thirds of the epithelium (CIN II).\n'
p662
sg4
(lp663
(dp664
g7
I121
sg8
VP22392
p665
sg10
I7
sg11
Vnm23-H1
p666
sg13
I1
sasg17
(lp667
(dp668
g7
I38
sg20
VC0334044
p669
sg10
I9
sg11
Vdysplasia
p670
sg13
I1
sa(dp671
g7
I63
sg20
VC0349458
p672
sg10
I5
sg11
VCIN I
p673
sg13
I2
sa(dp674
g7
I242
sg20
VC0349459
p675
sg10
I6
sg11
VCIN II
p676
sg13
I2
sa(dp677
g7
I63
sg20
VC0349458
p678
sg10
I5
sg11
VCIN I
p679
sg13
I2
sasa(dp680
g2
S'nm23-H1 Immunoreactivity was either absent or was significantly reduced in all of the high-grade CIN (CIN III) cases (N = 7; 100%) in which only the non-dysplastic superficial third of the squamous epithelium displayed nm23-H1 immunolabeling.\n'
p681
sg4
(lp682
(dp683
g7
I0
sg8
VP22392
p684
sg10
I7
sg11
Vnm23-H1
p685
sg13
I1
sa(dp686
g7
I0
sg8
VP22392
p687
sg10
I7
sg11
Vnm23-H1
p688
sg13
I1
sasg17
(lp689
(dp690
g7
I102
sg20
VC0851140
p691
sg10
I7
sg11
VCIN III
p692
sg13
I2
sa(dp693
g7
I86
sg20
VC1512433
p694
sg10
I14
sg11
Vhigh-grade CIN
p695
sg13
I2
sa(dp696
g7
I153
sg20
VC0334044
p697
sg10
I10
sg11
Vdysplastic
p698
sg13
I1
sasa(dp699
g2
S'The purpose of this retrospective study was to investigate the relationship of Nm23 protein expression with 1) histology in ductal breast carcinoma in situ and 2) the variables considered to be the major prognostic indicators in invasive breast carcinoma.\n'
p700
sg4
(lp701
(dp702
g7
I79
sg8
VP15531
p703
sg10
I12
sg11
VNm23 protein
p704
sg13
I2
sasg17
(lp705
(dp706
g7
I124
sg20
VC0007124
p707
sg10
I31
sg11
Vductal breast carcinoma in situ
p708
sg13
I5
sa(dp709
g7
I229
sg20
VC0853879
p710
sg10
I25
sg11
Vinvasive breast carcinoma
p711
sg13
I3
sasa(dp712
g2
S'Nm23 negativity distinguished comedo ductal carcinoma in situ from the other histological types, a finding consistent with the fact that comedo histology is known to have a higher likelihood of becoming invasive and of having higher cell proliferation rates and higher expression of growth factor (c-erb B2) receptor.\n'
p713
sg4
(lp714
(dp715
g7
I283
sg8
g59
sg10
I13
sg11
Vgrowth factor
p716
sg13
I2
sasg17
(lp717
(dp718
g7
I238
sg20
VC0334094
p719
sg10
I13
sg11
Vproliferation
p720
sg13
I1
sa(dp721
g7
I37
sg20
VC0007124
p722
sg10
I24
sg11
Vductal carcinoma in situ
p723
sg13
I4
sa(dp724
g7
I30
sg20
VC0221228
p725
sg10
I6
sg11
Vcomedo
p726
sg13
I1
sa(dp727
g7
I30
sg20
VC0221228
p728
sg10
I6
sg11
Vcomedo
p729
sg13
I1
sasa(dp730
g2
S'Nm23-negative tumor cells have been observed in comedo ductal carcinoma in situ lesions in two independent studies, indicating that decreases in nm23 expression begin prior to actual histologically identifiable invasion.\n'
p731
sg4
(lp732
(dp733
g7
I145
sg8
VP15531
p734
sg10
I4
sg11
Vnm23
p735
sg13
I1
sasg17
(lp736
(dp737
g7
I48
sg20
VC0221228
p738
sg10
I6
sg11
Vcomedo
p739
sg13
I1
sa(dp740
g7
I211
sg20
VC2699153
p741
sg10
I8
sg11
Vinvasion
p742
sg13
I1
sa(dp743
g7
I14
sg20
VC0027651
p744
sg10
I5
sg11
Vtumor
p745
sg13
I1
sa(dp746
g7
I55
sg20
VC0007124
p747
sg10
I24
sg11
Vductal carcinoma in situ
p748
sg13
I4
sasa(dp749
g2
S'Among the cases of CIS with no invasion, LCIS and comedo DCIS expressed more nm23 than noncomedo DCIS (P &lt; or = 0.03).\n'
p750
sg4
(lp751
(dp752
g7
I77
sg8
VP15531
p753
sg10
I4
sg11
Vnm23
p754
sg13
I1
sasg17
(lp755
(dp756
g7
I31
sg20
VC2699153
p757
sg10
I8
sg11
Vinvasion
p758
sg13
I1
sa(dp759
g7
I19
sg20
VC0007099
p760
sg10
I3
sg11
VCIS
p761
sg13
I1
sa(dp762
g7
I57
sg20
VC0007124
p763
sg10
I4
sg11
VDCIS
p764
sg13
I1
sa(dp765
g7
I41
sg20
VC0334381
p766
sg10
I4
sg11
VLCIS
p767
sg13
I1
sa(dp768
g7
I57
sg20
VC0007124
p769
sg10
I4
sg11
VDCIS
p770
sg13
I1
sa(dp771
g7
I50
sg20
VC0221228
p772
sg10
I6
sg11
Vcomedo
p773
sg13
I1
sasa(dp774
g2
S'NaF-induced vasocontraction at pCa 7.0 was inhibited by pretreatment with Rho kinase inhibitors H1152 or Y27632 but not with a MLCK inhibitor ML-7 or a PKC inhibitor Ro31-8220.\n'
p775
sg4
(lp776
(dp777
g7
I74
sg8
VP08100
p778
sg10
I10
sg11
VRho kinase
p779
sg13
I2
sa(dp780
g7
I127
sg8
VP56539
p781
sg10
I4
sg11
VMLCK
p782
sg13
I1
sa(dp783
g7
I152
sg8
VP17252
p784
sg10
I3
sg11
VPKC
p785
sg13
I1
sasg17
(lp786
(dp787
g7
I31
sg20
VC0268398
p788
sg10
I3
sg11
VpCa
p789
sg13
I1
sa(dp790
g7
I152
sg20
VC1868682
p791
sg10
I3
sg11
VPKC
p792
sg13
I1
sasa(dp793
g2
S'The carboxy-terminal domains of gB and gM directed a predominantly intracellular localization of gDB and gDM, while full-length gD and a tail-less gD mutant (gDc) were preferentially expressed on the cell surface.\n'
p794
sg4
(lp795
(dp796
g7
I147
sg8
VP09466
p797
sg10
I9
sg11
VgD mutant
p798
sg13
I2
sa(dp799
g7
I158
sg8
VP16260
p800
sg10
I3
sg11
VgDc
p801
sg13
I1
sasg17
(lp802
(dp803
g7
I105
sg20
VC0085207
p804
sg10
I3
sg11
VgDM
p805
sg13
I1
sa(dp806
g7
I150
sg20
VC0596988
p807
sg10
I6
sg11
Vmutant
p808
sg13
I1
sasa(dp809
g2
S'SALL4 is aberrantly expressed in human myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).\n'
p810
sg4
(lp811
(dp812
g7
I0
sg8
g59
sg10
I5
sg11
VSALL4
p813
sg13
I1
sasg17
(lp814
(dp815
g7
I66
sg20
VC0265219
p816
sg10
I3
sg11
VMDS
p817
sg13
I1
sa(dp818
g7
I75
sg20
VC0023467
p819
sg10
I22
sg11
Vacute myeloid leukemia
p820
sg13
I3
sa(dp821
g7
I39
sg20
VC0033027
p822
sg10
I25
sg11
Vmyelodysplastic syndromes
p823
sg13
I2
sa(dp824
g7
I99
sg20
VC0023467
p825
sg10
I3
sg11
VAML
p826
sg13
I1
sasa(dp827
g2
S'Constitutive expression of SALL4 transgene readily induces acute myeloid leukemia (AML) development in mice.\n'
p828
sg4
(lp829
(dp830
g7
I27
sg8
g59
sg10
I15
sg11
VSALL4 transgene
p831
sg13
I2
sasg17
(lp832
(dp833
g7
I83
sg20
VC0023467
p834
sg10
I3
sg11
VAML
p835
sg13
I1
sa(dp836
g7
I59
sg20
VC0023467
p837
sg10
I22
sg11
Vacute myeloid leukemia
p838
sg13
I3
sasa(dp839
g2
S'Sal-like protein 4 (SALL4) is a transcription factor that exists in two splice isoforms, SALL4a and SALL4b, and regulates transcription in embryonic stem cells, hematopoiesis, and acute myeloid leukemia.\n'
p840
sg4
(lp841
(dp842
g7
I0
sg8
g59
sg10
I18
sg11
VSal-like protein 4
p843
sg13
I3
sa(dp844
g7
I20
sg8
g59
sg10
I5
sg11
VSALL4
p845
sg13
I1
sasg17
(lp846
(dp847
g7
I180
sg20
VC0023467
p848
sg10
I22
sg11
Vacute myeloid leukemia
p849
sg13
I3
sasa(dp850
g2
S'Constitutive overexpression of SALL4 in mice induces acute myeloid leukemia.\n'
p851
sg4
(lp852
(dp853
g7
I31
sg8
g59
sg10
I5
sg11
VSALL4
p854
sg13
I1
sasg17
(lp855
(dp856
g7
I53
sg20
VC0023467
p857
sg10
I22
sg11
Vacute myeloid leukemia
p858
sg13
I3
sasa(dp859
g2
S'Lastly, we found that SALL4 expression is variable in acute myeloid leukemia, ranging from no expression to levels comparable to embryonic stem cells.\n'
p860
sg4
(lp861
(dp862
g7
I22
sg8
g59
sg10
I5
sg11
VSALL4
p863
sg13
I1
sasg17
(lp864
(dp865
g7
I54
sg20
VC0023467
p866
sg10
I22
sg11
Vacute myeloid leukemia
p867
sg13
I3
sasa(dp868
g2
S'These results show that SALL4 isoforms contribute to only a subset of acute myeloid leukemia and that overexpression of SALL4 isoforms impairs hematopoiesis through repression of BMI1.\n'
p869
sg4
(lp870
(dp871
g7
I179
sg8
VP35226
p872
sg10
I4
sg11
VBMI1
p873
sg13
I1
sa(dp874
g7
I24
sg8
g59
sg10
I14
sg11
VSALL4 isoforms
p875
sg13
I2
sa(dp876
g7
I24
sg8
g59
sg10
I14
sg11
VSALL4 isoforms
p877
sg13
I2
sasg17
(lp878
(dp879
g7
I70
sg20
VC0023467
p880
sg10
I22
sg11
Vacute myeloid leukemia
p881
sg13
I3
sasa(dp882
g2
S'SALL4 transgenic mice develop MDS prior to acute myeloid leukemia (AML) transformation.\n'
p883
sg4
(lp884
(dp885
g7
I0
sg8
g59
sg10
I5
sg11
VSALL4
p886
sg13
I1
sasg17
(lp887
(dp888
g7
I30
sg20
VC0265219
p889
sg10
I3
sg11
VMDS
p890
sg13
I1
sa(dp891
g7
I72
sg20
VC1510411
p892
sg10
I14
sg11
Vtransformation
p893
sg13
I1
sa(dp894
g7
I67
sg20
VC0023467
p895
sg10
I3
sg11
VAML
p896
sg13
I1
sa(dp897
g7
I43
sg20
VC0023467
p898
sg10
I22
sg11
Vacute myeloid leukemia
p899
sg13
I3
sasa(dp900
g2
S'The embryonic self-renewal factor SALL4 has been implicated in the development of human acute myeloid leukemia (AML).\n'
p901
sg4
(lp902
(dp903
g7
I4
sg8
g59
sg10
I35
sg11
Vembryonic self-renewal factor SALL4
p904
sg13
I4
sasg17
(lp905
(dp906
g7
I88
sg20
VC0023467
p907
sg10
I22
sg11
Vacute myeloid leukemia
p908
sg13
I3
sa(dp909
g7
I112
sg20
VC0023467
p910
sg10
I3
sg11
VAML
p911
sg13
I1
sasa(dp912
g2
S'The aim of this study was to investigate the expression level of the SALL4 gene and its clinical significance in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).\n'
p913
sg4
(lp914
(dp915
g7
I69
sg8
g59
sg10
I10
sg11
VSALL4 gene
p916
sg13
I2
sasg17
(lp917
(dp918
g7
I151
sg20
VC0023467
p919
sg10
I3
sg11
VAML
p920
sg13
I1
sa(dp921
g7
I186
sg20
VC0023473
p922
sg10
I3
sg11
VCML
p923
sg13
I1
sa(dp924
g7
I160
sg20
VC0023473
p925
sg10
I24
sg11
Vchronic myeloid leukemia
p926
sg13
I3
sa(dp927
g7
I127
sg20
VC0023467
p928
sg10
I22
sg11
Vacute myeloid leukemia
p929
sg13
I3
sasa(dp930
g2
S'The aim was therefore to investigate the variation of GnRH-R expression with prostate tumour progression using Dunning rat adenocarcinoma sublines representing different prostate tumour grades.\n'
p931
sg4
(lp932
(dp933
g7
I54
sg8
VP30968
p934
sg10
I6
sg11
VGnRH-R
p935
sg13
I1
sasg17
(lp936
(dp937
g7
I119
sg20
VC1882551
p938
sg10
I18
sg11
Vrat adenocarcinoma
p939
sg13
I2
sa(dp940
g7
I86
sg20
VC0178874
p941
sg10
I18
sg11
Vtumour progression
p942
sg13
I2
sa(dp943
g7
I86
sg20
VC0027651
p944
sg10
I6
sg11
Vtumour
p945
sg13
I1
sasa(dp946
g2
S'Four selected patients older than 70 years of age with advanced adenocarcinoma of the prostate who were treated with a depot injection of LHRH and antiandrogen therapy had their treatment discontinued.\n'
p947
sg4
(lp948
(dp949
g7
I138
sg8
VP01148
p950
sg10
I4
sg11
VLHRH
p951
sg13
I1
sasg17
(lp952
(dp953
g7
I64
sg20
VC0007112
p954
sg10
I30
sg11
Vadenocarcinoma of the prostate
p955
sg13
I4
sasa(dp956
g2
S'In the first procedure, electroanatomic mapping (EAM) revealed a total of 139 ATs in 105 patients, including 88 cavotricuspid isthmus dependent atrial flutters (IDAFs), 5 mitral annulus reentrant tachycardias (MARTs), 44 intra-atrial reentrant tachycardias (IARTs) and 2 focal ATs (FATs).\n'
p957
sg4
(lp958
(dp959
g7
I282
sg8
g59
sg10
I4
sg11
VFATs
p960
sg13
I1
sa(dp961
g7
I269
sg8
VP30520
p962
sg10
I11
sg11
V2 focal ATs
p963
sg13
I3
sasg17
(lp964
(dp965
g7
I24
sg20
VC1719788
p966
sg10
I23
sg11
Velectroanatomic mapping
p967
sg13
I2
sa(dp968
g7
I78
sg20
VC1567742
p969
sg10
I3
sg11
VATs
p970
sg13
I1
sa(dp971
g7
I49
sg20
VC1719788
p972
sg10
I3
sg11
VEAM
p973
sg13
I1
sa(dp974
g7
I78
sg20
VC1567742
p975
sg10
I3
sg11
VATs
p976
sg13
I1
sa(dp977
g7
I144
sg20
VC0004239
p978
sg10
I15
sg11
Vatrial flutters
p979
sg13
I2
sasa(dp980
g2
S'A total of 23 ATs were identified in redo procedures including 4 IDAFs, 2 MARTs, 12 IARTs and 5 FATs.\n'
p981
sg4
(lp982
sg17
(lp983
(dp984
g7
I14
sg20
VC1567742
p985
sg10
I3
sg11
VATs
p986
sg13
I1
sasa(dp987
g2
S'Also in FATs, the RAFW was the most common site (77.8%) of the ectopic focus.\n'
p988
sg4
(lp989
(dp990
g7
I8
sg8
g59
sg10
I4
sg11
VFATs
p991
sg13
I1
sasg17
(lp992
sa(dp993
g2
S'Ninety per cent of FATs were successfully ablated.\n'
p994
sg4
(lp995
sg17
(lp996
sa(dp997
g2
S'Resistin is a cytokine related with inflammation and ischemic heart disease.\n'
p998
sg4
(lp999
(dp1000
g7
I0
sg8
g59
sg10
I8
sg11
VResistin
p1001
sg13
I1
sasg17
(lp1002
(dp1003
g7
I53
sg20
VC0151744
p1004
sg10
I22
sg11
Vischemic heart disease
p1005
sg13
I3
sa(dp1006
g7
I36
sg20
VC0021368
p1007
sg10
I12
sg11
Vinflammation
p1008
sg13
I1
sasa(dp1009
g2
S'Our previous study has shown higher levels of serum Resistin in KD patients with coronary aneurysm.\n'
p1010
sg4
(lp1011
sg17
(lp1012
(dp1013
g7
I81
sg20
VC0010051
p1014
sg10
I17
sg11
Vcoronary aneurysm
p1015
sg13
I2
sasa(dp1016
g2
S'In this study, we examined the association of the RETN SNPs in - 420 and + 299 in patients with idiopathic dilated cardiomyopathy (IDCM).\n'
p1017
sg4
(lp1018
(dp1019
g7
I50
sg8
g59
sg10
I9
sg11
VRETN SNPs
p1020
sg13
I2
sasg17
(lp1021
(dp1022
g7
I96
sg20
VC1449563
p1023
sg10
I33
sg11
Vidiopathic dilated cardiomyopathy
p1024
sg13
I3
sa(dp1025
g7
I131
sg20
VC1449563
p1026
sg10
I4
sg11
VIDCM
p1027
sg13
I1
sasa(dp1028
g2
S'Bi-DOCS were associated with genes related to pancreas development and beta-cell function, including transcription factors mutated in monogenic diabetes (PDX1, NKX2-2, HNF1A; FDR &lt; 0.05).\n'
p1029
sg4
(lp1030
(dp1031
g7
I154
sg8
VP52945
p1032
sg10
I4
sg11
VPDX1
p1033
sg13
I1
sa(dp1034
g7
I168
sg8
VP20823
p1035
sg10
I5
sg11
VHNF1A
p1036
sg13
I1
sa(dp1037
g7
I160
sg8
g59
sg10
I6
sg11
VNKX2-2
p1038
sg13
I1
sasg17
(lp1039
(dp1040
g7
I144
sg20
VC0011849
p1041
sg10
I8
sg11
Vdiabetes
p1042
sg13
I1
sasa(dp1043
g2
S'We aimed to characterize mosaic populations of pancreatic islet cells from patients with atypical congenital hyperinsulinism in infancy (CHI-A) and the expression profile of NKX2.2, a key transcription factor expressed in Beta-cells but suppressed in Delta-cells in the mature pancreas.\n'
p1044
sg4
(lp1045
(dp1046
g7
I174
sg8
g59
sg10
I6
sg11
VNKX2.2
p1047
sg13
I1
sasg17
(lp1048
(dp1049
g7
I109
sg20
VC0020459
p1050
sg10
I15
sg11
Vhyperinsulinism
p1051
sg13
I1
sasa(dp1052
g2
S'The expression of early transcription factors (TF), including Ngn3, FoxA1 and Nkx2.2, was not compromised by chronic hyperglycemia.\n'
p1053
sg4
(lp1054
(dp1055
g7
I62
sg8
g59
sg10
I4
sg11
VNgn3
p1056
sg13
I1
sa(dp1057
g7
I68
sg8
VP55317
p1058
sg10
I5
sg11
VFoxA1
p1059
sg13
I1
sa(dp1060
g7
I18
sg8
VP19883
p1061
sg10
I27
sg11
Vearly transcription factors
p1062
sg13
I3
sa(dp1063
g7
I78
sg8
g59
sg10
I6
sg11
VNkx2.2
p1064
sg13
I1
sasg17
(lp1065
(dp1066
g7
I109
sg20
VC0342300
p1067
sg10
I21
sg11
Vchronic hyperglycemia
p1068
sg13
I2
sasa(dp1069
g2
S'Since cell proliferation has a strong requirement for iron, cancer cells express high levels of transferrin receptors (TfnR), making its ligand, transferrin (Tfn), of great interest as a delivery agent for therapeutics.\n'
p1070
sg4
(lp1071
(dp1072
g7
I96
sg8
VP02787
p1073
sg10
I21
sg11
Vtransferrin receptors
p1074
sg13
I2
sa(dp1075
g7
I119
sg8
VP02787
p1076
sg10
I3
sg11
VTfn
p1077
sg13
I1
sa(dp1078
g7
I96
sg8
VP02787
p1079
sg10
I11
sg11
Vtransferrin
p1080
sg13
I1
sa(dp1081
g7
I119
sg8
VP02786
p1082
sg10
I4
sg11
VTfnR
p1083
sg13
I1
sasg17
(lp1084
(dp1085
g7
I11
sg20
VC0334094
p1086
sg10
I13
sg11
Vproliferation
p1087
sg13
I1
sa(dp1088
g7
I60
sg20
VC0006826
p1089
sg10
I6
sg11
Vcancer
p1090
sg13
I1
sasa(dp1091
g2
S'There have been significant advances in our understanding of how TFIIIB-mediated transcription is deregulated in a variety of cancers.\n'
p1092
sg4
(lp1093
sg17
(lp1094
(dp1095
g7
I126
sg20
VC0006826
p1096
sg10
I7
sg11
Vcancers
p1097
sg13
I1
sasa(dp1098
g2
S'RESULTS: Using breast, cervical, prostate and glioblastoma cancer cells we demonstrate: (1) PTEN inhibition of gene external RNA pol III transcription is cell type specific, (2) PTEN-mediated inhibition of U6 transcription occurs via the C2 lipid-binding domain and (3) PTEN repression of U6 transcription occurs, at least in part, through the TFIIIB subunit BRF2.\n'
p1099
sg4
(lp1100
(dp1101
g7
I92
sg8
VP60484
p1102
sg10
I4
sg11
VPTEN
p1103
sg13
I1
sa(dp1104
g7
I344
sg8
VP47974
p1105
sg10
I19
sg11
VTFIIIB subunit BRF2
p1106
sg13
I3
sa(dp1107
g7
I92
sg8
VP60484
p1108
sg10
I4
sg11
VPTEN
p1109
sg13
I1
sa(dp1110
g7
I125
sg8
VP10266
p1111
sg10
I11
sg11
VRNA pol III
p1112
sg13
I3
sa(dp1113
g7
I92
sg8
VP60484
p1114
sg10
I4
sg11
VPTEN
p1115
sg13
I1
sasg17
(lp1116
(dp1117
g7
I59
sg20
VC0006826
p1118
sg10
I6
sg11
Vcancer
p1119
sg13
I1
sa(dp1120
g7
I46
sg20
VC0017636
p1121
sg10
I12
sg11
Vglioblastoma
p1122
sg13
I1
sasa(dp1123
g2
S'In addition, PE cells have elevated levels of the retinoblastoma protein RB, which is known to bind and repress TFIIIB.\n'
p1124
sg4
(lp1125
(dp1126
g7
I50
sg8
g59
sg10
I25
sg11
Vretinoblastoma protein RB
p1127
sg13
I3
sasg17
(lp1128
(dp1129
g7
I50
sg20
VC0035335
p1130
sg10
I14
sg11
Vretinoblastoma
p1131
sg13
I1
sasa(dp1132
g2
S'We found that c-Fos expression in the mitochondria of neuroblastoma Neuro2a cells was augmented by oxygen and glucose deprivation (OGD), which is a common in vitro model for brain ischemia.\n'
p1133
sg4
(lp1134
(dp1135
g7
I14
sg8
VP01100
p1136
sg10
I5
sg11
Vc-Fos
p1137
sg13
I1
sasg17
(lp1138
(dp1139
g7
I99
sg20
VC0432283
p1140
sg10
I30
sg11
Voxygen and glucose deprivation
p1141
sg13
I4
sa(dp1142
g7
I131
sg20
VC0432283
p1143
sg10
I3
sg11
VOGD
p1144
sg13
I1
sa(dp1145
g7
I54
sg20
VC0027819
p1146
sg10
I13
sg11
Vneuroblastoma
p1147
sg13
I1
sa(dp1148
g7
I174
sg20
VC0007786
p1149
sg10
I14
sg11
Vbrain ischemia
p1150
sg13
I2
sasa(dp1151
g2
S'Because impaired prefrontal cortical Gamma-oscillations are thought to underlie the cognitive impairments in schizophrenia, the authors investigated whether KCNS3 mRNA levels are altered in the prefrontal cortex of schizophrenia subjects.\n'
p1152
sg4
(lp1153
(dp1154
g7
I157
sg8
g59
sg10
I10
sg11
VKCNS3 mRNA
p1155
sg13
I2
sasg17
(lp1156
(dp1157
g7
I109
sg20
VC0036341
p1158
sg10
I13
sg11
Vschizophrenia
p1159
sg13
I1
sa(dp1160
g7
I84
sg20
VC0338656
p1161
sg10
I21
sg11
Vcognitive impairments
p1162
sg13
I2
sa(dp1163
g7
I109
sg20
VC0036341
p1164
sg10
I13
sg11
Vschizophrenia
p1165
sg13
I1
sa(dp1166
g7
I8
sg20
VC0684336
p1167
sg10
I8
sg11
Vimpaired
p1168
sg13
I1
sasa(dp1169
g2
S'KCNS3 mRNA expression was evaluated by in situ hybridization in 22 matched pairs of schizophrenia and comparison subjects and by microarray analyses of pooled samples of individually dissected neurons that were labeled with Vicia villosa agglutinin (VVA), a parvalbumin neuron-selective marker, in a separate cohort of 14 pairs.\n'
p1170
sg4
(lp1171
(dp1172
g7
I0
sg8
g59
sg10
I10
sg11
VKCNS3 mRNA
p1173
sg13
I2
sa(dp1174
g7
I258
sg8
VP20472
p1175
sg10
I11
sg11
Vparvalbumin
p1176
sg13
I1
sasg17
(lp1177
(dp1178
g7
I84
sg20
VC0036341
p1179
sg10
I13
sg11
Vschizophrenia
p1180
sg13
I1
sasa(dp1181
g2
S'By in situ hybridization, KCNS3 mRNA levels were 23% lower in schizophrenia subjects.\n'
p1182
sg4
(lp1183
(dp1184
g7
I26
sg8
g59
sg10
I10
sg11
VKCNS3 mRNA
p1185
sg13
I2
sasg17
(lp1186
(dp1187
g7
I62
sg20
VC0036341
p1188
sg10
I13
sg11
Vschizophrenia
p1189
sg13
I1
sasa(dp1190
g2
S'By microarray, KCNS3 mRNA levels were lower by 40% in VVA-labeled neurons from schizophrenia subjects.\n'
p1191
sg4
(lp1192
(dp1193
g7
I15
sg8
g59
sg10
I10
sg11
VKCNS3 mRNA
p1194
sg13
I2
sasg17
(lp1195
(dp1196
g7
I79
sg20
VC0036341
p1197
sg10
I13
sg11
Vschizophrenia
p1198
sg13
I1
sasa(dp1199
g2
S'These findings reveal lower KCNS3 expression in prefrontal cortical parvalbumin neurons in schizophrenia, providing a molecular basis for compromised detection of coincident synaptic inputs to parvalbumin neurons that could contribute to altered Gamma-oscillations and impaired cognition in schizophrenia.\n'
p1200
sg4
(lp1201
(dp1202
g7
I28
sg8
g59
sg10
I5
sg11
VKCNS3
p1203
sg13
I1
sa(dp1204
g7
I68
sg8
VP20472
p1205
sg10
I11
sg11
Vparvalbumin
p1206
sg13
I1
sasg17
(lp1207
(dp1208
g7
I269
sg20
VC0338656
p1209
sg10
I18
sg11
Vimpaired cognition
p1210
sg13
I2
sa(dp1211
g7
I91
sg20
VC0036341
p1212
sg10
I13
sg11
Vschizophrenia
p1213
sg13
I1
sa(dp1214
g7
I91
sg20
VC0036341
p1215
sg10
I13
sg11
Vschizophrenia
p1216
sg13
I1
sasa(dp1217
g2
S'KCNS3 and LHX6 might be useful for characterizing cell-type specific molecular alterations of cortical GABA neurotransmission and for the development of novel treatments targeting PV and/or SST neurons in schizophrenia.\n'
p1218
sg4
(lp1219
(dp1220
g7
I0
sg8
g59
sg10
I5
sg11
VKCNS3
p1221
sg13
I1
sa(dp1222
g7
I10
sg8
g59
sg10
I4
sg11
VLHX6
p1223
sg13
I1
sasg17
(lp1224
(dp1225
g7
I205
sg20
VC0036341
p1226
sg10
I13
sg11
Vschizophrenia
p1227
sg13
I1
sasa(dp1228
g2
S"TYRO3, AXL, and MERTK (TAM) receptors are a family of receptor tyrosine kinases that maintain homeostasis through the clearance of apoptotic cells, and when defective, contribute to chronic inflammatory and autoimmune diseases such as atherosclerosis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and Crohn's disease.\n"
p1229
sg4
(lp1230
(dp1231
g7
I0
sg8
g59
sg10
I5
sg11
VTYRO3
p1232
sg13
I1
sa(dp1233
g7
I54
sg8
VP29401
p1234
sg10
I25
sg11
Vreceptor tyrosine kinases
p1235
sg13
I3
sa(dp1236
g7
I7
sg8
VP30530
p1237
sg10
I3
sg11
VAXL
p1238
sg13
I1
sa(dp1239
g7
I16
sg8
g59
sg10
I21
sg11
VMERTK (TAM) receptors
p1240
sg13
I3
sasg17
(lp1241
(dp1242
g7
I328
sg20
VC0010346
p1243
sg10
I15
sg11
VCrohn's disease
p1244
sg13
I2
sa(dp1245
g7
I235
sg20
VC0004153
p1246
sg10
I15
sg11
Vatherosclerosis
p1247
sg13
I1
sa(dp1248
g7
I207
sg20
VC0004364
p1249
sg10
I19
sg11
Vautoimmune diseases
p1250
sg13
I2
sa(dp1251
g7
I241
sg20
VC0036429
p1252
sg10
I9
sg11
Vsclerosis
p1253
sg13
I1
sa(dp1254
g7
I302
sg20
VC0003873
p1255
sg10
I20
sg11
Vrheumatoid arthritis
p1256
sg13
I2
sa(dp1257
g7
I272
sg20
VC0024141
p1258
sg10
I28
sg11
Vsystemic lupus erythematosus
p1259
sg13
I3
sa(dp1260
g7
I23
sg20
VC1834582
p1261
sg10
I3
sg11
VTAM
p1262
sg13
I1
sasa(dp1263
g2
S'We analyzed the expression and clinical relevance of Axl on the surface of CD14+ monocytes/macrophages (mAxl, membrane Axl) and in the plasma (sAxl, soluble Axl) from patients with systemic lupus erythematosus (SLE).\n'
p1264
sg4
(lp1265
(dp1266
g7
I53
sg8
VP30530
p1267
sg10
I3
sg11
VAxl
p1268
sg13
I1
sa(dp1269
g7
I75
sg8
VP08571
p1270
sg10
I5
sg11
VCD14+
p1271
sg13
I1
sa(dp1272
g7
I53
sg8
VP30530
p1273
sg10
I3
sg11
VAxl
p1274
sg13
I1
sasg17
(lp1275
(dp1276
g7
I181
sg20
VC0024141
p1277
sg10
I28
sg11
Vsystemic lupus erythematosus
p1278
sg13
I3
sa(dp1279
g7
I211
sg20
VC0024141
p1280
sg10
I3
sg11
VSLE
p1281
sg13
I1
sasa(dp1282
g2
S'Strong correlations with disease activity indices (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), complement reduction, titer of circulating anti-dsDNA) were found for sMER, not for sAXL.\n'
p1283
sg4
(lp1284
sg17
(lp1285
(dp1286
g7
I51
sg20
VC0024141
p1287
sg10
I28
sg11
VSystemic Lupus Erythematosus
p1288
sg13
I3
sasa(dp1289
g2
S'To clarify the biological role of the 90K/Mac-2BP glycoprotein, we evaluated the ability of two MAbs SP-2 and 1A4.22, to reveal this glycoprotein in both serum and tissue from hepatocellular carcinoma (HCC) patients.\n'
p1290
sg4
(lp1291
(dp1292
g7
I42
sg8
VP29966
p1293
sg10
I20
sg11
VMac-2BP glycoprotein
p1294
sg13
I2
sa(dp1295
g7
I38
sg8
g59
sg10
I3
sg11
V90K
p1296
sg13
I1
sasg17
(lp1297
(dp1298
g7
I202
sg20
VC2239176
p1299
sg10
I3
sg11
VHCC
p1300
sg13
I1
sa(dp1301
g7
I176
sg20
VC2239176
p1302
sg10
I24
sg11
Vhepatocellular carcinoma
p1303
sg13
I2
sasa(dp1304
g2
S'The IC50 (95 % confidence limits) of curcin on SGC-7901, Sp2/0, and human hepatoma was 0.23 (0.15-0.32) mg/L, 0.66 (0.35-0.97) mg/L, 3.16 (2.74-3.58) mg/L, respectively.\n'
p1305
sg4
(lp1306
(dp1307
g7
I57
sg8
g59
sg10
I5
sg11
VSp2/0
p1308
sg13
I1
sasg17
(lp1309
(dp1310
g7
I74
sg20
VC0023903
p1311
sg10
I8
sg11
Vhepatoma
p1312
sg13
I1
sasa(dp1313
g2
S'The purpose of this study was to evaluate histologic criteria that may differentiate CTD-UIP from I-UIP, including fibroblastic foci (FFs), lymphoid aggregates (LAs), and the presence of nonspecific interstitial pneumonia pattern.\n'
p1314
sg4
(lp1315
sg17
(lp1316
(dp1317
g7
I89
sg20
VC0085786
p1318
sg10
I3
sg11
VUIP
p1319
sg13
I1
sa(dp1320
g7
I187
sg20
VC1290344
p1321
sg10
I34
sg11
Vnonspecific interstitial pneumonia
p1322
sg13
I3
sa(dp1323
g7
I134
sg20
VC0265263
p1324
sg10
I3
sg11
VFFs
p1325
sg13
I1
sa(dp1326
g7
I89
sg20
VC0085786
p1327
sg10
I3
sg11
VUIP
p1328
sg13
I1
sasa(dp1329
g2
S'In the work presented here, we used 16S rRNA Illumina sequencing to determine whether a connection exists between oral nitrate-reducing bacteria, nitrates for cardiovascular disease, and migraines, which are a common side effect of nitrate medications (U. Thadani and T. Rodgers, Expert Opin Drug Saf 5:667-674, 2006, http://dx.doi.org/10.1517/14740338.5.5.667).\n'
p1330
sg4
(lp1331
sg17
(lp1332
(dp1333
g7
I217
sg20
VC0879626
p1334
sg10
I11
sg11
Vside effect
p1335
sg13
I2
sa(dp1336
g7
I187
sg20
VC0149931
p1337
sg10
I9
sg11
Vmigraines
p1338
sg13
I1
sa(dp1339
g7
I159
sg20
VC0007222
p1340
sg10
I22
sg11
Vcardiovascular disease
p1341
sg13
I2
sasa(dp1342
g2
S"Safinamide is being developed in phase III for treatment of Parkinson's disease, whereas the development in epilepsy relates to the industrial strategy of the company.\n"
p1343
sg4
(lp1344
sg17
(lp1345
(dp1346
g7
I60
sg20
VC0030567
p1347
sg10
I19
sg11
VParkinson's disease
p1348
sg13
I2
sa(dp1349
g7
I108
sg20
VC0014544
p1350
sg10
I8
sg11
Vepilepsy
p1351
sg13
I1
sasa(dp1352
g2
S'Duplicate samples from the same animals were also examined by electron microscopy for the presence of abnormal brain fibrils (scrapie-associated fibrils; SAFs).\n'
p1353
sg4
(lp1354
sg17
(lp1355
(dp1356
g7
I126
sg20
VC0036457
p1357
sg10
I7
sg11
Vscrapie
p1358
sg13
I1
sasa(dp1359
g2
S'A statistical comparison was made between the results of the statutory neurohistopathological method for the post mortem diagnosis of bovine spongiform encephalopathy (BSE) and the detection of abnormal brain fibrils (SAF).\n'
p1360
sg4
(lp1361
sg17
(lp1362
(dp1363
g7
I134
sg20
VC0085209
p1364
sg10
I32
sg11
Vbovine spongiform encephalopathy
p1365
sg13
I3
sa(dp1366
g7
I168
sg20
VC0085209
p1367
sg10
I3
sg11
VBSE
p1368
sg13
I1
sasa(dp1369
g2
S'The histopathological diagnosis of BSE, validated on a single section of the medulla for the statutory diagnosis of large numbers of cases, is supplemented where necessary by fibril (SAF) examination which performs similarly to the histological diagnosis in the majority of cases.\n'
p1370
sg4
(lp1371
sg17
(lp1372
(dp1373
g7
I35
sg20
VC0085209
p1374
sg10
I3
sg11
VBSE
p1375
sg13
I1
sasa(dp1376
g2
S'Using hepatocellular carcinoma (HCC) as a cancer model, we show that hypoxia, through stabilization of hypoxia-inducible factor-1 (HIF-1), induces ectoenzyme, ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2/CD39L1), in cancer cells, causing its overexpression in HCC clinical specimens.\n'
p1377
sg4
(lp1378
(dp1379
g7
I103
sg8
g59
sg10
I26
sg11
Vhypoxia-inducible factor-1
p1380
sg13
I2
sa(dp1381
g7
I216
sg8
g59
sg10
I6
sg11
VCD39L1
p1382
sg13
I1
sa(dp1383
g7
I159
sg8
g59
sg10
I48
sg11
Vectonucleoside triphosphate diphosphohydrolase 2
p1384
sg13
I4
sa(dp1385
g7
I209
sg8
g59
sg10
I6
sg11
VENTPD2
p1386
sg13
I1
sa(dp1387
g7
I131
sg8
g59
sg10
I5
sg11
VHIF-1
p1388
sg13
I1
sasg17
(lp1389
(dp1390
g7
I6
sg20
VC2239176
p1391
sg10
I24
sg11
Vhepatocellular carcinoma
p1392
sg13
I2
sa(dp1393
g7
I69
sg20
VC0242184
p1394
sg10
I7
sg11
Vhypoxia
p1395
sg13
I1
sa(dp1396
g7
I32
sg20
VC2239176
p1397
sg10
I3
sg11
VHCC
p1398
sg13
I1
sa(dp1399
g7
I69
sg20
VC0242184
p1400
sg10
I7
sg11
Vhypoxia
p1401
sg13
I1
sa(dp1402
g7
I42
sg20
VC0006826
p1403
sg10
I6
sg11
Vcancer
p1404
sg13
I1
sa(dp1405
g7
I32
sg20
VC2239176
p1406
sg10
I3
sg11
VHCC
p1407
sg13
I1
sa(dp1408
g7
I42
sg20
VC0006826
p1409
sg10
I6
sg11
Vcancer
p1410
sg13
I1
sasa(dp1411
g2
S"Here, the authors show that in hepatocellular carcinoma, hypoxia induces the expression of ENTPD2 on cancer cells leading to elevated extracellular 5'-AMP, which in turn promote the maintenance of MDSCs by preventing their differentiation.\n"
p1412
sg4
(lp1413
(dp1414
g7
I91
sg8
g59
sg10
I6
sg11
VENTPD2
p1415
sg13
I1
sasg17
(lp1416
(dp1417
g7
I57
sg20
VC0242184
p1418
sg10
I7
sg11
Vhypoxia
p1419
sg13
I1
sa(dp1420
g7
I31
sg20
VC1512411
p1421
sg10
I24
sg11
Vhepatocellular carcinoma
p1422
sg13
I2
sa(dp1423
g7
I101
sg20
VC0006826
p1424
sg10
I6
sg11
Vcancer
p1425
sg13
I1
sasa(dp1426
g2
S'Ecto-ATPase gene expression is increased in a human hepatoma whereas it is undetectable in the normal liver.\n'
p1427
sg4
(lp1428
(dp1429
g7
I0
sg8
g59
sg10
I4
sg11
VEcto
p1430
sg13
I1
sa(dp1431
g7
I5
sg8
VP38606
p1432
sg10
I6
sg11
VATPase
p1433
sg13
I1
sasg17
(lp1434
(dp1435
g7
I52
sg20
VC0023903
p1436
sg10
I8
sg11
Vhepatoma
p1437
sg13
I1
sasa(dp1438
g2
S'Those patterns, together with results of enzyme assays, Western blotting, or semiquantitative RT-PCR show that NTPDase2 is the main ectonucleotidase for murine and human hepatoma cells, NTPDase3 for chick hepatocytes and LMH cells, and an E-NPP enzyme for chick cardiac myocytes.\n'
p1439
sg4
(lp1440
(dp1441
g7
I111
sg8
g59
sg10
I8
sg11
VNTPDase2
p1442
sg13
I1
sa(dp1443
g7
I186
sg8
g59
sg10
I8
sg11
VNTPDase3
p1444
sg13
I1
sa(dp1445
g7
I239
sg8
VP01189
p1446
sg10
I12
sg11
VE-NPP enzyme
p1447
sg13
I2
sasg17
(lp1448
(dp1449
g7
I170
sg20
VC0023903
p1450
sg10
I8
sg11
Vhepatoma
p1451
sg13
I1
sasa(dp1452
g2
S'Evidence for NTPDase2 expression was lacking in all cells except the mouse and human hepatoma cells.\n'
p1453
sg4
(lp1454
(dp1455
g7
I13
sg8
g59
sg10
I8
sg11
VNTPDase2
p1456
sg13
I1
sasg17
(lp1457
(dp1458
g7
I85
sg20
VC0023903
p1459
sg10
I8
sg11
Vhepatoma
p1460
sg13
I1
sasa(dp1461
g2
S'TCDD increased expression of the NTPDase2 gene but only in the mouse and not in the human hepatoma cells.\n'
p1462
sg4
(lp1463
(dp1464
g7
I33
sg8
g59
sg10
I13
sg11
VNTPDase2 gene
p1465
sg13
I2
sasg17
(lp1466
(dp1467
g7
I90
sg20
VC0023903
p1468
sg10
I8
sg11
Vhepatoma
p1469
sg13
I1
sasa(dp1470
g2
S'The failure of TCDD to increase ATP metabolism in HUVEC, chick LMH cells, hepatocytes, and cardiac myocytes can be attributed to their lack of NTPDase2 expression, while the increase in ATP metabolism by TCDD in the mouse but not the human hepatoma cells can be explained by differences in TCDD effects on mouse and human hepatoma NTPDase2 gene expression.\n'
p1471
sg4
(lp1472
(dp1473
g7
I143
sg8
g59
sg10
I8
sg11
VNTPDase2
p1474
sg13
I1
sasg17
(lp1475
(dp1476
g7
I240
sg20
VC0023903
p1477
sg10
I8
sg11
Vhepatoma
p1478
sg13
I1
sa(dp1479
g7
I240
sg20
VC0023903
p1480
sg10
I8
sg11
Vhepatoma
p1481
sg13
I1
sasa(dp1482
g2
S'Bile acid transport activity and ecto-ATPase expression were analyzed in primary rat hepatocytes, rat hepatoma HTC cells, and specially adapted HTC (HTC-R) cells using plasma membrane vesicles and Northern blot, slot blot, ribonuclease protection assay, and Western blot analyses.\n'
p1483
sg4
(lp1484
(dp1485
g7
I33
sg8
g59
sg10
I11
sg11
Vecto-ATPase
p1486
sg13
I1
sasg17
(lp1487
(dp1488
g7
I102
sg20
VC0023903
p1489
sg10
I8
sg11
Vhepatoma
p1490
sg13
I1
sa(dp1491
g7
I184
sg20
VC0333262
p1492
sg10
I8
sg11
Vvesicles
p1493
sg13
I1
sasa(dp1494
g2
S'Using this cDNA as a probe to clone the mercurial-insensitive ectoATPase (MI-ectoATPase) of human hepatoma Li-7A cells, the cDNA obtained was that of CEA which has no ATPase activity.\n'
p1495
sg4
(lp1496
(dp1497
g7
I150
sg8
VP40198
p1498
sg10
I3
sg11
VCEA
p1499
sg13
I1
sa(dp1500
g7
I66
sg8
VP38606
p1501
sg10
I6
sg11
VATPase
p1502
sg13
I1
sa(dp1503
g7
I62
sg8
g59
sg10
I10
sg11
VectoATPase
p1504
sg13
I1
sa(dp1505
g7
I74
sg8
g59
sg10
I13
sg11
VMI-ectoATPase
p1506
sg13
I1
sasg17
(lp1507
(dp1508
g7
I98
sg20
VC0023903
p1509
sg10
I8
sg11
Vhepatoma
p1510
sg13
I1
sasa(dp1511
g2
S'A mercurial-insensitive ectoATPase, which was more active with CaATP than with MgATP, was induced when human hepatoma (Li-7A) cells were cultured in the presence of epidermal growth factor (EGF) and cholera toxin.\n'
p1512
sg4
(lp1513
(dp1514
g7
I24
sg8
g59
sg10
I10
sg11
VectoATPase
p1515
sg13
I1
sa(dp1516
g7
I165
sg8
VP01133
p1517
sg10
I47
sg11
Vepidermal growth factor (EGF) and cholera toxin
p1518
sg13
I7
sasg17
(lp1519
(dp1520
g7
I109
sg20
VC0023903
p1521
sg10
I8
sg11
Vhepatoma
p1522
sg13
I1
sa(dp1523
g7
I199
sg20
VC0008354
p1524
sg10
I7
sg11
Vcholera
p1525
sg13
I1
sasa(dp1526
g2
S'Grade 1-2 acneiform skin rash, paronychia, and desquamation, and grade 2-3 dry skin and pruritis were observed.\n'
p1527
sg4
(lp1528
sg17
(lp1529
(dp1530
g7
I75
sg20
VC0151908
p1531
sg10
I8
sg11
Vdry skin
p1532
sg13
I2
sa(dp1533
g7
I88
sg20
VC0033774
p1534
sg10
I8
sg11
Vpruritis
p1535
sg13
I1
sa(dp1536
g7
I31
sg20
VC0030578
p1537
sg10
I10
sg11
Vparonychia
p1538
sg13
I1
sa(dp1539
g7
I20
sg20
VC0015230
p1540
sg10
I9
sg11
Vskin rash
p1541
sg13
I2
sasa(dp1542
g2
S'Our data show that a strong association exists between the presence of DSP and illness duration, HbA1(c), smoking, thereby indicating that cessation of smoking and near normal glycemic control would be additional precautions to delay the beginning or progression of polyneuropathy.\n'
p1543
sg4
(lp1544
(dp1545
g7
I97
sg8
VP69905
p1546
sg10
I4
sg11
VHbA1
p1547
sg13
I1
sasg17
(lp1548
(dp1549
g7
I266
sg20
VC0152025
p1550
sg10
I14
sg11
Vpolyneuropathy
p1551
sg13
I1
sasa(dp1552
g2
S'We investigated the relationship between blood levels of HbA1, an indicator of diabetic control, and the polyneuropathy index (PNI), an indicator of diabetic polyneuropathy.\n'
p1553
sg4
(lp1554
(dp1555
g7
I57
sg8
VP69905
p1556
sg10
I4
sg11
VHbA1
p1557
sg13
I1
sasg17
(lp1558
(dp1559
g7
I105
sg20
VC0152025
p1560
sg10
I14
sg11
Vpolyneuropathy
p1561
sg13
I1
sa(dp1562
g7
I149
sg20
VC0271680
p1563
sg10
I23
sg11
Vdiabetic polyneuropathy
p1564
sg13
I2
sasa(dp1565
g2
S'However, since there were many patients whose HbA1 levels were not correlated with the reduction in PNI, there may be some unknown factors, possibly genetic, that play a role in the progression of polyneuropathy in diabetic patients.\n'
p1566
sg4
(lp1567
(dp1568
g7
I46
sg8
VP69905
p1569
sg10
I4
sg11
VHbA1
p1570
sg13
I1
sasg17
(lp1571
(dp1572
g7
I197
sg20
VC0152025
p1573
sg10
I14
sg11
Vpolyneuropathy
p1574
sg13
I1
sasa(dp1575
g2
S'Therefore, serum miR-200c and miR-371-5p have ability as the useful diagnostic biomarkers and therapeutic targets in Kawasaki disease.\n'
p1576
sg4
(lp1577
(dp1578
g7
I30
sg8
g59
sg10
I10
sg11
VmiR-371-5p
p1579
sg13
I1
sa(dp1580
g7
I17
sg8
g59
sg10
I8
sg11
VmiR-200c
p1581
sg13
I1
sasg17
(lp1582
(dp1583
g7
I117
sg20
VC0026691
p1584
sg10
I16
sg11
VKawasaki disease
p1585
sg13
I2
sasa(dp1586
g2
S'The association between genetic variation in the SSTR1-MIPOL1 and TSLP-SLC25A46 loci and age at onset is the first report of age at onset effects in allergic rhinitis.\n'
p1587
sg4
(lp1588
(dp1589
g7
I55
sg8
g59
sg10
I6
sg11
VMIPOL1
p1590
sg13
I1
sa(dp1591
g7
I66
sg8
g59
sg10
I18
sg11
VTSLP-SLC25A46 loci
p1592
sg13
I2
sa(dp1593
g7
I49
sg8
VP30872
p1594
sg10
I5
sg11
VSSTR1
p1595
sg13
I1
sasg17
(lp1596
(dp1597
g7
I149
sg20
VC2607914
p1598
sg10
I17
sg11
Vallergic rhinitis
p1599
sg13
I2
sasa(dp1600
g2
S'Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression in tumor samples of several microRNAs, including the miR-200 family, along progression from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b and miR-7 in IDC patients with regional or distant metastases relative to patients with primary node-negative tumors.\n'
p1601
sg4
(lp1602
(dp1603
g7
I140
sg8
g59
sg10
I14
sg11
VmiR-200 family
p1604
sg13
I2
sa(dp1605
g7
I261
sg8
g59
sg10
I8
sg11
VmiR-200b
p1606
sg13
I1
sa(dp1607
g7
I274
sg8
g59
sg10
I5
sg11
VmiR-7
p1608
sg13
I1
sasg17
(lp1609
(dp1610
g7
I205
sg20
VC0027627
p1611
sg10
I10
sg11
Vmetastases
p1612
sg13
I1
sa(dp1613
g7
I187
sg20
VC0027651
p1614
sg10
I6
sg11
Vtumors
p1615
sg13
I1
sa(dp1616
g7
I12
sg20
VC1134719
p1617
sg10
I29
sg11
Vinvasive ductal breast cancer
p1618
sg13
I4
sa(dp1619
g7
I205
sg20
VC0027627
p1620
sg10
I10
sg11
Vmetastases
p1621
sg13
I1
sa(dp1622
g7
I90
sg20
VC0027651
p1623
sg10
I5
sg11
Vtumor
p1624
sg13
I1
sa(dp1625
g7
I43
sg20
VC1449563
p1626
sg10
I3
sg11
VIDC
p1627
sg13
I1
sa(dp1628
g7
I179
sg20
VC0677930
p1629
sg10
I14
sg11
Vprimary tumors
p1630
sg13
I2
sa(dp1631
g7
I43
sg20
VC1449563
p1632
sg10
I3
sg11
VIDC
p1633
sg13
I1
sasa(dp1634
g2
S'Our data suggest that miR-200b regulates EMT of chemo-resistant breast cancer cells by targeting FN1.\n'
p1635
sg4
(lp1636
(dp1637
g7
I22
sg8
g59
sg10
I8
sg11
VmiR-200b
p1638
sg13
I1
sasg17
(lp1639
(dp1640
g7
I64
sg20
VC0678222
p1641
sg10
I13
sg11
Vbreast cancer
p1642
sg13
I2
sasa(dp1643
g2
S'miR-200b-based therapy may be an effective strategy in treating advanced breast cancer patients.\n'
p1644
sg4
(lp1645
(dp1646
g7
I0
sg8
g59
sg10
I3
sg11
VmiR
p1647
sg13
I1
sasg17
(lp1648
(dp1649
g7
I73
sg20
VC0678222
p1650
sg10
I13
sg11
Vbreast cancer
p1651
sg13
I2
sasa(dp1652
g2
S'Here, we report for the first time that the suppression of ERBeta in MDA-MB-231 breast cancer cells leads to significant changes in the expression profiles of specific microRNAs, including miR-10b, miR-200b and miR-145.\n'
p1653
sg4
(lp1654
(dp1655
g7
I189
sg8
g59
sg10
I7
sg11
VmiR-10b
p1656
sg13
I1
sa(dp1657
g7
I211
sg8
g59
sg10
I7
sg11
VmiR-145
p1658
sg13
I1
sa(dp1659
g7
I198
sg8
g59
sg10
I8
sg11
VmiR-200b
p1660
sg13
I1
sasg17
(lp1661
(dp1662
g7
I44
sg20
VC0221103
p1663
sg10
I11
sg11
Vsuppression
p1664
sg13
I1
sa(dp1665
g7
I80
sg20
VC0678222
p1666
sg10
I13
sg11
Vbreast cancer
p1667
sg13
I2
sasa(dp1668
g2
S'We found that miR-200b level was decreased, whereas that of FUT4 was increased in tissues and serum of breast cancer compared with that in the control by real-time PCR, western blotting and enzyme-linked immunosorbent assay.\n'
p1669
sg4
(lp1670
(dp1671
g7
I60
sg8
VP22083
p1672
sg10
I4
sg11
VFUT4
p1673
sg13
I1
sa(dp1674
g7
I14
sg8
g59
sg10
I8
sg11
VmiR-200b
p1675
sg13
I1
sasg17
(lp1676
(dp1677
g7
I103
sg20
VC0678222
p1678
sg10
I13
sg11
Vbreast cancer
p1679
sg13
I2
sasa(dp1680
g2
S'The results also showed that miR-200b suppressed FUT4 expression and inhibited tumor growth and metastasis in MCF-7 and MDA-MB-231 breast cancer cells, as well as in the xenografted tumor tissues and metastatic lung tissues.\n'
p1681
sg4
(lp1682
(dp1683
g7
I29
sg8
g59
sg10
I8
sg11
VmiR-200b
p1684
sg13
I1
sa(dp1685
g7
I49
sg8
VP22083
p1686
sg10
I4
sg11
VFUT4
p1687
sg13
I1
sasg17
(lp1688
(dp1689
g7
I96
sg20
VC0027627
p1690
sg10
I10
sg11
Vmetastasis
p1691
sg13
I1
sa(dp1692
g7
I79
sg20
VC0027651
p1693
sg10
I5
sg11
Vtumor
p1694
sg13
I1
sa(dp1695
g7
I79
sg20
VC0598934
p1696
sg10
I12
sg11
Vtumor growth
p1697
sg13
I2
sa(dp1698
g7
I131
sg20
VC0678222
p1699
sg10
I13
sg11
Vbreast cancer
p1700
sg13
I2
sasa(dp1701
g2
S'In conclusion, the study highlights that FUT4 could apply as a novel target for miR-200b that suppress the proliferation and metastasis of breast cancer cells by reducing Alfa1,3-fucosylation and LeY biosynthesis of glycoproteins.\n'
p1702
sg4
(lp1703
(dp1704
g7
I80
sg8
g59
sg10
I8
sg11
VmiR-200b
p1705
sg13
I1
sa(dp1706
g7
I41
sg8
VP22083
p1707
sg10
I4
sg11
VFUT4
p1708
sg13
I1
sasg17
(lp1709
(dp1710
g7
I125
sg20
VC0027627
p1711
sg10
I10
sg11
Vmetastasis
p1712
sg13
I1
sa(dp1713
g7
I107
sg20
VC0334094
p1714
sg10
I13
sg11
Vproliferation
p1715
sg13
I1
sa(dp1716
g7
I139
sg20
VC0678222
p1717
sg10
I13
sg11
Vbreast cancer
p1718
sg13
I2
sasa(dp1719
g2
S'miR-200b and FUT4 are potential diagnostic and therapeutic targets for breast cancer.\n'
p1720
sg4
(lp1721
(dp1722
g7
I13
sg8
VP22083
p1723
sg10
I4
sg11
VFUT4
p1724
sg13
I1
sa(dp1725
g7
I0
sg8
g59
sg10
I8
sg11
VmiR-200b
p1726
sg13
I1
sasg17
(lp1727
(dp1728
g7
I71
sg20
VC0678222
p1729
sg10
I13
sg11
Vbreast cancer
p1730
sg13
I2
sasa(dp1731
g2
S'We isolated cells from the primary mammary tumor, the circulation, and metastatic lesions in the lung in TA2 mice and found that the long noncoding RNA (lncRNA) H19 mediated EMT and MET by differentially acting as a sponge for the microRNAs miR-200b/c and let-7b.\n'
p1732
sg4
(lp1733
(dp1734
g7
I241
sg8
g59
sg10
I3
sg11
VmiR
p1735
sg13
I1
sa(dp1736
g7
I174
sg8
g59
sg10
I3
sg11
VEMT
p1737
sg13
I1
sasg17
(lp1738
(dp1739
g7
I35
sg20
VC1458155
p1740
sg10
I13
sg11
Vmammary tumor
p1741
sg13
I2
sasa(dp1742
g2
S'MicroRNA-200b (miR-200b) is a tumor suppressor in multiple tumor types, including gastric cancer, breast cancer, ovarian cancer and glioma.\n'
p1743
sg4
(lp1744
(dp1745
g7
I0
sg8
g59
sg10
I13
sg11
VMicroRNA-200b
p1746
sg13
I1
sa(dp1747
g7
I15
sg8
g59
sg10
I8
sg11
VmiR-200b
p1748
sg13
I1
sasg17
(lp1749
(dp1750
g7
I30
sg20
VC0027651
p1751
sg10
I5
sg11
Vtumor
p1752
sg13
I1
sa(dp1753
g7
I90
sg20
VC0006826
p1754
sg10
I6
sg11
Vcancer
p1755
sg13
I1
sa(dp1756
g7
I105
sg20
VC1140680
p1757
sg10
I15
sg11
Vcancer, ovarian
p1758
sg13
I2
sa(dp1759
g7
I132
sg20
VC0017638
p1760
sg10
I6
sg11
Vglioma
p1761
sg13
I1
sa(dp1762
g7
I30
sg20
VC0027651
p1763
sg10
I5
sg11
Vtumor
p1764
sg13
I1
sa(dp1765
g7
I90
sg20
VC0006142
p1766
sg10
I14
sg11
Vcancer, breast
p1767
sg13
I2
sasa(dp1768
g2
S'The aim of this study was to investigate the role of miR-222, miR-29a, miR-34a, miR-130a, miR-90b, miR-200b, miR-452, miR-197, miR-138, miR-210, miR-423, miR-4298, miR-4644, miR-139, miR-1246, miR-1268a, miR-140, miR-149, miR-3178, miR-3613, miR-4258, miR-574, miR-671, miR-6780b, miR-7107, miR-744 and miR-7847 linked to drug resistance in breast cancer formalin-fixed paraffin-embedded tissues and the association of prognosis with miRNAs, thus providing effective targets in chemotherapy, as well as potential biomarkers for guiding effective treatments of breast cancer.\n'
p1769
sg4
(lp1770
(dp1771
g7
I174
sg8
g59
sg10
I7
sg11
VmiR-139
p1772
sg13
I1
sa(dp1773
g7
I222
sg8
g59
sg10
I8
sg11
VmiR-3178
p1774
sg13
I1
sa(dp1775
g7
I242
sg8
g59
sg10
I8
sg11
VmiR-4258
p1776
sg13
I1
sa(dp1777
g7
I270
sg8
g59
sg10
I9
sg11
VmiR-6780b
p1778
sg13
I1
sa(dp1779
g7
I118
sg8
g59
sg10
I7
sg11
VmiR-197
p1780
sg13
I1
sa(dp1781
g7
I154
sg8
g59
sg10
I8
sg11
VmiR-4298
p1782
sg13
I1
sa(dp1783
g7
I261
sg8
g59
sg10
I7
sg11
VmiR-671
p1784
sg13
I1
sa(dp1785
g7
I183
sg8
g59
sg10
I8
sg11
VmiR-1246
p1786
sg13
I1
sa(dp1787
g7
I193
sg8
g59
sg10
I9
sg11
VmiR-1268a
p1788
sg13
I1
sa(dp1789
g7
I99
sg8
g59
sg10
I8
sg11
VmiR-200b
p1790
sg13
I1
sa(dp1791
g7
I53
sg8
g59
sg10
I7
sg11
VmiR-222
p1792
sg13
I1
sa(dp1793
g7
I281
sg8
g59
sg10
I8
sg11
VmiR-7107
p1794
sg13
I1
sa(dp1795
g7
I62
sg8
g59
sg10
I7
sg11
VmiR-29a
p1796
sg13
I1
sa(dp1797
g7
I145
sg8
g59
sg10
I7
sg11
VmiR-423
p1798
sg13
I1
sa(dp1799
g7
I213
sg8
g59
sg10
I7
sg11
VmiR-149
p1800
sg13
I1
sa(dp1801
g7
I204
sg8
g59
sg10
I7
sg11
VmiR-140
p1802
sg13
I1
sa(dp1803
g7
I80
sg8
g59
sg10
I8
sg11
VmiR-130a
p1804
sg13
I1
sa(dp1805
g7
I127
sg8
g59
sg10
I7
sg11
VmiR-138
p1806
sg13
I1
sa(dp1807
g7
I109
sg8
g59
sg10
I7
sg11
VmiR-452
p1808
sg13
I1
sa(dp1809
g7
I232
sg8
g59
sg10
I8
sg11
VmiR-3613
p1810
sg13
I1
sa(dp1811
g7
I291
sg8
g59
sg10
I7
sg11
VmiR-744
p1812
sg13
I1
sa(dp1813
g7
I71
sg8
g59
sg10
I7
sg11
VmiR-34a
p1814
sg13
I1
sa(dp1815
g7
I252
sg8
g59
sg10
I7
sg11
VmiR-574
p1816
sg13
I1
sa(dp1817
g7
I164
sg8
g59
sg10
I8
sg11
VmiR-4644
p1818
sg13
I1
sa(dp1819
g7
I90
sg8
g59
sg10
I7
sg11
VmiR-90b
p1820
sg13
I1
sa(dp1821
g7
I136
sg8
g59
sg10
I7
sg11
VmiR-210
p1822
sg13
I1
sa(dp1823
g7
I303
sg8
g59
sg10
I8
sg11
VmiR-7847
p1824
sg13
I1
sasg17
(lp1825
(dp1826
g7
I341
sg20
VC0678222
p1827
sg10
I13
sg11
Vbreast cancer
p1828
sg13
I2
sa(dp1829
g7
I341
sg20
VC0678222
p1830
sg10
I13
sg11
Vbreast cancer
p1831
sg13
I2
sasa(dp1832
g2
S'The study was performed in group of 158 patients (145 women, 13 men) operated because of non-toxic goitre --115 patients--(SNN) and toxic--43 patients--(SNT).\n'
p1833
sg4
(lp1834
sg17
(lp1835
(dp1836
g7
I89
sg20
VC0221777
p1837
sg10
I16
sg11
Vnon-toxic goitre
p1838
sg13
I2
sasa(dp1839
g2
S'DS treatment neither caused adverse events, particularly bleeding or thrombocytopenia, nor induced significant changes in serum albumin, total bilirubin, prothrombin time, and residual liver function.\n'
p1840
sg4
(lp1841
(dp1842
g7
I128
sg8
VP00441
p1843
sg10
I7
sg11
Valbumin
p1844
sg13
I1
sa(dp1845
g7
I154
sg8
VP00734
p1846
sg10
I11
sg11
Vprothrombin
p1847
sg13
I1
sasg17
(lp1848
(dp1849
g7
I57
sg20
VC0019080
p1850
sg10
I8
sg11
Vbleeding
p1851
sg13
I1
sasa(dp1852
g2
S'All 5 patients had varying severities of leukopenia, anemia, thrombocytopenia, prolonged prothrombin time, and hypofibrinogenemia.\n'
p1853
sg4
(lp1854
(dp1855
g7
I89
sg8
VP00734
p1856
sg10
I11
sg11
Vprothrombin
p1857
sg13
I1
sasg17
(lp1858
(dp1859
g7
I53
sg20
VC0002871
p1860
sg10
I6
sg11
Vanemia
p1861
sg13
I1
sa(dp1862
g7
I41
sg20
VC0023530
p1863
sg10
I10
sg11
Vleukopenia
p1864
sg13
I1
sa(dp1865
g7
I111
sg20
VC0553681
p1866
sg10
I18
sg11
Vhypofibrinogenemia
p1867
sg13
I1
sasa(dp1868
g2
S'Accumulating evidence has demonstrated that the Sigma-1 receptor (Sigma-1R) possesses neuroprotective effects and is a potential novel therapeutic target for certain psychiatric diseases, including post-traumatic stress disorder (PTSD) accompanied with anxiety disorder.\n'
p1869
sg4
(lp1870
(dp1871
g7
I48
sg8
g59
sg10
I16
sg11
VSigma-1 receptor
p1872
sg13
I2
sa(dp1873
g7
I66
sg8
g59
sg10
I8
sg11
VSigma-1R
p1874
sg13
I1
sasg17
(lp1875
(dp1876
g7
I230
sg20
VC0038436
p1877
sg10
I4
sg11
VPTSD
p1878
sg13
I1
sa(dp1879
g7
I198
sg20
VC0038436
p1880
sg10
I30
sg11
Vpost-traumatic stress disorder
p1881
sg13
I3
sa(dp1882
g7
I253
sg20
VC0003469
p1883
sg10
I16
sg11
Vanxiety disorder
p1884
sg13
I2
sa(dp1885
g7
I76
sg20
VC0850310
p1886
sg10
I9
sg11
Vpossesses
p1887
sg13
I1
sasa(dp1888
g2
S'Molecular genetic studies point to potential risk loci of psychotic depression shared with schizoaffective disorder (1q42, 22q11, 19p13), depression, bipolar disorder, and schizophrenia (6p, 8p22, 10p13-12, 10p14, 13q13-14, 13q32, 18p, 22q11-13) and several vulnerability genes possibly contributing to an increased risk of psychotic symptoms in depression (eg, BDNF, DBH, DTNBP1, DRD2, DRD4, GSK-3beta, MAO-A).\n'
p1889
sg4
(lp1890
(dp1891
g7
I404
sg8
VP21397
p1892
sg10
I5
sg11
VMAO-A
p1893
sg13
I1
sa(dp1894
g7
I373
sg8
g59
sg10
I6
sg11
VDTNBP1
p1895
sg13
I1
sa(dp1896
g7
I381
sg8
VP14416
p1897
sg10
I4
sg11
VDRD2
p1898
sg13
I1
sa(dp1899
g7
I393
sg8
VP49841
p1900
sg10
I9
sg11
VGSK-3beta
p1901
sg13
I1
sa(dp1902
g7
I368
sg8
VP09172
p1903
sg10
I3
sg11
VDBH
p1904
sg13
I1
sa(dp1905
g7
I387
sg8
VP21917
p1906
sg10
I4
sg11
VDRD4
p1907
sg13
I1
sasg17
(lp1908
(dp1909
g7
I172
sg20
VC0036341
p1910
sg10
I13
sg11
Vschizophrenia
p1911
sg13
I1
sa(dp1912
g7
I138
sg20
VC0005587
p1913
sg10
I19
sg11
Vdepression, bipolar
p1914
sg13
I2
sa(dp1915
g7
I91
sg20
VC0036337
p1916
sg10
I24
sg11
Vschizoaffective disorder
p1917
sg13
I2
sa(dp1918
g7
I324
sg20
VC0871189
p1919
sg10
I18
sg11
Vpsychotic symptoms
p1920
sg13
I2
sa(dp1921
g7
I58
sg20
VC0270458
p1922
sg10
I20
sg11
Vpsychotic depression
p1923
sg13
I2
sa(dp1924
g7
I68
sg20
VC0011581
p1925
sg10
I10
sg11
Vdepression
p1926
sg13
I1
sasa(dp1927
g2
S'In this 26-week, prospective, open-label, double-blind, parallel-group study, 90 patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder were recruited and divided into two groups according to their DRD2 genotype (A1A1, n=14; A1A2+A2A2, n=76).\n'
p1928
sg4
(lp1929
(dp1930
g7
I227
sg8
VP14416
p1931
sg10
I13
sg11
VDRD2 genotype
p1932
sg13
I2
sasg17
(lp1933
(dp1934
g7
I95
sg20
VC0036341
p1935
sg10
I13
sg11
Vschizophrenia
p1936
sg13
I1
sa(dp1937
g7
I139
sg20
VC0036358
p1938
sg10
I25
sg11
Vschizophreniform disorder
p1939
sg13
I2
sa(dp1940
g7
I110
sg20
VC0036337
p1941
sg10
I24
sg11
Vschizoaffective disorder
p1942
sg13
I2
sa(dp1943
g7
I49
sg20
VC0456909
p1944
sg10
I5
sg11
Vblind
p1945
sg13
I1
sasa(dp1946
g2
S'We tested whether allelic variation at DRD2 and five surrounding loci cosegregated with schizophrenia in 112 small- to moderate-size Irish families containing two or more members affected with schizophrenia or schizoaffective disorder, defined by DSM-III-R.\n'
p1947
sg4
(lp1948
(dp1949
g7
I39
sg8
VP14416
p1950
sg10
I4
sg11
VDRD2
p1951
sg13
I1
sasg17
(lp1952
(dp1953
g7
I88
sg20
VC0036341
p1954
sg10
I13
sg11
Vschizophrenia
p1955
sg13
I1
sa(dp1956
g7
I210
sg20
VC0036337
p1957
sg10
I24
sg11
Vschizoaffective disorder
p1958
sg13
I2
sa(dp1959
g7
I88
sg20
VC0036341
p1960
sg10
I13
sg11
Vschizophrenia
p1961
sg13
I1
sasa(dp1962
g2
S'Therefore, niacin was effective against iodoacetamide-induced colitis through ameliorating pathologic angiogenesis and inflammatory changes in a GPR109A-dependent manner.\n'
p1963
sg4
(lp1964
(dp1965
g7
I145
sg8
g59
sg10
I7
sg11
VGPR109A
p1966
sg13
I1
sasg17
(lp1967
(dp1968
g7
I62
sg20
VC0009319
p1969
sg10
I7
sg11
Vcolitis
p1970
sg13
I1
sa(dp1971
g7
I91
sg20
VC0027686
p1972
sg10
I23
sg11
Vpathologic angiogenesis
p1973
sg13
I2
sasa(dp1974
g2
S'Niacin, a pharmacological Gpr109a agonist, suppressed colitis and colon cancer in a Gpr109a-dependent manner.\n'
p1975
sg4
(lp1976
(dp1977
g7
I26
sg8
g59
sg10
I7
sg11
VGpr109a
p1978
sg13
I1
sasg17
(lp1979
(dp1980
g7
I66
sg20
VC0699790
p1981
sg10
I12
sg11
Vcolon cancer
p1982
sg13
I2
sa(dp1983
g7
I54
sg20
VC0009319
p1984
sg10
I7
sg11
Vcolitis
p1985
sg13
I1
sasa(dp1986
g2
S'The gene fragment encoding 19 kDa antigen and the upstream control element (19-ss) was amplified by PCR from the mycobacteria tuberculosis H37Rv.Subsequently, the 19-ss gene was cloned into the E.coli-BCG shuttle vector pOLYG, which can schlepped and expressed exogenous antigen gene on cell wall of mycobacteria and containing the Der p2 gene.\n'
p1987
sg4
(lp1988
sg17
(lp1989
(dp1990
g7
I126
sg20
VC0041296
p1991
sg10
I12
sg11
Vtuberculosis
p1992
sg13
I1
sasa(dp1993
g2
S'In conclusion, this study demonstrated that E. pekinensis induces inflammation and increases the expression of AQP3, causing disorders of water metabolism, which may lead to gastrointestinal side effects such as diarrhea.\n'
p1994
sg4
(lp1995
(dp1996
g7
I111
sg8
g59
sg10
I4
sg11
VAQP3
p1997
sg13
I1
sasg17
(lp1998
(dp1999
g7
I66
sg20
VC0021368
p2000
sg10
I12
sg11
Vinflammation
p2001
sg13
I1
sa(dp2002
g7
I212
sg20
VC0011991
p2003
sg10
I8
sg11
Vdiarrhea
p2004
sg13
I1
sasa(dp2005
g2
S'Since trophoblast apoptosis is exacerbated in preeclampsia, we hypothesized that placental AQP3 is increased in these placentas in order to trigger the programmed cell death.\n'
p2006
sg4
(lp2007
(dp2008
g7
I91
sg8
g59
sg10
I4
sg11
VAQP3
p2009
sg13
I1
sasg17
(lp2010
(dp2011
g7
I46
sg20
VC0032914
p2012
sg10
I12
sg11
Vpreeclampsia
p2013
sg13
I1
sasa(dp2014
g2
S'Here, we examined mRNA levels, protein expression and localization of AQP3 in placentas from pregnancies complicated by preeclampsia and against what we expected, we found that AQP3 expression was significantly reduced, both at protein and mRNA levels, compared to normal placentas.\n'
p2015
sg4
(lp2016
(dp2017
g7
I70
sg8
g59
sg10
I4
sg11
VAQP3
p2018
sg13
I1
sa(dp2019
g7
I70
sg8
g59
sg10
I4
sg11
VAQP3
p2020
sg13
I1
sasg17
(lp2021
(dp2022
g7
I120
sg20
VC0032914
p2023
sg10
I12
sg11
Vpreeclampsia
p2024
sg13
I1
sasa(dp2025
g2
S'In the light of our results, further studies are required to evaluate whether the decreased expression of AQP3 might be an adaptive response of the placenta to reduce the trophoblast apoptosis, which is related to the clinical manifestations of preeclampsia.\n'
p2026
sg4
(lp2027
(dp2028
g7
I106
sg8
g59
sg10
I4
sg11
VAQP3
p2029
sg13
I1
sasg17
(lp2030
(dp2031
g7
I245
sg20
VC0032914
p2032
sg10
I12
sg11
Vpreeclampsia
p2033
sg13
I1
sasa(dp2034
g2
S'We hypothesized that AQP3 expression in intestinal epithelial cells is altered in intestinal inflammation and that these changes are driven by tumor necrosis factor (TNF) Alfa Human colonic adenocarcinoma (HT-29) cells were treated with TNFAlfa to investigate signaling mechanisms in vitro.\n'
p2035
sg4
(lp2036
(dp2037
g7
I166
sg8
VP01375
p2038
sg10
I3
sg11
VTNF
p2039
sg13
I1
sa(dp2040
g7
I21
sg8
g59
sg10
I4
sg11
VAQP3
p2041
sg13
I1
sa(dp2042
g7
I143
sg8
VP01375
p2043
sg10
I21
sg11
Vtumor necrosis factor
p2044
sg13
I3
sasg17
(lp2045
(dp2046
g7
I93
sg20
VC0021368
p2047
sg10
I12
sg11
Vinflammation
p2048
sg13
I1
sa(dp2049
g7
I143
sg20
VC0333516
p2050
sg10
I14
sg11
Vtumor necrosis
p2051
sg13
I2
sa(dp2052
g7
I182
sg20
VC0338106
p2053
sg10
I22
sg11
Vcolonic adenocarcinoma
p2054
sg13
I2
sasa(dp2055
g2
S'Increasing evidence suggests that the water/glycerol channel aquaporin-3 (AQP3) plays a pivotal role in cancer metastasis.\n'
p2056
sg4
(lp2057
(dp2058
g7
I74
sg8
g59
sg10
I4
sg11
VAQP3
p2059
sg13
I1
sa(dp2060
g7
I61
sg8
g59
sg10
I11
sg11
Vaquaporin-3
p2061
sg13
I1
sasg17
(lp2062
(dp2063
g7
I104
sg20
VC0006826
p2064
sg10
I6
sg11
Vcancer
p2065
sg13
I1
sa(dp2066
g7
I111
sg20
VC0027627
p2067
sg10
I10
sg11
Vmetastasis
p2068
sg13
I1
sasa(dp2069
g2
S'AQP3 knockout mice were resistant to skin tumor formation and overexpression correlated with metastasis and poor prognosis in patients with breast or gastric cancer.\n'
p2070
sg4
(lp2071
(dp2072
g7
I0
sg8
g59
sg10
I4
sg11
VAQP3
p2073
sg13
I1
sasg17
(lp2074
(dp2075
g7
I150
sg20
VC0024623
p2076
sg10
I14
sg11
Vgastric cancer
p2077
sg13
I2
sa(dp2078
g7
I37
sg20
VC0037286
p2079
sg10
I10
sg11
Vskin tumor
p2080
sg13
I2
sa(dp2081
g7
I93
sg20
VC0027627
p2082
sg10
I10
sg11
Vmetastasis
p2083
sg13
I1
sasa(dp2084
g2
S'In cultured cancer cells, increased AQP3 expression stimulated several intracellular signaling pathways and resulted in increased cell proliferation, migration, and invasion as well as aggravation of epithelial-to-mesenchymal transition.\n'
p2085
sg4
(lp2086
(dp2087
g7
I36
sg8
g59
sg10
I4
sg11
VAQP3
p2088
sg13
I1
sasg17
(lp2089
(dp2090
g7
I135
sg20
VC0334094
p2091
sg10
I13
sg11
Vproliferation
p2092
sg13
I1
sa(dp2093
g7
I12
sg20
VC0006826
p2094
sg10
I6
sg11
Vcancer
p2095
sg13
I1
sa(dp2096
g7
I226
sg20
VC0599156
p2097
sg10
I10
sg11
Vtransition
p2098
sg13
I1
sa(dp2099
g7
I165
sg20
VC2699153
p2100
sg10
I8
sg11
Vinvasion
p2101
sg13
I1
sasa(dp2102
g2
S'Here, we give a thorough review of current knowledge regarding AQP3 expression in cancer and how AQP3 contributes to cancer progression via signaling that modulates cellular mechanisms.\n'
p2103
sg4
(lp2104
(dp2105
g7
I63
sg8
g59
sg10
I4
sg11
VAQP3
p2106
sg13
I1
sa(dp2107
g7
I63
sg8
g59
sg10
I4
sg11
VAQP3
p2108
sg13
I1
sasg17
(lp2109
(dp2110
g7
I117
sg20
VC0178874
p2111
sg10
I18
sg11
Vcancer progression
p2112
sg13
I2
sa(dp2113
g7
I82
sg20
VC0006826
p2114
sg10
I6
sg11
Vcancer
p2115
sg13
I1
sasa(dp2116
g2
S'This review article will expand our understanding of the known pathophysiological findings regarding AQP3 in cancer.\n'
p2117
sg4
(lp2118
(dp2119
g7
I101
sg8
g59
sg10
I4
sg11
VAQP3
p2120
sg13
I1
sasg17
(lp2121
(dp2122
g7
I109
sg20
VC0006826
p2123
sg10
I6
sg11
Vcancer
p2124
sg13
I1
sasa(dp2125
g2
S'However, the relationships of AQP3 with GIM classification and with other proteins, and their roles in the transition from GIM to gastric carcinoma (GC) remain unknown.\n'
p2126
sg4
(lp2127
(dp2128
g7
I30
sg8
g59
sg10
I4
sg11
VAQP3
p2129
sg13
I1
sasg17
(lp2130
(dp2131
g7
I149
sg20
VC0699791
p2132
sg10
I2
sg11
VGC
p2133
sg13
I1
sa(dp2134
g7
I107
sg20
VC0599156
p2135
sg10
I10
sg11
Vtransition
p2136
sg13
I1
sa(dp2137
g7
I130
sg20
VC0699791
p2138
sg10
I17
sg11
Vgastric carcinoma
p2139
sg13
I2
sasa(dp2140
g2
S'The expression of retinoid X receptor Gamma (RXRGamma) and the clinicopathological parameters of total 69 patients with papillary thyroid carcinoma (PTC) larger than 1 cm were examined.\n'
p2141
sg4
(lp2142
(dp2143
g7
I18
sg8
VP48443
p2144
sg10
I25
sg11
Vretinoid X receptor Gamma
p2145
sg13
I4
sa(dp2146
g7
I45
sg8
VP48443
p2147
sg10
I8
sg11
VRXRGamma
p2148
sg13
I1
sasg17
(lp2149
(dp2150
g7
I120
sg20
VC0238463
p2151
sg10
I27
sg11
Vpapillary thyroid carcinoma
p2152
sg13
I3
sa(dp2153
g7
I149
sg20
VC0238463
p2154
sg10
I3
sg11
VPTC
p2155
sg13
I1
sasa(dp2156
g2
S'LGD1069 therapy decreases proliferation in an anaplastic thyroid cancer cell line that expresses retinoid X receptor-gamma, and this effect is confirmed with decreased tumor size in vivo in a nude mouse model.\n'
p2157
sg4
(lp2158
(dp2159
g7
I97
sg8
VP48443
p2160
sg10
I25
sg11
Vretinoid X receptor-gamma
p2161
sg13
I3
sasg17
(lp2162
(dp2163
g7
I46
sg20
VC0238461
p2164
sg10
I25
sg11
Vanaplastic thyroid cancer
p2165
sg13
I3
sa(dp2166
g7
I168
sg20
VC0027651
p2167
sg10
I5
sg11
Vtumor
p2168
sg13
I1
sa(dp2169
g7
I26
sg20
VC0334094
p2170
sg10
I13
sg11
Vproliferation
p2171
sg13
I1
sasa(dp2172
g2
S'The possibility should be considered to use cis-retinoic acid as an independent therapeutic approach in patients with radioiodine non-avid foci of thyroid carcinoma especially those showing high expression of RARb and RXRg receptors.\n'
p2173
sg4
(lp2174
(dp2175
g7
I209
sg8
VP10826
p2176
sg10
I4
sg11
VRARb
p2177
sg13
I1
sa(dp2178
g7
I218
sg8
VP48443
p2179
sg10
I14
sg11
VRXRg receptors
p2180
sg13
I2
sasg17
(lp2181
(dp2182
g7
I147
sg20
VC0549473
p2183
sg10
I17
sg11
Vthyroid carcinoma
p2184
sg13
I2
sa(dp2185
g7
I44
sg20
VC0007099
p2186
sg10
I3
sg11
Vcis
p2187
sg13
I1
sasa(dp2188
g2
S'We studied three thyroid carcinoma cell lines: BHP 5-16 (PPARgamma-/RXRgamma+), BHP 2-7 (PPARgamma+/-/RXRgamma-), and DRO-90 (RXRgamma+/PPARgamma+).\n'
p2189
sg4
(lp2190
(dp2191
g7
I118
sg8
VP84090
p2192
sg10
I6
sg11
VDRO-90
p2193
sg13
I1
sa(dp2194
g7
I68
sg8
VP48443
p2195
sg10
I9
sg11
VRXRgamma+
p2196
sg13
I1
sa(dp2197
g7
I80
sg8
VP48443
p2198
sg10
I32
sg11
VBHP 2-7 (PPARgamma+/-/RXRgamma-)
p2199
sg13
I3
sasg17
(lp2200
(dp2201
g7
I17
sg20
VC0549473
p2202
sg10
I17
sg11
Vthyroid carcinoma
p2203
sg13
I2
sasa(dp2204
g2
S'The in vivo studies on the subcutaneous human ovarian carcinoma SKOV-3 xenograft model confirmed that PEG-P(LG-DTDP-Pt) micelles showed significant antitumor activity and reduced side effects, compared with free cisplatin.\n'
p2205
sg4
(lp2206
(dp2207
g7
I102
sg8
VP09466
p2208
sg10
I5
sg11
VPEG-P
p2209
sg13
I1
sasg17
(lp2210
(dp2211
g7
I46
sg20
VC0029925
p2212
sg10
I17
sg11
Vovarian carcinoma
p2213
sg13
I2
sasa(dp2214
g2
S'PtBz-SFNs trigger strong cytotoxic effects against human ovarian carcinoma A2780 cells and their cisplatin-resistant variant A2780cisR cells.\n'
p2215
sg4
(lp2216
(dp2217
g7
I0
sg8
VP31947
p2218
sg10
I9
sg11
VPtBz-SFNs
p2219
sg13
I1
sasg17
(lp2220
(dp2221
g7
I57
sg20
VC0029925
p2222
sg10
I17
sg11
Vovarian carcinoma
p2223
sg13
I2
sasa(dp2224
g2
S'trans-7,8, the neutral cis- or trans-[PtCl2{NH=C(NH2)R}2] (cis-1-3 and trans-1-3) and the cationic cis- or trans-[Pt(NH3)2{NH=C(NH2)R}2](Cl)2 (cis-4-6 and trans-4-6) (R=NMe2 [1,4], NEt2 [2,5], NC5H10 [3,6]) in two human cancer cell lines, CH1 (ovarian carcinoma) and SW480 (colon cancer), confirmed that the cytotoxicity of several trans-configured (trans-3,6) complexes is higher than that of cis-congeners (cis-3,6).\n'
p2225
sg4
(lp2226
(dp2227
g7
I239
sg8
g59
sg10
I3
sg11
VCH1
p2228
sg13
I1
sasg17
(lp2229
(dp2230
g7
I23
sg20
VC0007099
p2231
sg10
I3
sg11
Vcis
p2232
sg13
I1
sa(dp2233
g7
I308
sg20
VC0596402
p2234
sg10
I12
sg11
Vcytotoxicity
p2235
sg13
I1
sa(dp2236
g7
I23
sg20
VC0007099
p2237
sg10
I3
sg11
Vcis
p2238
sg13
I1
sa(dp2239
g7
I244
sg20
VC0029925
p2240
sg10
I17
sg11
Vovarian carcinoma
p2241
sg13
I2
sa(dp2242
g7
I23
sg20
VC0007099
p2243
sg10
I3
sg11
Vcis
p2244
sg13
I1
sa(dp2245
g7
I274
sg20
VC0699790
p2246
sg10
I12
sg11
Vcolon cancer
p2247
sg13
I2
sa(dp2248
g7
I23
sg20
VC0007099
p2249
sg10
I3
sg11
Vcis
p2250
sg13
I1
sa(dp2251
g7
I220
sg20
VC0006826
p2252
sg10
I6
sg11
Vcancer
p2253
sg13
I1
sa(dp2254
g7
I23
sg20
VC0007099
p2255
sg10
I3
sg11
Vcis
p2256
sg13
I1
sa(dp2257
g7
I23
sg20
VC0007099
p2258
sg10
I3
sg11
Vcis
p2259
sg13
I1
sasa(dp2260
g2
S'Upon NIR light illumination, the Pt(IV) prodrug complex is activated at the surface of the nanoparticle and active components are selectively released which display cytotoxicity against human ovarian carcinoma A2780 cells and its cisplatin-resistant variant A2780cis cells.\n'
p2261
sg4
(lp2262
sg17
(lp2263
(dp2264
g7
I165
sg20
VC0596402
p2265
sg10
I12
sg11
Vcytotoxicity
p2266
sg13
I1
sa(dp2267
g7
I192
sg20
VC0029925
p2268
sg10
I17
sg11
Vovarian carcinoma
p2269
sg13
I2
sasa(dp2270
g2
S'Although no definite boundaries exist, it may be suggested that the IL-6/Th17/IL-17 pathway primarily drives systemic inflammation while the IL-12/Th1/IFN-Gamma pathway dominates in vascular wall inflammation both in TAK and giant cell arteritis.\n'
p2271
sg4
(lp2272
(dp2273
g7
I68
sg8
VP05231
p2274
sg10
I4
sg11
VIL-6
p2275
sg13
I1
sa(dp2276
g7
I151
sg8
VP01562
p2277
sg10
I3
sg11
VIFN
p2278
sg13
I1
sa(dp2279
g7
I217
sg8
VP50750
p2280
sg10
I3
sg11
VTAK
p2281
sg13
I1
sasg17
(lp2282
(dp2283
g7
I118
sg20
VC0021368
p2284
sg10
I12
sg11
Vinflammation
p2285
sg13
I1
sa(dp2286
g7
I225
sg20
VC0039483
p2287
sg10
I20
sg11
Vgiant cell arteritis
p2288
sg13
I3
sa(dp2289
g7
I118
sg20
VC0021368
p2290
sg10
I12
sg11
Vinflammation
p2291
sg13
I1
sasa(dp2292
g2
S'Recently, the following news were reported: * Early aging of the immune system with thymus insufficiency has now been reported for both patients with rheumatoid arthritis and axial spondyloarthritis, without prethymic lack of progenitors at least in rheumatoid arthritis.. * For giant cell arteritis, the most frequent vasculitis in the elderly, an increased expression of IL-17A in temporal artery biopsies coincides with good prognosis and reponse to glucocorticoids.. * Concerning immunosenescence in systemic lupus erythematosus, BAFF appears to have an important role for relapses after B-cell depletion.. For the future it can be anticipated that the use of unified classification criteria for rheumatic diseases (as with the new 2012 EULAR / ACR classification criteria for polymyalgia rheumatica) will ensure better comparability of immunological studies also in the elderly.\n'
p2293
sg4
(lp2294
sg17
(lp2295
(dp2296
g7
I150
sg20
VC0003873
p2297
sg10
I20
sg11
Vrheumatoid arthritis
p2298
sg13
I2
sa(dp2299
g7
I150
sg20
VC0003873
p2300
sg10
I20
sg11
Vrheumatoid arthritis
p2301
sg13
I2
sa(dp2302
g7
I700
sg20
VC0035435
p2303
sg10
I18
sg11
Vrheumatic diseases
p2304
sg13
I2
sa(dp2305
g7
I175
sg20
VC3203547
p2306
sg10
I23
sg11
Vaxial spondyloarthritis
p2307
sg13
I2
sa(dp2308
g7
I504
sg20
VC0024141
p2309
sg10
I28
sg11
Vsystemic lupus erythematosus
p2310
sg13
I3
sa(dp2311
g7
I319
sg20
VC0042384
p2312
sg10
I10
sg11
Vvasculitis
p2313
sg13
I1
sa(dp2314
g7
I781
sg20
VC0032533
p2315
sg10
I22
sg11
Vpolymyalgia rheumatica
p2316
sg13
I2
sa(dp2317
g7
I484
sg20
VC0596761
p2318
sg10
I16
sg11
Vimmunosenescence
p2319
sg13
I1
sa(dp2320
g7
I279
sg20
VC0039483
p2321
sg10
I20
sg11
Vgiant cell arteritis
p2322
sg13
I3
sasa(dp2323
g2
S'Hemochromatosis gene (HFE) mutations and the hepatitis C virus (HCV) are known risk factors for porphyria cutanea tarda (PCT), but interactions with erythrocytic uroporphyrinogen decarboxylase (UROD) have seldom been addressed.\n'
p2324
sg4
(lp2325
(dp2326
g7
I0
sg8
VP22607
p2327
sg10
I20
sg11
VHemochromatosis gene
p2328
sg13
I2
sa(dp2329
g7
I194
sg8
VP06132
p2330
sg10
I4
sg11
VUROD
p2331
sg13
I1
sa(dp2332
g7
I162
sg8
VP06132
p2333
sg10
I30
sg11
Vuroporphyrinogen decarboxylase
p2334
sg13
I2
sasg17
(lp2335
(dp2336
g7
I121
sg20
VC0162566
p2337
sg10
I3
sg11
VPCT
p2338
sg13
I1
sa(dp2339
g7
I96
sg20
VC0162566
p2340
sg10
I23
sg11
Vporphyria cutanea tarda
p2341
sg13
I3
sa(dp2342
g7
I0
sg20
VC0018995
p2343
sg10
I15
sg11
VHemochromatosis
p2344
sg13
I1
sa(dp2345
g7
I45
sg20
VC0019196
p2346
sg10
I11
sg11
Vhepatitis C
p2347
sg13
I2
sasa(dp2348
g2
S'It is now considered that hepatic iron overload related to the combination of heterogeneous genetic traits and environmental factors, including alcoholism and viral hepatitis, precipitates the expression of PCT through the inhibition of uroporphyrinogen decarboxylase (Uro.D).\n'
p2349
sg4
(lp2350
(dp2351
g7
I269
sg8
VP10746
p2352
sg10
I5
sg11
VUro.D
p2353
sg13
I1
sa(dp2354
g7
I237
sg8
VP06132
p2355
sg10
I30
sg11
Vuroporphyrinogen decarboxylase
p2356
sg13
I2
sasg17
(lp2357
(dp2358
g7
I207
sg20
VC0162566
p2359
sg10
I3
sg11
VPCT
p2360
sg13
I1
sa(dp2361
g7
I144
sg20
VC0001973
p2362
sg10
I10
sg11
Valcoholism
p2363
sg13
I1
sa(dp2364
g7
I34
sg20
VC0282193
p2365
sg10
I13
sg11
Viron overload
p2366
sg13
I2
sa(dp2367
g7
I159
sg20
VC0042721
p2368
sg10
I15
sg11
Vviral hepatitis
p2369
sg13
I2
sasa(dp2370
g2
S'RAGs could enable general practitioners to be more effective gatekeepers to genetics services, empowering them to reassure the majority of patients with a family history of breast and ovarian cancer who are not at increased genetic risk.\n'
p2371
sg4
(lp2372
(dp2373
g7
I0
sg8
VP52803
p2374
sg10
I4
sg11
VRAGs
p2375
sg13
I1
sasg17
(lp2376
(dp2377
g7
I184
sg20
VC1140680
p2378
sg10
I14
sg11
Vovarian cancer
p2379
sg13
I2
sasa(dp2380
g2
S'The serum concentrations of immunosuppressive acidic protein (IAP), CA 125, alpha-1-antitrypsin (AL-1-AT), C-reactive protein (CRP) and ceruloplasmin (COP) were determined in 63 patients with ovarian carcinoma (mean age 56.9 +/- 11.1 years).\n'
p2381
sg4
(lp2382
(dp2383
g7
I28
sg8
VP10997
p2384
sg10
I32
sg11
Vimmunosuppressive acidic protein
p2385
sg13
I3
sa(dp2386
g7
I151
sg8
g59
sg10
I3
sg11
VCOP
p2387
sg13
I1
sa(dp2388
g7
I68
sg8
g59
sg10
I6
sg11
VCA 125
p2389
sg13
I2
sa(dp2390
g7
I127
sg8
VP02741
p2391
sg10
I3
sg11
VCRP
p2392
sg13
I1
sa(dp2393
g7
I76
sg8
VP25100
p2394
sg10
I19
sg11
Valpha-1-antitrypsin
p2395
sg13
I1
sa(dp2396
g7
I62
sg8
VP10997
p2397
sg10
I3
sg11
VIAP
p2398
sg13
I1
sa(dp2399
g7
I107
sg8
VP02741
p2400
sg10
I18
sg11
VC-reactive protein
p2401
sg13
I2
sa(dp2402
g7
I97
sg8
VP52803
p2403
sg10
I7
sg11
VAL-1-AT
p2404
sg13
I1
sa(dp2405
g7
I136
sg8
VP00450
p2406
sg10
I13
sg11
Vceruloplasmin
p2407
sg13
I1
sasg17
(lp2408
(dp2409
g7
I192
sg20
VC0029925
p2410
sg10
I17
sg11
Vovarian carcinoma
p2411
sg13
I2
sasa(dp2412
g2
S'However, remarkably little is known about whether ClC-3 is involved in atherosclerosis.\n'
p2413
sg4
(lp2414
(dp2415
g7
I50
sg8
VP51790
p2416
sg10
I5
sg11
VClC-3
p2417
sg13
I1
sasg17
(lp2418
(dp2419
g7
I71
sg20
VC0004153
p2420
sg10
I15
sg11
Vatherosclerosis
p2421
sg13
I1
sasa(dp2422
g2
S'The ClC-3 chloride channel (and current, ICl,ClC-3) plays an important role in cell volume regulation, proliferation, and apoptosis in vascular smooth muscle cells, and is a potential target for prevention of vascular remodelling and stroke.\n'
p2423
sg4
(lp2424
(dp2425
g7
I4
sg8
VP51790
p2426
sg10
I5
sg11
VClC-3
p2427
sg13
I1
sasg17
(lp2428
(dp2429
g7
I103
sg20
VC0334094
p2430
sg10
I13
sg11
Vproliferation
p2431
sg13
I1
sa(dp2432
g7
I234
sg20
VC0038454
p2433
sg10
I6
sg11
Vstroke
p2434
sg13
I1
sasa(dp2435
g2
S'We previously reported that diabetes decreased the expression of renal tight junction (TJ) proteins claudin-5 in glomerulus, and claudin-2 and occludin in proximal tubule through an oxidative stress dependent way.\n'
p2436
sg4
(lp2437
(dp2438
g7
I100
sg8
g59
sg10
I9
sg11
Vclaudin-5
p2439
sg13
I1
sa(dp2440
g7
I129
sg8
VP57739
p2441
sg10
I9
sg11
Vclaudin-2
p2442
sg13
I1
sa(dp2443
g7
I143
sg8
g59
sg10
I8
sg11
Voccludin
p2444
sg13
I1
sasg17
(lp2445
(dp2446
g7
I28
sg20
VC0011849
p2447
sg10
I8
sg11
Vdiabetes
p2448
sg13
I1
sa(dp2449
g7
I182
sg20
VC0242606
p2450
sg10
I16
sg11
Voxidative stress
p2451
sg13
I2
sasa(dp2452
g2
S'We also found that diabetes induced tyrosine nitration (3-NT), SUMOylation and phosphorylation in serine residues of claudin-2 and atRA prevented these changes.\n'
p2453
sg4
(lp2454
(dp2455
g7
I117
sg8
VP57739
p2456
sg10
I9
sg11
Vclaudin-2
p2457
sg13
I1
sasg17
(lp2458
(dp2459
g7
I19
sg20
VC0011849
p2460
sg10
I8
sg11
Vdiabetes
p2461
sg13
I1
sasa(dp2462
g2
S'A case-control study was designed to compare the frequencies of the polymorphism at four sites in the SUFU gene in control and NTDs group, as well as in subtype groups, including anencephaly, spina bifida and encephalocele.\n'
p2463
sg4
(lp2464
(dp2465
g7
I102
sg8
g59
sg10
I9
sg11
VSUFU gene
p2466
sg13
I2
sasg17
(lp2467
(dp2468
g7
I192
sg20
VC0080178
p2469
sg10
I12
sg11
Vspina bifida
p2470
sg13
I2
sa(dp2471
g7
I209
sg20
VC0014065
p2472
sg10
I13
sg11
Vencephalocele
p2473
sg13
I1
sa(dp2474
g7
I179
sg20
VC0002902
p2475
sg10
I11
sg11
Vanencephaly
p2476
sg13
I1
sasa(dp2477
g2
S'Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications.\n'
p2478
sg4
(lp2479
(dp2480
g7
I271
sg8
VP08684
p2481
sg10
I6
sg11
VCYP3A4
p2482
sg13
I1
sa(dp2483
g7
I150
sg8
VP10632
p2484
sg10
I6
sg11
VCYP2C8
p2485
sg13
I1
sa(dp2486
g7
I110
sg8
VP20853
p2487
sg10
I15
sg11
Vcytochrome P450
p2488
sg13
I2
sa(dp2489
g7
I127
sg8
g59
sg10
I3
sg11
VCYP
p2490
sg13
I1
sasg17
(lp2491
(dp2492
g7
I43
sg20
VC0600139
p2493
sg10
I15
sg11
Vprostate cancer
p2494
sg13
I2
sasa(dp2495
g2
S'Unexplored electrochemical behavior of abiraterone, a recent and widely used prostate cancer drug, in interaction with cytochrome P450 3A4 (CYP3A4) enzyme and multiwalled carbon nanotubes (MWCNTs) is investigated in this work.\n'
p2496
sg4
(lp2497
(dp2498
g7
I119
sg8
VP08684
p2499
sg10
I19
sg11
Vcytochrome P450 3A4
p2500
sg13
I3
sa(dp2501
g7
I140
sg8
VP08684
p2502
sg10
I6
sg11
VCYP3A4
p2503
sg13
I1
sasg17
(lp2504
(dp2505
g7
I77
sg20
VC0600139
p2506
sg10
I15
sg11
Vprostate cancer
p2507
sg13
I2
sasa(dp2508
g2
S'Scutellariae radix (SR) could significantly increase the activity of glutathione peroxidase, catalase, and superoxide dismutase associated with OS in lipopolysaccharide-induced RAW264.7 cell damage and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced ulcerative colitis ratsThe level of malondialdehyde was markedly reduced by SR both in vitro and in vivo SR could decrease the severity of acute TNBS-induced colitis in ratsSR could significantly downregulate the expression of transforming growth factor beta 1 protein in colon tissue.\n'
p2509
sg4
(lp2510
(dp2511
g7
I93
sg8
VP04040
p2512
sg10
I8
sg11
Vcatalase
p2513
sg13
I1
sa(dp2514
g7
I107
sg8
VP00441
p2515
sg10
I20
sg11
Vsuperoxide dismutase
p2516
sg13
I2
sa(dp2517
g7
I69
sg8
VP59796
p2518
sg10
I22
sg11
Vglutathione peroxidase
p2519
sg13
I2
sa(dp2520
g7
I480
sg8
VP01137
p2521
sg10
I41
sg11
Vtransforming growth factor beta 1 protein
p2522
sg13
I6
sasg17
(lp2523
(dp2524
g7
I264
sg20
VC0009319
p2525
sg10
I7
sg11
Vcolitis
p2526
sg13
I1
sa(dp2527
g7
I186
sg20
VC0599732
p2528
sg10
I11
sg11
Vcell damage
p2529
sg13
I2
sa(dp2530
g7
I253
sg20
VC0009324
p2531
sg10
I18
sg11
Vulcerative colitis
p2532
sg13
I2
sasa(dp2533
g2
S'Abbreviations used: OS: Oxidative stress, UC: Ulcerative colitis, SR: Scutellariae radix, TNBS: 2,4,6-trinitrobenzene sulfonic acid, DAI: Disease activity index, MPO: Myeloperoxidase, GSH-PX: Glutathione peroxidase, CAT: Catalase, SOD: Superoxide dismutase, MDA: Malondialdehyde, TGF-Beta1: Transforming growth factor beta 1, OD: Optical density, ROS: Reactive oxygen species.\n'
p2534
sg4
(lp2535
(dp2536
g7
I221
sg8
VP04040
p2537
sg10
I8
sg11
VCatalase
p2538
sg13
I1
sa(dp2539
g7
I167
sg8
VP05164
p2540
sg10
I15
sg11
VMyeloperoxidase
p2541
sg13
I1
sa(dp2542
g7
I291
sg8
VP01137
p2543
sg10
I33
sg11
VTransforming growth factor beta 1
p2544
sg13
I5
sa(dp2545
g7
I231
sg8
VP00441
p2546
sg10
I3
sg11
VSOD
p2547
sg13
I1
sa(dp2548
g7
I162
sg8
VP05164
p2549
sg10
I3
sg11
VMPO
p2550
sg13
I1
sa(dp2551
g7
I133
sg8
g59
sg10
I3
sg11
VDAI
p2552
sg13
I1
sa(dp2553
g7
I216
sg8
VP04040
p2554
sg10
I3
sg11
VCAT
p2555
sg13
I1
sa(dp2556
g7
I236
sg8
VP00441
p2557
sg10
I20
sg11
VSuperoxide dismutase
p2558
sg13
I2
sa(dp2559
g7
I280
sg8
VP01137
p2560
sg10
I9
sg11
VTGF-Beta1
p2561
sg13
I1
sa(dp2562
g7
I192
sg8
VP59796
p2563
sg10
I22
sg11
VGlutathione peroxidase
p2564
sg13
I2
sa(dp2565
g7
I184
sg8
VP15538
p2566
sg10
I6
sg11
VGSH-PX
p2567
sg13
I1
sasg17
(lp2568
(dp2569
g7
I24
sg20
VC0242606
p2570
sg10
I16
sg11
VOxidative stress
p2571
sg13
I2
sa(dp2572
g7
I46
sg20
VC0009324
p2573
sg10
I18
sg11
VUlcerative colitis
p2574
sg13
I2
sa(dp2575
g7
I184
sg20
VC1260386
p2576
sg10
I3
sg11
VGSH
p2577
sg13
I1
sasa(dp2578
g2
S'A 14-year-old girl presented with encephalopathy, delirium and ophthalmoplegia following a 3day history of high-grade fever.\n'
p2579
sg4
(lp2580
sg17
(lp2581
(dp2582
g7
I63
sg20
VC0029089
p2583
sg10
I15
sg11
Vophthalmoplegia
p2584
sg13
I1
sa(dp2585
g7
I50
sg20
VC0011206
p2586
sg10
I8
sg11
Vdelirium
p2587
sg13
I1
sa(dp2588
g7
I34
sg20
VC0085584
p2589
sg10
I14
sg11
Vencephalopathy
p2590
sg13
I1
sasa(dp2591
g2
S'During in vitro culture period, the undifferentiated rat spermatogonial colonies co-expressed E-cadherin and glial-derived neurotrophic factor family receptor alpha-1 or E-cadherin and promyelocytic leukemia zinc finger.\n'
p2592
sg4
(lp2593
(dp2594
g7
I94
sg8
VP12830
p2595
sg10
I10
sg11
VE-cadherin
p2596
sg13
I1
sa(dp2597
g7
I94
sg8
VP12830
p2598
sg10
I10
sg11
VE-cadherin
p2599
sg13
I1
sa(dp2600
g7
I109
sg8
VP20783
p2601
sg10
I57
sg11
Vglial-derived neurotrophic factor family receptor alpha-1
p2602
sg13
I6
sasg17
(lp2603
(dp2604
g7
I185
sg20
VC2745900
p2605
sg10
I22
sg11
Vpromyelocytic leukemia
p2606
sg13
I2
sasa(dp2607
g2
S"Adenosine deaminase (ADA), 5'nucleotidase (5'NT), ecto-5'NT, purine nucleoside phosphorylase (PNP), hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), adenosine kinase (AK), AMP-deaminase (AMPD) and adenylate kinase (AdKin) activities were assayed in peripheral blood lymphoid cells from 20 patients with B-cell type chronic lymphocytic leukemia (CLL).\n"
p2608
sg4
(lp2609
(dp2610
g7
I61
sg8
VP00491
p2611
sg10
I31
sg11
Vpurine nucleoside phosphorylase
p2612
sg13
I3
sa(dp2613
g7
I246
sg8
VP55263
p2614
sg10
I16
sg11
Vadenylate kinase
p2615
sg13
I2
sa(dp2616
g7
I148
sg8
VP00492
p2617
sg10
I5
sg11
VHGPRT
p2618
sg13
I1
sa(dp2619
g7
I216
sg8
VP55263
p2620
sg10
I2
sg11
VAK
p2621
sg13
I1
sa(dp2622
g7
I198
sg8
VP55263
p2623
sg10
I16
sg11
Vadenosine kinase
p2624
sg13
I2
sa(dp2625
g7
I191
sg8
VP07741
p2626
sg10
I4
sg11
VAPRT
p2627
sg13
I1
sa(dp2628
g7
I221
sg8
VP23109
p2629
sg10
I13
sg11
VAMP-deaminase
p2630
sg13
I1
sa(dp2631
g7
I94
sg8
VP00491
p2632
sg10
I3
sg11
VPNP
p2633
sg13
I1
sa(dp2634
g7
I50
sg8
g59
sg10
I9
sg11
Vecto-5'NT
p2635
sg13
I1
sa(dp2636
g7
I236
sg8
VP23109
p2637
sg10
I4
sg11
VAMPD
p2638
sg13
I1
sa(dp2639
g7
I0
sg8
VP00813
p2640
sg10
I41
sg11
VAdenosine deaminase (ADA), 5'nucleotidase
p2641
sg13
I4
sa(dp2642
g7
I156
sg8
VP07741
p2643
sg10
I33
sg11
Vadenine phosphoribosyltransferase
p2644
sg13
I2
sa(dp2645
g7
I100
sg8
VP00492
p2646
sg10
I46
sg11
Vhypoxanthine-guanine phosphoribosyltransferase
p2647
sg13
I2
sa(dp2648
g7
I264
sg8
VP55263
p2649
sg10
I5
sg11
VAdKin
p2650
sg13
I1
sasg17
(lp2651
(dp2652
g7
I364
sg20
VC0023434
p2653
sg10
I28
sg11
Vchronic lymphocytic leukemia
p2654
sg13
I3
sa(dp2655
g7
I394
sg20
VC0023434
p2656
sg10
I3
sg11
VCLL
p2657
sg13
I1
sasa(dp2658
g2
S"Adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP), 5'nucleotidase (5'NT), ecto-5'NT, hypoxanthine-guanine phosphoribosyltransferase(HGPRT), adenine phosphoribosyltransferase(APRT), adenosine kinase(AK), AMP deaminase (AMPD) and adenylate kinase(AdKin) activities were assayed in leukemic cells from bone marrow and/or peripheral blood of 43 newly diagnosed children with acute lymphoblastic leukemia(ALL).\n"
p2659
sg4
(lp2660
(dp2661
g7
I21
sg8
VP00813
p2662
sg10
I3
sg11
VADA
p2663
sg13
I1
sa(dp2664
g7
I155
sg8
VP07741
p2665
sg10
I33
sg11
Vadenine phosphoribosyltransferase
p2666
sg13
I2
sa(dp2667
g7
I60
sg8
VP00491
p2668
sg10
I3
sg11
VPNP
p2669
sg13
I1
sa(dp2670
g7
I189
sg8
VP07741
p2671
sg10
I4
sg11
VAPRT
p2672
sg13
I1
sa(dp2673
g7
I218
sg8
VP23109
p2674
sg10
I20
sg11
VAMP deaminase (AMPD)
p2675
sg13
I3
sa(dp2676
g7
I27
sg8
VP00491
p2677
sg10
I31
sg11
Vpurine nucleoside phosphorylase
p2678
sg13
I3
sa(dp2679
g7
I243
sg8
VP55263
p2680
sg10
I16
sg11
Vadenylate kinase
p2681
sg13
I2
sa(dp2682
g7
I147
sg8
VP00492
p2683
sg10
I5
sg11
VHGPRT
p2684
sg13
I1
sa(dp2685
g7
I0
sg8
VP00813
p2686
sg10
I19
sg11
VAdenosine deaminase
p2687
sg13
I2
sa(dp2688
g7
I89
sg8
g59
sg10
I9
sg11
Vecto-5'NT
p2689
sg13
I1
sa(dp2690
g7
I213
sg8
VP55263
p2691
sg10
I2
sg11
VAK
p2692
sg13
I1
sa(dp2693
g7
I196
sg8
VP55263
p2694
sg10
I16
sg11
Vadenosine kinase
p2695
sg13
I2
sa(dp2696
g7
I100
sg8
VP00492
p2697
sg10
I46
sg11
Vhypoxanthine-guanine phosphoribosyltransferase
p2698
sg13
I2
sasg17
(lp2699
(dp2700
g7
I386
sg20
VC1961102
p2701
sg10
I28
sg11
Vacute lymphoblastic leukemia
p2702
sg13
I3
sasa(dp2703
g2
S"ADA activity was higher in E-rosette positive leukemia(E+ ALL), while HGPRT, APRT, PNP, 5'NT, ecto-5'NT and AdKin activities were found to be lower in E+ ALL as compared to E- ALL.\n"
p2704
sg4
(lp2705
(dp2706
g7
I70
sg8
VP00492
p2707
sg10
I5
sg11
VHGPRT
p2708
sg13
I1
sa(dp2709
g7
I94
sg8
g59
sg10
I9
sg11
Vecto-5'NT
p2710
sg13
I1
sa(dp2711
g7
I77
sg8
VP07741
p2712
sg10
I4
sg11
VAPRT
p2713
sg13
I1
sa(dp2714
g7
I0
sg8
VP00813
p2715
sg10
I3
sg11
VADA
p2716
sg13
I1
sa(dp2717
g7
I83
sg8
VP00491
p2718
sg10
I3
sg11
VPNP
p2719
sg13
I1
sasg17
(lp2720
(dp2721
g7
I46
sg20
VC0023418
p2722
sg10
I8
sg11
Vleukemia
p2723
sg13
I1
sasa(dp2724
g2
S'To demonstrate the role of CXCR1/CXCR2-expressing neutrophils in hepatic injury, we investigated CXCR1/CXCR2 receptor expression in 17 hepatitis B virus-related ACLF patients in comparison to 42 chronic hepatitis B and 18 healthy controls.\n'
p2725
sg4
(lp2726
(dp2727
g7
I33
sg8
VP25025
p2728
sg10
I5
sg11
VCXCR2
p2729
sg13
I1
sa(dp2730
g7
I103
sg8
VP25025
p2731
sg10
I14
sg11
VCXCR2 receptor
p2732
sg13
I2
sasg17
(lp2733
(dp2734
g7
I135
sg20
VC0019163
p2735
sg10
I11
sg11
Vhepatitis B
p2736
sg13
I2
sa(dp2737
g7
I195
sg20
VC0524909
p2738
sg10
I19
sg11
Vchronic hepatitis B
p2739
sg13
I3
sasa(dp2740
g2
S'In this study, we investigated the dynamic expression of CXCR1 and CXCR2 on neutrophils, and found that patients with hepatitis B virus-related ACLF displayed low expression of CXCR1 and CXCR2 on peripheral neutrophils compared with healthy subjects and patients with chronic hepatitis B.\n'
p2741
sg4
(lp2742
(dp2743
g7
I67
sg8
VP25025
p2744
sg10
I5
sg11
VCXCR2
p2745
sg13
I1
sa(dp2746
g7
I67
sg8
VP25025
p2747
sg10
I5
sg11
VCXCR2
p2748
sg13
I1
sasg17
(lp2749
(dp2750
g7
I268
sg20
VC0524909
p2751
sg10
I19
sg11
Vchronic hepatitis B
p2752
sg13
I3
sa(dp2753
g7
I118
sg20
VC0019163
p2754
sg10
I11
sg11
Vhepatitis B
p2755
sg13
I2
sasa(dp2756
g2
S'We observed a preferential migration of CXCR2-expressing, central memory CD4 T cells in response to HIV infection of RTECs.\n'
p2757
sg4
(lp2758
(dp2759
g7
I40
sg8
VP25025
p2760
sg10
I5
sg11
VCXCR2
p2761
sg13
I1
sa(dp2762
g7
I73
sg8
VP01730
p2763
sg10
I5
sg11
VCD4 T
p2764
sg13
I2
sasg17
(lp2765
(dp2766
g7
I100
sg20
VC0019693
p2767
sg10
I13
sg11
VHIV infection
p2768
sg13
I2
sasa(dp2769
g2
S'Down-regulation or heterozygous mutations of Kruppel-like factor 1 (KLF1) is associated with elevated HbF levels in non-thalassemia subjects.\n'
p2770
sg4
(lp2771
(dp2772
g7
I45
sg8
g59
sg10
I21
sg11
VKruppel-like factor 1
p2773
sg13
I3
sa(dp2774
g7
I68
sg8
g59
sg10
I4
sg11
VKLF1
p2775
sg13
I1
sasg17
(lp2776
(dp2777
g7
I120
sg20
VC0039730
p2778
sg10
I11
sg11
Vthalassemia
p2779
sg13
I1
sasa(dp2780
g2
S'This study confirms that experimental down-regulation of KLF1 in Beta0-thalassemia/HbE-derived erythroblasts significantly increases HbF production (up to 52.3 +/- 2.4%), albeit with slightly delayed erythroid terminal differentiation.\n'
p2781
sg4
(lp2782
(dp2783
g7
I83
sg8
VP02100
p2784
sg10
I3
sg11
VHbE
p2785
sg13
I1
sa(dp2786
g7
I57
sg8
g59
sg10
I4
sg11
VKLF1
p2787
sg13
I1
sa(dp2788
g7
I65
sg8
VP69905
p2789
sg10
I17
sg11
VBeta0-thalassemia
p2790
sg13
I1
sasg17
(lp2791
(dp2792
g7
I71
sg20
VC0039730
p2793
sg10
I11
sg11
Vthalassemia
p2794
sg13
I1
sasa(dp2795
g2
S'KLF1 exome sequencing of 130 Thai Beta0-thalassemia/HbE patients without co-inheritance of Alfa-thalassemia found six patients with KLF1 heterozygous mutations including rs2072596 (p.F182L; n = 5) and rs745347362 (p.P284L; n = 1) missense mutations.\n'
p2796
sg4
(lp2797
(dp2798
g7
I0
sg8
g59
sg10
I4
sg11
VKLF1
p2799
sg13
I1
sa(dp2800
g7
I0
sg8
g59
sg10
I4
sg11
VKLF1
p2801
sg13
I1
sasg17
(lp2802
(dp2803
g7
I40
sg20
VC0039730
p2804
sg10
I11
sg11
Vthalassemia
p2805
sg13
I1
sa(dp2806
g7
I40
sg20
VC0039730
p2807
sg10
I11
sg11
Vthalassemia
p2808
sg13
I1
sasa(dp2809
g2
S'These results suggest that while reduction of KLF1 expression in Beta0-thalassemia/HbE erythroblasts can increase HbF levels, it is not sufficient to alleviate the clinical phenotype.\n'
p2810
sg4
(lp2811
(dp2812
g7
I83
sg8
VP02100
p2813
sg10
I3
sg11
VHbE
p2814
sg13
I1
sa(dp2815
g7
I65
sg8
VP69905
p2816
sg10
I17
sg11
VBeta0-thalassemia
p2817
sg13
I1
sa(dp2818
g7
I46
sg8
g59
sg10
I4
sg11
VKLF1
p2819
sg13
I1
sasg17
(lp2820
(dp2821
g7
I71
sg20
VC0039730
p2822
sg10
I11
sg11
Vthalassemia
p2823
sg13
I1
sasa(dp2824
g2
S'The co-inheritance of this novel KLF1 variant might have increased the HbF levels in the mother and may have ameliorated the clinical manifestations of the 6-year-old untransfused Beta-thalassemia homozygous child.\n'
p2825
sg4
(lp2826
(dp2827
g7
I33
sg8
g59
sg10
I4
sg11
VKLF1
p2828
sg13
I1
sasg17
(lp2829
(dp2830
g7
I180
sg20
VC0005283
p2831
sg10
I16
sg11
VBeta-thalassemia
p2832
sg13
I1
sasa(dp2833
g2
S'Here, we found that KLF1 mutations modulate the phenotype in a cohort of Alfa-thalassemia carriers.\n'
p2834
sg4
(lp2835
(dp2836
g7
I20
sg8
g59
sg10
I4
sg11
VKLF1
p2837
sg13
I1
sasg17
(lp2838
(dp2839
g7
I78
sg20
VC0039730
p2840
sg10
I11
sg11
Vthalassemia
p2841
sg13
I1
sasa(dp2842
g2
S'Application of CRISPR technology to induce an indel in the KLF1 gene in adult erythroid progenitors may provide a method for activating fetal hemoglobin expression in individuals with Beta-thalassemia or sickle cell disease.\n'
p2843
sg4
(lp2844
(dp2845
g7
I59
sg8
g59
sg10
I9
sg11
VKLF1 gene
p2846
sg13
I2
sa(dp2847
g7
I136
sg8
VP14207
p2848
sg10
I16
sg11
Vfetal hemoglobin
p2849
sg13
I2
sasg17
(lp2850
(dp2851
g7
I204
sg20
VC0002895
p2852
sg10
I19
sg11
Vsickle cell disease
p2853
sg13
I3
sa(dp2854
g7
I184
sg20
VC0005283
p2855
sg10
I16
sg11
VBeta-thalassemia
p2856
sg13
I1
sasa(dp2857
g2
S'CD133(+) stem cells were isolated from umbilical cord blood of a newborn with minor Beta-thalassemia in order to evaluate the effects of these two drugs on the in vitro expression of GATA-1 and EKLF genes as erythroid transcription factors.\n'
p2858
sg4
(lp2859
(dp2860
g7
I194
sg8
g59
sg10
I10
sg11
VEKLF genes
p2861
sg13
I2
sa(dp2862
g7
I0
sg8
g59
sg10
I5
sg11
VCD133
p2863
sg13
I1
sa(dp2864
g7
I183
sg8
VP15976
p2865
sg10
I6
sg11
VGATA-1
p2866
sg13
I1
sasg17
(lp2867
(dp2868
g7
I49
sg20
VC0035334
p2869
sg10
I4
sg11
Vcord
p2870
sg13
I1
sa(dp2871
g7
I84
sg20
VC0005283
p2872
sg10
I16
sg11
VBeta-thalassemia
p2873
sg13
I1
sasa(dp2874
g2
S'Using a series of experiments in human prostate cancer cell lines, we validate the highest ranking prediction (TNRC6B) as a ceRNA of PTEN.\n'
p2875
sg4
(lp2876
(dp2877
g7
I111
sg8
g59
sg10
I6
sg11
VTNRC6B
p2878
sg13
I1
sa(dp2879
g7
I133
sg8
VP60484
p2880
sg10
I4
sg11
VPTEN
p2881
sg13
I1
sasg17
(lp2882
(dp2883
g7
I39
sg20
VC0600139
p2884
sg10
I15
sg11
Vprostate cancer
p2885
sg13
I2
sasa(dp2886
g2
S"Five miR-SNPs in miRNA processing machinery genes, including XPO5 (rs11077), RAN (rs14035), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348), in 168 non-Hodgkin's lymphoma (NHL) patients were evaluated for their association with the cancer risk and outcomes associated with NHL.\n"
p2887
sg4
(lp2888
(dp2889
g7
I92
sg8
g59
sg10
I6
sg11
VTNRC6B
p2890
sg13
I1
sa(dp2891
g7
I5
sg8
g59
sg10
I8
sg11
VmiR-SNPs
p2892
sg13
I1
sa(dp2893
g7
I135
sg8
VP57678
p2894
sg10
I6
sg11
VGEMIN4
p2895
sg13
I1
sa(dp2896
g7
I112
sg8
g59
sg10
I6
sg11
VGEMIN3
p2897
sg13
I1
sasg17
(lp2898
(dp2899
g7
I162
sg20
VC0024305
p2900
sg10
I22
sg11
Vnon-Hodgkin's lymphoma
p2901
sg13
I2
sa(dp2902
g7
I186
sg20
VC0024305
p2903
sg10
I3
sg11
VNHL
p2904
sg13
I1
sa(dp2905
g7
I246
sg20
VC0006826
p2906
sg10
I6
sg11
Vcancer
p2907
sg13
I1
sa(dp2908
g7
I186
sg20
VC0024305
p2909
sg10
I3
sg11
VNHL
p2910
sg13
I1
sasa(dp2911
g2
S'In this study, we investigated six miR-SNPs in microRNA processing machinery genes, including rs11077 of the XPO5 gene, rs14035 of the RAN gene, rs3742330 of the Dicer gene, rs9623117 of the TNRC6B gene, rs197412 of the GEMIN3 gene, and rs2740348 of the GEMIN4 gene, in gastric cancer patients and subsequently evaluated their potential roles in gastric cancer risk in a case control study.\n'
p2912
sg4
(lp2913
(dp2914
g7
I220
sg8
g59
sg10
I11
sg11
VGEMIN3 gene
p2915
sg13
I2
sa(dp2916
g7
I191
sg8
g59
sg10
I11
sg11
VTNRC6B gene
p2917
sg13
I2
sa(dp2918
g7
I35
sg8
g59
sg10
I8
sg11
VmiR-SNPs
p2919
sg13
I1
sa(dp2920
g7
I254
sg8
VP57678
p2921
sg10
I11
sg11
VGEMIN4 gene
p2922
sg13
I2
sasg17
(lp2923
(dp2924
g7
I270
sg20
VC0024623
p2925
sg10
I14
sg11
Vgastric cancer
p2926
sg13
I2
sa(dp2927
g7
I270
sg20
VC0024623
p2928
sg10
I14
sg11
Vgastric cancer
p2929
sg13
I2
sasa(dp2930
g2
S'The results indicate that the C/C genotype of rs14035 from RAN, the A/A genotype of rs3742330 from Dicer, and the T/T genotype of rs9623117 from TNRC6B are significantly associated with gastric cancer risk.\n'
p2931
sg4
(lp2932
(dp2933
g7
I130
sg8
g59
sg10
I21
sg11
Vrs9623117 from TNRC6B
p2934
sg13
I3
sasg17
(lp2935
(dp2936
g7
I186
sg20
VC0024623
p2937
sg10
I14
sg11
Vgastric cancer
p2938
sg13
I2
sasa(dp2939
g2
S'We genotyped 6 miR-SNPs of miRNA processing machinery genes including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348) in a case-control study to evaluate their impact on colorectal cancer (CRC) risk.\n'
p2940
sg4
(lp2941
(dp2942
g7
I120
sg8
g59
sg10
I6
sg11
VTNRC6B
p2943
sg13
I1
sa(dp2944
g7
I140
sg8
g59
sg10
I6
sg11
VGEMIN3
p2945
sg13
I1
sa(dp2946
g7
I163
sg8
VP57678
p2947
sg10
I6
sg11
VGEMIN4
p2948
sg13
I1
sasg17
(lp2949
(dp2950
g7
I234
sg20
VC1527249
p2951
sg10
I17
sg11
Vcolorectal cancer
p2952
sg13
I2
sa(dp2953
g7
I253
sg20
VC1527249
p2954
sg10
I3
sg11
VCRC
p2955
sg13
I1
sasa(dp2956
g2
S'In this study, we found that let-7c-5p expression was clearly downregulated in breast cancer tissues compared with that of corresponding adjacent tissues.\n'
p2957
sg4
(lp2958
sg17
(lp2959
(dp2960
g7
I79
sg20
VC0678222
p2961
sg10
I13
sg11
Vbreast cancer
p2962
sg13
I2
sasa(dp2963
g2
S'Furthermore, overexpression of let-7c-5p in MCF-7 breast cancer cells could significantly inhibit cell proliferation and induce cell apoptosis.\n'
p2964
sg4
(lp2965
sg17
(lp2966
(dp2967
g7
I50
sg20
VC0678222
p2968
sg10
I13
sg11
Vbreast cancer
p2969
sg13
I2
sa(dp2970
g7
I103
sg20
VC0334094
p2971
sg10
I13
sg11
Vproliferation
p2972
sg13
I1
sasa(dp2973
g2
S'Collectively, the present study suggested that let-7c-5p acted as a tumor suppressor in breast cancer possibly by negatively regulating ERCC6, which took an important part in nucleotide excision repair and it may provide a new potential strategy for breast cancer therapy.\n'
p2974
sg4
(lp2975
(dp2976
g7
I136
sg8
g59
sg10
I5
sg11
VERCC6
p2977
sg13
I1
sasg17
(lp2978
(dp2979
g7
I88
sg20
VC0678222
p2980
sg10
I13
sg11
Vbreast cancer
p2981
sg13
I2
sa(dp2982
g7
I68
sg20
VC0027651
p2983
sg10
I5
sg11
Vtumor
p2984
sg13
I1
sa(dp2985
g7
I88
sg20
VC0678222
p2986
sg10
I13
sg11
Vbreast cancer
p2987
sg13
I2
sasa(dp2988
g2
S'When paired teratomas from the same animals were compared, transchromosomic tumours showed a three-fold lower percentage of neuroectodermal tissue, as well as significantly reduced mRNA levels for neuron specific (Tubb3) and glia specific (Gfap) genes, relative to euploid controls.\n'
p2989
sg4
(lp2990
(dp2991
g7
I214
sg8
VP04350
p2992
sg10
I5
sg11
VTubb3
p2993
sg13
I1
sasg17
(lp2994
(dp2995
g7
I76
sg20
VC0027651
p2996
sg10
I7
sg11
Vtumours
p2997
sg13
I1
sa(dp2998
g7
I12
sg20
VC0039538
p2999
sg10
I9
sg11
Vteratomas
p3000
sg13
I1
sasa(dp3001
g2
S'We determined SLLP1 expression in myeloma cell lines and 394 BM samples from myeloma patients (n = 177) and BM samples from healthy donors (n = 11).\n'
p3002
sg4
(lp3003
(dp3004
g7
I14
sg8
g59
sg10
I5
sg11
VSLLP1
p3005
sg13
I1
sasg17
(lp3006
(dp3007
g7
I34
sg20
VC0026764
p3008
sg10
I7
sg11
Vmyeloma
p3009
sg13
I1
sa(dp3010
g7
I34
sg20
VC0026764
p3011
sg10
I7
sg11
Vmyeloma
p3012
sg13
I1
sasa(dp3013
g2
S'896 blood samples and 64 BM samples from myeloma patients (n = 263) and blood from healthy donors (n = 112) were analyzed for anti-SLLP1 antibodies.\n'
p3014
sg4
(lp3015
(dp3016
g7
I126
sg8
g59
sg10
I21
sg11
Vanti-SLLP1 antibodies
p3017
sg13
I2
sasg17
(lp3018
(dp3019
g7
I41
sg20
VC0026764
p3020
sg10
I7
sg11
Vmyeloma
p3021
sg13
I1
sasa(dp3022
g2
S'In this study, we determined whether SLLP1 is a novel cancer-testis antigen in hematologic malignancies SLLP1 expression in hematologic tumor cells and normal tissues was determined using a combination of reverse transcription-PCR, real-time PCR, and Western blot analysis.\n'
p3023
sg4
(lp3024
(dp3025
g7
I37
sg8
g59
sg10
I5
sg11
VSLLP1
p3026
sg13
I1
sa(dp3027
g7
I37
sg8
g59
sg10
I5
sg11
VSLLP1
p3028
sg13
I1
sasg17
(lp3029
(dp3030
g7
I136
sg20
VC0027651
p3031
sg10
I5
sg11
Vtumor
p3032
sg13
I1
sa(dp3033
g7
I79
sg20
VC0376545
p3034
sg10
I24
sg11
Vhematologic malignancies
p3035
sg13
I2
sa(dp3036
g7
I54
sg20
VC0006826
p3037
sg10
I6
sg11
Vcancer
p3038
sg13
I1
sasa(dp3039
g2
S'SLLP1 was aberrantly expressed in the tumor cells from 2 of 9 acute myeloid leukemia, 3 of 11 chronic lymphocytic leukemia, 4 of 14 chronic myeloid leukemia, and 6 of 17 multiple myeloma.\n'
p3040
sg4
(lp3041
(dp3042
g7
I0
sg8
g59
sg10
I5
sg11
VSLLP1
p3043
sg13
I1
sasg17
(lp3044
(dp3045
g7
I62
sg20
VC0023467
p3046
sg10
I22
sg11
Vacute myeloid leukemia
p3047
sg13
I3
sa(dp3048
g7
I94
sg20
VC0023434
p3049
sg10
I28
sg11
Vchronic lymphocytic leukemia
p3050
sg13
I3
sa(dp3051
g7
I132
sg20
VC0023473
p3052
sg10
I24
sg11
Vchronic myeloid leukemia
p3053
sg13
I3
sa(dp3054
g7
I170
sg20
VC0026764
p3055
sg10
I16
sg11
Vmultiple myeloma
p3056
sg13
I2
sa(dp3057
g7
I38
sg20
VC0027651
p3058
sg10
I5
sg11
Vtumor
p3059
sg13
I1
sasa(dp3060
g2
S'SLLP1 is a novel cancer-testis antigen in hematologic malignancies and is capable of eliciting B-cell immune responses in vivo in cancer-bearing individuals.\n'
p3061
sg4
(lp3062
(dp3063
g7
I0
sg8
g59
sg10
I5
sg11
VSLLP1
p3064
sg13
I1
sasg17
(lp3065
(dp3066
g7
I17
sg20
VC0006826
p3067
sg10
I6
sg11
Vcancer
p3068
sg13
I1
sa(dp3069
g7
I42
sg20
VC0376545
p3070
sg10
I24
sg11
Vhematologic malignancies
p3071
sg13
I2
sa(dp3072
g7
I17
sg20
VC0006826
p3073
sg10
I6
sg11
Vcancer
p3074
sg13
I1
sasa(dp3075
g2
S'SLLP1 mRNA (size, approximately 1 kb) appeared to be expressed only in the testis and in the Burkitt lymphoma Raji cell line.\n'
p3076
sg4
(lp3077
(dp3078
g7
I0
sg8
g59
sg10
I10
sg11
VSLLP1 mRNA
p3079
sg13
I2
sasg17
(lp3080
(dp3081
g7
I93
sg20
VC0006413
p3082
sg10
I16
sg11
VBurkitt lymphoma
p3083
sg13
I2
sasa(dp3084
g2
S'Prostatic calculi are seen in chronic prostatitis, chronic pelvic pain syndrome and benign prostate hyperplasia; however, in patients with AKU, prostatic calculi and/or calcifications are more extensive.\n'
p3085
sg4
(lp3086
sg17
(lp3087
(dp3088
g7
I30
sg20
VC0085696
p3089
sg10
I19
sg11
Vchronic prostatitis
p3090
sg13
I2
sa(dp3091
g7
I139
sg20
VC0002066
p3092
sg10
I3
sg11
VAKU
p3093
sg13
I1
sa(dp3094
g7
I51
sg20
VC1536168
p3095
sg10
I28
sg11
Vchronic pelvic pain syndrome
p3096
sg13
I4
sa(dp3097
g7
I84
sg20
VC0005001
p3098
sg10
I27
sg11
Vbenign prostate hyperplasia
p3099
sg13
I3
sasa(dp3100
g2
S'Levosulpiride is a 5HT4 agonist/D2 antagonist prokinetic agent used to improve gastric emptying in patients with functional dyspepsia or gastroparesis.\n'
p3101
sg4
(lp3102
sg17
(lp3103
(dp3104
g7
I124
sg20
VC0013395
p3105
sg10
I9
sg11
Vdyspepsia
p3106
sg13
I1
sa(dp3107
g7
I137
sg20
VC0152020
p3108
sg10
I13
sg11
Vgastroparesis
p3109
sg13
I1
sasa(dp3110
g2
S'Serotonin 5-hydroxytryptamine 4(5-HT4) receptor agonists have been widely prescribed as a prokinetics drug for patients with gastro-esophageal reflux disease and functional dyspepsia.\n'
p3111
sg4
(lp3112
(dp3113
g7
I0
sg8
VP34969
p3114
sg10
I47
sg11
VSerotonin 5-hydroxytryptamine 4(5-HT4) receptor
p3115
sg13
I4
sasg17
(lp3116
(dp3117
g7
I125
sg20
VC0017168
p3118
sg10
I32
sg11
Vgastro-esophageal reflux disease
p3119
sg13
I3
sa(dp3120
g7
I173
sg20
VC0013395
p3121
sg10
I9
sg11
Vdyspepsia
p3122
sg13
I1
sasa(dp3123
g2
S'Tumour cells were immunopositive for pancytokeratin, vimentin, CD10, CK19 and AMACR, confirming a diagnosis of tubulocystic renal cell carcinoma (TC-RCC).\n'
p3124
sg4
(lp3125
(dp3126
g7
I37
sg8
g59
sg10
I14
sg11
Vpancytokeratin
p3127
sg13
I1
sa(dp3128
g7
I63
sg8
VP08473
p3129
sg10
I4
sg11
VCD10
p3130
sg13
I1
sa(dp3131
g7
I78
sg8
g59
sg10
I5
sg11
VAMACR
p3132
sg13
I1
sasg17
(lp3133
(dp3134
g7
I0
sg20
VC0027651
p3135
sg10
I6
sg11
VTumour
p3136
sg13
I1
sa(dp3137
g7
I149
sg20
VC0007134
p3138
sg10
I3
sg11
VRCC
p3139
sg13
I1
sa(dp3140
g7
I124
sg20
VC0007134
p3141
sg10
I20
sg11
Vrenal cell carcinoma
p3142
sg13
I3
sasa(dp3143
g2
S'However, C3F positive individuals with migraine were found to have an increased incidence of osteoarthritis (Chi square = 10.06; p &lt; 0.0008) and hypertension (Chi square = 5.18; p &lt; 0.01).\n'
p3144
sg4
(lp3145
(dp3146
g7
I9
sg8
g59
sg10
I3
sg11
VC3F
p3147
sg13
I1
sasg17
(lp3148
(dp3149
g7
I93
sg20
VC0029408
p3150
sg10
I14
sg11
Vosteoarthritis
p3151
sg13
I1
sa(dp3152
g7
I148
sg20
VC0020538
p3153
sg10
I12
sg11
Vhypertension
p3154
sg13
I1
sa(dp3155
g7
I39
sg20
VC0149931
p3156
sg10
I8
sg11
Vmigraine
p3157
sg13
I1
sasa(dp3158
g2
S'An increased frequency of the rarer C3F allele has been reported in patients with the autoantibody nephritic factor and in several other autoimmune conditions such as rheumatoid arthritis and IgA nephropathy.\n'
p3159
sg4
(lp3160
(dp3161
g7
I36
sg8
g59
sg10
I10
sg11
VC3F allele
p3162
sg13
I2
sa(dp3163
g7
I192
sg8
VP11912
p3164
sg10
I3
sg11
VIgA
p3165
sg13
I1
sasg17
(lp3166
(dp3167
g7
I167
sg20
VC0003873
p3168
sg10
I20
sg11
Vrheumatoid arthritis
p3169
sg13
I2
sa(dp3170
g7
I192
sg20
VC0017661
p3171
sg10
I15
sg11
VIgA nephropathy
p3172
sg13
I2
sa(dp3173
g7
I137
sg20
VC0443146
p3174
sg10
I10
sg11
Vautoimmune
p3175
sg13
I1
sasa(dp3176
g2
S'Immunohistochemical expressions of SIRT1, DBC1, Beta-catenin, surviving, and p53 were evaluated using 2 mm tumor cores from 349 colorectal cancer patients for tissue microarray.\n'
p3177
sg4
(lp3178
(dp3179
g7
I48
sg8
VP35222
p3180
sg10
I12
sg11
VBeta-catenin
p3181
sg13
I1
sa(dp3182
g7
I42
sg8
g59
sg10
I4
sg11
VDBC1
p3183
sg13
I1
sa(dp3184
g7
I77
sg8
VP42771
p3185
sg10
I3
sg11
Vp53
p3186
sg13
I1
sa(dp3187
g7
I35
sg8
g59
sg10
I5
sg11
VSIRT1
p3188
sg13
I1
sasg17
(lp3189
(dp3190
g7
I128
sg20
VC1527249
p3191
sg10
I17
sg11
Vcolorectal cancer
p3192
sg13
I2
sa(dp3193
g7
I107
sg20
VC0027651
p3194
sg10
I5
sg11
Vtumor
p3195
sg13
I1
sasa(dp3196
g2
S'Deleted in breast cancer 1 (DBC1) was initially cloned from a region homozygously deleted in breast cancers, but its role in colorectal cancer remains unknown.\n'
p3197
sg4
(lp3198
(dp3199
g7
I28
sg8
g59
sg10
I4
sg11
VDBC1
p3200
sg13
I1
sa(dp3201
g7
I0
sg8
g59
sg10
I26
sg11
VDeleted in breast cancer 1
p3202
sg13
I5
sasg17
(lp3203
(dp3204
g7
I125
sg20
VC1527249
p3205
sg10
I17
sg11
Vcolorectal cancer
p3206
sg13
I2
sa(dp3207
g7
I11
sg20
VC0006142
p3208
sg10
I13
sg11
Vbreast cancer
p3209
sg13
I2
sa(dp3210
g7
I93
sg20
VC0006142
p3211
sg10
I14
sg11
Vbreast cancers
p3212
sg13
I2
sasa(dp3213
g2
S'The present study aims to examine the expression level of DBC1 and assess its prognostic value in human colorectal cancer.\n'
p3214
sg4
(lp3215
(dp3216
g7
I58
sg8
g59
sg10
I4
sg11
VDBC1
p3217
sg13
I1
sasg17
(lp3218
(dp3219
g7
I104
sg20
VC1527249
p3220
sg10
I17
sg11
Vcolorectal cancer
p3221
sg13
I2
sasa(dp3222
g2
S'Immunohistochemical staining was performed to detect the expression level of DBC1 in a series of 186 colorectal cancer patients.\n'
p3223
sg4
(lp3224
(dp3225
g7
I77
sg8
g59
sg10
I4
sg11
VDBC1
p3226
sg13
I1
sasg17
(lp3227
(dp3228
g7
I101
sg20
VC1527249
p3229
sg10
I17
sg11
Vcolorectal cancer
p3230
sg13
I2
sasa(dp3231
g2
S'Compared with the corresponding non-tumor tissues, a higher expression level of DBC1 was detected in colorectal cancer (P &lt; 0.01).\n'
p3232
sg4
(lp3233
(dp3234
g7
I80
sg8
g59
sg10
I4
sg11
VDBC1
p3235
sg13
I1
sasg17
(lp3236
(dp3237
g7
I36
sg20
VC0027651
p3238
sg10
I5
sg11
Vtumor
p3239
sg13
I1
sa(dp3240
g7
I101
sg20
VC1527249
p3241
sg10
I17
sg11
Vcolorectal cancer
p3242
sg13
I2
sasa(dp3243
g2
S'Univariate Cox regression suggested that DBC1 expression, poorly differentiation status and the presence of lymph node metastasis predict shorter overall survival in colorectal cancer (P &lt; 0.05).\n'
p3244
sg4
(lp3245
(dp3246
g7
I41
sg8
g59
sg10
I4
sg11
VDBC1
p3247
sg13
I1
sasg17
(lp3248
(dp3249
g7
I166
sg20
VC1527249
p3250
sg10
I17
sg11
Vcolorectal cancer
p3251
sg13
I2
sa(dp3252
g7
I108
sg20
VC0686619
p3253
sg10
I21
sg11
Vlymph node metastasis
p3254
sg13
I3
sasa(dp3255
g2
S'Multivariate Cox regression analysis indicated that DBC1 acts as an independent prognostic factor in colorectal cancer (P &lt; 0.01).\n'
p3256
sg4
(lp3257
(dp3258
g7
I52
sg8
g59
sg10
I4
sg11
VDBC1
p3259
sg13
I1
sasg17
(lp3260
(dp3261
g7
I101
sg20
VC1527249
p3262
sg10
I17
sg11
Vcolorectal cancer
p3263
sg13
I2
sasa(dp3264
g2
S'These results suggest that DBC1 is over-expressed in colorectal cancer and that it might serve as a predictor for selecting patients at high risk of poor prognosis.\n'
p3265
sg4
(lp3266
(dp3267
g7
I27
sg8
g59
sg10
I4
sg11
VDBC1
p3268
sg13
I1
sasg17
(lp3269
(dp3270
g7
I53
sg20
VC1527249
p3271
sg10
I17
sg11
Vcolorectal cancer
p3272
sg13
I2
sasa(dp3273
g2
S'By targeting PAD2, NTZ increased the deamination (citrullination) and turnover of Beta-catenin in colon cancer cells.\n'
p3274
sg4
(lp3275
(dp3276
g7
I13
sg8
g59
sg10
I4
sg11
VPAD2
p3277
sg13
I1
sa(dp3278
g7
I82
sg8
VP35222
p3279
sg10
I12
sg11
VBeta-catenin
p3280
sg13
I1
sasg17
(lp3281
(dp3282
g7
I98
sg20
VC0699790
p3283
sg10
I12
sg11
Vcolon cancer
p3284
sg13
I2
sasa(dp3285
g2
S'In Wnt-activated colon cancer cells, knockout of either PAD2 or Beta-catenin substantially increased resistance to NTZ treatment.\n'
p3286
sg4
(lp3287
(dp3288
g7
I56
sg8
g59
sg10
I4
sg11
VPAD2
p3289
sg13
I1
sa(dp3290
g7
I64
sg8
VP35222
p3291
sg10
I12
sg11
VBeta-catenin
p3292
sg13
I1
sasg17
(lp3293
(dp3294
g7
I17
sg20
VC0699790
p3295
sg10
I12
sg11
Vcolon cancer
p3296
sg13
I2
sasa(dp3297
g2
S'PAD2, PAD4, and citrullinated proteins are found in the synovium of rheumatoid arthritis patients.\n'
p3298
sg4
(lp3299
(dp3300
g7
I0
sg8
g59
sg10
I4
sg11
VPAD2
p3301
sg13
I1
sa(dp3302
g7
I6
sg8
g59
sg10
I4
sg11
VPAD4
p3303
sg13
I1
sasg17
(lp3304
(dp3305
g7
I68
sg20
VC0003873
p3306
sg10
I20
sg11
Vrheumatoid arthritis
p3307
sg13
I2
sasa(dp3308
g2
S'The isozymes hPAD2 and hPAD4 have been implicated in the development and progression of several autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.\n'
p3309
sg4
(lp3310
sg17
(lp3311
(dp3312
g7
I96
sg20
VC0004364
p3313
sg10
I19
sg11
Vautoimmune diseases
p3314
sg13
I2
sa(dp3315
g7
I127
sg20
VC0003873
p3316
sg10
I20
sg11
Vrheumatoid arthritis
p3317
sg13
I2
sa(dp3318
g7
I152
sg20
VC0026769
p3319
sg10
I18
sg11
Vmultiple sclerosis
p3320
sg13
I2
sasa(dp3321
g2
S'The peptidylarginine deiminase PADI2 has been implicated in chronic inflammatory diseases and cancer.\n'
p3322
sg4
(lp3323
(dp3324
g7
I4
sg8
g59
sg10
I32
sg11
Vpeptidylarginine deiminase PADI2
p3325
sg13
I3
sasg17
(lp3326
(dp3327
g7
I94
sg20
VC0006826
p3328
sg10
I6
sg11
Vcancer
p3329
sg13
I1
sasa(dp3330
g2
S'PADI2 expression was required for survival and cell-cycle progression of prostate cancer cells, and PADI2 promoted proliferation of prostate cancer cells under androgen-deprived or castration conditions in vitro and in vivo Cytoplasmic PADI2 protected the androgen receptor (AR) against proteasome-mediated degradation and facilitated AR binding to its target genes after nuclear translocation and citrullination of histone H3 amino acid residue R26.\n'
p3331
sg4
(lp3332
(dp3333
g7
I275
sg8
VP10275
p3334
sg10
I2
sg11
VAR
p3335
sg13
I1
sa(dp3336
g7
I256
sg8
VP10275
p3337
sg10
I17
sg11
Vandrogen receptor
p3338
sg13
I2
sa(dp3339
g7
I275
sg8
VP10275
p3340
sg10
I2
sg11
VAR
p3341
sg13
I1
sa(dp3342
g7
I0
sg8
g59
sg10
I5
sg11
VPADI2
p3343
sg13
I1
sa(dp3344
g7
I416
sg8
g59
sg10
I10
sg11
Vhistone H3
p3345
sg13
I2
sa(dp3346
g7
I224
sg8
g59
sg10
I17
sg11
VCytoplasmic PADI2
p3347
sg13
I2
sa(dp3348
g7
I0
sg8
g59
sg10
I5
sg11
VPADI2
p3349
sg13
I1
sasg17
(lp3350
(dp3351
g7
I73
sg20
VC0600139
p3352
sg10
I15
sg11
Vprostate cancer
p3353
sg13
I2
sa(dp3354
g7
I115
sg20
VC0334094
p3355
sg10
I13
sg11
Vproliferation
p3356
sg13
I1
sa(dp3357
g7
I380
sg20
VC0040715
p3358
sg10
I13
sg11
Vtranslocation
p3359
sg13
I1
sa(dp3360
g7
I58
sg20
VC1739135
p3361
sg10
I30
sg11
Vprogression of prostate cancer
p3362
sg13
I4
sasa(dp3363
g2
S'Notably, coadministration of the PADI inhibitor Cl-Amidine and the AR signaling inhibitor enzalutamide synergized in inhibiting CRPC cell proliferation in vitro and tumor growth in vivo Overall, our results establish PADI2 as a key mediator for AR in prostate cancer progression, especially CRPC, and they suggest PADI as novel therapeutic targets in this disease setting.\n'
p3364
sg4
(lp3365
(dp3366
g7
I217
sg8
g59
sg10
I5
sg11
VPADI2
p3367
sg13
I1
sasg17
(lp3368
(dp3369
g7
I260
sg20
VC0178874
p3370
sg10
I18
sg11
Vcancer progression
p3371
sg13
I2
sa(dp3372
g7
I165
sg20
VC0598934
p3373
sg10
I12
sg11
Vtumor growth
p3374
sg13
I2
sa(dp3375
g7
I138
sg20
VC0334094
p3376
sg10
I13
sg11
Vproliferation
p3377
sg13
I1
sasa(dp3378
g2
S'The effects of endothelial endothelin-1 (ET-1) over-expression in a transgenic mouse model using Tie-1 promoter (TET-1 mice) on pathophysiological changes of retinal ischemia were investigated by intraluminal insertion of a microfilament up to middle cerebral artery (MCA) to transiently block the ophthalmic artery.\n'
p3379
sg4
(lp3380
(dp3381
g7
I27
sg8
VP20800
p3382
sg10
I12
sg11
Vendothelin-1
p3383
sg13
I1
sa(dp3384
g7
I41
sg8
VP05305
p3385
sg10
I4
sg11
VET-1
p3386
sg13
I1
sa(dp3387
g7
I97
sg8
VP35590
p3388
sg10
I14
sg11
VTie-1 promoter
p3389
sg13
I2
sasg17
(lp3390
(dp3391
g7
I158
sg20
VC0162291
p3392
sg10
I16
sg11
Vretinal ischemia
p3393
sg13
I2
sasa(dp3394
g2
S'In agreement with the decreased FoxO3 activity in Beta-thalassemia, the expression of FoxO3 target genes was also found to decrease, concurrent with elevated phosphorylation of AKT, most clearly at the late stage of erythroid differentiation.\n'
p3395
sg4
(lp3396
(dp3397
g7
I177
sg8
g59
sg10
I3
sg11
VAKT
p3398
sg13
I1
sa(dp3399
g7
I32
sg8
g59
sg10
I5
sg11
VFoxO3
p3400
sg13
I1
sa(dp3401
g7
I86
sg8
g59
sg10
I18
sg11
VFoxO3 target genes
p3402
sg13
I3
sasg17
(lp3403
(dp3404
g7
I50
sg20
VC0005283
p3405
sg10
I16
sg11
VBeta-thalassemia
p3406
sg13
I1
sasa(dp3407
g2
S'Our findings provide further evidence for the involvement of FoxO3 during terminal erythropoiesis and confirm the modulation of the PI3K/AKT pathway as a potential therapeutic strategy for Beta-thalassemia.\n'
p3408
sg4
(lp3409
(dp3410
g7
I137
sg8
g59
sg10
I3
sg11
VAKT
p3411
sg13
I1
sa(dp3412
g7
I132
sg8
VP42336
p3413
sg10
I4
sg11
VPI3K
p3414
sg13
I1
sa(dp3415
g7
I61
sg8
g59
sg10
I5
sg11
VFoxO3
p3416
sg13
I1
sasg17
(lp3417
(dp3418
g7
I189
sg20
VC0005283
p3419
sg10
I16
sg11
VBeta-thalassemia
p3420
sg13
I1
sasa(dp3421
g2
S'Western blot analysis revealed that Notch2HCS mutant splenocytes had increased phospho-Akt and phospho-Jun N-terminal kinase, and gene expression analysis of splenic CD19+ B cells demonstrated induction of Hes1 and Hes5 in Notch2HCS mutants.\n'
p3422
sg4
(lp3423
(dp3424
g7
I223
sg8
g59
sg10
I17
sg11
VNotch2HCS mutants
p3425
sg13
I2
sa(dp3426
g7
I87
sg8
g59
sg10
I3
sg11
VAkt
p3427
sg13
I1
sa(dp3428
g7
I95
sg8
VP45983
p3429
sg10
I29
sg11
Vphospho-Jun N-terminal kinase
p3430
sg13
I3
sa(dp3431
g7
I206
sg8
g59
sg10
I4
sg11
VHes1
p3432
sg13
I1
sa(dp3433
g7
I215
sg8
g59
sg10
I4
sg11
VHes5
p3434
sg13
I1
sasg17
(lp3435
(dp3436
g7
I46
sg20
VC0596988
p3437
sg10
I6
sg11
Vmutant
p3438
sg13
I1
sasa(dp3439
g2
S'The bone marrow transplantation further suggested that the amelioration of atherosclerosis might be attributed to the effects of IRF3 deficiency mainly in endothelial cells, as well as in macrophages.\n'
p3440
sg4
(lp3441
(dp3442
g7
I129
sg8
g59
sg10
I4
sg11
VIRF3
p3443
sg13
I1
sasg17
(lp3444
(dp3445
g7
I75
sg20
VC0004153
p3446
sg10
I15
sg11
Vatherosclerosis
p3447
sg13
I1
sasa(dp3448
g2
S'Thus, our study suggests that IRF3 might be a potential target for the treatment of atherosclerosis development.\n'
p3449
sg4
(lp3450
(dp3451
g7
I30
sg8
g59
sg10
I4
sg11
VIRF3
p3452
sg13
I1
sasg17
(lp3453
(dp3454
g7
I84
sg20
VC0004153
p3455
sg10
I15
sg11
Vatherosclerosis
p3456
sg13
I1
sasa(dp3457
g2
S'We examined cell cycle-related molecules in K562 transfected with NIC or RBP-J(R218H), and found that the protein level of the retinoblastoma gene product (the Rb protein) was induced in K562 expressing NIC, and down-regulated in K562 expressing RBP-J(R218H).\n'
p3458
sg4
(lp3459
(dp3460
g7
I73
sg8
g59
sg10
I5
sg11
VRBP-J
p3461
sg13
I1
sa(dp3462
g7
I73
sg8
g59
sg10
I5
sg11
VRBP-J
p3463
sg13
I1
sa(dp3464
g7
I127
sg8
g59
sg10
I27
sg11
Vretinoblastoma gene product
p3465
sg13
I3
sasg17
(lp3466
(dp3467
g7
I127
sg20
VC0035335
p3468
sg10
I14
sg11
Vretinoblastoma
p3469
sg13
I1
sasa(dp3470
g2
S"Two negative regulatory elements, the 3'-retinoblastoma control element (RCE) and the binding site for Epstein-Barr virus C-promoter binding factor 1 (CBF1), also contributed to CpG ODN induction of hIL-6 gene expression.\n"
p3471
sg4
(lp3472
(dp3473
g7
I199
sg8
VP01771
p3474
sg10
I10
sg11
VhIL-6 gene
p3475
sg13
I2
sa(dp3476
g7
I41
sg8
g59
sg10
I30
sg11
Vretinoblastoma control element
p3477
sg13
I3
sa(dp3478
g7
I151
sg8
g59
sg10
I4
sg11
VCBF1
p3479
sg13
I1
sa(dp3480
g7
I103
sg8
VP63244
p3481
sg10
I46
sg11
VEpstein-Barr virus C-promoter binding factor 1
p3482
sg13
I6
sasg17
(lp3483
(dp3484
g7
I41
sg20
VC0035335
p3485
sg10
I14
sg11
Vretinoblastoma
p3486
sg13
I1
sasa(dp3487
g2
S'All data and technical reports of the 15 rounds of polio SIAs from June 2013 through June 2015 and routine immunization coverages for DPT-Hib-HepB 3 and measles were observed.\n'
p3488
sg4
(lp3489
(dp3490
g7
I134
sg8
g59
sg10
I14
sg11
VDPT-Hib-HepB 3
p3491
sg13
I2
sasg17
(lp3492
(dp3493
g7
I51
sg20
VC0032371
p3494
sg10
I5
sg11
Vpolio
p3495
sg13
I1
sa(dp3496
g7
I153
sg20
VC0025007
p3497
sg10
I7
sg11
Vmeasles
p3498
sg13
I1
sasa(dp3499
g2
S'According to the Ethiopian Health Sector Development Plan IV annual performance report (HSDP IV), Ethiopia targeted to reach 90% coverage with DPT-Hib-HepB 3 (Pentavalent3) vaccine and 86% coverage with measles vaccine in 2010- 2011.\n'
p3500
sg4
(lp3501
(dp3502
g7
I143
sg8
g59
sg10
I14
sg11
VDPT-Hib-HepB 3
p3503
sg13
I2
sasg17
(lp3504
(dp3505
g7
I203
sg20
VC0025007
p3506
sg10
I7
sg11
Vmeasles
p3507
sg13
I1
sa(dp3508
g7
I53
sg20
VC0270724
p3509
sg10
I4
sg11
VPlan
p3510
sg13
I1
sasa(dp3511
g2
S'Only 24.5% of Syrian refugee children in Jordan and 12.5% in Lebanon were fully immunized through routine vaccination services (having received from non-campaign sources: measles, polio 1-3, and DPT 1-3 in Jordan and Lebanon, and BCG in Jordan).\n'
p3512
sg4
(lp3513
(dp3514
g7
I195
sg8
g59
sg10
I7
sg11
VDPT 1-3
p3515
sg13
I2
sasg17
(lp3516
(dp3517
g7
I171
sg20
VC0025007
p3518
sg10
I7
sg11
Vmeasles
p3519
sg13
I1
sa(dp3520
g7
I180
sg20
VC0032371
p3521
sg10
I5
sg11
Vpolio
p3522
sg13
I1
sasa(dp3523
g2
S"Methods: We utilized datasets from the Demographic and Health Surveys Program, available for Benin, Burkina Faso, The Gambia, Ghana, Guinea, Cote d'Ivoire, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo, to obtain coverage for Bacillus Calmette-Guerin, polio, measles, and diphtheria, pertussis and tetanus (DPT) vaccines in children aged 12 - 23 months.\n"
p3524
sg4
(lp3525
sg17
(lp3526
(dp3527
g7
I268
sg20
VC0032371
p3528
sg10
I5
sg11
Vpolio
p3529
sg13
I1
sa(dp3530
g7
I300
sg20
VC0043167
p3531
sg10
I9
sg11
Vpertussis
p3532
sg13
I1
sa(dp3533
g7
I288
sg20
VC0012546
p3534
sg10
I10
sg11
Vdiphtheria
p3535
sg13
I1
sa(dp3536
g7
I275
sg20
VC0025007
p3537
sg10
I7
sg11
Vmeasles
p3538
sg13
I1
sa(dp3539
g7
I314
sg20
VC0039614
p3540
sg10
I7
sg11
Vtetanus
p3541
sg13
I1
sasa(dp3542
g2
S'We also calculated the DPT1-to-DPT3 and DPT1-to-measles dropouts, and proportions of the fully immunised child (FIC).\n'
p3543
sg4
(lp3544
sg17
(lp3545
(dp3546
g7
I48
sg20
VC0025007
p3547
sg10
I7
sg11
Vmeasles
p3548
sg13
I1
sasa(dp3549
g2
S'Similarly, DPT1-measles dropout exceeded 10% in all but four countries.\n'
p3550
sg4
(lp3551
sg17
(lp3552
(dp3553
g7
I16
sg20
VC0025007
p3554
sg10
I7
sg11
Vmeasles
p3555
sg13
I1
sasa(dp3556
g2
S'We defined full immunization coverage (FIC) as having received one dose of BCG (bacille Calmette-Guerin), one dose of measles, three doses of polio, and three doses of DPT vaccines.\n'
p3557
sg4
(lp3558
sg17
(lp3559
(dp3560
g7
I118
sg20
VC0025007
p3561
sg10
I7
sg11
Vmeasles
p3562
sg13
I1
sa(dp3563
g7
I142
sg20
VC0032371
p3564
sg10
I5
sg11
Vpolio
p3565
sg13
I1
sasa(dp3566
g2
S'Using Medecins Sans Frontieres (MSF)-provided data and modifying our decision-tree models, we estimated if administering Haemophilus influenzae type b (Hib)-containing (pentavalent vaccine, also with diphtheria pertussis and tetanus [DPT] and hepatitis B) and pneumococcal conjugate (PCV) vaccines were cost-effective against hospitalized pneumonia.\n'
p3567
sg4
(lp3568
(dp3569
g7
I6
sg8
g59
sg10
I13
sg11
VMedecins Sans
p3570
sg13
I2
sasg17
(lp3571
(dp3572
g7
I243
sg20
VC0019163
p3573
sg10
I11
sg11
Vhepatitis B
p3574
sg13
I2
sa(dp3575
g7
I200
sg20
VC0012546
p3576
sg10
I10
sg11
Vdiphtheria
p3577
sg13
I1
sa(dp3578
g7
I211
sg20
VC0043167
p3579
sg10
I9
sg11
Vpertussis
p3580
sg13
I1
sa(dp3581
g7
I225
sg20
VC0039614
p3582
sg10
I7
sg11
Vtetanus
p3583
sg13
I1
sa(dp3584
g7
I339
sg20
VC0032285
p3585
sg10
I9
sg11
Vpneumonia
p3586
sg13
I1
sasa(dp3587
g2
S'Median coverage across all districts for each of eight vaccine doses (1 Bacille Calmette-Guerin dose, 3 DPT doses, 3 oral poliovirus vaccine doses, and 1 measles vaccine dose) was &lt;50%.\n'
p3588
sg4
(lp3589
sg17
(lp3590
(dp3591
g7
I154
sg20
VC0025007
p3592
sg10
I7
sg11
Vmeasles
p3593
sg13
I1
sasa(dp3594
g2
S'The primary outcome was full vaccination coverage with all five vaccines (1 dose of BCG, 3 doses of hepatitis B, 3 doses of OPV, 3 doses of DPT and 1 dose of measles vaccine), and the secondary outcome was coverage with each dose of the five individual vaccines.\n'
p3595
sg4
(lp3596
sg17
(lp3597
(dp3598
g7
I158
sg20
VC0025007
p3599
sg10
I7
sg11
Vmeasles
p3600
sg13
I1
sa(dp3601
g7
I100
sg20
VC0019163
p3602
sg10
I11
sg11
Vhepatitis B
p3603
sg13
I2
sasa(dp3604
g2
S'The current data strongly suggest that cathepsin-S degradation of nidogen-1 is strongly associated with NSCLC, which needs validation in larger clinical cohorts.\n'
p3605
sg4
(lp3606
(dp3607
g7
I66
sg8
VP14543
p3608
sg10
I9
sg11
Vnidogen-1
p3609
sg13
I1
sa(dp3610
g7
I39
sg8
VP25774
p3611
sg10
I11
sg11
Vcathepsin-S
p3612
sg13
I1
sasg17
(lp3613
(dp3614
g7
I104
sg20
VC0007131
p3615
sg10
I5
sg11
VNSCLC
p3616
sg13
I1
sasa(dp3617
g2
S'The mRNA expression levels of 9 genes, including EGF, Cathepsin K, Cathepsin S, COX-2, MMP-9, PDGF, uPA, VEGFA, HGF, were evaluated by real-time PCR in 98 NSCLC.\n'
p3618
sg4
(lp3619
(dp3620
g7
I94
sg8
VP04085
p3621
sg10
I4
sg11
VPDGF
p3622
sg13
I1
sa(dp3623
g7
I100
sg8
VP00749
p3624
sg10
I3
sg11
VuPA
p3625
sg13
I1
sa(dp3626
g7
I112
sg8
VP05231
p3627
sg10
I3
sg11
VHGF
p3628
sg13
I1
sa(dp3629
g7
I49
sg8
VP01133
p3630
sg10
I3
sg11
VEGF
p3631
sg13
I1
sa(dp3632
g7
I87
sg8
VP14780
p3633
sg10
I5
sg11
VMMP-9
p3634
sg13
I1
sa(dp3635
g7
I54
sg8
VP43235
p3636
sg10
I11
sg11
VCathepsin K
p3637
sg13
I2
sa(dp3638
g7
I80
sg8
VP35354
p3639
sg10
I5
sg11
VCOX-2
p3640
sg13
I1
sa(dp3641
g7
I67
sg8
VP25774
p3642
sg10
I11
sg11
VCathepsin S
p3643
sg13
I2
sasg17
(lp3644
(dp3645
g7
I112
sg20
VC0399440
p3646
sg10
I3
sg11
VHGF
p3647
sg13
I1
sa(dp3648
g7
I155
sg20
VC0007131
p3649
sg10
I5
sg11
VNSCLC
p3650
sg13
I1
sasa(dp3651
g2
S'The mRNA expression levels of IL-10, cathepsin B, cathepsin S, which were closely related with TAM according to the literatures, were evaluated by Quantitative real-time RT-PCR in 63 NSCLC.\n'
p3652
sg4
(lp3653
(dp3654
g7
I37
sg8
VP07858
p3655
sg10
I11
sg11
Vcathepsin B
p3656
sg13
I2
sa(dp3657
g7
I50
sg8
VP25774
p3658
sg10
I11
sg11
Vcathepsin S
p3659
sg13
I2
sasg17
(lp3660
(dp3661
g7
I183
sg20
VC0007131
p3662
sg10
I5
sg11
VNSCLC
p3663
sg13
I1
sa(dp3664
g7
I95
sg20
VC1834582
p3665
sg10
I3
sg11
VTAM
p3666
sg13
I1
sasa(dp3667
g2
S'The expression of 13 Cathepsins was examined using DNA-microarray technology in tumor tissues of 89 surgically treated NSCLC patients.\n'
p3668
sg4
(lp3669
sg17
(lp3670
(dp3671
g7
I80
sg20
VC0027651
p3672
sg10
I5
sg11
Vtumor
p3673
sg13
I1
sa(dp3674
g7
I119
sg20
VC0007131
p3675
sg10
I5
sg11
VNSCLC
p3676
sg13
I1
sasa(dp3677
g2
S'The combined expression level of Cathepsins B and K identifies high-risk NSCLC patients.\n'
p3678
sg4
(lp3679
(dp3680
g7
I33
sg8
VP25774
p3681
sg10
I12
sg11
VCathepsins B
p3682
sg13
I2
sasg17
(lp3683
(dp3684
g7
I73
sg20
VC0007131
p3685
sg10
I5
sg11
VNSCLC
p3686
sg13
I1
sasa(dp3687
g2
S'We measured plasma cystatin C concentration and activity of cathepsins B and L in tumor tissue as possible markers for the efficiency of antitumor therapy and prognostic criteria for Lewis lung adenocarcinoma in mice.\n'
p3688
sg4
(lp3689
(dp3690
g7
I60
sg8
VP25774
p3691
sg10
I18
sg11
Vcathepsins B and L
p3692
sg13
I4
sa(dp3693
g7
I12
sg8
VP01034
p3694
sg10
I17
sg11
Vplasma cystatin C
p3695
sg13
I3
sasg17
(lp3696
(dp3697
g7
I82
sg20
VC0027651
p3698
sg10
I5
sg11
Vtumor
p3699
sg13
I1
sa(dp3700
g7
I189
sg20
VC0152013
p3701
sg10
I19
sg11
Vlung adenocarcinoma
p3702
sg13
I2
sasa(dp3703
g2
S'We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with pre-eclampsia induced by TLR3 or TLR7 activation.\n'
p3704
sg4
(lp3705
(dp3706
g7
I157
sg8
g59
sg10
I4
sg11
VTLR3
p3707
sg13
I1
sa(dp3708
g7
I165
sg8
g59
sg10
I4
sg11
VTLR7
p3709
sg13
I1
sasg17
(lp3710
(dp3711
g7
I25
sg20
VC1704436
p3712
sg10
I3
sg11
VPAD
p3713
sg13
I1
sa(dp3714
g7
I132
sg20
VC0032914
p3715
sg10
I13
sg11
Vpre-eclampsia
p3716
sg13
I1
sa(dp3717
g7
I63
sg20
VC0021368
p3718
sg10
I12
sg11
Vinflammation
p3719
sg13
I1
sasa(dp3720
g2
S'Although this is the first study of the association between TLR3 polymorphisms and preeclampsia, we found that TLR3 polymorphisms are unlikely to play a significant role in the development of preeclampsia in the Chinese Han population.\n'
p3721
sg4
(lp3722
(dp3723
g7
I60
sg8
g59
sg10
I4
sg11
VTLR3
p3724
sg13
I1
sa(dp3725
g7
I60
sg8
g59
sg10
I4
sg11
VTLR3
p3726
sg13
I1
sasg17
(lp3727
(dp3728
g7
I83
sg20
VC0032914
p3729
sg10
I12
sg11
Vpreeclampsia
p3730
sg13
I1
sa(dp3731
g7
I83
sg20
VC0032914
p3732
sg10
I12
sg11
Vpreeclampsia
p3733
sg13
I1
sasa(dp3734
g2
S'Here, we examined the role of microRNA-182 (miR-182) in pancreatic cancer development.\n'
p3735
sg4
(lp3736
sg17
(lp3737
(dp3738
g7
I56
sg20
VC0235974
p3739
sg10
I17
sg11
Vpancreatic cancer
p3740
sg13
I2
sasa(dp3741
g2
S'Analysis of human pancreatic cancer specimens and cell lines showed that miR-182 is overexpressed in pancreatic cancer and promotes tumor proliferation and invasion.\n'
p3742
sg4
(lp3743
(dp3744
g7
I73
sg8
g59
sg10
I7
sg11
VmiR-182
p3745
sg13
I1
sasg17
(lp3746
(dp3747
g7
I18
sg20
VC0235974
p3748
sg10
I17
sg11
Vpancreatic cancer
p3749
sg13
I2
sa(dp3750
g7
I132
sg20
VC0027651
p3751
sg10
I5
sg11
Vtumor
p3752
sg13
I1
sa(dp3753
g7
I18
sg20
VC0235974
p3754
sg10
I17
sg11
Vpancreatic cancer
p3755
sg13
I2
sa(dp3756
g7
I156
sg20
VC2699153
p3757
sg10
I8
sg11
Vinvasion
p3758
sg13
I1
sa(dp3759
g7
I138
sg20
VC0334094
p3760
sg10
I13
sg11
Vproliferation
p3761
sg13
I1
sasa(dp3762
g2
S'The oncogenic effect of miR-182 and its reversal by Beta-TrCP2 were confirmed in vivo This study suggests that Beta-TrCP and miR-182 may be possible biomarkers and targets for early detection and treatment of pancreatic cancer.\n'
p3763
sg4
(lp3764
(dp3765
g7
I24
sg8
g59
sg10
I7
sg11
VmiR-182
p3766
sg13
I1
sa(dp3767
g7
I24
sg8
g59
sg10
I7
sg11
VmiR-182
p3768
sg13
I1
sa(dp3769
g7
I52
sg8
g59
sg10
I9
sg11
VBeta-TrCP
p3770
sg13
I1
sasg17
(lp3771
(dp3772
g7
I209
sg20
VC0235974
p3773
sg10
I17
sg11
Vpancreatic cancer
p3774
sg13
I2
sasa(dp3775
g2
S'However, less information on the circulating miR-182 in pancreatic cancer (PCa) is available.\n'
p3776
sg4
(lp3777
(dp3778
g7
I45
sg8
g59
sg10
I7
sg11
VmiR-182
p3779
sg13
I1
sasg17
(lp3780
(dp3781
g7
I56
sg20
VC0235974
p3782
sg10
I17
sg11
Vpancreatic cancer
p3783
sg13
I2
sa(dp3784
g7
I75
sg20
VC0268398
p3785
sg10
I3
sg11
VPCa
p3786
sg13
I1
sasa(dp3787
g2
S'Our data suggest that circulating miR-182 may be a potential and useful noninvasive tumor marker for diagnosis and prognosis of pancreatic cancer.\n'
p3788
sg4
(lp3789
(dp3790
g7
I34
sg8
g59
sg10
I7
sg11
VmiR-182
p3791
sg13
I1
sasg17
(lp3792
(dp3793
g7
I128
sg20
VC0235974
p3794
sg10
I17
sg11
Vpancreatic cancer
p3795
sg13
I2
sa(dp3796
g7
I84
sg20
VC0027651
p3797
sg10
I5
sg11
Vtumor
p3798
sg13
I1
sasa(dp3799
g2
S'In this study, we investigated the role and underlying mechanism of action of miR-182 in papillary thyroid carcinoma (PTC).\n'
p3800
sg4
(lp3801
(dp3802
g7
I78
sg8
g59
sg10
I7
sg11
VmiR-182
p3803
sg13
I1
sasg17
(lp3804
(dp3805
g7
I118
sg20
VC0238463
p3806
sg10
I3
sg11
VPTC
p3807
sg13
I1
sa(dp3808
g7
I89
sg20
VC0238463
p3809
sg10
I27
sg11
Vpapillary thyroid carcinoma
p3810
sg13
I3
sasa(dp3811
g2
S'In this study, we use mouse and human medulloblastoma stem-like cells belonging to the Sonic Hedgehog subgroup (SHH MB-SLCs) and demonstrate that genetic suppression of EZH2 reduces the level of its histone mark H3K27me3 and lowers proliferation and self-renewal.\n'
p3812
sg4
(lp3813
(dp3814
g7
I199
sg8
VP62805
p3815
sg10
I7
sg11
Vhistone
p3816
sg13
I1
sa(dp3817
g7
I112
sg8
g59
sg10
I11
sg11
VSHH MB-SLCs
p3818
sg13
I2
sa(dp3819
g7
I169
sg8
g59
sg10
I4
sg11
VEZH2
p3820
sg13
I1
sa(dp3821
g7
I87
sg8
g59
sg10
I23
sg11
VSonic Hedgehog subgroup
p3822
sg13
I3
sasg17
(lp3823
(dp3824
g7
I38
sg20
VC0025149
p3825
sg10
I15
sg11
Vmedulloblastoma
p3826
sg13
I1
sa(dp3827
g7
I232
sg20
VC0334094
p3828
sg10
I13
sg11
Vproliferation
p3829
sg13
I1
sa(dp3830
g7
I154
sg20
VC0221103
p3831
sg10
I11
sg11
Vsuppression
p3832
sg13
I1
sasa(dp3833
g2
S'Here, we reported more abundant expression of maternal embryonic leucine-zipper kinase (MELK) and enhancer of zeste homolog 2 (EZH2) in medulloblastoma stem-like cells than in neural stem cells and the interaction between the two proteins could mediate the self-renewal of sonic hedgehog subtype medulloblastoma.\n'
p3834
sg4
(lp3835
(dp3836
g7
I46
sg8
VP30740
p3837
sg10
I40
sg11
Vmaternal embryonic leucine-zipper kinase
p3838
sg13
I4
sa(dp3839
g7
I98
sg8
g59
sg10
I27
sg11
Venhancer of zeste homolog 2
p3840
sg13
I5
sa(dp3841
g7
I127
sg8
g59
sg10
I4
sg11
VEZH2
p3842
sg13
I1
sa(dp3843
g7
I88
sg8
g59
sg10
I4
sg11
VMELK
p3844
sg13
I1
sasg17
(lp3845
(dp3846
g7
I136
sg20
VC0025149
p3847
sg10
I15
sg11
Vmedulloblastoma
p3848
sg13
I1
sa(dp3849
g7
I136
sg20
VC0025149
p3850
sg10
I15
sg11
Vmedulloblastoma
p3851
sg13
I1
sasa(dp3852
g2
S'In human medulloblastoma, extensive nodularity and large-cell/anaplastic subgroups differed according to the staining levels of MELK and EZH2 from the other two subgroups.\n'
p3853
sg4
(lp3854
(dp3855
g7
I137
sg8
g59
sg10
I4
sg11
VEZH2
p3856
sg13
I1
sa(dp3857
g7
I128
sg8
g59
sg10
I4
sg11
VMELK
p3858
sg13
I1
sasg17
(lp3859
(dp3860
g7
I9
sg20
VC0025149
p3861
sg10
I15
sg11
Vmedulloblastoma
p3862
sg13
I1
sasa(dp3863
g2
S'Mechanistically, MELK bound to and phosphorylated EZH2, and its methylation was induced by EZH2 in medulloblastoma, which could regulate the proliferation of cancer stem-like cells.\n'
p3864
sg4
(lp3865
(dp3866
g7
I17
sg8
g59
sg10
I4
sg11
VMELK
p3867
sg13
I1
sa(dp3868
g7
I50
sg8
g59
sg10
I4
sg11
VEZH2
p3869
sg13
I1
sa(dp3870
g7
I50
sg8
g59
sg10
I4
sg11
VEZH2
p3871
sg13
I1
sasg17
(lp3872
(dp3873
g7
I141
sg20
VC0334094
p3874
sg10
I13
sg11
Vproliferation
p3875
sg13
I1
sa(dp3876
g7
I158
sg20
VC0006826
p3877
sg10
I6
sg11
Vcancer
p3878
sg13
I1
sa(dp3879
g7
I99
sg20
VC0025149
p3880
sg10
I15
sg11
Vmedulloblastoma
p3881
sg13
I1
sasa(dp3882
g2
S'In xenografts, loss of MELK or EZH2 attenuated medulloblastoma stem-like cell-derived tumor growth and promoted differentiation.\n'
p3883
sg4
(lp3884
(dp3885
g7
I23
sg8
g59
sg10
I4
sg11
VMELK
p3886
sg13
I1
sa(dp3887
g7
I31
sg8
g59
sg10
I4
sg11
VEZH2
p3888
sg13
I1
sasg17
(lp3889
(dp3890
g7
I86
sg20
VC0598934
p3891
sg10
I12
sg11
Vtumor growth
p3892
sg13
I2
sa(dp3893
g7
I47
sg20
VC0025149
p3894
sg10
I15
sg11
Vmedulloblastoma
p3895
sg13
I1
sasa(dp3896
g2
S'These findings indicate that MELK-induced phosphorylation and EZH2-mediated methylation in MELK/EZH2 pathway are essential for medulloblastoma stem-like cell-derived tumor proliferation, thereby identifying a potential therapeutic strategy for these patients.Implications: This study demonstrates that the interaction occurring between MELK and EZH2 promotes self-proliferation and stemness, thus representing an attractive therapeutic target and potential candidate for diagnosis of medulloblastoma.\n'
p3897
sg4
(lp3898
(dp3899
g7
I62
sg8
g59
sg10
I4
sg11
VEZH2
p3900
sg13
I1
sa(dp3901
g7
I29
sg8
g59
sg10
I4
sg11
VMELK
p3902
sg13
I1
sa(dp3903
g7
I62
sg8
g59
sg10
I4
sg11
VEZH2
p3904
sg13
I1
sa(dp3905
g7
I62
sg8
g59
sg10
I4
sg11
VEZH2
p3906
sg13
I1
sa(dp3907
g7
I29
sg8
g59
sg10
I4
sg11
VMELK
p3908
sg13
I1
sa(dp3909
g7
I29
sg8
g59
sg10
I4
sg11
VMELK
p3910
sg13
I1
sasg17
(lp3911
(dp3912
g7
I172
sg20
VC0334094
p3913
sg10
I13
sg11
Vproliferation
p3914
sg13
I1
sa(dp3915
g7
I172
sg20
VC0334094
p3916
sg10
I13
sg11
Vproliferation
p3917
sg13
I1
sa(dp3918
g7
I127
sg20
VC0025149
p3919
sg10
I15
sg11
Vmedulloblastoma
p3920
sg13
I1
sa(dp3921
g7
I166
sg20
VC0027651
p3922
sg10
I5
sg11
Vtumor
p3923
sg13
I1
sa(dp3924
g7
I127
sg20
VC0025149
p3925
sg10
I15
sg11
Vmedulloblastoma
p3926
sg13
I1
sasa(dp3927
g2
S'The most aggressive of four medulloblastoma (MB) subgroups are cMyc-driven group 3 (G3) tumors, some of which overexpress EZH2, the histone H3K27 mono-, di-, and trimethylase of polycomb-repressive complex 2.\n'
p3928
sg4
(lp3929
(dp3930
g7
I132
sg8
VP62805
p3931
sg10
I13
sg11
Vhistone H3K27
p3932
sg13
I2
sa(dp3933
g7
I122
sg8
g59
sg10
I4
sg11
VEZH2
p3934
sg13
I1
sasg17
(lp3935
(dp3936
g7
I88
sg20
VC0027651
p3937
sg10
I6
sg11
Vtumors
p3938
sg13
I1
sa(dp3939
g7
I9
sg20
VC0001807
p3940
sg10
I10
sg11
Vaggressive
p3941
sg13
I1
sa(dp3942
g7
I146
sg20
VC0021345
p3943
sg10
I4
sg11
Vmono
p3944
sg13
I1
sa(dp3945
g7
I45
sg20
VC0025149
p3946
sg10
I2
sg11
VMB
p3947
sg13
I1
sa(dp3948
g7
I28
sg20
VC0025149
p3949
sg10
I15
sg11
Vmedulloblastoma
p3950
sg13
I1
sasa(dp3951
g2
S'Phase II trials for brain tumors will investigate agents that act on cMET, PDGFRA, or EZH2 in HGG, DIPG, or medulloblastoma, respectively.\n'
p3952
sg4
(lp3953
(dp3954
g7
I86
sg8
g59
sg10
I4
sg11
VEZH2
p3955
sg13
I1
sa(dp3956
g7
I75
sg8
VP16234
p3957
sg10
I6
sg11
VPDGFRA
p3958
sg13
I1
sasg17
(lp3959
(dp3960
g7
I20
sg20
VC0006118
p3961
sg10
I12
sg11
Vbrain tumors
p3962
sg13
I2
sa(dp3963
g7
I108
sg20
VC0025149
p3964
sg10
I15
sg11
Vmedulloblastoma
p3965
sg13
I1
sasa(dp3966
g2
S'Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme.\n'
p3967
sg4
(lp3968
(dp3969
g7
I88
sg8
g59
sg10
I4
sg11
VEZH2
p3970
sg13
I1
sasg17
(lp3971
(dp3972
g7
I168
sg20
VC0025149
p3973
sg10
I15
sg11
Vmedulloblastoma
p3974
sg13
I1
sa(dp3975
g7
I153
sg20
VC0678222
p3976
sg10
I13
sg11
Vbreast cancer
p3977
sg13
I2
sa(dp3978
g7
I189
sg20
VC1621958
p3979
sg10
I23
sg11
Vglioblastoma multiforme
p3980
sg13
I2
sa(dp3981
g7
I112
sg20
VC0006826
p3982
sg10
I12
sg11
Vmalignancies
p3983
sg13
I1
sa(dp3984
g7
I136
sg20
VC0600139
p3985
sg10
I15
sg11
Vprostate cancer
p3986
sg13
I2
sasa(dp3987
g2
S'Silencing of OTX2 in D425 medulloblastoma cells resulted in downregulation of polycomb genes such as EZH2, EED, SUZ12 and RBBP4 and upregulation of H3K27 demethylases KDM6A, KDM6B,                 JARID2 and KDM7A.\n'
p3988
sg4
(lp3989
(dp3990
g7
I148
sg8
g59
sg10
I24
sg11
VH3K27 demethylases KDM6A
p3991
sg13
I3
sa(dp3992
g7
I101
sg8
g59
sg10
I4
sg11
VEZH2
p3993
sg13
I1
sa(dp3994
g7
I13
sg8
VP32243
p3995
sg10
I4
sg11
VOTX2
p3996
sg13
I1
sa(dp3997
g7
I197
sg8
g59
sg10
I6
sg11
VJARID2
p3998
sg13
I1
sa(dp3999
g7
I208
sg8
g59
sg10
I5
sg11
VKDM7A
p4000
sg13
I1
sa(dp4001
g7
I174
sg8
g59
sg10
I5
sg11
VKDM6B
p4002
sg13
I1
sa(dp4003
g7
I112
sg8
g59
sg10
I5
sg11
VSUZ12
p4004
sg13
I1
sa(dp4005
g7
I122
sg8
g59
sg10
I5
sg11
VRBBP4
p4006
sg13
I1
sa(dp4007
g7
I107
sg8
g59
sg10
I3
sg11
VEED
p4008
sg13
I1
sasg17
(lp4009
(dp4010
g7
I26
sg20
VC0025149
p4011
sg10
I15
sg11
Vmedulloblastoma
p4012
sg13
I1
sasa(dp4013
g2
S'Peripheral blood mononuclear cells of typhoid fever patients had a higher percentage of lymphocytic cells expressing intracellular granzyme A and granzyme B, but not granzyme K, compared to controls.\n'
p4014
sg4
(lp4015
(dp4016
g7
I146
sg8
VP10144
p4017
sg10
I10
sg11
Vgranzyme B
p4018
sg13
I2
sa(dp4019
g7
I131
sg8
VP12544
p4020
sg10
I10
sg11
Vgranzyme A
p4021
sg13
I2
sasg17
(lp4022
(dp4023
g7
I38
sg20
VC0041466
p4024
sg10
I13
sg11
Vtyphoid fever
p4025
sg13
I2
sasa(dp4026
g2
S'The pediatric sarcoma Alveolar Rhabdomyosarcoma, which is primarily characterized by the expression of the PAX3-FOXO1 oncogenic fusion protein, consists of undifferentiated muscle cells.\n'
p4027
sg4
(lp4028
(dp4029
g7
I107
sg8
VP23760
p4030
sg10
I4
sg11
VPAX3
p4031
sg13
I1
sa(dp4032
g7
I112
sg8
g59
sg10
I5
sg11
VFOXO1
p4033
sg13
I1
sasg17
(lp4034
(dp4035
g7
I22
sg20
VC0206655
p4036
sg10
I25
sg11
VAlveolar Rhabdomyosarcoma
p4037
sg13
I2
sa(dp4038
g7
I14
sg20
VC1261473
p4039
sg10
I7
sg11
Vsarcoma
p4040
sg13
I1
sasa(dp4041
g2
S'One specific example for such a cancer type is alveolar rhabdomyosarcoma, which is associated in the majority of cases with the fusion protein PAX3-FOXO1.\n'
p4042
sg4
(lp4043
(dp4044
g7
I143
sg8
VP23760
p4045
sg10
I4
sg11
VPAX3
p4046
sg13
I1
sa(dp4047
g7
I148
sg8
g59
sg10
I5
sg11
VFOXO1
p4048
sg13
I1
sasg17
(lp4049
(dp4050
g7
I47
sg20
VC0206655
p4051
sg10
I25
sg11
Valveolar rhabdomyosarcoma
p4052
sg13
I2
sa(dp4053
g7
I32
sg20
VC0006826
p4054
sg10
I6
sg11
Vcancer
p4055
sg13
I1
sasa(dp4056
g2
S'In this review, we will discuss the current knowledge regarding potential therapeutic targets that might contribute to indirect interference with PAX3-FOXO1 activity in alveolar rhabdomyosarcoma at the different molecular levels and extrapolate these findings to fusion transcription factors in general.\n'
p4057
sg4
(lp4058
(dp4059
g7
I151
sg8
g59
sg10
I5
sg11
VFOXO1
p4060
sg13
I1
sa(dp4061
g7
I146
sg8
VP23760
p4062
sg10
I4
sg11
VPAX3
p4063
sg13
I1
sasg17
(lp4064
(dp4065
g7
I169
sg20
VC0206655
p4066
sg10
I25
sg11
Valveolar rhabdomyosarcoma
p4067
sg13
I2
sasa(dp4068
g2
S'This study is also the first to demonstrate FOXO1 gene rearrangements in malignant ectomesenchymoma with alveolar rhabdomyosarcoma subtype.\n'
p4069
sg4
(lp4070
(dp4071
g7
I44
sg8
g59
sg10
I10
sg11
VFOXO1 gene
p4072
sg13
I2
sasg17
(lp4073
(dp4074
g7
I105
sg20
VC0206655
p4075
sg10
I25
sg11
Valveolar rhabdomyosarcoma
p4076
sg13
I2
sa(dp4077
g7
I73
sg20
VC0431111
p4078
sg10
I26
sg11
Vmalignant ectomesenchymoma
p4079
sg13
I2
sasa(dp4080
g2
S'Alveolar rhabdomyosarcoma (aRMS) is a pediatric soft tissue cancer commonly associated with a chromosomal translocation that leads to the expression of a Pax3:Foxo1 or Pax7:Foxo1 fusion protein, the developmental underpinnings of which may give clues to its therapeutic approaches.\n'
p4081
sg4
(lp4082
(dp4083
g7
I159
sg8
g59
sg10
I5
sg11
VFoxo1
p4084
sg13
I1
sa(dp4085
g7
I173
sg8
g59
sg10
I20
sg11
VFoxo1 fusion protein
p4086
sg13
I3
sa(dp4087
g7
I154
sg8
VP23760
p4088
sg10
I4
sg11
VPax3
p4089
sg13
I1
sa(dp4090
g7
I168
sg8
VP23759
p4091
sg10
I4
sg11
VPax7
p4092
sg13
I1
sasg17
(lp4093
(dp4094
g7
I0
sg20
VC0206655
p4095
sg10
I25
sg11
VAlveolar rhabdomyosarcoma
p4096
sg13
I2
sa(dp4097
g7
I27
sg20
VC0206655
p4098
sg10
I4
sg11
VaRMS
p4099
sg13
I1
sa(dp4100
g7
I94
sg20
VC0040715
p4101
sg10
I25
sg11
Vchromosomal translocation
p4102
sg13
I2
sa(dp4103
g7
I60
sg20
VC0006826
p4104
sg10
I6
sg11
Vcancer
p4105
sg13
I1
sasa(dp4106
g2
S'We show that interactions within the PAX3 and FOXO1 domains are restricted to their respective TADs in normal conditions, while in a patient-derived alveolar rhabdomyosarcoma cell line, harbouring the diagnostic t(2;13)(q35;q14) translocation that brings together the PAX3 and FOXO1 genes, the PAX3 promoter interacts ectopically with FOXO1 sequences.\n'
p4107
sg4
(lp4108
(dp4109
g7
I46
sg8
g59
sg10
I13
sg11
VFOXO1 domains
p4110
sg13
I2
sa(dp4111
g7
I37
sg8
VP23760
p4112
sg10
I4
sg11
VPAX3
p4113
sg13
I1
sa(dp4114
g7
I277
sg8
g59
sg10
I11
sg11
VFOXO1 genes
p4115
sg13
I2
sa(dp4116
g7
I335
sg8
g59
sg10
I15
sg11
VFOXO1 sequences
p4117
sg13
I2
sa(dp4118
g7
I37
sg8
VP23760
p4119
sg10
I4
sg11
VPAX3
p4120
sg13
I1
sa(dp4121
g7
I294
sg8
VP23760
p4122
sg10
I13
sg11
VPAX3 promoter
p4123
sg13
I2
sasg17
(lp4124
(dp4125
g7
I149
sg20
VC0206655
p4126
sg10
I25
sg11
Valveolar rhabdomyosarcoma
p4127
sg13
I2
sa(dp4128
g7
I229
sg20
VC0040715
p4129
sg10
I13
sg11
Vtranslocation
p4130
sg13
I1
sasa(dp4131
g2
S'The chromosomal translocation that leads to alveolar rhabdomyosarcoma development generates a novel TAD that is likely to favour ectopic PAX3:FOXO1 oncogene activation in non-PAX3 territories.\n'
p4132
sg4
(lp4133
(dp4134
g7
I142
sg8
g59
sg10
I14
sg11
VFOXO1 oncogene
p4135
sg13
I2
sa(dp4136
g7
I137
sg8
VP23760
p4137
sg10
I4
sg11
VPAX3
p4138
sg13
I1
sa(dp4139
g7
I137
sg8
VP23760
p4140
sg10
I4
sg11
VPAX3
p4141
sg13
I1
sasg17
(lp4142
(dp4143
g7
I148
sg20
VC1518575
p4144
sg10
I19
sg11
Voncogene activation
p4145
sg13
I2
sa(dp4146
g7
I4
sg20
VC0040715
p4147
sg10
I25
sg11
Vchromosomal translocation
p4148
sg13
I2
sa(dp4149
g7
I44
sg20
VC0206655
p4150
sg10
I25
sg11
Valveolar rhabdomyosarcoma
p4151
sg13
I2
sasa(dp4152
g2
S"In myasthenia gravis, anti-Kv1.4 and anti-Lrp4 have been characterized as promising novel autoantibodies for the diagnosis of hitherto 'seronegative' myasthenia gravis.\n"
p4153
sg4
(lp4154
(dp4155
g7
I37
sg8
g59
sg10
I9
sg11
Vanti-Lrp4
p4156
sg13
I1
sa(dp4157
g7
I22
sg8
VP22459
p4158
sg10
I10
sg11
Vanti-Kv1.4
p4159
sg13
I1
sasg17
(lp4160
(dp4161
g7
I3
sg20
VC0026896
p4162
sg10
I17
sg11
Vmyasthenia gravis
p4163
sg13
I2
sa(dp4164
g7
I3
sg20
VC0026896
p4165
sg10
I17
sg11
Vmyasthenia gravis
p4166
sg13
I2
sasa(dp4167
g2
S'In a recent study on the submandibular gland of diabetic subjects, we found changed expression of statherin, a salivary protein of fundamental importance in preserving tooth integrity, whose reduction was related with the high incidence of oral diseases in patients with diabetes.\n'
p4168
sg4
(lp4169
(dp4170
g7
I98
sg8
VP02808
p4171
sg10
I9
sg11
Vstatherin
p4172
sg13
I1
sasg17
(lp4173
(dp4174
g7
I271
sg20
VC0011849
p4175
sg10
I8
sg11
Vdiabetes
p4176
sg13
I1
sasa(dp4177
g2
S'The goal of this report is to extend the study to human parotid gland and to compare the effects of diabetes on statherin expression with those previously described in submandibular gland.\n'
p4178
sg4
(lp4179
sg17
(lp4180
(dp4181
g7
I100
sg20
VC0011849
p4182
sg10
I8
sg11
Vdiabetes
p4183
sg13
I1
sasa(dp4184
g2
S'The results indicate that diabetes affects statherin secretion in labial glands and support the hypothesis that the increased susceptibility to oral diseases associated with diabetes could be related with a reduced statherin secretion.\n'
p4185
sg4
(lp4186
(dp4187
g7
I43
sg8
VP02808
p4188
sg10
I9
sg11
Vstatherin
p4189
sg13
I1
sasg17
(lp4190
(dp4191
g7
I26
sg20
VC0011849
p4192
sg10
I8
sg11
Vdiabetes
p4193
sg13
I1
sa(dp4194
g7
I26
sg20
VC0011849
p4195
sg10
I8
sg11
Vdiabetes
p4196
sg13
I1
sasa(dp4197
g2
S'The results obtained suggest that a reduced statherin secretion by salivary glands might be partly responsible for a less effective protection of the oral tissues, resulting in an higher incidence of caries and oral infections associated with diabetes.\n'
p4198
sg4
(lp4199
(dp4200
g7
I44
sg8
VP02808
p4201
sg10
I9
sg11
Vstatherin
p4202
sg13
I1
sasg17
(lp4203
(dp4204
g7
I243
sg20
VC0011849
p4205
sg10
I8
sg11
Vdiabetes
p4206
sg13
I1
sa(dp4207
g7
I216
sg20
VC0021311
p4208
sg10
I10
sg11
Vinfections
p4209
sg13
I1
sa(dp4210
g7
I200
sg20
VC0333519
p4211
sg10
I6
sg11
Vcaries
p4212
sg13
I1
sasa(dp4213
g2
S'Paxillin (PXN) gene mutations are associated with lung adenocarcinoma progression and PXN is known to be a target gene of microRNA-218 (miR-218).\n'
p4214
sg4
(lp4215
(dp4216
g7
I136
sg8
g59
sg10
I7
sg11
VmiR-218
p4217
sg13
I1
sa(dp4218
g7
I0
sg8
VP49023
p4219
sg10
I8
sg11
VPaxillin
p4220
sg13
I1
sa(dp4221
g7
I122
sg8
g59
sg10
I12
sg11
VmicroRNA-218
p4222
sg13
I1
sa(dp4223
g7
I10
sg8
VP49023
p4224
sg10
I3
sg11
VPXN
p4225
sg13
I1
sa(dp4226
g7
I10
sg8
VP49023
p4227
sg10
I3
sg11
VPXN
p4228
sg13
I1
sasg17
(lp4229
(dp4230
g7
I50
sg20
VC0152013
p4231
sg10
I19
sg11
Vlung adenocarcinoma
p4232
sg13
I2
sasa(dp4233
g2
S'FISH and IHC analysis of lung adenocarcinoma suggests that relatively small-scale genomic rearrangements of chromosome 12 are associated with paxillin overexpression in lung adenocarcinoma.\n'
p4234
sg4
(lp4235
(dp4236
g7
I142
sg8
VP49023
p4237
sg10
I8
sg11
Vpaxillin
p4238
sg13
I1
sasg17
(lp4239
(dp4240
g7
I25
sg20
VC0152013
p4241
sg10
I19
sg11
Vlung adenocarcinoma
p4242
sg13
I2
sa(dp4243
g7
I25
sg20
VC0152013
p4244
sg10
I19
sg11
Vlung adenocarcinoma
p4245
sg13
I2
sasa(dp4246
g2
S'Using lung adenocarcinoma FFPE samples and cell lines derived from lung adenocarcinomas, we demonstrated that the gene copy number for MET in lung adenocarcinoma tissue samples was preferentially increased over EGFR, HGF, and PXN and that it positively correlated with a better prognosis.\n'
p4247
sg4
(lp4248
(dp4249
g7
I217
sg8
VP05231
p4250
sg10
I3
sg11
VHGF
p4251
sg13
I1
sa(dp4252
g7
I226
sg8
VP49023
p4253
sg10
I3
sg11
VPXN
p4254
sg13
I1
sasg17
(lp4255
(dp4256
g7
I72
sg20
VC0001418
p4257
sg10
I15
sg11
Vadenocarcinomas
p4258
sg13
I1
sa(dp4259
g7
I217
sg20
VC0399440
p4260
sg10
I3
sg11
VHGF
p4261
sg13
I1
sa(dp4262
g7
I6
sg20
VC0152013
p4263
sg10
I19
sg11
Vlung adenocarcinoma
p4264
sg13
I2
sa(dp4265
g7
I6
sg20
VC0152013
p4266
sg10
I19
sg11
Vlung adenocarcinoma
p4267
sg13
I2
sasa(dp4268
g2
S'By proteomic analysis of striatal lysates from Rhes-heterozygous mice with wild-type or partial or complete knockout of Rasgrp1, we identified a diverse set of Rhes-interacting proteins, the "Rhesactome," and determined that RasGRP1 affected the composition of the amphetamine-induced Rhesactome, which included PDE2A (phosphodiesterase 2A; a protein associated with major depressive disorder), LRRC7 (leucine-rich repeat-containing 7; a protein associated with bipolar disorder and ADHD), and DLG2 (discs large homolog 2; a protein associated with chronic pain).\n'
p4269
sg4
(lp4270
(dp4271
g7
I494
sg8
g59
sg10
I4
sg11
VDLG2
p4272
sg13
I1
sa(dp4273
g7
I395
sg8
g59
sg10
I5
sg11
VLRRC7
p4274
sg13
I1
sa(dp4275
g7
I500
sg8
g59
sg10
I21
sg11
Vdiscs large homolog 2
p4276
sg13
I4
sa(dp4277
g7
I402
sg8
VP30740
p4278
sg10
I32
sg11
Vleucine-rich repeat-containing 7
p4279
sg13
I3
sa(dp4280
g7
I312
sg8
g59
sg10
I5
sg11
VPDE2A
p4281
sg13
I1
sa(dp4282
g7
I319
sg8
VP22413
p4283
sg10
I20
sg11
Vphosphodiesterase 2A
p4284
sg13
I2
sa(dp4285
g7
I160
sg8
g59
sg10
I25
sg11
VRhes-interacting proteins
p4286
sg13
I2
sasg17
(lp4287
(dp4288
g7
I483
sg20
VC1263846
p4289
sg10
I4
sg11
VADHD
p4290
sg13
I1
sa(dp4291
g7
I549
sg20
VC0150055
p4292
sg10
I12
sg11
Vchronic pain
p4293
sg13
I2
sa(dp4294
g7
I462
sg20
VC0005586
p4295
sg10
I16
sg11
Vbipolar disorder
p4296
sg13
I2
sa(dp4297
g7
I367
sg20
VC1269683
p4298
sg10
I25
sg11
Vmajor depressive disorder
p4299
sg13
I3
sasa(dp4300
g2
S'To investigate the expression of miR-96 and related target genes in the regulation of prostatic cancer, we compared the expression of miR-96 in both prostatic cancer and adjacent normal tissues, and explored the role of miR-96 in prostate cancer.\n'
p4301
sg4
(lp4302
(dp4303
g7
I33
sg8
g59
sg10
I6
sg11
VmiR-96
p4304
sg13
I1
sa(dp4305
g7
I33
sg8
g59
sg10
I6
sg11
VmiR-96
p4306
sg13
I1
sa(dp4307
g7
I33
sg8
g59
sg10
I6
sg11
VmiR-96
p4308
sg13
I1
sasg17
(lp4309
(dp4310
g7
I86
sg20
VC0376358
p4311
sg10
I16
sg11
Vprostatic cancer
p4312
sg13
I2
sa(dp4313
g7
I230
sg20
VC0376358
p4314
sg10
I15
sg11
Vprostate cancer
p4315
sg13
I2
sa(dp4316
g7
I86
sg20
VC0376358
p4317
sg10
I16
sg11
Vprostatic cancer
p4318
sg13
I2
sasa(dp4319
g2
S'The expressional alternation of miR-96 target genes, forkhead box O1 (FOXO1) and forkhead box O3a (FOXO3a), in prostatic cancer, was confirmed by PC-3 cells transfected with miR-96 and anti miR-96.\n'
p4320
sg4
(lp4321
(dp4322
g7
I32
sg8
g59
sg10
I6
sg11
VmiR-96
p4323
sg13
I1
sa(dp4324
g7
I53
sg8
g59
sg10
I15
sg11
Vforkhead box O1
p4325
sg13
I3
sa(dp4326
g7
I81
sg8
g59
sg10
I16
sg11
Vforkhead box O3a
p4327
sg13
I3
sa(dp4328
g7
I185
sg8
g59
sg10
I11
sg11
Vanti miR-96
p4329
sg13
I2
sa(dp4330
g7
I70
sg8
g59
sg10
I5
sg11
VFOXO1
p4331
sg13
I1
sa(dp4332
g7
I99
sg8
g59
sg10
I6
sg11
VFOXO3a
p4333
sg13
I1
sa(dp4334
g7
I32
sg8
g59
sg10
I6
sg11
VmiR-96
p4335
sg13
I1
sasg17
(lp4336
(dp4337
g7
I111
sg20
VC0376358
p4338
sg10
I16
sg11
Vprostatic cancer
p4339
sg13
I2
sa(dp4340
g7
I17
sg20
VC0919661
p4341
sg10
I11
sg11
Valternation
p4342
sg13
I1
sasa(dp4343
g2
S'As target genes of miR-96, FOXO1 and FOXO3a confer protection against prostatic cancer, while the inhibition of FOXO1 and FOXO3a enhances cancer proliferation.\n'
p4344
sg4
(lp4345
(dp4346
g7
I37
sg8
g59
sg10
I6
sg11
VFOXO3a
p4347
sg13
I1
sa(dp4348
g7
I19
sg8
g59
sg10
I6
sg11
VmiR-96
p4349
sg13
I1
sa(dp4350
g7
I27
sg8
g59
sg10
I5
sg11
VFOXO1
p4351
sg13
I1
sa(dp4352
g7
I37
sg8
g59
sg10
I6
sg11
VFOXO3a
p4353
sg13
I1
sa(dp4354
g7
I27
sg8
g59
sg10
I5
sg11
VFOXO1
p4355
sg13
I1
sasg17
(lp4356
(dp4357
g7
I145
sg20
VC0334094
p4358
sg10
I13
sg11
Vproliferation
p4359
sg13
I1
sa(dp4360
g7
I70
sg20
VC0376358
p4361
sg10
I16
sg11
Vprostatic cancer
p4362
sg13
I2
sa(dp4363
g7
I80
sg20
VC0006826
p4364
sg10
I6
sg11
Vcancer
p4365
sg13
I1
sasa(dp4366
g2
S'Recent research suggested that microRNA 96 (miR-96) might function as an oncogene in several types of cancers.\n'
p4367
sg4
(lp4368
(dp4369
g7
I31
sg8
g59
sg10
I11
sg11
VmicroRNA 96
p4370
sg13
I2
sa(dp4371
g7
I44
sg8
g59
sg10
I6
sg11
VmiR-96
p4372
sg13
I1
sasg17
(lp4373
(dp4374
g7
I102
sg20
VC0006826
p4375
sg10
I7
sg11
Vcancers
p4376
sg13
I1
sasa(dp4377
g2
S'Therefore, this study determined to probe into the mechanism of miR-96 in hepatocellular carcinoma (HCC) cells.\n'
p4378
sg4
(lp4379
(dp4380
g7
I64
sg8
g59
sg10
I6
sg11
VmiR-96
p4381
sg13
I1
sasg17
(lp4382
(dp4383
g7
I100
sg20
VC2239176
p4384
sg10
I3
sg11
VHCC
p4385
sg13
I1
sa(dp4386
g7
I74
sg20
VC2239176
p4387
sg10
I24
sg11
Vhepatocellular carcinoma
p4388
sg13
I2
sasa(dp4389
g2
S'Results using an 84-cancer specific miRNA panel identified the upregulation of miR-141-3p and miR-96-5p along with a downregulation of miR-26, miR-126-3p, miR-23b, miR-195-5p, miR-374a and let-7 family of miRNAs in endometrial cancer.\n'
p4390
sg4
(lp4391
(dp4392
g7
I164
sg8
g59
sg10
I10
sg11
VmiR-195-5p
p4393
sg13
I1
sa(dp4394
g7
I143
sg8
g59
sg10
I10
sg11
VmiR-126-3p
p4395
sg13
I1
sa(dp4396
g7
I155
sg8
g59
sg10
I7
sg11
VmiR-23b
p4397
sg13
I1
sa(dp4398
g7
I176
sg8
g59
sg10
I8
sg11
VmiR-374a
p4399
sg13
I1
sa(dp4400
g7
I135
sg8
g59
sg10
I6
sg11
VmiR-26
p4401
sg13
I1
sa(dp4402
g7
I94
sg8
g59
sg10
I9
sg11
VmiR-96-5p
p4403
sg13
I1
sa(dp4404
g7
I79
sg8
g59
sg10
I10
sg11
VmiR-141-3p
p4405
sg13
I1
sasg17
(lp4406
(dp4407
g7
I215
sg20
VC0476089
p4408
sg10
I18
sg11
Vendometrial cancer
p4409
sg13
I2
sa(dp4410
g7
I20
sg20
VC0006826
p4411
sg10
I6
sg11
Vcancer
p4412
sg13
I1
sasa(dp4413
g2
S'In the present study, we determined the expression of miR-96 and the function of its target genes in lung cancer through bioinformatic analysis.\n'
p4414
sg4
(lp4415
(dp4416
g7
I54
sg8
g59
sg10
I6
sg11
VmiR-96
p4417
sg13
I1
sasg17
(lp4418
(dp4419
g7
I101
sg20
VC0684249
p4420
sg10
I11
sg11
Vlung cancer
p4421
sg13
I2
sasa(dp4422
g2
S'Compared to the control group, expression of miR-96 was significantly increased in non-small cell lung cancer (NSCLC) (GSE51855), lung adenocarcinoma (GSE48414), stage I adenocarcinoma tissues (GSE63805) and the plasma of lung cancer patients (GSE68951).\n'
p4423
sg4
(lp4424
(dp4425
g7
I45
sg8
g59
sg10
I6
sg11
VmiR-96
p4426
sg13
I1
sasg17
(lp4427
(dp4428
g7
I98
sg20
VC0684249
p4429
sg10
I11
sg11
Vlung cancer
p4430
sg13
I2
sa(dp4431
g7
I83
sg20
VC0007131
p4432
sg10
I26
sg11
Vnon-small cell lung cancer
p4433
sg13
I4
sa(dp4434
g7
I135
sg20
VC0001418
p4435
sg10
I14
sg11
Vadenocarcinoma
p4436
sg13
I1
sa(dp4437
g7
I111
sg20
VC0007131
p4438
sg10
I5
sg11
VNSCLC
p4439
sg13
I1
sa(dp4440
g7
I130
sg20
VC0152013
p4441
sg10
I19
sg11
Vlung adenocarcinoma
p4442
sg13
I2
sasa(dp4443
g2
S'miR-96 was also elevated in six different NSCLC cell lines.\n'
p4444
sg4
(lp4445
(dp4446
g7
I0
sg8
g59
sg10
I6
sg11
VmiR-96
p4447
sg13
I1
sasg17
(lp4448
(dp4449
g7
I42
sg20
VC0007131
p4450
sg10
I5
sg11
VNSCLC
p4451
sg13
I1
sasa(dp4452
g2
S'However, the expression level of miR-96 was not related to the age, gender, clinical stage and histological subtype of the NSCLC patients.\n'
p4453
sg4
(lp4454
(dp4455
g7
I33
sg8
g59
sg10
I6
sg11
VmiR-96
p4456
sg13
I1
sasg17
(lp4457
(dp4458
g7
I123
sg20
VC0007131
p4459
sg10
I5
sg11
VNSCLC
p4460
sg13
I1
sasa(dp4461
g2
S'In conclusion, miR-96, functioning as an oncogene, may play an important role in the development and progression of lung cancer.\n'
p4462
sg4
(lp4463
(dp4464
g7
I15
sg8
g59
sg10
I6
sg11
VmiR-96
p4465
sg13
I1
sasg17
(lp4466
(dp4467
g7
I116
sg20
VC0684249
p4468
sg10
I11
sg11
Vlung cancer
p4469
sg13
I2
sasa(dp4470
g2
S'miR-96 may have the potential to serve as a molecular biomarker for the early diagnosis of NSCLC.\n'
p4471
sg4
(lp4472
(dp4473
g7
I0
sg8
g59
sg10
I6
sg11
VmiR-96
p4474
sg13
I1
sasg17
(lp4475
(dp4476
g7
I91
sg20
VC0007131
p4477
sg10
I5
sg11
VNSCLC
p4478
sg13
I1
sasa(dp4479
g2
S'However, other functions of miR-96-5p in breast cancer, particularly those that are associated with autophagy, remain unknown.\n'
p4480
sg4
(lp4481
(dp4482
g7
I28
sg8
g59
sg10
I9
sg11
VmiR-96-5p
p4483
sg13
I1
sasg17
(lp4484
(dp4485
g7
I41
sg20
VC0678222
p4486
sg10
I13
sg11
Vbreast cancer
p4487
sg13
I2
sasa(dp4488
g2
S'miR-96-5p expression was demonstrated to be upregulated in breast cancer cells compared with in normal breast epithelial cells.\n'
p4489
sg4
(lp4490
(dp4491
g7
I0
sg8
g59
sg10
I9
sg11
VmiR-96-5p
p4492
sg13
I1
sasg17
(lp4493
(dp4494
g7
I59
sg20
VC0678222
p4495
sg10
I13
sg11
Vbreast cancer
p4496
sg13
I2
sasa(dp4497
g2
S'These data indicate that miR-96-5p is involved in the progression of breast cancer cells and may represent a potential therapeutic target for the treatment of breast cancer.\n'
p4498
sg4
(lp4499
(dp4500
g7
I25
sg8
g59
sg10
I9
sg11
VmiR-96-5p
p4501
sg13
I1
sasg17
(lp4502
(dp4503
g7
I69
sg20
VC0678222
p4504
sg10
I13
sg11
Vbreast cancer
p4505
sg13
I2
sa(dp4506
g7
I69
sg20
VC0678222
p4507
sg10
I13
sg11
Vbreast cancer
p4508
sg13
I2
sasa(dp4509
g2
S'Moreover, miR-96 and miR-182 are onco-microRNAs that increase proliferation, migration, and tumorigenesis in breast cancer cells.\n'
p4510
sg4
(lp4511
(dp4512
g7
I10
sg8
g59
sg10
I6
sg11
VmiR-96
p4513
sg13
I1
sa(dp4514
g7
I21
sg8
g59
sg10
I7
sg11
VmiR-182
p4515
sg13
I1
sasg17
(lp4516
(dp4517
g7
I92
sg20
VC0007621
p4518
sg10
I13
sg11
Vtumorigenesis
p4519
sg13
I1
sa(dp4520
g7
I109
sg20
VC0678222
p4521
sg10
I13
sg11
Vbreast cancer
p4522
sg13
I2
sa(dp4523
g7
I62
sg20
VC0334094
p4524
sg10
I13
sg11
Vproliferation
p4525
sg13
I1
sasa(dp4526
g2
S'Initially, bioinformatics tools were used to identify the target genes that have binding sites for miR-7, MiR-9, MiR-96, and miR-182 and are also associated with breast cancer.\n'
p4527
sg4
(lp4528
(dp4529
g7
I106
sg8
g59
sg10
I5
sg11
VMiR-9
p4530
sg13
I1
sa(dp4531
g7
I125
sg8
g59
sg10
I7
sg11
VmiR-182
p4532
sg13
I1
sa(dp4533
g7
I99
sg8
g59
sg10
I5
sg11
VmiR-7
p4534
sg13
I1
sa(dp4535
g7
I113
sg8
g59
sg10
I6
sg11
VMiR-96
p4536
sg13
I1
sasg17
(lp4537
(dp4538
g7
I162
sg20
VC0678222
p4539
sg10
I13
sg11
Vbreast cancer
p4540
sg13
I2
sasa(dp4541
g2
S'Respectively, three, three, three, and seven genes were found to have binding sites for miR-7, miR-9, miR-96, and miR-182 and were associated with breast cancer.\n'
p4542
sg4
(lp4543
(dp4544
g7
I95
sg8
g59
sg10
I5
sg11
VmiR-9
p4545
sg13
I1
sa(dp4546
g7
I88
sg8
g59
sg10
I5
sg11
VmiR-7
p4547
sg13
I1
sa(dp4548
g7
I114
sg8
g59
sg10
I7
sg11
VmiR-182
p4549
sg13
I1
sa(dp4550
g7
I102
sg8
g59
sg10
I6
sg11
VmiR-96
p4551
sg13
I1
sasg17
(lp4552
(dp4553
g7
I147
sg20
VC0678222
p4554
sg10
I13
sg11
Vbreast cancer
p4555
sg13
I2
sasa(dp4556
g2
S'Moreover, miR-96 may play an oncogenic role in breast cancer by suppressing the apoptosis through the regulation of ABCA1.\n'
p4557
sg4
(lp4558
(dp4559
g7
I10
sg8
g59
sg10
I6
sg11
VmiR-96
p4560
sg13
I1
sasg17
(lp4561
(dp4562
g7
I47
sg20
VC0678222
p4563
sg10
I13
sg11
Vbreast cancer
p4564
sg13
I2
sasa(dp4565
g2
S'Based on medullary traction as responsible for idiopathic syringomyelia (SMI), idiopathic scoliosis (ESCID), Arnold Chiari malformation (ARCH), platybasia (PTB), basilar impression (IMB), odontoid recess (RTO) kinking of the brain stem (KTC) and considering the medullary traction to be transmitted by the filum terminale (FT), a surgical technique for the section of FT (SFT) is described in three cases of SMI, one of ESCID, and one of ARCH with no lumbar dysraphia.\n'
p4566
sg4
(lp4567
sg17
(lp4568
(dp4569
g7
I137
sg20
VC0003803
p4570
sg10
I4
sg11
VARCH
p4571
sg13
I1
sa(dp4572
g7
I73
sg20
VC0039144
p4573
sg10
I3
sg11
VSMI
p4574
sg13
I1
sa(dp4575
g7
I109
sg20
VC0003803
p4576
sg10
I26
sg11
VArnold Chiari malformation
p4577
sg13
I3
sa(dp4578
g7
I79
sg20
VC0595995
p4579
sg10
I20
sg11
Vidiopathic scoliosis
p4580
sg13
I2
sa(dp4581
g7
I137
sg20
VC0003803
p4582
sg10
I4
sg11
VARCH
p4583
sg13
I1
sa(dp4584
g7
I144
sg20
VC0032209
p4585
sg10
I10
sg11
Vplatybasia
p4586
sg13
I1
sa(dp4587
g7
I156
sg20
VC0032209
p4588
sg10
I3
sg11
VPTB
p4589
sg13
I1
sa(dp4590
g7
I162
sg20
VC0032209
p4591
sg10
I18
sg11
Vbasilar impression
p4592
sg13
I2
sa(dp4593
g7
I287
sg20
VC0242781
p4594
sg10
I11
sg11
Vtransmitted
p4595
sg13
I1
sa(dp4596
g7
I73
sg20
VC0039144
p4597
sg10
I3
sg11
VSMI
p4598
sg13
I1
sa(dp4599
g7
I58
sg20
VC0039144
p4600
sg10
I13
sg11
Vsyringomyelia
p4601
sg13
I1
sa(dp4602
g7
I458
sg20
VC0332915
p4603
sg10
I9
sg11
Vdysraphia
p4604
sg13
I1
sasa(dp4605
g2
S'A common aetiopathogenic theory for basilar groove (IMB), platybasia (PTB), odontoid retrocession (RTO), kinking of the brainstem (KTC) applied to idiopathic syringomyelia (SMI), idiopathic scoliosis (ESCID) and Arnold-Chiari malformation (ARCH) is presented.\n'
p4606
sg4
(lp4607
sg17
(lp4608
(dp4609
g7
I240
sg20
VC0555206
p4610
sg10
I4
sg11
VARCH
p4611
sg13
I1
sa(dp4612
g7
I70
sg20
VC0032209
p4613
sg10
I3
sg11
VPTB
p4614
sg13
I1
sa(dp4615
g7
I212
sg20
VC0555206
p4616
sg10
I26
sg11
VArnold-Chiari malformation
p4617
sg13
I2
sa(dp4618
g7
I179
sg20
VC0595995
p4619
sg10
I20
sg11
Vidiopathic scoliosis
p4620
sg13
I2
sa(dp4621
g7
I85
sg20
VC0333044
p4622
sg10
I12
sg11
Vretrocession
p4623
sg13
I1
sa(dp4624
g7
I173
sg20
VC0039144
p4625
sg10
I3
sg11
VSMI
p4626
sg13
I1
sa(dp4627
g7
I99
sg20
VC0333044
p4628
sg10
I3
sg11
VRTO
p4629
sg13
I1
sa(dp4630
g7
I158
sg20
VC0039144
p4631
sg10
I13
sg11
Vsyringomyelia
p4632
sg13
I1
sa(dp4633
g7
I58
sg20
VC0032209
p4634
sg10
I10
sg11
Vplatybasia
p4635
sg13
I1
sasa(dp4636
g2
S'The major theories of the pathogenesis of idiopathic syringomyelia (SMI), idiopathic scoliosis (ESCID) and the Arnold-Chiari malformation (ARCH) are reviewed.\n'
p4637
sg4
(lp4638
sg17
(lp4639
(dp4640
g7
I74
sg20
VC0595995
p4641
sg10
I20
sg11
Vidiopathic scoliosis
p4642
sg13
I2
sa(dp4643
g7
I68
sg20
VC0039144
p4644
sg10
I3
sg11
VSMI
p4645
sg13
I1
sa(dp4646
g7
I139
sg20
VC0555206
p4647
sg10
I4
sg11
VARCH
p4648
sg13
I1
sa(dp4649
g7
I26
sg20
VC0699748
p4650
sg10
I12
sg11
Vpathogenesis
p4651
sg13
I1
sa(dp4652
g7
I53
sg20
VC0039144
p4653
sg10
I13
sg11
Vsyringomyelia
p4654
sg13
I1
sa(dp4655
g7
I111
sg20
VC0555206
p4656
sg10
I26
sg11
VArnold-Chiari malformation
p4657
sg13
I2
sasa(dp4658
g2
S'The CXCL13 expression levels correlated with the degree of chronic gastritis and bacterial colonization.\n'
p4659
sg4
(lp4660
(dp4661
g7
I4
sg8
g59
sg10
I6
sg11
VCXCL13
p4662
sg13
I1
sasg17
(lp4663
(dp4664
g7
I59
sg20
VC0085695
p4665
sg10
I17
sg11
Vchronic gastritis
p4666
sg13
I2
sasa(dp4667
g2
S'The enhanced induction of CXCL13 may be involved in the pathogenesis of H. pylori-associated gastritis.\n'
p4668
sg4
(lp4669
(dp4670
g7
I26
sg8
g59
sg10
I6
sg11
VCXCL13
p4671
sg13
I1
sasg17
(lp4672
(dp4673
g7
I56
sg20
VC0699748
p4674
sg10
I12
sg11
Vpathogenesis
p4675
sg13
I1
sa(dp4676
g7
I93
sg20
VC0017152
p4677
sg10
I9
sg11
Vgastritis
p4678
sg13
I1
sasa(dp4679
g2
S'We have studied the expression of 2 chemokines that attract B lymphocytes, BCA-1 and SLC, in gastric tissue samples obtained from patients with chronic gastritis induced by Hp infection or nonsteroidal anti-inflammatory drugs, as well as from patients with Hp-associated low-grade and high-grade gastric lymphomas.\n'
p4680
sg4
(lp4681
(dp4682
g7
I75
sg8
g59
sg10
I5
sg11
VBCA-1
p4683
sg13
I1
sa(dp4684
g7
I85
sg8
g59
sg10
I3
sg11
VSLC
p4685
sg13
I1
sasg17
(lp4686
(dp4687
g7
I176
sg20
VC0009450
p4688
sg10
I9
sg11
Vinfection
p4689
sg13
I1
sa(dp4690
g7
I144
sg20
VC0085695
p4691
sg10
I17
sg11
Vchronic gastritis
p4692
sg13
I2
sa(dp4693
g7
I296
sg20
VC0349532
p4694
sg10
I17
sg11
Vgastric lymphomas
p4695
sg13
I2
sasa(dp4696
g2
S'Our findings indicate that BCA-1, which functions as a homing chemokine in normal lymphoid tissue, is induced in chronic Hp gastritis and is involved in the formation of lymphoid follicles and gastric lymphomas of the MALT type.\n'
p4697
sg4
(lp4698
(dp4699
g7
I27
sg8
g59
sg10
I5
sg11
VBCA-1
p4700
sg13
I1
sasg17
(lp4701
(dp4702
g7
I124
sg20
VC0017152
p4703
sg10
I9
sg11
Vgastritis
p4704
sg13
I1
sa(dp4705
g7
I193
sg20
VC0349532
p4706
sg10
I17
sg11
Vgastric lymphomas
p4707
sg13
I2
sasa(dp4708
g2
S'We provide novel functional data that posttranscriptional silencing of gene RPL19 using RNAi not only abrogates the malignant phenotype of PC-3M prostate cancer cells but is selective with respect to transcription and translation of other genes.\n'
p4709
sg4
(lp4710
(dp4711
g7
I71
sg8
VP84098
p4712
sg10
I10
sg11
Vgene RPL19
p4713
sg13
I2
sasg17
(lp4714
(dp4715
g7
I145
sg20
VC0600139
p4716
sg10
I15
sg11
Vprostate cancer
p4717
sg13
I2
sasa(dp4718
g2
S'We attempted to specifically quantify transcripts of faecal cytokeratin 19 (CK19) and ribosomal protein L19 (RPL19) RNA expression of colorectal cancer and clarify their correlation with clinicopathological parameters and survival in combination.\n'
p4719
sg4
(lp4720
(dp4721
g7
I86
sg8
VP84098
p4722
sg10
I21
sg11
Vribosomal protein L19
p4723
sg13
I3
sa(dp4724
g7
I53
sg8
g59
sg10
I21
sg11
Vfaecal cytokeratin 19
p4725
sg13
I3
sa(dp4726
g7
I109
sg8
VP84098
p4727
sg10
I5
sg11
VRPL19
p4728
sg13
I1
sasg17
(lp4729
(dp4730
g7
I134
sg20
VC1527249
p4731
sg10
I17
sg11
Vcolorectal cancer
p4732
sg13
I2
sasa(dp4733
g2
S'RPL19 was overexpressed in the lung cancer tissue from patient H1224.\n'
p4734
sg4
(lp4735
(dp4736
g7
I0
sg8
VP84098
p4737
sg10
I5
sg11
VRPL19
p4738
sg13
I1
sasg17
(lp4739
(dp4740
g7
I31
sg20
VC0684249
p4741
sg10
I11
sg11
Vlung cancer
p4742
sg13
I2
sasa(dp4743
g2
S'All of the normal tissues examined expressed lower levels of RPL19 mRNA than that of the lung cancer tissue.\n'
p4744
sg4
(lp4745
(dp4746
g7
I61
sg8
VP84098
p4747
sg10
I10
sg11
VRPL19 mRNA
p4748
sg13
I2
sasg17
(lp4749
(dp4750
g7
I89
sg20
VC0684249
p4751
sg10
I11
sg11
Vlung cancer
p4752
sg13
I2
sasa(dp4753
g2
S'RPL19 was also found to be overexpressed in 12 of 30 (40%) non-small-cell lung cancer tissues by immunohistochemical staining.\n'
p4754
sg4
(lp4755
(dp4756
g7
I0
sg8
VP84098
p4757
sg10
I5
sg11
VRPL19
p4758
sg13
I1
sasg17
(lp4759
(dp4760
g7
I74
sg20
VC0684249
p4761
sg10
I11
sg11
Vlung cancer
p4762
sg13
I2
sasa(dp4763
g2
S'In addition, the suppression of RPL19 expression by transfection with small interfering RNA resulted in the suppression of cyclinD1, D3 synthesis, and the growth inhibition of lung cancer cell lines overexpressing RPL19.\n'
p4764
sg4
(lp4765
(dp4766
g7
I32
sg8
VP84098
p4767
sg10
I5
sg11
VRPL19
p4768
sg13
I1
sa(dp4769
g7
I32
sg8
VP84098
p4770
sg10
I5
sg11
VRPL19
p4771
sg13
I1
sasg17
(lp4772
(dp4773
g7
I176
sg20
VC0684249
p4774
sg10
I11
sg11
Vlung cancer
p4775
sg13
I2
sa(dp4776
g7
I17
sg20
VC0221103
p4777
sg10
I11
sg11
Vsuppression
p4778
sg13
I1
sa(dp4779
g7
I17
sg20
VC0221103
p4780
sg10
I11
sg11
Vsuppression
p4781
sg13
I1
sasa(dp4782
g2
S'The gene encoding ribosomal protein L19 (RPL19), a prognostic marker for human prostate cancer, is differentially expressed in CRC patients.\n'
p4783
sg4
(lp4784
(dp4785
g7
I41
sg8
VP84098
p4786
sg10
I5
sg11
VRPL19
p4787
sg13
I1
sa(dp4788
g7
I18
sg8
VP84098
p4789
sg10
I21
sg11
Vribosomal protein L19
p4790
sg13
I3
sasg17
(lp4791
(dp4792
g7
I127
sg20
VC1527249
p4793
sg10
I3
sg11
VCRC
p4794
sg13
I1
sa(dp4795
g7
I79
sg20
VC0600139
p4796
sg10
I15
sg11
Vprostate cancer
p4797
sg13
I2
sasa(dp4798
g2
S'We tested cytokeratin 19 (CK19), maspin, mammaglobin, GAPDH and RPL19 genes for their level of expression and linearity of amplification in serial dilutions of RNA extracted from the MDA-MB-231, UACC-812, T47D and HS578T breast cancer cell lines.\n'
p4799
sg4
(lp4800
(dp4801
g7
I41
sg8
g59
sg10
I11
sg11
Vmammaglobin
p4802
sg13
I1
sa(dp4803
g7
I26
sg8
g59
sg10
I4
sg11
VCK19
p4804
sg13
I1
sa(dp4805
g7
I10
sg8
g59
sg10
I14
sg11
Vcytokeratin 19
p4806
sg13
I2
sa(dp4807
g7
I54
sg8
VP04406
p4808
sg10
I5
sg11
VGAPDH
p4809
sg13
I1
sa(dp4810
g7
I33
sg8
VP36952
p4811
sg10
I6
sg11
Vmaspin
p4812
sg13
I1
sa(dp4813
g7
I64
sg8
VP84098
p4814
sg10
I11
sg11
VRPL19 genes
p4815
sg13
I2
sasg17
(lp4816
(dp4817
g7
I123
sg20
VC1705759
p4818
sg10
I13
sg11
Vamplification
p4819
sg13
I1
sa(dp4820
g7
I221
sg20
VC0678222
p4821
sg10
I13
sg11
Vbreast cancer
p4822
sg13
I2
sasa(dp4823
g2
S'Methods I analyzed selected articles about calcium-sensing receptors, FHH, PHPT, CASR, GNA11, and AP2S1.\n'
p4824
sg4
(lp4825
(dp4826
g7
I70
sg8
VP41180
p4827
sg10
I3
sg11
VFHH
p4828
sg13
I1
sa(dp4829
g7
I81
sg8
VP41180
p4830
sg10
I4
sg11
VCASR
p4831
sg13
I1
sa(dp4832
g7
I87
sg8
VP29992
p4833
sg10
I5
sg11
VGNA11
p4834
sg13
I1
sa(dp4835
g7
I98
sg8
VP53680
p4836
sg10
I5
sg11
VAP2S1
p4837
sg13
I1
sasg17
(lp4838
sa(dp4839
g2
S'Results FHH usually results from a heterozygous germline inactivating mutation of the CASR, and less frequently from mutation of GNA11 or AP2S1.\n'
p4840
sg4
(lp4841
(dp4842
g7
I129
sg8
VP29992
p4843
sg10
I5
sg11
VGNA11
p4844
sg13
I1
sa(dp4845
g7
I138
sg8
VP53680
p4846
sg10
I5
sg11
VAP2S1
p4847
sg13
I1
sasg17
(lp4848
sa(dp4849
g2
S'FHH reflects heterozygous germline mutation of CASR, GNA11, or AP2S1.\n'
p4850
sg4
(lp4851
(dp4852
g7
I47
sg8
VP41180
p4853
sg10
I4
sg11
VCASR
p4854
sg13
I1
sa(dp4855
g7
I53
sg8
VP29992
p4856
sg10
I5
sg11
VGNA11
p4857
sg13
I1
sa(dp4858
g7
I63
sg8
VP53680
p4859
sg10
I5
sg11
VAP2S1
p4860
sg13
I1
sa(dp4861
g7
I0
sg8
VP41180
p4862
sg10
I3
sg11
VFHH
p4863
sg13
I1
sasg17
(lp4864
(dp4865
g7
I26
sg20
VC1705427
p4866
sg10
I17
sg11
Vgermline mutation
p4867
sg13
I2
sasa(dp4868
g2
S'Patients with familial hyperparathyroidism and low urinary calcium excretion may have familial hypocalciuric hypercalcemia (FHH) with mutations in one of three genes: the calcium-sensing receptor (CaSR) defining FHH-type 1, the adaptor-related protein complex 2 (AP2S1) related to FHH-type 3 or the G-protein subunit alpha11 (GNA11) associated with FHH-type 2.\n'
p4869
sg4
(lp4870
(dp4871
g7
I349
sg8
VP41180
p4872
sg10
I10
sg11
VFHH-type 2
p4873
sg13
I2
sa(dp4874
g7
I281
sg8
VP41180
p4875
sg10
I10
sg11
VFHH-type 3
p4876
sg13
I2
sa(dp4877
g7
I299
sg8
VP29992
p4878
sg10
I33
sg11
VG-protein subunit alpha11 (GNA11)
p4879
sg13
I4
sa(dp4880
g7
I263
sg8
VP53680
p4881
sg10
I5
sg11
VAP2S1
p4882
sg13
I1
sa(dp4883
g7
I212
sg8
VP41180
p4884
sg10
I10
sg11
VFHH-type 1
p4885
sg13
I2
sasg17
(lp4886
(dp4887
g7
I124
sg20
VC0342637
p4888
sg10
I3
sg11
VFHH
p4889
sg13
I1
sa(dp4890
g7
I124
sg20
VC0342637
p4891
sg10
I3
sg11
VFHH
p4892
sg13
I1
sa(dp4893
g7
I86
sg20
VC0342637
p4894
sg10
I36
sg11
Vfamilial hypocalciuric hypercalcemia
p4895
sg13
I3
sa(dp4896
g7
I14
sg20
VC0271846
p4897
sg10
I28
sg11
Vfamilial hyperparathyroidism
p4898
sg13
I2
sa(dp4899
g7
I124
sg20
VC0342637
p4900
sg10
I3
sg11
VFHH
p4901
sg13
I1
sa(dp4902
g7
I124
sg20
VC0342637
p4903
sg10
I3
sg11
VFHH
p4904
sg13
I1
sasa(dp4905
g2
S'Clinically, patients with AP2S1 mutations had significant cognitive and behavioral disorders, and higher blood calcium and magnesium levels than patients with FHH1.\n'
p4906
sg4
(lp4907
(dp4908
g7
I159
sg8
VP41180
p4909
sg10
I4
sg11
VFHH1
p4910
sg13
I1
sasg17
(lp4911
(dp4912
g7
I159
sg20
VC1809471
p4913
sg10
I4
sg11
VFHH1
p4914
sg13
I1
sa(dp4915
g7
I72
sg20
VC0004930
p4916
sg10
I20
sg11
Vbehavioral disorders
p4917
sg13
I2
sasa(dp4918
g2
S'CaSR and AP2S1 sequencing is worthwhile in patients with familial hyperparathyroidism and phenotype suggesting FHH as it can diagnose up to 50% of cases.\n'
p4919
sg4
(lp4920
(dp4921
g7
I0
sg8
VP41180
p4922
sg10
I4
sg11
VCaSR
p4923
sg13
I1
sa(dp4924
g7
I9
sg8
VP53680
p4925
sg10
I5
sg11
VAP2S1
p4926
sg13
I1
sasg17
(lp4927
(dp4928
g7
I57
sg20
VC0271846
p4929
sg10
I28
sg11
Vfamilial hyperparathyroidism
p4930
sg13
I2
sasa(dp4931
g2
S'Recently, mutations affecting codon 15 in the gene AP2S1 have been shown to cause FHH type 3 in up to 26% of CASR-negative FHH patients.\n'
p4932
sg4
(lp4933
(dp4934
g7
I82
sg8
VP41180
p4935
sg10
I10
sg11
VFHH type 3
p4936
sg13
I3
sa(dp4937
g7
I51
sg8
VP53680
p4938
sg10
I5
sg11
VAP2S1
p4939
sg13
I1
sasg17
(lp4940
sa(dp4941
g2
S'We hypothesized that mutations in AP2S1 and GNA11 are causative in Danish patients with suspected FHH and that these mutations are not found in patients with primary hyperparathyroidism (PHPT), which is the main differential diagnostic disorder.\n'
p4942
sg4
(lp4943
(dp4944
g7
I44
sg8
VP29992
p4945
sg10
I5
sg11
VGNA11
p4946
sg13
I1
sa(dp4947
g7
I34
sg8
VP53680
p4948
sg10
I5
sg11
VAP2S1
p4949
sg13
I1
sasg17
(lp4950
(dp4951
g7
I187
sg20
VC0221002
p4952
sg10
I4
sg11
VPHPT
p4953
sg13
I1
sa(dp4954
g7
I158
sg20
VC0221002
p4955
sg10
I27
sg11
Vprimary hyperparathyroidism
p4956
sg13
I2
sasa(dp4957
g2
S'In 33 CASR-negative patients with suspected FHH, we found two (~6%) with a mutation in AP2S1 (p.Arg15Leu and p.Arg15His).\n'
p4958
sg4
(lp4959
(dp4960
g7
I87
sg8
VP53680
p4961
sg10
I5
sg11
VAP2S1
p4962
sg13
I1
sasg17
(lp4963
sa(dp4964
g2
S'We suggest that the best diagnostic approach to hyperparathyroid hypercalcemic patients suspected to have FHH is to screen the CASR and AP2S1 codon 15 for mutations.\n'
p4965
sg4
(lp4966
(dp4967
g7
I136
sg8
VP53680
p4968
sg10
I14
sg11
VAP2S1 codon 15
p4969
sg13
I3
sa(dp4970
g7
I127
sg8
VP41180
p4971
sg10
I4
sg11
VCASR
p4972
sg13
I1
sasg17
(lp4973
(dp4974
g7
I48
sg20
VC0745106
p4975
sg10
I16
sg11
Vhyperparathyroid
p4976
sg13
I1
sasa(dp4977
g2
S'Thus, loss- and gain-of-function mutations of the GNA11 gene on chromosome 19p13.3, which encodes the G-protein Alfa-11 (GAlfa11) subunit, lead to FHH type 2 and ADH type 2, respectively; whilst loss-of-function mutations of AP2S1 on chromosome 19q13.3, which encodes the adaptor-related protein complex 2 sigma (AP2Sigma) subunit, cause FHH type 3.\n'
p4978
sg4
(lp4979
(dp4980
g7
I162
sg8
VP07327
p4981
sg10
I10
sg11
VADH type 2
p4982
sg13
I3
sa(dp4983
g7
I225
sg8
VP53680
p4984
sg10
I5
sg11
VAP2S1
p4985
sg13
I1
sa(dp4986
g7
I147
sg8
VP41180
p4987
sg10
I10
sg11
VFHH type 2
p4988
sg13
I3
sa(dp4989
g7
I50
sg8
VP29992
p4990
sg10
I10
sg11
VGNA11 gene
p4991
sg13
I2
sa(dp4992
g7
I121
sg8
g59
sg10
I7
sg11
VGAlfa11
p4993
sg13
I1
sa(dp4994
g7
I102
sg8
g59
sg10
I17
sg11
VG-protein Alfa-11
p4995
sg13
I2
sa(dp4996
g7
I338
sg8
VP41180
p4997
sg10
I10
sg11
VFHH type 3
p4998
sg13
I3
sasg17
(lp4999
sa(dp5000
g2
S'Familial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous condition resembling primary hyperparathyroidism (PHPT) but not curable by surgery; FHH types 1, 2, and 3 are due to loss-of-function mutations of the CASR, GNA11, or AP2S1 genes, respectively.\n'
p5001
sg4
(lp5002
(dp5003
g7
I225
sg8
VP41180
p5004
sg10
I4
sg11
VCASR
p5005
sg13
I1
sa(dp5006
g7
I231
sg8
VP29992
p5007
sg10
I5
sg11
VGNA11
p5008
sg13
I1
sa(dp5009
g7
I241
sg8
VP53680
p5010
sg10
I11
sg11
VAP2S1 genes
p5011
sg13
I2
sasg17
(lp5012
(dp5013
g7
I124
sg20
VC0221002
p5014
sg10
I4
sg11
VPHPT
p5015
sg13
I1
sa(dp5016
g7
I74
sg20
VC0012634
p5017
sg10
I9
sg11
Vcondition
p5018
sg13
I1
sa(dp5019
g7
I38
sg20
VC0342637
p5020
sg10
I3
sg11
VFHH
p5021
sg13
I1
sa(dp5022
g7
I38
sg20
VC0342637
p5023
sg10
I3
sg11
VFHH
p5024
sg13
I1
sa(dp5025
g7
I95
sg20
VC0221002
p5026
sg10
I27
sg11
Vprimary hyperparathyroidism
p5027
sg13
I2
sa(dp5028
g7
I0
sg20
VC0342637
p5029
sg10
I36
sg11
VFamilial hypocalciuric hypercalcemia
p5030
sg13
I3
sasa(dp5031
g2
S'FHH3 was recently found to be caused by codon Arg15 (p.R15) mutations in the adaptor-related protein complex 2, Sigma-2 subunit that interacts with the CaSR and is encoded by the AP2S1 gene.\n'
p5032
sg4
(lp5033
(dp5034
g7
I179
sg8
VP53680
p5035
sg10
I10
sg11
VAP2S1 gene
p5036
sg13
I2
sa(dp5037
g7
I152
sg8
VP41180
p5038
sg10
I4
sg11
VCaSR
p5039
sg13
I1
sasg17
(lp5040
sa(dp5041
g2
S'The objective of the study was to assess the prevalence of AP2S1 mutations, and describe the phenotype of FHH3, in an independent cohort of FHH subjects lacking CASR mutations.\n'
p5042
sg4
(lp5043
(dp5044
g7
I59
sg8
VP53680
p5045
sg10
I5
sg11
VAP2S1
p5046
sg13
I1
sa(dp5047
g7
I161
sg8
VP41180
p5048
sg10
I14
sg11
VCASR mutations
p5049
sg13
I2
sasg17
(lp5050
sa(dp5051
g2
S'The results affirm that a significant number of patients suspected of having FHH but proven negative for CASR mutation have AP2S1 p.R15 mutations.\n'
p5052
sg4
(lp5053
(dp5054
g7
I105
sg8
VP41180
p5055
sg10
I4
sg11
VCASR
p5056
sg13
I1
sa(dp5057
g7
I77
sg8
VP41180
p5058
sg10
I3
sg11
VFHH
p5059
sg13
I1
sa(dp5060
g7
I124
sg8
VP53680
p5061
sg10
I21
sg11
VAP2S1 p.R15 mutations
p5062
sg13
I3
sasg17
(lp5063
sa(dp5064
g2
S'Screening for AP2S1 p.R15 mutations in such cases should be considered, given the clinical benefits (avoiding unnecessary parathyroidectomy) that have already been demonstrated for CASR screening in FHH1.\n'
p5065
sg4
(lp5066
(dp5067
g7
I14
sg8
VP53680
p5068
sg10
I7
sg11
VAP2S1 p
p5069
sg13
I2
sa(dp5070
g7
I199
sg8
VP41180
p5071
sg10
I4
sg11
VFHH1
p5072
sg13
I1
sasg17
(lp5073
(dp5074
g7
I199
sg20
VC1809471
p5075
sg10
I4
sg11
VFHH1
p5076
sg13
I1
sasa(dp5077
g2
S'mRNA expression analysis was performed on 32 cervical cancer cases to determine the expression of the EGFR ligands amphiregulin, Beta-cellulin, epidermal growth factor (EGF), epiregulin, heparin-binding EGF-like growth factor (HB-EGF) and transforming growth factor Alfa (TGFAlfa).\n'
p5078
sg4
(lp5079
(dp5080
g7
I102
sg8
VP01133
p5081
sg10
I3
sg11
VEGF
p5082
sg13
I1
sa(dp5083
g7
I187
sg8
g59
sg10
I38
sg11
Vheparin-binding EGF-like growth factor
p5084
sg13
I4
sa(dp5085
g7
I175
sg8
g59
sg10
I10
sg11
Vepiregulin
p5086
sg13
I1
sa(dp5087
g7
I129
sg8
VP35070
p5088
sg10
I13
sg11
VBeta-cellulin
p5089
sg13
I1
sa(dp5090
g7
I227
sg8
g59
sg10
I6
sg11
VHB-EGF
p5091
sg13
I1
sa(dp5092
g7
I115
sg8
VP15514
p5093
sg10
I12
sg11
Vamphiregulin
p5094
sg13
I1
sa(dp5095
g7
I239
sg8
VP01135
p5096
sg10
I31
sg11
Vtransforming growth factor Alfa
p5097
sg13
I4
sa(dp5098
g7
I144
sg8
VP01133
p5099
sg10
I23
sg11
Vepidermal growth factor
p5100
sg13
I3
sasg17
(lp5101
(dp5102
g7
I45
sg20
VC0302592
p5103
sg10
I15
sg11
Vcervical cancer
p5104
sg13
I2
sasa(dp5105
g2
S'We further demonstrated that miR-34c-5p inhibited ovarian cancer stemness through downregulation of the AREG-EGFR-ERK pathway.\n'
p5106
sg4
(lp5107
(dp5108
g7
I29
sg8
g59
sg10
I10
sg11
VmiR-34c-5p
p5109
sg13
I1
sa(dp5110
g7
I104
sg8
VP15514
p5111
sg10
I4
sg11
VAREG
p5112
sg13
I1
sa(dp5113
g7
I114
sg8
VP29323
p5114
sg10
I3
sg11
VERK
p5115
sg13
I1
sasg17
(lp5116
(dp5117
g7
I50
sg20
VC1140680
p5118
sg10
I14
sg11
Vovarian cancer
p5119
sg13
I2
sasa(dp5120
g2
S'Overexpression of AREG was found to be correlated with advanced ovarian cancer stages and poor prognosis.\n'
p5121
sg4
(lp5122
(dp5123
g7
I18
sg8
VP15514
p5124
sg10
I4
sg11
VAREG
p5125
sg13
I1
sasg17
(lp5126
(dp5127
g7
I64
sg20
VC1140680
p5128
sg10
I14
sg11
Vovarian cancer
p5129
sg13
I2
sasa(dp5130
g2
S'Taken together, our data suggest that AREG promotes ovarian cancer stemness and drug resistance via the AREG-EGFR-ERK pathway and this is inhibited by miR-34c-5p.\n'
p5131
sg4
(lp5132
(dp5133
g7
I38
sg8
VP15514
p5134
sg10
I4
sg11
VAREG
p5135
sg13
I1
sa(dp5136
g7
I151
sg8
g59
sg10
I10
sg11
VmiR-34c-5p
p5137
sg13
I1
sa(dp5138
g7
I38
sg8
VP15514
p5139
sg10
I4
sg11
VAREG
p5140
sg13
I1
sa(dp5141
g7
I114
sg8
VP29323
p5142
sg10
I3
sg11
VERK
p5143
sg13
I1
sasg17
(lp5144
(dp5145
g7
I52
sg20
VC1140680
p5146
sg10
I14
sg11
Vovarian cancer
p5147
sg13
I2
sasa(dp5148
g2
S'Targeting AREG, miR-34c-5p could be a potential strategy for anti-cancer-stem cell therapy in ovarian cancer.\n'
p5149
sg4
(lp5150
(dp5151
g7
I16
sg8
g59
sg10
I10
sg11
VmiR-34c-5p
p5152
sg13
I1
sa(dp5153
g7
I10
sg8
VP15514
p5154
sg10
I4
sg11
VAREG
p5155
sg13
I1
sasg17
(lp5156
(dp5157
g7
I66
sg20
VC0006826
p5158
sg10
I6
sg11
Vcancer
p5159
sg13
I1
sa(dp5160
g7
I94
sg20
VC1140680
p5161
sg10
I14
sg11
Vovarian cancer
p5162
sg13
I2
sasa(dp5163
g2
S'In endometrial cancer tissues, downregulation of LSR and upregulation of AREG were observed together with malignancy, and Yes-associated protein (YAP) was present in the nuclei.\n'
p5164
sg4
(lp5165
(dp5166
g7
I122
sg8
VP07947
p5167
sg10
I22
sg11
VYes-associated protein
p5168
sg13
I2
sa(dp5169
g7
I146
sg8
VP46937
p5170
sg10
I3
sg11
VYAP
p5171
sg13
I1
sasg17
(lp5172
(dp5173
g7
I3
sg20
VC0476089
p5174
sg10
I18
sg11
Vendometrial cancer
p5175
sg13
I2
sa(dp5176
g7
I106
sg20
VC0006826
p5177
sg10
I10
sg11
Vmalignancy
p5178
sg13
I1
sasa(dp5179
g2
S'The loss of LSR promoted cell invasion and migration via upregulation of TEAD1/AREG dependent on YAP/pYAP and AMOT/Merlin in human endometrial cancer cells.\n'
p5180
sg4
(lp5181
(dp5182
g7
I97
sg8
VP46937
p5183
sg10
I3
sg11
VYAP
p5184
sg13
I1
sa(dp5185
g7
I110
sg8
g59
sg10
I4
sg11
VAMOT
p5186
sg13
I1
sa(dp5187
g7
I79
sg8
VP15514
p5188
sg10
I4
sg11
VAREG
p5189
sg13
I1
sa(dp5190
g7
I73
sg8
VP28347
p5191
sg10
I5
sg11
VTEAD1
p5192
sg13
I1
sasg17
(lp5193
(dp5194
g7
I131
sg20
VC0476089
p5195
sg10
I18
sg11
Vendometrial cancer
p5196
sg13
I2
sa(dp5197
g7
I25
sg20
VC2699153
p5198
sg10
I13
sg11
Vcell invasion
p5199
sg13
I2
sasa(dp5200
g2
S'Amphiregulin (AREG), the most abundant EGFR ligand in ovarian cancer, binds exclusively to EGFR and stimulates ovarian cancer cell invasion by down-regulating E-cadherin expression.\n'
p5201
sg4
(lp5202
(dp5203
g7
I39
sg8
g59
sg10
I11
sg11
VEGFR ligand
p5204
sg13
I2
sa(dp5205
g7
I14
sg8
VP15514
p5206
sg10
I4
sg11
VAREG
p5207
sg13
I1
sa(dp5208
g7
I159
sg8
VP12830
p5209
sg10
I10
sg11
VE-cadherin
p5210
sg13
I1
sa(dp5211
g7
I0
sg8
VP15514
p5212
sg10
I12
sg11
VAmphiregulin
p5213
sg13
I1
sasg17
(lp5214
(dp5215
g7
I54
sg20
VC1140680
p5216
sg10
I14
sg11
Vovarian cancer
p5217
sg13
I2
sa(dp5218
g7
I126
sg20
VC2699153
p5219
sg10
I13
sg11
Vcell invasion
p5220
sg13
I2
sa(dp5221
g7
I54
sg20
VC1140680
p5222
sg10
I14
sg11
Vovarian cancer
p5223
sg13
I2
sasa(dp5224
g2
S'In the present study, we show that treatment with AREG up-regulated SPRY2 expression by activating the EGFR-mediated ERK1/2 signaling pathway in two human ovarian cancer cell lines, SKOV3 and OVCAR5.\n'
p5225
sg4
(lp5226
(dp5227
g7
I117
sg8
VP27361
p5228
sg10
I6
sg11
VERK1/2
p5229
sg13
I1
sa(dp5230
g7
I68
sg8
g59
sg10
I5
sg11
VSPRY2
p5231
sg13
I1
sasg17
(lp5232
(dp5233
g7
I155
sg20
VC1140680
p5234
sg10
I14
sg11
Vovarian cancer
p5235
sg13
I2
sasa(dp5236
g2
S'Amphiregulin (AREG) binds exclusively to the epidermal growth factor receptor (EGFR) and has been considered to be a dominant autocrine/paracrine EGFR ligand in ovarian cancer.\n'
p5237
sg4
(lp5238
(dp5239
g7
I146
sg8
g59
sg10
I11
sg11
VEGFR ligand
p5240
sg13
I2
sa(dp5241
g7
I79
sg8
VP01133
p5242
sg10
I4
sg11
VEGFR
p5243
sg13
I1
sa(dp5244
g7
I14
sg8
VP15514
p5245
sg10
I4
sg11
VAREG
p5246
sg13
I1
sa(dp5247
g7
I45
sg8
VP01133
p5248
sg10
I32
sg11
Vepidermal growth factor receptor
p5249
sg13
I4
sa(dp5250
g7
I0
sg8
VP15514
p5251
sg10
I12
sg11
VAmphiregulin
p5252
sg13
I1
sasg17
(lp5253
(dp5254
g7
I161
sg20
VC1140680
p5255
sg10
I14
sg11
Vovarian cancer
p5256
sg13
I2
sasa(dp5257
g2
S'In the present study, we first examined the effects of AREG on SPRY4 expression and the possible underlying molecular mechanisms involved in this process in two human ovarian cancer cell lines.\n'
p5258
sg4
(lp5259
(dp5260
g7
I63
sg8
g59
sg10
I5
sg11
VSPRY4
p5261
sg13
I1
sa(dp5262
g7
I55
sg8
VP15514
p5263
sg10
I4
sg11
VAREG
p5264
sg13
I1
sasg17
(lp5265
(dp5266
g7
I167
sg20
VC1140680
p5267
sg10
I14
sg11
Vovarian cancer
p5268
sg13
I2
sasa(dp5269
g2
S'TGF-Alfa and amphiregulin (AREG), via EGFR, inhibit the Hippo signaling pathway and activate YAP to induce cervical cancer cell proliferation and migration.\n'
p5270
sg4
(lp5271
(dp5272
g7
I27
sg8
VP15514
p5273
sg10
I4
sg11
VAREG
p5274
sg13
I1
sa(dp5275
g7
I93
sg8
VP46937
p5276
sg10
I3
sg11
VYAP
p5277
sg13
I1
sa(dp5278
g7
I13
sg8
VP15514
p5279
sg10
I12
sg11
Vamphiregulin
p5280
sg13
I1
sa(dp5281
g7
I0
sg8
g59
sg10
I8
sg11
VTGF-Alfa
p5282
sg13
I1
sasg17
(lp5283
(dp5284
g7
I107
sg20
VC0302592
p5285
sg10
I15
sg11
Vcervical cancer
p5286
sg13
I2
sa(dp5287
g7
I128
sg20
VC0334094
p5288
sg10
I13
sg11
Vproliferation
p5289
sg13
I1
sasa(dp5290
g2
S'Activated YAP allows for up-regulation of TGF-Alfa, AREG, and EGFR, forming a positive signaling loop to drive cervical cancer cell proliferation.\n'
p5291
sg4
(lp5292
(dp5293
g7
I42
sg8
g59
sg10
I8
sg11
VTGF-Alfa
p5294
sg13
I1
sa(dp5295
g7
I52
sg8
VP15514
p5296
sg10
I4
sg11
VAREG
p5297
sg13
I1
sasg17
(lp5298
(dp5299
g7
I111
sg20
VC0302592
p5300
sg10
I15
sg11
Vcervical cancer
p5301
sg13
I2
sa(dp5302
g7
I132
sg20
VC0334094
p5303
sg10
I13
sg11
Vproliferation
p5304
sg13
I1
sasa(dp5305
g2
S'In this study, we report that the EGFR ligand amphiregulin (AREG) stimulates cell invasion and down-regulates E-cadherin expression in two human ovarian cancer cell lines, SKOV3 and OVCAR5.\n'
p5306
sg4
(lp5307
(dp5308
g7
I60
sg8
VP15514
p5309
sg10
I4
sg11
VAREG
p5310
sg13
I1
sa(dp5311
g7
I110
sg8
VP12830
p5312
sg10
I10
sg11
VE-cadherin
p5313
sg13
I1
sa(dp5314
g7
I46
sg8
VP15514
p5315
sg10
I12
sg11
Vamphiregulin
p5316
sg13
I1
sasg17
(lp5317
(dp5318
g7
I145
sg20
VC1140680
p5319
sg10
I14
sg11
Vovarian cancer
p5320
sg13
I2
sa(dp5321
g7
I77
sg20
VC2699153
p5322
sg10
I13
sg11
Vcell invasion
p5323
sg13
I2
sasa(dp5324
g2
S'This study demonstrates that AREG induces ovarian cancer cell invasion by down-regulating E-cadherin expression.\n'
p5325
sg4
(lp5326
(dp5327
g7
I90
sg8
VP12830
p5328
sg10
I10
sg11
VE-cadherin
p5329
sg13
I1
sa(dp5330
g7
I29
sg8
VP15514
p5331
sg10
I4
sg11
VAREG
p5332
sg13
I1
sasg17
(lp5333
(dp5334
g7
I42
sg20
VC1140680
p5335
sg10
I14
sg11
Vovarian cancer
p5336
sg13
I2
sa(dp5337
g7
I57
sg20
VC2699153
p5338
sg10
I13
sg11
Vcell invasion
p5339
sg13
I2
sasa(dp5340
g2
S'Our comparison of a stratified population with type I psoriasis (n = 155) and healthy controls (N = 197) is the first to reveal a relationship between the CLMN, FBXL19, CCL4L, C17orf51, TYK2, IL13, SLC22A4, CDKAL1, and HLA-B/MICA genes.\n'
p5341
sg4
(lp5342
(dp5343
g7
I176
sg8
g59
sg10
I8
sg11
VC17orf51
p5344
sg13
I1
sa(dp5345
g7
I161
sg8
g59
sg10
I6
sg11
VFBXL19
p5346
sg13
I1
sa(dp5347
g7
I192
sg8
VP35225
p5348
sg10
I4
sg11
VIL13
p5349
sg13
I1
sa(dp5350
g7
I225
sg8
VP01893
p5351
sg10
I10
sg11
VMICA genes
p5352
sg13
I2
sa(dp5353
g7
I186
sg8
VP29597
p5354
sg10
I4
sg11
VTYK2
p5355
sg13
I1
sa(dp5356
g7
I219
sg8
VP30461
p5357
sg10
I5
sg11
VHLA-B
p5358
sg13
I1
sa(dp5359
g7
I207
sg8
g59
sg10
I6
sg11
VCDKAL1
p5360
sg13
I1
sa(dp5361
g7
I198
sg8
g59
sg10
I7
sg11
VSLC22A4
p5362
sg13
I1
sa(dp5363
g7
I155
sg8
g59
sg10
I4
sg11
VCLMN
p5364
sg13
I1
sasg17
(lp5365
(dp5366
g7
I54
sg20
VC0033860
p5367
sg10
I9
sg11
Vpsoriasis
p5368
sg13
I1
sa(dp5369
g7
I225
sg20
VC0700319
p5370
sg10
I4
sg11
VMICA
p5371
sg13
I1
sasa(dp5372
g2
S'To detect the expression level of macrophage inflammatory protein-1 (MIP-1)Alfa, MIP-1Beta and monocyte chemoattractant protein-1 (MCP-1) in with psoriasis vulgaris and explore the role in the pathogenesis of psoriasis vulgaris.\n'
p5373
sg4
(lp5374
(dp5375
g7
I34
sg8
VP09603
p5376
sg10
I33
sg11
Vmacrophage inflammatory protein-1
p5377
sg13
I3
sa(dp5378
g7
I131
sg8
VP41597
p5379
sg10
I5
sg11
VMCP-1
p5380
sg13
I1
sa(dp5381
g7
I81
sg8
g59
sg10
I9
sg11
VMIP-1Beta
p5382
sg13
I1
sa(dp5383
g7
I95
sg8
VP13500
p5384
sg10
I34
sg11
Vmonocyte chemoattractant protein-1
p5385
sg13
I3
sa(dp5386
g7
I69
sg8
g59
sg10
I5
sg11
VMIP-1
p5387
sg13
I1
sasg17
(lp5388
(dp5389
g7
I193
sg20
VC0699748
p5390
sg10
I12
sg11
Vpathogenesis
p5391
sg13
I1
sa(dp5392
g7
I146
sg20
VC0263361
p5393
sg10
I18
sg11
Vpsoriasis vulgaris
p5394
sg13
I2
sa(dp5395
g7
I69
sg20
VC1851100
p5396
sg10
I3
sg11
VMIP
p5397
sg13
I1
sa(dp5398
g7
I146
sg20
VC0263361
p5399
sg10
I18
sg11
Vpsoriasis vulgaris
p5400
sg13
I2
sa(dp5401
g7
I69
sg20
VC1851100
p5402
sg10
I3
sg11
VMIP
p5403
sg13
I1
sasa(dp5404
g2
S'The level of MIP-1Alfa, MIP-1Beta and MCP-1 in peripheral blood from 50 patients with psoriasis vulgaris and 50 normal controls were measured by enzyme linked immunosorbent assay.\n'
p5405
sg4
(lp5406
(dp5407
g7
I13
sg8
g59
sg10
I9
sg11
VMIP-1Alfa
p5408
sg13
I1
sa(dp5409
g7
I24
sg8
g59
sg10
I9
sg11
VMIP-1Beta
p5410
sg13
I1
sa(dp5411
g7
I38
sg8
VP41597
p5412
sg10
I5
sg11
VMCP-1
p5413
sg13
I1
sasg17
(lp5414
(dp5415
g7
I13
sg20
VC1851100
p5416
sg10
I3
sg11
VMIP
p5417
sg13
I1
sa(dp5418
g7
I86
sg20
VC0263361
p5419
sg10
I18
sg11
Vpsoriasis vulgaris
p5420
sg13
I2
sa(dp5421
g7
I13
sg20
VC1851100
p5422
sg10
I3
sg11
VMIP
p5423
sg13
I1
sasa(dp5424
g2
S'The level of MIP-1Alfa, MIP-1Beta and MCP-1 was compared between psoriasis vulgaris patients at active stage and resting stage.\n'
p5425
sg4
(lp5426
(dp5427
g7
I13
sg8
g59
sg10
I9
sg11
VMIP-1Alfa
p5428
sg13
I1
sa(dp5429
g7
I24
sg8
g59
sg10
I9
sg11
VMIP-1Beta
p5430
sg13
I1
sa(dp5431
g7
I38
sg8
VP41597
p5432
sg10
I5
sg11
VMCP-1
p5433
sg13
I1
sasg17
(lp5434
(dp5435
g7
I13
sg20
VC1851100
p5436
sg10
I3
sg11
VMIP
p5437
sg13
I1
sa(dp5438
g7
I65
sg20
VC0263361
p5439
sg10
I18
sg11
Vpsoriasis vulgaris
p5440
sg13
I2
sa(dp5441
g7
I13
sg20
VC1851100
p5442
sg10
I3
sg11
VMIP
p5443
sg13
I1
sasa(dp5444
g2
S'The content of MIP-1Alfa, MIP-1Beta and MCP-1 in patients with psoriasis vulgaris was (1342.78 +/- 210.30), (175.28 +/- 28.18) and (266.86 +/- 32.75) ng/L, respectively, significantly higher than those in control group (P&lt;0.05).\n'
p5445
sg4
(lp5446
(dp5447
g7
I26
sg8
g59
sg10
I9
sg11
VMIP-1Beta
p5448
sg13
I1
sa(dp5449
g7
I40
sg8
VP41597
p5450
sg10
I5
sg11
VMCP-1
p5451
sg13
I1
sa(dp5452
g7
I15
sg8
g59
sg10
I9
sg11
VMIP-1Alfa
p5453
sg13
I1
sasg17
(lp5454
(dp5455
g7
I63
sg20
VC0263361
p5456
sg10
I18
sg11
Vpsoriasis vulgaris
p5457
sg13
I2
sa(dp5458
g7
I15
sg20
VC1851100
p5459
sg10
I3
sg11
VMIP
p5460
sg13
I1
sa(dp5461
g7
I15
sg20
VC1851100
p5462
sg10
I3
sg11
VMIP
p5463
sg13
I1
sasa(dp5464
g2
S'The expression level of MIP-1Alfa, MIP-1Beta and MCP-1 in peripheral blood of patients with psoriasis vulgaris was positively correlated with PASI (P&lt;0.01).\n'
p5465
sg4
(lp5466
(dp5467
g7
I24
sg8
g59
sg10
I9
sg11
VMIP-1Alfa
p5468
sg13
I1
sa(dp5469
g7
I35
sg8
g59
sg10
I9
sg11
VMIP-1Beta
p5470
sg13
I1
sa(dp5471
g7
I49
sg8
VP41597
p5472
sg10
I5
sg11
VMCP-1
p5473
sg13
I1
sasg17
(lp5474
(dp5475
g7
I24
sg20
VC1851100
p5476
sg10
I3
sg11
VMIP
p5477
sg13
I1
sa(dp5478
g7
I92
sg20
VC0263361
p5479
sg10
I18
sg11
Vpsoriasis vulgaris
p5480
sg13
I2
sa(dp5481
g7
I24
sg20
VC1851100
p5482
sg10
I3
sg11
VMIP
p5483
sg13
I1
sasa(dp5484
g2
S'After acitretin therapy, expression level of MIP-1Alfa, MIP-1Beta and MCP-1 in peripheral blood of patients with psoriasis vulgaris was significantly decreased.\n'
p5485
sg4
(lp5486
(dp5487
g7
I45
sg8
g59
sg10
I9
sg11
VMIP-1Alfa
p5488
sg13
I1
sa(dp5489
g7
I70
sg8
VP41597
p5490
sg10
I5
sg11
VMCP-1
p5491
sg13
I1
sa(dp5492
g7
I56
sg8
g59
sg10
I9
sg11
VMIP-1Beta
p5493
sg13
I1
sasg17
(lp5494
(dp5495
g7
I45
sg20
VC1851100
p5496
sg10
I3
sg11
VMIP
p5497
sg13
I1
sa(dp5498
g7
I45
sg20
VC1851100
p5499
sg10
I3
sg11
VMIP
p5500
sg13
I1
sa(dp5501
g7
I113
sg20
VC0263361
p5502
sg10
I18
sg11
Vpsoriasis vulgaris
p5503
sg13
I2
sasa(dp5504
g2
S'Chemokine factor MIP-1Alfa, MIP-1Beta and MCP-1 may be involved in the pathogenesis of psoriasis vulgaris.\n'
p5505
sg4
(lp5506
(dp5507
g7
I42
sg8
VP41597
p5508
sg10
I5
sg11
VMCP-1
p5509
sg13
I1
sa(dp5510
g7
I0
sg8
g59
sg10
I26
sg11
VChemokine factor MIP-1Alfa
p5511
sg13
I3
sa(dp5512
g7
I28
sg8
g59
sg10
I9
sg11
VMIP-1Beta
p5513
sg13
I1
sasg17
(lp5514
(dp5515
g7
I87
sg20
VC0263361
p5516
sg10
I18
sg11
Vpsoriasis vulgaris
p5517
sg13
I2
sa(dp5518
g7
I17
sg20
VC1851100
p5519
sg10
I3
sg11
VMIP
p5520
sg13
I1
sa(dp5521
g7
I17
sg20
VC1851100
p5522
sg10
I3
sg11
VMIP
p5523
sg13
I1
sa(dp5524
g7
I71
sg20
VC0699748
p5525
sg10
I12
sg11
Vpathogenesis
p5526
sg13
I1
sasa(dp5527
g2
S"As the products of CCL3L1 and CCL4L1 potentially play a role in autoimmunity we performed case control association studies with Crohn's disease, rheumatoid arthritis and psoriasis clinical cohorts.\n"
p5528
sg4
(lp5529
(dp5530
g7
I19
sg8
VP16619
p5531
sg10
I6
sg11
VCCL3L1
p5532
sg13
I1
sasg17
(lp5533
(dp5534
g7
I145
sg20
VC0003873
p5535
sg10
I20
sg11
Vrheumatoid arthritis
p5536
sg13
I2
sa(dp5537
g7
I128
sg20
VC0010346
p5538
sg10
I15
sg11
VCrohn's disease
p5539
sg13
I2
sa(dp5540
g7
I64
sg20
VC0004368
p5541
sg10
I12
sg11
Vautoimmunity
p5542
sg13
I1
sa(dp5543
g7
I170
sg20
VC0033860
p5544
sg10
I9
sg11
Vpsoriasis
p5545
sg13
I1
sasa(dp5546
g2
S'The aim of this study is to evaluate the relationship between CCL4L polymorphisms (including single-nucleotide polymorphisms (SNPs) and copy number variation (CNV)) and the course and prognosis of psoriasis.\n'
p5547
sg4
(lp5548
sg17
(lp5549
(dp5550
g7
I197
sg20
VC0033860
p5551
sg10
I9
sg11
Vpsoriasis
p5552
sg13
I1
sasa(dp5553
g2
S'Our results showed that a high CNV (&gt;=3 copies) is associated with psoriasis severity, whereas moderate disease correlated with a lower CNV (&lt;=2 copies); specifically, the CCL4L1 allele frequency is higher in severe psoriasis, whereas CCL4L2 is more frequent in patients with a milder disease.\n'
p5554
sg4
(lp5555
sg17
(lp5556
(dp5557
g7
I70
sg20
VC0033860
p5558
sg10
I9
sg11
Vpsoriasis
p5559
sg13
I1
sa(dp5560
g7
I70
sg20
VC0033860
p5561
sg10
I9
sg11
Vpsoriasis
p5562
sg13
I1
sasa(dp5563
g2
S'Serum samples from 85 patients with AA, 20 patients with atopic dermatitis, 20 patients with psoriasis vulgaris and 28 normal controls were examined by the cytometric bead array assay assessing monokine induced by interferon (IFN)-gamma (MIG), RANTES, interleukin-8 (IL-8), IFN-inducible protein-10, monocyte chemoattractant protein-1, macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and eotaxin levels.\n'
p5564
sg4
(lp5565
(dp5566
g7
I336
sg8
g59
sg10
I44
sg11
Vmacrophage inflammatory protein (MIP)-1alpha
p5567
sg13
I4
sa(dp5568
g7
I252
sg8
VP60568
p5569
sg10
I13
sg11
Vinterleukin-8
p5570
sg13
I1
sa(dp5571
g7
I238
sg8
g59
sg10
I3
sg11
VMIG
p5572
sg13
I1
sa(dp5573
g7
I267
sg8
VP60568
p5574
sg10
I4
sg11
VIL-8
p5575
sg13
I1
sa(dp5576
g7
I274
sg8
VP01562
p5577
sg10
I60
sg11
VIFN-inducible protein-10, monocyte chemoattractant protein-1
p5578
sg13
I5
sa(dp5579
g7
I396
sg8
VP51671
p5580
sg10
I7
sg11
Veotaxin
p5581
sg13
I1
sa(dp5582
g7
I244
sg8
VP13501
p5583
sg10
I6
sg11
VRANTES
p5584
sg13
I1
sa(dp5585
g7
I214
sg8
VP01563
p5586
sg10
I22
sg11
Vinterferon (IFN)-gamma
p5587
sg13
I2
sa(dp5588
g7
I382
sg8
g59
sg10
I9
sg11
VMIP-1beta
p5589
sg13
I1
sasg17
(lp5590
(dp5591
g7
I57
sg20
VC0011615
p5592
sg10
I17
sg11
Vatopic dermatitis
p5593
sg13
I2
sa(dp5594
g7
I369
sg20
VC1851100
p5595
sg10
I3
sg11
VMIP
p5596
sg13
I1
sa(dp5597
g7
I336
sg20
VC1851100
p5598
sg10
I31
sg11
Vmacrophage inflammatory protein
p5599
sg13
I3
sa(dp5600
g7
I369
sg20
VC1851100
p5601
sg10
I3
sg11
VMIP
p5602
sg13
I1
sa(dp5603
g7
I93
sg20
VC0263361
p5604
sg10
I18
sg11
Vpsoriasis vulgaris
p5605
sg13
I2
sasa(dp5606
g2
S'We identified a novel NUP98-HOXC11 fusion gene in a pediatric patient with de novo acute myeloid leukemia having t(11;12)(p15;q13).\n'
p5607
sg4
(lp5608
(dp5609
g7
I28
sg8
g59
sg10
I6
sg11
VHOXC11
p5610
sg13
I1
sasg17
(lp5611
(dp5612
g7
I83
sg20
VC0023467
p5613
sg10
I22
sg11
Vacute myeloid leukemia
p5614
sg13
I3
sasa(dp5615
g2
S'After running the algorithm on two data sets [triple-negative breast cancer, (TNBC), and estrogen receptor-negative breast cancer, (ERNBC)], we conclude that EpCAM and Beta1 integrin are enough to accurately predict TNBC stage, being ALDH1, CD24, CD61, and CK5 the necessary markers to exactly predict ERNBC stage.\n'
p5616
sg4
(lp5617
(dp5618
g7
I89
sg8
VP03372
p5619
sg10
I17
sg11
Vestrogen receptor
p5620
sg13
I2
sa(dp5621
g7
I234
sg8
VP00352
p5622
sg10
I5
sg11
VALDH1
p5623
sg13
I1
sa(dp5624
g7
I241
sg8
VP25063
p5625
sg10
I4
sg11
VCD24
p5626
sg13
I1
sa(dp5627
g7
I257
sg8
VP02533
p5628
sg10
I3
sg11
VCK5
p5629
sg13
I1
sa(dp5630
g7
I158
sg8
VP16422
p5631
sg10
I5
sg11
VEpCAM
p5632
sg13
I1
sa(dp5633
g7
I247
sg8
VP05106
p5634
sg10
I4
sg11
VCD61
p5635
sg13
I1
sasg17
(lp5636
(dp5637
g7
I62
sg20
VC0678222
p5638
sg10
I13
sg11
Vbreast cancer
p5639
sg13
I2
sa(dp5640
g7
I62
sg20
VC0678222
p5641
sg10
I13
sg11
Vbreast cancer
p5642
sg13
I2
sasa(dp5643
g2
S'In conclusion, IL-8 activates the PI3K/Akt pathway, which in turn activates NF-KB, resulting in the upregulation of integrin Beta3 expression and increased invasion of estrogen receptor-negative breast cancer cells.\n'
p5644
sg4
(lp5645
(dp5646
g7
I168
sg8
VP03372
p5647
sg10
I17
sg11
Vestrogen receptor
p5648
sg13
I2
sa(dp5649
g7
I39
sg8
g59
sg10
I3
sg11
VAkt
p5650
sg13
I1
sa(dp5651
g7
I34
sg8
VP42336
p5652
sg10
I4
sg11
VPI3K
p5653
sg13
I1
sasg17
(lp5654
(dp5655
g7
I156
sg20
VC2699153
p5656
sg10
I8
sg11
Vinvasion
p5657
sg13
I1
sa(dp5658
g7
I195
sg20
VC0678222
p5659
sg10
I13
sg11
Vbreast cancer
p5660
sg13
I2
sasa(dp5661
g2
S'This review provides clinical and molecular information for several of the commonest syndromes associated with A/M: Anophthalmia-Esophageal-Genital syndrome, caused by SOX2 mutations, Anophthalmia and pituitary abnormalities caused by OTX2 mutations, Matthew-Wood syndrome caused by STRA6 mutations, oculofaciocardiodental syndrome and Lenz microphthalmia caused by BCOR mutations, Microphthalmia Linear Skin pigmentation syndrome caused by HCCS mutations, Anophthalmia, pituitary abnormalities, polysyndactyly caused by BMP4 mutations and Waardenburg anophthalmia caused by mutations in SMOC1.\n'
p5662
sg4
(lp5663
(dp5664
g7
I588
sg8
g59
sg10
I5
sg11
VSMOC1
p5665
sg13
I1
sa(dp5666
g7
I168
sg8
VP48431
p5667
sg10
I14
sg11
VSOX2 mutations
p5668
sg13
I2
sa(dp5669
g7
I521
sg8
VP12644
p5670
sg10
I14
sg11
VBMP4 mutations
p5671
sg13
I2
sa(dp5672
g7
I235
sg8
VP32243
p5673
sg10
I4
sg11
VOTX2
p5674
sg13
I1
sasg17
(lp5675
(dp5676
g7
I552
sg20
VC0003119
p5677
sg10
I12
sg11
Vanophthalmia
p5678
sg13
I1
sa(dp5679
g7
I496
sg20
VC0265553
p5680
sg10
I14
sg11
Vpolysyndactyly
p5681
sg13
I1
sa(dp5682
g7
I85
sg20
VC0039082
p5683
sg10
I8
sg11
Vsyndrome
p5684
sg13
I1
sa(dp5685
g7
I116
sg20
VC0003119
p5686
sg10
I12
sg11
VAnophthalmia
p5687
sg13
I1
sa(dp5688
g7
I116
sg20
VC1859773
p5689
sg10
I40
sg11
VAnophthalmia-Esophageal-Genital syndrome
p5690
sg13
I2
sa(dp5691
g7
I85
sg20
VC0039082
p5692
sg10
I9
sg11
Vsyndromes
p5693
sg13
I1
sa(dp5694
g7
I300
sg20
VC2931601
p5695
sg10
I31
sg11
Voculofaciocardiodental syndrome
p5696
sg13
I2
sa(dp5697
g7
I341
sg20
VC0026010
p5698
sg10
I14
sg11
Vmicrophthalmia
p5699
sg13
I1
sa(dp5700
g7
I251
sg20
VC1832661
p5701
sg10
I21
sg11
VMatthew-Wood syndrome
p5702
sg13
I2
sa(dp5703
g7
I382
sg20
VC0026010
p5704
sg10
I14
sg11
VMicrophthalmia
p5705
sg13
I1
sa(dp5706
g7
I116
sg20
VC0003119
p5707
sg10
I12
sg11
VAnophthalmia
p5708
sg13
I1
sasa(dp5709
g2
S'Eye malformations, most commonly coloboma, and cleft palate occur in a significant proportion of Smoc1(tm1a/tm1a) embryos and pups.\n'
p5710
sg4
(lp5711
(dp5712
g7
I97
sg8
g59
sg10
I5
sg11
VSmoc1
p5713
sg13
I1
sasg17
(lp5714
(dp5715
g7
I47
sg20
VC0008925
p5716
sg10
I12
sg11
Vcleft palate
p5717
sg13
I2
sa(dp5718
g7
I33
sg20
VC0009363
p5719
sg10
I8
sg11
Vcoloboma
p5720
sg13
I1
sa(dp5721
g7
I0
sg20
VC0015393
p5722
sg10
I17
sg11
VEye malformations
p5723
sg13
I2
sasa(dp5724
g2
S'The expression of one of the nine mammalian PRMTs, PRMT5, affects the levels of symmetric dimethylarginine (SDMA) at Arg-3 on histone H4, leading to the repression of genes which are related to disease progression in lymphoma and leukemia.\n'
p5725
sg4
(lp5726
(dp5727
g7
I51
sg8
g59
sg10
I5
sg11
VPRMT5
p5728
sg13
I1
sa(dp5729
g7
I126
sg8
VP62805
p5730
sg10
I10
sg11
Vhistone H4
p5731
sg13
I2
sasg17
(lp5732
(dp5733
g7
I217
sg20
VC0024299
p5734
sg10
I8
sg11
Vlymphoma
p5735
sg13
I1
sa(dp5736
g7
I230
sg20
VC0023418
p5737
sg10
I8
sg11
Vleukemia
p5738
sg13
I1
sa(dp5739
g7
I194
sg20
VC0242656
p5740
sg10
I19
sg11
Vdisease progression
p5741
sg13
I2
sasa(dp5742
g2
S'In addition, our study has shown that Belinostat and DZNep together with RA caused a depletion in HDAC1 and HDAC2 protein levels, HDAC2 gene expression and increased hyperacetylation of histone H4 in both leukemia cell lines.\n'
p5743
sg4
(lp5744
(dp5745
g7
I98
sg8
g59
sg10
I5
sg11
VHDAC1
p5746
sg13
I1
sa(dp5747
g7
I186
sg8
VP62805
p5748
sg10
I10
sg11
Vhistone H4
p5749
sg13
I2
sa(dp5750
g7
I108
sg8
g59
sg10
I13
sg11
VHDAC2 protein
p5751
sg13
I2
sa(dp5752
g7
I130
sg8
g59
sg10
I10
sg11
VHDAC2 gene
p5753
sg13
I2
sasg17
(lp5754
(dp5755
g7
I205
sg20
VC0023418
p5756
sg10
I8
sg11
Vleukemia
p5757
sg13
I1
sasa(dp5758
g2
S'IL-18 was localized by immunohistochemical analysis in brain sections obtained from tuberous sclerosis and encephalitis patients, as well as from gender- and age-matched controls, and in the brain sections of both Reeler and wild-type mice.\n'
p5759
sg4
(lp5760
sg17
(lp5761
(dp5762
g7
I107
sg20
VC0014038
p5763
sg10
I12
sg11
Vencephalitis
p5764
sg13
I1
sa(dp5765
g7
I84
sg20
VC0041341
p5766
sg10
I18
sg11
Vtuberous sclerosis
p5767
sg13
I2
sasa(dp5768
g2
S'IL-18 was detected within glial cells and neurons in the brain of subjects affected by tuberous sclerosis and encephalitis whereas in healthy subjects, only a weak IL-18 positivity was detected at the level of glial cells.\n'
p5769
sg4
(lp5770
sg17
(lp5771
(dp5772
g7
I87
sg20
VC0041341
p5773
sg10
I18
sg11
Vtuberous sclerosis
p5774
sg13
I2
sa(dp5775
g7
I110
sg20
VC0014038
p5776
sg10
I12
sg11
Vencephalitis
p5777
sg13
I1
sasa(dp5778
g2
S'Intrathecal elevations of interleukin-6 and interleukin-8 in all four types of central nervous system manifestations, and of interleukin-18 in late-onset encephalitis were observed.\n'
p5779
sg4
(lp5780
(dp5781
g7
I26
sg8
VP05231
p5782
sg10
I13
sg11
Vinterleukin-6
p5783
sg13
I1
sa(dp5784
g7
I44
sg8
VP60568
p5785
sg10
I13
sg11
Vinterleukin-8
p5786
sg13
I1
sa(dp5787
g7
I125
sg8
g59
sg10
I14
sg11
Vinterleukin-18
p5788
sg13
I1
sasg17
(lp5789
(dp5790
g7
I87
sg20
VC0027769
p5791
sg10
I7
sg11
Vnervous
p5792
sg13
I1
sa(dp5793
g7
I154
sg20
VC0014038
p5794
sg10
I12
sg11
Vencephalitis
p5795
sg13
I1
sasa(dp5796
g2
S'This led us to examine the potential role of IL-18 in the pathogenesis of VSV encephalitis.\n'
p5797
sg4
(lp5798
sg17
(lp5799
(dp5800
g7
I78
sg20
VC0014038
p5801
sg10
I12
sg11
Vencephalitis
p5802
sg13
I1
sa(dp5803
g7
I58
sg20
VC0699748
p5804
sg10
I12
sg11
Vpathogenesis
p5805
sg13
I1
sasa(dp5806
g2
S'Lafora disease (LD), also known as progressive myoclonic epilepsy-2 (EPM2), is a rare, fatal autosomal recessive disorder typically starting during adolescence in otherwise neurologically normal individuals.\n'
p5807
sg4
(lp5808
(dp5809
g7
I69
sg8
g59
sg10
I4
sg11
VEPM2
p5810
sg13
I1
sa(dp5811
g7
I57
sg8
VP10646
p5812
sg10
I10
sg11
Vepilepsy-2
p5813
sg13
I1
sasg17
(lp5814
(dp5815
g7
I0
sg20
VC0751783
p5816
sg10
I14
sg11
VLafora disease
p5817
sg13
I2
sa(dp5818
g7
I16
sg20
VC0751783
p5819
sg10
I2
sg11
VLD
p5820
sg13
I1
sa(dp5821
g7
I69
sg20
VC0751783
p5822
sg10
I4
sg11
VEPM2
p5823
sg13
I1
sa(dp5824
g7
I35
sg20
VC0751778
p5825
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p5826
sg13
I3
sasa(dp5827
g2
S'Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss-of-function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin.\n'
p5828
sg4
(lp5829
(dp5830
g7
I144
sg8
VP62979
p5831
sg10
I19
sg11
Vubiquitin E3 ligase
p5832
sg13
I3
sa(dp5833
g7
I108
sg8
g59
sg10
I28
sg11
Vglycogen phosphatase laforin
p5834
sg13
I3
sasg17
(lp5835
(dp5836
g7
I0
sg20
VC0751783
p5837
sg10
I14
sg11
VLafora disease
p5838
sg13
I2
sa(dp5839
g7
I16
sg20
VC0751783
p5840
sg10
I2
sg11
VLD
p5841
sg13
I1
sa(dp5842
g7
I43
sg20
VC0014544
p5843
sg10
I8
sg11
Vepilepsy
p5844
sg13
I1
sasa(dp5845
g2
S'Lafora disease (LD) is a rare adolescent-onset progressive myoclonic epilepsy caused by loss-of-function mutations either in the EPM2A gene encoding laforin or in the EPM2B gene encoding malin.\n'
p5846
sg4
(lp5847
(dp5848
g7
I129
sg8
g59
sg10
I27
sg11
VEPM2A gene encoding laforin
p5849
sg13
I4
sa(dp5850
g7
I167
sg8
g59
sg10
I25
sg11
VEPM2B gene encoding malin
p5851
sg13
I4
sasg17
(lp5852
(dp5853
g7
I0
sg20
VC0751783
p5854
sg10
I14
sg11
VLafora disease
p5855
sg13
I2
sa(dp5856
g7
I16
sg20
VC0751783
p5857
sg10
I2
sg11
VLD
p5858
sg13
I1
sa(dp5859
g7
I47
sg20
VC0751778
p5860
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p5861
sg13
I3
sa(dp5862
g7
I129
sg20
VC0751783
p5863
sg10
I5
sg11
VEPM2A
p5864
sg13
I1
sa(dp5865
g7
I167
sg20
VC1850764
p5866
sg10
I5
sg11
VEPM2B
p5867
sg13
I1
sasa(dp5868
g2
S'Lafora disease (LD) is an autosomal recessive progressive myoclonus epilepsy due to mutations in the EPM2A (laforin) and EPM2B (malin) genes, with no substantial genotype-phenotype differences between the two.\n'
p5869
sg4
(lp5870
(dp5871
g7
I108
sg8
g59
sg10
I7
sg11
Vlaforin
p5872
sg13
I1
sa(dp5873
g7
I101
sg8
g59
sg10
I5
sg11
VEPM2A
p5874
sg13
I1
sa(dp5875
g7
I121
sg8
g59
sg10
I5
sg11
VEPM2B
p5876
sg13
I1
sa(dp5877
g7
I128
sg8
g59
sg10
I5
sg11
Vmalin
p5878
sg13
I1
sasg17
(lp5879
(dp5880
g7
I46
sg20
VC0751778
p5881
sg10
I30
sg11
Vprogressive myoclonus epilepsy
p5882
sg13
I3
sa(dp5883
g7
I0
sg20
VC0751783
p5884
sg10
I14
sg11
VLafora disease
p5885
sg13
I2
sa(dp5886
g7
I101
sg20
VC0751783
p5887
sg10
I5
sg11
VEPM2A
p5888
sg13
I1
sa(dp5889
g7
I121
sg20
VC1850764
p5890
sg10
I5
sg11
VEPM2B
p5891
sg13
I1
sa(dp5892
g7
I16
sg20
VC0751783
p5893
sg10
I2
sg11
VLD
p5894
sg13
I1
sasa(dp5895
g2
S"The lack of Lafora's bodies in skin specimens and the molecular analysis excluding mutations in Laforin and Malin genes ruled out Lafora disease.\n"
p5896
sg4
(lp5897
(dp5898
g7
I96
sg8
g59
sg10
I7
sg11
VLaforin
p5899
sg13
I1
sa(dp5900
g7
I108
sg8
g59
sg10
I11
sg11
VMalin genes
p5901
sg13
I2
sasg17
(lp5902
(dp5903
g7
I130
sg20
VC0751783
p5904
sg10
I14
sg11
VLafora disease
p5905
sg13
I2
sasa(dp5906
g2
S'Hybrid (C56BL/6 x DBA) (BDF1; H-2b/H-2d) mice bearing the P815 leukemia (H-2d) were grafted with a (CBA x C57BL/6)F1 (CBF1; H-2k/H-2b) cell suspension, comprising bone marrow cells (BMC; 25 x 10(6)/mouse) and spleen cells (SC; 55 x 10(6)/mouse) on day-4, then treated with cyclophosphamide (200 mg/kg) on day-2 and finally grafted once more with CBF1 cells (25 x 10(6) BMC + 7 x 10(6) SC) on day 0.\n'
p5907
sg4
(lp5908
(dp5909
g7
I118
sg8
g59
sg10
I4
sg11
VCBF1
p5910
sg13
I1
sasg17
(lp5911
(dp5912
g7
I18
sg20
VC0398550
p5913
sg10
I3
sg11
VDBA
p5914
sg13
I1
sa(dp5915
g7
I63
sg20
VC0023418
p5916
sg10
I8
sg11
Vleukemia
p5917
sg13
I1
sasa(dp5918
g2
S'A TL+ leukemia of a (B6 X A)F1 hybrid mouse (H-2b/H-2a) was previously subjected to immunoselection against H-2a by passage in (B6 X A.SW)F1 mice (H-2b/H-2s).\n'
p5919
sg4
(lp5920
sg17
(lp5921
(dp5922
g7
I6
sg20
VC0023418
p5923
sg10
I8
sg11
Vleukemia
p5924
sg13
I1
sasa(dp5925
g2
S'We describe a novel mutation in PSTPIP1 resulting in pyoderma gangrenosum, acne and ulcerative colitis.\n'
p5926
sg4
(lp5927
(dp5928
g7
I32
sg8
g59
sg10
I7
sg11
VPSTPIP1
p5929
sg13
I1
sasg17
(lp5930
(dp5931
g7
I53
sg20
VC0085652
p5932
sg10
I20
sg11
Vpyoderma gangrenosum
p5933
sg13
I2
sa(dp5934
g7
I14
sg20
VC2985438
p5935
sg10
I14
sg11
Vnovel mutation
p5936
sg13
I2
sa(dp5937
g7
I84
sg20
VC0009324
p5938
sg10
I18
sg11
Vulcerative colitis
p5939
sg13
I2
sa(dp5940
g7
I75
sg20
VC0001144
p5941
sg10
I4
sg11
Vacne
p5942
sg13
I1
sasa(dp5943
g2
S'This CD2BP1-mediated biochemical pathway(s) may function in common inflammatory disorders with apparent etiological overlap, such as rheumatoid arthritis and inflammatory bowel disease.\n'
p5944
sg4
(lp5945
(dp5946
g7
I5
sg8
g59
sg10
I6
sg11
VCD2BP1
p5947
sg13
I1
sasg17
(lp5948
(dp5949
g7
I158
sg20
VC0021390
p5950
sg10
I26
sg11
Vinflammatory bowel disease
p5951
sg13
I3
sa(dp5952
g7
I133
sg20
VC0003873
p5953
sg10
I20
sg11
Vrheumatoid arthritis
p5954
sg13
I2
sasa(dp5955
g2
S'Moreover, METTL13-dependent inhibition of bladder cancer cell migration and invasion is mediated by downregulation of FAK (Focal adhesion kinase) phosphorylation, AKT (v-akt murine thymoma viral oncogene) phosphorylation, Beta-catenin expression and MMP-9 expression.\n'
p5956
sg4
(lp5957
(dp5958
g7
I118
sg8
g59
sg10
I3
sg11
VFAK
p5959
sg13
I1
sa(dp5960
g7
I250
sg8
VP14780
p5961
sg10
I5
sg11
VMMP-9
p5962
sg13
I1
sa(dp5963
g7
I222
sg8
VP35222
p5964
sg10
I12
sg11
VBeta-catenin
p5965
sg13
I1
sa(dp5966
g7
I168
sg8
g59
sg10
I35
sg11
Vv-akt murine thymoma viral oncogene
p5967
sg13
I5
sa(dp5968
g7
I163
sg8
g59
sg10
I3
sg11
VAKT
p5969
sg13
I1
sa(dp5970
g7
I123
sg8
g59
sg10
I21
sg11
VFocal adhesion kinase
p5971
sg13
I3
sasg17
(lp5972
(dp5973
g7
I42
sg20
VC0699885
p5974
sg10
I14
sg11
Vbladder cancer
p5975
sg13
I2
sa(dp5976
g7
I76
sg20
VC2699153
p5977
sg10
I8
sg11
Vinvasion
p5978
sg13
I1
sa(dp5979
g7
I181
sg20
VC0040100
p5980
sg10
I7
sg11
Vthymoma
p5981
sg13
I1
sa(dp5982
g7
I129
sg20
VC0001511
p5983
sg10
I8
sg11
Vadhesion
p5984
sg13
I1
sasa(dp5985
g2
S'Here, we identify miR-543 as a direct regulator of FAK and TWIST1 expression in endometrial cancer.\n'
p5986
sg4
(lp5987
(dp5988
g7
I59
sg8
g59
sg10
I6
sg11
VTWIST1
p5989
sg13
I1
sa(dp5990
g7
I51
sg8
g59
sg10
I3
sg11
VFAK
p5991
sg13
I1
sasg17
(lp5992
(dp5993
g7
I80
sg20
VC0476089
p5994
sg10
I18
sg11
Vendometrial cancer
p5995
sg13
I2
sasa(dp5996
g2
S'Forced expression of miR-543 in endometrial cancer cell lines decreases both endogenous FAK and TWIST1 mRNA and protein levels.\n'
p5997
sg4
(lp5998
(dp5999
g7
I21
sg8
g59
sg10
I7
sg11
VmiR-543
p6000
sg13
I1
sa(dp6001
g7
I96
sg8
g59
sg10
I11
sg11
VTWIST1 mRNA
p6002
sg13
I2
sa(dp6003
g7
I88
sg8
g59
sg10
I3
sg11
VFAK
p6004
sg13
I1
sasg17
(lp6005
(dp6006
g7
I32
sg20
VC0476089
p6007
sg10
I18
sg11
Vendometrial cancer
p6008
sg13
I2
sasa(dp6009
g2
S'Forced expression of miR-543 in aggressive endometrial cancer cell lines also impairs tumor cell monolayer proliferation, anchorage-independent growth, migration and invasion.\n'
p6010
sg4
(lp6011
(dp6012
g7
I21
sg8
g59
sg10
I7
sg11
VmiR-543
p6013
sg13
I1
sasg17
(lp6014
(dp6015
g7
I32
sg20
VC0001807
p6016
sg10
I10
sg11
Vaggressive
p6017
sg13
I1
sa(dp6018
g7
I166
sg20
VC2699153
p6019
sg10
I8
sg11
Vinvasion
p6020
sg13
I1
sa(dp6021
g7
I86
sg20
VC0027651
p6022
sg10
I5
sg11
Vtumor
p6023
sg13
I1
sa(dp6024
g7
I43
sg20
VC0476089
p6025
sg10
I18
sg11
Vendometrial cancer
p6026
sg13
I2
sa(dp6027
g7
I107
sg20
VC0334094
p6028
sg10
I13
sg11
Vproliferation
p6029
sg13
I1
sasa(dp6030
g2
S'miR-543 expression is decreased in endometrial cancer and serves as a tumor suppressor by targeting FAK and TWIST1 expression.\n'
p6031
sg4
(lp6032
(dp6033
g7
I0
sg8
g59
sg10
I7
sg11
VmiR-543
p6034
sg13
I1
sa(dp6035
g7
I100
sg8
g59
sg10
I3
sg11
VFAK
p6036
sg13
I1
sa(dp6037
g7
I108
sg8
g59
sg10
I6
sg11
VTWIST1
p6038
sg13
I1
sasg17
(lp6039
(dp6040
g7
I70
sg20
VC0027651
p6041
sg10
I5
sg11
Vtumor
p6042
sg13
I1
sa(dp6043
g7
I35
sg20
VC0476089
p6044
sg10
I18
sg11
Vendometrial cancer
p6045
sg13
I2
sasa(dp6046
g2
S'CD22-targeted recombinant immunotoxins (rIT) are active in hairy cell leukemia or acute lymphoblastic leukemia (ALL), but not in mantle cell lymphoma (MCL) patients.\n'
p6047
sg4
(lp6048
(dp6049
g7
I14
sg8
g59
sg10
I24
sg11
Vrecombinant immunotoxins
p6050
sg13
I2
sa(dp6051
g7
I40
sg8
g59
sg10
I3
sg11
VrIT
p6052
sg13
I1
sasg17
(lp6053
(dp6054
g7
I59
sg20
VC0023443
p6055
sg10
I19
sg11
Vhairy cell leukemia
p6056
sg13
I3
sa(dp6057
g7
I151
sg20
VC1708350
p6058
sg10
I3
sg11
VMCL
p6059
sg13
I1
sa(dp6060
g7
I112
sg20
VC1961102
p6061
sg10
I3
sg11
VALL
p6062
sg13
I1
sa(dp6063
g7
I82
sg20
VC1961102
p6064
sg10
I28
sg11
Vacute lymphoblastic leukemia
p6065
sg13
I3
sa(dp6066
g7
I129
sg20
VC0334634
p6067
sg10
I20
sg11
Vmantle cell lymphoma
p6068
sg13
I3
sasa(dp6069
g2
S'#####CD5+#B#####(small B cell lymphoma, SBL)##################2003#1##2015#5###########92#CD5+SBL#############, 92#######(bone marrow biopsy, BMB)##########################IgH/CCND1#######(fluorescence in situ hybridization, FISH)###############/#########(chronic lymphocytic leukemia/small lymphocytic lymphoma, CLL/SLL)56#(60.9%), ######(mantle cell lymphoma, MCL)23#(25.0%), ####13#(14.1%), ########(follicular lymphoma, FL)5#, #########(lymphoplasmacytic lymphoma, LPL)4#, ########(splenic marginal zone lymphoma, SMZL)4################(28#), ######(25#), ###(19#)####(18#)####, ######(2#)######################CD19, CD20#CD5#############CLL/SLL###4~5#, MCL########&lt;=3##13######SBL#, 5#FL###CD10#3#FL, 1#LPL, 3#SMZL##CD23#CLL/SLL#MCL#CD23, sIgM, FMC7, CD11C, CD22#############(P&lt;0.01)#############MCL###cyclin D1#FISH####MCL##IgH/CCND1######CD5+ SBL#########, ###########################CD5+ SBL, ###CLL/SLL###########.\n'
p6070
sg4
(lp6071
(dp6072
g7
I176
sg8
VP24385
p6073
sg10
I5
sg11
VCCND1
p6074
sg13
I1
sa(dp6075
g7
I317
sg8
g59
sg10
I3
sg11
VSLL
p6076
sg13
I1
sa(dp6077
g7
I621
sg8
VP35900
p6078
sg10
I4
sg11
VCD20
p6079
sg13
I1
sa(dp6080
g7
I698
sg8
VP08473
p6081
sg10
I6
sg11
VCD10#3
p6082
sg13
I1
sa(dp6083
g7
I724
sg8
VP06734
p6084
sg10
I4
sg11
VCD23
p6085
sg13
I1
sa(dp6086
g7
I317
sg8
g59
sg10
I3
sg11
VSLL
p6087
sg13
I1
sa(dp6088
g7
I313
sg8
VP04207
p6089
sg10
I7
sg11
VCLL/SLL
p6090
sg13
I1
sa(dp6091
g7
I5
sg8
VP06127
p6092
sg10
I3
sg11
VCD5
p6093
sg13
I1
sa(dp6094
g7
I759
sg8
VP20702
p6095
sg10
I5
sg11
VCD11C
p6096
sg13
I1
sa(dp6097
g7
I172
sg8
VP01877
p6098
sg10
I3
sg11
VIgH
p6099
sg13
I1
sa(dp6100
g7
I5
sg8
VP06127
p6101
sg10
I4
sg11
VCD5+
p6102
sg13
I1
sa(dp6103
g7
I172
sg8
VP01877
p6104
sg10
I3
sg11
VIgH
p6105
sg13
I1
sa(dp6106
g7
I724
sg8
VP06734
p6107
sg10
I4
sg11
VCD23
p6108
sg13
I1
sa(dp6109
g7
I313
sg8
VP04207
p6110
sg10
I3
sg11
VCLL
p6111
sg13
I1
sa(dp6112
g7
I176
sg8
VP24385
p6113
sg10
I5
sg11
VCCND1
p6114
sg13
I1
sa(dp6115
g7
I5
sg8
VP06127
p6116
sg10
I4
sg11
VCD5+
p6117
sg13
I1
sa(dp6118
g7
I317
sg8
g59
sg10
I3
sg11
VSLL
p6119
sg13
I1
sa(dp6120
g7
I313
sg8
VP04207
p6121
sg10
I3
sg11
VCLL
p6122
sg13
I1
sa(dp6123
g7
I313
sg8
VP04207
p6124
sg10
I3
sg11
VCLL
p6125
sg13
I1
sa(dp6126
g7
I615
sg8
VP15391
p6127
sg10
I4
sg11
VCD19
p6128
sg13
I1
sa(dp6129
g7
I362
sg8
VP07954
p6130
sg10
I3
sg11
VMCL
p6131
sg13
I1
sa(dp6132
g7
I813
sg8
VP24385
p6133
sg10
I9
sg11
Vcyclin D1
p6134
sg13
I2
sasg17
(lp6135
(dp6136
g7
I256
sg20
VC1302547
p6137
sg10
I55
sg11
Vchronic lymphocytic leukemia/small lymphocytic lymphoma
p6138
sg13
I5
sa(dp6139
g7
I313
sg20
VC1302547
p6140
sg10
I7
sg11
VCLL/SLL
p6141
sg13
I1
sa(dp6142
g7
I486
sg20
VC0349632
p6143
sg10
I30
sg11
Vsplenic marginal zone lymphoma
p6144
sg13
I4
sa(dp6145
g7
I23
sg20
VC0079731
p6146
sg10
I15
sg11
VB cell lymphoma
p6147
sg13
I3
sa(dp6148
g7
I362
sg20
VC1708350
p6149
sg10
I3
sg11
VMCL
p6150
sg13
I1
sa(dp6151
g7
I313
sg20
VC1302547
p6152
sg10
I7
sg11
VCLL/SLL
p6153
sg13
I1
sa(dp6154
g7
I362
sg20
VC1708350
p6155
sg10
I3
sg11
VMCL
p6156
sg13
I1
sa(dp6157
g7
I362
sg20
VC1708350
p6158
sg10
I3
sg11
VMCL
p6159
sg13
I1
sa(dp6160
g7
I403
sg20
VC0024301
p6161
sg10
I19
sg11
Vfollicular lymphoma
p6162
sg13
I2
sa(dp6163
g7
I340
sg20
VC0334634
p6164
sg10
I20
sg11
Vmantle cell lymphoma
p6165
sg13
I3
sa(dp6166
g7
I362
sg20
VC1708350
p6167
sg10
I3
sg11
VMCL
p6168
sg13
I1
sa(dp6169
g7
I313
sg20
VC1302547
p6170
sg10
I7
sg11
VCLL/SLL
p6171
sg13
I1
sa(dp6172
g7
I362
sg20
VC1708350
p6173
sg10
I3
sg11
VMCL
p6174
sg13
I1
sa(dp6175
g7
I313
sg20
VC1302547
p6176
sg10
I7
sg11
VCLL/SLL
p6177
sg13
I1
sa(dp6178
g7
I441
sg20
VC0024419
p6179
sg10
I26
sg11
Vlymphoplasmacytic lymphoma
p6180
sg13
I2
sasa(dp6181
g2
S'Moreover, increased hepatic iNKT cell abundance in the absence of MTP is associated with susceptibility to severe iNKT cell-mediated hepatitis, thus demonstrating the importance of CD1d-dependent control of liver iNKT cells in maintaining immunological homeostasis in the liver.\n'
p6182
sg4
(lp6183
(dp6184
g7
I66
sg8
VP53582
p6185
sg10
I3
sg11
VMTP
p6186
sg13
I1
sa(dp6187
g7
I181
sg8
VP15813
p6188
sg10
I4
sg11
VCD1d
p6189
sg13
I1
sasg17
(lp6190
(dp6191
g7
I133
sg20
VC0019159
p6192
sg10
I9
sg11
Vhepatitis
p6193
sg13
I1
sasa(dp6194
g2
S'CD1d expression on T cells in peripheral blood samples and liver sections from autoimmune hepatitis patients and healthy individuals were also examined.\n'
p6195
sg4
(lp6196
(dp6197
g7
I0
sg8
VP15813
p6198
sg10
I4
sg11
VCD1d
p6199
sg13
I1
sasg17
(lp6200
(dp6201
g7
I79
sg20
VC0241910
p6202
sg10
I20
sg11
Vautoimmune hepatitis
p6203
sg13
I2
sasa(dp6204
g2
S'Lck-CD1dTgJAlfa18o and Lck-CD1dTgJAlfa18+ mice developed similar degrees of liver pathology resembling chronic autoimmune hepatitis in humans.\n'
p6205
sg4
(lp6206
sg17
(lp6207
(dp6208
g7
I82
sg20
VC0677042
p6209
sg10
I9
sg11
Vpathology
p6210
sg13
I1
sa(dp6211
g7
I111
sg20
VC0241910
p6212
sg10
I20
sg11
Vautoimmune hepatitis
p6213
sg13
I2
sasa(dp6214
g2
S'A similar mechanism could be extended to humans as CD1d expression is upregulated on activated human T cells and increased presence of CD1d-expressing T cells was observed in autoimmune hepatitis patients.\n'
p6215
sg4
(lp6216
(dp6217
g7
I51
sg8
VP15813
p6218
sg10
I4
sg11
VCD1d
p6219
sg13
I1
sa(dp6220
g7
I51
sg8
VP15813
p6221
sg10
I4
sg11
VCD1d
p6222
sg13
I1
sasg17
(lp6223
(dp6224
g7
I175
sg20
VC0241910
p6225
sg10
I20
sg11
Vautoimmune hepatitis
p6226
sg13
I2
sasa(dp6227
g2
S'Lay summary: CD1d overexpression on T cells enhances crosstalk between type II NKT cells and T cells, resulting in their aberrant activation and leading to the development of chronic autoimmune liver disease.\n'
p6228
sg4
(lp6229
(dp6230
g7
I13
sg8
VP15813
p6231
sg10
I4
sg11
VCD1d
p6232
sg13
I1
sasg17
(lp6233
(dp6234
g7
I183
sg20
VC0400936
p6235
sg10
I24
sg11
Vautoimmune liver disease
p6236
sg13
I3
sasa(dp6237
g2
S'CD1d expression was down-regulated in the biliary epithelium of patients with late primary sclerosing cholangitis, primary biliary cirrhosis, and alcoholic cirrhosis compared to healthy controls.\n'
p6238
sg4
(lp6239
(dp6240
g7
I0
sg8
VP15813
p6241
sg10
I4
sg11
VCD1d
p6242
sg13
I1
sasg17
(lp6243
(dp6244
g7
I83
sg20
VC0566602
p6245
sg10
I30
sg11
Vprimary sclerosing cholangitis
p6246
sg13
I3
sa(dp6247
g7
I146
sg20
VC0023891
p6248
sg10
I19
sg11
Valcoholic cirrhosis
p6249
sg13
I2
sa(dp6250
g7
I115
sg20
VC0008312
p6251
sg10
I25
sg11
Vprimary biliary cirrhosis
p6252
sg13
I3
sasa(dp6253
g2
S'Patients with alcoholic hepatitis showed significantly increased plasma PS levels and enhanced liver expression of PS and CD1d compared with controls.\n'
p6254
sg4
(lp6255
(dp6256
g7
I122
sg8
VP15813
p6257
sg10
I4
sg11
VCD1d
p6258
sg13
I1
sasg17
(lp6259
(dp6260
g7
I14
sg20
VC0019187
p6261
sg10
I19
sg11
Valcoholic hepatitis
p6262
sg13
I2
sasa(dp6263
g2
S'In order to explore the role of Gal-3 in NKT-cell-dependent pathology, we induced hepatitis in C57BL/6 WT and Gal-3-deficient mice by using specific ligand for NKT cells: Alfa-galactosylceramide, glycolipid Ag presented by CD1d.\n'
p6264
sg4
(lp6265
(dp6266
g7
I32
sg8
VP16278
p6267
sg10
I5
sg11
VGal-3
p6268
sg13
I1
sa(dp6269
g7
I223
sg8
VP15813
p6270
sg10
I4
sg11
VCD1d
p6271
sg13
I1
sa(dp6272
g7
I171
sg8
VP54803
p6273
sg10
I23
sg11
VAlfa-galactosylceramide
p6274
sg13
I1
sasg17
(lp6275
(dp6276
g7
I82
sg20
VC0019159
p6277
sg10
I9
sg11
Vhepatitis
p6278
sg13
I1
sa(dp6279
g7
I60
sg20
VC0677042
p6280
sg10
I9
sg11
Vpathology
p6281
sg13
I1
sasa(dp6282
g2
S'We investigated the expression of 6 CT genes (MAGE-E1, SOX-6, SCP-1, SSX-2, SSX-4, and HOM-TES-85) using reverse-transcription polymerase chain reaction in 26 meningiomas and 32 other various brain tumor specimens, obtained from the patients during tumor surgery from 2000 to 2005.\n'
p6283
sg4
(lp6284
(dp6285
g7
I87
sg8
g59
sg10
I10
sg11
VHOM-TES-85
p6286
sg13
I1
sa(dp6287
g7
I76
sg8
g59
sg10
I5
sg11
VSSX-4
p6288
sg13
I1
sa(dp6289
g7
I46
sg8
VP43355
p6290
sg10
I4
sg11
VMAGE
p6291
sg13
I1
sa(dp6292
g7
I62
sg8
g59
sg10
I5
sg11
VSCP-1
p6293
sg13
I1
sa(dp6294
g7
I69
sg8
g59
sg10
I5
sg11
VSSX-2
p6295
sg13
I1
sa(dp6296
g7
I55
sg8
VP35712
p6297
sg10
I5
sg11
VSOX-6
p6298
sg13
I1
sasg17
(lp6299
(dp6300
g7
I159
sg20
VC0025286
p6301
sg10
I11
sg11
Vmeningiomas
p6302
sg13
I1
sa(dp6303
g7
I192
sg20
VC0006118
p6304
sg10
I11
sg11
Vbrain tumor
p6305
sg13
I2
sa(dp6306
g7
I198
sg20
VC0027651
p6307
sg10
I5
sg11
Vtumor
p6308
sg13
I1
sasa(dp6309
g2
S'The most frequently expressed CT genes of meningiomas were MAGE-E1, which were found in 22/26 (85%) meningioma samples, followed by SOX-6 (9/26 or 35%).\n'
p6310
sg4
(lp6311
sg17
(lp6312
(dp6313
g7
I42
sg20
VC0025286
p6314
sg10
I10
sg11
Vmeningioma
p6315
sg13
I1
sa(dp6316
g7
I42
sg20
VC0025286
p6317
sg10
I11
sg11
Vmeningiomas
p6318
sg13
I1
sasa(dp6319
g2
S'The data presented here suggest that MAGE-E1 and SOX-6 genes are expressed in a high percentage of human central nervous system tumors, which implies the CT genes could be the potential targets of immunotherapy for human central nervous system tumors.\n'
p6320
sg4
(lp6321
(dp6322
g7
I49
sg8
VP35712
p6323
sg10
I11
sg11
VSOX-6 genes
p6324
sg13
I2
sa(dp6325
g7
I37
sg8
VP43355
p6326
sg10
I4
sg11
VMAGE
p6327
sg13
I1
sasg17
(lp6328
(dp6329
g7
I105
sg20
VC0085136
p6330
sg10
I29
sg11
Vcentral nervous system tumors
p6331
sg13
I4
sa(dp6332
g7
I105
sg20
VC0085136
p6333
sg10
I29
sg11
Vcentral nervous system tumors
p6334
sg13
I4
sasa(dp6335
g2
S"The restriction fragment length polymorphism of the two human HLA-B-associated transcripts (BATs) genes, BAT1 and BAT2, identifying polymorphic bands of 12, 8, 2.5, and 1.1 kb, and at 3.3, 2.7, 2.3, and 0.9 kb, respectively, was investigated in patients with primary biliary cirrhosis (PBC), systemic lupus erythematosus (SLE), pauciarticular juvenile rheumatoid arthritis (P-JRA), rheumatoid arthritis (RA), and primary Sjoegren's syndrome (pSS), and in healthy Danes.\n"
p6336
sg4
(lp6337
(dp6338
g7
I56
sg8
VP30461
p6339
sg10
I34
sg11
Vhuman HLA-B-associated transcripts
p6340
sg13
I3
sa(dp6341
g7
I105
sg8
VP82251
p6342
sg10
I4
sg11
VBAT1
p6343
sg13
I1
sasg17
(lp6344
(dp6345
g7
I352
sg20
VC0003873
p6346
sg10
I20
sg11
Vrheumatoid arthritis
p6347
sg13
I2
sa(dp6348
g7
I322
sg20
VC0024141
p6349
sg10
I3
sg11
VSLE
p6350
sg13
I1
sa(dp6351
g7
I442
sg20
VC1832588
p6352
sg10
I3
sg11
VpSS
p6353
sg13
I1
sa(dp6354
g7
I413
sg20
VC1832588
p6355
sg10
I27
sg11
Vprimary Sjoegren's syndrome
p6356
sg13
I3
sa(dp6357
g7
I286
sg20
VC0008312
p6358
sg10
I3
sg11
VPBC
p6359
sg13
I1
sa(dp6360
g7
I328
sg20
VC0157917
p6361
sg10
I44
sg11
Vpauciarticular juvenile rheumatoid arthritis
p6362
sg13
I4
sa(dp6363
g7
I374
sg20
VC0157917
p6364
sg10
I5
sg11
VP-JRA
p6365
sg13
I1
sa(dp6366
g7
I292
sg20
VC0024141
p6367
sg10
I28
sg11
Vsystemic lupus erythematosus
p6368
sg13
I3
sa(dp6369
g7
I377
sg20
VC0003873
p6370
sg10
I2
sg11
VRA
p6371
sg13
I1
sa(dp6372
g7
I259
sg20
VC0008312
p6373
sg10
I25
sg11
Vprimary biliary cirrhosis
p6374
sg13
I3
sasa(dp6375
g2
S'Progranulin (PGRN) has been shown to be involved in the process of inflammation, wound healing, and cartilage development; and its role in the progression of breast and ovarian cancer is also well established.\n'
p6376
sg4
(lp6377
sg17
(lp6378
(dp6379
g7
I67
sg20
VC0021368
p6380
sg10
I12
sg11
Vinflammation
p6381
sg13
I1
sa(dp6382
g7
I169
sg20
VC1140680
p6383
sg10
I14
sg11
Vovarian cancer
p6384
sg13
I2
sasa(dp6385
g2
S'In this paper, we aimed to explore whether progranulin (PGRN) could induce epithelial ovarian cancer cells to undergo an epithelial mesenchymal transition (EMT) program directly and through its activation of cancer associated fibroblasts (CAFs) indirectly.\n'
p6386
sg4
(lp6387
sg17
(lp6388
(dp6389
g7
I208
sg20
VC0795907
p6390
sg10
I29
sg11
Vcancer associated fibroblasts
p6391
sg13
I3
sa(dp6392
g7
I144
sg20
VC0599156
p6393
sg10
I10
sg11
Vtransition
p6394
sg13
I1
sa(dp6395
g7
I239
sg20
VC0795907
p6396
sg10
I4
sg11
VCAFs
p6397
sg13
I1
sa(dp6398
g7
I75
sg20
VC0677886
p6399
sg10
I25
sg11
Vepithelial ovarian cancer
p6400
sg13
I3
sasa(dp6401
g2
S'Immunohistochemistry(IHC) staining of tissue samples of 78 cases of epithelial ovarian cancer (EOC) patients found that PGRN expression levels were negatively correlated with E-cadherin levels (r=-0.289, P=0.013) and positively correlated with Slug levels (r=0.332, P=0.003); Cell experiments showed that PGRN overexpression could increase the migratory and invasive abilities of A2780 cells significantly.\n'
p6402
sg4
(lp6403
(dp6404
g7
I175
sg8
VP12830
p6405
sg10
I10
sg11
VE-cadherin
p6406
sg13
I1
sasg17
(lp6407
(dp6408
g7
I95
sg20
VC0677886
p6409
sg10
I3
sg11
VEOC
p6410
sg13
I1
sa(dp6411
g7
I68
sg20
VC0677886
p6412
sg10
I25
sg11
Vepithelial ovarian cancer
p6413
sg13
I3
sasa(dp6414
g2
S'The pharmacokinetics (PK) and therapeutic effect of 2P-EPI (Mw ~100 kDa) were determined in mice bearing human ovarian carcinoma A2780 xenografts.\n'
p6415
sg4
(lp6416
sg17
(lp6417
(dp6418
g7
I55
sg20
VC0267963
p6419
sg10
I3
sg11
VEPI
p6420
sg13
I1
sa(dp6421
g7
I111
sg20
VC0029925
p6422
sg10
I17
sg11
Vovarian carcinoma
p6423
sg13
I2
sasa(dp6424
g2
S'Here we aimed to investigate the diagnostic value of the levels of the growth factor Granulin, which has been associated with epithelial ovarian carcinoma, in the pathogenesis of POF.\n'
p6425
sg4
(lp6426
(dp6427
g7
I71
sg8
g59
sg10
I22
sg11
Vgrowth factor Granulin
p6428
sg13
I3
sasg17
(lp6429
(dp6430
g7
I137
sg20
VC0029925
p6431
sg10
I17
sg11
Vovarian carcinoma
p6432
sg13
I2
sa(dp6433
g7
I163
sg20
VC0699748
p6434
sg10
I12
sg11
Vpathogenesis
p6435
sg13
I1
sa(dp6436
g7
I179
sg20
VC0085215
p6437
sg10
I3
sg11
VPOF
p6438
sg13
I1
sasa(dp6439
g2
S'Overexpression of progranulin (also named acrogranin, PC-cell-derived growth factor, or granulin-epithelin precursor) is associated with ovarian cancer, specifically with cell proliferation, malignancy, chemoresistance, and shortened overall survival.\n'
p6440
sg4
(lp6441
(dp6442
g7
I54
sg8
g59
sg10
I29
sg11
VPC-cell-derived growth factor
p6443
sg13
I3
sa(dp6444
g7
I88
sg8
VP01275
p6445
sg10
I28
sg11
Vgranulin-epithelin precursor
p6446
sg13
I2
sasg17
(lp6447
(dp6448
g7
I191
sg20
VC0006826
p6449
sg10
I10
sg11
Vmalignancy
p6450
sg13
I1
sa(dp6451
g7
I137
sg20
VC1140680
p6452
sg10
I14
sg11
Vovarian cancer
p6453
sg13
I2
sa(dp6454
g7
I176
sg20
VC0334094
p6455
sg10
I13
sg11
Vproliferation
p6456
sg13
I1
sasa(dp6457
g2
S'The objective of the current study is to identify the signaling pathways involved in the regulation of progranulin expression in ovarian cancer cell lines.\n'
p6458
sg4
(lp6459
sg17
(lp6460
(dp6461
g7
I129
sg20
VC1140680
p6462
sg10
I14
sg11
Vovarian cancer
p6463
sg13
I2
sasa(dp6464
g2
S'We studied the relation of protein kinase C (PKC), phosphatidylinositol 3-kinase, protein kinase A, P38, extracellular signal-regulated kinase, and Akt pathways on the modulation of progranulin expression levels in NIH-OVCAR-3 and SK-OV-3 ovarian cancer cell lines.\n'
p6465
sg4
(lp6466
(dp6467
g7
I148
sg8
g59
sg10
I3
sg11
VAkt
p6468
sg13
I1
sa(dp6469
g7
I51
sg8
VP42336
p6470
sg10
I29
sg11
Vphosphatidylinositol 3-kinase
p6471
sg13
I2
sa(dp6472
g7
I82
sg8
VP17612
p6473
sg10
I16
sg11
Vprotein kinase A
p6474
sg13
I3
sa(dp6475
g7
I27
sg8
VP17252
p6476
sg10
I16
sg11
Vprotein kinase C
p6477
sg13
I3
sa(dp6478
g7
I45
sg8
VP17252
p6479
sg10
I3
sg11
VPKC
p6480
sg13
I1
sa(dp6481
g7
I105
sg8
VP53779
p6482
sg10
I37
sg11
Vextracellular signal-regulated kinase
p6483
sg13
I3
sa(dp6484
g7
I100
sg8
VP46108
p6485
sg10
I3
sg11
VP38
p6486
sg13
I1
sasg17
(lp6487
(dp6488
g7
I239
sg20
VC1140680
p6489
sg10
I14
sg11
Vovarian cancer
p6490
sg13
I2
sa(dp6491
g7
I27
sg20
VC1868682
p6492
sg10
I16
sg11
Vprotein kinase C
p6493
sg13
I3
sa(dp6494
g7
I45
sg20
VC1868682
p6495
sg10
I3
sg11
VPKC
p6496
sg13
I1
sasa(dp6497
g2
S'Inhibition of PKC signal transduction pathway by calphostin C decreased in a dose-dependent manner protein but not mRNA levels of progranulin in both ovarian cancer cell lines.\n'
p6498
sg4
(lp6499
(dp6500
g7
I14
sg8
VP17252
p6501
sg10
I3
sg11
VPKC
p6502
sg13
I1
sasg17
(lp6503
(dp6504
g7
I150
sg20
VC1140680
p6505
sg10
I14
sg11
Vovarian cancer
p6506
sg13
I2
sa(dp6507
g7
I14
sg20
VC1868682
p6508
sg10
I3
sg11
VPKC
p6509
sg13
I1
sasa(dp6510
g2
S'These results suggest that the PKC signaling is involved in the regulation of progranulin protein expression in 2 different ovarian cancer cell lines.\n'
p6511
sg4
(lp6512
(dp6513
g7
I31
sg8
VP17252
p6514
sg10
I3
sg11
VPKC
p6515
sg13
I1
sasg17
(lp6516
(dp6517
g7
I31
sg20
VC1868682
p6518
sg10
I3
sg11
VPKC
p6519
sg13
I1
sa(dp6520
g7
I124
sg20
VC1140680
p6521
sg10
I14
sg11
Vovarian cancer
p6522
sg13
I2
sasa(dp6523
g2
S'Inhibiting these intracellular signal transduction pathways may provide a future therapeutic target for hindering the cellular proliferation and invasion in ovarian cancer produced by progranulin.\n'
p6524
sg4
(lp6525
sg17
(lp6526
(dp6527
g7
I145
sg20
VC2699153
p6528
sg10
I8
sg11
Vinvasion
p6529
sg13
I1
sa(dp6530
g7
I118
sg20
VC0020507
p6531
sg10
I22
sg11
Vcellular proliferation
p6532
sg13
I2
sa(dp6533
g7
I157
sg20
VC1140680
p6534
sg10
I14
sg11
Vovarian cancer
p6535
sg13
I2
sasa(dp6536
g2
S'It has been recently demonstrated that progranulin is overexpressed in ovarian cancer and that this protein is involved in the stimulation of cell proliferation, malignancy, and chemoresistance in ovarian cancer.\n'
p6537
sg4
(lp6538
sg17
(lp6539
(dp6540
g7
I147
sg20
VC0334094
p6541
sg10
I13
sg11
Vproliferation
p6542
sg13
I1
sa(dp6543
g7
I162
sg20
VC0006826
p6544
sg10
I10
sg11
Vmalignancy
p6545
sg13
I1
sa(dp6546
g7
I71
sg20
VC1140680
p6547
sg10
I14
sg11
Vovarian cancer
p6548
sg13
I2
sa(dp6549
g7
I71
sg20
VC1140680
p6550
sg10
I14
sg11
Vovarian cancer
p6551
sg13
I2
sasa(dp6552
g2
S'The goal of the present study was to establish the differences in progranulin expression among normal, benign, and malignant ovarian tissues and to identify the signal transduction pathways activated by progranulin in an ovarian cancer cell line.\n'
p6553
sg4
(lp6554
sg17
(lp6555
(dp6556
g7
I221
sg20
VC1140680
p6557
sg10
I14
sg11
Vovarian cancer
p6558
sg13
I2
sasa(dp6559
g2
S'Progranulin expression may be potentially involved in the pathogenesis and malignant progression of ovarian cancer, and thus may represent a therapeutic target for this particular malignancy.\n'
p6560
sg4
(lp6561
sg17
(lp6562
(dp6563
g7
I100
sg20
VC1140680
p6564
sg10
I14
sg11
Vovarian cancer
p6565
sg13
I2
sa(dp6566
g7
I180
sg20
VC0006826
p6567
sg10
I10
sg11
Vmalignancy
p6568
sg13
I1
sa(dp6569
g7
I58
sg20
VC0699748
p6570
sg10
I12
sg11
Vpathogenesis
p6571
sg13
I1
sasa(dp6572
g2
S'To investigate the inhibitory effects of an antisense PC cell derived growth factor (PCDGF) vector on proliferation and invasion of highly malignant ovarian cancer cell lines Sw626 and A2780 cells, and preliminarily explore the related mechanisms.\n'
p6573
sg4
(lp6574
(dp6575
g7
I54
sg8
g59
sg10
I29
sg11
VPC cell derived growth factor
p6576
sg13
I5
sa(dp6577
g7
I85
sg8
g59
sg10
I5
sg11
VPCDGF
p6578
sg13
I1
sasg17
(lp6579
(dp6580
g7
I102
sg20
VC0334094
p6581
sg10
I13
sg11
Vproliferation
p6582
sg13
I1
sa(dp6583
g7
I149
sg20
VC1140680
p6584
sg10
I14
sg11
Vovarian cancer
p6585
sg13
I2
sa(dp6586
g7
I120
sg20
VC2699153
p6587
sg10
I8
sg11
Vinvasion
p6588
sg13
I1
sasa(dp6589
g2
S'The antisense PCDGF vector may inhibit markedly the proliferation and invasion of highly malignant ovarian cancer cells, and partially reverses their malignant phenotype.\n'
p6590
sg4
(lp6591
sg17
(lp6592
(dp6593
g7
I99
sg20
VC1140680
p6594
sg10
I14
sg11
Vovarian cancer
p6595
sg13
I2
sa(dp6596
g7
I70
sg20
VC2699153
p6597
sg10
I8
sg11
Vinvasion
p6598
sg13
I1
sa(dp6599
g7
I52
sg20
VC0334094
p6600
sg10
I13
sg11
Vproliferation
p6601
sg13
I1
sasa(dp6602
g2
S'Our findings indicate that PCDGF may become a new target for antisense gene therapy of ovarian cancer.\n'
p6603
sg4
(lp6604
sg17
(lp6605
(dp6606
g7
I87
sg20
VC1140680
p6607
sg10
I14
sg11
Vovarian cancer
p6608
sg13
I2
sasa(dp6609
g2
S'Similarly, specific programs dedicated to social cognitive training such as Social Cognition and Interaction Training (SCIT), Reasoning and Rehabilitation Mental Health Program (R&amp;R2 MHP) and Metacognitive Training (MCT) have shown their positive impact on the control and reduction of global aggressive attitudes and on the numbers of physical and verbal aggressive incidents in schizophrenia.\n'
p6610
sg4
(lp6611
sg17
(lp6612
(dp6613
g7
I297
sg20
VC0001807
p6614
sg10
I10
sg11
Vaggressive
p6615
sg13
I1
sa(dp6616
g7
I384
sg20
VC0036341
p6617
sg10
I13
sg11
Vschizophrenia
p6618
sg13
I1
sa(dp6619
g7
I297
sg20
VC0001807
p6620
sg10
I10
sg11
Vaggressive
p6621
sg13
I1
sa(dp6622
g7
I76
sg20
VC1848140
p6623
sg10
I16
sg11
VSocial Cognition
p6624
sg13
I2
sasa(dp6625
g2
S"Protein aggregates are hallmarks of nearly all age-related neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and several polyglutamine diseases such as Huntington's disease and different forms of spinocerebellar ataxias (SCA; SCA1-3, SCA6, and SCA7).\n"
p6626
sg4
(lp6627
(dp6628
g7
I305
sg8
g59
sg10
I4
sg11
VSCA7
p6629
sg13
I1
sa(dp6630
g7
I287
sg8
VP54253
p6631
sg10
I6
sg11
VSCA1-3
p6632
sg13
I1
sasg17
(lp6633
(dp6634
g7
I305
sg20
VC0752125
p6635
sg10
I4
sg11
VSCA7
p6636
sg13
I1
sa(dp6637
g7
I282
sg20
VC0087012
p6638
sg10
I3
sg11
VSCA
p6639
sg13
I1
sa(dp6640
g7
I59
sg20
VC0524851
p6641
sg10
I26
sg11
Vneurodegenerative diseases
p6642
sg13
I2
sa(dp6643
g7
I118
sg20
VC0030567
p6644
sg10
I19
sg11
VParkinson's disease
p6645
sg13
I2
sa(dp6646
g7
I287
sg20
VC0752120
p6647
sg10
I4
sg11
VSCA1
p6648
sg13
I1
sa(dp6649
g7
I139
sg20
VC0002736
p6650
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p6651
sg13
I3
sa(dp6652
g7
I213
sg20
VC0020179
p6653
sg10
I20
sg11
VHuntington's disease
p6654
sg13
I2
sa(dp6655
g7
I257
sg20
VC0087012
p6656
sg10
I23
sg11
Vspinocerebellar ataxias
p6657
sg13
I2
sa(dp6658
g7
I97
sg20
VC1521724
p6659
sg10
I19
sg11
VAlzheimer's disease
p6660
sg13
I2
sa(dp6661
g7
I295
sg20
VC0752124
p6662
sg10
I4
sg11
VSCA6
p6663
sg13
I1
sasa(dp6664
g2
S'The assessment in haemostasis system, fibrinogen, tissue plasminogen activator (t-PA) and its inhibitor type-1, von Willebrand factor and beta-thromboglobulin (beta-TG) levels and the changes in renin-angiotensin system (RAS), by determined angiotensin converting enzyme I (ACE) activity, in patients with essential hypertension (in relation to left ventricular hypertrophy) in comparison with normotension subjects.\n'
p6665
sg4
(lp6666
(dp6667
g7
I241
sg8
VP12821
p6668
sg10
I31
sg11
Vangiotensin converting enzyme I
p6669
sg13
I4
sa(dp6670
g7
I221
sg8
VP01116
p6671
sg10
I3
sg11
VRAS
p6672
sg13
I1
sa(dp6673
g7
I50
sg8
VP00747
p6674
sg10
I28
sg11
Vtissue plasminogen activator
p6675
sg13
I3
sa(dp6676
g7
I138
sg8
VP02775
p6677
sg10
I20
sg11
Vbeta-thromboglobulin
p6678
sg13
I1
sa(dp6679
g7
I80
sg8
VP00747
p6680
sg10
I4
sg11
Vt-PA
p6681
sg13
I1
sa(dp6682
g7
I160
sg8
VP02775
p6683
sg10
I7
sg11
Vbeta-TG
p6684
sg13
I1
sa(dp6685
g7
I112
sg8
VP04275
p6686
sg10
I21
sg11
Vvon Willebrand factor
p6687
sg13
I3
sa(dp6688
g7
I274
sg8
VP12821
p6689
sg10
I3
sg11
VACE
p6690
sg13
I1
sa(dp6691
g7
I195
sg8
VP01116
p6692
sg10
I24
sg11
Vrenin-angiotensin system
p6693
sg13
I2
sa(dp6694
g7
I38
sg8
VP22087
p6695
sg10
I10
sg11
Vfibrinogen
p6696
sg13
I1
sasg17
(lp6697
(dp6698
g7
I345
sg20
VC0149721
p6699
sg10
I28
sg11
Vleft ventricular hypertrophy
p6700
sg13
I3
sa(dp6701
g7
I306
sg20
VC0085580
p6702
sg10
I22
sg11
Vessential hypertension
p6703
sg13
I2
sasa(dp6704
g2
S'In patients with essential hypertension, increased level of platelet activity expressed as the concentrations of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) were observed.\n'
p6705
sg4
(lp6706
(dp6707
g7
I148
sg8
VP02776
p6708
sg10
I17
sg11
Vplatelet factor 4
p6709
sg13
I3
sa(dp6710
g7
I167
sg8
VP02776
p6711
sg10
I3
sg11
VPF4
p6712
sg13
I1
sa(dp6713
g7
I135
sg8
VP02775
p6714
sg10
I7
sg11
Vbeta-TG
p6715
sg13
I1
sa(dp6716
g7
I113
sg8
VP02775
p6717
sg10
I20
sg11
Vbeta-thromboglobulin
p6718
sg13
I1
sasg17
(lp6719
(dp6720
g7
I17
sg20
VC0085580
p6721
sg10
I22
sg11
Vessential hypertension
p6722
sg13
I2
sasa(dp6723
g2
S'To evaluate the effect of antihypertensive therapy on platelet activation in essential hypertension, the plasma levels of beta-thromboglobulin (beta-TG) were examined in 45 patients with essential hypertension and 20 age-matched normotensive control subjects.\n'
p6724
sg4
(lp6725
(dp6726
g7
I144
sg8
VP02775
p6727
sg10
I7
sg11
Vbeta-TG
p6728
sg13
I1
sa(dp6729
g7
I122
sg8
VP02775
p6730
sg10
I20
sg11
Vbeta-thromboglobulin
p6731
sg13
I1
sasg17
(lp6732
(dp6733
g7
I77
sg20
VC0085580
p6734
sg10
I22
sg11
Vessential hypertension
p6735
sg13
I2
sa(dp6736
g7
I77
sg20
VC0085580
p6737
sg10
I22
sg11
Vessential hypertension
p6738
sg13
I2
sasa(dp6739
g2
S'The MKP-3 is known as the main Erk1/2 phosphatase and FoxO1 activator, which has repercussions on the gluconeogenesis pathway and hyperglycemia in obese mice.\n'
p6740
sg4
(lp6741
(dp6742
g7
I54
sg8
g59
sg10
I15
sg11
VFoxO1 activator
p6743
sg13
I2
sa(dp6744
g7
I31
sg8
VP27361
p6745
sg10
I18
sg11
VErk1/2 phosphatase
p6746
sg13
I2
sa(dp6747
g7
I4
sg8
g59
sg10
I5
sg11
VMKP-3
p6748
sg13
I1
sasg17
(lp6749
(dp6750
g7
I147
sg20
VC0028754
p6751
sg10
I5
sg11
Vobese
p6752
sg13
I1
sa(dp6753
g7
I130
sg20
VC0020456
p6754
sg10
I13
sg11
Vhyperglycemia
p6755
sg13
I1
sasa(dp6756
g2
S'However, the hypothalamic interaction between MKP-3 and FoxO1 during obesity was not investigated yet.\n'
p6757
sg4
(lp6758
(dp6759
g7
I46
sg8
g59
sg10
I15
sg11
VMKP-3 and FoxO1
p6760
sg13
I3
sasg17
(lp6761
(dp6762
g7
I69
sg20
VC0028754
p6763
sg10
I7
sg11
Vobesity
p6764
sg13
I1
sasa(dp6765
g2
S'The results indicate that obesity in mice increased the MKP-3 protein content in the hypothalamus.\n'
p6766
sg4
(lp6767
(dp6768
g7
I56
sg8
g59
sg10
I13
sg11
VMKP-3 protein
p6769
sg13
I2
sasg17
(lp6770
(dp6771
g7
I26
sg20
VC0028754
p6772
sg10
I7
sg11
Vobesity
p6773
sg13
I1
sasa(dp6774
g2
S'Taken together, our study reports that obesity is associated with increased protein levels of hypothalamic MKP-3, which is related to the reduction of FoxO1 and Erk1/2 phosphorylation in the hypothalamus as well as to an increase in body weight and a reduction in energy expenditure.\n'
p6775
sg4
(lp6776
(dp6777
g7
I151
sg8
g59
sg10
I5
sg11
VFoxO1
p6778
sg13
I1
sa(dp6779
g7
I161
sg8
VP27361
p6780
sg10
I6
sg11
VErk1/2
p6781
sg13
I1
sa(dp6782
g7
I107
sg8
g59
sg10
I5
sg11
VMKP-3
p6783
sg13
I1
sasg17
(lp6784
(dp6785
g7
I39
sg20
VC0028754
p6786
sg10
I7
sg11
Vobesity
p6787
sg13
I1
sasa(dp6788
g2
S'Nevertheless, after 26 weeks of high-fat diet exposure, we observed comparable body weight, fat and lean mass in DUSP6 WT and KO mice, suggesting overall normal susceptibility to develop obesity.\n'
p6789
sg4
(lp6790
(dp6791
g7
I113
sg8
g59
sg10
I8
sg11
VDUSP6 WT
p6792
sg13
I2
sasg17
(lp6793
(dp6794
g7
I187
sg20
VC0028754
p6795
sg10
I7
sg11
Vobesity
p6796
sg13
I1
sasa(dp6797
g2
S'Our data are in conflict to earlier reports that propose protection from diet-induced obesity and glucose intolerance in DUSP6 deficient mice.\n'
p6798
sg4
(lp6799
(dp6800
g7
I121
sg8
g59
sg10
I5
sg11
VDUSP6
p6801
sg13
I1
sasg17
(lp6802
(dp6803
g7
I98
sg20
VC0271650
p6804
sg10
I19
sg11
Vglucose intolerance
p6805
sg13
I2
sa(dp6806
g7
I86
sg20
VC0028754
p6807
sg10
I7
sg11
Vobesity
p6808
sg13
I1
sasa(dp6809
g2
S'Thus, the role of MKP-3 in the hypothalamus is closely associated with FoxO1 dephosphorylation and may provide a potential therapeutic target against hypothalamic disorders related to obesity and unbalanced food intake control.\n'
p6810
sg4
(lp6811
(dp6812
g7
I71
sg8
g59
sg10
I5
sg11
VFoxO1
p6813
sg13
I1
sa(dp6814
g7
I18
sg8
g59
sg10
I5
sg11
VMKP-3
p6815
sg13
I1
sasg17
(lp6816
(dp6817
g7
I184
sg20
VC0028754
p6818
sg10
I7
sg11
Vobesity
p6819
sg13
I1
sasa(dp6820
g2
S'Dusp6-deficient mice have been shown to be resistant to diet-induced obesity, but the mechanism behind this remains unclear.\n'
p6821
sg4
(lp6822
(dp6823
g7
I0
sg8
g59
sg10
I5
sg11
VDusp6
p6824
sg13
I1
sasg17
(lp6825
(dp6826
g7
I69
sg20
VC0028754
p6827
sg10
I7
sg11
Vobesity
p6828
sg13
I1
sasa(dp6829
g2
S'16S ribosomal RNA gene analysis demonstrated that dusp6-deficient mice harbour unique gut microbiota with resistance to diet-induced-obesity-mediated alteration of the gut microbiome.\n'
p6830
sg4
(lp6831
sg17
(lp6832
(dp6833
g7
I133
sg20
VC0028754
p6834
sg10
I7
sg11
Vobesity
p6835
sg13
I1
sasa(dp6836
g2
S'This study demonstrates that dusp6 deficiency is a strong genetic factor shaping gut microbiota, and that it confers obesity protection by ameliorating the gut microbiota response to diet-mediated stress.\n'
p6837
sg4
(lp6838
(dp6839
g7
I29
sg8
g59
sg10
I5
sg11
Vdusp6
p6840
sg13
I1
sasg17
(lp6841
(dp6842
g7
I117
sg20
VC0028754
p6843
sg10
I7
sg11
Vobesity
p6844
sg13
I1
sasa(dp6845
g2
S'In recent, it was reported that MKP3 deficient mice are resistant to diet-induced obesity, and display enhanced energy expenditure.\n'
p6846
sg4
(lp6847
(dp6848
g7
I32
sg8
g59
sg10
I4
sg11
VMKP3
p6849
sg13
I1
sasg17
(lp6850
(dp6851
g7
I82
sg20
VC0028754
p6852
sg10
I7
sg11
Vobesity
p6853
sg13
I1
sasa(dp6854
g2
S'Our laboratory recently demonstrated that MKP-3 plays an important role in obesity-related hyperglycemia by promoting hepatic glucose output.\n'
p6855
sg4
(lp6856
(dp6857
g7
I42
sg8
g59
sg10
I5
sg11
VMKP-3
p6858
sg13
I1
sasg17
(lp6859
(dp6860
g7
I75
sg20
VC0028754
p6861
sg10
I7
sg11
Vobesity
p6862
sg13
I1
sa(dp6863
g7
I91
sg20
VC0020456
p6864
sg10
I13
sg11
Vhyperglycemia
p6865
sg13
I1
sasa(dp6866
g2
S'This study shows that MKP-3 deficiency attenuates body weight gain induced by a high-fat diet (HFD) and protects mice from developing obesity-related hepatosteatosis.\n'
p6867
sg4
(lp6868
(dp6869
g7
I22
sg8
g59
sg10
I5
sg11
VMKP-3
p6870
sg13
I1
sasg17
(lp6871
(dp6872
g7
I134
sg20
VC0028754
p6873
sg10
I7
sg11
Vobesity
p6874
sg13
I1
sasa(dp6875
g2
S'We investigated Beta-defensin family expression in liver cancer in publicly available datasets and found that among all the Beta-defensins tested, only Beta-defensin 1 was significantly downregulated, suggesting Beta-defensin 1 plays a crucial role in liver cancer development.\n'
p6876
sg4
(lp6877
(dp6878
g7
I152
sg8
VP60022
p6879
sg10
I15
sg11
VBeta-defensin 1
p6880
sg13
I2
sa(dp6881
g7
I124
sg8
g59
sg10
I14
sg11
VBeta-defensins
p6882
sg13
I1
sa(dp6883
g7
I152
sg8
VP60022
p6884
sg10
I15
sg11
VBeta-defensin 1
p6885
sg13
I2
sa(dp6886
g7
I16
sg8
VP59861
p6887
sg10
I20
sg11
VBeta-defensin family
p6888
sg13
I2
sasg17
(lp6889
(dp6890
g7
I51
sg20
VC0345904
p6891
sg10
I12
sg11
Vliver cancer
p6892
sg13
I2
sa(dp6893
g7
I51
sg20
VC0345904
p6894
sg10
I12
sg11
Vliver cancer
p6895
sg13
I2
sasa(dp6896
g2
S'Furthermore, the downregulation of Beta-defensin 1 and E-cadherin, and upregulation of hepatocyte growth factor-regulated tyrosine kinase substrate, were further confirmed in liver cancer and adjacent normal tissue collected from in-house Chinese liver cancer patients.\n'
p6897
sg4
(lp6898
(dp6899
g7
I87
sg8
VP29401
p6900
sg10
I50
sg11
Vhepatocyte growth factor-regulated tyrosine kinase
p6901
sg13
I5
sa(dp6902
g7
I35
sg8
VP60022
p6903
sg10
I15
sg11
VBeta-defensin 1
p6904
sg13
I2
sa(dp6905
g7
I55
sg8
VP12830
p6906
sg10
I10
sg11
VE-cadherin
p6907
sg13
I1
sasg17
(lp6908
(dp6909
g7
I175
sg20
VC0345904
p6910
sg10
I12
sg11
Vliver cancer
p6911
sg13
I2
sa(dp6912
g7
I175
sg20
VC0345904
p6913
sg10
I12
sg11
Vliver cancer
p6914
sg13
I2
sasa(dp6915
g2
S'Together, our results suggest Beta-defensin 1 plays an important role in protecting HCV progression and liver cancer development.\n'
p6916
sg4
(lp6917
(dp6918
g7
I30
sg8
VP60022
p6919
sg10
I15
sg11
VBeta-defensin 1
p6920
sg13
I2
sasg17
(lp6921
(dp6922
g7
I104
sg20
VC0345904
p6923
sg10
I12
sg11
Vliver cancer
p6924
sg13
I2
sasa(dp6925
g2
S'mRNA expression of the AMPs Alfa defensin (HNP-1); cathelicidin (LL-37); and Beta defensins (hBD-1, hBD-2, hBD-3, hBD-4) in human uveal and cutaneous melanoma cell lines, primary human uveal melanocytes, and primary human uveal melanoma cells was determined by reverse transcriptase polymerase chain reaction.\n'
p6926
sg4
(lp6927
(dp6928
g7
I107
sg8
VP81534
p6929
sg10
I5
sg11
VhBD-3
p6930
sg13
I1
sa(dp6931
g7
I93
sg8
VP60022
p6932
sg10
I5
sg11
VhBD-1
p6933
sg13
I1
sa(dp6934
g7
I23
sg8
VP30566
p6935
sg10
I18
sg11
VAMPs Alfa defensin
p6936
sg13
I3
sa(dp6937
g7
I77
sg8
VP59665
p6938
sg10
I14
sg11
VBeta defensins
p6939
sg13
I2
sa(dp6940
g7
I114
sg8
g59
sg10
I5
sg11
VhBD-4
p6941
sg13
I1
sa(dp6942
g7
I43
sg8
VP59665
p6943
sg10
I5
sg11
VHNP-1
p6944
sg13
I1
sa(dp6945
g7
I261
sg8
VP63136
p6946
sg10
I21
sg11
Vreverse transcriptase
p6947
sg13
I2
sa(dp6948
g7
I100
sg8
g59
sg10
I5
sg11
VhBD-2
p6949
sg13
I1
sasg17
(lp6950
(dp6951
g7
I140
sg20
VC0025202
p6952
sg10
I18
sg11
Vcutaneous melanoma
p6953
sg13
I2
sa(dp6954
g7
I93
sg20
VC1840321
p6955
sg10
I3
sg11
VhBD
p6956
sg13
I1
sa(dp6957
g7
I222
sg20
VC0220633
p6958
sg10
I14
sg11
Vuveal melanoma
p6959
sg13
I2
sa(dp6960
g7
I93
sg20
VC1840321
p6961
sg10
I3
sg11
VhBD
p6962
sg13
I1
sa(dp6963
g7
I93
sg20
VC1840321
p6964
sg10
I3
sg11
VhBD
p6965
sg13
I1
sa(dp6966
g7
I93
sg20
VC1840321
p6967
sg10
I3
sg11
VhBD
p6968
sg13
I1
sasa(dp6969
g2
S"Moreover, BPC supplementation restored pancreatitis mediated disruption of intestinal barrier integrity by upregulating tight junction proteins (ZO-1, occludin), antimicrobial peptides (DEFB1, CRAMP), MUC-2, TFF3 expression and by enhancing SCFA's production.\n"
p6970
sg4
(lp6971
(dp6972
g7
I208
sg8
g59
sg10
I4
sg11
VTFF3
p6973
sg13
I1
sa(dp6974
g7
I193
sg8
VP49913
p6975
sg10
I5
sg11
VCRAMP
p6976
sg13
I1
sa(dp6977
g7
I201
sg8
g59
sg10
I5
sg11
VMUC-2
p6978
sg13
I1
sa(dp6979
g7
I186
sg8
VP60022
p6980
sg10
I5
sg11
VDEFB1
p6981
sg13
I1
sa(dp6982
g7
I151
sg8
g59
sg10
I8
sg11
Voccludin
p6983
sg13
I1
sa(dp6984
g7
I145
sg8
g59
sg10
I4
sg11
VZO-1
p6985
sg13
I1
sasg17
(lp6986
(dp6987
g7
I39
sg20
VC0030305
p6988
sg10
I12
sg11
Vpancreatitis
p6989
sg13
I1
sa(dp6990
g7
I193
sg20
VC0026821
p6991
sg10
I5
sg11
VCRAMP
p6992
sg13
I1
sasa(dp6993
g2
S'The aim of this study was to investigate the shared molecular pathways of obesity and cancer by exploring the role of RIZ1 in obesity and the phospatidylinositol 3-kinase (PI3K)/V-Akt murine thymoma viral oncogene homolog (PKB) (AKT)/mechanistic target of rapamycin (mTOR) pathway.\n'
p6994
sg4
(lp6995
(dp6996
g7
I267
sg8
VP42345
p6997
sg10
I4
sg11
VmTOR
p6998
sg13
I1
sa(dp6999
g7
I118
sg8
g59
sg10
I4
sg11
VRIZ1
p7000
sg13
I1
sa(dp7001
g7
I233
sg8
VP42345
p7002
sg10
I32
sg11
V/mechanistic target of rapamycin
p7003
sg13
I4
sa(dp7004
g7
I172
sg8
VP42336
p7005
sg10
I4
sg11
VPI3K
p7006
sg13
I1
sa(dp7007
g7
I142
sg8
VP33981
p7008
sg10
I28
sg11
Vphospatidylinositol 3-kinase
p7009
sg13
I2
sa(dp7010
g7
I223
sg8
VP31749
p7011
sg10
I3
sg11
VPKB
p7012
sg13
I1
sa(dp7013
g7
I180
sg8
g59
sg10
I41
sg11
VAkt murine thymoma viral oncogene homolog
p7014
sg13
I6
sasg17
(lp7015
(dp7016
g7
I86
sg20
VC0006826
p7017
sg10
I6
sg11
Vcancer
p7018
sg13
I1
sa(dp7019
g7
I74
sg20
VC0028754
p7020
sg10
I7
sg11
Vobesity
p7021
sg13
I1
sa(dp7022
g7
I74
sg20
VC0028754
p7023
sg10
I7
sg11
Vobesity
p7024
sg13
I1
sa(dp7025
g7
I191
sg20
VC0040100
p7026
sg10
I7
sg11
Vthymoma
p7027
sg13
I1
sasa(dp7028
g2
S'The results identify RIZ1 as an important regulator of both Akt3 transcription and AKT phosphorylation and suggest a role for RIZ1 in HF-induced obesity and the AKT pathway.\n'
p7029
sg4
(lp7030
(dp7031
g7
I21
sg8
g59
sg10
I4
sg11
VRIZ1
p7032
sg13
I1
sa(dp7033
g7
I60
sg8
g59
sg10
I4
sg11
VAkt3
p7034
sg13
I1
sa(dp7035
g7
I83
sg8
g59
sg10
I3
sg11
VAKT
p7036
sg13
I1
sa(dp7037
g7
I83
sg8
g59
sg10
I3
sg11
VAKT
p7038
sg13
I1
sa(dp7039
g7
I21
sg8
g59
sg10
I4
sg11
VRIZ1
p7040
sg13
I1
sasg17
(lp7041
(dp7042
g7
I145
sg20
VC0028754
p7043
sg10
I7
sg11
Vobesity
p7044
sg13
I1
sasa(dp7045
g2
S'To examine the function of C8bp in platelets, we tested platelets from patients suffering from paroxysmal nocturnal hemoglobinuria (PNH).\n'
p7046
sg4
(lp7047
(dp7048
g7
I27
sg8
VP13987
p7049
sg10
I4
sg11
VC8bp
p7050
sg13
I1
sasg17
(lp7051
(dp7052
g7
I80
sg20
VC0683278
p7053
sg10
I9
sg11
Vsuffering
p7054
sg13
I1
sa(dp7055
g7
I132
sg20
VC0024790
p7056
sg10
I3
sg11
VPNH
p7057
sg13
I1
sa(dp7058
g7
I95
sg20
VC0024790
p7059
sg10
I35
sg11
Vparoxysmal nocturnal hemoglobinuria
p7060
sg13
I3
sasa(dp7061
g2
S'These anti-idiotypic antisera were shown to react against an overlapping epitope(s) on C8bp/HRF as indicated by the following evidence: (i) all three types of antisera reacted against partially purified C8bp/HRF and against a 65 kDa protein band in cell lysates; reactivity was only observed against disulfide-reduced antigens; (ii) the three antibodies react with a protein band in normal erythrocytes (E) but not with type III E of patients with paroxysmal nocturnal hemoglobinuria or with a mutant B lymphoblastoid cell line, both of which cell types are known to be deficient in C8bp/HRF; and (iii) the three antibodies compete with each other for binding to C8bp/HRF.\n'
p7062
sg4
(lp7063
(dp7064
g7
I87
sg8
VP13987
p7065
sg10
I4
sg11
VC8bp
p7066
sg13
I1
sa(dp7067
g7
I92
sg8
VP13693
p7068
sg10
I3
sg11
VHRF
p7069
sg13
I1
sa(dp7070
g7
I87
sg8
VP13987
p7071
sg10
I4
sg11
VC8bp
p7072
sg13
I1
sa(dp7073
g7
I92
sg8
VP13693
p7074
sg10
I3
sg11
VHRF
p7075
sg13
I1
sa(dp7076
g7
I92
sg8
VP13693
p7077
sg10
I3
sg11
VHRF
p7078
sg13
I1
sa(dp7079
g7
I92
sg8
VP13693
p7080
sg10
I3
sg11
VHRF
p7081
sg13
I1
sa(dp7082
g7
I87
sg8
VP13987
p7083
sg10
I4
sg11
VC8bp
p7084
sg13
I1
sa(dp7085
g7
I87
sg8
VP13987
p7086
sg10
I4
sg11
VC8bp
p7087
sg13
I1
sasg17
(lp7088
(dp7089
g7
I448
sg20
VC0024790
p7090
sg10
I35
sg11
Vparoxysmal nocturnal hemoglobinuria
p7091
sg13
I3
sa(dp7092
g7
I494
sg20
VC0596988
p7093
sg10
I6
sg11
Vmutant
p7094
sg13
I1
sasa(dp7095
g2
S'Lack of C8bp as seen in patients with paroxysmal nocturnal hemoglobinuria type III results in enhanced susceptibility of the cells toward C5b-9.\n'
p7096
sg4
(lp7097
(dp7098
g7
I8
sg8
VP13987
p7099
sg10
I4
sg11
VC8bp
p7100
sg13
I1
sasg17
(lp7101
(dp7102
g7
I38
sg20
VC0024790
p7103
sg10
I35
sg11
Vparoxysmal nocturnal hemoglobinuria
p7104
sg13
I3
sasa(dp7105
g2
S'The main band of fibromodulin had a normal migration rate in fibrochondrogenesis, Desbuquois dysplasia, Kniest dysplasia, and pseudoachondroplasia.\n'
p7106
sg4
(lp7107
(dp7108
g7
I17
sg8
g59
sg10
I12
sg11
Vfibromodulin
p7109
sg13
I1
sasg17
(lp7110
(dp7111
g7
I126
sg20
VC0410538
p7112
sg10
I20
sg11
Vpseudoachondroplasia
p7113
sg13
I1
sa(dp7114
g7
I104
sg20
VC0265279
p7115
sg10
I16
sg11
VKniest dysplasia
p7116
sg13
I2
sa(dp7117
g7
I61
sg20
VC0265282
p7118
sg10
I19
sg11
Vfibrochondrogenesis
p7119
sg13
I1
sa(dp7120
g7
I82
sg20
VC0432242
p7121
sg10
I20
sg11
VDesbuquois dysplasia
p7122
sg13
I2
sasa(dp7123
g2
S'Ablation of both genes in Ezh1-/-::Ezh2f/f::cTNT-Cre embryos caused lethal heart malformations, including hypertrabeculation, compact myocardial hypoplasia, and ventricular septal defect.\n'
p7124
sg4
(lp7125
(dp7126
g7
I49
sg8
g59
sg10
I3
sg11
VCre
p7127
sg13
I1
sa(dp7128
g7
I44
sg8
VP45379
p7129
sg10
I4
sg11
VcTNT
p7130
sg13
I1
sa(dp7131
g7
I26
sg8
g59
sg10
I4
sg11
VEzh1
p7132
sg13
I1
sasg17
(lp7133
(dp7134
g7
I145
sg20
VC0243069
p7135
sg10
I10
sg11
Vhypoplasia
p7136
sg13
I1
sa(dp7137
g7
I75
sg20
VC0018798
p7138
sg10
I19
sg11
Vheart malformations
p7139
sg13
I2
sa(dp7140
g7
I161
sg20
VC0018818
p7141
sg10
I25
sg11
Vventricular septal defect
p7142
sg13
I3
sasa(dp7143
g2
S'In myocardial infarction performed outside of the neonatal regenerative window, EZH1 but not EZH2 likewise improved heart function and stimulated cardiac myocyte proliferation.\n'
p7144
sg4
(lp7145
(dp7146
g7
I80
sg8
g59
sg10
I4
sg11
VEZH1
p7147
sg13
I1
sasg17
(lp7148
(dp7149
g7
I3
sg20
VC0027051
p7150
sg10
I21
sg11
Vmyocardial infarction
p7151
sg13
I2
sa(dp7152
g7
I162
sg20
VC0334094
p7153
sg10
I13
sg11
Vproliferation
p7154
sg13
I1
sasa(dp7155
g2
S'In this study, we investigated the effects of homocysteine (Hcy) on the expression of enhancer of zeste homolog 2 (EZH2), and tested our hypothesis that Hcy-induced atherosclerosis is mediated by increased EZH2 expression, which is regulated by miR-92a.\n'
p7156
sg4
(lp7157
(dp7158
g7
I115
sg8
g59
sg10
I4
sg11
VEZH2
p7159
sg13
I1
sa(dp7160
g7
I115
sg8
g59
sg10
I4
sg11
VEZH2
p7161
sg13
I1
sa(dp7162
g7
I245
sg8
g59
sg10
I7
sg11
VmiR-92a
p7163
sg13
I1
sa(dp7164
g7
I86
sg8
g59
sg10
I27
sg11
Venhancer of zeste homolog 2
p7165
sg13
I5
sasg17
(lp7166
(dp7167
g7
I165
sg20
VC0004153
p7168
sg10
I15
sg11
Vatherosclerosis
p7169
sg13
I1
sasa(dp7170
g2
S'These data suggested that EZH2 plays a key role in Hcy-mediated lipid metabolism disorders, and that miR-92a may be a novel therapeutic target in Hcy-related atherosclerosis.\n'
p7171
sg4
(lp7172
(dp7173
g7
I26
sg8
g59
sg10
I4
sg11
VEZH2
p7174
sg13
I1
sa(dp7175
g7
I101
sg8
g59
sg10
I7
sg11
VmiR-92a
p7176
sg13
I1
sasg17
(lp7177
(dp7178
g7
I158
sg20
VC0004153
p7179
sg10
I15
sg11
Vatherosclerosis
p7180
sg13
I1
sa(dp7181
g7
I64
sg20
VC0154251
p7182
sg10
I26
sg11
Vlipid metabolism disorders
p7183
sg13
I3
sasa(dp7184
g2
S'Here, we analyzed the expression of Six1 and its regulating factor Ezh2 in cardiac tissue of patients with end-stage dilative cardiomyopathy (DCM).\n'
p7185
sg4
(lp7186
(dp7187
g7
I36
sg8
g59
sg10
I4
sg11
VSix1
p7188
sg13
I1
sa(dp7189
g7
I60
sg8
g59
sg10
I11
sg11
Vfactor Ezh2
p7190
sg13
I2
sasg17
(lp7191
(dp7192
g7
I126
sg20
VC0878544
p7193
sg10
I14
sg11
Vcardiomyopathy
p7194
sg13
I1
sasa(dp7195
g2
S'Polycomb protein EZH2 induced DNMT1 expression and methyl-CpG-binding protein-2 (MeCP2) recruitment, and stimulated the binding of DNMT1 and MeCP2 to ABCA1 promoter, thereby promoting ABCA1 gene DNA methylation and atherosclerosis.\n'
p7196
sg4
(lp7197
(dp7198
g7
I51
sg8
g59
sg10
I28
sg11
Vmethyl-CpG-binding protein-2
p7199
sg13
I2
sa(dp7200
g7
I30
sg8
VP26358
p7201
sg10
I5
sg11
VDNMT1
p7202
sg13
I1
sa(dp7203
g7
I30
sg8
VP26358
p7204
sg10
I5
sg11
VDNMT1
p7205
sg13
I1
sa(dp7206
g7
I0
sg8
g59
sg10
I21
sg11
VPolycomb protein EZH2
p7207
sg13
I3
sa(dp7208
g7
I81
sg8
VP51608
p7209
sg10
I5
sg11
VMeCP2
p7210
sg13
I1
sa(dp7211
g7
I81
sg8
VP51608
p7212
sg10
I5
sg11
VMeCP2
p7213
sg13
I1
sasg17
(lp7214
(dp7215
g7
I215
sg20
VC0004153
p7216
sg10
I15
sg11
Vatherosclerosis
p7217
sg13
I1
sa(dp7218
g7
I88
sg20
VC0271510
p7219
sg10
I11
sg11
Vrecruitment
p7220
sg13
I1
sasa(dp7221
g2
S'Conversely, EZH2 overexpression stimulated DNMT1-induced ABCA1 gene promoter methylation and atherosclerosis.\n'
p7222
sg4
(lp7223
(dp7224
g7
I43
sg8
VP26358
p7225
sg10
I5
sg11
VDNMT1
p7226
sg13
I1
sa(dp7227
g7
I12
sg8
g59
sg10
I4
sg11
VEZH2
p7228
sg13
I1
sasg17
(lp7229
(dp7230
g7
I93
sg20
VC0004153
p7231
sg10
I15
sg11
Vatherosclerosis
p7232
sg13
I1
sasa(dp7233
g2
S'EZH2-induced downregulation of ABCA1 gene expression promotes foam cell formation and the development of atherosclerosis by DNA methylation of ABCA1 gene promoter.\n'
p7234
sg4
(lp7235
(dp7236
g7
I0
sg8
g59
sg10
I4
sg11
VEZH2
p7237
sg13
I1
sasg17
(lp7238
(dp7239
g7
I105
sg20
VC0004153
p7240
sg10
I15
sg11
Vatherosclerosis
p7241
sg13
I1
sasa(dp7242
g2
S'The expression levels of E-cadherin were reduced, and those of snail family zinc finger 1, fibronectin, Alfa-smooth muscle actin and fibroblast secretory protein 1 increased in esophageal cancer cells following treatment with human recombinant EMMPRIN under hypoxic conditions.\n'
p7243
sg4
(lp7244
(dp7245
g7
I25
sg8
VP12830
p7246
sg10
I10
sg11
VE-cadherin
p7247
sg13
I1
sa(dp7248
g7
I104
sg8
VP68032
p7249
sg10
I24
sg11
VAlfa-smooth muscle actin
p7250
sg13
I3
sa(dp7251
g7
I133
sg8
VP14222
p7252
sg10
I30
sg11
Vfibroblast secretory protein 1
p7253
sg13
I4
sa(dp7254
g7
I63
sg8
g59
sg10
I26
sg11
Vsnail family zinc finger 1
p7255
sg13
I5
sasg17
(lp7256
(dp7257
g7
I258
sg20
VC0242184
p7258
sg10
I7
sg11
Vhypoxic
p7259
sg13
I1
sa(dp7260
g7
I177
sg20
VC0014859
p7261
sg10
I17
sg11
Vesophageal cancer
p7262
sg13
I2
sasa(dp7263
g2
S'A total of 17 adults (age, 57-85 years) with symmetrical sensorineural hearing loss were tested in the sound field using hearing aids fit to target (NAL-NL2).\n'
p7264
sg4
(lp7265
(dp7266
g7
I149
sg8
g59
sg10
I7
sg11
VNAL-NL2
p7267
sg13
I1
sasg17
(lp7268
(dp7269
g7
I134
sg20
VC0036572
p7270
sg10
I3
sg11
Vfit
p7271
sg13
I1
sa(dp7272
g7
I57
sg20
VC0018784
p7273
sg10
I26
sg11
Vsensorineural hearing loss
p7274
sg13
I3
sasa(dp7275
g2
S'The National Acoustic Laboratories-Nonlinear 2 (NAL-NL2) prescription of amplification was chosen because audibility is intentionally not prescribed in the presence of larger sensorineural hearing loss thresholds.\n'
p7276
sg4
(lp7277
sg17
(lp7278
(dp7279
g7
I175
sg20
VC0018784
p7280
sg10
I26
sg11
Vsensorineural hearing loss
p7281
sg13
I3
sa(dp7282
g7
I73
sg20
VC1705759
p7283
sg10
I13
sg11
Vamplification
p7284
sg13
I1
sasa(dp7285
g2
S'The binding ability of thirteen lectins, AAL, LCA, LTL, ConA, NML, NPL, DBA, HAL, PTL II, WFL, ECL, GSL II and PHA-L to glycan were elevated, and a definite indication that glycan containing terminal AlfaFuc and +/- Sia-Le, core fucose, Alfa-man, gal-Beta(Alfa) GalNAc, Beta1,6 GlcNAc branching and tetraantennary complex oligosaccharides structures were increased.\n'
p7286
sg4
(lp7287
(dp7288
g7
I111
sg8
g59
sg10
I5
sg11
VPHA-L
p7289
sg13
I1
sa(dp7290
g7
I82
sg8
VP16233
p7291
sg10
I6
sg11
VPTL II
p7292
sg13
I2
sa(dp7293
g7
I95
sg8
g59
sg10
I3
sg11
VECL
p7294
sg13
I1
sa(dp7295
g7
I62
sg8
g59
sg10
I3
sg11
VNML
p7296
sg13
I1
sa(dp7297
g7
I262
sg8
g59
sg10
I6
sg11
VGalNAc
p7298
sg13
I1
sa(dp7299
g7
I72
sg8
VP39019
p7300
sg10
I3
sg11
VDBA
p7301
sg13
I1
sa(dp7302
g7
I77
sg8
VP42357
p7303
sg10
I3
sg11
VHAL
p7304
sg13
I1
sa(dp7305
g7
I90
sg8
g59
sg10
I3
sg11
VWFL
p7306
sg13
I1
sa(dp7307
g7
I67
sg8
VP98179
p7308
sg10
I3
sg11
VNPL
p7309
sg13
I1
sa(dp7310
g7
I100
sg8
VP10619
p7311
sg10
I6
sg11
VGSL II
p7312
sg13
I2
sa(dp7313
g7
I247
sg8
VP16278
p7314
sg10
I8
sg11
Vgal-Beta
p7315
sg13
I1
sasg17
(lp7316
(dp7317
g7
I100
sg20
VC0268233
p7318
sg10
I3
sg11
VGSL
p7319
sg13
I1
sa(dp7320
g7
I72
sg20
VC0398550
p7321
sg10
I3
sg11
VDBA
p7322
sg13
I1
sa(dp7323
g7
I46
sg20
VC0339527
p7324
sg10
I3
sg11
VLCA
p7325
sg13
I1
sa(dp7326
g7
I111
sg20
VC0030779
p7327
sg10
I3
sg11
VPHA
p7328
sg13
I1
sasa(dp7329
g2
S'Hearing aids fitted based on the DSL v5 procedure would seem to be more appropriate than the NAL-NL1 procedure for children with moderately severe to profound sensorineural hearing loss, at least in quiet listening environments.\n'
p7330
sg4
(lp7331
sg17
(lp7332
(dp7333
g7
I159
sg20
VC0018784
p7334
sg10
I26
sg11
Vsensorineural hearing loss
p7335
sg13
I3
sa(dp7336
g7
I13
sg20
VC0036572
p7337
sg10
I6
sg11
Vfitted
p7338
sg13
I1
sasa(dp7339
g2
S'Although alleles in the TMEM182 gene did not show significant association with glaucoma in the second round, subjects with the A/A allele in TMEM182 rs869833 showed worse visual field mean deviation (p=0.01).\n'
p7340
sg4
(lp7341
sg17
(lp7342
(dp7343
g7
I79
sg20
VC0017601
p7344
sg10
I8
sg11
Vglaucoma
p7345
sg13
I1
sasa(dp7346
g2
S'Given the association between GKD and type 2 diabetes mellitus, it is interesting that the mother had gestational diabetes while carrying an affected fetus.\n'
p7347
sg4
(lp7348
sg17
(lp7349
(dp7350
g7
I38
sg20
VC0011860
p7351
sg10
I24
sg11
Vtype 2 diabetes mellitus
p7352
sg13
I4
sa(dp7353
g7
I30
sg20
VC0268418
p7354
sg10
I3
sg11
VGKD
p7355
sg13
I1
sa(dp7356
g7
I102
sg20
VC0085207
p7357
sg10
I20
sg11
Vgestational diabetes
p7358
sg13
I2
sasa(dp7359
g2
S"Further investigations may help elucidate the role of GKD in the carrier mother's gestational diabetes.\n"
p7360
sg4
(lp7361
(dp7362
g7
I54
sg8
VP32189
p7363
sg10
I3
sg11
VGKD
p7364
sg13
I1
sasg17
(lp7365
(dp7366
g7
I82
sg20
VC0085207
p7367
sg10
I20
sg11
Vgestational diabetes
p7368
sg13
I2
sa(dp7369
g7
I54
sg20
VC0268418
p7370
sg10
I3
sg11
VGKD
p7371
sg13
I1
sasa(dp7372
g2
S'Glycerol kinase (GK) is at the interface of fat and carbohydrate metabolism and has been implicated in insulin resistance and type 2 diabetes mellitus.\n'
p7373
sg4
(lp7374
(dp7375
g7
I103
sg8
VP01308
p7376
sg10
I7
sg11
Vinsulin
p7377
sg13
I1
sasg17
(lp7378
(dp7379
g7
I103
sg20
VC0021655
p7380
sg10
I18
sg11
Vinsulin resistance
p7381
sg13
I2
sa(dp7382
g7
I126
sg20
VC0011860
p7383
sg10
I24
sg11
Vtype 2 diabetes mellitus
p7384
sg13
I4
sasa(dp7385
g2
S'This study elucidates the complex network of glycerol kinase and further confirms a possible role for glycerol kinase deficiency, a simple Mendelian disorder, in insulin resistance, and type 2 diabetes mellitus, a common complex genetic disorder.\n'
p7386
sg4
(lp7387
(dp7388
g7
I162
sg8
VP01308
p7389
sg10
I7
sg11
Vinsulin
p7390
sg13
I1
sa(dp7391
g7
I45
sg8
VP32189
p7392
sg10
I15
sg11
Vglycerol kinase
p7393
sg13
I2
sasg17
(lp7394
(dp7395
g7
I186
sg20
VC0011860
p7396
sg10
I24
sg11
Vtype 2 diabetes mellitus
p7397
sg13
I4
sa(dp7398
g7
I102
sg20
VC0268418
p7399
sg10
I26
sg11
Vglycerol kinase deficiency
p7400
sg13
I3
sa(dp7401
g7
I229
sg20
VC0019247
p7402
sg10
I16
sg11
Vgenetic disorder
p7403
sg13
I2
sa(dp7404
g7
I162
sg20
VC0021655
p7405
sg10
I18
sg11
Vinsulin resistance
p7406
sg13
I2
sasa(dp7407
g2
S'Mutations in the GK gene result in a rare inborn error of metabolism, GK deficiency (GKD), and at least one of these mutations (N288D) is associated with insulin resistance and diabetes mellitus.\n'
p7408
sg4
(lp7409
(dp7410
g7
I154
sg8
VP01308
p7411
sg10
I7
sg11
Vinsulin
p7412
sg13
I1
sasg17
(lp7413
(dp7414
g7
I177
sg20
VC0011849
p7415
sg10
I17
sg11
Vdiabetes mellitus
p7416
sg13
I2
sa(dp7417
g7
I154
sg20
VC0021655
p7418
sg10
I18
sg11
Vinsulin resistance
p7419
sg13
I2
sa(dp7420
g7
I70
sg20
VC0268418
p7421
sg10
I13
sg11
VGK deficiency
p7422
sg13
I2
sa(dp7423
g7
I42
sg20
VC0025521
p7424
sg10
I26
sg11
Vinborn error of metabolism
p7425
sg13
I4
sa(dp7426
g7
I85
sg20
VC0268418
p7427
sg10
I3
sg11
VGKD
p7428
sg13
I1
sasa(dp7429
g2
S'In an attempt to identify potential modifiers of the GKD phenotype, and to elucidate better the relationship between GKD and diabetes mellitus, we investigated the GK promoter.\n'
p7430
sg4
(lp7431
(dp7432
g7
I53
sg8
VP32189
p7433
sg10
I13
sg11
VGKD phenotype
p7434
sg13
I2
sasg17
(lp7435
(dp7436
g7
I53
sg20
VC0268418
p7437
sg10
I3
sg11
VGKD
p7438
sg13
I1
sa(dp7439
g7
I53
sg20
VC0268418
p7440
sg10
I3
sg11
VGKD
p7441
sg13
I1
sa(dp7442
g7
I125
sg20
VC0011849
p7443
sg10
I17
sg11
Vdiabetes mellitus
p7444
sg13
I2
sasa(dp7445
g2
S'The involvement of both GK and HNF-4alpha in the etiology of diabetes mellitus is intriguing, and we speculate that HNF-4alpha represents a potential modifier of the GKD phenotype.\n'
p7446
sg4
(lp7447
(dp7448
g7
I166
sg8
VP32189
p7449
sg10
I13
sg11
VGKD phenotype
p7450
sg13
I2
sa(dp7451
g7
I31
sg8
g59
sg10
I10
sg11
VHNF-4alpha
p7452
sg13
I1
sa(dp7453
g7
I31
sg8
g59
sg10
I10
sg11
VHNF-4alpha
p7454
sg13
I1
sasg17
(lp7455
(dp7456
g7
I61
sg20
VC0011849
p7457
sg10
I17
sg11
Vdiabetes mellitus
p7458
sg13
I2
sa(dp7459
g7
I166
sg20
VC0268418
p7460
sg10
I3
sg11
VGKD
p7461
sg13
I1
sasa(dp7462
g2
S'p120 (CagA), p33, p30 (OMP), and p19 (OMP) seropositivity was more often present in patients with higher grades of the histological parameters of gastritis and seropositivity to protein p95 (VacA) with endoscopic presence of duodenal ulcer.\n'
p7463
sg4
(lp7464
(dp7465
g7
I13
sg8
VP24941
p7466
sg10
I3
sg11
Vp33
p7467
sg13
I1
sa(dp7468
g7
I18
sg8
g59
sg10
I3
sg11
Vp30
p7469
sg13
I1
sa(dp7470
g7
I6
sg8
VP05109
p7471
sg10
I4
sg11
VCagA
p7472
sg13
I1
sa(dp7473
g7
I0
sg8
VP46087
p7474
sg10
I4
sg11
Vp120
p7475
sg13
I1
sa(dp7476
g7
I186
sg8
g59
sg10
I3
sg11
Vp95
p7477
sg13
I1
sa(dp7478
g7
I23
sg8
VP47874
p7479
sg10
I3
sg11
VOMP
p7480
sg13
I1
sa(dp7481
g7
I33
sg8
VP55273
p7482
sg10
I3
sg11
Vp19
p7483
sg13
I1
sa(dp7484
g7
I23
sg8
VP47874
p7485
sg10
I3
sg11
VOMP
p7486
sg13
I1
sasg17
(lp7487
(dp7488
g7
I146
sg20
VC0017152
p7489
sg10
I9
sg11
Vgastritis
p7490
sg13
I1
sa(dp7491
g7
I225
sg20
VC0013295
p7492
sg10
I14
sg11
Vduodenal ulcer
p7493
sg13
I2
sasa(dp7494
g2
S'In the present report, we use a mouse model of bone cancer pain and examine whether oral administration of a selective small molecule Trk inhibitor (ARRY-470, which blocks TrkA, TrkB and TrkC kinase activity at low nm concentrations) has a significant effect on cancer-induced pain behaviors, tumor-induced remodeling of sensory nerve fibers, tumor growth and tumor-induced bone remodeling.\n'
p7495
sg4
(lp7496
(dp7497
g7
I178
sg8
g59
sg10
I4
sg11
VTrkB
p7498
sg13
I1
sa(dp7499
g7
I172
sg8
VP06753
p7500
sg10
I4
sg11
VTrkA
p7501
sg13
I1
sa(dp7502
g7
I187
sg8
g59
sg10
I11
sg11
VTrkC kinase
p7503
sg13
I2
sa(dp7504
g7
I134
sg8
VP55039
p7505
sg10
I3
sg11
VTrk
p7506
sg13
I1
sasg17
(lp7507
(dp7508
g7
I293
sg20
VC0027651
p7509
sg10
I5
sg11
Vtumor
p7510
sg13
I1
sa(dp7511
g7
I293
sg20
VC0027651
p7512
sg10
I5
sg11
Vtumor
p7513
sg13
I1
sa(dp7514
g7
I343
sg20
VC0598934
p7515
sg10
I12
sg11
Vtumor growth
p7516
sg13
I2
sa(dp7517
g7
I47
sg20
VC0585442
p7518
sg10
I11
sg11
Vbone cancer
p7519
sg13
I2
sa(dp7520
g7
I52
sg20
VC0006826
p7521
sg10
I6
sg11
Vcancer
p7522
sg13
I1
sa(dp7523
g7
I52
sg20
VC0596240
p7524
sg10
I11
sg11
Vcancer pain
p7525
sg13
I2
sasa(dp7526
g2
S'Modulation of myostatin levels and myostatin/HGF balance by the use of different HD modalities might represent a novel approach to the prevention and treatment of HD-related muscle wasting syndrome.\n'
p7527
sg4
(lp7528
(dp7529
g7
I45
sg8
VP05231
p7530
sg10
I3
sg11
VHGF
p7531
sg13
I1
sa(dp7532
g7
I14
sg8
g59
sg10
I9
sg11
Vmyostatin
p7533
sg13
I1
sa(dp7534
g7
I14
sg8
g59
sg10
I9
sg11
Vmyostatin
p7535
sg13
I1
sasg17
(lp7536
(dp7537
g7
I45
sg20
VC0399440
p7538
sg10
I3
sg11
VHGF
p7539
sg13
I1
sa(dp7540
g7
I181
sg20
VC0043046
p7541
sg10
I16
sg11
Vwasting syndrome
p7542
sg13
I2
sasa(dp7543
g2
S'Hgf is also a known downstream target of Gata4 and it has been demonstrated that the expression of Hgf was significantly downregulated in PPF cells of Gata4 knockouts with congenital diaphragmatic hernia (CDH).\n'
p7544
sg4
(lp7545
(dp7546
g7
I0
sg8
VP05231
p7547
sg10
I3
sg11
VHgf
p7548
sg13
I1
sa(dp7549
g7
I41
sg8
VP43694
p7550
sg10
I5
sg11
VGata4
p7551
sg13
I1
sa(dp7552
g7
I0
sg8
VP05231
p7553
sg10
I3
sg11
VHgf
p7554
sg13
I1
sasg17
(lp7555
(dp7556
g7
I0
sg20
VC0399440
p7557
sg10
I3
sg11
VHgf
p7558
sg13
I1
sa(dp7559
g7
I205
sg20
VC0235833
p7560
sg10
I3
sg11
VCDH
p7561
sg13
I1
sa(dp7562
g7
I0
sg20
VC0399440
p7563
sg10
I3
sg11
VHgf
p7564
sg13
I1
sa(dp7565
g7
I172
sg20
VC0235833
p7566
sg10
I31
sg11
Vcongenital diaphragmatic hernia
p7567
sg13
I3
sasa(dp7568
g2
S'In vaccinia cutaneous-infected mice, DNGR-1-mediated crosspresentation was required for optimal Trm cell priming but not for their skin differentiation or for circulating memory T cell generation.\n'
p7569
sg4
(lp7570
sg17
(lp7571
(dp7572
g7
I3
sg20
VC0042214
p7573
sg10
I8
sg11
Vvaccinia
p7574
sg13
I1
sasa(dp7575
g2
S'The aim of this study was to assess the association between the TNFR1 rs2234649 polymorphism and ankylosing spondylitis susceptibility in a Russian Caucasian population.\n'
p7576
sg4
(lp7577
(dp7578
g7
I64
sg8
VP20333
p7579
sg10
I15
sg11
VTNFR1 rs2234649
p7580
sg13
I2
sasg17
(lp7581
(dp7582
g7
I97
sg20
VC0038013
p7583
sg10
I22
sg11
Vankylosing spondylitis
p7584
sg13
I2
sasa(dp7585
g2
S'To discover how NLRP3 and TNFRSF1A polymorphisms affect the efficacy of traditional medicine and etanercept for ankylosing spondylitis (AS) patients.\n'
p7586
sg4
(lp7587
(dp7588
g7
I26
sg8
VP19438
p7589
sg10
I8
sg11
VTNFRSF1A
p7590
sg13
I1
sasg17
(lp7591
(dp7592
g7
I112
sg20
VC0038013
p7593
sg10
I22
sg11
Vankylosing spondylitis
p7594
sg13
I2
sa(dp7595
g7
I136
sg20
VC0038013
p7596
sg10
I2
sg11
VAS
p7597
sg13
I1
sasa(dp7598
g2
S'The effects of the TNF- Alfa blockers infliximab or etanercept on the levels of TNF- Alfa , TNF-receptor 1 (TNF-R1), and TNF-receptor 2 (TNF-R2), as well as the levels of the inflammation markers CRP and IL-6, were measured in ankylosing spondylitis (AS) and rheumatoid arthritis (RA) patients receiving treatment with either compound.\n'
p7599
sg4
(lp7600
(dp7601
g7
I19
sg8
VP01375
p7602
sg10
I3
sg11
VTNF
p7603
sg13
I1
sa(dp7604
g7
I92
sg8
VP01375
p7605
sg10
I14
sg11
VTNF-receptor 1
p7606
sg13
I2
sa(dp7607
g7
I196
sg8
VP02741
p7608
sg10
I3
sg11
VCRP
p7609
sg13
I1
sa(dp7610
g7
I121
sg8
VP01375
p7611
sg10
I14
sg11
VTNF-receptor 2
p7612
sg13
I2
sa(dp7613
g7
I137
sg8
VP01375
p7614
sg10
I6
sg11
VTNF-R2
p7615
sg13
I1
sa(dp7616
g7
I108
sg8
VP01375
p7617
sg10
I6
sg11
VTNF-R1
p7618
sg13
I1
sa(dp7619
g7
I19
sg8
VP01375
p7620
sg10
I9
sg11
VTNF- Alfa
p7621
sg13
I2
sa(dp7622
g7
I204
sg8
VP05231
p7623
sg10
I4
sg11
VIL-6
p7624
sg13
I1
sasg17
(lp7625
(dp7626
g7
I259
sg20
VC0003873
p7627
sg10
I20
sg11
Vrheumatoid arthritis
p7628
sg13
I2
sa(dp7629
g7
I227
sg20
VC0038013
p7630
sg10
I22
sg11
Vankylosing spondylitis
p7631
sg13
I2
sa(dp7632
g7
I251
sg20
VC0038013
p7633
sg10
I2
sg11
VAS
p7634
sg13
I1
sa(dp7635
g7
I175
sg20
VC0021368
p7636
sg10
I12
sg11
Vinflammation
p7637
sg13
I1
sa(dp7638
g7
I281
sg20
VC0003873
p7639
sg10
I2
sg11
VRA
p7640
sg13
I1
sasa(dp7641
g2
S'To replicate the possible genetic association between ankylosing spondylitis (AS) and TNFRSF1A.\n'
p7642
sg4
(lp7643
(dp7644
g7
I86
sg8
VP19438
p7645
sg10
I8
sg11
VTNFRSF1A
p7646
sg13
I1
sasg17
(lp7647
(dp7648
g7
I54
sg20
VC0038013
p7649
sg10
I22
sg11
Vankylosing spondylitis
p7650
sg13
I2
sa(dp7651
g7
I78
sg20
VC0038013
p7652
sg10
I2
sg11
VAS
p7653
sg13
I1
sasa(dp7654
g2
S'The objective of this study was to evaluate the differences in allele and genotype frequencies of -383 tumor necrosis factor receptor 1 (TNFR1) polymorphism between ankylosing spondylitis (AS) and controls.\n'
p7655
sg4
(lp7656
(dp7657
g7
I137
sg8
VP20333
p7658
sg10
I5
sg11
VTNFR1
p7659
sg13
I1
sa(dp7660
g7
I103
sg8
VP01375
p7661
sg10
I32
sg11
Vtumor necrosis factor receptor 1
p7662
sg13
I5
sasg17
(lp7663
(dp7664
g7
I189
sg20
VC0038013
p7665
sg10
I2
sg11
VAS
p7666
sg13
I1
sa(dp7667
g7
I103
sg20
VC0333516
p7668
sg10
I14
sg11
Vtumor necrosis
p7669
sg13
I2
sa(dp7670
g7
I165
sg20
VC0038013
p7671
sg10
I22
sg11
Vankylosing spondylitis
p7672
sg13
I2
sasa(dp7673
g2
S'Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P &lt; 5 x 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P &lt; 5 x 10(-6) overall, with support in each of the three datasets studied).\n'
p7674
sg4
(lp7675
(dp7676
g7
I84
sg8
VP29460
p7677
sg10
I5
sg11
VIL12B
p7678
sg13
I1
sa(dp7679
g7
I66
sg8
VP36941
p7680
sg10
I4
sg11
VLTBR
p7681
sg13
I1
sa(dp7682
g7
I256
sg8
g59
sg10
I6
sg11
VTBKBP1
p7683
sg13
I1
sa(dp7684
g7
I264
sg8
VP58335
p7685
sg10
I6
sg11
VANTXR2
p7686
sg13
I1
sa(dp7687
g7
I59
sg8
g59
sg10
I5
sg11
VRUNX3
p7688
sg13
I1
sa(dp7689
g7
I275
sg8
g59
sg10
I5
sg11
VCARD9
p7690
sg13
I1
sa(dp7691
g7
I248
sg8
VP35408
p7692
sg10
I6
sg11
VPTGER4
p7693
sg13
I1
sa(dp7694
g7
I71
sg8
VP19438
p7695
sg10
I8
sg11
VTNFRSF1A
p7696
sg13
I1
sasg17
(lp7697
(dp7698
g7
I127
sg20
VC0038013
p7699
sg10
I22
sg11
Vankylosing spondylitis
p7700
sg13
I2
sasa(dp7701
g2
S'Obtained results indicate that miR-30a-5p, miR-126-3p and miR-486-5p are downregulated, while miR-205-5p and miR-210-3p are upregulated in NSCLC tissue.\n'
p7702
sg4
(lp7703
(dp7704
g7
I43
sg8
g59
sg10
I10
sg11
VmiR-126-3p
p7705
sg13
I1
sa(dp7706
g7
I94
sg8
g59
sg10
I10
sg11
VmiR-205-5p
p7707
sg13
I1
sa(dp7708
g7
I109
sg8
g59
sg10
I10
sg11
VmiR-210-3p
p7709
sg13
I1
sa(dp7710
g7
I58
sg8
g59
sg10
I10
sg11
VmiR-486-5p
p7711
sg13
I1
sa(dp7712
g7
I31
sg8
g59
sg10
I10
sg11
VmiR-30a-5p
p7713
sg13
I1
sasg17
(lp7714
(dp7715
g7
I139
sg20
VC0007131
p7716
sg10
I5
sg11
VNSCLC
p7717
sg13
I1
sasa(dp7718
g2
S'Moreover, performed stepwise discriminant analysis determined the model including miR-30a-5p and miR-210-3p which tested on the test set (n= 30) revealed an AUC of 0.969 and provided 100% sensitivity and 80% specificity in discriminating NSCLC tissue from non-cancerous lung tissue.\n'
p7719
sg4
(lp7720
(dp7721
g7
I82
sg8
g59
sg10
I10
sg11
VmiR-30a-5p
p7722
sg13
I1
sa(dp7723
g7
I97
sg8
g59
sg10
I10
sg11
VmiR-210-3p
p7724
sg13
I1
sasg17
(lp7725
(dp7726
g7
I238
sg20
VC0007131
p7727
sg10
I5
sg11
VNSCLC
p7728
sg13
I1
sasa(dp7729
g2
S'Moreover, miR-30a-5p together with miR-210-3p with excellent sensitivity and acceptable specificity may distinguish cancer tissue form non-cancerous tissue and thus may become a potential diagnostic biomarker for NSCLC.\n'
p7730
sg4
(lp7731
(dp7732
g7
I10
sg8
g59
sg10
I10
sg11
VmiR-30a-5p
p7733
sg13
I1
sa(dp7734
g7
I35
sg8
g59
sg10
I10
sg11
VmiR-210-3p
p7735
sg13
I1
sasg17
(lp7736
(dp7737
g7
I213
sg20
VC0007131
p7738
sg10
I5
sg11
VNSCLC
p7739
sg13
I1
sa(dp7740
g7
I116
sg20
VC0006826
p7741
sg10
I6
sg11
Vcancer
p7742
sg13
I1
sasa(dp7743
g2
S'We performed this meta-analysis to provide a comprehensive evaluation of the role of MicroRNA-210 (miR-210) expression on the overall survival (OS) rate of cancers.\n'
p7744
sg4
(lp7745
sg17
(lp7746
(dp7747
g7
I156
sg20
VC0006826
p7748
sg10
I7
sg11
Vcancers
p7749
sg13
I1
sasa(dp7750
g2
S'We searched for relevant available literatures on miR-210 and cancer until November 1st, 2016 on the databases PubMed, EMBASE, Cochrane Library, and Science Direct database.\n'
p7751
sg4
(lp7752
sg17
(lp7753
(dp7754
g7
I62
sg20
VC0006826
p7755
sg10
I6
sg11
Vcancer
p7756
sg13
I1
sasa(dp7757
g2
S'Subgroup analysis was performed to evaluate the specific role of miR-210 in ethnicity and the type of cancers.\n'
p7758
sg4
(lp7759
(dp7760
g7
I65
sg8
g59
sg10
I7
sg11
VmiR-210
p7761
sg13
I1
sasg17
(lp7762
(dp7763
g7
I102
sg20
VC0006826
p7764
sg10
I7
sg11
Vcancers
p7765
sg13
I1
sasa(dp7766
g2
S'The present meta-analysis suggests that high expressed miR-210 is significantly associated with OS in cancer patients, which has the potential to be a prognostic marker in cancers.\n'
p7767
sg4
(lp7768
(dp7769
g7
I55
sg8
g59
sg10
I7
sg11
VmiR-210
p7770
sg13
I1
sasg17
(lp7771
(dp7772
g7
I102
sg20
VC0006826
p7773
sg10
I6
sg11
Vcancer
p7774
sg13
I1
sa(dp7775
g7
I172
sg20
VC0006826
p7776
sg10
I7
sg11
Vcancers
p7777
sg13
I1
sasa(dp7778
g2
S'The roles of miR-210 in rat adrenal gland pheochromocytoma (PC-12) cells remain unknown.\n'
p7779
sg4
(lp7780
(dp7781
g7
I13
sg8
g59
sg10
I7
sg11
VmiR-210
p7782
sg13
I1
sasg17
(lp7783
(dp7784
g7
I28
sg20
VC0031511
p7785
sg10
I30
sg11
Vadrenal gland pheochromocytoma
p7786
sg13
I3
sasa(dp7787
g2
S'The number of pleural tumor foci, the volume of pleural effusion, the LMVD and the VEGF-C expression levels in the tumor tissue were significantly reduced in the H-ITCZ-treated group.\n'
p7788
sg4
(lp7789
(dp7790
g7
I83
sg8
VP49767
p7791
sg10
I6
sg11
VVEGF-C
p7792
sg13
I1
sasg17
(lp7793
(dp7794
g7
I22
sg20
VC0027651
p7795
sg10
I5
sg11
Vtumor
p7796
sg13
I1
sa(dp7797
g7
I14
sg20
VC0032229
p7798
sg10
I13
sg11
Vpleural tumor
p7799
sg13
I2
sa(dp7800
g7
I48
sg20
VC0032227
p7801
sg10
I16
sg11
Vpleural effusion
p7802
sg13
I2
sasa(dp7803
g2
S'We assessed the mRNA expression of VEGF, VEGF type C (VEGF-C) and their receptors together with the microvessel density (VD) and microlymphatic vessel density (LVD) in pursuit of their connection and prognostic value in malignant pleural mesothelioma (MPM).\n'
p7804
sg4
(lp7805
(dp7806
g7
I54
sg8
VP49767
p7807
sg10
I6
sg11
VVEGF-C
p7808
sg13
I1
sa(dp7809
g7
I41
sg8
VP49767
p7810
sg10
I11
sg11
VVEGF type C
p7811
sg13
I3
sasg17
(lp7812
(dp7813
g7
I252
sg20
VC0812413
p7814
sg10
I3
sg11
VMPM
p7815
sg13
I1
sa(dp7816
g7
I220
sg20
VC0812413
p7817
sg10
I30
sg11
Vmalignant pleural mesothelioma
p7818
sg13
I3
sasa(dp7819
g2
S'In this study, we detected the role of miR-132 in development and progression of pancreatic cancer and the underlying mechanism.\n'
p7820
sg4
(lp7821
sg17
(lp7822
(dp7823
g7
I81
sg20
VC0235974
p7824
sg10
I17
sg11
Vpancreatic cancer
p7825
sg13
I2
sasa(dp7826
g2
S'First, the expression of miR-132 in pancreatic carcinoma and adjacent non-cancerous tissues were detected by qRT-PCR.\n'
p7827
sg4
(lp7828
(dp7829
g7
I25
sg8
g59
sg10
I7
sg11
VmiR-132
p7830
sg13
I1
sasg17
(lp7831
(dp7832
g7
I36
sg20
VC0235974
p7833
sg10
I20
sg11
Vpancreatic carcinoma
p7834
sg13
I2
sasa(dp7835
g2
S'Then, the role of miR-132 in biological function of pancreatic carcinoma cells was investigated.\n'
p7836
sg4
(lp7837
(dp7838
g7
I18
sg8
g59
sg10
I7
sg11
VmiR-132
p7839
sg13
I1
sasg17
(lp7840
(dp7841
g7
I52
sg20
VC0235974
p7842
sg10
I20
sg11
Vpancreatic carcinoma
p7843
sg13
I2
sasa(dp7844
g2
S'Our results identified that miR-132 was generally upregulated in pancreatic carcinoma, and phosphatase and tensin homolog (PTEN) was generally downregulated.\n'
p7845
sg4
(lp7846
(dp7847
g7
I91
sg8
VP60484
p7848
sg10
I30
sg11
Vphosphatase and tensin homolog
p7849
sg13
I4
sa(dp7850
g7
I123
sg8
VP60484
p7851
sg10
I4
sg11
VPTEN
p7852
sg13
I1
sasg17
(lp7853
(dp7854
g7
I65
sg20
VC0235974
p7855
sg10
I20
sg11
Vpancreatic carcinoma
p7856
sg13
I2
sasa(dp7857
g2
S'miR-132 and PTEN were associated with advanced tumor size, lymph node metastasis and Tumor-Nodes-Metastases (TNM) stage of pancreatic carcinoma.\n'
p7858
sg4
(lp7859
(dp7860
g7
I0
sg8
g59
sg10
I7
sg11
VmiR-132
p7861
sg13
I1
sa(dp7862
g7
I12
sg8
VP60484
p7863
sg10
I4
sg11
VPTEN
p7864
sg13
I1
sasg17
(lp7865
(dp7866
g7
I47
sg20
VC0027651
p7867
sg10
I5
sg11
Vtumor
p7868
sg13
I1
sa(dp7869
g7
I59
sg20
VC0686619
p7870
sg10
I21
sg11
Vlymph node metastasis
p7871
sg13
I3
sa(dp7872
g7
I123
sg20
VC0235974
p7873
sg10
I20
sg11
Vpancreatic carcinoma
p7874
sg13
I2
sa(dp7875
g7
I85
sg20
VC0027651
p7876
sg10
I5
sg11
VTumor
p7877
sg13
I1
sa(dp7878
g7
I97
sg20
VC0027627
p7879
sg10
I10
sg11
VMetastases
p7880
sg13
I1
sasa(dp7881
g2
S'Downregulation of miR-132 inhibited proliferation, migration and invasion of pancreatic carcinoma cells.\n'
p7882
sg4
(lp7883
sg17
(lp7884
(dp7885
g7
I77
sg20
VC0235974
p7886
sg10
I20
sg11
Vpancreatic carcinoma
p7887
sg13
I2
sa(dp7888
g7
I36
sg20
VC0334094
p7889
sg10
I13
sg11
Vproliferation
p7890
sg13
I1
sa(dp7891
g7
I65
sg20
VC2699153
p7892
sg10
I8
sg11
Vinvasion
p7893
sg13
I1
sasa(dp7894
g2
S'In contrast, overexpression of miR-132 promoted proliferation, migration and invasion of pancreatic carcinoma cells.\n'
p7895
sg4
(lp7896
sg17
(lp7897
(dp7898
g7
I48
sg20
VC0334094
p7899
sg10
I13
sg11
Vproliferation
p7900
sg13
I1
sa(dp7901
g7
I77
sg20
VC2699153
p7902
sg10
I8
sg11
Vinvasion
p7903
sg13
I1
sa(dp7904
g7
I89
sg20
VC0235974
p7905
sg10
I20
sg11
Vpancreatic carcinoma
p7906
sg13
I2
sasa(dp7907
g2
S'Overexpression of PTEN abrogated the induction of miR-132 on proliferation, migration and invasion of pancreatic carcinoma cells.\n'
p7908
sg4
(lp7909
(dp7910
g7
I18
sg8
VP60484
p7911
sg10
I4
sg11
VPTEN
p7912
sg13
I1
sasg17
(lp7913
(dp7914
g7
I102
sg20
VC0235974
p7915
sg10
I20
sg11
Vpancreatic carcinoma
p7916
sg13
I2
sa(dp7917
g7
I61
sg20
VC0334094
p7918
sg10
I13
sg11
Vproliferation
p7919
sg13
I1
sa(dp7920
g7
I90
sg20
VC2699153
p7921
sg10
I8
sg11
Vinvasion
p7922
sg13
I1
sasa(dp7923
g2
S'Taken together, miR-132 promotes the proliferation, invasion and migration of human pancreatic cancer by inhibition of PTEN, and could be a tumor oncogene in development and progression of pancreatic carcinoma, and might be a candidate prognostic biomarker and a promising target for new treatment of human pancreatic cancer.\n'
p7924
sg4
(lp7925
(dp7926
g7
I119
sg8
VP60484
p7927
sg10
I4
sg11
VPTEN
p7928
sg13
I1
sasg17
(lp7929
(dp7930
g7
I189
sg20
VC0235974
p7931
sg10
I20
sg11
Vpancreatic carcinoma
p7932
sg13
I2
sa(dp7933
g7
I84
sg20
VC0235974
p7934
sg10
I17
sg11
Vpancreatic cancer
p7935
sg13
I2
sa(dp7936
g7
I140
sg20
VC0027651
p7937
sg10
I5
sg11
Vtumor
p7938
sg13
I1
sa(dp7939
g7
I52
sg20
VC2699153
p7940
sg10
I8
sg11
Vinvasion
p7941
sg13
I1
sa(dp7942
g7
I37
sg20
VC0334094
p7943
sg10
I13
sg11
Vproliferation
p7944
sg13
I1
sa(dp7945
g7
I84
sg20
VC0235974
p7946
sg10
I17
sg11
Vpancreatic cancer
p7947
sg13
I2
sasa(dp7948
g2
S'Although miR-132 has been studied in various human tumors, few studies have investigated the role of miR-132 in hepatocellular carcinoma (HCC).\n'
p7949
sg4
(lp7950
(dp7951
g7
I9
sg8
g59
sg10
I7
sg11
VmiR-132
p7952
sg13
I1
sa(dp7953
g7
I9
sg8
g59
sg10
I7
sg11
VmiR-132
p7954
sg13
I1
sasg17
(lp7955
(dp7956
g7
I112
sg20
VC2239176
p7957
sg10
I24
sg11
Vhepatocellular carcinoma
p7958
sg13
I2
sa(dp7959
g7
I138
sg20
VC2239176
p7960
sg10
I3
sg11
VHCC
p7961
sg13
I1
sa(dp7962
g7
I51
sg20
VC0027651
p7963
sg10
I6
sg11
Vtumors
p7964
sg13
I1
sasa(dp7965
g2
S'To investigate the effects of co-transfection of miR-520c-3p and miR-132 on proliferation and apoptosis of hepatocellular carcinoma Huh7.\n'
p7966
sg4
(lp7967
(dp7968
g7
I49
sg8
g59
sg10
I11
sg11
VmiR-520c-3p
p7969
sg13
I1
sa(dp7970
g7
I65
sg8
g59
sg10
I7
sg11
VmiR-132
p7971
sg13
I1
sasg17
(lp7972
(dp7973
g7
I76
sg20
VC0334094
p7974
sg10
I13
sg11
Vproliferation
p7975
sg13
I1
sa(dp7976
g7
I107
sg20
VC1512411
p7977
sg10
I24
sg11
Vhepatocellular carcinoma
p7978
sg13
I2
sasa(dp7979
g2
S'Hepatocellular carcinoma Huh7 was cultured in vitro and lipidosome was used to transfect miR-520c-3p and miR-132, respectively or together.\n'
p7980
sg4
(lp7981
(dp7982
g7
I89
sg8
g59
sg10
I11
sg11
VmiR-520c-3p
p7983
sg13
I1
sa(dp7984
g7
I105
sg8
g59
sg10
I7
sg11
VmiR-132
p7985
sg13
I1
sasg17
(lp7986
(dp7987
g7
I0
sg20
VC1512411
p7988
sg10
I24
sg11
VHepatocellular carcinoma
p7989
sg13
I2
sasa(dp7990
g2
S'The co-transfection of miR-520c-3p and miR-132 can target-regulate the expression of GPC3 and YAP, enhance the exhibition effect on proliferation of hepatocellular carcinoma Huh7 and induce cell apoptosis synergistically.\n'
p7991
sg4
(lp7992
(dp7993
g7
I23
sg8
g59
sg10
I11
sg11
VmiR-520c-3p
p7994
sg13
I1
sa(dp7995
g7
I39
sg8
g59
sg10
I7
sg11
VmiR-132
p7996
sg13
I1
sa(dp7997
g7
I85
sg8
VP51654
p7998
sg10
I4
sg11
VGPC3
p7999
sg13
I1
sa(dp8000
g7
I94
sg8
VP46937
p8001
sg10
I3
sg11
VYAP
p8002
sg13
I1
sasg17
(lp8003
(dp8004
g7
I149
sg20
VC1512411
p8005
sg10
I24
sg11
Vhepatocellular carcinoma
p8006
sg13
I2
sa(dp8007
g7
I132
sg20
VC0334094
p8008
sg10
I13
sg11
Vproliferation
p8009
sg13
I1
sasa(dp8010
g2
S'Paired and single cell line analyses under these experimental conditions identified TATA-Box Binding Protein (TBP) and Importin 8 (IPO8) to be stable in non-small cell lung cancer.\n'
p8011
sg4
(lp8012
(dp8013
g7
I110
sg8
VP20226
p8014
sg10
I3
sg11
VTBP
p8015
sg13
I1
sa(dp8016
g7
I84
sg8
VP20226
p8017
sg10
I24
sg11
VTATA-Box Binding Protein
p8018
sg13
I3
sa(dp8019
g7
I119
sg8
g59
sg10
I10
sg11
VImportin 8
p8020
sg13
I2
sa(dp8021
g7
I131
sg8
g59
sg10
I4
sg11
VIPO8
p8022
sg13
I1
sasg17
(lp8023
(dp8024
g7
I153
sg20
VC0007131
p8025
sg10
I26
sg11
Vnon-small cell lung cancer
p8026
sg13
I4
sasa(dp8027
g2
S'Thus, we evaluated the effect of serum availability on the expression of commonly used HKG (ACTB, B2M, GAPDH, GUSB, HPRT1, IPO8, MRPL19, PGK1, PPIA, RPLP0, RPS23, SDHA, TBP, UBC, and YWHAZ) in seven colon adenocarcinoma cell lines (Caco-2, DLD-1, HCT116, HT29, Lovo, SW480, and SW620).\n'
p8028
sg4
(lp8029
(dp8030
g7
I110
sg8
VP08236
p8031
sg10
I4
sg11
VGUSB
p8032
sg13
I1
sa(dp8033
g7
I98
sg8
VP61769
p8034
sg10
I3
sg11
VB2M
p8035
sg13
I1
sa(dp8036
g7
I123
sg8
g59
sg10
I4
sg11
VIPO8
p8037
sg13
I1
sa(dp8038
g7
I169
sg8
VP20226
p8039
sg10
I3
sg11
VTBP
p8040
sg13
I1
sa(dp8041
g7
I240
sg8
VP98173
p8042
sg10
I5
sg11
VDLD-1
p8043
sg13
I1
sa(dp8044
g7
I137
sg8
VP00558
p8045
sg10
I4
sg11
VPGK1
p8046
sg13
I1
sa(dp8047
g7
I103
sg8
VP04406
p8048
sg10
I5
sg11
VGAPDH
p8049
sg13
I1
sa(dp8050
g7
I156
sg8
VP62266
p8051
sg10
I5
sg11
VRPS23
p8052
sg13
I1
sa(dp8053
g7
I92
sg8
VP63261
p8054
sg10
I4
sg11
VACTB
p8055
sg13
I1
sa(dp8056
g7
I149
sg8
VP05388
p8057
sg10
I5
sg11
VRPLP0
p8058
sg13
I1
sa(dp8059
g7
I143
sg8
VP62937
p8060
sg10
I4
sg11
VPPIA
p8061
sg13
I1
sa(dp8062
g7
I116
sg8
VP55884
p8063
sg10
I5
sg11
VHPRT1
p8064
sg13
I1
sa(dp8065
g7
I129
sg8
VP49406
p8066
sg10
I6
sg11
VMRPL19
p8067
sg13
I1
sa(dp8068
g7
I163
sg8
VP31040
p8069
sg10
I4
sg11
VSDHA
p8070
sg13
I1
sa(dp8071
g7
I174
sg8
g59
sg10
I3
sg11
VUBC
p8072
sg13
I1
sasg17
(lp8073
(dp8074
g7
I199
sg20
VC0338106
p8075
sg10
I20
sg11
Vcolon adenocarcinoma
p8076
sg13
I2
sasa(dp8077
g2
S'The use of MRPL19, IPO8 and PPIA was identified as the best reference gene combination for the normalization of gene expression levels in endometrial carcinoma.\n'
p8078
sg4
(lp8079
(dp8080
g7
I28
sg8
VP62937
p8081
sg10
I4
sg11
VPPIA
p8082
sg13
I1
sa(dp8083
g7
I19
sg8
g59
sg10
I4
sg11
VIPO8
p8084
sg13
I1
sa(dp8085
g7
I11
sg8
VP49406
p8086
sg10
I6
sg11
VMRPL19
p8087
sg13
I1
sasg17
(lp8088
(dp8089
g7
I138
sg20
VC0476089
p8090
sg10
I21
sg11
Vendometrial carcinoma
p8091
sg13
I2
sasa(dp8092
g2
S'Expression stability of 15 HKG (ACTB, B2M, GAPDH, GUSB, HPRT1, IPO8, MRPL19, PGK1, PPIA, RPLP0, RPS23, SDHA, TBP, UBC, and YWHAZ) in 166 bowel specimens (91 normal, 35 cancerous, and 40 inflamed) was ranked by coefficients of variation (CV%) or using dedicated software: geNorm and NormFinder.\n'
p8093
sg4
(lp8094
(dp8095
g7
I77
sg8
VP00558
p8096
sg10
I4
sg11
VPGK1
p8097
sg13
I1
sa(dp8098
g7
I50
sg8
VP08236
p8099
sg10
I4
sg11
VGUSB
p8100
sg13
I1
sa(dp8101
g7
I38
sg8
VP61769
p8102
sg10
I3
sg11
VB2M
p8103
sg13
I1
sa(dp8104
g7
I109
sg8
VP20226
p8105
sg10
I3
sg11
VTBP
p8106
sg13
I1
sa(dp8107
g7
I56
sg8
VP55884
p8108
sg10
I5
sg11
VHPRT1
p8109
sg13
I1
sa(dp8110
g7
I63
sg8
g59
sg10
I4
sg11
VIPO8
p8111
sg13
I1
sa(dp8112
g7
I43
sg8
VP04406
p8113
sg10
I5
sg11
VGAPDH
p8114
sg13
I1
sa(dp8115
g7
I114
sg8
g59
sg10
I3
sg11
VUBC
p8116
sg13
I1
sa(dp8117
g7
I32
sg8
VP63261
p8118
sg10
I4
sg11
VACTB
p8119
sg13
I1
sa(dp8120
g7
I96
sg8
VP62266
p8121
sg10
I5
sg11
VRPS23
p8122
sg13
I1
sa(dp8123
g7
I103
sg8
VP31040
p8124
sg10
I4
sg11
VSDHA
p8125
sg13
I1
sa(dp8126
g7
I89
sg8
VP05388
p8127
sg10
I5
sg11
VRPLP0
p8128
sg13
I1
sa(dp8129
g7
I83
sg8
VP62937
p8130
sg10
I4
sg11
VPPIA
p8131
sg13
I1
sa(dp8132
g7
I69
sg8
VP49406
p8133
sg10
I6
sg11
VMRPL19
p8134
sg13
I1
sasg17
(lp8135
sa(dp8136
g2
S'The RPS23, PPIA, and RPLP0 were top-ranked, whereas IPO8, UBC and TBP were the lowest-ranked HKG across inflamed/cancerous/normal colonic tissues.\n'
p8137
sg4
(lp8138
(dp8139
g7
I66
sg8
VP20226
p8140
sg10
I3
sg11
VTBP
p8141
sg13
I1
sa(dp8142
g7
I58
sg8
g59
sg10
I3
sg11
VUBC
p8143
sg13
I1
sa(dp8144
g7
I11
sg8
VP62937
p8145
sg10
I4
sg11
VPPIA
p8146
sg13
I1
sa(dp8147
g7
I4
sg8
VP62266
p8148
sg10
I5
sg11
VRPS23
p8149
sg13
I1
sa(dp8150
g7
I21
sg8
VP05388
p8151
sg10
I5
sg11
VRPLP0
p8152
sg13
I1
sa(dp8153
g7
I52
sg8
g59
sg10
I4
sg11
VIPO8
p8154
sg13
I1
sasg17
(lp8155
sa(dp8156
g2
S'With respect to 14 of the 15 common reference genes (B2M, GAPDH, GUSB, HMBS, HPRT1, IPO8, PGK1, POLR2A, PPIA, RPLP0, TBP, TFRC, UBC, and YWHAZ), the expression levels were either too low to be easily detected, or exhibited a high degree of variability either between lung normal and squamous-cell carcinoma samples, or even among samples of the same tissue type.\n'
p8157
sg4
(lp8158
(dp8159
g7
I84
sg8
g59
sg10
I4
sg11
VIPO8
p8160
sg13
I1
sa(dp8161
g7
I71
sg8
VP08397
p8162
sg10
I4
sg11
VHMBS
p8163
sg13
I1
sa(dp8164
g7
I110
sg8
VP05388
p8165
sg10
I5
sg11
VRPLP0
p8166
sg13
I1
sa(dp8167
g7
I65
sg8
VP08236
p8168
sg10
I4
sg11
VGUSB
p8169
sg13
I1
sa(dp8170
g7
I96
sg8
VP24928
p8171
sg10
I6
sg11
VPOLR2A
p8172
sg13
I1
sa(dp8173
g7
I117
sg8
VP20226
p8174
sg10
I3
sg11
VTBP
p8175
sg13
I1
sa(dp8176
g7
I90
sg8
VP00558
p8177
sg10
I4
sg11
VPGK1
p8178
sg13
I1
sa(dp8179
g7
I122
sg8
VP02786
p8180
sg10
I4
sg11
VTFRC
p8181
sg13
I1
sa(dp8182
g7
I77
sg8
VP55884
p8183
sg10
I5
sg11
VHPRT1
p8184
sg13
I1
sa(dp8185
g7
I104
sg8
VP62937
p8186
sg10
I4
sg11
VPPIA
p8187
sg13
I1
sa(dp8188
g7
I58
sg8
VP04406
p8189
sg10
I5
sg11
VGAPDH
p8190
sg13
I1
sa(dp8191
g7
I128
sg8
g59
sg10
I3
sg11
VUBC
p8192
sg13
I1
sa(dp8193
g7
I53
sg8
VP61769
p8194
sg10
I3
sg11
VB2M
p8195
sg13
I1
sasg17
(lp8196
(dp8197
g7
I297
sg20
VC0007097
p8198
sg10
I9
sg11
Vcarcinoma
p8199
sg13
I1
sasa(dp8200
g2
S'After 4 weeks of CPAP therapy, there were no significant differences in ESS (PSG 6.4 +/- 3.8 vs home monitoring [HM] 6.5 +/- 3.8, P = .71), PSQI (PSG 5.4 +/- 3.1 vs HM 6.2 +/- 3.4, P = .30), SAQLI (PSG 4.5 +/- 1.1 vs HM 4.6 +/- 1.1, P = .85), SF-36 vitality (PSG 62.2 +/- 23.3 vs HM 64.1 +/- 18.4, P = .79), SF-36 HM (PSG 84.0 +/- 10.4 vs HM 81.3 +/- 14.9, P = .39), and BP (PSG 129/84 +/- 11/0 vs HM 125/81 +/- 13/9, P = .121).\n'
p8201
sg4
(lp8202
(dp8203
g7
I318
sg8
g59
sg10
I6
sg11
VPSG 84
p8204
sg13
I2
sa(dp8205
g7
I146
sg8
g59
sg10
I7
sg11
VPSG 5.4
p8206
sg13
I2
sa(dp8207
g7
I198
sg8
g59
sg10
I5
sg11
VPSG 4
p8208
sg13
I2
sasg17
(lp8209
sa(dp8210
g2
S'Thus, we propose that serum MMP-7 (alone or in combination with GGT) is a diagnostic biomarker for biliary atresia and may serve as a therapeutic target.\n'
p8211
sg4
(lp8212
(dp8213
g7
I22
sg8
VP09237
p8214
sg10
I11
sg11
Vserum MMP-7
p8215
sg13
I2
sa(dp8216
g7
I64
sg8
VP36268
p8217
sg10
I3
sg11
VGGT
p8218
sg13
I1
sasg17
(lp8219
(dp8220
g7
I99
sg20
VC0005411
p8221
sg10
I15
sg11
Vbiliary atresia
p8222
sg13
I2
sasa(dp8223
g2
S'We aimed to evaluate the diagnostic value of anti-smooth muscle antibodies (ASMA) and two liver markers (gamma-glutamyl transpeptidase [GGT] and alkaline phosphatase [ALP]) for differentiating between patients with extrahepatic biliary atresia (EHBA) and idiopathic neonatal hepatitis (INH).\n'
p8224
sg4
(lp8225
(dp8226
g7
I167
sg8
VP03973
p8227
sg10
I3
sg11
VALP
p8228
sg13
I1
sa(dp8229
g7
I145
sg8
VP10696
p8230
sg10
I20
sg11
Valkaline phosphatase
p8231
sg13
I2
sa(dp8232
g7
I105
sg8
VP36268
p8233
sg10
I29
sg11
Vgamma-glutamyl transpeptidase
p8234
sg13
I2
sa(dp8235
g7
I45
sg8
VP29536
p8236
sg10
I29
sg11
Vanti-smooth muscle antibodies
p8237
sg13
I3
sa(dp8238
g7
I76
sg8
VP68133
p8239
sg10
I4
sg11
VASMA
p8240
sg13
I1
sa(dp8241
g7
I136
sg8
VP36268
p8242
sg10
I3
sg11
VGGT
p8243
sg13
I1
sasg17
(lp8244
(dp8245
g7
I215
sg20
VC0005411
p8246
sg10
I28
sg11
Vextrahepatic biliary atresia
p8247
sg13
I3
sa(dp8248
g7
I245
sg20
VC0005411
p8249
sg10
I4
sg11
VEHBA
p8250
sg13
I1
sa(dp8251
g7
I266
sg20
VC0027613
p8252
sg10
I18
sg11
Vneonatal hepatitis
p8253
sg13
I2
sasa(dp8254
g2
S'In univariate analyses, gallbladder size, triangular cord sign, spleen size and ARFI values were found to be associated with biliary atresia, though only the triangular cord sign remained significant when elevated gamma glutamyltransferase (GGT) was included as a predictor.\n'
p8255
sg4
(lp8256
(dp8257
g7
I214
sg8
VP36269
p8258
sg10
I25
sg11
Vgamma glutamyltransferase
p8259
sg13
I2
sa(dp8260
g7
I241
sg8
VP36268
p8261
sg10
I3
sg11
VGGT
p8262
sg13
I1
sasg17
(lp8263
(dp8264
g7
I125
sg20
VC0005411
p8265
sg10
I15
sg11
Vbiliary atresia
p8266
sg13
I2
sa(dp8267
g7
I53
sg20
VC0234615
p8268
sg10
I9
sg11
Vcord sign
p8269
sg13
I2
sa(dp8270
g7
I53
sg20
VC0234615
p8271
sg10
I9
sg11
Vcord sign
p8272
sg13
I2
sasa(dp8273
g2
S'Here we sought to determine whether YY1 is upregulated in the cervical cancer tissues and YY1 inhibition contributes to apoptosis of cervical cancer cells, which is at least partly p53 dependent.\n'
p8274
sg4
(lp8275
(dp8276
g7
I36
sg8
VP25490
p8277
sg10
I3
sg11
VYY1
p8278
sg13
I1
sa(dp8279
g7
I36
sg8
VP25490
p8280
sg10
I3
sg11
VYY1
p8281
sg13
I1
sa(dp8282
g7
I181
sg8
VP42771
p8283
sg10
I3
sg11
Vp53
p8284
sg13
I1
sasg17
(lp8285
(dp8286
g7
I62
sg20
VC0302592
p8287
sg10
I15
sg11
Vcervical cancer
p8288
sg13
I2
sa(dp8289
g7
I62
sg20
VC0302592
p8290
sg10
I15
sg11
Vcervical cancer
p8291
sg13
I2
sasa(dp8292
g2
S'Therefore, YY1 can be a potential therapeutic target for cervical cancer treatment by arsenic trioxide (As2O3).\n'
p8293
sg4
(lp8294
(dp8295
g7
I11
sg8
VP25490
p8296
sg10
I3
sg11
VYY1
p8297
sg13
I1
sasg17
(lp8298
(dp8299
g7
I57
sg20
VC0302592
p8300
sg10
I15
sg11
Vcervical cancer
p8301
sg13
I2
sasa(dp8302
g2
S'The expression level of YY1 was examined and analyzed by Western blot in pathologically confirmed primary cervical cancer samples, in the adjacent normal samples, as well as in normal cervix samples.\n'
p8303
sg4
(lp8304
(dp8305
g7
I24
sg8
VP25490
p8306
sg10
I3
sg11
VYY1
p8307
sg13
I1
sasg17
(lp8308
(dp8309
g7
I106
sg20
VC0302592
p8310
sg10
I15
sg11
Vcervical cancer
p8311
sg13
I2
sasa(dp8312
g2
S'Treatment of HeLa cells with As2O3, a known anti-cervical cancer agent, reduced both protein and mRNA levels of YY1 in HeLa cells.\n'
p8313
sg4
(lp8314
(dp8315
g7
I112
sg8
VP25490
p8316
sg10
I3
sg11
VYY1
p8317
sg13
I1
sasg17
(lp8318
(dp8319
g7
I49
sg20
VC0302592
p8320
sg10
I15
sg11
Vcervical cancer
p8321
sg13
I2
sasa(dp8322
g2
S'These results demonstrated that the expression of YY1 is upregulated in cervical carcinomas and that YY1 plays a critical role in the progression of HPV-positive cervical cancer.\n'
p8323
sg4
(lp8324
(dp8325
g7
I50
sg8
VP25490
p8326
sg10
I3
sg11
VYY1
p8327
sg13
I1
sa(dp8328
g7
I50
sg8
VP25490
p8329
sg10
I3
sg11
VYY1
p8330
sg13
I1
sasg17
(lp8331
(dp8332
g7
I81
sg20
VC0007097
p8333
sg10
I10
sg11
Vcarcinomas
p8334
sg13
I1
sa(dp8335
g7
I162
sg20
VC0302592
p8336
sg10
I15
sg11
Vcervical cancer
p8337
sg13
I2
sasa(dp8338
g2
S'Thus, YY1 is an As2O3 target and could serve as a potential drug sensitizer for anti-cervical cancer therapy.\n'
p8339
sg4
(lp8340
(dp8341
g7
I6
sg8
VP25490
p8342
sg10
I3
sg11
VYY1
p8343
sg13
I1
sasg17
(lp8344
(dp8345
g7
I85
sg20
VC0302592
p8346
sg10
I15
sg11
Vcervical cancer
p8347
sg13
I2
sasa(dp8348
g2
S'VEGF and TGF-beta1 mRNA overexpression was found to be associated with progression from low-grade to high-grade cervical intraepithelial neoplasia (CIN), while YY1 showed constitutively elevated transcript levels in CIN and cervical cancer compared to controls.\n'
p8349
sg4
(lp8350
(dp8351
g7
I9
sg8
VP01137
p8352
sg10
I14
sg11
VTGF-beta1 mRNA
p8353
sg13
I2
sa(dp8354
g7
I160
sg8
VP25490
p8355
sg10
I3
sg11
VYY1
p8356
sg13
I1
sasg17
(lp8357
(dp8358
g7
I148
sg20
VC0206708
p8359
sg10
I3
sg11
VCIN
p8360
sg13
I1
sa(dp8361
g7
I148
sg20
VC0206708
p8362
sg10
I3
sg11
VCIN
p8363
sg13
I1
sa(dp8364
g7
I224
sg20
VC0302592
p8365
sg10
I15
sg11
Vcervical cancer
p8366
sg13
I2
sa(dp8367
g7
I112
sg20
VC0206708
p8368
sg10
I34
sg11
Vcervical intraepithelial neoplasia
p8369
sg13
I3
sasa(dp8370
g2
S'Comparison of the two groups revealed that isolates from cervical cancers predominantly carry changes in sequences of YY1 binding sites (especially at nucleotide 7519), while variants from asymptomatic carriers contained nucleotide changes within or close to transcription binding sites for AP-1, Oct-1, NF1, Tef-1, Tef-2, Sp1, YY1 and viral E2.\n'
p8371
sg4
(lp8372
(dp8373
g7
I309
sg8
g59
sg10
I5
sg11
VTef-1
p8374
sg13
I1
sa(dp8375
g7
I118
sg8
VP25490
p8376
sg10
I3
sg11
VYY1
p8377
sg13
I1
sa(dp8378
g7
I291
sg8
VP01100
p8379
sg10
I4
sg11
VAP-1
p8380
sg13
I1
sa(dp8381
g7
I297
sg8
VP14859
p8382
sg10
I5
sg11
VOct-1
p8383
sg13
I1
sa(dp8384
g7
I304
sg8
VP21359
p8385
sg10
I3
sg11
VNF1
p8386
sg13
I1
sa(dp8387
g7
I323
sg8
VP08047
p8388
sg10
I3
sg11
VSp1
p8389
sg13
I1
sa(dp8390
g7
I118
sg8
VP25490
p8391
sg10
I17
sg11
VYY1 binding sites
p8392
sg13
I3
sa(dp8393
g7
I316
sg8
g59
sg10
I5
sg11
VTef-2
p8394
sg13
I1
sasg17
(lp8395
(dp8396
g7
I304
sg20
VC0027831
p8397
sg10
I3
sg11
VNF1
p8398
sg13
I1
sa(dp8399
g7
I57
sg20
VC0007847
p8400
sg10
I16
sg11
Vcervical cancers
p8401
sg13
I2
sasa(dp8402
g2
S'Significant positive genetic correlations were observed between anorexia nervosa and schizophrenia, neuroticism, educational attainment, and high-density lipoprotein cholesterol, and significant negative genetic correlations were observed between anorexia nervosa and body mass index, insulin, glucose, and lipid phenotypes.\n'
p8403
sg4
(lp8404
(dp8405
g7
I285
sg8
VP01308
p8406
sg10
I7
sg11
Vinsulin
p8407
sg13
I1
sa(dp8408
g7
I141
sg8
VP28845
p8409
sg10
I36
sg11
Vhigh-density lipoprotein cholesterol
p8410
sg13
I3
sasg17
(lp8411
(dp8412
g7
I64
sg20
VC0003125
p8413
sg10
I16
sg11
Vanorexia nervosa
p8414
sg13
I2
sa(dp8415
g7
I64
sg20
VC0003125
p8416
sg10
I16
sg11
Vanorexia nervosa
p8417
sg13
I2
sa(dp8418
g7
I85
sg20
VC0036341
p8419
sg10
I13
sg11
Vschizophrenia
p8420
sg13
I1
sa(dp8421
g7
I100
sg20
VC1842981
p8422
sg10
I11
sg11
Vneuroticism
p8423
sg13
I1
sasa(dp8424
g2
S'Diabulimia is an eating disorder specific to patients with diabetes characterized by limiting and/or skipping insulin dosing.\n'
p8425
sg4
(lp8426
(dp8427
g7
I110
sg8
VP01308
p8428
sg10
I7
sg11
Vinsulin
p8429
sg13
I1
sasg17
(lp8430
(dp8431
g7
I17
sg20
VC0013473
p8432
sg10
I15
sg11
Veating disorder
p8433
sg13
I2
sa(dp8434
g7
I59
sg20
VC0011849
p8435
sg10
I8
sg11
Vdiabetes
p8436
sg13
I1
sasa(dp8437
g2
S'The purpose of this study was to investigate eating patterns among male and female adolescents with type 1 diabetes (T1D), and the associations with age, zBMI, eating disorder (ED) pathology, intentional insulin omission, and metabolic control.\n'
p8438
sg4
(lp8439
(dp8440
g7
I204
sg8
VP01308
p8441
sg10
I7
sg11
Vinsulin
p8442
sg13
I1
sasg17
(lp8443
(dp8444
g7
I117
sg20
VC0011854
p8445
sg10
I3
sg11
VT1D
p8446
sg13
I1
sa(dp8447
g7
I100
sg20
VC0011854
p8448
sg10
I15
sg11
Vtype 1 diabetes
p8449
sg13
I3
sa(dp8450
g7
I160
sg20
VC0013473
p8451
sg10
I15
sg11
Veating disorder
p8452
sg13
I2
sa(dp8453
g7
I177
sg20
VC0013473
p8454
sg10
I2
sg11
VED
p8455
sg13
I1
sa(dp8456
g7
I181
sg20
VC0677042
p8457
sg10
I9
sg11
Vpathology
p8458
sg13
I1
sasa(dp8459
g2
S'Since to date, there are no available studies on serum vaspin concentrations in patients with anorexia nervosa (AN), the aim of our study is to assess serum vaspin concentrations in girls with AN in comparison to healthy subjects and determine its relationship with body weight, body masss index (BMI) and insulin.\n'
p8460
sg4
(lp8461
(dp8462
g7
I306
sg8
VP01308
p8463
sg10
I7
sg11
Vinsulin
p8464
sg13
I1
sasg17
(lp8465
(dp8466
g7
I112
sg20
VC0003125
p8467
sg10
I2
sg11
VAN
p8468
sg13
I1
sa(dp8469
g7
I112
sg20
VC0003125
p8470
sg10
I2
sg11
VAN
p8471
sg13
I1
sa(dp8472
g7
I94
sg20
VC0003125
p8473
sg10
I16
sg11
Vanorexia nervosa
p8474
sg13
I2
sasa(dp8475
g2
S'[3H]FLT uptake after 5-fluorouracil treatment in vitro and [18F]FLT uptake after capecitabine (360 mg/kg/day) in athymic nude mice (Balb/c-nu) with xenografts (n = 10-12 per group) were measured using eight human colon cancer cell lines.\n'
p8476
sg4
(lp8477
sg17
(lp8478
(dp8479
g7
I213
sg20
VC0699790
p8480
sg10
I12
sg11
Vcolon cancer
p8481
sg13
I2
sasa(dp8482
g2
S"This retrospective study was done to examine whether the heterogeneity in primary tumor F-18-fluorodeoxyglucose (18F-FDG) and 18F-3'-fluoro-3'-deoxythymidine (18F-FLT) distribution can predict prognosis of patients with colorectal cancer who received surgery.\n"
p8483
sg4
(lp8484
sg17
(lp8485
(dp8486
g7
I74
sg20
VC0677930
p8487
sg10
I13
sg11
Vprimary tumor
p8488
sg13
I2
sa(dp8489
g7
I220
sg20
VC1527249
p8490
sg10
I17
sg11
Vcolorectal cancer
p8491
sg13
I2
sasa(dp8492
g2
S'The enrolled 32 patients with colorectal cancer underwent both 18F-FDG- and 18F-FLT-PET/CT studies before surgery.\n'
p8493
sg4
(lp8494
sg17
(lp8495
(dp8496
g7
I30
sg20
VC1527249
p8497
sg10
I17
sg11
Vcolorectal cancer
p8498
sg13
I2
sasa(dp8499
g2
S'18F-FDG PET heterogeneity parameters, IV and SZV, have a potential to be strong prognostic factors to predict PFS of patients with surgically resected colorectal cancer and are more useful than 18F-FLT-PET/CT heterogeneity parameters.\n'
p8500
sg4
(lp8501
sg17
(lp8502
(dp8503
g7
I151
sg20
VC1527249
p8504
sg10
I17
sg11
Vcolorectal cancer
p8505
sg13
I2
sasa(dp8506
g2
S'Our previous studies in colorectal cancer (CRC) cells have demonstrated an intracrine VEGF/VEGFR1 signalling mechanism that mediates CRC cell survival and chemo-sensitivity.\n'
p8507
sg4
(lp8508
(dp8509
g7
I91
sg8
VP17948
p8510
sg10
I6
sg11
VVEGFR1
p8511
sg13
I1
sasg17
(lp8512
(dp8513
g7
I43
sg20
VC1527249
p8514
sg10
I3
sg11
VCRC
p8515
sg13
I1
sa(dp8516
g7
I43
sg20
VC1527249
p8517
sg10
I3
sg11
VCRC
p8518
sg13
I1
sa(dp8519
g7
I24
sg20
VC1527249
p8520
sg10
I17
sg11
Vcolorectal cancer
p8521
sg13
I2
sasa(dp8522
g2
S'We tested whether variation in three serum biomarkers such as the natural c-MET ligand (hepatocyte growth factor), soluble vascular endothelial growth factor receptor 1, and vascular endothelial growth factor-A was associated with efficacy in metastatic colorectal cancer patients treated in the prospective BECOX study.\n'
p8523
sg4
(lp8524
(dp8525
g7
I74
sg8
VP08581
p8526
sg10
I12
sg11
Vc-MET ligand
p8527
sg13
I2
sa(dp8528
g7
I88
sg8
VP05231
p8529
sg10
I24
sg11
Vhepatocyte growth factor
p8530
sg13
I3
sa(dp8531
g7
I123
sg8
VP17948
p8532
sg10
I45
sg11
Vvascular endothelial growth factor receptor 1
p8533
sg13
I6
sa(dp8534
g7
I174
sg8
g59
sg10
I36
sg11
Vvascular endothelial growth factor-A
p8535
sg13
I4
sasg17
(lp8536
(dp8537
g7
I243
sg20
VC0948380
p8538
sg10
I28
sg11
Vmetastatic colorectal cancer
p8539
sg13
I3
sasa(dp8540
g2
S'Serum levels of vascular endothelial growth factor-A165, soluble vascular endothelial growth factor receptor 1, and hepatocyte growth factor were assessed by enzyme-linked immunosorbent assay method basally and every 3 cycles (at the time of computed tomography evaluation) in a preplanned translational study in the first-line BECOX trial in metastatic colorectal cancer patients treated with CAPOX plus bevacizumab.\n'
p8541
sg4
(lp8542
(dp8543
g7
I65
sg8
VP17948
p8544
sg10
I45
sg11
Vvascular endothelial growth factor receptor 1
p8545
sg13
I6
sa(dp8546
g7
I116
sg8
VP05231
p8547
sg10
I24
sg11
Vhepatocyte growth factor
p8548
sg13
I3
sa(dp8549
g7
I16
sg8
g59
sg10
I34
sg11
Vvascular endothelial growth factor
p8550
sg13
I4
sasg17
(lp8551
(dp8552
g7
I343
sg20
VC0948380
p8553
sg10
I28
sg11
Vmetastatic colorectal cancer
p8554
sg13
I3
sasa(dp8555
g2
S'Additionally, fisetin downregulated VEGFR1, p-ERK1/2, p38 and pJNK, ameliorating liver cancer progression.\n'
p8556
sg4
(lp8557
(dp8558
g7
I54
sg8
VP46108
p8559
sg10
I3
sg11
Vp38
p8560
sg13
I1
sa(dp8561
g7
I44
sg8
VP27361
p8562
sg10
I8
sg11
Vp-ERK1/2
p8563
sg13
I1
sa(dp8564
g7
I36
sg8
VP17948
p8565
sg10
I6
sg11
VVEGFR1
p8566
sg13
I1
sasg17
(lp8567
(dp8568
g7
I87
sg20
VC0178874
p8569
sg10
I18
sg11
Vcancer progression
p8570
sg13
I2
sasa(dp8571
g2
S'Two hepatocellular carcinoma cell lines (Hep3B and HepG2) were screened for expression of VEGF by quantitative real-time polymerase chain reaction (PCR) and its receptors VEGF-R1, VEGF-R2, and neuropilin-1 expression by reverse transcriptase-PCR, respectively.\n'
p8572
sg4
(lp8573
(dp8574
g7
I220
sg8
VP63136
p8575
sg10
I21
sg11
Vreverse transcriptase
p8576
sg13
I2
sa(dp8577
g7
I193
sg8
g59
sg10
I12
sg11
Vneuropilin-1
p8578
sg13
I1
sasg17
(lp8579
(dp8580
g7
I4
sg20
VC1512411
p8581
sg10
I24
sg11
Vhepatocellular carcinoma
p8582
sg13
I2
sasa(dp8583
g2
S'In addition, there was also an 8.43 Mb deletion in the 4p16.1p16.3 region, which involved FGFR3, LETM1, WHSC1 and WHSC2 and other 64 OMIM genes and spanned the Wolf-Hirschhorn syndrome region.\n'
p8584
sg4
(lp8585
(dp8586
g7
I114
sg8
g59
sg10
I5
sg11
VWHSC2
p8587
sg13
I1
sa(dp8588
g7
I97
sg8
g59
sg10
I5
sg11
VLETM1
p8589
sg13
I1
sa(dp8590
g7
I90
sg8
VP22607
p8591
sg10
I5
sg11
VFGFR3
p8592
sg13
I1
sasg17
(lp8593
(dp8594
g7
I160
sg20
VC1956097
p8595
sg10
I24
sg11
VWolf-Hirschhorn syndrome
p8596
sg13
I2
sasa(dp8597
g2
S'Multiple linear regression analysis revealed plasma miR-133a and its myocardial target Wolf-Hirschhorn syndrome candidate 2/Negative elongation factor A as opposite predictors of the LV mass loss (g) after AVR.\n'
p8598
sg4
(lp8599
sg17
(lp8600
(dp8601
g7
I87
sg20
VC1956097
p8602
sg10
I24
sg11
VWolf-Hirschhorn syndrome
p8603
sg13
I2
sasa(dp8604
g2
S'The second case which had an interstitial microdeletion encompassing WHSC 1 and WHSC 2 genes at 4p16.3 presented with less striking clinical features of WHS and had an apparently "normal" karyotype.\n'
p8605
sg4
(lp8606
(dp8607
g7
I80
sg8
VP01893
p8608
sg10
I12
sg11
VWHSC 2 genes
p8609
sg13
I3
sasg17
(lp8610
(dp8611
g7
I69
sg20
VC1956097
p8612
sg10
I3
sg11
VWHS
p8613
sg13
I1
sasa(dp8614
g2
S'Employing a unique panel of patient-derived cell lines with differing-sized 4p deletions, we provide evidence that haploinsufficiency of SLBP and/or WHSC2 (NELF-A) contributes to several novel cellular phenotypes of WHS, including delayed progression from S-phase into M-phase, reduced DNA replication in asynchronous culture and altered higher order chromatin assembly.\n'
p8615
sg4
(lp8616
(dp8617
g7
I137
sg8
g59
sg10
I4
sg11
VSLBP
p8618
sg13
I1
sa(dp8619
g7
I156
sg8
VP18615
p8620
sg10
I6
sg11
VNELF-A
p8621
sg13
I1
sa(dp8622
g7
I149
sg8
g59
sg10
I5
sg11
VWHSC2
p8623
sg13
I1
sasg17
(lp8624
(dp8625
g7
I149
sg20
VC1956097
p8626
sg10
I3
sg11
VWHS
p8627
sg13
I1
sasa(dp8628
g2
S'The microduplication did not involve WHSC1 and WHSC2 which are considered in the critical region for WHS and trisomy 4p.\n'
p8629
sg4
(lp8630
(dp8631
g7
I47
sg8
g59
sg10
I5
sg11
VWHSC2
p8632
sg13
I1
sa(dp8633
g7
I101
sg8
VP28360
p8634
sg10
I18
sg11
VWHS and trisomy 4p
p8635
sg13
I4
sasg17
(lp8636
(dp8637
g7
I109
sg20
VC0041107
p8638
sg10
I7
sg11
Vtrisomy
p8639
sg13
I1
sa(dp8640
g7
I37
sg20
VC1956097
p8641
sg10
I3
sg11
VWHS
p8642
sg13
I1
sasa(dp8643
g2
S'Using multiple linear regression analysis, an equation was developed (adjusted R^2=0.73; p&lt;0.0001) that included positive [preoperative LVM, microRNA-133a, serum response factor (SRF, which is known to be a transactivator of miR-133) and age] and negative [body mass index (BMI), Wolf-Hirschhorn syndrome candidate-2 (WHSC2, which is a target for repression by miR-133a), Beta-myosin heavy chain, myosin light chain-2, diabetes mellitus, and male gender] independent predictors of LVM reduction.\n'
p8644
sg4
(lp8645
(dp8646
g7
I364
sg8
g59
sg10
I8
sg11
VmiR-133a
p8647
sg13
I1
sa(dp8648
g7
I321
sg8
g59
sg10
I5
sg11
VWHSC2
p8649
sg13
I1
sa(dp8650
g7
I400
sg8
VP10916
p8651
sg10
I20
sg11
Vmyosin light chain-2
p8652
sg13
I3
sa(dp8653
g7
I182
sg8
g59
sg10
I3
sg11
VSRF
p8654
sg13
I1
sa(dp8655
g7
I228
sg8
g59
sg10
I7
sg11
VmiR-133
p8656
sg13
I1
sa(dp8657
g7
I159
sg8
VP11831
p8658
sg10
I21
sg11
Vserum response factor
p8659
sg13
I3
sa(dp8660
g7
I283
sg8
VP28360
p8661
sg10
I36
sg11
VWolf-Hirschhorn syndrome candidate-2
p8662
sg13
I3
sa(dp8663
g7
I375
sg8
VP13535
p8664
sg10
I23
sg11
VBeta-myosin heavy chain
p8665
sg13
I3
sasg17
(lp8666
(dp8667
g7
I139
sg20
VC1858854
p8668
sg10
I3
sg11
VLVM
p8669
sg13
I1
sa(dp8670
g7
I139
sg20
VC1858854
p8671
sg10
I3
sg11
VLVM
p8672
sg13
I1
sa(dp8673
g7
I283
sg20
VC1956097
p8674
sg10
I24
sg11
VWolf-Hirschhorn syndrome
p8675
sg13
I2
sa(dp8676
g7
I422
sg20
VC0011849
p8677
sg10
I17
sg11
Vdiabetes mellitus
p8678
sg13
I2
sasa(dp8679
g2
S'Therefore, we propose that overexpression of candidate genes in WHS (WHSC1, WHSC2 and LETM1) due to a duplication causes a clinical entity different to both the WHS and 4p trisomy syndrome.\n'
p8680
sg4
(lp8681
(dp8682
g7
I64
sg8
VP28360
p8683
sg10
I3
sg11
VWHS
p8684
sg13
I1
sa(dp8685
g7
I86
sg8
g59
sg10
I5
sg11
VLETM1
p8686
sg13
I1
sa(dp8687
g7
I76
sg8
g59
sg10
I5
sg11
VWHSC2
p8688
sg13
I1
sasg17
(lp8689
(dp8690
g7
I64
sg20
VC1956097
p8691
sg10
I3
sg11
VWHS
p8692
sg13
I1
sa(dp8693
g7
I102
sg20
VC1705960
p8694
sg10
I11
sg11
Vduplication
p8695
sg13
I1
sa(dp8696
g7
I180
sg20
VC0039082
p8697
sg10
I8
sg11
Vsyndrome
p8698
sg13
I1
sa(dp8699
g7
I172
sg20
VC0041107
p8700
sg10
I7
sg11
Vtrisomy
p8701
sg13
I1
sa(dp8702
g7
I64
sg20
VC1956097
p8703
sg10
I3
sg11
VWHS
p8704
sg13
I1
sasa(dp8705
g2
S'The smallest deletion detected in a WHS patient thus far includes two candidate genes, WHSC1 and WHSC2.\n'
p8706
sg4
(lp8707
(dp8708
g7
I97
sg8
g59
sg10
I5
sg11
VWHSC2
p8709
sg13
I1
sasg17
(lp8710
(dp8711
g7
I36
sg20
VC1956097
p8712
sg10
I3
sg11
VWHS
p8713
sg13
I1
sasa(dp8714
g2
S'Starting from making a connection between the syndrome phenotype and cytogenetic abnormalities, through gradual shortening of the length of the critical region WHSCR (finally up to 165 kb), and sequencing it, at least 2 genes (WHSC1 and WHSC2) were identified.\n'
p8715
sg4
(lp8716
(dp8717
g7
I237
sg8
g59
sg10
I5
sg11
VWHSC2
p8718
sg13
I1
sasg17
(lp8719
(dp8720
g7
I46
sg20
VC0039082
p8721
sg10
I8
sg11
Vsyndrome
p8722
sg13
I1
sa(dp8723
g7
I69
sg20
VC0008625
p8724
sg10
I25
sg11
Vcytogenetic abnormalities
p8725
sg13
I2
sasa(dp8726
g2
S'The deletion encompasses 191.5 kb and includes WHSC2, but not LETM1.\n'
p8727
sg4
(lp8728
(dp8729
g7
I47
sg8
g59
sg10
I5
sg11
VWHSC2
p8730
sg13
I1
sa(dp8731
g7
I62
sg8
g59
sg10
I5
sg11
VLETM1
p8732
sg13
I1
sasg17
(lp8733
sa(dp8734
g2
S'The association of GS with haemolytic anemias, e.g., Hereditary Spherocytosis (HS) or Congenital Dyserythropoietic Anemia type 2 (CDA 2), increase the hyperbilirubinemia level and the risk of cholelithiasis.\n'
p8735
sg4
(lp8736
(dp8737
g7
I86
sg8
VP32320
p8738
sg10
I42
sg11
VCongenital Dyserythropoietic Anemia type 2
p8739
sg13
I5
sa(dp8740
g7
I130
sg8
VP32320
p8741
sg10
I5
sg11
VCDA 2
p8742
sg13
I2
sasg17
(lp8743
(dp8744
g7
I192
sg20
VC0008350
p8745
sg10
I14
sg11
Vcholelithiasis
p8746
sg13
I1
sa(dp8747
g7
I53
sg20
VC0037889
p8748
sg10
I24
sg11
VHereditary Spherocytosis
p8749
sg13
I2
sa(dp8750
g7
I86
sg20
VC0002876
p8751
sg10
I35
sg11
VCongenital Dyserythropoietic Anemia
p8752
sg13
I3
sa(dp8753
g7
I130
sg20
VC0002876
p8754
sg10
I3
sg11
VCDA
p8755
sg13
I1
sa(dp8756
g7
I151
sg20
VC0020433
p8757
sg10
I18
sg11
Vhyperbilirubinemia
p8758
sg13
I1
sa(dp8759
g7
I79
sg20
VC0037889
p8760
sg10
I2
sg11
VHS
p8761
sg13
I1
sa(dp8762
g7
I38
sg20
VC0002871
p8763
sg10
I7
sg11
Vanemias
p8764
sg13
I1
sasa(dp8765
g2
S"A case of a woman with congenital dyserythropoietic anemia type II (CDA-II), Gilbert's syndrome (GS) and trophic malleolar ulceration is described.\n"
p8766
sg4
(lp8767
(dp8768
g7
I23
sg8
VP32320
p8769
sg10
I43
sg11
Vcongenital dyserythropoietic anemia type II
p8770
sg13
I5
sa(dp8771
g7
I68
sg8
VP32320
p8772
sg10
I6
sg11
VCDA-II
p8773
sg13
I1
sasg17
(lp8774
(dp8775
g7
I123
sg20
VC0041582
p8776
sg10
I10
sg11
Vulceration
p8777
sg13
I1
sa(dp8778
g7
I23
sg20
VC1306589
p8779
sg10
I43
sg11
Vcongenital dyserythropoietic anemia type II
p8780
sg13
I5
sa(dp8781
g7
I77
sg20
VC0017551
p8782
sg10
I18
sg11
VGilbert's syndrome
p8783
sg13
I2
sa(dp8784
g7
I68
sg20
VC1306589
p8785
sg10
I6
sg11
VCDA-II
p8786
sg13
I1
sa(dp8787
g7
I97
sg20
VC0017551
p8788
sg10
I2
sg11
VGS
p8789
sg13
I1
sasa(dp8790
g2
S'We show that the combined effect of an increased bilirubin load caused by dyserythropoiesis in CDA II and decreased bilirubin conjugation caused by reduced expression of uridine diphosphate glucuronosyl transferase (UGT1A) would increase the risk of hyperbilirubinemia (P &lt;.005) and gallstone formation (chi(2): P &lt;.\n'
p8791
sg4
(lp8792
(dp8793
g7
I170
sg8
g59
sg10
I44
sg11
Vuridine diphosphate glucuronosyl transferase
p8794
sg13
I4
sa(dp8795
g7
I216
sg8
VP35504
p8796
sg10
I5
sg11
VUGT1A
p8797
sg13
I1
sa(dp8798
g7
I95
sg8
VP32320
p8799
sg10
I6
sg11
VCDA II
p8800
sg13
I2
sasg17
(lp8801
(dp8802
g7
I250
sg20
VC0020433
p8803
sg10
I18
sg11
Vhyperbilirubinemia
p8804
sg13
I1
sa(dp8805
g7
I74
sg20
VC0221143
p8806
sg10
I17
sg11
Vdyserythropoiesis
p8807
sg13
I1
sa(dp8808
g7
I286
sg20
VC0947622
p8809
sg10
I9
sg11
Vgallstone
p8810
sg13
I1
sa(dp8811
g7
I95
sg20
VC1306589
p8812
sg10
I6
sg11
VCDA II
p8813
sg13
I2
sasa(dp8814
g2
S"We also noted that the nonphosphorylatable mutant Vgll4-4A (S58A/S155A/T159A/S280A) suppressed tumorigenesis in pancreatic cancer cells in vitro and in vivo to a greater extent than did wild-type Vgll4, suggesting that mitotic phosphorylation inhibits Vgll4's tumor-suppressive activity.\n"
p8815
sg4
(lp8816
(dp8817
g7
I50
sg8
g59
sg10
I8
sg11
VVgll4-4A
p8818
sg13
I1
sa(dp8819
g7
I50
sg8
g59
sg10
I5
sg11
VVgll4
p8820
sg13
I1
sa(dp8821
g7
I50
sg8
g59
sg10
I5
sg11
VVgll4
p8822
sg13
I1
sasg17
(lp8823
(dp8824
g7
I95
sg20
VC0027651
p8825
sg10
I5
sg11
Vtumor
p8826
sg13
I1
sa(dp8827
g7
I43
sg20
VC0596988
p8828
sg10
I6
sg11
Vmutant
p8829
sg13
I1
sa(dp8830
g7
I95
sg20
VC0007621
p8831
sg10
I13
sg11
Vtumorigenesis
p8832
sg13
I1
sa(dp8833
g7
I112
sg20
VC0235974
p8834
sg10
I17
sg11
Vpancreatic cancer
p8835
sg13
I2
sasa(dp8836
g2
S'Here, we report that diminished VGLL4 expression, but not VGLL1-3, correlated with both shorter relapse-free survival and shorter disease-specific survival of cancer patients with different molecular subtypes of breast cancer.\n'
p8837
sg4
(lp8838
(dp8839
g7
I32
sg8
g59
sg10
I5
sg11
VVGLL4
p8840
sg13
I1
sa(dp8841
g7
I58
sg8
g59
sg10
I7
sg11
VVGLL1-3
p8842
sg13
I1
sasg17
(lp8843
(dp8844
g7
I96
sg20
VC0277556
p8845
sg10
I7
sg11
Vrelapse
p8846
sg13
I1
sa(dp8847
g7
I159
sg20
VC0006826
p8848
sg10
I6
sg11
Vcancer
p8849
sg13
I1
sa(dp8850
g7
I212
sg20
VC0678222
p8851
sg10
I13
sg11
Vbreast cancer
p8852
sg13
I2
sasa(dp8853
g2
S'Additionally, we further demonstrate that overexpression of VGLL4 reduces breast cancer cell proliferation, migration, intravasation/extravasation potential, favors cell death, and suppresses tumor growth in vivo.\n'
p8854
sg4
(lp8855
(dp8856
g7
I60
sg8
g59
sg10
I5
sg11
VVGLL4
p8857
sg13
I1
sasg17
(lp8858
(dp8859
g7
I74
sg20
VC0678222
p8860
sg10
I13
sg11
Vbreast cancer
p8861
sg13
I2
sa(dp8862
g7
I93
sg20
VC0334094
p8863
sg10
I13
sg11
Vproliferation
p8864
sg13
I1
sa(dp8865
g7
I192
sg20
VC0598934
p8866
sg10
I12
sg11
Vtumor growth
p8867
sg13
I2
sa(dp8868
g7
I133
sg20
VC0015376
p8869
sg10
I13
sg11
Vextravasation
p8870
sg13
I1
sasa(dp8871
g2
S'VGLL4 may be a promising therapeutic target in breast cancer.\n'
p8872
sg4
(lp8873
(dp8874
g7
I0
sg8
g59
sg10
I5
sg11
VVGLL4
p8875
sg13
I1
sasg17
(lp8876
(dp8877
g7
I47
sg20
VC0678222
p8878
sg10
I13
sg11
Vbreast cancer
p8879
sg13
I2
sasa(dp8880
g2
S'Further investigation in the prostate cancer cohort revealed that gene expression of SERPINA, STX7, PDIA2, FMP5, GP1BB, VGLL4, KCNMA1, SHMT2, SAA4 and DIDO1 influence the prognostic significance of TWIST and vice versa.\n'
p8881
sg4
(lp8882
(dp8883
g7
I135
sg8
VP34896
p8884
sg10
I5
sg11
VSHMT2
p8885
sg13
I1
sa(dp8886
g7
I100
sg8
g59
sg10
I5
sg11
VPDIA2
p8887
sg13
I1
sa(dp8888
g7
I113
sg8
VP13224
p8889
sg10
I5
sg11
VGP1BB
p8890
sg13
I1
sa(dp8891
g7
I120
sg8
g59
sg10
I5
sg11
VVGLL4
p8892
sg13
I1
sa(dp8893
g7
I142
sg8
VP35542
p8894
sg10
I4
sg11
VSAA4
p8895
sg13
I1
sa(dp8896
g7
I94
sg8
g59
sg10
I4
sg11
VSTX7
p8897
sg13
I1
sasg17
(lp8898
(dp8899
g7
I29
sg20
VC0600139
p8900
sg10
I15
sg11
Vprostate cancer
p8901
sg13
I2
sasa(dp8902
g2
S'The expression of VGLL4 is significantly downregulated in clinical colorectal carcinoma (CRC) specimens, positively associated with patient survival rate, and inversely correlated with the expression of Wnt target genes in CRCs.\n'
p8903
sg4
(lp8904
(dp8905
g7
I18
sg8
g59
sg10
I5
sg11
VVGLL4
p8906
sg13
I1
sasg17
(lp8907
(dp8908
g7
I67
sg20
VC0009402
p8909
sg10
I20
sg11
Vcolorectal carcinoma
p8910
sg13
I2
sa(dp8911
g7
I89
sg20
VC1527249
p8912
sg10
I3
sg11
VCRC
p8913
sg13
I1
sasa(dp8914
g2
S'Gastric cancer (GC) is one of the most common malignant tumors and recent data demonstrates the tumor suppressor role of VGLL4 in GC, but the mechanisms for VGLL4 downregulation in GC remain to be elucidated.\n'
p8915
sg4
(lp8916
(dp8917
g7
I121
sg8
g59
sg10
I5
sg11
VVGLL4
p8918
sg13
I1
sa(dp8919
g7
I121
sg8
g59
sg10
I5
sg11
VVGLL4
p8920
sg13
I1
sasg17
(lp8921
(dp8922
g7
I16
sg20
VC0024623
p8923
sg10
I2
sg11
VGC
p8924
sg13
I1
sa(dp8925
g7
I0
sg20
VC0024623
p8926
sg10
I14
sg11
VGastric cancer
p8927
sg13
I2
sa(dp8928
g7
I46
sg20
VC0006826
p8929
sg10
I16
sg11
Vmalignant tumors
p8930
sg13
I2
sa(dp8931
g7
I56
sg20
VC0027651
p8932
sg10
I5
sg11
Vtumor
p8933
sg13
I1
sa(dp8934
g7
I16
sg20
VC0024623
p8935
sg10
I2
sg11
VGC
p8936
sg13
I1
sa(dp8937
g7
I16
sg20
VC0024623
p8938
sg10
I2
sg11
VGC
p8939
sg13
I1
sasa(dp8940
g2
S'In the present study, we investigated the effect of NGB overexpression on survival as well as on the size and occurrence of myocardial infarctions (MI) in a mouse model of acute MI (AMI) and a model of advanced atherosclerosis (ApoE -/- Fbn1 C1039G+/- mice), in which coronary plaques and MI develop in mice being fed a Western-type diet.\n'
p8941
sg4
(lp8942
(dp8943
g7
I52
sg8
g59
sg10
I3
sg11
VNGB
p8944
sg13
I1
sa(dp8945
g7
I228
sg8
VP02649
p8946
sg10
I4
sg11
VApoE
p8947
sg13
I1
sa(dp8948
g7
I237
sg8
VP35555
p8949
sg10
I4
sg11
VFbn1
p8950
sg13
I1
sasg17
(lp8951
(dp8952
g7
I182
sg20
VC0027051
p8953
sg10
I3
sg11
VAMI
p8954
sg13
I1
sa(dp8955
g7
I277
sg20
VC0333463
p8956
sg10
I7
sg11
Vplaques
p8957
sg13
I1
sa(dp8958
g7
I211
sg20
VC0004153
p8959
sg10
I15
sg11
Vatherosclerosis
p8960
sg13
I1
sa(dp8961
g7
I148
sg20
VC0021308
p8962
sg10
I2
sg11
VMI
p8963
sg13
I1
sa(dp8964
g7
I172
sg20
VC0155626
p8965
sg10
I8
sg11
Vacute MI
p8966
sg13
I2
sa(dp8967
g7
I148
sg20
VC0021308
p8968
sg10
I2
sg11
VMI
p8969
sg13
I1
sa(dp8970
g7
I124
sg20
VC0027051
p8971
sg10
I22
sg11
Vmyocardial infarctions
p8972
sg13
I2
sasa(dp8973
g2
S'Because apolipoprotein deficient mice with a heterozygous mutation (C1039G+/-) in the fibrillin-1 gene (ApoE-/-Fbn1C1039G+/-) manifest substantial IP neovascularization, they represent a unique tool to further investigate angiogenesis and its role in atherosclerosis.\n'
p8974
sg4
(lp8975
(dp8976
g7
I86
sg8
VP35555
p8977
sg10
I16
sg11
Vfibrillin-1 gene
p8978
sg13
I2
sa(dp8979
g7
I104
sg8
VP02649
p8980
sg10
I4
sg11
VApoE
p8981
sg13
I1
sasg17
(lp8982
(dp8983
g7
I251
sg20
VC0004153
p8984
sg10
I15
sg11
Vatherosclerosis
p8985
sg13
I1
sa(dp8986
g7
I150
sg20
VC0027686
p8987
sg10
I18
sg11
Vneovascularization
p8988
sg13
I1
sasa(dp8989
g2
S'Although lack of a valuable animal model of IP neovascularization impeded the investigation of a causal and straightforward link between neovascularization and atherosclerosis, recent evidence shows that vein grafts in ApoE*3 Leiden mice as well as plaques in ApoE(-/-) Fbn1(C1039G+/-) mice are useful models for intraplaque neovessel research.\n'
p8990
sg4
(lp8991
(dp8992
g7
I260
sg8
VP02649
p8993
sg10
I14
sg11
VApoE(-/-) Fbn1
p8994
sg13
I2
sasg17
(lp8995
(dp8996
g7
I47
sg20
VC0027686
p8997
sg10
I18
sg11
Vneovascularization
p8998
sg13
I1
sa(dp8999
g7
I47
sg20
VC0027686
p9000
sg10
I18
sg11
Vneovascularization
p9001
sg13
I1
sa(dp9002
g7
I160
sg20
VC0004153
p9003
sg10
I15
sg11
Vatherosclerosis
p9004
sg13
I1
sa(dp9005
g7
I249
sg20
VC0333463
p9006
sg10
I7
sg11
Vplaques
p9007
sg13
I1
sasa(dp9008
g2
S'We recently reported that apolipoprotein E (ApoE)-deficient mice with a mutation in the fibrillin-1 gene (ApoE(-/-)Fbn1(C1039G+/-)) develop accelerated atherosclerosis with enhanced inflammation, atherosclerotic plaque rupture, myocardial infarction and sudden death.\n'
p9009
sg4
(lp9010
(dp9011
g7
I106
sg8
VP02649
p9012
sg10
I13
sg11
VApoE(-/-)Fbn1
p9013
sg13
I1
sa(dp9014
g7
I26
sg8
VP02649
p9015
sg10
I16
sg11
Vapolipoprotein E
p9016
sg13
I2
sa(dp9017
g7
I88
sg8
VP35555
p9018
sg10
I16
sg11
Vfibrillin-1 gene
p9019
sg13
I2
sa(dp9020
g7
I44
sg8
VP02649
p9021
sg10
I4
sg11
VApoE
p9022
sg13
I1
sasg17
(lp9023
(dp9024
g7
I212
sg20
VC0011389
p9025
sg10
I6
sg11
Vplaque
p9026
sg13
I1
sa(dp9027
g7
I152
sg20
VC0004153
p9028
sg10
I15
sg11
Vatherosclerosis
p9029
sg13
I1
sa(dp9030
g7
I254
sg20
VC0011071
p9031
sg10
I12
sg11
Vsudden death
p9032
sg13
I2
sa(dp9033
g7
I228
sg20
VC0027051
p9034
sg10
I21
sg11
Vmyocardial infarction
p9035
sg13
I2
sa(dp9036
g7
I182
sg20
VC0021368
p9037
sg10
I12
sg11
Vinflammation
p9038
sg13
I1
sasa(dp9039
g2
S'In addition, we found a genomic deletion encompassing MAP1B in one patient with intellectual disability, microcephaly and seizures and deletions encompassing MYO16 in two unrelated patients with intellectual disability, autism and microcephaly.\n'
p9040
sg4
(lp9041
(dp9042
g7
I54
sg8
VP46821
p9043
sg10
I5
sg11
VMAP1B
p9044
sg13
I1
sasg17
(lp9045
(dp9046
g7
I80
sg20
VC0025362
p9047
sg10
I23
sg11
Vintellectual disability
p9048
sg13
I2
sa(dp9049
g7
I80
sg20
VC0025362
p9050
sg10
I23
sg11
Vintellectual disability
p9051
sg13
I2
sa(dp9052
g7
I105
sg20
VC0025958
p9053
sg10
I12
sg11
Vmicrocephaly
p9054
sg13
I1
sa(dp9055
g7
I105
sg20
VC0025958
p9056
sg10
I12
sg11
Vmicrocephaly
p9057
sg13
I1
sa(dp9058
g7
I122
sg20
VC0036572
p9059
sg10
I8
sg11
Vseizures
p9060
sg13
I1
sa(dp9061
g7
I220
sg20
VC0004352
p9062
sg10
I6
sg11
Vautism
p9063
sg13
I1
sasa(dp9064
g2
S'Furthermore, PBMCs miR-122, -720, and -3149 were increased in the AMI patients compared with the unstable angina (UA) patients (all P &lt; 0.05).\n'
p9065
sg4
(lp9066
sg17
(lp9067
(dp9068
g7
I97
sg20
VC0002965
p9069
sg10
I15
sg11
Vunstable angina
p9070
sg13
I2
sa(dp9071
g7
I114
sg20
VC0002965
p9072
sg10
I2
sg11
VUA
p9073
sg13
I1
sa(dp9074
g7
I66
sg20
VC0027051
p9075
sg10
I3
sg11
VAMI
p9076
sg13
I1
sasa(dp9077
g2
S'The aim of this study is to determine the prognostic value of miR-122-5p in a large cohort of comatose survivors of out-of-hospital cardiac arrest.\n'
p9078
sg4
(lp9079
(dp9080
g7
I62
sg8
g59
sg10
I10
sg11
VmiR-122-5p
p9081
sg13
I1
sasg17
(lp9082
(dp9083
g7
I94
sg20
VC0009421
p9084
sg10
I8
sg11
Vcomatose
p9085
sg13
I1
sa(dp9086
g7
I116
sg20
VC2936490
p9087
sg10
I30
sg11
Vout-of-hospital cardiac arrest
p9088
sg13
I3
sasa(dp9089
g2
S'Circulating levels of miR-122-5p improve the prediction of outcome after out-of-hospital cardiac arrest.\n'
p9090
sg4
(lp9091
(dp9092
g7
I22
sg8
g59
sg10
I10
sg11
VmiR-122-5p
p9093
sg13
I1
sasg17
(lp9094
(dp9095
g7
I73
sg20
VC2936490
p9096
sg10
I30
sg11
Vout-of-hospital cardiac arrest
p9097
sg13
I3
sasa(dp9098
g2
S'The resected specimen showed schwannoma histology, with tumor cells expressing S100 protein and WT1.\n'
p9099
sg4
(lp9100
(dp9101
g7
I79
sg8
VP04271
p9102
sg10
I12
sg11
VS100 protein
p9103
sg13
I2
sa(dp9104
g7
I96
sg8
g59
sg10
I3
sg11
VWT1
p9105
sg13
I1
sasg17
(lp9106
(dp9107
g7
I56
sg20
VC0027651
p9108
sg10
I5
sg11
Vtumor
p9109
sg13
I1
sa(dp9110
g7
I29
sg20
VC0027809
p9111
sg10
I10
sg11
Vschwannoma
p9112
sg13
I1
sa(dp9113
g7
I96
sg20
VC0027708
p9114
sg10
I3
sg11
VWT1
p9115
sg13
I1
sasa(dp9116
g2
S'SIRT1 immunoreactivity was reviewed in a series of 164 soft tissue tumors including alveolar soft part sarcoma, angiomyolipoma, clear cell sarcoma, desmoid/fibromatosis, desmoplastic small round cell tumor, Ewing sarcoma, gastrointestinal stromal tumor, glomus tumor, leiomyoma, leiomyosarcoma, lipoma, liposarcoma, malignant peripheral nerve sheath tumor, nodular fasciitis, osteosarcoma, rhabdomyosarcoma, schwannoma, solitary fibrous tumor, synovial sarcoma, undifferentiated pleomorphic sarcoma, and Wilms tumor.\n'
p9117
sg4
(lp9118
(dp9119
g7
I0
sg8
g59
sg10
I5
sg11
VSIRT1
p9120
sg13
I1
sasg17
(lp9121
(dp9122
g7
I444
sg20
VC0039101
p9123
sg10
I16
sg11
Vsynovial sarcoma
p9124
sg13
I2
sa(dp9125
g7
I420
sg20
VC1266119
p9126
sg10
I22
sg11
Vsolitary fibrous tumor
p9127
sg13
I3
sa(dp9128
g7
I462
sg20
VC1704218
p9129
sg10
I36
sg11
Vundifferentiated pleomorphic sarcoma
p9130
sg13
I3
sa(dp9131
g7
I390
sg20
VC0035412
p9132
sg10
I16
sg11
Vrhabdomyosarcoma
p9133
sg13
I1
sa(dp9134
g7
I408
sg20
VC0027809
p9135
sg10
I10
sg11
Vschwannoma
p9136
sg13
I1
sa(dp9137
g7
I254
sg20
VC0017653
p9138
sg10
I12
sg11
Vglomus tumor
p9139
sg13
I2
sa(dp9140
g7
I268
sg20
VC0023267
p9141
sg10
I9
sg11
Vleiomyoma
p9142
sg13
I1
sa(dp9143
g7
I156
sg20
VC0016048
p9144
sg10
I12
sg11
Vfibromatosis
p9145
sg13
I1
sa(dp9146
g7
I207
sg20
VC0553580
p9147
sg10
I13
sg11
VEwing sarcoma
p9148
sg13
I2
sa(dp9149
g7
I112
sg20
VC0206633
p9150
sg10
I14
sg11
Vangiomyolipoma
p9151
sg13
I1
sa(dp9152
g7
I376
sg20
VC0029463
p9153
sg10
I12
sg11
Vosteosarcoma
p9154
sg13
I1
sa(dp9155
g7
I128
sg20
VC0206651
p9156
sg10
I18
sg11
Vclear cell sarcoma
p9157
sg13
I3
sa(dp9158
g7
I148
sg20
VC0079218
p9159
sg10
I7
sg11
Vdesmoid
p9160
sg13
I1
sa(dp9161
g7
I120
sg20
VC3489413
p9162
sg10
I6
sg11
Vlipoma
p9163
sg13
I1
sa(dp9164
g7
I303
sg20
VC0023827
p9165
sg10
I11
sg11
Vliposarcoma
p9166
sg13
I1
sa(dp9167
g7
I170
sg20
VC0281508
p9168
sg10
I35
sg11
Vdesmoplastic small round cell tumor
p9169
sg13
I5
sa(dp9170
g7
I84
sg20
VC0206657
p9171
sg10
I26
sg11
Valveolar soft part sarcoma
p9172
sg13
I4
sa(dp9173
g7
I222
sg20
VC0238198
p9174
sg10
I30
sg11
Vgastrointestinal stromal tumor
p9175
sg13
I3
sa(dp9176
g7
I55
sg20
VC0037579
p9177
sg10
I18
sg11
Vsoft tissue tumors
p9178
sg13
I3
sa(dp9179
g7
I504
sg20
VC0027708
p9180
sg10
I11
sg11
VWilms tumor
p9181
sg13
I2
sa(dp9182
g7
I279
sg20
VC0023269
p9183
sg10
I14
sg11
Vleiomyosarcoma
p9184
sg13
I1
sa(dp9185
g7
I357
sg20
VC0410005
p9186
sg10
I17
sg11
Vnodular fasciitis
p9187
sg13
I2
sa(dp9188
g7
I316
sg20
VC0751690
p9189
sg10
I39
sg11
Vmalignant peripheral nerve sheath tumor
p9190
sg13
I5
sasa(dp9191
g2
S'We analyze the immunohistochemical expression of WT1 in 101 samples consisting of 13 normal nerves, 10 neurofibromas, 69 schwannomas and 9 malignant peripheral nerve sheath tumors (MPNST).\n'
p9192
sg4
(lp9193
(dp9194
g7
I49
sg8
g59
sg10
I3
sg11
VWT1
p9195
sg13
I1
sasg17
(lp9196
(dp9197
g7
I49
sg20
VC0027708
p9198
sg10
I3
sg11
VWT1
p9199
sg13
I1
sa(dp9200
g7
I121
sg20
VC0027809
p9201
sg10
I11
sg11
Vschwannomas
p9202
sg13
I1
sa(dp9203
g7
I103
sg20
VC0027830
p9204
sg10
I13
sg11
Vneurofibromas
p9205
sg13
I1
sa(dp9206
g7
I181
sg20
VC0751690
p9207
sg10
I5
sg11
VMPNST
p9208
sg13
I1
sa(dp9209
g7
I139
sg20
VC0751690
p9210
sg10
I40
sg11
Vmalignant peripheral nerve sheath tumors
p9211
sg13
I5
sasa(dp9212
g2
S'In 50 vestibular schwannomas tumor growth extension was correlated to WT1 expression.\n'
p9213
sg4
(lp9214
(dp9215
g7
I70
sg8
g59
sg10
I3
sg11
VWT1
p9216
sg13
I1
sasg17
(lp9217
(dp9218
g7
I6
sg20
VC0027859
p9219
sg10
I22
sg11
Vvestibular schwannomas
p9220
sg13
I2
sa(dp9221
g7
I29
sg20
VC0598934
p9222
sg10
I12
sg11
Vtumor growth
p9223
sg13
I2
sa(dp9224
g7
I70
sg20
VC0027708
p9225
sg10
I3
sg11
VWT1
p9226
sg13
I1
sasa(dp9227
g2
S'In peripheral nerve sheath tumors, cytoplasmic WT1 protein is expressed in the cytoplasm of the neoplastic cells in all tumors, including MPNST, neurofibromas and schwannomas.\n'
p9228
sg4
(lp9229
(dp9230
g7
I35
sg8
g59
sg10
I23
sg11
Vcytoplasmic WT1 protein
p9231
sg13
I3
sasg17
(lp9232
(dp9233
g7
I145
sg20
VC0027830
p9234
sg10
I13
sg11
Vneurofibromas
p9235
sg13
I1
sa(dp9236
g7
I27
sg20
VC0027651
p9237
sg10
I6
sg11
Vtumors
p9238
sg13
I1
sa(dp9239
g7
I3
sg20
VC0751689
p9240
sg10
I30
sg11
Vperipheral nerve sheath tumors
p9241
sg13
I4
sa(dp9242
g7
I163
sg20
VC0027809
p9243
sg10
I11
sg11
Vschwannomas
p9244
sg13
I1
sa(dp9245
g7
I138
sg20
VC0751690
p9246
sg10
I5
sg11
VMPNST
p9247
sg13
I1
sa(dp9248
g7
I47
sg20
VC0027708
p9249
sg10
I3
sg11
VWT1
p9250
sg13
I1
sasa(dp9251
g2
S'The authors report a case of multiple intra-dural schwannomas of the conus medullaris expressing HIF-1, galectin-3, cox-2 and Wilms tumor-1 protein; which to the best of our knowledge has not been previously reported in schwanomatosis.\n'
p9252
sg4
(lp9253
(dp9254
g7
I97
sg8
g59
sg10
I5
sg11
VHIF-1
p9255
sg13
I1
sa(dp9256
g7
I104
sg8
VP17931
p9257
sg10
I10
sg11
Vgalectin-3
p9258
sg13
I1
sa(dp9259
g7
I126
sg8
g59
sg10
I21
sg11
VWilms tumor-1 protein
p9260
sg13
I3
sa(dp9261
g7
I116
sg8
VP35354
p9262
sg10
I5
sg11
Vcox-2
p9263
sg13
I1
sasg17
(lp9264
(dp9265
g7
I126
sg20
VC0027708
p9266
sg10
I11
sg11
VWilms tumor
p9267
sg13
I2
sa(dp9268
g7
I50
sg20
VC0027809
p9269
sg10
I11
sg11
Vschwannomas
p9270
sg13
I1
sasa(dp9271
g2
S'Within the group of tumors that express a dominant or occasional small round cell pattern "SRCT" (neoplasms of the Central Nervous System excluded) are included: Ewing\'s sarcoma and peripheral neuroectodermal tumor (Es/pPNET) comprising its varieties, neuroblastoma, desmoplastic small round cell tumor, rhabdomyosarcoma, alveolar, solid and embryonal, small cell osteosarcoma, chondrosarcoma, myxoid and mesenchymal, round cell and myxoid liposarcoma, synovial sarcoma (monophasic undiffentiated), primitive malignant peripheral nerve sheath tumor (malignant small cell schwannoma), malignant non-Hogdkin lymphoma, Merkel cell tumor of the skin (small cell carcinoma including neuroendocrine carcinoma).\n'
p9272
sg4
(lp9273
sg17
(lp9274
(dp9275
g7
I606
sg20
VC0024299
p9276
sg10
I8
sg11
Vlymphoma
p9277
sg13
I1
sa(dp9278
g7
I571
sg20
VC0027809
p9279
sg10
I10
sg11
Vschwannoma
p9280
sg13
I1
sa(dp9281
g7
I182
sg20
VC0684337
p9282
sg10
I32
sg11
Vperipheral neuroectodermal tumor
p9283
sg13
I3
sa(dp9284
g7
I304
sg20
VC0206655
p9285
sg10
I26
sg11
Vrhabdomyosarcoma, alveolar
p9286
sg13
I2
sa(dp9287
g7
I433
sg20
VC0206634
p9288
sg10
I18
sg11
Vmyxoid liposarcoma
p9289
sg13
I2
sa(dp9290
g7
I453
sg20
VC0039101
p9291
sg10
I16
sg11
Vsynovial sarcoma
p9292
sg13
I2
sa(dp9293
g7
I219
sg20
VC0684337
p9294
sg10
I5
sg11
VpPNET
p9295
sg13
I1
sa(dp9296
g7
I353
sg20
VC0279622
p9297
sg10
I23
sg11
Vsmall cell osteosarcoma
p9298
sg13
I3
sa(dp9299
g7
I162
sg20
VC0553580
p9300
sg10
I15
sg11
VEwing's sarcoma
p9301
sg13
I2
sa(dp9302
g7
I628
sg20
VC0037286
p9303
sg10
I17
sg11
Vtumor of the skin
p9304
sg13
I4
sa(dp9305
g7
I678
sg20
VC0206695
p9306
sg10
I24
sg11
Vneuroendocrine carcinoma
p9307
sg13
I2
sa(dp9308
g7
I98
sg20
VC0027651
p9309
sg10
I9
sg11
Vneoplasms
p9310
sg13
I1
sa(dp9311
g7
I647
sg20
VC0262584
p9312
sg10
I20
sg11
Vsmall cell carcinoma
p9313
sg13
I3
sa(dp9314
g7
I20
sg20
VC0027651
p9315
sg10
I6
sg11
Vtumors
p9316
sg13
I1
sa(dp9317
g7
I252
sg20
VC0027819
p9318
sg10
I13
sg11
Vneuroblastoma
p9319
sg13
I1
sa(dp9320
g7
I123
sg20
VC0027769
p9321
sg10
I7
sg11
VNervous
p9322
sg13
I1
sa(dp9323
g7
I509
sg20
VC0751690
p9324
sg10
I39
sg11
Vmalignant peripheral nerve sheath tumor
p9325
sg13
I5
sa(dp9326
g7
I267
sg20
VC0281508
p9327
sg10
I35
sg11
Vdesmoplastic small round cell tumor
p9328
sg13
I5
sa(dp9329
g7
I378
sg20
VC0008479
p9330
sg10
I14
sg11
Vchondrosarcoma
p9331
sg13
I1
sasa(dp9332
g2
S'The main differential diagnosis includes hypertrophic scar, dermatofibroma (fibrous histiocytoma), pilar leiomyoma, neurofibroma, adult myofibromatosis, extra-abdominal fibromatosis and plaque-stage dermatofibrosarcoma protuberans.\n'
p9333
sg4
(lp9334
sg17
(lp9335
(dp9336
g7
I186
sg20
VC0011389
p9337
sg10
I6
sg11
Vplaque
p9338
sg13
I1
sa(dp9339
g7
I136
sg20
VC0206648
p9340
sg10
I15
sg11
Vmyofibromatosis
p9341
sg13
I1
sa(dp9342
g7
I199
sg20
VC0392784
p9343
sg10
I31
sg11
Vdermatofibrosarcoma protuberans
p9344
sg13
I2
sa(dp9345
g7
I41
sg20
VC0162810
p9346
sg10
I17
sg11
Vhypertrophic scar
p9347
sg13
I2
sa(dp9348
g7
I153
sg20
VC1275420
p9349
sg10
I28
sg11
Vextra-abdominal fibromatosis
p9350
sg13
I2
sa(dp9351
g7
I116
sg20
VC0027830
p9352
sg10
I12
sg11
Vneurofibroma
p9353
sg13
I1
sa(dp9354
g7
I60
sg20
VC0002991
p9355
sg10
I14
sg11
Vdermatofibroma
p9356
sg13
I1
sa(dp9357
g7
I76
sg20
VC0206644
p9358
sg10
I20
sg11
Vfibrous histiocytoma
p9359
sg13
I2
sa(dp9360
g7
I99
sg20
VC1709540
p9361
sg10
I15
sg11
Vpilar leiomyoma
p9362
sg13
I2
sasa(dp9363
g2
S'Data from patients with histiocytomas displaying induction of pilar epithelium in the epidermis above the lesions was compared with data from controls who did not show this change.\n'
p9364
sg4
(lp9365
sg17
(lp9366
(dp9367
g7
I24
sg20
VC1509147
p9368
sg10
I13
sg11
Vhistiocytomas
p9369
sg13
I1
sasa(dp9370
g2
S'Serial sectioning of histiocytomas showed that the induction of pilar epithelium was a focal phenomenon, often missed in routine sections.\n'
p9371
sg4
(lp9372
sg17
(lp9373
(dp9374
g7
I21
sg20
VC1509147
p9375
sg10
I13
sg11
Vhistiocytomas
p9376
sg13
I1
sasa(dp9377
g2
S'Bile acids deactivate certain enzymes, such as prolyl endopeptidases (PEPs), which are investigated as candidates for protease-based therapy for celiac sprue.\n'
p9378
sg4
(lp9379
(dp9380
g7
I70
sg8
VP28838
p9381
sg10
I4
sg11
VPEPs
p9382
sg13
I1
sa(dp9383
g7
I47
sg8
g59
sg10
I21
sg11
Vprolyl endopeptidases
p9384
sg13
I2
sasg17
(lp9385
(dp9386
g7
I70
sg20
VC1846609
p9387
sg10
I4
sg11
VPEPs
p9388
sg13
I1
sa(dp9389
g7
I145
sg20
VC0007570
p9390
sg10
I12
sg11
Vceliac sprue
p9391
sg13
I2
sa(dp9392
g7
I47
sg20
VC1846609
p9393
sg10
I21
sg11
Vprolyl endopeptidases
p9394
sg13
I2
sasa(dp9395
g2
S'To establish the proof of principle, the assay was applied to proline-specific endopeptidases (PEPs), a group of enzymes recently proposed as adjuvant therapy for celiac disease (a highly prevalent immunogenetic enteropathy).\n'
p9396
sg4
(lp9397
(dp9398
g7
I62
sg8
VP28838
p9399
sg10
I31
sg11
Vproline-specific endopeptidases
p9400
sg13
I2
sa(dp9401
g7
I95
sg8
VP28838
p9402
sg10
I4
sg11
VPEPs
p9403
sg13
I1
sasg17
(lp9404
(dp9405
g7
I163
sg20
VC0007570
p9406
sg10
I14
sg11
Vceliac disease
p9407
sg13
I2
sa(dp9408
g7
I62
sg20
VC1846609
p9409
sg10
I31
sg11
Vproline-specific endopeptidases
p9410
sg13
I2
sa(dp9411
g7
I95
sg20
VC1846609
p9412
sg10
I4
sg11
VPEPs
p9413
sg13
I1
sa(dp9414
g7
I212
sg20
VC0021831
p9415
sg10
I11
sg11
Venteropathy
p9416
sg13
I1
sasa(dp9417
g2
S'Due to their unique ability to cleave immunotoxic gluten peptides endoproteolytically, prolyl endopeptidases (PEPs) are attractive oral therapeutic candidates for protecting celiac sprue patients from the toxic effects of dietary gluten.\n'
p9418
sg4
(lp9419
(dp9420
g7
I110
sg8
VP28838
p9421
sg10
I4
sg11
VPEPs
p9422
sg13
I1
sa(dp9423
g7
I87
sg8
g59
sg10
I21
sg11
Vprolyl endopeptidases
p9424
sg13
I2
sasg17
(lp9425
(dp9426
g7
I110
sg20
VC1846609
p9427
sg10
I4
sg11
VPEPs
p9428
sg13
I1
sa(dp9429
g7
I87
sg20
VC1846609
p9430
sg10
I21
sg11
Vprolyl endopeptidases
p9431
sg13
I2
sa(dp9432
g7
I174
sg20
VC0007570
p9433
sg10
I12
sg11
Vceliac sprue
p9434
sg13
I2
sasa(dp9435
g2
S'The purpose of this study was to assess IL-37 profile in acute coronary syndrome (ACS) and the prognostic role of this cytokine in patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).\n'
p9436
sg4
(lp9437
sg17
(lp9438
(dp9439
g7
I82
sg20
VC0948089
p9440
sg10
I3
sg11
VACS
p9441
sg13
I1
sa(dp9442
g7
I145
sg20
VC1536220
p9443
sg10
I48
sg11
VST-segment elevation acute myocardial infarction
p9444
sg13
I5
sa(dp9445
g7
I195
sg20
VC1536220
p9446
sg10
I5
sg11
VSTEMI
p9447
sg13
I1
sa(dp9448
g7
I57
sg20
VC0948089
p9449
sg10
I23
sg11
Vacute coronary syndrome
p9450
sg13
I3
sasa(dp9451
g2
S'Plasma interleukin-37 levels were measured in 41 patients with ST elevation myocardial infarction (STEMI), 41 patients with non-STEMI, 42 patients with unstable angina, and 40 controls.\n'
p9452
sg4
(lp9453
(dp9454
g7
I7
sg8
VP60568
p9455
sg10
I14
sg11
Vinterleukin-37
p9456
sg13
I1
sasg17
(lp9457
(dp9458
g7
I63
sg20
VC1536220
p9459
sg10
I34
sg11
VST elevation myocardial infarction
p9460
sg13
I4
sa(dp9461
g7
I152
sg20
VC0002965
p9462
sg10
I15
sg11
Vunstable angina
p9463
sg13
I2
sa(dp9464
g7
I99
sg20
VC1536220
p9465
sg10
I5
sg11
VSTEMI
p9466
sg13
I1
sa(dp9467
g7
I99
sg20
VC1536220
p9468
sg10
I5
sg11
VSTEMI
p9469
sg13
I1
sasa(dp9470
g2
S'However, the exact role of IL-37 and IL-37 plus troponin I (TnI)-treated dendritic cells (DCs) in ventricular remodeling after myocardial infarction (MI) remains elusive.\n'
p9471
sg4
(lp9472
(dp9473
g7
I48
sg8
VP24821
p9474
sg10
I10
sg11
Vtroponin I
p9475
sg13
I2
sa(dp9476
g7
I60
sg8
VP48788
p9477
sg10
I3
sg11
VTnI
p9478
sg13
I1
sasg17
(lp9479
(dp9480
g7
I73
sg20
VC0268238
p9481
sg10
I15
sg11
Vdendritic cells
p9482
sg13
I2
sa(dp9483
g7
I150
sg20
VC0027051
p9484
sg10
I2
sg11
VMI
p9485
sg13
I1
sa(dp9486
g7
I127
sg20
VC0027051
p9487
sg10
I21
sg11
Vmyocardial infarction
p9488
sg13
I2
sa(dp9489
g7
I90
sg20
VC0268238
p9490
sg10
I3
sg11
VDCs
p9491
sg13
I1
sasa(dp9492
g2
S'Transgenic mice expressing human IL-37 (IL37-tg) exhibit less severe inflammation in models of endotoxin shock, colitis, myocardial infarction, lung, and spinal cord injury.\n'
p9493
sg4
(lp9494
sg17
(lp9495
(dp9496
g7
I121
sg20
VC0027051
p9497
sg10
I21
sg11
Vmyocardial infarction
p9498
sg13
I2
sa(dp9499
g7
I161
sg20
VC0035334
p9500
sg10
I4
sg11
Vcord
p9501
sg13
I1
sa(dp9502
g7
I112
sg20
VC0009319
p9503
sg10
I7
sg11
Vcolitis
p9504
sg13
I1
sa(dp9505
g7
I69
sg20
VC0021368
p9506
sg10
I12
sg11
Vinflammation
p9507
sg13
I1
sasa(dp9508
g2
S'To investigate the temporal changes of serum interleukin-37 (IL-37) concentration following acute ST-segment elevation myocardial infarction (ASTEMI) and the relationship between IL-37 and C-reactive protein (CRP) in patients with ASTEMI.\n'
p9509
sg4
(lp9510
(dp9511
g7
I209
sg8
VP02741
p9512
sg10
I3
sg11
VCRP
p9513
sg13
I1
sa(dp9514
g7
I61
sg8
VP60568
p9515
sg10
I5
sg11
VIL-37
p9516
sg13
I1
sa(dp9517
g7
I45
sg8
VP60568
p9518
sg10
I14
sg11
Vinterleukin-37
p9519
sg13
I1
sa(dp9520
g7
I189
sg8
VP02741
p9521
sg10
I18
sg11
VC-reactive protein
p9522
sg13
I2
sa(dp9523
g7
I61
sg8
VP60568
p9524
sg10
I5
sg11
VIL-37
p9525
sg13
I1
sasg17
(lp9526
(dp9527
g7
I119
sg20
VC0027051
p9528
sg10
I21
sg11
Vmyocardial infarction
p9529
sg13
I2
sasa(dp9530
g2
S'Venous blood was collected at days 1, 3, 5, and 7 after myocardial infarction for measurement of serum IL-37 and CRP levels using enzyme-linked immunosorbent assay (ELISA).\n'
p9531
sg4
(lp9532
(dp9533
g7
I97
sg8
g59
sg10
I11
sg11
Vserum IL-37
p9534
sg13
I2
sa(dp9535
g7
I113
sg8
VP02741
p9536
sg10
I3
sg11
VCRP
p9537
sg13
I1
sasg17
(lp9538
(dp9539
g7
I56
sg20
VC0027051
p9540
sg10
I21
sg11
Vmyocardial infarction
p9541
sg13
I2
sasa(dp9542
g2
S'Compared with the control group, the patients in ASTEMI group showed a significant acute elevation of IL-37 level on day 1 following myocardial infarction; IL-37 level reached the peak on day 3 and began to decrease on day 5, followed by a significant decrease on day 7.\n'
p9543
sg4
(lp9544
sg17
(lp9545
(dp9546
g7
I133
sg20
VC0027051
p9547
sg10
I21
sg11
Vmyocardial infarction
p9548
sg13
I2
sasa(dp9549
g2
S'A recent study found that IL-37 elevated significantly in peripheral blood of patients with acute myocardial infarction.\n'
p9550
sg4
(lp9551
sg17
(lp9552
(dp9553
g7
I92
sg20
VC0155626
p9554
sg10
I27
sg11
Vacute myocardial infarction
p9555
sg13
I3
sasa(dp9556
g2
S'We aimed to explore the effect IL-37 on cardiac function after mice myocardial infarction (MI) and its mechanism.\n'
p9557
sg4
(lp9558
sg17
(lp9559
(dp9560
g7
I68
sg20
VC0027051
p9561
sg10
I21
sg11
Vmyocardial infarction
p9562
sg13
I2
sa(dp9563
g7
I91
sg20
VC0027051
p9564
sg10
I2
sg11
VMI
p9565
sg13
I1
sasa(dp9566
g2
S'However, the plasma levels of IL-37 in patients with acute coronary syndrome (ACS, including unstable angina pectoris and acute myocardial infarction) have yet to be investigated.\n'
p9567
sg4
(lp9568
sg17
(lp9569
(dp9570
g7
I93
sg20
VC0002965
p9571
sg10
I24
sg11
Vunstable angina pectoris
p9572
sg13
I3
sa(dp9573
g7
I53
sg20
VC0948089
p9574
sg10
I23
sg11
Vacute coronary syndrome
p9575
sg13
I3
sa(dp9576
g7
I122
sg20
VC0155626
p9577
sg10
I27
sg11
Vacute myocardial infarction
p9578
sg13
I3
sa(dp9579
g7
I78
sg20
VC0948089
p9580
sg10
I3
sg11
VACS
p9581
sg13
I1
sasa(dp9582
g2
S'Plasma IL-37, IL-18, and IL-18BP levels were measured in 50 patients with stable angina pectoris (SAP), 75 patients with unstable angina pectoris (UAP), 67 patients with acute myocardial infarction (AMI), and 65 control patients.\n'
p9583
sg4
(lp9584
sg17
(lp9585
(dp9586
g7
I147
sg20
VC0002965
p9587
sg10
I3
sg11
VUAP
p9588
sg13
I1
sa(dp9589
g7
I199
sg20
VC0155626
p9590
sg10
I3
sg11
VAMI
p9591
sg13
I1
sa(dp9592
g7
I98
sg20
VC0699826
p9593
sg10
I3
sg11
VSAP
p9594
sg13
I1
sa(dp9595
g7
I121
sg20
VC0002965
p9596
sg10
I24
sg11
Vunstable angina pectoris
p9597
sg13
I3
sa(dp9598
g7
I74
sg20
VC0699826
p9599
sg10
I22
sg11
Vstable angina pectoris
p9600
sg13
I3
sa(dp9601
g7
I170
sg20
VC0155626
p9602
sg10
I27
sg11
Vacute myocardial infarction
p9603
sg13
I3
sasa(dp9604
g2
S'This mutation is normally associated with a mild to moderate course of Becker muscular dystrophy but the father suffered from a severe course of Becker muscular dystrophy suggesting MYF6 as a modifier.\n'
p9605
sg4
(lp9606
(dp9607
g7
I182
sg8
VP23409
p9608
sg10
I4
sg11
VMYF6
p9609
sg13
I1
sasg17
(lp9610
(dp9611
g7
I71
sg20
VC0917713
p9612
sg10
I25
sg11
VBecker muscular dystrophy
p9613
sg13
I3
sa(dp9614
g7
I112
sg20
VC0683278
p9615
sg10
I8
sg11
Vsuffered
p9616
sg13
I1
sa(dp9617
g7
I71
sg20
VC0917713
p9618
sg10
I25
sg11
VBecker muscular dystrophy
p9619
sg13
I3
sasa(dp9620
g2
S'The ratio of FA values within the cerebral peduncles of the affected and unaffected hemispheres (rFA) was calculated for each patient (n = 40) and assessed for correlation with Brunnstrom stage (BRS, 1-6), motor component of the functional independence measure (FIM-motor, 13-91), and the total length of stay (LOS) until discharge from rehabilitation (P &lt; .05).\n'
p9621
sg4
(lp9622
sg17
(lp9623
(dp9624
g7
I262
sg20
VC0393929
p9625
sg10
I3
sg11
VFIM
p9626
sg13
I1
sasa(dp9627
g2
S'Correlation coefficients were statistically significant between rFA and shoulder/elbow/forearm BRS (.696), hand BRS (.779), lower extremity BRS (.631), FIM-motor (.442), and LOS (-.598).\n'
p9628
sg4
(lp9629
sg17
(lp9630
(dp9631
g7
I152
sg20
VC0393929
p9632
sg10
I3
sg11
VFIM
p9633
sg13
I1
sasa(dp9634
g2
S'Ratios between FA values in the affected and unaffected hemispheres (rFA) were assessed by BRS and FIM-motor scores.\n'
p9635
sg4
(lp9636
sg17
(lp9637
(dp9638
g7
I99
sg20
VC0393929
p9639
sg10
I3
sg11
VFIM
p9640
sg13
I1
sasa(dp9641
g2
S'Analysis revealed significant relationships between rFA and BRS data (correlation coefficient: .687 for shoulder/elbow/forearm, .579 for hand, and .623 for lower extremities) but no significance relationship between rFA and FIM-motor scores.\n'
p9642
sg4
(lp9643
(dp9644
g7
I224
sg8
VP28329
p9645
sg10
I3
sg11
VFIM
p9646
sg13
I1
sasg17
(lp9647
(dp9648
g7
I224
sg20
VC0393929
p9649
sg10
I3
sg11
VFIM
p9650
sg13
I1
sasa(dp9651
g2
S'In contrast, analysis of rFA and FIM-motor scores did not reveal statistical significance.\n'
p9652
sg4
(lp9653
(dp9654
g7
I33
sg8
VP28329
p9655
sg10
I3
sg11
VFIM
p9656
sg13
I1
sasg17
(lp9657
(dp9658
g7
I33
sg20
VC0393929
p9659
sg10
I3
sg11
VFIM
p9660
sg13
I1
sasa(dp9661
g2
S'Submucous cleft palate (SMCP) classically involves bifid uvula, zona pellucida, and notched hard palate.\n'
p9662
sg4
(lp9663
sg17
(lp9664
(dp9665
g7
I24
sg20
VC0432103
p9666
sg10
I4
sg11
VSMCP
p9667
sg13
I1
sa(dp9668
g7
I64
sg20
VC0019360
p9669
sg10
I4
sg11
Vzona
p9670
sg13
I1
sa(dp9671
g7
I51
sg20
VC0266122
p9672
sg10
I11
sg11
Vbifid uvula
p9673
sg13
I2
sa(dp9674
g7
I0
sg20
VC0432103
p9675
sg10
I22
sg11
VSubmucous cleft palate
p9676
sg13
I3
sasa(dp9677
g2
S'Validate an assessment protocol for diagnosis of occult submucous cleft palate (OSMCP) and identify physical examination features present in patients with OSMCP in the relaxed and activated palate positions.\n'
p9678
sg4
(lp9679
sg17
(lp9680
(dp9681
g7
I49
sg20
VC0432104
p9682
sg10
I29
sg11
Voccult submucous cleft palate
p9683
sg13
I4
sa(dp9684
g7
I80
sg20
VC0432104
p9685
sg10
I5
sg11
VOSMCP
p9686
sg13
I1
sa(dp9687
g7
I80
sg20
VC0432104
p9688
sg10
I5
sg11
VOSMCP
p9689
sg13
I1
sasa(dp9690
g2
S'This study aimed to evaluate the craniofacial morphology of unoperated adult submucous cleft palate (SMCP) patients and to explore the possible correlation between the intrinsic growth insufficiency of the maxillofacial complex and the severity of the cleft.\n'
p9691
sg4
(lp9692
sg17
(lp9693
(dp9694
g7
I101
sg20
VC0432103
p9695
sg10
I4
sg11
VSMCP
p9696
sg13
I1
sa(dp9697
g7
I77
sg20
VC0432103
p9698
sg10
I22
sg11
Vsubmucous cleft palate
p9699
sg13
I3
sasa(dp9700
g2
S'A total of 20 unoperated SMCP patients, 20 unoperated overt cleft palate (OCP) patients, and 32 normal controls, ages between 18 and 30, were included for cephalometric analysis.\n'
p9701
sg4
(lp9702
sg17
(lp9703
(dp9704
g7
I74
sg20
VC1282359
p9705
sg10
I3
sg11
VOCP
p9706
sg13
I1
sa(dp9707
g7
I54
sg20
VC1282359
p9708
sg10
I18
sg11
Vovert cleft palate
p9709
sg13
I3
sasa(dp9710
g2
S'Because some patients with submucous cleft palate (SMCP) are asymptomatic, surgical treatment is conventionally delayed until hypernasal resonance is identified during speech production.\n'
p9711
sg4
(lp9712
sg17
(lp9713
(dp9714
g7
I27
sg20
VC0432103
p9715
sg10
I22
sg11
Vsubmucous cleft palate
p9716
sg13
I3
sa(dp9717
g7
I51
sg20
VC0432103
p9718
sg10
I4
sg11
VSMCP
p9719
sg13
I1
sasa(dp9720
g2
S'Since 69% of individuals with 22q11.2 deletion have a palatal abnormality, we studied the prevalence of 22q11.2 deletion syndrome in 378 Iranian patients during a 5-year period, including 291 patients affected with cleft palate only without cleft lip (CPO) and 87 patients affected with velopharyngeal incompetence (VPI) and/or submucous cleft palate (SMCP).\n'
p9721
sg4
(lp9722
sg17
(lp9723
(dp9724
g7
I328
sg20
VC0432103
p9725
sg10
I22
sg11
Vsubmucous cleft palate
p9726
sg13
I3
sa(dp9727
g7
I352
sg20
VC0432103
p9728
sg10
I4
sg11
VSMCP
p9729
sg13
I1
sa(dp9730
g7
I287
sg20
VC0042454
p9731
sg10
I27
sg11
Vvelopharyngeal incompetence
p9732
sg13
I2
sa(dp9733
g7
I104
sg20
VC0220704
p9734
sg10
I25
sg11
V22q11.2 deletion syndrome
p9735
sg13
I3
sa(dp9736
g7
I215
sg20
VC0008925
p9737
sg10
I12
sg11
Vcleft palate
p9738
sg13
I2
sa(dp9739
g7
I316
sg20
VC0042454
p9740
sg10
I3
sg11
VVPI
p9741
sg13
I1
sa(dp9742
g7
I241
sg20
VC0008924
p9743
sg10
I9
sg11
Vcleft lip
p9744
sg13
I2
sasa(dp9745
g2
S'Submucous cleft palate (SMCP) is a relatively rare variant of the common pathology of cleft palate with specific anatomic and clinical features.\n'
p9746
sg4
(lp9747
sg17
(lp9748
(dp9749
g7
I24
sg20
VC0432103
p9750
sg10
I4
sg11
VSMCP
p9751
sg13
I1
sa(dp9752
g7
I73
sg20
VC0677042
p9753
sg10
I9
sg11
Vpathology
p9754
sg13
I1
sa(dp9755
g7
I10
sg20
VC0008925
p9756
sg10
I12
sg11
Vcleft palate
p9757
sg13
I2
sa(dp9758
g7
I0
sg20
VC0432103
p9759
sg10
I22
sg11
VSubmucous cleft palate
p9760
sg13
I3
sasa(dp9761
g2
S'In this study, 366 patients with VPD were retrospectively stratified into cleft lip and palate (CLP), cleft palate (CP), submucous cleft palate (SMCP), occult submucous cleft palate (OSMCP), and non-CP groups.\n'
p9762
sg4
(lp9763
sg17
(lp9764
(dp9765
g7
I145
sg20
VC0432103
p9766
sg10
I4
sg11
VSMCP
p9767
sg13
I1
sa(dp9768
g7
I121
sg20
VC0432103
p9769
sg10
I22
sg11
Vsubmucous cleft palate
p9770
sg13
I3
sa(dp9771
g7
I152
sg20
VC0432104
p9772
sg10
I29
sg11
Voccult submucous cleft palate
p9773
sg13
I4
sa(dp9774
g7
I74
sg20
VC0158646
p9775
sg10
I20
sg11
Vcleft lip and palate
p9776
sg13
I4
sa(dp9777
g7
I116
sg20
VC0008925
p9778
sg10
I2
sg11
VCP
p9779
sg13
I1
sa(dp9780
g7
I102
sg20
VC0008925
p9781
sg10
I12
sg11
Vcleft palate
p9782
sg13
I2
sa(dp9783
g7
I116
sg20
VC0008925
p9784
sg10
I2
sg11
VCP
p9785
sg13
I1
sa(dp9786
g7
I96
sg20
VC0158646
p9787
sg10
I3
sg11
VCLP
p9788
sg13
I1
sa(dp9789
g7
I183
sg20
VC0432104
p9790
sg10
I5
sg11
VOSMCP
p9791
sg13
I1
sasa(dp9792
g2
S'The postoperative speech outcomes of submucous cleft palate (SMCP) surgery are known to be poorer than those of other types of cleft palate.\n'
p9793
sg4
(lp9794
sg17
(lp9795
(dp9796
g7
I37
sg20
VC0432103
p9797
sg10
I22
sg11
Vsubmucous cleft palate
p9798
sg13
I3
sa(dp9799
g7
I61
sg20
VC0432103
p9800
sg10
I4
sg11
VSMCP
p9801
sg13
I1
sa(dp9802
g7
I47
sg20
VC0008925
p9803
sg10
I12
sg11
Vcleft palate
p9804
sg13
I2
sasa(dp9805
g2
S'We attempted to objectively characterize the postoperative complications and speech outcomes of the surgical treatment of SMCP through a comparison with the outcomes of incomplete cleft palate (ICP).\n'
p9806
sg4
(lp9807
sg17
(lp9808
(dp9809
g7
I169
sg20
VC0268318
p9810
sg10
I23
sg11
Vincomplete cleft palate
p9811
sg13
I3
sa(dp9812
g7
I194
sg20
VC0268318
p9813
sg10
I3
sg11
VICP
p9814
sg13
I1
sa(dp9815
g7
I45
sg20
VC0032787
p9816
sg10
I27
sg11
Vpostoperative complications
p9817
sg13
I2
sasa(dp9818
g2
S'The aim of this study was to visualize bony defects of the palate and vomer in submucous cleft palate patients (SMCP) by three-dimensional (3D) computed tomography (CT) reconstruction and to classify the range of bony defects.\n'
p9819
sg4
(lp9820
sg17
(lp9821
(dp9822
g7
I79
sg20
VC0432103
p9823
sg10
I22
sg11
Vsubmucous cleft palate
p9824
sg13
I3
sasa(dp9825
g2
S'Objective : Submucous cleft palate (SMCP) is a congenital condition associated with abnormal development of the soft palate musculature.\n'
p9826
sg4
(lp9827
sg17
(lp9828
(dp9829
g7
I12
sg20
VC0432103
p9830
sg10
I22
sg11
VSubmucous cleft palate
p9831
sg13
I3
sa(dp9832
g7
I84
sg20
VC0000768
p9833
sg10
I20
sg11
Vabnormal development
p9834
sg13
I2
sa(dp9835
g7
I58
sg20
VC0012634
p9836
sg10
I9
sg11
Vcondition
p9837
sg13
I1
sa(dp9838
g7
I36
sg20
VC0432103
p9839
sg10
I4
sg11
VSMCP
p9840
sg13
I1
sasa(dp9841
g2
S'Adrenomedullin (ADM) is closely related to calcitonin gene-related peptide, which has a known causative role in migraine.\n'
p9842
sg4
(lp9843
(dp9844
g7
I16
sg8
VP35318
p9845
sg10
I3
sg11
VADM
p9846
sg13
I1
sa(dp9847
g7
I43
sg8
VP06881
p9848
sg10
I31
sg11
Vcalcitonin gene-related peptide
p9849
sg13
I3
sa(dp9850
g7
I0
sg8
VP35318
p9851
sg10
I14
sg11
VAdrenomedullin
p9852
sg13
I1
sasg17
(lp9853
(dp9854
g7
I112
sg20
VC0149931
p9855
sg10
I8
sg11
Vmigraine
p9856
sg13
I1
sasa(dp9857
g2
S'1-Piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS), a calcitonin gene-related peptide (CGRP) receptor antagonist, can alleviate the symptoms of migraine and is highly selective for CGRP over adrenomedullin (AM) receptors.\n'
p9858
sg4
(lp9859
(dp9860
g7
I343
sg8
VP35318
p9861
sg10
I29
sg11
Vadrenomedullin (AM) receptors
p9862
sg13
I3
sa(dp9863
g7
I239
sg8
VP80511
p9864
sg10
I4
sg11
VCGRP
p9865
sg13
I1
sa(dp9866
g7
I206
sg8
VP06881
p9867
sg10
I47
sg11
Vcalcitonin gene-related peptide (CGRP) receptor
p9868
sg13
I5
sasg17
(lp9869
(dp9870
g7
I296
sg20
VC0149931
p9871
sg10
I8
sg11
Vmigraine
p9872
sg13
I1
sasa(dp9873
g2
S'The study of the determination of the DME/S is then performed in subjects with normal MEVS/VC X 100 and clinically suspect of bronchial obstruction (tobacco addicts, patients at stage I of chronic bronchitis, asthmatic patients outside the attacks).\n'
p9874
sg4
(lp9875
sg17
(lp9876
(dp9877
g7
I197
sg20
VC1319018
p9878
sg10
I21
sg11
Vbronchitis, asthmatic
p9879
sg13
I2
sa(dp9880
g7
I136
sg20
VC0028778
p9881
sg10
I11
sg11
Vobstruction
p9882
sg13
I1
sasa(dp9883
g2
S'Plasma gastrin, somatostatin, pancreatic polypeptide and vasoactive intestinal peptide were measured by RIA in patients with hyperparathyroidism.\n'
p9884
sg4
(lp9885
(dp9886
g7
I7
sg8
VP01350
p9887
sg10
I7
sg11
Vgastrin
p9888
sg13
I1
sa(dp9889
g7
I16
sg8
VP61278
p9890
sg10
I12
sg11
Vsomatostatin
p9891
sg13
I1
sasg17
(lp9892
(dp9893
g7
I125
sg20
VC0020502
p9894
sg10
I19
sg11
Vhyperparathyroidism
p9895
sg13
I1
sasa(dp9896
g2
S'An understanding of this expanded peptide recognition will allow for the identification of novel physiologically relevant SH2B1/peptide interactions, which can contribute to the design of obesity and diabetes pharmaceuticals to target the ligand-binding interface of SH2B1 with high specificity.\n'
p9897
sg4
(lp9898
(dp9899
g7
I122
sg8
g59
sg10
I5
sg11
VSH2B1
p9900
sg13
I1
sa(dp9901
g7
I122
sg8
g59
sg10
I5
sg11
VSH2B1
p9902
sg13
I1
sasg17
(lp9903
(dp9904
g7
I188
sg20
VC0028754
p9905
sg10
I7
sg11
Vobesity
p9906
sg13
I1
sa(dp9907
g7
I200
sg20
VC0011849
p9908
sg10
I8
sg11
Vdiabetes
p9909
sg13
I1
sasa(dp9910
g2
S'A 200~240 kb SH2B1-containing deletion region on 16p11.2 is associated with early-onset obesity and developmental delay.\n'
p9911
sg4
(lp9912
(dp9913
g7
I13
sg8
g59
sg10
I5
sg11
VSH2B1
p9914
sg13
I1
sasg17
(lp9915
(dp9916
g7
I88
sg20
VC0028754
p9917
sg10
I7
sg11
Vobesity
p9918
sg13
I1
sa(dp9919
g7
I100
sg20
VC0424605
p9920
sg10
I19
sg11
Vdevelopmental delay
p9921
sg13
I2
sasa(dp9922
g2
S'The objective of this study was to evaluate the influence of genetic variants related to obesity identified by genome-wide association studies (MC4R, TMEM18, KCTD15, SH2B1, SEC16B, BDNF, NEGR1, OLFM4 and HOXB5 genes) on anthropometric and dietary phenotypes in two Brazilian cohorts followed-up since birth.\n'
p9923
sg4
(lp9924
(dp9925
g7
I150
sg8
g59
sg10
I6
sg11
VTMEM18
p9926
sg13
I1
sa(dp9927
g7
I194
sg8
g59
sg10
I5
sg11
VOLFM4
p9928
sg13
I1
sa(dp9929
g7
I204
sg8
VP20719
p9930
sg10
I11
sg11
VHOXB5 genes
p9931
sg13
I2
sa(dp9932
g7
I187
sg8
g59
sg10
I5
sg11
VNEGR1
p9933
sg13
I1
sa(dp9934
g7
I166
sg8
g59
sg10
I5
sg11
VSH2B1
p9935
sg13
I1
sa(dp9936
g7
I158
sg8
g59
sg10
I6
sg11
VKCTD15
p9937
sg13
I1
sa(dp9938
g7
I173
sg8
g59
sg10
I6
sg11
VSEC16B
p9939
sg13
I1
sa(dp9940
g7
I144
sg8
VP32245
p9941
sg10
I4
sg11
VMC4R
p9942
sg13
I1
sasg17
(lp9943
(dp9944
g7
I89
sg20
VC0028754
p9945
sg10
I7
sg11
Vobesity
p9946
sg13
I1
sasa(dp9947
g2
S'In this study, we aimed to analyze pairwise interactions that are associated with Body Mass Index (BMI) between SNPs from twelve genes robustly associated with obesity (BDNF, ETV5, FAIM2, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, SEC16B, SH2B1, and TMEM18).\n'
p9948
sg4
(lp9949
(dp9950
g7
I209
sg8
VP32245
p9951
sg10
I4
sg11
VMC4R
p9952
sg13
I1
sa(dp9953
g7
I188
sg8
g59
sg10
I3
sg11
VFTO
p9954
sg13
I1
sa(dp9955
g7
I222
sg8
g59
sg10
I5
sg11
VNEGR1
p9956
sg13
I1
sa(dp9957
g7
I175
sg8
VP41161
p9958
sg10
I4
sg11
VETV5
p9959
sg13
I1
sa(dp9960
g7
I229
sg8
g59
sg10
I6
sg11
VSEC16B
p9961
sg13
I1
sa(dp9962
g7
I181
sg8
g59
sg10
I5
sg11
VFAIM2
p9963
sg13
I1
sa(dp9964
g7
I193
sg8
g59
sg10
I6
sg11
VGNPDA2
p9965
sg13
I1
sa(dp9966
g7
I237
sg8
g59
sg10
I5
sg11
VSH2B1
p9967
sg13
I1
sa(dp9968
g7
I248
sg8
g59
sg10
I6
sg11
VTMEM18
p9969
sg13
I1
sa(dp9970
g7
I201
sg8
g59
sg10
I6
sg11
VKCTD15
p9971
sg13
I1
sa(dp9972
g7
I215
sg8
g59
sg10
I5
sg11
VMTCH2
p9973
sg13
I1
sasg17
(lp9974
(dp9975
g7
I160
sg20
VC0028754
p9976
sg10
I7
sg11
Vobesity
p9977
sg13
I1
sasa(dp9978
g2
S'Due to the pleiotropic effects of related phenotypes, we tested six of these obesity-related genetic variants for their association with physical activity: fat mass and obesity-associated (FTO)(rs9939609)T&gt;A, potassium channel tetramerization domain containing (KCTD15) (rs11084753)G&gt;A, melanocortin receptor4 (MC4R)(rs17782313)T&gt;C, neuronal growth regulator 1 (NEGR1)(rs2815752)A&gt;G, SH2B adapter protein 1 (SH2B1)(rs7498665)A&gt;G, and transmembrane protein18 (TMEM18)(rs6548238)C&gt;T. European-American women (n = 263) and men (n = 229) (23.5 +/- 0.3 years, 24.6 +/- 0.2 kg/m2) were genotyped and completed the Paffenbarger physical activity Questionnaire.\n'
p9979
sg4
(lp9980
(dp9981
g7
I317
sg8
VP32245
p9982
sg10
I4
sg11
VMC4R
p9983
sg13
I1
sa(dp9984
g7
I396
sg8
g59
sg10
I22
sg11
VSH2B adapter protein 1
p9985
sg13
I4
sa(dp9986
g7
I293
sg8
g59
sg10
I22
sg11
Vmelanocortin receptor4
p9987
sg13
I2
sa(dp9988
g7
I371
sg8
g59
sg10
I5
sg11
VNEGR1
p9989
sg13
I1
sa(dp9990
g7
I342
sg8
g59
sg10
I27
sg11
Vneuronal growth regulator 1
p9991
sg13
I4
sa(dp9992
g7
I420
sg8
g59
sg10
I5
sg11
VSH2B1
p9993
sg13
I1
sasg17
(lp9994
(dp9995
g7
I77
sg20
VC0028754
p9996
sg10
I7
sg11
Vobesity
p9997
sg13
I1
sa(dp9998
g7
I77
sg20
VC0028754
p9999
sg10
I7
sg11
Vobesity
p10000
sg13
I1
sasa(dp10001
g2
S'Out of 107 CpG sites, 38 are located in gene promoters, including genes strongly implicated in obesity (MIR148A, BDNF, PTPMT1, NR1H3, MGAT1, SCGB3A1, HOXC12, PMAIP1, PSIP1, RPS10-NUDT3, RPS10, SKOR1, MAP2K5, SIX5, AGRN, IMMP1L, ELP4, ITIH4, SEMA3G, POMC, ADCY3, SSPN, LGR4, TUFM, MIR4721, SULT1A1, SULT1A2, APOBR, CLN3, SPNS1, SH2B1, ATXN2L, and IL27).\n'
p10002
sg4
(lp10003
(dp10004
g7
I314
sg8
g59
sg10
I4
sg11
VCLN3
p10005
sg13
I1
sa(dp10006
g7
I220
sg8
g59
sg10
I6
sg11
VIMMP1L
p10007
sg13
I1
sa(dp10008
g7
I158
sg8
g59
sg10
I6
sg11
VPMAIP1
p10009
sg13
I1
sa(dp10010
g7
I127
sg8
g59
sg10
I5
sg11
VNR1H3
p10011
sg13
I1
sa(dp10012
g7
I298
sg8
VP50226
p10013
sg10
I7
sg11
VSULT1A2
p10014
sg13
I1
sa(dp10015
g7
I134
sg8
VP26572
p10016
sg10
I5
sg11
VMGAT1
p10017
sg13
I1
sa(dp10018
g7
I327
sg8
g59
sg10
I5
sg11
VSH2B1
p10019
sg13
I1
sa(dp10020
g7
I173
sg8
VP46783
p10021
sg10
I5
sg11
VRPS10
p10022
sg13
I1
sa(dp10023
g7
I166
sg8
g59
sg10
I5
sg11
VPSIP1
p10024
sg13
I1
sa(dp10025
g7
I200
sg8
g59
sg10
I6
sg11
VMAP2K5
p10026
sg13
I1
sa(dp10027
g7
I150
sg8
VP31275
p10028
sg10
I6
sg11
VHOXC12
p10029
sg13
I1
sa(dp10030
g7
I214
sg8
g59
sg10
I4
sg11
VAGRN
p10031
sg13
I1
sa(dp10032
g7
I249
sg8
VP01189
p10033
sg10
I4
sg11
VPOMC
p10034
sg13
I1
sa(dp10035
g7
I179
sg8
g59
sg10
I5
sg11
VNUDT3
p10036
sg13
I1
sa(dp10037
g7
I262
sg8
g59
sg10
I4
sg11
VSSPN
p10038
sg13
I1
sa(dp10039
g7
I141
sg8
g59
sg10
I7
sg11
VSCGB3A1
p10040
sg13
I1
sa(dp10041
g7
I274
sg8
VP49411
p10042
sg10
I4
sg11
VTUFM
p10043
sg13
I1
sa(dp10044
g7
I228
sg8
g59
sg10
I4
sg11
VELP4
p10045
sg13
I1
sa(dp10046
g7
I268
sg8
g59
sg10
I4
sg11
VLGR4
p10047
sg13
I1
sa(dp10048
g7
I234
sg8
g59
sg10
I5
sg11
VITIH4
p10049
sg13
I1
sa(dp10050
g7
I208
sg8
g59
sg10
I4
sg11
VSIX5
p10051
sg13
I1
sa(dp10052
g7
I173
sg8
VP46783
p10053
sg10
I5
sg11
VRPS10
p10054
sg13
I1
sa(dp10055
g7
I346
sg8
g59
sg10
I4
sg11
VIL27
p10056
sg13
I1
sa(dp10057
g7
I241
sg8
g59
sg10
I6
sg11
VSEMA3G
p10058
sg13
I1
sa(dp10059
g7
I119
sg8
g59
sg10
I6
sg11
VPTPMT1
p10060
sg13
I1
sa(dp10061
g7
I289
sg8
VP50225
p10062
sg10
I7
sg11
VSULT1A1
p10063
sg13
I1
sa(dp10064
g7
I255
sg8
VP40145
p10065
sg10
I5
sg11
VADCY3
p10066
sg13
I1
sasg17
(lp10067
(dp10068
g7
I314
sg20
VC2931674
p10069
sg10
I4
sg11
VCLN3
p10070
sg13
I1
sa(dp10071
g7
I95
sg20
VC0028754
p10072
sg10
I7
sg11
Vobesity
p10073
sg13
I1
sasa(dp10074
g2
S'The phylogeny based on partial cytochrome b (cyt b) sequences suggests that this parasite is most closely related to Plasmodium tejerai (cyt b lineage pSPMAG01), a common malaria parasite of American birds.\n'
p10075
sg4
(lp10076
(dp10077
g7
I31
sg8
g59
sg10
I30
sg11
Vcytochrome b (cyt b) sequences
p10078
sg13
I5
sasg17
(lp10079
(dp10080
g7
I171
sg20
VC0024530
p10081
sg10
I7
sg11
Vmalaria
p10082
sg13
I1
sasa(dp10083
g2
S'Based on HRM analysis of vertebrate cytochrome b, 16S rRNA and COI PCR products, humans (72.36%) were the prominent blood-meal hosts of malaria vectors, but 20.91% of blood-meals were from non-human vertebrate hosts.\n'
p10084
sg4
(lp10085
(dp10086
g7
I63
sg8
VP00395
p10087
sg10
I16
sg11
VCOI PCR products
p10088
sg13
I3
sasg17
(lp10089
(dp10090
g7
I136
sg20
VC0024530
p10091
sg10
I7
sg11
Vmalaria
p10092
sg13
I1
sa(dp10093
g7
I63
sg20
VC0009363
p10094
sg10
I3
sg11
VCOI
p10095
sg13
I1
sasa(dp10096
g2
S'RelB(lo) DCs, generated in the presence of an nuclear factor-KB inhibitor, induce T-regulatory (Treg) cells and suppress inflammation in a model of rheumatoid arthritis.\n'
p10097
sg4
(lp10098
(dp10099
g7
I0
sg8
g59
sg10
I12
sg11
VRelB(lo) DCs
p10100
sg13
I2
sa(dp10101
g7
I46
sg8
VP01160
p10102
sg10
I17
sg11
Vnuclear factor-KB
p10103
sg13
I2
sasg17
(lp10104
(dp10105
g7
I121
sg20
VC0021368
p10106
sg10
I12
sg11
Vinflammation
p10107
sg13
I1
sa(dp10108
g7
I148
sg20
VC0003873
p10109
sg10
I20
sg11
Vrheumatoid arthritis
p10110
sg13
I2
sa(dp10111
g7
I9
sg20
VC0268238
p10112
sg10
I3
sg11
VDCs
p10113
sg13
I1
sasa(dp10114
g2
S'In T1DM patients, late LPS-mediated nuclear DNA binding by RelA, p50, c-Rel, and RelB was impaired as compared with type 2 DM, rheumatoid arthritis, and healthy subjects, associated with impaired DC CD40 and MHC class I induction but normal cytokine production.\n'
p10115
sg4
(lp10116
(dp10117
g7
I59
sg8
g59
sg10
I4
sg11
VRelA
p10118
sg13
I1
sa(dp10119
g7
I65
sg8
VP19838
p10120
sg10
I3
sg11
Vp50
p10121
sg13
I1
sa(dp10122
g7
I199
sg8
VP25942
p10123
sg10
I4
sg11
VCD40
p10124
sg13
I1
sa(dp10125
g7
I208
sg8
VP30486
p10126
sg10
I11
sg11
VMHC class I
p10127
sg13
I3
sa(dp10128
g7
I70
sg8
g59
sg10
I5
sg11
Vc-Rel
p10129
sg13
I1
sa(dp10130
g7
I81
sg8
g59
sg10
I4
sg11
VRelB
p10131
sg13
I1
sasg17
(lp10132
(dp10133
g7
I90
sg20
VC0684336
p10134
sg10
I8
sg11
Vimpaired
p10135
sg13
I1
sa(dp10136
g7
I127
sg20
VC0003873
p10137
sg10
I20
sg11
Vrheumatoid arthritis
p10138
sg13
I2
sa(dp10139
g7
I23
sg20
VC0175697
p10140
sg10
I3
sg11
VLPS
p10141
sg13
I1
sa(dp10142
g7
I90
sg20
VC0684336
p10143
sg10
I8
sg11
Vimpaired
p10144
sg13
I1
sasa(dp10145
g2
S'Thereafter, we found that KLF8 binds to the upstream sequence of AC132217.4, activating its expression at the transcriptional level, which accelerated OSCC metastasis via the AC132217.4-IGF2 axis both in vitro and in vivo.\n'
p10146
sg4
(lp10147
(dp10148
g7
I26
sg8
g59
sg10
I4
sg11
VKLF8
p10149
sg13
I1
sa(dp10150
g7
I186
sg8
VP01344
p10151
sg10
I4
sg11
VIGF2
p10152
sg13
I1
sasg17
(lp10153
(dp10154
g7
I156
sg20
VC0027627
p10155
sg10
I10
sg11
Vmetastasis
p10156
sg13
I1
sasa(dp10157
g2
S'We also revealed that the expression level of AC132217.4 was increased in OSCC tissues, and this elevation correlated with KLF8 and IGF2 expression.\n'
p10158
sg4
(lp10159
(dp10160
g7
I132
sg8
VP01344
p10161
sg10
I4
sg11
VIGF2
p10162
sg13
I1
sa(dp10163
g7
I123
sg8
g59
sg10
I4
sg11
VKLF8
p10164
sg13
I1
sasg17
(lp10165
sa(dp10166
g2
S'Thus, our data demonstrate that the KLF8-AC132217.4-IGF2 signalling pathway plays a critical role in OSCC metastasis.\n'
p10167
sg4
(lp10168
(dp10169
g7
I52
sg8
VP01344
p10170
sg10
I4
sg11
VIGF2
p10171
sg13
I1
sa(dp10172
g7
I36
sg8
g59
sg10
I15
sg11
VKLF8-AC132217.4
p10173
sg13
I1
sasg17
(lp10174
(dp10175
g7
I106
sg20
VC0027627
p10176
sg10
I10
sg11
Vmetastasis
p10177
sg13
I1
sasa(dp10178
g2
S'Kruppel-like factor 8 (KLF8) is highly expressed in hepatocellular carcinoma (HCC) and contributes to tumor initiation and progression by promoting HCC cell proliferation and invasion.\n'
p10179
sg4
(lp10180
(dp10181
g7
I23
sg8
g59
sg10
I4
sg11
VKLF8
p10182
sg13
I1
sa(dp10183
g7
I0
sg8
g59
sg10
I21
sg11
VKruppel-like factor 8
p10184
sg13
I3
sasg17
(lp10185
(dp10186
g7
I157
sg20
VC0334094
p10187
sg10
I13
sg11
Vproliferation
p10188
sg13
I1
sa(dp10189
g7
I78
sg20
VC2239176
p10190
sg10
I3
sg11
VHCC
p10191
sg13
I1
sa(dp10192
g7
I175
sg20
VC2699153
p10193
sg10
I8
sg11
Vinvasion
p10194
sg13
I1
sa(dp10195
g7
I78
sg20
VC2239176
p10196
sg10
I3
sg11
VHCC
p10197
sg13
I1
sa(dp10198
g7
I102
sg20
VC0598935
p10199
sg10
I16
sg11
Vtumor initiation
p10200
sg13
I2
sa(dp10201
g7
I52
sg20
VC2239176
p10202
sg10
I24
sg11
Vhepatocellular carcinoma
p10203
sg13
I2
sasa(dp10204
g2
S'Taken together, this work identified KLF8-induced FHL2 activation as a novel and critical signaling mechanism underlying human breast/colorectal cancer invasion and metastasis.\n'
p10205
sg4
(lp10206
(dp10207
g7
I50
sg8
VP14222
p10208
sg10
I4
sg11
VFHL2
p10209
sg13
I1
sa(dp10210
g7
I37
sg8
g59
sg10
I4
sg11
VKLF8
p10211
sg13
I1
sasg17
(lp10212
(dp10213
g7
I50
sg20
VC1863727
p10214
sg10
I4
sg11
VFHL2
p10215
sg13
I1
sa(dp10216
g7
I134
sg20
VC1527249
p10217
sg10
I17
sg11
Vcolorectal cancer
p10218
sg13
I2
sa(dp10219
g7
I152
sg20
VC2699153
p10220
sg10
I8
sg11
Vinvasion
p10221
sg13
I1
sa(dp10222
g7
I165
sg20
VC0027627
p10223
sg10
I10
sg11
Vmetastasis
p10224
sg13
I1
sasa(dp10225
g2
S'These results demonstrated for the first time that KLF8 modulates the formation and invasive ability of nasopharyngeal carcinoma.\n'
p10226
sg4
(lp10227
(dp10228
g7
I51
sg8
g59
sg10
I4
sg11
VKLF8
p10229
sg13
I1
sasg17
(lp10230
(dp10231
g7
I104
sg20
VC2931822
p10232
sg10
I24
sg11
Vnasopharyngeal carcinoma
p10233
sg13
I2
sasa(dp10234
g2
S'However, the role of KLF8 in colorectal cancer remains unknown.\n'
p10235
sg4
(lp10236
(dp10237
g7
I21
sg8
g59
sg10
I4
sg11
VKLF8
p10238
sg13
I1
sasg17
(lp10239
(dp10240
g7
I29
sg20
VC1527249
p10241
sg10
I17
sg11
Vcolorectal cancer
p10242
sg13
I2
sasa(dp10243
g2
S'The aims of the present study were to examine KLF8 expression in colorectal cancers, to determine the role of KLF8 in cell differentiation and to investigate the antiproliferative effect of KLF8 silencing.\n'
p10244
sg4
(lp10245
(dp10246
g7
I46
sg8
g59
sg10
I4
sg11
VKLF8
p10247
sg13
I1
sa(dp10248
g7
I46
sg8
g59
sg10
I4
sg11
VKLF8
p10249
sg13
I1
sa(dp10250
g7
I46
sg8
g59
sg10
I4
sg11
VKLF8
p10251
sg13
I1
sasg17
(lp10252
(dp10253
g7
I65
sg20
VC1527249
p10254
sg10
I18
sg11
Vcolorectal cancers
p10255
sg13
I2
sasa(dp10256
g2
S'In addition, the biological impact of KLF8 knockdown on colorectal cancer cells was investigated in vitro and in vivo.\n'
p10257
sg4
(lp10258
(dp10259
g7
I38
sg8
g59
sg10
I4
sg11
VKLF8
p10260
sg13
I1
sasg17
(lp10261
(dp10262
g7
I56
sg20
VC1527249
p10263
sg10
I17
sg11
Vcolorectal cancer
p10264
sg13
I2
sasa(dp10265
g2
S'In this study, the clinicopathologic correlation of KLF8 expression with gastric adenocarcinoma in Taiwan was investigated.\n'
p10266
sg4
(lp10267
(dp10268
g7
I52
sg8
g59
sg10
I4
sg11
VKLF8
p10269
sg13
I1
sasg17
(lp10270
(dp10271
g7
I73
sg20
VC0278701
p10272
sg10
I22
sg11
Vgastric adenocarcinoma
p10273
sg13
I2
sasa(dp10274
g2
S'The nuclear expression of KLF8 was significantly higher in the diffused type of gastric adenocarcinoma compared with the intestinal type (P = .036).\n'
p10275
sg4
(lp10276
(dp10277
g7
I26
sg8
g59
sg10
I4
sg11
VKLF8
p10278
sg13
I1
sasg17
(lp10279
(dp10280
g7
I80
sg20
VC0278701
p10281
sg10
I22
sg11
Vgastric adenocarcinoma
p10282
sg13
I2
sasa(dp10283
g2
S'Positive nuclear KLF8 might be correlated with lower survival in gastric adenocarcinoma patients and might be an oncogene property in gastric adenocarcinoma carcinogenesis.\n'
p10284
sg4
(lp10285
(dp10286
g7
I9
sg8
g59
sg10
I12
sg11
Vnuclear KLF8
p10287
sg13
I2
sasg17
(lp10288
(dp10289
g7
I65
sg20
VC0278701
p10290
sg10
I22
sg11
Vgastric adenocarcinoma
p10291
sg13
I2
sa(dp10292
g7
I157
sg20
VC0596263
p10293
sg10
I14
sg11
Vcarcinogenesis
p10294
sg13
I1
sa(dp10295
g7
I65
sg20
VC0278701
p10296
sg10
I22
sg11
Vgastric adenocarcinoma
p10297
sg13
I2
sasa(dp10298
g2
S'Whether a focal adhesion kinase (FAK)-Kruppel-like factor 8 (KLF8)-matrix metalloproteinase (MMP)-9/E-cadherin signaling axis exists in hepatocellular carcinoma (HCC) remains unknown.\n'
p10299
sg4
(lp10300
(dp10301
g7
I33
sg8
g59
sg10
I3
sg11
VFAK
p10302
sg13
I1
sa(dp10303
g7
I38
sg8
g59
sg10
I61
sg11
VKruppel-like factor 8 (KLF8)-matrix metalloproteinase (MMP)-9
p10304
sg13
I6
sa(dp10305
g7
I10
sg8
g59
sg10
I21
sg11
Vfocal adhesion kinase
p10306
sg13
I3
sa(dp10307
g7
I100
sg8
VP12830
p10308
sg10
I10
sg11
VE-cadherin
p10309
sg13
I1
sasg17
(lp10310
(dp10311
g7
I16
sg20
VC0001511
p10312
sg10
I8
sg11
Vadhesion
p10313
sg13
I1
sa(dp10314
g7
I136
sg20
VC2239176
p10315
sg10
I24
sg11
Vhepatocellular carcinoma
p10316
sg13
I2
sa(dp10317
g7
I162
sg20
VC2239176
p10318
sg10
I3
sg11
VHCC
p10319
sg13
I1
sasa(dp10320
g2
S'Here we report the mechanisms by which KLF8 crosstalks with Wnt/Beta-catenin signaling pathway and regulates hepatocellular carcinoma (HCC) cells proliferation.\n'
p10321
sg4
(lp10322
(dp10323
g7
I39
sg8
g59
sg10
I15
sg11
VKLF8 crosstalks
p10324
sg13
I2
sasg17
(lp10325
(dp10326
g7
I135
sg20
VC2239176
p10327
sg10
I3
sg11
VHCC
p10328
sg13
I1
sa(dp10329
g7
I146
sg20
VC0334094
p10330
sg10
I13
sg11
Vproliferation
p10331
sg13
I1
sa(dp10332
g7
I109
sg20
VC2239176
p10333
sg10
I24
sg11
Vhepatocellular carcinoma
p10334
sg13
I2
sasa(dp10335
g2
S'As impaired serotonergic and dopaminergic neurotransmission is implicated in the pathogenesis of depression and schizophrenia this study sought to investigate the putative association between several functional gene polymorphisms (SERT 5-HTTLPR, MAO-A VNTR, COMT Val158Met and DAT VNTR) and schizophrenia.\n'
p10336
sg4
(lp10337
(dp10338
g7
I246
sg8
VP21397
p10339
sg10
I10
sg11
VMAO-A VNTR
p10340
sg13
I2
sa(dp10341
g7
I277
sg8
g59
sg10
I8
sg11
VDAT VNTR
p10342
sg13
I2
sa(dp10343
g7
I258
sg8
VP21964
p10344
sg10
I14
sg11
VCOMT Val158Met
p10345
sg13
I2
sasg17
(lp10346
(dp10347
g7
I81
sg20
VC0699748
p10348
sg10
I12
sg11
Vpathogenesis
p10349
sg13
I1
sa(dp10350
g7
I3
sg20
VC0684336
p10351
sg10
I8
sg11
Vimpaired
p10352
sg13
I1
sa(dp10353
g7
I112
sg20
VC0036341
p10354
sg10
I13
sg11
Vschizophrenia
p10355
sg13
I1
sa(dp10356
g7
I112
sg20
VC0036341
p10357
sg10
I13
sg11
Vschizophrenia
p10358
sg13
I1
sa(dp10359
g7
I97
sg20
VC0011581
p10360
sg10
I10
sg11
Vdepression
p10361
sg13
I1
sasa(dp10362
g2
S'The purpose of the present study was to investigate the patterns of interregional correlations of serotonin transporter (SERT) availability with glucose metabolism using 7-Tesla magnetic resonance imaging (MRI) and high-resolution positron emission tomography (PET) with 11C-3-amino-4-(2-dimethylaminomethylphenylthio)benzonitrile ([11C]DASB) and [18F]fluorodeoxyglucose ([18F]FDG) in antipsychotic-free patients with schizophrenia in order to shed new light on the disrupted functional connectivity in schizophrenia.\n'
p10363
sg4
(lp10364
(dp10365
g7
I121
sg8
VP31645
p10366
sg10
I4
sg11
VSERT
p10367
sg13
I1
sa(dp10368
g7
I98
sg8
VP31645
p10369
sg10
I21
sg11
Vserotonin transporter
p10370
sg13
I2
sasg17
(lp10371
(dp10372
g7
I418
sg20
VC0036341
p10373
sg10
I13
sg11
Vschizophrenia
p10374
sg13
I1
sa(dp10375
g7
I418
sg20
VC0036341
p10376
sg10
I13
sg11
Vschizophrenia
p10377
sg13
I1
sasa(dp10378
g2
S'In SERT availability, the region of interest (ROI)-based analyses showed no significant group differences in any region, except for the anterior hippocampus where the SERT availability was lower in patients with schizophrenia than in controls.\n'
p10379
sg4
(lp10380
sg17
(lp10381
(dp10382
g7
I212
sg20
VC0036341
p10383
sg10
I13
sg11
Vschizophrenia
p10384
sg13
I1
sasa(dp10385
g2
S"Hirschsprung's disease was found in 47 (7.2%) patients with characteristic features of absence of ganglion cells, increased AChE activity in the lamina propria and muscularis mucosae, thick nerve fibers in the submucosa, and a lack of NADPH-d-positive fibers in muscularis mucosae.\n"
p10386
sg4
(lp10387
(dp10388
g7
I235
sg8
VP30043
p10389
sg10
I7
sg11
VNADPH-d
p10390
sg13
I1
sasg17
(lp10391
(dp10392
g7
I124
sg20
VC0234238
p10393
sg10
I4
sg11
VAChE
p10394
sg13
I1
sa(dp10395
g7
I98
sg20
VC1258666
p10396
sg10
I8
sg11
Vganglion
p10397
sg13
I1
sa(dp10398
g7
I0
sg20
VC0019569
p10399
sg10
I22
sg11
VHirschsprung's disease
p10400
sg13
I2
sasa(dp10401
g2
S"The purpose of this study was to investigate the specificity and sensitivity of NADPH-diaphorase (NADPH-D) staining in suction rectal biopsies (SRB) to determine whether it can be used as a diagnostic test for Hirschsprung's disease (HD) and related disorders.\n"
p10402
sg4
(lp10403
(dp10404
g7
I80
sg8
VP29475
p10405
sg10
I16
sg11
VNADPH-diaphorase
p10406
sg13
I1
sa(dp10407
g7
I98
sg8
VP30043
p10408
sg10
I7
sg11
VNADPH-D
p10409
sg13
I1
sasg17
(lp10410
(dp10411
g7
I210
sg20
VC0019569
p10412
sg10
I22
sg11
VHirschsprung's disease
p10413
sg13
I2
sa(dp10414
g7
I234
sg20
VC0019569
p10415
sg10
I2
sg11
VHD
p10416
sg13
I1
sasa(dp10417
g2
S'Methylenetetrahydrofolate dehydrogenase (MTHFD1) deficiency has recently been reported to cause a folate-responsive syndrome displaying a phenotype that includes megaloblastic anemia and severe combined immunodeficiency.\n'
p10418
sg4
(lp10419
(dp10420
g7
I41
sg8
VP11586
p10421
sg10
I6
sg11
VMTHFD1
p10422
sg13
I1
sasg17
(lp10423
(dp10424
g7
I116
sg20
VC0039082
p10425
sg10
I8
sg11
Vsyndrome
p10426
sg13
I1
sa(dp10427
g7
I187
sg20
VC0085110
p10428
sg10
I32
sg11
Vsevere combined immunodeficiency
p10429
sg13
I3
sa(dp10430
g7
I162
sg20
VC0002888
p10431
sg10
I20
sg11
Vmegaloblastic anemia
p10432
sg13
I2
sasa(dp10433
g2
S'Exome sequencing demonstrated MTHFD1 deficiency as a novel cause of a combined immunodeficiency.\n'
p10434
sg4
(lp10435
(dp10436
g7
I30
sg8
VP11586
p10437
sg10
I6
sg11
VMTHFD1
p10438
sg13
I1
sasg17
(lp10439
(dp10440
g7
I70
sg20
VC0494261
p10441
sg10
I25
sg11
Vcombined immunodeficiency
p10442
sg13
I2
sasa(dp10443
g2
S'Whole exome sequencing of DNA from a patient with severe combined immunodeficiency (SCID), megaloblastic anemia and hemolytic uremic syndrome identified mutations in the MTHFD1 gene, which encodes a trifunctional enzyme involved in interconversion of folate coenzyme derivatives.\n'
p10444
sg4
(lp10445
(dp10446
g7
I170
sg8
VP11586
p10447
sg10
I11
sg11
VMTHFD1 gene
p10448
sg13
I2
sasg17
(lp10449
(dp10450
g7
I116
sg20
VC0019061
p10451
sg10
I25
sg11
Vhemolytic uremic syndrome
p10452
sg13
I3
sa(dp10453
g7
I91
sg20
VC0002888
p10454
sg10
I20
sg11
Vmegaloblastic anemia
p10455
sg13
I2
sa(dp10456
g7
I84
sg20
VC0085110
p10457
sg10
I4
sg11
VSCID
p10458
sg13
I1
sa(dp10459
g7
I50
sg20
VC0085110
p10460
sg10
I32
sg11
Vsevere combined immunodeficiency
p10461
sg13
I3
sasa(dp10462
g2
S'Human mutations in MTHFD1 have recently been identified in patients with severe combined immunodeficiency (SCID).\n'
p10463
sg4
(lp10464
(dp10465
g7
I19
sg8
VP11586
p10466
sg10
I6
sg11
VMTHFD1
p10467
sg13
I1
sasg17
(lp10468
(dp10469
g7
I73
sg20
VC0085110
p10470
sg10
I32
sg11
Vsevere combined immunodeficiency
p10471
sg13
I3
sa(dp10472
g7
I107
sg20
VC0085110
p10473
sg10
I4
sg11
VSCID
p10474
sg13
I1
sasa(dp10475
g2
S'To date, only one patient with MTHFD1 deficiency, presenting with hyperhomocysteinemia, megaloblastic anaemia, hemolytic uremic syndrome (HUS) and severe combined immunodeficiency, has been identified (Watkins et al J Med Genet 48:590-2, 2011).\n'
p10476
sg4
(lp10477
(dp10478
g7
I31
sg8
VP11586
p10479
sg10
I6
sg11
VMTHFD1
p10480
sg13
I1
sasg17
(lp10481
(dp10482
g7
I147
sg20
VC0085110
p10483
sg10
I32
sg11
Vsevere combined immunodeficiency
p10484
sg13
I3
sa(dp10485
g7
I138
sg20
VC0019061
p10486
sg10
I3
sg11
VHUS
p10487
sg13
I1
sa(dp10488
g7
I88
sg20
VC0002888
p10489
sg10
I21
sg11
Vmegaloblastic anaemia
p10490
sg13
I2
sa(dp10491
g7
I111
sg20
VC0019061
p10492
sg10
I25
sg11
Vhemolytic uremic syndrome
p10493
sg13
I3
sa(dp10494
g7
I66
sg20
VC0598608
p10495
sg10
I20
sg11
Vhyperhomocysteinemia
p10496
sg13
I1
sasa(dp10497
g2
S'In the present study, we investigated whether PTER affects TRAIL-induced apoptosis and its mechanism in TRAIL-resistant triple negative breast cancer (TNBC) cells.\n'
p10498
sg4
(lp10499
(dp10500
g7
I46
sg8
g59
sg10
I4
sg11
VPTER
p10501
sg13
I1
sa(dp10502
g7
I59
sg8
VP50591
p10503
sg10
I5
sg11
VTRAIL
p10504
sg13
I1
sa(dp10505
g7
I59
sg8
VP50591
p10506
sg10
I5
sg11
VTRAIL
p10507
sg13
I1
sasg17
(lp10508
(dp10509
g7
I136
sg20
VC0678222
p10510
sg10
I13
sg11
Vbreast cancer
p10511
sg13
I2
sasa(dp10512
g2
S'Here we investigated the potential of PTER-isothiocyanate (ITC) conjugate, a novel class of hybrid compound (PTER-ITC) synthesized by appending an ITC moiety to the PTER backbone, to induce apoptotic cell death in hormone-dependent (MCF-7) and -independent (MDA-MB-231) breast cancer cell lines and to elucidate PPARGamma involvement in PTER-ITC action.\n'
p10513
sg4
(lp10514
(dp10515
g7
I38
sg8
g59
sg10
I4
sg11
VPTER
p10516
sg13
I1
sa(dp10517
g7
I38
sg8
g59
sg10
I4
sg11
VPTER
p10518
sg13
I1
sa(dp10519
g7
I109
sg8
g59
sg10
I8
sg11
VPTER-ITC
p10520
sg13
I1
sa(dp10521
g7
I38
sg8
g59
sg10
I4
sg11
VPTER
p10522
sg13
I1
sasg17
(lp10523
(dp10524
g7
I270
sg20
VC0678222
p10525
sg10
I13
sg11
Vbreast cancer
p10526
sg13
I2
sasa(dp10527
g2
S'Our results showed that when pre-treated with PPARGamma antagonists or PPARGamma siRNA, both breast cancer cell lines suppressed PTER-ITC-induced apoptosis, as determined by annexin V/propidium iodide staining and cleaved caspase-9 expression.\n'
p10528
sg4
(lp10529
(dp10530
g7
I129
sg8
g59
sg10
I4
sg11
VPTER
p10531
sg13
I1
sa(dp10532
g7
I222
sg8
VP55211
p10533
sg10
I9
sg11
Vcaspase-9
p10534
sg13
I1
sasg17
(lp10535
(dp10536
g7
I93
sg20
VC0678222
p10537
sg10
I13
sg11
Vbreast cancer
p10538
sg13
I2
sasa(dp10539
g2
S'Furthermore, PTER-ITC significantly increased PPARGamma mRNA and protein levels in a dose-dependent manner and modulated expression of PPARGamma-related genes in both breast cancer cell lines.\n'
p10540
sg4
(lp10541
(dp10542
g7
I135
sg8
VP01893
p10543
sg10
I23
sg11
VPPARGamma-related genes
p10544
sg13
I2
sa(dp10545
g7
I13
sg8
g59
sg10
I8
sg11
VPTER-ITC
p10546
sg13
I1
sasg17
(lp10547
(dp10548
g7
I167
sg20
VC0678222
p10549
sg10
I13
sg11
Vbreast cancer
p10550
sg13
I2
sasa(dp10551
g2
S'Collectively, our observations suggest potential applications for PTER-ITC in breast cancer prevention and treatment through modulation of the PPARGamma activation pathway.\n'
p10552
sg4
(lp10553
(dp10554
g7
I66
sg8
g59
sg10
I4
sg11
VPTER
p10555
sg13
I1
sasg17
(lp10556
(dp10557
g7
I78
sg20
VC0678222
p10558
sg10
I13
sg11
Vbreast cancer
p10559
sg13
I2
sasa(dp10560
g2
S'In present study, it was found that MT1M was downregulated in more than 77.1% (91/118) of hepatocellular carcinoma (HCC) tissues compared with adjacent non-tumor tissues.\n'
p10561
sg4
(lp10562
(dp10563
g7
I36
sg8
VP13640
p10564
sg10
I4
sg11
VMT1M
p10565
sg13
I1
sasg17
(lp10566
(dp10567
g7
I90
sg20
VC2239176
p10568
sg10
I24
sg11
Vhepatocellular carcinoma
p10569
sg13
I2
sa(dp10570
g7
I156
sg20
VC0027651
p10571
sg10
I5
sg11
Vtumor
p10572
sg13
I1
sa(dp10573
g7
I116
sg20
VC2239176
p10574
sg10
I3
sg11
VHCC
p10575
sg13
I1
sasa(dp10576
g2
S'In the fully-adjusted model, higher IGFBP3 was associated with increased incidence of colorectal cancer (SHR = 1.20, 95% CI 1.01-1.43; P = .041 for every 1 standard deviation increase in IGFBP3) but not other cancers.\n'
p10577
sg4
(lp10578
(dp10579
g7
I36
sg8
VP17936
p10580
sg10
I6
sg11
VIGFBP3
p10581
sg13
I1
sa(dp10582
g7
I36
sg8
VP17936
p10583
sg10
I6
sg11
VIGFBP3
p10584
sg13
I1
sasg17
(lp10585
(dp10586
g7
I86
sg20
VC1527249
p10587
sg10
I17
sg11
Vcolorectal cancer
p10588
sg13
I2
sa(dp10589
g7
I209
sg20
VC0006826
p10590
sg10
I7
sg11
Vcancers
p10591
sg13
I1
sasa(dp10592
g2
S'Higher IGFBP3 predicted increased incidence of colorectal cancer in older men independent of conventional risk factors and total IGF1.\n'
p10593
sg4
(lp10594
(dp10595
g7
I7
sg8
VP17936
p10596
sg10
I6
sg11
VIGFBP3
p10597
sg13
I1
sa(dp10598
g7
I129
sg8
VP01343
p10599
sg10
I4
sg11
VIGF1
p10600
sg13
I1
sasg17
(lp10601
(dp10602
g7
I47
sg20
VC1527249
p10603
sg10
I17
sg11
Vcolorectal cancer
p10604
sg13
I2
sasa(dp10605
g2
S'Circulating insulin-like growth factor 1 (IGF-1) may be directly associated with colorectal cancer risk, and IGF binding protein 3 (IGFBP-3) is one of the most abundantly expressed binding proteins in various cancers.\n'
p10606
sg4
(lp10607
(dp10608
g7
I12
sg8
VP01308
p10609
sg10
I28
sg11
Vinsulin-like growth factor 1
p10610
sg13
I4
sa(dp10611
g7
I42
sg8
VP01343
p10612
sg10
I5
sg11
VIGF-1
p10613
sg13
I1
sa(dp10614
g7
I132
sg8
VP17936
p10615
sg10
I7
sg11
VIGFBP-3
p10616
sg13
I1
sa(dp10617
g7
I109
sg8
VP17936
p10618
sg10
I21
sg11
VIGF binding protein 3
p10619
sg13
I4
sasg17
(lp10620
(dp10621
g7
I81
sg20
VC1527249
p10622
sg10
I17
sg11
Vcolorectal cancer
p10623
sg13
I2
sa(dp10624
g7
I209
sg20
VC0006826
p10625
sg10
I7
sg11
Vcancers
p10626
sg13
I1
sasa(dp10627
g2
S'Lyme Borrelia utilize a combination of Ixodes-produced inhibitors and native proteins [i.e., factor H-binding proteins (FHBPs)/complement regulator-acquiring surface proteins, p43, BBK32, BGA66, BGA71, CD59-like protein] to inhibit complement, while some relapsing fever spirochetes use C4b-binding protein and likely Ornithodoros-produced inhibitors.\n'
p10628
sg4
(lp10629
(dp10630
g7
I176
sg8
VP49411
p10631
sg10
I3
sg11
Vp43
p10632
sg13
I1
sa(dp10633
g7
I202
sg8
VP13987
p10634
sg10
I17
sg11
VCD59-like protein
p10635
sg13
I2
sa(dp10636
g7
I93
sg8
VP63244
p10637
sg10
I25
sg11
Vfactor H-binding proteins
p10638
sg13
I3
sa(dp10639
g7
I287
sg8
VP04003
p10640
sg10
I19
sg11
VC4b-binding protein
p10641
sg13
I2
sa(dp10642
g7
I120
sg8
VP63244
p10643
sg10
I5
sg11
VFHBPs
p10644
sg13
I1
sasg17
(lp10645
(dp10646
g7
I255
sg20
VC0035021
p10647
sg10
I15
sg11
Vrelapsing fever
p10648
sg13
I2
sa(dp10649
g7
I5
sg20
VC0024198
p10650
sg10
I8
sg11
VBorrelia
p10651
sg13
I1
sasa(dp10652
g2
S'A highly homologous receptor for C4bp was also found in the African tick-borne relapsing fever spirochete B. duttonii.\n'
p10653
sg4
(lp10654
(dp10655
g7
I33
sg8
VP04003
p10656
sg10
I4
sg11
VC4bp
p10657
sg13
I1
sasg17
(lp10658
(dp10659
g7
I68
sg20
VC0035022
p10660
sg10
I26
sg11
Vtick-borne relapsing fever
p10661
sg13
I3
sasa(dp10662
g2
S'More importantly, the relapsing fever spirochetes specifically bind host C4b-binding protein, a major regulator of the antibody-mediated classical complement pathway.\n'
p10663
sg4
(lp10664
(dp10665
g7
I73
sg8
VP04003
p10666
sg10
I19
sg11
VC4b-binding protein
p10667
sg13
I2
sasg17
(lp10668
(dp10669
g7
I22
sg20
VC0035021
p10670
sg10
I15
sg11
Vrelapsing fever
p10671
sg13
I2
sasa(dp10672
g2
S'The affected child was found to have inherited 3 deleterious mutations in two nephronophthisis genes, NPHP3 and NPHP4.\n'
p10673
sg4
(lp10674
(dp10675
g7
I112
sg8
g59
sg10
I5
sg11
VNPHP4
p10676
sg13
I1
sasg17
(lp10677
(dp10678
g7
I78
sg20
VC0687120
p10679
sg10
I16
sg11
Vnephronophthisis
p10680
sg13
I1
sa(dp10681
g7
I102
sg20
VC1858392
p10682
sg10
I5
sg11
VNPHP3
p10683
sg13
I1
sa(dp10684
g7
I112
sg20
VC1847013
p10685
sg10
I5
sg11
VNPHP4
p10686
sg13
I1
sasa(dp10687
g2
S'The present study was designed to explore mutations of NPHP2 and NPHP3 and clinical features in 18 Chinese infantile nephronophthisis (NPHP) patients.\n'
p10688
sg4
(lp10689
(dp10690
g7
I55
sg8
g59
sg10
I5
sg11
VNPHP2
p10691
sg13
I1
sasg17
(lp10692
(dp10693
g7
I65
sg20
VC1858392
p10694
sg10
I5
sg11
VNPHP3
p10695
sg13
I1
sa(dp10696
g7
I55
sg20
VC1865872
p10697
sg10
I5
sg11
VNPHP2
p10698
sg13
I1
sa(dp10699
g7
I107
sg20
VC1865872
p10700
sg10
I26
sg11
Vinfantile nephronophthisis
p10701
sg13
I2
sasa(dp10702
g2
S'Liver involvement was observed in all patients with NPHP3 mutations and congenital heart disease in two patients harbouring NPHP3 mutation of c.2369 T &gt; C (p.L790P).\n'
p10703
sg4
(lp10704
sg17
(lp10705
(dp10706
g7
I52
sg20
VC1858392
p10707
sg10
I5
sg11
VNPHP3
p10708
sg13
I1
sa(dp10709
g7
I72
sg20
VC0152021
p10710
sg10
I24
sg11
Vcongenital heart disease
p10711
sg13
I3
sa(dp10712
g7
I52
sg20
VC1858392
p10713
sg10
I5
sg11
VNPHP3
p10714
sg13
I1
sasa(dp10715
g2
S'Mutational analysis of the two who survived beyond post-delivery demonstrated compound heterozygous novel frameshift mutations in the nephronophthisis type 3 gene (NPHP3).\n'
p10716
sg4
(lp10717
sg17
(lp10718
(dp10719
g7
I106
sg20
VC0079380
p10720
sg10
I20
sg11
Vframeshift mutations
p10721
sg13
I2
sa(dp10722
g7
I134
sg20
VC1858392
p10723
sg10
I28
sg11
Vnephronophthisis type 3 gene
p10724
sg13
I4
sa(dp10725
g7
I164
sg20
VC1858392
p10726
sg10
I5
sg11
VNPHP3
p10727
sg13
I1
sasa(dp10728
g2
S'Progressive supranuclear palsy (PSP) with predominant cerebellar ataxia (PSP-C) is a rare phenotype of PSP.\n'
p10729
sg4
(lp10730
sg17
(lp10731
(dp10732
g7
I32
sg20
VC0038868
p10733
sg10
I3
sg11
VPSP
p10734
sg13
I1
sa(dp10735
g7
I32
sg20
VC0038868
p10736
sg10
I3
sg11
VPSP
p10737
sg13
I1
sa(dp10738
g7
I0
sg20
VC0038868
p10739
sg10
I30
sg11
VProgressive supranuclear palsy
p10740
sg13
I3
sa(dp10741
g7
I54
sg20
VC0007758
p10742
sg10
I17
sg11
Vcerebellar ataxia
p10743
sg13
I2
sa(dp10744
g7
I32
sg20
VC0038868
p10745
sg10
I3
sg11
VPSP
p10746
sg13
I1
sasa(dp10747
g2
S'Patients who develop progressive supranuclear palsy with predominant cerebellar ataxia (PSP-C) develop cerebellar ataxia as the initial and principal symptom, may be misdiagnosed as having multiple system atrophy with predominant cerebellar features (MSA-C).\n'
p10748
sg4
(lp10749
(dp10750
g7
I46
sg8
g59
sg10
I40
sg11
Vpalsy with predominant cerebellar ataxia
p10751
sg13
I5
sa(dp10752
g7
I88
sg8
g59
sg10
I5
sg11
VPSP-C
p10753
sg13
I1
sasg17
(lp10754
(dp10755
g7
I150
sg20
VC1457887
p10756
sg10
I7
sg11
Vsymptom
p10757
sg13
I1
sa(dp10758
g7
I21
sg20
VC0038868
p10759
sg10
I30
sg11
Vprogressive supranuclear palsy
p10760
sg13
I3
sa(dp10761
g7
I88
sg20
VC0038868
p10762
sg10
I3
sg11
VPSP
p10763
sg13
I1
sa(dp10764
g7
I189
sg20
VC0393571
p10765
sg10
I23
sg11
Vmultiple system atrophy
p10766
sg13
I3
sa(dp10767
g7
I251
sg20
VC0393571
p10768
sg10
I3
sg11
VMSA
p10769
sg13
I1
sa(dp10770
g7
I69
sg20
VC0007758
p10771
sg10
I17
sg11
Vcerebellar ataxia
p10772
sg13
I2
sa(dp10773
g7
I69
sg20
VC0007758
p10774
sg10
I17
sg11
Vcerebellar ataxia
p10775
sg13
I2
sasa(dp10776
g2
S'A 14 kDa protein detected in pre-treatment saliva from the OSCC patients was identified as a truncated cystatin SA-I, with deletion of three amino acids from the N-terminus.\n'
p10777
sg4
(lp10778
(dp10779
g7
I103
sg8
VP09228
p10780
sg10
I13
sg11
Vcystatin SA-I
p10781
sg13
I2
sasg17
(lp10782
sa(dp10783
g2
S'The authors propose that ProteinChip analysis may provide a reliable screening test for early diagnosis of OSCC and that truncated cystatin SA-I might be a useful tumor biomarker for OSCC.\n'
p10784
sg4
(lp10785
(dp10786
g7
I131
sg8
VP09228
p10787
sg10
I13
sg11
Vcystatin SA-I
p10788
sg13
I2
sasg17
(lp10789
(dp10790
g7
I163
sg20
VC0027651
p10791
sg10
I5
sg11
Vtumor
p10792
sg13
I1
sasa(dp10793
g2
S'We examined the TRAIL-mediated cytotoxicity rates of clonally-related primary and metastatic oral cancer (OC) cells and correlated them with the expression levels of TRAIL receptors, cathepsin B and cystatins A, B, C and M. Two pairs of primary (686Tu and 101A) and metastatic (686Ln and 101B) OC cell lines were treated with various concentrations (5 to 1000 ng/ml) of recombinant human TRAIL protein for 14 h, and cell viability and apoptotic rate were determined.\n'
p10794
sg4
(lp10795
(dp10796
g7
I183
sg8
VP07858
p10797
sg10
I11
sg11
Vcathepsin B
p10798
sg13
I2
sa(dp10799
g7
I166
sg8
VP50591
p10800
sg10
I15
sg11
VTRAIL receptors
p10801
sg13
I2
sa(dp10802
g7
I370
sg8
VP50591
p10803
sg10
I31
sg11
Vrecombinant human TRAIL protein
p10804
sg13
I4
sasg17
(lp10805
(dp10806
g7
I106
sg20
VC0153381
p10807
sg10
I2
sg11
VOC
p10808
sg13
I1
sa(dp10809
g7
I93
sg20
VC0153381
p10810
sg10
I11
sg11
Voral cancer
p10811
sg13
I2
sa(dp10812
g7
I106
sg20
VC0153381
p10813
sg10
I2
sg11
VOC
p10814
sg13
I1
sa(dp10815
g7
I31
sg20
VC0596402
p10816
sg10
I12
sg11
Vcytotoxicity
p10817
sg13
I1
sasa(dp10818
g2
S'We have now studied the expression of both cystatins A and B in benign prostatic hyperplasias (BPH), prostatic intraepithelial neoplasias (PIN) and carcinomas of the prostatic epithelium and compared it with the expression of high molecular weight (HMW) cytokeratin as well as the proliferation markers cyclin A and Ki-67.\n'
p10819
sg4
(lp10820
(dp10821
g7
I316
sg8
VP46013
p10822
sg10
I5
sg11
VKi-67
p10823
sg13
I1
sa(dp10824
g7
I303
sg8
VP20248
p10825
sg10
I8
sg11
Vcyclin A
p10826
sg13
I2
sa(dp10827
g7
I226
sg8
g59
sg10
I39
sg11
Vhigh molecular weight (HMW) cytokeratin
p10828
sg13
I5
sasg17
(lp10829
(dp10830
g7
I95
sg20
VC0005001
p10831
sg10
I3
sg11
VBPH
p10832
sg13
I1
sa(dp10833
g7
I148
sg20
VC0007097
p10834
sg10
I10
sg11
Vcarcinomas
p10835
sg13
I1
sa(dp10836
g7
I101
sg20
VC0282612
p10837
sg10
I36
sg11
Vprostatic intraepithelial neoplasias
p10838
sg13
I3
sa(dp10839
g7
I281
sg20
VC0334094
p10840
sg10
I13
sg11
Vproliferation
p10841
sg13
I1
sa(dp10842
g7
I64
sg20
VC0005001
p10843
sg10
I29
sg11
Vbenign prostatic hyperplasias
p10844
sg13
I3
sa(dp10845
g7
I139
sg20
VC0282612
p10846
sg10
I3
sg11
VPIN
p10847
sg13
I1
sasa(dp10848
g2
S'Binary logistic regression to generate a propensity score and receiver operating characteristic curves were developed for each of the noninvasive markers for predicting CKD, and the area under the receiver operating characteristic curve was greatest for FIB-4 score (0.750), followed by NFS (0.710), AAR (0.594), APRI (0.587), and BARD score (0.561).\n'
p10849
sg4
(lp10850
sg17
(lp10851
sa(dp10852
g2
S'A cut-off value of 1.100 for FIB-4 score gave a sensitivity of 68.85% and a specificity of 71.07% for predicting CKD.\n'
p10853
sg4
(lp10854
sg17
(lp10855
sa(dp10856
g2
S'In multiple logistic regression analysis, only FIB-4 score &gt;=1.100 (OR 2.660, 95% CI 1.201-5.889; p = .016), older age, higher diastolic blood pressure and higher uric acid were independent predictors of CKD.\n'
p10857
sg4
(lp10858
sg17
(lp10859
sa(dp10860
g2
S'High noninvasive fibrosis score is associated with an increased risk of prevalent CKD; the FIB-4 is the better predictor.\n'
p10861
sg4
(lp10862
sg17
(lp10863
(dp10864
g7
I17
sg20
VC0016059
p10865
sg10
I8
sg11
Vfibrosis
p10866
sg13
I1
sasa(dp10867
g2
S'With a cut-off value of 1.100 for FIB-4, it is useful in excluding the presence of CKD in patients with NAFLD.\n'
p10868
sg4
(lp10869
(dp10870
g7
I34
sg8
VP22087
p10871
sg10
I5
sg11
VFIB-4
p10872
sg13
I1
sasg17
(lp10873
(dp10874
g7
I104
sg20
VC0400966
p10875
sg10
I5
sg11
VNAFLD
p10876
sg13
I1
sasa(dp10877
g2
S'Cox regression models were used to determine the association of FIB4 with the risk of major LRE (gastrointestinal bleeding, ascites, hepatic encephalopathy, hepato-renal syndrome or hepatocellular carcinoma) or LRD.\n'
p10878
sg4
(lp10879
sg17
(lp10880
(dp10881
g7
I170
sg20
VC0039082
p10882
sg10
I8
sg11
Vsyndrome
p10883
sg13
I1
sa(dp10884
g7
I97
sg20
VC0017181
p10885
sg10
I25
sg11
Vgastrointestinal bleeding
p10886
sg13
I2
sa(dp10887
g7
I133
sg20
VC0019151
p10888
sg10
I22
sg11
Vhepatic encephalopathy
p10889
sg13
I2
sa(dp10890
g7
I182
sg20
VC1512411
p10891
sg10
I24
sg11
Vhepatocellular carcinoma
p10892
sg13
I2
sasa(dp10893
g2
S'Interleukin-6, hyaluronic acid, and the FIB-4 hepatic fibrosis index were higher among participants who developed progressive CKD, but were no longer associated with progressive CKD after adjustment.\n'
p10894
sg4
(lp10895
(dp10896
g7
I0
sg8
VP05231
p10897
sg10
I13
sg11
VInterleukin-6
p10898
sg13
I1
sa(dp10899
g7
I40
sg8
VP22087
p10900
sg10
I5
sg11
VFIB-4
p10901
sg13
I1
sasg17
(lp10902
(dp10903
g7
I46
sg20
VC0239946
p10904
sg10
I16
sg11
Vhepatic fibrosis
p10905
sg13
I2
sasa(dp10906
g2
S'The objectives of this study were to develop a reliable method to detect SQSTM1/P392L post-zygotic mutations, by optimizing a polymerase chain reaction (PCR)-clamping method reported to be effective in detecting post-zygotic mutations in peripheral blood from patients with fibrous dysplasia; and to evaluate the frequency of this post-zygotic mutation in PDB patients.\n'
p10907
sg4
(lp10908
(dp10909
g7
I73
sg8
g59
sg10
I6
sg11
VSQSTM1
p10910
sg13
I1
sasg17
(lp10911
(dp10912
g7
I356
sg20
VC0029401
p10913
sg10
I3
sg11
VPDB
p10914
sg13
I1
sa(dp10915
g7
I274
sg20
VC0259779
p10916
sg10
I17
sg11
Vfibrous dysplasia
p10917
sg13
I2
sasa(dp10918
g2
S'The FC features of 20 D/THL (11 BCL2(+)/MYC(+), 5 BCL6(+)/MYC(+), 4 BCL2(+)/BCL6(+)/MYC(+)) were evaluated, compared to 20 B-lymphoblastic leukemias (B-LBL), and correlated with overall survival.\n'
p10919
sg4
(lp10920
(dp10921
g7
I50
sg8
VP41182
p10922
sg10
I4
sg11
VBCL6
p10923
sg13
I1
sa(dp10924
g7
I40
sg8
VP12524
p10925
sg10
I3
sg11
VMYC
p10926
sg13
I1
sasg17
(lp10927
(dp10928
g7
I139
sg20
VC0023418
p10929
sg10
I9
sg11
Vleukemias
p10930
sg13
I1
sasa(dp10931
g2
S'We conclude that expression of TdT in a B-cell lymphoma with mature features or expression of surface light chain in a case otherwise suggestive of B-lymphoblastic leukemia/lymphoma should prompt an expedited evaluation for DHL/THL.\n'
p10932
sg4
(lp10933
(dp10934
g7
I31
sg8
VP04053
p10935
sg10
I3
sg11
VTdT
p10936
sg13
I1
sa(dp10937
g7
I228
sg8
g59
sg10
I3
sg11
VTHL
p10938
sg13
I1
sasg17
(lp10939
(dp10940
g7
I47
sg20
VC0024299
p10941
sg10
I8
sg11
Vlymphoma
p10942
sg13
I1
sa(dp10943
g7
I150
sg20
VC0023448
p10944
sg10
I22
sg11
Vlymphoblastic leukemia
p10945
sg13
I2
sa(dp10946
g7
I40
sg20
VC0079731
p10947
sg10
I15
sg11
VB-cell lymphoma
p10948
sg13
I2
sasa(dp10949
g2
S'The genotoxicity and cytotoxicity of a Chinese medicinal herb, Tripterygium hypoglaucum (level) Hutch (THH), was investigated in human promyelocytic leukemia (HL-60) cells using the hypoxanthine-guanine phosphoribosyltransferase mutation assay.\n'
p10950
sg4
(lp10951
(dp10952
g7
I182
sg8
VP00492
p10953
sg10
I46
sg11
Vhypoxanthine-guanine phosphoribosyltransferase
p10954
sg13
I2
sasg17
(lp10955
(dp10956
g7
I4
sg20
VC0598309
p10957
sg10
I12
sg11
Vgenotoxicity
p10958
sg13
I1
sa(dp10959
g7
I21
sg20
VC0596402
p10960
sg10
I12
sg11
Vcytotoxicity
p10961
sg13
I1
sa(dp10962
g7
I135
sg20
VC2745900
p10963
sg10
I22
sg11
Vpromyelocytic leukemia
p10964
sg13
I2
sasa(dp10965
g2
S'As CCR7 is expressed on activated dendritic cells (DCs), and these cells require CCR7 to migrate to the draining lymph node, we expected decreased migration of DCs into the lymph node in the absence of CCR7 during cutaneous leishmaniasis.\n'
p10966
sg4
(lp10967
(dp10968
g7
I51
sg8
g59
sg10
I3
sg11
VDCs
p10969
sg13
I1
sa(dp10970
g7
I3
sg8
VP32248
p10971
sg10
I4
sg11
VCCR7
p10972
sg13
I1
sa(dp10973
g7
I3
sg8
VP32248
p10974
sg10
I4
sg11
VCCR7
p10975
sg13
I1
sa(dp10976
g7
I34
sg8
g59
sg10
I15
sg11
Vdendritic cells
p10977
sg13
I2
sa(dp10978
g7
I3
sg8
VP32248
p10979
sg10
I4
sg11
VCCR7
p10980
sg13
I1
sasg17
(lp10981
(dp10982
g7
I51
sg20
VC0268238
p10983
sg10
I3
sg11
VDCs
p10984
sg13
I1
sa(dp10985
g7
I34
sg20
VC0268238
p10986
sg10
I15
sg11
Vdendritic cells
p10987
sg13
I2
sa(dp10988
g7
I51
sg20
VC0268238
p10989
sg10
I3
sg11
VDCs
p10990
sg13
I1
sa(dp10991
g7
I214
sg20
VC0023283
p10992
sg10
I23
sg11
Vcutaneous leishmaniasis
p10993
sg13
I2
sasa(dp10994
g2
S'The IOPs were compared between wild-type and LPLA2-deficient mice during their aging, after topical administration of antiglaucoma medications such as travoprost, dorzolamide, or timolol maleate, or after induction of endotoxin-induced uveitis (EIU) using lipopolysaccharide (LPS).\n'
p10995
sg4
(lp10996
(dp10997
g7
I45
sg8
g59
sg10
I5
sg11
VLPLA2
p10998
sg13
I1
sasg17
(lp10999
(dp11000
g7
I256
sg20
VC0175697
p11001
sg10
I18
sg11
Vlipopolysaccharide
p11002
sg13
I1
sa(dp11003
g7
I276
sg20
VC0175697
p11004
sg10
I3
sg11
VLPS
p11005
sg13
I1
sa(dp11006
g7
I236
sg20
VC0042164
p11007
sg10
I7
sg11
Vuveitis
p11008
sg13
I1
sasa(dp11009
g2
S'The present study was conducted to elucidate the pathophysiological roles of the lysosomal phospholipase A2 (LPLA2), a phospholipid-degrading enzyme, and the production of oxidized phospholipids (oxPLs) in autoimmune uveitis using a rat model.\n'
p11010
sg4
(lp11011
(dp11012
g7
I81
sg8
VP04054
p11013
sg10
I26
sg11
Vlysosomal phospholipase A2
p11014
sg13
I3
sa(dp11015
g7
I109
sg8
g59
sg10
I5
sg11
VLPLA2
p11016
sg13
I1
sasg17
(lp11017
(dp11018
g7
I206
sg20
VC0443146
p11019
sg10
I10
sg11
Vautoimmune
p11020
sg13
I1
sa(dp11021
g7
I217
sg20
VC0042164
p11022
sg10
I7
sg11
Vuveitis
p11023
sg13
I1
sasa(dp11024
g2
S'This study was conducted to elucidate pathophysiological roles of the lysosomal phospholipase A2 (LPLA2), a phospholipid-degrading enzyme, of the aqueous humor (AH) in uveitis using an animal model and clinical specimens.\n'
p11025
sg4
(lp11026
(dp11027
g7
I70
sg8
VP04054
p11028
sg10
I26
sg11
Vlysosomal phospholipase A2
p11029
sg13
I3
sa(dp11030
g7
I98
sg8
g59
sg10
I5
sg11
VLPLA2
p11031
sg13
I1
sasg17
(lp11032
(dp11033
g7
I161
sg20
VC0595936
p11034
sg10
I2
sg11
VAH
p11035
sg13
I1
sa(dp11036
g7
I146
sg20
VC0595936
p11037
sg10
I13
sg11
Vaqueous humor
p11038
sg13
I2
sa(dp11039
g7
I168
sg20
VC0042164
p11040
sg10
I7
sg11
Vuveitis
p11041
sg13
I1
sasa(dp11042
g2
S'Sixty-five human AH specimens, in which 11 eyes had a history of chronic uveitis, were collected during patient cataract surgeries and used to determine LPLA2 activity.\n'
p11043
sg4
(lp11044
(dp11045
g7
I153
sg8
g59
sg10
I5
sg11
VLPLA2
p11046
sg13
I1
sasg17
(lp11047
(dp11048
g7
I65
sg20
VC2733384
p11049
sg10
I15
sg11
Vchronic uveitis
p11050
sg13
I2
sa(dp11051
g7
I112
sg20
VC0086543
p11052
sg10
I8
sg11
Vcataract
p11053
sg13
I1
sasa(dp11054
g2
S'In the clinical specimens, the AH obtained from the patients with a history of uveitis possessed significantly higher LPLA2 activity than that from the senile patients with cataract but without other ocular diseases.\n'
p11055
sg4
(lp11056
(dp11057
g7
I118
sg8
g59
sg10
I5
sg11
VLPLA2
p11058
sg13
I1
sasg17
(lp11059
(dp11060
g7
I173
sg20
VC0086543
p11061
sg10
I8
sg11
Vcataract
p11062
sg13
I1
sa(dp11063
g7
I79
sg20
VC0042164
p11064
sg10
I7
sg11
Vuveitis
p11065
sg13
I1
sa(dp11066
g7
I87
sg20
VC0850310
p11067
sg10
I9
sg11
Vpossessed
p11068
sg13
I1
sasa(dp11069
g2
S'Analysis of bronchoalveolar lavage fluid collected from human patients with P. aeruginosa pneumonia demonstrated cytotoxic activity, and lavage fluid contained amyloid molecules, including oligomeric Tau and ABeta.\n'
p11070
sg4
(lp11071
(dp11072
g7
I200
sg8
VP49768
p11073
sg10
I3
sg11
VTau
p11074
sg13
I1
sa(dp11075
g7
I208
sg8
g59
sg10
I5
sg11
VABeta
p11076
sg13
I1
sasg17
(lp11077
(dp11078
g7
I160
sg20
VC0011560
p11079
sg10
I7
sg11
Vamyloid
p11080
sg13
I1
sa(dp11081
g7
I90
sg20
VC0032285
p11082
sg10
I9
sg11
Vpneumonia
p11083
sg13
I1
sasa(dp11084
g2
S'Meta-regression demonstrated a positive correlation between the degree of CPAP and the incidence of pneumonia with a regression coefficient of +0.61 (95 % CI 0.02-1.21, P = 0.048, Tau (2) = 0.078, r (2) = 7.87 %).\n'
p11085
sg4
(lp11086
(dp11087
g7
I74
sg8
g59
sg10
I4
sg11
VCPAP
p11088
sg13
I1
sasg17
(lp11089
(dp11090
g7
I100
sg20
VC0032285
p11091
sg10
I9
sg11
Vpneumonia
p11092
sg13
I1
sasa(dp11093
g2
S'We conclude that the use of etanercept along with antituberculosis treatment appears to be safe and effective in patients with pulmonary tuberculosis presenting with acute respiratory failure.\n'
p11094
sg4
(lp11095
sg17
(lp11096
(dp11097
g7
I166
sg20
VC0264490
p11098
sg10
I25
sg11
Vacute respiratory failure
p11099
sg13
I3
sa(dp11100
g7
I127
sg20
VC0041327
p11101
sg10
I22
sg11
Vpulmonary tuberculosis
p11102
sg13
I2
sasa(dp11103
g2
S'PubMed, EMBASE, CINAHL, SCOPUS, and the Cochrane Library were searched from inception until January 2013 using the following keywords in various combinations: ARDS, treatment, nitric oxide, heliox, steroids, surfactant, etanercept, prostaglandin therapy, inhaled beta adrenergic receptor agonists, N-acetylcysteine, ipratroprium bromide, dornase, plasminogen activators, fibrinolytics or other anticoagulants, and children.\n'
p11104
sg4
(lp11105
(dp11106
g7
I263
sg8
g59
sg10
I24
sg11
Vbeta adrenergic receptor
p11107
sg13
I3
sa(dp11108
g7
I347
sg8
VP00747
p11109
sg10
I22
sg11
Vplasminogen activators
p11110
sg13
I2
sasg17
(lp11111
(dp11112
g7
I159
sg20
VC0035222
p11113
sg10
I4
sg11
VARDS
p11114
sg13
I1
sasa(dp11115
g2
S'The patient then rapidly developed irreversible type II respiratory failure despite the administration of etanercept and an anti-cytomegalovirus agent and died on the eighth re-MV day.\n'
p11116
sg4
(lp11117
sg17
(lp11118
(dp11119
g7
I56
sg20
VC1145670
p11120
sg10
I19
sg11
Vrespiratory failure
p11121
sg13
I2
sasa(dp11122
g2
S'-tumor necrosis factor (TNF); acute lung injury (ALI); acute respiratory distress syndrome (ARDS); positive end-expiratory pressure (PEEP);epithelial sodium channel (ENaC);neural precursor cell-expressed developmentally downregulated (gene 4) protein (Nedd4-2);serum and glucocorticoid dependent kinase (Sgk-1);insulin-like growth factor 1 (IGF-1);Protein Kinase C (PKC);reactive oxygen species (ROS);myosin light chain (MLC);pneumolysin (PLY);listeriolysin (LLO);interleukin (IL);bronchoalveolar lavage fluids (BALF);Bacillus Calmette-Guerin (BCG);TNF receptor type 1 (TNFR1); TNF receptor type 2 (TNF-R2);\n'
p11123
sg4
(lp11124
(dp11125
g7
I578
sg8
VP01375
p11126
sg10
I19
sg11
VTNF receptor type 2
p11127
sg13
I4
sa(dp11128
g7
I366
sg8
VP17252
p11129
sg10
I3
sg11
VPKC
p11130
sg13
I1
sa(dp11131
g7
I1
sg8
VP01375
p11132
sg10
I21
sg11
Vtumor necrosis factor
p11133
sg13
I3
sa(dp11134
g7
I464
sg8
VP60568
p11135
sg10
I16
sg11
Vinterleukin (IL)
p11136
sg13
I2
sa(dp11137
g7
I271
sg8
VP19525
p11138
sg10
I31
sg11
Vglucocorticoid dependent kinase
p11139
sg13
I3
sa(dp11140
g7
I421
sg8
VP60660
p11141
sg10
I3
sg11
VMLC
p11142
sg13
I1
sa(dp11143
g7
I599
sg8
VP01375
p11144
sg10
I6
sg11
VTNF-R2
p11145
sg13
I1
sa(dp11146
g7
I24
sg8
VP01375
p11147
sg10
I3
sg11
VTNF
p11148
sg13
I1
sa(dp11149
g7
I549
sg8
VP01375
p11150
sg10
I19
sg11
VTNF receptor type 1
p11151
sg13
I4
sa(dp11152
g7
I401
sg8
VP08590
p11153
sg10
I18
sg11
Vmyosin light chain
p11154
sg13
I3
sa(dp11155
g7
I311
sg8
VP01308
p11156
sg10
I28
sg11
Vinsulin-like growth factor 1
p11157
sg13
I4
sa(dp11158
g7
I348
sg8
VP17252
p11159
sg10
I16
sg11
VProtein Kinase C
p11160
sg13
I3
sa(dp11161
g7
I341
sg8
VP01343
p11162
sg10
I5
sg11
VIGF-1
p11163
sg13
I1
sa(dp11164
g7
I252
sg8
VP46934
p11165
sg10
I7
sg11
VNedd4-2
p11166
sg13
I1
sa(dp11167
g7
I570
sg8
VP20333
p11168
sg10
I5
sg11
VTNFR1
p11169
sg13
I1
sasg17
(lp11170
(dp11171
g7
I92
sg20
VC0035222
p11172
sg10
I4
sg11
VARDS
p11173
sg13
I1
sa(dp11174
g7
I55
sg20
VC0035222
p11175
sg10
I35
sg11
Vacute respiratory distress syndrome
p11176
sg13
I4
sa(dp11177
g7
I1
sg20
VC0333516
p11178
sg10
I14
sg11
Vtumor necrosis
p11179
sg13
I2
sa(dp11180
g7
I366
sg20
VC1868682
p11181
sg10
I3
sg11
VPKC
p11182
sg13
I1
sasa(dp11183
g2
S'The aim of the present study was to replicate the previously reported association of KLF12 gene polymorphisms with rheumatoid arthritis (RA).\n'
p11184
sg4
(lp11185
(dp11186
g7
I85
sg8
g59
sg10
I10
sg11
VKLF12 gene
p11187
sg13
I2
sasg17
(lp11188
(dp11189
g7
I115
sg20
VC0003873
p11190
sg10
I20
sg11
Vrheumatoid arthritis
p11191
sg13
I2
sa(dp11192
g7
I137
sg20
VC0003873
p11193
sg10
I2
sg11
VRA
p11194
sg13
I1
sasa(dp11195
g2
S"Furthermore, the integration of our data with those from previous genome-wide association studies showed that KLF12 and PTPRT are the unique loci that are commonly associated in 3 different studies (P = 0.004 and P = 0.002 for KLF12 in the Wellcome Trust Case Control Consortium study and the Brigham and Women's Rheumatoid Arthritis Sequential Study genome-wide association study, respectively).\n"
p11196
sg4
(lp11197
(dp11198
g7
I120
sg8
g59
sg10
I5
sg11
VPTPRT
p11199
sg13
I1
sa(dp11200
g7
I110
sg8
g59
sg10
I5
sg11
VKLF12
p11201
sg13
I1
sa(dp11202
g7
I110
sg8
g59
sg10
I5
sg11
VKLF12
p11203
sg13
I1
sasg17
(lp11204
(dp11205
g7
I313
sg20
VC0003873
p11206
sg10
I20
sg11
VRheumatoid Arthritis
p11207
sg13
I2
sasa(dp11208
g2
S'Whole exome sequencing of DNA from a patient with severe combined immunodeficiency (SCID), megaloblastic anemia and hemolytic uremic syndrome identified mutations in the MTHFD1 gene, which encodes a trifunctional enzyme involved in interconversion of folate coenzyme derivatives.\n'
p11209
sg4
(lp11210
(dp11211
g7
I170
sg8
VP11586
p11212
sg10
I11
sg11
VMTHFD1 gene
p11213
sg13
I2
sasg17
(lp11214
(dp11215
g7
I116
sg20
VC0019061
p11216
sg10
I25
sg11
Vhemolytic uremic syndrome
p11217
sg13
I3
sa(dp11218
g7
I91
sg20
VC0002888
p11219
sg10
I20
sg11
Vmegaloblastic anemia
p11220
sg13
I2
sa(dp11221
g7
I84
sg20
VC0085110
p11222
sg10
I4
sg11
VSCID
p11223
sg13
I1
sa(dp11224
g7
I50
sg20
VC0085110
p11225
sg10
I32
sg11
Vsevere combined immunodeficiency
p11226
sg13
I3
sasa(dp11227
g2
S'To date, only one patient with MTHFD1 deficiency, presenting with hyperhomocysteinemia, megaloblastic anaemia, hemolytic uremic syndrome (HUS) and severe combined immunodeficiency, has been identified (Watkins et al J Med Genet 48:590-2, 2011).\n'
p11228
sg4
(lp11229
(dp11230
g7
I31
sg8
VP11586
p11231
sg10
I6
sg11
VMTHFD1
p11232
sg13
I1
sasg17
(lp11233
(dp11234
g7
I147
sg20
VC0085110
p11235
sg10
I32
sg11
Vsevere combined immunodeficiency
p11236
sg13
I3
sa(dp11237
g7
I138
sg20
VC0019061
p11238
sg10
I3
sg11
VHUS
p11239
sg13
I1
sa(dp11240
g7
I88
sg20
VC0002888
p11241
sg10
I21
sg11
Vmegaloblastic anaemia
p11242
sg13
I2
sa(dp11243
g7
I111
sg20
VC0019061
p11244
sg10
I25
sg11
Vhemolytic uremic syndrome
p11245
sg13
I3
sa(dp11246
g7
I66
sg20
VC0598608
p11247
sg10
I20
sg11
Vhyperhomocysteinemia
p11248
sg13
I1
sasa(dp11249
g2
S'Serum METRNL levels were significantly lower in subjects with diabetes mellitus compared with those without diabetes.\n'
p11250
sg4
(lp11251
sg17
(lp11252
(dp11253
g7
I62
sg20
VC0011849
p11254
sg10
I17
sg11
Vdiabetes mellitus
p11255
sg13
I2
sa(dp11256
g7
I62
sg20
VC0011849
p11257
sg10
I8
sg11
Vdiabetes
p11258
sg13
I1
sasa(dp11259
g2
S'Metrnl and OSM levels were assessed at baseline, 6, and 12 months after laparoscopic sleeve gastrectomy (LSG) in 25 patients with obesity, as well as in 33 normal-weight controls.\n'
p11260
sg4
(lp11261
(dp11262
g7
I11
sg8
VP13725
p11263
sg10
I3
sg11
VOSM
p11264
sg13
I1
sa(dp11265
g7
I0
sg8
g59
sg10
I6
sg11
VMetrnl
p11266
sg13
I1
sasg17
(lp11267
(dp11268
g7
I130
sg20
VC0028754
p11269
sg10
I7
sg11
Vobesity
p11270
sg13
I1
sasa(dp11271
g2
S'At baseline, patients with obesity showed lower Metrnl and higher OSM levels compared to controls.\n'
p11272
sg4
(lp11273
sg17
(lp11274
(dp11275
g7
I27
sg20
VC0028754
p11276
sg10
I7
sg11
Vobesity
p11277
sg13
I1
sasa(dp11278
g2
S'Our data indicate that LSG conversely modulated Metrnl and OSM levels, and suggest that a dual approach modulating these two molecules might provide a novel strategy for obesity and type 2 diabetes treatment.International Journal of Obesity accepted article preview online, 30 October 2017. doi:10.1038/ijo.2017.268.\n'
p11279
sg4
(lp11280
(dp11281
g7
I59
sg8
VP13725
p11282
sg10
I3
sg11
VOSM
p11283
sg13
I1
sa(dp11284
g7
I48
sg8
g59
sg10
I6
sg11
VMetrnl
p11285
sg13
I1
sasg17
(lp11286
(dp11287
g7
I182
sg20
VC0011860
p11288
sg10
I15
sg11
Vtype 2 diabetes
p11289
sg13
I3
sa(dp11290
g7
I233
sg20
VC0028754
p11291
sg10
I7
sg11
VObesity
p11292
sg13
I1
sa(dp11293
g7
I170
sg20
VC0028754
p11294
sg10
I7
sg11
Vobesity
p11295
sg13
I1
sa(dp11296
g7
I303
sg20
VC0264080
p11297
sg10
I3
sg11
Vijo
p11298
sg13
I1
sasa(dp11299
g2
S'We systematically evaluated the role of METRNL for human adipogenesis and its association with obesity, browning and hyperinsulinemia in children.\n'
p11300
sg4
(lp11301
(dp11302
g7
I40
sg8
g59
sg10
I6
sg11
VMETRNL
p11303
sg13
I1
sasg17
(lp11304
(dp11305
g7
I117
sg20
VC0020459
p11306
sg10
I16
sg11
Vhyperinsulinemia
p11307
sg13
I1
sa(dp11308
g7
I95
sg20
VC0028754
p11309
sg10
I7
sg11
Vobesity
p11310
sg13
I1
sasa(dp11311
g2
S'These interactions with adipose tissue dynamics may contribute to the clinically observed body mass index-independent association of METRNL expression with hyperinsulinemia and adipose tissue inflammation in human samples.\n'
p11312
sg4
(lp11313
(dp11314
g7
I133
sg8
g59
sg10
I6
sg11
VMETRNL
p11315
sg13
I1
sasg17
(lp11316
(dp11317
g7
I156
sg20
VC0020459
p11318
sg10
I16
sg11
Vhyperinsulinemia
p11319
sg13
I1
sa(dp11320
g7
I192
sg20
VC0021368
p11321
sg10
I12
sg11
Vinflammation
p11322
sg13
I1
sasa(dp11323
g2
S'This may also explain our observations of increased METRNL expression in adipocytes but not SVF cells in obese children compared with lean children and the subsequent hyperinsulinemia.\n'
p11324
sg4
(lp11325
(dp11326
g7
I52
sg8
g59
sg10
I6
sg11
VMETRNL
p11327
sg13
I1
sasg17
(lp11328
(dp11329
g7
I167
sg20
VC0020459
p11330
sg10
I16
sg11
Vhyperinsulinemia
p11331
sg13
I1
sa(dp11332
g7
I105
sg20
VC0028754
p11333
sg10
I5
sg11
Vobese
p11334
sg13
I1
sasa(dp11335
g2
S'Subfatin is a novel adipokine regulated by adipogenesis and obesity, with tissue distribution different from its homologue Meteorin.\n'
p11336
sg4
(lp11337
(dp11338
g7
I123
sg8
g59
sg10
I8
sg11
VMeteorin
p11339
sg13
I1
sasg17
(lp11340
(dp11341
g7
I60
sg20
VC0028754
p11342
sg10
I7
sg11
Vobesity
p11343
sg13
I1
sasa(dp11344
g2
S'We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation.\n'
p11345
sg4
(lp11346
(dp11347
g7
I46
sg8
g59
sg10
I5
sg11
VNoxO1
p11348
sg13
I1
sa(dp11349
g7
I89
sg8
VP62993
p11350
sg10
I4
sg11
VGrb2
p11351
sg13
I1
sa(dp11352
g7
I128
sg8
VP22681
p11353
sg10
I3
sg11
VCbl
p11354
sg13
I1
sa(dp11355
g7
I100
sg8
VP22681
p11356
sg10
I26
sg11
VCasitas B-lineage lymphoma
p11357
sg13
I3
sa(dp11358
g7
I270
sg8
VP01133
p11359
sg10
I3
sg11
VEGF
p11360
sg13
I1
sa(dp11361
g7
I46
sg8
g59
sg10
I41
sg11
VNoxO1 and growth receptor-bound protein 2
p11362
sg13
I6
sa(dp11363
g7
I245
sg8
VP01133
p11364
sg10
I23
sg11
Vepidermal growth factor
p11365
sg13
I3
sasg17
(lp11366
(dp11367
g7
I118
sg20
VC0024299
p11368
sg10
I8
sg11
Vlymphoma
p11369
sg13
I1
sasa(dp11370
g2
S'CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice.\n'
p11371
sg4
(lp11372
(dp11373
g7
I21
sg8
g59
sg10
I5
sg11
VNoxO1
p11374
sg13
I1
sasg17
(lp11375
(dp11376
g7
I45
sg20
VC0699790
p11377
sg10
I12
sg11
Vcolon cancer
p11378
sg13
I2
sa(dp11379
g7
I120
sg20
VC0027651
p11380
sg10
I5
sg11
Vtumor
p11381
sg13
I1
sasa(dp11382
g2
S'Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon.\n'
p11383
sg4
(lp11384
(dp11385
g7
I42
sg8
g59
sg10
I5
sg11
VNoxO1
p11386
sg13
I1
sasg17
(lp11387
(dp11388
g7
I86
sg20
VC0699790
p11389
sg10
I12
sg11
Vcolon cancer
p11390
sg13
I2
sasa(dp11391
g2
S'Moreover, the microarray analysis and colony formation assay indicated that NADPH oxidase organizer 1 (Noxo1) and Gna14 are induced in tumor epithelial cells in a TNF-Alfa-dependent manner, and have an important role in tumorigenicity and tumor-initiating cell property of gastric cancer cells.\n'
p11392
sg4
(lp11393
(dp11394
g7
I103
sg8
g59
sg10
I5
sg11
VNoxo1
p11395
sg13
I1
sa(dp11396
g7
I114
sg8
g59
sg10
I5
sg11
VGna14
p11397
sg13
I1
sa(dp11398
g7
I76
sg8
g59
sg10
I25
sg11
VNADPH oxidase organizer 1
p11399
sg13
I4
sa(dp11400
g7
I163
sg8
VP01375
p11401
sg10
I3
sg11
VTNF
p11402
sg13
I1
sasg17
(lp11403
(dp11404
g7
I135
sg20
VC0027651
p11405
sg10
I5
sg11
Vtumor
p11406
sg13
I1
sa(dp11407
g7
I135
sg20
VC0027651
p11408
sg10
I5
sg11
Vtumor
p11409
sg13
I1
sa(dp11410
g7
I220
sg20
VC1519697
p11411
sg10
I14
sg11
Vtumorigenicity
p11412
sg13
I1
sa(dp11413
g7
I273
sg20
VC0024623
p11414
sg10
I14
sg11
Vgastric cancer
p11415
sg13
I2
sasa(dp11416
g2
S'To investigate whether NOX and NOX accessory gene expression might be a factor common to specific human tumour types, this study measured the expression levels of NOX genes 1-5, dual oxidase 1 and 2, as well as those of NOX accessory genes NoxO1, NoxA1, p47(phox), p67(phox) and p22(phox) in human cancer cell lines and in tumour and adjacent normal tissue pairs by quantitative, real-time RT-PCR.\n'
p11417
sg4
(lp11418
(dp11419
g7
I163
sg8
VP01893
p11420
sg10
I13
sg11
VNOX genes 1-5
p11421
sg13
I3
sa(dp11422
g7
I258
sg8
VP19878
p11423
sg10
I4
sg11
Vphox
p11424
sg13
I1
sa(dp11425
g7
I258
sg8
VP19878
p11426
sg10
I4
sg11
Vphox
p11427
sg13
I1
sa(dp11428
g7
I258
sg8
VP19878
p11429
sg10
I4
sg11
Vphox
p11430
sg13
I1
sa(dp11431
g7
I254
sg8
VP08567
p11432
sg10
I3
sg11
Vp47
p11433
sg13
I1
sa(dp11434
g7
I178
sg8
g59
sg10
I20
sg11
Vdual oxidase 1 and 2
p11435
sg13
I5
sa(dp11436
g7
I265
sg8
VP20138
p11437
sg10
I3
sg11
Vp67
p11438
sg13
I1
sa(dp11439
g7
I247
sg8
g59
sg10
I5
sg11
VNoxA1
p11440
sg13
I1
sa(dp11441
g7
I240
sg8
g59
sg10
I5
sg11
VNoxO1
p11442
sg13
I1
sa(dp11443
g7
I279
sg8
g59
sg10
I3
sg11
Vp22
p11444
sg13
I1
sasg17
(lp11445
(dp11446
g7
I104
sg20
VC0027651
p11447
sg10
I6
sg11
Vtumour
p11448
sg13
I1
sa(dp11449
g7
I298
sg20
VC0006826
p11450
sg10
I6
sg11
Vcancer
p11451
sg13
I1
sa(dp11452
g7
I104
sg20
VC0027651
p11453
sg10
I6
sg11
Vtumour
p11454
sg13
I1
sasa(dp11455
g2
S'PCR of human stomach cDNA libraries showed that Nox1 and Nox organizer 1 (NOXO1) messages were absent from normal stomachs, while they were specifically coexpressed in intestinal- and diffuse-type adenocarcinomas including signet-ring cell carcinoma.\n'
p11456
sg4
(lp11457
(dp11458
g7
I74
sg8
g59
sg10
I5
sg11
VNOXO1
p11459
sg13
I1
sa(dp11460
g7
I48
sg8
g59
sg10
I4
sg11
VNox1
p11461
sg13
I1
sa(dp11462
g7
I57
sg8
g59
sg10
I15
sg11
VNox organizer 1
p11463
sg13
I3
sasg17
(lp11464
(dp11465
g7
I223
sg20
VC0206696
p11466
sg10
I26
sg11
Vsignet-ring cell carcinoma
p11467
sg13
I3
sa(dp11468
g7
I197
sg20
VC0001418
p11469
sg10
I15
sg11
Vadenocarcinomas
p11470
sg13
I1
sasa(dp11471
g2
S'Immunohistochemistry showed that Nox1 and NOXO1 proteins were absent from chronic atrophic gastritis (15 cases), adenomas (4 cases), or surrounding tissues of adenocarcinomas (45 cases).\n'
p11472
sg4
(lp11473
(dp11474
g7
I42
sg8
g59
sg10
I14
sg11
VNOXO1 proteins
p11475
sg13
I2
sa(dp11476
g7
I33
sg8
g59
sg10
I4
sg11
VNox1
p11477
sg13
I1
sasg17
(lp11478
(dp11479
g7
I74
sg20
VC0017154
p11480
sg10
I26
sg11
Vchronic atrophic gastritis
p11481
sg13
I3
sa(dp11482
g7
I159
sg20
VC0001418
p11483
sg10
I15
sg11
Vadenocarcinomas
p11484
sg13
I1
sa(dp11485
g7
I113
sg20
VC0001430
p11486
sg10
I8
sg11
Vadenomas
p11487
sg13
I1
sasa(dp11488
g2
S'Confocal microscopy revealed that Nox1, NOXO1, Nox activator 1, and p22(phox) were predominantly associated with Golgi apparatus in these cancer cells, while diffuse-type adenocarcinomas also contained cancer cells having Nox1 and its partner proteins in their nuclei.\n'
p11489
sg4
(lp11490
(dp11491
g7
I47
sg8
g59
sg10
I15
sg11
VNox activator 1
p11492
sg13
I3
sa(dp11493
g7
I72
sg8
VP19878
p11494
sg10
I4
sg11
Vphox
p11495
sg13
I1
sa(dp11496
g7
I34
sg8
g59
sg10
I4
sg11
VNox1
p11497
sg13
I1
sa(dp11498
g7
I40
sg8
g59
sg10
I5
sg11
VNOXO1
p11499
sg13
I1
sa(dp11500
g7
I34
sg8
g59
sg10
I4
sg11
VNox1
p11501
sg13
I1
sa(dp11502
g7
I68
sg8
g59
sg10
I3
sg11
Vp22
p11503
sg13
I1
sasg17
(lp11504
(dp11505
g7
I138
sg20
VC0006826
p11506
sg10
I6
sg11
Vcancer
p11507
sg13
I1
sa(dp11508
g7
I138
sg20
VC0006826
p11509
sg10
I6
sg11
Vcancer
p11510
sg13
I1
sa(dp11511
g7
I171
sg20
VC0001418
p11512
sg10
I15
sg11
Vadenocarcinomas
p11513
sg13
I1
sasa(dp11514
g2
S'Interestingly, the IL1RL1, HLA, IL13 and C11orf30 regions are overlapping susceptibility loci among atopic dermatitis and asthma or allergic rhinitis.\n'
p11515
sg4
(lp11516
(dp11517
g7
I27
sg8
VP30486
p11518
sg10
I3
sg11
VHLA
p11519
sg13
I1
sa(dp11520
g7
I19
sg8
g59
sg10
I6
sg11
VIL1RL1
p11521
sg13
I1
sa(dp11522
g7
I32
sg8
VP35225
p11523
sg10
I4
sg11
VIL13
p11524
sg13
I1
sa(dp11525
g7
I41
sg8
g59
sg10
I8
sg11
VC11orf30
p11526
sg13
I1
sasg17
(lp11527
(dp11528
g7
I100
sg20
VC0011615
p11529
sg10
I17
sg11
Vatopic dermatitis
p11530
sg13
I2
sa(dp11531
g7
I122
sg20
VC0004096
p11532
sg10
I6
sg11
Vasthma
p11533
sg13
I1
sa(dp11534
g7
I132
sg20
VC2607914
p11535
sg10
I17
sg11
Vallergic rhinitis
p11536
sg13
I2
sasa(dp11537
g2
S'Of these, only rs3771180 in IL1RL1 was associated with any other allergic disease (for hay fever, OR 0.64, 95% CI 0.53-0.77, P = 2.5*10(-6) ).\n'
p11538
sg4
(lp11539
(dp11540
g7
I28
sg8
g59
sg10
I6
sg11
VIL1RL1
p11541
sg13
I1
sasg17
(lp11542
(dp11543
g7
I87
sg20
VC0018621
p11544
sg10
I9
sg11
Vhay fever
p11545
sg13
I2
sasa(dp11546
g2
S'Serum levels of IL-16, IL-33 and the decoy receptor of IL-33, soluble ST2, are elevated in allergic rhinitis.\n'
p11547
sg4
(lp11548
(dp11549
g7
I16
sg8
g59
sg10
I5
sg11
VIL-16
p11550
sg13
I1
sasg17
(lp11551
(dp11552
g7
I91
sg20
VC2607914
p11553
sg10
I17
sg11
Vallergic rhinitis
p11554
sg13
I2
sasa(dp11555
g2
S'Recent studies show that IL-16, soluble ST2 or anti-IL-33 reduce type 2 cytokines (such as IL-5) and eosinophilia in murine models of allergic asthma or allergic rhinitis respectively.\n'
p11556
sg4
(lp11557
(dp11558
g7
I65
sg8
VP01374
p11559
sg10
I16
sg11
Vtype 2 cytokines
p11560
sg13
I3
sa(dp11561
g7
I91
sg8
VP05113
p11562
sg10
I4
sg11
VIL-5
p11563
sg13
I1
sa(dp11564
g7
I25
sg8
g59
sg10
I18
sg11
VIL-16, soluble ST2
p11565
sg13
I3
sasg17
(lp11566
(dp11567
g7
I134
sg20
VC0155877
p11568
sg10
I15
sg11
Vallergic asthma
p11569
sg13
I2
sa(dp11570
g7
I153
sg20
VC2607914
p11571
sg10
I17
sg11
Vallergic rhinitis
p11572
sg13
I2
sa(dp11573
g7
I101
sg20
VC0014457
p11574
sg10
I12
sg11
Veosinophilia
p11575
sg13
I1
sasa(dp11576
g2
S'In this study, we studied the release of IL-5, IL-16, IL-33 and soluble ST2 in allergic rhinitis patients after nasal allergen challenge and natural pollen exposure.\n'
p11577
sg4
(lp11578
(dp11579
g7
I47
sg8
g59
sg10
I5
sg11
VIL-16
p11580
sg13
I1
sa(dp11581
g7
I41
sg8
VP05113
p11582
sg10
I4
sg11
VIL-5
p11583
sg13
I1
sasg17
(lp11584
(dp11585
g7
I79
sg20
VC2607914
p11586
sg10
I17
sg11
Vallergic rhinitis
p11587
sg13
I2
sasa(dp11588
g2
S'The observed upregulation of soluble ST2 and IL-16 after nasal allergen challenge and during peak pollination season suggests potential regulatory roles of these cytokines in the inflammatory reaction in allergic rhinitis.\n'
p11589
sg4
(lp11590
(dp11591
g7
I45
sg8
g59
sg10
I5
sg11
VIL-16
p11592
sg13
I1
sa(dp11593
g7
I37
sg8
VP10767
p11594
sg10
I3
sg11
VST2
p11595
sg13
I1
sasg17
(lp11596
(dp11597
g7
I204
sg20
VC2607914
p11598
sg10
I17
sg11
Vallergic rhinitis
p11599
sg13
I2
sa(dp11600
g7
I179
sg20
VC0021368
p11601
sg10
I21
sg11
Vinflammatory reaction
p11602
sg13
I2
sasa(dp11603
g2
S'Interestingly, the IL1RL1, HLA, IL13 and C11orf30 regions are overlapping susceptibility loci among atopic dermatitis and asthma or allergic rhinitis.\n'
p11604
sg4
(lp11605
(dp11606
g7
I27
sg8
VP30486
p11607
sg10
I3
sg11
VHLA
p11608
sg13
I1
sa(dp11609
g7
I19
sg8
g59
sg10
I6
sg11
VIL1RL1
p11610
sg13
I1
sa(dp11611
g7
I32
sg8
VP35225
p11612
sg10
I4
sg11
VIL13
p11613
sg13
I1
sa(dp11614
g7
I41
sg8
g59
sg10
I8
sg11
VC11orf30
p11615
sg13
I1
sasg17
(lp11616
(dp11617
g7
I100
sg20
VC0011615
p11618
sg10
I17
sg11
Vatopic dermatitis
p11619
sg13
I2
sa(dp11620
g7
I122
sg20
VC0004096
p11621
sg10
I6
sg11
Vasthma
p11622
sg13
I1
sa(dp11623
g7
I132
sg20
VC2607914
p11624
sg10
I17
sg11
Vallergic rhinitis
p11625
sg13
I2
sasa(dp11626
g2
S'KM-HN-1 expression was observed in various cancer tissues and cancer cell lines at both mRNA and protein levels.\n'
p11627
sg4
(lp11628
(dp11629
g7
I0
sg8
g59
sg10
I7
sg11
VKM-HN-1
p11630
sg13
I1
sasg17
(lp11631
(dp11632
g7
I43
sg20
VC0006826
p11633
sg10
I6
sg11
Vcancer
p11634
sg13
I1
sa(dp11635
g7
I43
sg20
VC0006826
p11636
sg10
I6
sg11
Vcancer
p11637
sg13
I1
sasa(dp11638
g2
S'Immunofluorescence staining of an esophageal cancer cell line revealed that KM-HN-1 protein was present exclusively in the nucleus during mitosis.\n'
p11639
sg4
(lp11640
(dp11641
g7
I76
sg8
g59
sg10
I15
sg11
VKM-HN-1 protein
p11642
sg13
I2
sasg17
(lp11643
(dp11644
g7
I34
sg20
VC0014859
p11645
sg10
I17
sg11
Vesophageal cancer
p11646
sg13
I2
sasa(dp11647
g2
S'Higher levels of IgG antibodies specific to KM-HN-1 were detected in many types and numbers of cancer patients but not in healthy donors.\n'
p11648
sg4
(lp11649
(dp11650
g7
I44
sg8
g59
sg10
I7
sg11
VKM-HN-1
p11651
sg13
I1
sasg17
(lp11652
(dp11653
g7
I95
sg20
VC0006826
p11654
sg10
I6
sg11
Vcancer
p11655
sg13
I1
sasa(dp11656
g2
S'The CTL lines specific to KM-HN-1, generated from HLA-A*2402-positive healthy donors and cancer patients, killed human leukocyte antigen (HLA)-A24-positive cancer cells expressing KM-HN-1 but not cell lines that did not express either KM-HN-1 or HLA-A24.\n'
p11657
sg4
(lp11658
(dp11659
g7
I113
sg8
VP05534
p11660
sg10
I23
sg11
Vhuman leukocyte antigen
p11661
sg13
I3
sa(dp11662
g7
I26
sg8
g59
sg10
I7
sg11
VKM-HN-1
p11663
sg13
I1
sa(dp11664
g7
I26
sg8
g59
sg10
I7
sg11
VKM-HN-1
p11665
sg13
I1
sa(dp11666
g7
I26
sg8
g59
sg10
I7
sg11
VKM-HN-1
p11667
sg13
I1
sa(dp11668
g7
I50
sg8
VP30486
p11669
sg10
I3
sg11
VHLA
p11670
sg13
I1
sa(dp11671
g7
I50
sg8
VP30447
p11672
sg10
I10
sg11
VHLA-A*2402
p11673
sg13
I1
sa(dp11674
g7
I246
sg8
VP05534
p11675
sg10
I7
sg11
VHLA-A24
p11676
sg13
I1
sasg17
(lp11677
(dp11678
g7
I89
sg20
VC0006826
p11679
sg10
I6
sg11
Vcancer
p11680
sg13
I1
sa(dp11681
g7
I89
sg20
VC0006826
p11682
sg10
I6
sg11
Vcancer
p11683
sg13
I1
sasa(dp11684
g2
S'We identified a novel cancer/testis antigen, KM-HN-1, which elicited humoral immune responses in patients with various types of cancer.\n'
p11685
sg4
(lp11686
(dp11687
g7
I22
sg8
VP15735
p11688
sg10
I21
sg11
Vcancer/testis antigen
p11689
sg13
I2
sa(dp11690
g7
I45
sg8
g59
sg10
I7
sg11
VKM-HN-1
p11691
sg13
I1
sasg17
(lp11692
(dp11693
g7
I22
sg20
VC0006826
p11694
sg10
I6
sg11
Vcancer
p11695
sg13
I1
sa(dp11696
g7
I22
sg20
VC0006826
p11697
sg10
I6
sg11
Vcancer
p11698
sg13
I1
sasa(dp11699
g2
S'Furthermore, KM-HN-1-specific CTLs could be generated from both healthy donors and cancer patients, which indicated that KM-HN-1 can be a candidate for an ideal target for cancer immunotherapy.\n'
p11700
sg4
(lp11701
(dp11702
g7
I13
sg8
g59
sg10
I21
sg11
VKM-HN-1-specific CTLs
p11703
sg13
I2
sa(dp11704
g7
I13
sg8
g59
sg10
I7
sg11
VKM-HN-1
p11705
sg13
I1
sasg17
(lp11706
(dp11707
g7
I83
sg20
VC0006826
p11708
sg10
I6
sg11
Vcancer
p11709
sg13
I1
sa(dp11710
g7
I83
sg20
VC0006826
p11711
sg10
I6
sg11
Vcancer
p11712
sg13
I1
sasa(dp11713
g2
S'Intragenic deletions of the contactin-associated protein-like 2 gene (CNTNAP2) have been found in patients with Gilles de la Tourette syndrome, intellectual disability (ID), obsessive compulsive disorder, cortical dysplasia-focal epilepsy syndrome, autism, schizophrenia, Pitt-Hopkins syndrome, stuttering, and attention deficit hyperactivity disorder.\n'
p11714
sg4
(lp11715
(dp11716
g7
I28
sg8
g59
sg10
I40
sg11
Vcontactin-associated protein-like 2 gene
p11717
sg13
I4
sa(dp11718
g7
I70
sg8
g59
sg10
I7
sg11
VCNTNAP2
p11719
sg13
I1
sasg17
(lp11720
(dp11721
g7
I144
sg20
VC0025362
p11722
sg10
I23
sg11
Vintellectual disability
p11723
sg13
I2
sa(dp11724
g7
I311
sg20
VC1263846
p11725
sg10
I40
sg11
Vattention deficit hyperactivity disorder
p11726
sg13
I4
sa(dp11727
g7
I295
sg20
VC0038506
p11728
sg10
I10
sg11
Vstuttering
p11729
sg13
I1
sa(dp11730
g7
I249
sg20
VC0004352
p11731
sg10
I6
sg11
Vautism
p11732
sg13
I1
sa(dp11733
g7
I272
sg20
VC1970431
p11734
sg10
I21
sg11
VPitt-Hopkins syndrome
p11735
sg13
I2
sa(dp11736
g7
I205
sg20
VC1864887
p11737
sg10
I42
sg11
Vcortical dysplasia-focal epilepsy syndrome
p11738
sg13
I4
sa(dp11739
g7
I257
sg20
VC0036341
p11740
sg10
I13
sg11
Vschizophrenia
p11741
sg13
I1
sa(dp11742
g7
I112
sg20
VC0040517
p11743
sg10
I30
sg11
VGilles de la Tourette syndrome
p11744
sg13
I5
sa(dp11745
g7
I174
sg20
VC0028768
p11746
sg10
I29
sg11
Vobsessive compulsive disorder
p11747
sg13
I3
sa(dp11748
g7
I169
sg20
VC0025362
p11749
sg10
I2
sg11
VID
p11750
sg13
I1
sasa(dp11751
g2
S'Based on genomic rearrangements and copy number variations, the contactin-associated protein-like 2 gene (CNTNAP2) has been implicated in neurodevelopmental disorders such as Gilles de la Tourette syndrome, intellectual disability, obsessive compulsive disorder, cortical dysplasia-focal epilepsy syndrome, autism, schizophrenia, Pitt-Hopkins syndrome, and attention deficit hyperactivity disorder.\n'
p11752
sg4
(lp11753
(dp11754
g7
I106
sg8
g59
sg10
I7
sg11
VCNTNAP2
p11755
sg13
I1
sa(dp11756
g7
I64
sg8
g59
sg10
I40
sg11
Vcontactin-associated protein-like 2 gene
p11757
sg13
I4
sasg17
(lp11758
(dp11759
g7
I330
sg20
VC1970431
p11760
sg10
I21
sg11
VPitt-Hopkins syndrome
p11761
sg13
I2
sa(dp11762
g7
I207
sg20
VC0025362
p11763
sg10
I23
sg11
Vintellectual disability
p11764
sg13
I2
sa(dp11765
g7
I315
sg20
VC0036341
p11766
sg10
I13
sg11
Vschizophrenia
p11767
sg13
I1
sa(dp11768
g7
I263
sg20
VC1864887
p11769
sg10
I42
sg11
Vcortical dysplasia-focal epilepsy syndrome
p11770
sg13
I4
sa(dp11771
g7
I232
sg20
VC0028768
p11772
sg10
I29
sg11
Vobsessive compulsive disorder
p11773
sg13
I3
sa(dp11774
g7
I175
sg20
VC0040517
p11775
sg10
I30
sg11
VGilles de la Tourette syndrome
p11776
sg13
I5
sa(dp11777
g7
I307
sg20
VC0004352
p11778
sg10
I6
sg11
Vautism
p11779
sg13
I1
sa(dp11780
g7
I357
sg20
VC1263846
p11781
sg10
I40
sg11
Vattention deficit hyperactivity disorder
p11782
sg13
I4
sasa(dp11783
g2
S'Recently, a homozygous truncating variant in CPLX1 was suggested to be causative for migrating epilepsy and structural brain abnormalities.\n'
p11784
sg4
(lp11785
(dp11786
g7
I23
sg8
VP26640
p11787
sg10
I18
sg11
Vtruncating variant
p11788
sg13
I2
sa(dp11789
g7
I45
sg8
g59
sg10
I5
sg11
VCPLX1
p11790
sg13
I1
sasg17
(lp11791
(dp11792
g7
I95
sg20
VC0014544
p11793
sg10
I8
sg11
Vepilepsy
p11794
sg13
I1
sasa(dp11795
g2
S'However, the currently limited knowledge on CPLX1 suggests that loss of complexin 1 function may lead to a complex but variable clinical phenotype, and our findings encourage further investigations of CPLX1 in patients with ID, developmental delay and myoclonic epilepsy to unravel the phenotypic spectrum of carriers of CPLX1 variants.\n'
p11796
sg4
(lp11797
(dp11798
g7
I44
sg8
g59
sg10
I5
sg11
VCPLX1
p11799
sg13
I1
sa(dp11800
g7
I321
sg8
g59
sg10
I14
sg11
VCPLX1 variants
p11801
sg13
I2
sa(dp11802
g7
I72
sg8
g59
sg10
I11
sg11
Vcomplexin 1
p11803
sg13
I2
sa(dp11804
g7
I44
sg8
g59
sg10
I5
sg11
VCPLX1
p11805
sg13
I1
sasg17
(lp11806
(dp11807
g7
I228
sg20
VC0424605
p11808
sg10
I19
sg11
Vdevelopmental delay
p11809
sg13
I2
sa(dp11810
g7
I252
sg20
VC0014550
p11811
sg10
I18
sg11
Vmyoclonic epilepsy
p11812
sg13
I2
sasa(dp11813
g2
S"Downregulation of complexin 1 (CPLX1) mRNA was correlated with genotype, but the expression of other Parkinson's disease genes was not.\n"
p11814
sg4
(lp11815
(dp11816
g7
I18
sg8
g59
sg10
I11
sg11
Vcomplexin 1
p11817
sg13
I2
sa(dp11818
g7
I31
sg8
g59
sg10
I5
sg11
VCPLX1
p11819
sg13
I1
sasg17
(lp11820
(dp11821
g7
I101
sg20
VC0030567
p11822
sg10
I19
sg11
VParkinson's disease
p11823
sg13
I2
sasa(dp11824
g2
S'Therefore, AF and APH can be used as potential therapeutic agents against type 2 diabetes and associated metabolic disorders, including obesity, by enhancing glucose and lipid metabolism.\n'
p11825
sg4
(lp11826
sg17
(lp11827
(dp11828
g7
I136
sg20
VC0028754
p11829
sg10
I7
sg11
Vobesity
p11830
sg13
I1
sa(dp11831
g7
I74
sg20
VC0011860
p11832
sg10
I15
sg11
Vtype 2 diabetes
p11833
sg13
I3
sa(dp11834
g7
I105
sg20
VC0025517
p11835
sg10
I19
sg11
Vmetabolic disorders
p11836
sg13
I2
sasa(dp11837
g2
S'All our data suggest that APH can be used as potential therapeutic agents against type 2 diabetes and related metabolic disorders, including obesity, by enhancing glucose and lipid metabolism.\n'
p11838
sg4
(lp11839
(dp11840
g7
I26
sg8
VP13798
p11841
sg10
I3
sg11
VAPH
p11842
sg13
I1
sasg17
(lp11843
(dp11844
g7
I110
sg20
VC0025517
p11845
sg10
I19
sg11
Vmetabolic disorders
p11846
sg13
I2
sa(dp11847
g7
I82
sg20
VC0011860
p11848
sg10
I15
sg11
Vtype 2 diabetes
p11849
sg13
I3
sa(dp11850
g7
I141
sg20
VC0028754
p11851
sg10
I7
sg11
Vobesity
p11852
sg13
I1
sasa(dp11853
g2
S'Multivariable logistic regression analysis adjusted for ethnicity, body mass index, maternal age, parity, smoking status, social deprivation, hypertensive disease, antepartum haemorrhage (APH), diabetes and relevant pre-existing medical conditions.\n'
p11854
sg4
(lp11855
sg17
(lp11856
(dp11857
g7
I188
sg20
VC0269608
p11858
sg10
I3
sg11
VAPH
p11859
sg13
I1
sa(dp11860
g7
I164
sg20
VC0269608
p11861
sg10
I22
sg11
Vantepartum haemorrhage
p11862
sg13
I2
sa(dp11863
g7
I142
sg20
VC0020538
p11864
sg10
I20
sg11
Vhypertensive disease
p11865
sg13
I2
sa(dp11866
g7
I194
sg20
VC0011849
p11867
sg10
I8
sg11
Vdiabetes
p11868
sg13
I1
sasa(dp11869
g2
S'Distribution of gestational diabetes mellitus (GDM), antepartum hemorrhage (APH), maternal anemia, premature rupture of membrane (PROM), maternal occupation, parity, sheesha smoking, and parental consanguinity were significantly different (P &lt; 0.05) between mothers of LBW and normal birth weight NBW (&gt;=2500 g) babies.\n'
p11870
sg4
(lp11871
sg17
(lp11872
(dp11873
g7
I47
sg20
VC0085207
p11874
sg10
I3
sg11
VGDM
p11875
sg13
I1
sa(dp11876
g7
I53
sg20
VC0270027
p11877
sg10
I21
sg11
Vantepartum hemorrhage
p11878
sg13
I2
sa(dp11879
g7
I91
sg20
VC0002871
p11880
sg10
I6
sg11
Vanemia
p11881
sg13
I1
sa(dp11882
g7
I130
sg20
VC0015944
p11883
sg10
I4
sg11
VPROM
p11884
sg13
I1
sa(dp11885
g7
I99
sg20
VC0015944
p11886
sg10
I29
sg11
Vpremature rupture of membrane
p11887
sg13
I4
sa(dp11888
g7
I16
sg20
VC0085207
p11889
sg10
I29
sg11
Vgestational diabetes mellitus
p11890
sg13
I3
sa(dp11891
g7
I76
sg20
VC0270027
p11892
sg10
I3
sg11
VAPH
p11893
sg13
I1
sasa(dp11894
g2
S'Therefore, we suggest that APH-4 and APH-11 are novel dual PPARAlfa/Gamma agonists and are potentially useful for treating type 2 diabetes by enhancing glucose and lipid metabolism.\n'
p11895
sg4
(lp11896
(dp11897
g7
I37
sg8
VP13798
p11898
sg10
I6
sg11
VAPH-11
p11899
sg13
I1
sa(dp11900
g7
I27
sg8
VP13798
p11901
sg10
I5
sg11
VAPH-4
p11902
sg13
I1
sasg17
(lp11903
(dp11904
g7
I123
sg20
VC0011860
p11905
sg10
I15
sg11
Vtype 2 diabetes
p11906
sg13
I3
sasa(dp11907
g2
S'In comparison with the previously published experience with unilateral high-grade thalamic astrocytomas where H3F3A p.K27 was present in two-thirds of cases, the absence of this molecular subgroup in bithalamic gliomas was striking.\n'
p11908
sg4
(lp11909
(dp11910
g7
I110
sg8
VP84243
p11911
sg10
I11
sg11
VH3F3A p.K27
p11912
sg13
I2
sasg17
(lp11913
(dp11914
g7
I91
sg20
VC0004114
p11915
sg10
I12
sg11
Vastrocytomas
p11916
sg13
I1
sa(dp11917
g7
I211
sg20
VC0017638
p11918
sg10
I7
sg11
Vgliomas
p11919
sg13
I1
sasa(dp11920
g2
S'Compared with healthy controls, schizophrenia patients presented disruptions in diurnal rhythms of the expression of PER1, PER3, and NPAS2 and the release of orexin, accompanied by a delayed phase in the expression of PER2, decreases in PER3 and NPAS2 expression, and an increase in cortisol levels at baseline.\n'
p11921
sg4
(lp11922
(dp11923
g7
I123
sg8
VP56645
p11924
sg10
I4
sg11
VPER3
p11925
sg13
I1
sa(dp11926
g7
I117
sg8
g59
sg10
I4
sg11
VPER1
p11927
sg13
I1
sa(dp11928
g7
I218
sg8
g59
sg10
I4
sg11
VPER2
p11929
sg13
I1
sa(dp11930
g7
I133
sg8
g59
sg10
I5
sg11
VNPAS2
p11931
sg13
I1
sa(dp11932
g7
I133
sg8
g59
sg10
I5
sg11
VNPAS2
p11933
sg13
I1
sa(dp11934
g7
I123
sg8
VP56645
p11935
sg10
I4
sg11
VPER3
p11936
sg13
I1
sasg17
(lp11937
(dp11938
g7
I32
sg20
VC0036341
p11939
sg10
I13
sg11
Vschizophrenia
p11940
sg13
I1
sasa(dp11941
g2
S"Compared with conventional medicine alone, Ginkgo biboba in combination with conventional medicine was superior in improving Mini-Mental State Examination (MMSE) scores at 24 weeks for patients with Alzheimer's disease (MD 2.39, 95% CI 1.28 to 3.50, P&lt;0.0001) and mild cognitive impairment (MD 1.90, 95% CI 1.41 to 2.39, P&lt;0.00001), and Activity of Daily Living (ADL) scores at 24 weeks for Alzheimer's disease (MD -3.72, 95% CI -5.68 to -1.76, P=0.0002).\n"
p11942
sg4
(lp11943
sg17
(lp11944
(dp11945
g7
I199
sg20
VC1521724
p11946
sg10
I19
sg11
VAlzheimer's disease
p11947
sg13
I2
sa(dp11948
g7
I199
sg20
VC1521724
p11949
sg10
I19
sg11
VAlzheimer's disease
p11950
sg13
I2
sa(dp11951
g7
I267
sg20
VC1270972
p11952
sg10
I25
sg11
Vmild cognitive impairment
p11953
sg13
I3
sasa(dp11954
g2
S"Patients with multiple sclerosis (MS) (median 46.2 pg/ml, n=95), amyotrophic lateral sclerosis (ALS) (160.1 pg/ml, n=50), mild cognitive impairment/Alzheimer's disease (MCI/AD) (65.6 pg/ml, n=20), Guillain-Barre syndrome (GBS) (91.0 pg/ml, n=20) or subarachnoid hemorrhage (SAH) (345.0 pg/ml, n=20) had higher CSF NfH(SMI35) values than the reference cohort (27.1 pg/ml, n=73, p&lt;0.0001 for each comparison).\n"
p11955
sg4
(lp11956
(dp11957
g7
I303
sg8
VP12036
p11958
sg10
I14
sg11
Vhigher CSF NfH
p11959
sg13
I3
sasg17
(lp11960
(dp11961
g7
I122
sg20
VC1270972
p11962
sg10
I25
sg11
Vmild cognitive impairment
p11963
sg13
I3
sa(dp11964
g7
I65
sg20
VC0002736
p11965
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p11966
sg13
I3
sa(dp11967
g7
I197
sg20
VC0018378
p11968
sg10
I23
sg11
VGuillain-Barre syndrome
p11969
sg13
I2
sa(dp11970
g7
I34
sg20
VC0026769
p11971
sg10
I2
sg11
VMS
p11972
sg13
I1
sa(dp11973
g7
I222
sg20
VC1841700
p11974
sg10
I3
sg11
VGBS
p11975
sg13
I1
sa(dp11976
g7
I14
sg20
VC0026769
p11977
sg10
I18
sg11
Vmultiple sclerosis
p11978
sg13
I2
sa(dp11979
g7
I96
sg20
VC0002736
p11980
sg10
I3
sg11
VALS
p11981
sg13
I1
sa(dp11982
g7
I148
sg20
VC1521724
p11983
sg10
I19
sg11
VAlzheimer's disease
p11984
sg13
I2
sa(dp11985
g7
I169
sg20
VC1270972
p11986
sg10
I3
sg11
VMCI
p11987
sg13
I1
sa(dp11988
g7
I249
sg20
VC0038525
p11989
sg10
I23
sg11
Vsubarachnoid hemorrhage
p11990
sg13
I2
sa(dp11991
g7
I274
sg20
VC0038525
p11992
sg10
I3
sg11
VSAH
p11993
sg13
I1
sasa(dp11994
g2
S'The present study delineates four more patterns and their families: the achondroplasia pattern, spondyloepiphyseal dysplasia congenita pattern, the Larsen/OPD pattern and the Stickler/Kniest pattern.\n'
p11995
sg4
(lp11996
sg17
(lp11997
(dp11998
g7
I96
sg20
VC2745959
p11999
sg10
I38
sg11
Vspondyloepiphyseal dysplasia congenita
p12000
sg13
I3
sa(dp12001
g7
I72
sg20
VC0001080
p12002
sg10
I14
sg11
Vachondroplasia
p12003
sg13
I1
sasa(dp12004
g2
S'Glis2/NPHP7 is a transcriptional regulator mutated in type 7 nephronophthisis, an autosomal recessive ciliopathy associated with cystic and fibrotic kidney disease as well as characteristic extrarenal manifestations.\n'
p12005
sg4
(lp12006
(dp12007
g7
I6
sg8
g59
sg10
I5
sg11
VNPHP7
p12008
sg13
I1
sa(dp12009
g7
I0
sg8
g59
sg10
I5
sg11
VGlis2
p12010
sg13
I1
sasg17
(lp12011
(dp12012
g7
I149
sg20
VC0022658
p12013
sg10
I14
sg11
Vkidney disease
p12014
sg13
I2
sa(dp12015
g7
I61
sg20
VC0687120
p12016
sg10
I16
sg11
Vnephronophthisis
p12017
sg13
I1
sa(dp12018
g7
I6
sg20
VC1969092
p12019
sg10
I5
sg11
VNPHP7
p12020
sg13
I1
sasa(dp12021
g2
S'Although BBS11/TRIM32 represents a RING finger E3 ubiquitin ligase also involved in hereditary forms of muscular dystrophy, NPHP7/Glis2 is a Gli-like transcriptional repressor that localizes to the nucleus, deviating from the ciliary localization of most other ciliopathy-associated gene products.\n'
p12022
sg4
(lp12023
(dp12024
g7
I130
sg8
g59
sg10
I5
sg11
VGlis2
p12025
sg13
I1
sa(dp12026
g7
I124
sg8
g59
sg10
I5
sg11
VNPHP7
p12027
sg13
I1
sa(dp12028
g7
I141
sg8
VP08151
p12029
sg10
I34
sg11
VGli-like transcriptional repressor
p12030
sg13
I3
sa(dp12031
g7
I9
sg8
g59
sg10
I5
sg11
VBBS11
p12032
sg13
I1
sa(dp12033
g7
I35
sg8
g59
sg10
I31
sg11
VRING finger E3 ubiquitin ligase
p12034
sg13
I5
sa(dp12035
g7
I15
sg8
g59
sg10
I6
sg11
VTRIM32
p12036
sg13
I1
sasg17
(lp12037
(dp12038
g7
I124
sg20
VC1969092
p12039
sg10
I5
sg11
VNPHP7
p12040
sg13
I1
sa(dp12041
g7
I104
sg20
VC0026850
p12042
sg10
I18
sg11
Vmuscular dystrophy
p12043
sg13
I2
sa(dp12044
g7
I9
sg20
VC1859569
p12045
sg10
I5
sg11
VBBS11
p12046
sg13
I1
sasa(dp12047
g2
S'The knockdown of zebrafish bbs1 and nphp7.2 caused similar phenotypic changes including convergent extension defects, curvature of the body axis, hydrocephalus, abnormal heart looping and cystic pronephros, all consistent with an altered ciliary function.\n'
p12048
sg4
(lp12049
(dp12050
g7
I36
sg8
g59
sg10
I7
sg11
Vnphp7.2
p12051
sg13
I1
sa(dp12052
g7
I27
sg8
g59
sg10
I4
sg11
Vbbs1
p12053
sg13
I1
sasg17
(lp12054
(dp12055
g7
I36
sg20
VC1969092
p12056
sg10
I5
sg11
Vnphp7
p12057
sg13
I1
sa(dp12058
g7
I146
sg20
VC0020255
p12059
sg10
I13
sg11
Vhydrocephalus
p12060
sg13
I1
sasa(dp12061
g2
S'In addition, we present the first case of Caroli disease due to mutations in WDR19/NPHP13 and the second case ever with a recessive mutation in GLIS2/NPHP7.\n'
p12062
sg4
(lp12063
(dp12064
g7
I144
sg8
g59
sg10
I5
sg11
VGLIS2
p12065
sg13
I1
sa(dp12066
g7
I150
sg8
g59
sg10
I5
sg11
VNPHP7
p12067
sg13
I1
sa(dp12068
g7
I77
sg8
g59
sg10
I5
sg11
VWDR19
p12069
sg13
I1
sasg17
(lp12070
(dp12071
g7
I42
sg20
VC0162510
p12072
sg10
I14
sg11
VCaroli disease
p12073
sg13
I2
sa(dp12074
g7
I150
sg20
VC1969092
p12075
sg10
I5
sg11
VNPHP7
p12076
sg13
I1
sa(dp12077
g7
I83
sg20
VC3280612
p12078
sg10
I6
sg11
VNPHP13
p12079
sg13
I1
sasa(dp12080
g2
S'Asymptomatic subjects aged 6 to 12 years with myopia of 0.50 to 5.00 D and astigmatism of 1.25 to 3.50 D of axes 180 +/- 20 were fitted with Menicon Z Night Toric Lens (NKL Contactlenzen B.V., Emmen, The Netherlands).\n'
p12081
sg4
(lp12082
sg17
(lp12083
(dp12084
g7
I46
sg20
VC0027092
p12085
sg10
I6
sg11
Vmyopia
p12086
sg13
I1
sa(dp12087
g7
I75
sg20
VC0004106
p12088
sg10
I11
sg11
Vastigmatism
p12089
sg13
I1
sa(dp12090
g7
I129
sg20
VC0036572
p12091
sg10
I6
sg11
Vfitted
p12092
sg13
I1
sasa(dp12093
g2
S'In humans, a mutation in the Glis2 gene has been linked to the development of nephronophthisis (NPHP), a recessive cystic kidney disease, while mutations in Glis3 lead to an extended multisystem phenotype that includes the development of neonatal diabetes, polycystic kidneys, congenital hypothyroidism, and facial dysmorphism.\n'
p12094
sg4
(lp12095
(dp12096
g7
I157
sg8
g59
sg10
I5
sg11
VGlis3
p12097
sg13
I1
sa(dp12098
g7
I29
sg8
g59
sg10
I10
sg11
VGlis2 gene
p12099
sg13
I2
sasg17
(lp12100
(dp12101
g7
I115
sg20
VC1691228
p12102
sg10
I21
sg11
Vcystic kidney disease
p12103
sg13
I3
sa(dp12104
g7
I308
sg20
VC0266617
p12105
sg10
I18
sg11
Vfacial dysmorphism
p12106
sg13
I2
sa(dp12107
g7
I96
sg20
VC0687120
p12108
sg10
I4
sg11
VNPHP
p12109
sg13
I1
sa(dp12110
g7
I277
sg20
VC0342200
p12111
sg10
I25
sg11
Vcongenital hypothyroidism
p12112
sg13
I2
sa(dp12113
g7
I78
sg20
VC0687120
p12114
sg10
I16
sg11
Vnephronophthisis
p12115
sg13
I1
sa(dp12116
g7
I257
sg20
VC0022680
p12117
sg10
I18
sg11
Vpolycystic kidneys
p12118
sg13
I2
sa(dp12119
g7
I238
sg20
VC0158981
p12120
sg10
I17
sg11
Vneonatal diabetes
p12121
sg13
I2
sasa(dp12122
g2
S'Mutations in GLIS2 are linked to nephronophthisis, a chronic kidney disease characterized by renal fibrosis and atrophy in children and young adults.\n'
p12123
sg4
(lp12124
(dp12125
g7
I13
sg8
g59
sg10
I5
sg11
VGLIS2
p12126
sg13
I1
sasg17
(lp12127
(dp12128
g7
I112
sg20
VC0333641
p12129
sg10
I7
sg11
Vatrophy
p12130
sg13
I1
sa(dp12131
g7
I93
sg20
VC0151650
p12132
sg10
I14
sg11
Vrenal fibrosis
p12133
sg13
I2
sa(dp12134
g7
I33
sg20
VC0687120
p12135
sg10
I16
sg11
Vnephronophthisis
p12136
sg13
I1
sa(dp12137
g7
I53
sg20
VC1561643
p12138
sg10
I22
sg11
Vchronic kidney disease
p12139
sg13
I3
sasa(dp12140
g2
S'Two genes linked to schizophrenia, DTNBP1 and MUTED, encode proteins that belong to the endosome-localized Biogenesis of Lysosome-related Organelles Complex-1 (BLOC-1).\n'
p12141
sg4
(lp12142
(dp12143
g7
I46
sg8
g59
sg10
I5
sg11
VMUTED
p12144
sg13
I1
sa(dp12145
g7
I107
sg8
VP78537
p12146
sg10
I51
sg11
VBiogenesis of Lysosome-related Organelles Complex-1
p12147
sg13
I5
sa(dp12148
g7
I35
sg8
g59
sg10
I6
sg11
VDTNBP1
p12149
sg13
I1
sa(dp12150
g7
I160
sg8
VP78537
p12151
sg10
I6
sg11
VBLOC-1
p12152
sg13
I1
sasg17
(lp12153
(dp12154
g7
I20
sg20
VC0036341
p12155
sg10
I13
sg11
Vschizophrenia
p12156
sg13
I1
sasa(dp12157
g2
S'Disrupted in schizophrenia 1 (DISC1) controls the microtubule network that is used by viruses as a route to the nucleus, while DTNBP1, MUTED, and BLOC1S3 regulate endosomal to lysosomal routing that is also important in viral traffic.\n'
p12158
sg4
(lp12159
(dp12160
g7
I30
sg8
g59
sg10
I5
sg11
VDISC1
p12161
sg13
I1
sa(dp12162
g7
I146
sg8
g59
sg10
I7
sg11
VBLOC1S3
p12163
sg13
I1
sa(dp12164
g7
I0
sg8
g59
sg10
I28
sg11
VDisrupted in schizophrenia 1
p12165
sg13
I4
sa(dp12166
g7
I135
sg8
g59
sg10
I5
sg11
VMUTED
p12167
sg13
I1
sa(dp12168
g7
I127
sg8
g59
sg10
I6
sg11
VDTNBP1
p12169
sg13
I1
sasg17
(lp12170
(dp12171
g7
I13
sg20
VC0220702
p12172
sg10
I15
sg11
Vschizophrenia 1
p12173
sg13
I2
sasa(dp12174
g2
S'The schizophrenia susceptibility gene dystrobrevin-binding protein 1 (DTNBP1) encodes dysbindin, which along with its binding partner Muted is an essential component of the biogenesis of lysosome-related organelles complex 1 (BLOC-1).\n'
p12175
sg4
(lp12176
(dp12177
g7
I4
sg8
VP14222
p12178
sg10
I64
sg11
Vschizophrenia susceptibility gene dystrobrevin-binding protein 1
p12179
sg13
I6
sa(dp12180
g7
I226
sg8
VP78537
p12181
sg10
I6
sg11
VBLOC-1
p12182
sg13
I1
sa(dp12183
g7
I173
sg8
VP78537
p12184
sg10
I51
sg11
Vbiogenesis of lysosome-related organelles complex 1
p12185
sg13
I6
sa(dp12186
g7
I70
sg8
g59
sg10
I6
sg11
VDTNBP1
p12187
sg13
I1
sasg17
(lp12188
(dp12189
g7
I4
sg20
VC0036341
p12190
sg10
I13
sg11
Vschizophrenia
p12191
sg13
I1
sasa(dp12192
g2
S'The IR1 patients are characterized by higher prevalence of obesity, pathological waist, MetS, dyslipidemia and IGT/DM2.\n'
p12193
sg4
(lp12194
(dp12195
g7
I88
sg8
VP41162
p12196
sg10
I4
sg11
VMetS
p12197
sg13
I1
sasg17
(lp12198
(dp12199
g7
I94
sg20
VC0242339
p12200
sg10
I12
sg11
Vdyslipidemia
p12201
sg13
I1
sa(dp12202
g7
I115
sg20
VC2931689
p12203
sg10
I3
sg11
VDM2
p12204
sg13
I1
sa(dp12205
g7
I59
sg20
VC0028754
p12206
sg10
I7
sg11
Vobesity
p12207
sg13
I1
sasa(dp12208
g2
S'Pretreatment with SB203580, a p38 MAPK inhibitor, dramatically abrogated the upregulating effects of DG-1g on p-p38 MAPK/p38 MAPK, p-CREB/CREB, and p-Bad/Bad ratios and HIF-1[Formula: see text], VEGF-A, and vWF expression and the downregulating effects of DG-1g on GFAP, cytochrome c, cleaved caspase-3, and cerebral infarction.\n'
p12209
sg4
(lp12210
(dp12211
g7
I131
sg8
VP16220
p12212
sg10
I6
sg11
Vp-CREB
p12213
sg13
I1
sa(dp12214
g7
I148
sg8
g59
sg10
I5
sg11
Vp-Bad
p12215
sg13
I1
sa(dp12216
g7
I169
sg8
g59
sg10
I5
sg11
VHIF-1
p12217
sg13
I1
sa(dp12218
g7
I271
sg8
VP99999
p12219
sg10
I12
sg11
Vcytochrome c
p12220
sg13
I2
sa(dp12221
g7
I207
sg8
VP04275
p12222
sg10
I3
sg11
VvWF
p12223
sg13
I1
sa(dp12224
g7
I150
sg8
g59
sg10
I3
sg11
VBad
p12225
sg13
I1
sa(dp12226
g7
I293
sg8
VP42574
p12227
sg10
I9
sg11
Vcaspase-3
p12228
sg13
I1
sa(dp12229
g7
I30
sg8
VP46108
p12230
sg10
I8
sg11
Vp38 MAPK
p12231
sg13
I2
sa(dp12232
g7
I30
sg8
VP46108
p12233
sg10
I3
sg11
Vp38
p12234
sg13
I1
sa(dp12235
g7
I30
sg8
VP46108
p12236
sg10
I3
sg11
Vp38
p12237
sg13
I1
sa(dp12238
g7
I133
sg8
VP16220
p12239
sg10
I4
sg11
VCREB
p12240
sg13
I1
sasg17
(lp12241
(dp12242
g7
I308
sg20
VC0038454
p12243
sg10
I19
sg11
Vcerebral infarction
p12244
sg13
I2
sasa(dp12245
g2
S'SB203580, a specific inhibitor of p38 MAPK, administered 30 min prior to ischemia abrogated the downregulating effects of I-FA on cerebral infarction, and mitochondrial Bax and cleaved caspase-3 expression, and the upregulating effects of I-FA on the p-p38 MAPK/p38 MAPK ratio, p-p90RSK expression, p-Bad expression, and the p-CREB/CREB, and cytosolic and mitochondrial Bcl-2/Bax ratios.\n'
p12246
sg4
(lp12247
(dp12248
g7
I370
sg8
VP10415
p12249
sg10
I5
sg11
VBcl-2
p12250
sg13
I1
sa(dp12251
g7
I34
sg8
VP46108
p12252
sg10
I3
sg11
Vp38
p12253
sg13
I1
sa(dp12254
g7
I325
sg8
VP16220
p12255
sg10
I6
sg11
Vp-CREB
p12256
sg13
I1
sa(dp12257
g7
I327
sg8
VP16220
p12258
sg10
I4
sg11
VCREB
p12259
sg13
I1
sa(dp12260
g7
I34
sg8
VP46108
p12261
sg10
I3
sg11
Vp38
p12262
sg13
I1
sa(dp12263
g7
I185
sg8
VP42574
p12264
sg10
I9
sg11
Vcaspase-3
p12265
sg13
I1
sa(dp12266
g7
I34
sg8
VP46108
p12267
sg10
I3
sg11
Vp38
p12268
sg13
I1
sa(dp12269
g7
I299
sg8
g59
sg10
I5
sg11
Vp-Bad
p12270
sg13
I1
sasg17
(lp12271
(dp12272
g7
I73
sg20
VC0022116
p12273
sg10
I8
sg11
Vischemia
p12274
sg13
I1
sa(dp12275
g7
I130
sg20
VC0038454
p12276
sg10
I19
sg11
Vcerebral infarction
p12277
sg13
I2
sasa(dp12278
g2
S'Studies on small populations assessed the relevance of an oxytocin treatment in several endocrine and nutritional pathologies like post-surgery craniopharyngioma, panhypopituitarism and obesity.\n'
p12279
sg4
(lp12280
(dp12281
g7
I58
sg8
VP01178
p12282
sg10
I8
sg11
Voxytocin
p12283
sg13
I1
sasg17
(lp12284
(dp12285
g7
I163
sg20
VC0242343
p12286
sg10
I18
sg11
Vpanhypopituitarism
p12287
sg13
I1
sa(dp12288
g7
I186
sg20
VC0028754
p12289
sg10
I7
sg11
Vobesity
p12290
sg13
I1
sa(dp12291
g7
I144
sg20
VC0010276
p12292
sg10
I17
sg11
Vcraniopharyngioma
p12293
sg13
I1
sasa(dp12294
g2
S'Oxytocin is structurally related to vasopressin and is synthesised in the same hypothalamic nuclei, thus we hypothesised that patients with acquired central diabetes insipidus and anterior hypopituitarism would display an oxytocin deficiency.\n'
p12295
sg4
(lp12296
(dp12297
g7
I36
sg8
VP01185
p12298
sg10
I11
sg11
Vvasopressin
p12299
sg13
I1
sa(dp12300
g7
I222
sg8
VP01178
p12301
sg10
I8
sg11
Voxytocin
p12302
sg13
I1
sa(dp12303
g7
I0
sg8
VP01178
p12304
sg10
I8
sg11
VOxytocin
p12305
sg13
I1
sasg17
(lp12306
(dp12307
g7
I222
sg20
VC0342395
p12308
sg10
I19
sg11
Voxytocin deficiency
p12309
sg13
I2
sa(dp12310
g7
I189
sg20
VC0020635
p12311
sg10
I15
sg11
Vhypopituitarism
p12312
sg13
I1
sa(dp12313
g7
I149
sg20
VC0687720
p12314
sg10
I26
sg11
Vcentral diabetes insipidus
p12315
sg13
I3
sasa(dp12316
g2
S'Fifty-six participants (age 46.54 +/- 16.30 yrs; central diabetes insipidus: n = 20, 8 males; clinical control: n = 15, 6 males; healthy control: n = 20, 7 males) provided two saliva samples which were analysed for oxytocin and completed two empathy tasks.\n'
p12317
sg4
(lp12318
(dp12319
g7
I215
sg8
VP01178
p12320
sg10
I8
sg11
Voxytocin
p12321
sg13
I1
sasg17
(lp12322
(dp12323
g7
I49
sg20
VC0687720
p12324
sg10
I26
sg11
Vcentral diabetes insipidus
p12325
sg13
I3
sasa(dp12326
g2
S'Hypopituitary patients (both central diabetes insipidus and clinical control groups) had significantly lower oxytocin concentrations compared to healthy control participants.\n'
p12327
sg4
(lp12328
sg17
(lp12329
(dp12330
g7
I29
sg20
VC0687720
p12331
sg10
I26
sg11
Vcentral diabetes insipidus
p12332
sg13
I3
sasa(dp12333
g2
S"Regression analyses further revealed that central diabetes insipidus patients' oxytocin concentrations significantly predicted their performance on easy items of the reading the mind in the eyes task.\n"
p12334
sg4
(lp12335
sg17
(lp12336
(dp12337
g7
I42
sg20
VC0687720
p12338
sg10
I26
sg11
Vcentral diabetes insipidus
p12339
sg13
I3
sasa(dp12340
g2
S'Hypopituitarism may therefore be associated with reduced oxytocin concentrations and impaired empathic ability.\n'
p12341
sg4
(lp12342
(dp12343
g7
I57
sg8
VP01178
p12344
sg10
I8
sg11
Voxytocin
p12345
sg13
I1
sasg17
(lp12346
(dp12347
g7
I0
sg20
VC0020635
p12348
sg10
I15
sg11
VHypopituitarism
p12349
sg13
I1
sa(dp12350
g7
I85
sg20
VC0684336
p12351
sg10
I8
sg11
Vimpaired
p12352
sg13
I1
sasa(dp12353
g2
S'While further studies are needed to replicate these findings, our data suggest that oxytocin replacement may offer a therapeutic approach to improve psychological well-being in patients with hypopituitarism.\n'
p12354
sg4
(lp12355
(dp12356
g7
I84
sg8
VP01178
p12357
sg10
I8
sg11
Voxytocin
p12358
sg13
I1
sasg17
(lp12359
(dp12360
g7
I191
sg20
VC0020635
p12361
sg10
I15
sg11
Vhypopituitarism
p12362
sg13
I1
sa(dp12363
g7
I149
sg20
VC1306597
p12364
sg10
I13
sg11
Vpsychological
p12365
sg13
I1
sasa(dp12366
g2
S'Oxytocin was measured in saliva of craniopharyngioma patients and controls before and after standardized breakfast and associations with gender, body mass index, hypothalamic involvement, diabetes insipidus, and irradiation were analyzed.\n'
p12367
sg4
(lp12368
(dp12369
g7
I0
sg8
VP01178
p12370
sg10
I8
sg11
VOxytocin
p12371
sg13
I1
sasg17
(lp12372
(dp12373
g7
I35
sg20
VC0010276
p12374
sg10
I17
sg11
Vcraniopharyngioma
p12375
sg13
I1
sa(dp12376
g7
I188
sg20
VC0687720
p12377
sg10
I18
sg11
Vdiabetes insipidus
p12378
sg13
I2
sasa(dp12379
g2
S'In light of these findings, the authors believe that further research into the potential benefits of intranasal oxytocin therapy for patients with panhypopituitarism is necessary to determine whether a broader population may also benefit from intranasal oxytocin therapy.\n'
p12380
sg4
(lp12381
(dp12382
g7
I112
sg8
VP01178
p12383
sg10
I8
sg11
Voxytocin
p12384
sg13
I1
sa(dp12385
g7
I112
sg8
VP01178
p12386
sg10
I8
sg11
Voxytocin
p12387
sg13
I1
sasg17
(lp12388
(dp12389
g7
I147
sg20
VC0242343
p12390
sg10
I18
sg11
Vpanhypopituitarism
p12391
sg13
I1
sasa(dp12392
g2
S'We report four cases of panhypopituitarism who had spontaneous onset of labor, undermining the role of maternal oxytocin in the first phase of labor.\n'
p12393
sg4
(lp12394
(dp12395
g7
I103
sg8
VP01178
p12396
sg10
I17
sg11
Vmaternal oxytocin
p12397
sg13
I2
sasg17
(lp12398
(dp12399
g7
I24
sg20
VC0242343
p12400
sg10
I18
sg11
Vpanhypopituitarism
p12401
sg13
I1
sasa(dp12402
g2
S'This study investigated the expression level and prognostic significance of CD39 in human rectal adenocarcinoma.\n'
p12403
sg4
(lp12404
(dp12405
g7
I76
sg8
VP49961
p12406
sg10
I4
sg11
VCD39
p12407
sg13
I1
sasg17
(lp12408
(dp12409
g7
I90
sg20
VC0149978
p12410
sg10
I21
sg11
Vrectal adenocarcinoma
p12411
sg13
I2
sasa(dp12412
g2
S'In addition to primary tumors, CD39 was also abundantly expressed in liver metastases and tumor-draining lymph nodes from metastatic rectal adenocarcinoma.\n'
p12413
sg4
(lp12414
(dp12415
g7
I31
sg8
VP49961
p12416
sg10
I4
sg11
VCD39
p12417
sg13
I1
sasg17
(lp12418
(dp12419
g7
I23
sg20
VC0027651
p12420
sg10
I5
sg11
Vtumor
p12421
sg13
I1
sa(dp12422
g7
I69
sg20
VC0494165
p12423
sg10
I16
sg11
Vliver metastases
p12424
sg13
I2
sa(dp12425
g7
I133
sg20
VC0149978
p12426
sg10
I21
sg11
Vrectal adenocarcinoma
p12427
sg13
I2
sa(dp12428
g7
I15
sg20
VC0677930
p12429
sg10
I14
sg11
Vprimary tumors
p12430
sg13
I2
sasa(dp12431
g2
S'Taken together, the current study revealed that malignant epithelial cells of human rectal adenocarcinoma strongly express CD39 that may play a potential role in the tumor invasion and metastasis.\n'
p12432
sg4
(lp12433
(dp12434
g7
I123
sg8
VP49961
p12435
sg10
I4
sg11
VCD39
p12436
sg13
I1
sasg17
(lp12437
(dp12438
g7
I185
sg20
VC0027627
p12439
sg10
I10
sg11
Vmetastasis
p12440
sg13
I1
sa(dp12441
g7
I172
sg20
VC2699153
p12442
sg10
I8
sg11
Vinvasion
p12443
sg13
I1
sa(dp12444
g7
I166
sg20
VC0027651
p12445
sg10
I5
sg11
Vtumor
p12446
sg13
I1
sa(dp12447
g7
I84
sg20
VC0149978
p12448
sg10
I21
sg11
Vrectal adenocarcinoma
p12449
sg13
I2
sasa(dp12450
g2
S'The aim of this research was to prepare 99mTc-EDDA/HYNIC-Lys(Nal)-Urea-Glu (99mTc-EDDA/HYNIC-iPSMA) obtained from lyophilized kit formulations and evaluate the in vitro and in vivo radiopharmaceutical binding to prostate cancer cells over-expressing PSMA, as well as the 99mTc-EDDA/HYNIC-iPSMA normal biodistribution in humans and the preliminary uptake in patients with prostate cancer.\n'
p12451
sg4
(lp12452
sg17
(lp12453
(dp12454
g7
I212
sg20
VC0600139
p12455
sg10
I15
sg11
Vprostate cancer
p12456
sg13
I2
sa(dp12457
g7
I212
sg20
VC0600139
p12458
sg10
I15
sg11
Vprostate cancer
p12459
sg13
I2
sasa(dp12460
g2
S'Hepatocarcinoma (HepG2), lymphoma (Jurkat) and osteosarcoma (HOS) cells, incubated with 6.25, 12.5, 25, 50, 75 and 100% of Aba Eku (AEL), Olusosun (OSL), Awotan (AWL) and Nagpur (NPL) simulated leachates for 24 h, were assessed for cell viability using MTT assay and morphological alterations.\n'
p12461
sg4
(lp12462
sg17
(lp12463
(dp12464
g7
I0
sg20
VC2239176
p12465
sg10
I15
sg11
VHepatocarcinoma
p12466
sg13
I1
sa(dp12467
g7
I61
sg20
VC0265264
p12468
sg10
I3
sg11
VHOS
p12469
sg13
I1
sa(dp12470
g7
I47
sg20
VC0029463
p12471
sg10
I12
sg11
Vosteosarcoma
p12472
sg13
I1
sa(dp12473
g7
I25
sg20
VC0024299
p12474
sg10
I8
sg11
Vlymphoma
p12475
sg13
I1
sasa(dp12476
g2
S'Thirteen months later, he was hospitalized for lethargy and hyponatremia of 108 mEq/L, with an antidiuretic hormone level of 2.5 pg/mL, which suggested syndrome of inappropriate antidiuretic hormone secretion (SIADH).\n'
p12477
sg4
(lp12478
sg17
(lp12479
(dp12480
g7
I47
sg20
VC0023380
p12481
sg10
I8
sg11
Vlethargy
p12482
sg13
I1
sa(dp12483
g7
I210
sg20
VC0021141
p12484
sg10
I5
sg11
VSIADH
p12485
sg13
I1
sa(dp12486
g7
I152
sg20
VC0021141
p12487
sg10
I56
sg11
Vsyndrome of inappropriate antidiuretic hormone secretion
p12488
sg13
I6
sasa(dp12489
g2
S'Mutations of either AVPR2 or AQP2 result in a genetic disease known as nephrogenic diabetes insipidus, which is characterized by the lack of responsiveness of the collecting duct to the antidiuretic action of AVP.\n'
p12490
sg4
(lp12491
(dp12492
g7
I20
sg8
VP30518
p12493
sg10
I5
sg11
VAVPR2
p12494
sg13
I1
sa(dp12495
g7
I29
sg8
VP41181
p12496
sg10
I4
sg11
VAQP2
p12497
sg13
I1
sa(dp12498
g7
I20
sg8
VP01185
p12499
sg10
I3
sg11
VAVP
p12500
sg13
I1
sasg17
(lp12501
(dp12502
g7
I71
sg20
VC0162283
p12503
sg10
I30
sg11
Vnephrogenic diabetes insipidus
p12504
sg13
I3
sa(dp12505
g7
I46
sg20
VC0019247
p12506
sg10
I15
sg11
Vgenetic disease
p12507
sg13
I2
sasa(dp12508
g2
S'Here we provide an updated overview of the genetic defects causing NDI, the most recent strategies under investigation for rescuing the activity of mutated AVPR2 or AQP2, or for bypassing defective AVPR2 signaling and restoring AQP2 plasma membrane expression.\n'
p12509
sg4
(lp12510
(dp12511
g7
I165
sg8
VP41181
p12512
sg10
I4
sg11
VAQP2
p12513
sg13
I1
sa(dp12514
g7
I156
sg8
VP30518
p12515
sg10
I5
sg11
VAVPR2
p12516
sg13
I1
sa(dp12517
g7
I165
sg8
VP41181
p12518
sg10
I4
sg11
VAQP2
p12519
sg13
I1
sa(dp12520
g7
I156
sg8
VP30518
p12521
sg10
I5
sg11
VAVPR2
p12522
sg13
I1
sasg17
(lp12523
(dp12524
g7
I67
sg20
VC1563705
p12525
sg10
I3
sg11
VNDI
p12526
sg13
I1
sasa(dp12527
g2
S'Such disorders underlie syndromes of inappropriate secretion of antidiuretic hormone (SIADH) and edematous diseases, such as congestive heart failure and decompensated liver cirrhosis.\n'
p12528
sg4
(lp12529
sg17
(lp12530
(dp12531
g7
I24
sg20
VC0039082
p12532
sg10
I9
sg11
Vsyndromes
p12533
sg13
I1
sa(dp12534
g7
I51
sg20
VC0021141
p12535
sg10
I33
sg11
Vsecretion of antidiuretic hormone
p12536
sg13
I4
sa(dp12537
g7
I86
sg20
VC0021141
p12538
sg10
I5
sg11
VSIADH
p12539
sg13
I1
sa(dp12540
g7
I168
sg20
VC0023890
p12541
sg10
I15
sg11
Vliver cirrhosis
p12542
sg13
I2
sa(dp12543
g7
I125
sg20
VC0018802
p12544
sg10
I24
sg11
Vcongestive heart failure
p12545
sg13
I3
sa(dp12546
g7
I97
sg20
VC0013604
p12547
sg10
I9
sg11
Vedematous
p12548
sg13
I1
sasa(dp12549
g2
S'AVP-induced water retention could produce hyponatremia, and further accelerate poor long-term outcome of edematous diseases.\n'
p12550
sg4
(lp12551
(dp12552
g7
I0
sg8
VP01185
p12553
sg10
I3
sg11
VAVP
p12554
sg13
I1
sasg17
(lp12555
(dp12556
g7
I105
sg20
VC0013604
p12557
sg10
I9
sg11
Vedematous
p12558
sg13
I1
sasa(dp12559
g2
S'Central diabetes insipidus (DI) is a rare disease characterized by the excretion of excessive volumes of dilute urine due to reduced levels of the antidiuretic hormone arginine vasopressin (AVP), caused by an acquired or genetic defect in the neurohypophysis.\n'
p12560
sg4
(lp12561
(dp12562
g7
I190
sg8
VP01185
p12563
sg10
I3
sg11
VAVP
p12564
sg13
I1
sa(dp12565
g7
I147
sg8
VP01185
p12566
sg10
I41
sg11
Vantidiuretic hormone arginine vasopressin
p12567
sg13
I4
sasg17
(lp12568
(dp12569
g7
I0
sg20
VC0687720
p12570
sg10
I26
sg11
VCentral diabetes insipidus
p12571
sg13
I3
sa(dp12572
g7
I37
sg20
VC0678236
p12573
sg10
I12
sg11
Vrare disease
p12574
sg13
I2
sasa(dp12575
g2
S'The finding of novel autoantigens, GAPDH and ADH strengthen the hypothesis that DH is an autoimmune disease of the liver.\n'
p12576
sg4
(lp12577
(dp12578
g7
I35
sg8
VP04406
p12579
sg10
I5
sg11
VGAPDH
p12580
sg13
I1
sa(dp12581
g7
I45
sg8
VP07327
p12582
sg10
I3
sg11
VADH
p12583
sg13
I1
sasg17
(lp12584
(dp12585
g7
I89
sg20
VC0004364
p12586
sg10
I18
sg11
Vautoimmune disease
p12587
sg13
I2
sasa(dp12588
g2
S'To observe the influence of electroacupuncture (EA) stimulation with different electrical current intensities and therapeutic intervals on learning-memory ability and expression of Beta-amyloid peptide ABeta 1-40 and arginine vasopressin (AVP) genes in the hippocampal CA 1 region in vascular dementia (VD) rats, so as to provide evidence for treatment of VD.\n'
p12589
sg4
(lp12590
(dp12591
g7
I269
sg8
VP00915
p12592
sg10
I11
sg11
VCA 1 region
p12593
sg13
I3
sa(dp12594
g7
I239
sg8
VP01185
p12595
sg10
I3
sg11
VAVP
p12596
sg13
I1
sa(dp12597
g7
I181
sg8
VP01185
p12598
sg10
I56
sg11
VBeta-amyloid peptide ABeta 1-40 and arginine vasopressin
p12599
sg13
I7
sasg17
(lp12600
(dp12601
g7
I303
sg20
VC0497327
p12602
sg10
I2
sg11
VVD
p12603
sg13
I1
sa(dp12604
g7
I303
sg20
VC0497327
p12605
sg10
I2
sg11
VVD
p12606
sg13
I1
sa(dp12607
g7
I284
sg20
VC0011269
p12608
sg10
I17
sg11
Vvascular dementia
p12609
sg13
I2
sa(dp12610
g7
I186
sg20
VC0011560
p12611
sg10
I7
sg11
Vamyloid
p12612
sg13
I1
sasa(dp12613
g2
S'The present study investigated TAGLN2 expression patterns in HBV related hepatocellular carcinoma (HCC) tissues and its role in HBV transcription and replication.\n'
p12614
sg4
(lp12615
sg17
(lp12616
(dp12617
g7
I61
sg20
VC0019163
p12618
sg10
I3
sg11
VHBV
p12619
sg13
I1
sa(dp12620
g7
I61
sg20
VC0019163
p12621
sg10
I3
sg11
VHBV
p12622
sg13
I1
sa(dp12623
g7
I99
sg20
VC2239176
p12624
sg10
I3
sg11
VHCC
p12625
sg13
I1
sa(dp12626
g7
I73
sg20
VC2239176
p12627
sg10
I24
sg11
Vhepatocellular carcinoma
p12628
sg13
I2
sasa(dp12629
g2
S'Using Skyline software package, we demonstrated a statistically significant higher abundance of the C1R, LCN2, SLPI, FAM49B, TAGLN2, CFB, C3, C4B, LRG1, SERPINA1 candidate biomarkers in the saliva of OSCC patients.\n'
p12630
sg4
(lp12631
(dp12632
g7
I142
sg8
VP04003
p12633
sg10
I3
sg11
VC4B
p12634
sg13
I1
sa(dp12635
g7
I117
sg8
g59
sg10
I6
sg11
VFAM49B
p12636
sg13
I1
sa(dp12637
g7
I125
sg8
VP37802
p12638
sg10
I6
sg11
VTAGLN2
p12639
sg13
I1
sa(dp12640
g7
I147
sg8
VP02750
p12641
sg10
I4
sg11
VLRG1
p12642
sg13
I1
sa(dp12643
g7
I111
sg8
VP03973
p12644
sg10
I4
sg11
VSLPI
p12645
sg13
I1
sa(dp12646
g7
I105
sg8
VP80188
p12647
sg10
I4
sg11
VLCN2
p12648
sg13
I1
sa(dp12649
g7
I100
sg8
VP00736
p12650
sg10
I3
sg11
VC1R
p12651
sg13
I1
sasg17
(lp12652
sa(dp12653
g2
S'To investigate the relationship between the expression of transgelin-2 and the clinicopathological factors of colorectal carcinoma and evaluate the value of transgelin-2 in prognostic assessment of the colorectal cancer patients.\n'
p12654
sg4
(lp12655
(dp12656
g7
I58
sg8
VP37802
p12657
sg10
I12
sg11
Vtransgelin-2
p12658
sg13
I1
sa(dp12659
g7
I58
sg8
VP37802
p12660
sg10
I12
sg11
Vtransgelin-2
p12661
sg13
I1
sasg17
(lp12662
(dp12663
g7
I202
sg20
VC0009402
p12664
sg10
I17
sg11
Vcolorectal cancer
p12665
sg13
I2
sa(dp12666
g7
I110
sg20
VC0009402
p12667
sg10
I20
sg11
Vcolorectal carcinoma
p12668
sg13
I2
sasa(dp12669
g2
S'Using tissue microarray and immunohistochemical methods, we examined transgelin-2 of 120 colorectal cancer patients received surgical treatment from September 2002 to April 2004, including 74 male and 46 female, age from 26 to 89 years.\n'
p12670
sg4
(lp12671
sg17
(lp12672
(dp12673
g7
I89
sg20
VC1527249
p12674
sg10
I17
sg11
Vcolorectal cancer
p12675
sg13
I2
sasa(dp12676
g2
S'Analyzed the relationship between transgelin-2 and both the clinicopathological features and prognosis of the colorectal cancer by using X^2 test and Kaplan-Meier survival analysis.\n'
p12677
sg4
(lp12678
(dp12679
g7
I34
sg8
VP37802
p12680
sg10
I12
sg11
Vtransgelin-2
p12681
sg13
I1
sasg17
(lp12682
(dp12683
g7
I110
sg20
VC1527249
p12684
sg10
I17
sg11
Vcolorectal cancer
p12685
sg13
I2
sasa(dp12686
g2
S'Distant metastasis (RR = 8.318, 95%CI: 4.119 - 16.790), lymph nodes metastasis (RR = 2.794, 95%CI: 1.246 - 6.263) and transgelin-2 expression (RR = 1.834, 95%CI: 1.118- 2.973) were independent prognostic factors in patients with colorectal cancer (P &lt; 0.05).\n'
p12687
sg4
(lp12688
(dp12689
g7
I118
sg8
VP37802
p12690
sg10
I12
sg11
Vtransgelin-2
p12691
sg13
I1
sasg17
(lp12692
(dp12693
g7
I229
sg20
VC1527249
p12694
sg10
I17
sg11
Vcolorectal cancer
p12695
sg13
I2
sa(dp12696
g7
I8
sg20
VC0027627
p12697
sg10
I10
sg11
Vmetastasis
p12698
sg13
I1
sa(dp12699
g7
I8
sg20
VC0027627
p12700
sg10
I10
sg11
Vmetastasis
p12701
sg13
I1
sasa(dp12702
g2
S'The expression of transgelin-2 is correlated with clinicopathological features and prognosis in colorectal cancer, may be the potential marker of metastasis and the prognosis of colorectal cancer patients.\n'
p12703
sg4
(lp12704
(dp12705
g7
I18
sg8
VP37802
p12706
sg10
I12
sg11
Vtransgelin-2
p12707
sg13
I1
sasg17
(lp12708
(dp12709
g7
I96
sg20
VC1527249
p12710
sg10
I17
sg11
Vcolorectal cancer
p12711
sg13
I2
sa(dp12712
g7
I96
sg20
VC1527249
p12713
sg10
I17
sg11
Vcolorectal cancer
p12714
sg13
I2
sa(dp12715
g7
I146
sg20
VC0027627
p12716
sg10
I10
sg11
Vmetastasis
p12717
sg13
I1
sasa(dp12718
g2
S'In conclusion, epigenetic repression of the miR-1-133a cluster may play a critical             role in colorectal cancer metastasis by silencing TAGLN2.\n'
p12719
sg4
(lp12720
(dp12721
g7
I44
sg8
g59
sg10
I18
sg11
VmiR-1-133a cluster
p12722
sg13
I2
sa(dp12723
g7
I145
sg8
VP37802
p12724
sg10
I6
sg11
VTAGLN2
p12725
sg13
I1
sasg17
(lp12726
(dp12727
g7
I121
sg20
VC0027627
p12728
sg10
I10
sg11
Vmetastasis
p12729
sg13
I1
sa(dp12730
g7
I103
sg20
VC1527249
p12731
sg10
I17
sg11
Vcolorectal cancer
p12732
sg13
I2
sasa(dp12733
g2
S"Furthermore, among 22 m/z species that are differentially expressed in Barrett's adenocarcinoma cases with and without regional lymph node metastasis, one was identified as TAGLN2.\n"
p12734
sg4
(lp12735
(dp12736
g7
I173
sg8
VP37802
p12737
sg10
I6
sg11
VTAGLN2
p12738
sg13
I1
sasg17
(lp12739
(dp12740
g7
I71
sg20
VC1332460
p12741
sg10
I24
sg11
VBarrett's adenocarcinoma
p12742
sg13
I2
sa(dp12743
g7
I128
sg20
VC0686619
p12744
sg10
I21
sg11
Vlymph node metastasis
p12745
sg13
I3
sasa(dp12746
g2
S"In the validation set, we found a correlation of the expression levels of COX7A2 and TAGLN2 with a poor prognosis while S100-A10 was confirmed by multivariate analysis as a novel independent prognostic factor in Barrett's adenocarcinoma.\n"
p12747
sg4
(lp12748
(dp12749
g7
I74
sg8
VP14406
p12750
sg10
I6
sg11
VCOX7A2
p12751
sg13
I1
sa(dp12752
g7
I85
sg8
VP37802
p12753
sg10
I6
sg11
VTAGLN2
p12754
sg13
I1
sasg17
(lp12755
(dp12756
g7
I212
sg20
VC1332460
p12757
sg10
I24
sg11
VBarrett's adenocarcinoma
p12758
sg13
I2
sasa(dp12759
g2
S'The clinical situations associated with increased bleeding risk (old symptoms) in patients with type 3 vWD compared to obligatory carriers were epistaxis [odds ratio (OR) = 175.5; 95% confidence interval (CI) 14.55-2116.69; P &lt; 0.001], cutaneous symptoms (OR = 108; 95% CI 10.16-1147.39; P &lt; 0.001) and hemarthrosis (OR = 19.5%; 95% CI 4.32-156.46; P &lt; 0.001).\n'
p12760
sg4
(lp12761
sg17
(lp12762
(dp12763
g7
I50
sg20
VC0019080
p12764
sg10
I8
sg11
Vbleeding
p12765
sg13
I1
sa(dp12766
g7
I96
sg20
VC1264041
p12767
sg10
I10
sg11
Vtype 3 vWD
p12768
sg13
I3
sa(dp12769
g7
I144
sg20
VC0014591
p12770
sg10
I9
sg11
Vepistaxis
p12771
sg13
I1
sa(dp12772
g7
I309
sg20
VC0018924
p12773
sg10
I12
sg11
Vhemarthrosis
p12774
sg13
I1
sasa(dp12775
g2
S'Up to 40% of patients with type 3 VWD experience joint bleeding, which can lead to haemophilic arthropathy.\n'
p12776
sg4
(lp12777
sg17
(lp12778
(dp12779
g7
I83
sg20
VC0263725
p12780
sg10
I23
sg11
Vhaemophilic arthropathy
p12781
sg13
I2
sa(dp12782
g7
I49
sg20
VC0018924
p12783
sg10
I14
sg11
Vjoint bleeding
p12784
sg13
I2
sa(dp12785
g7
I27
sg20
VC1264041
p12786
sg10
I10
sg11
Vtype 3 VWD
p12787
sg13
I3
sasa(dp12788
g2
S'The rationale for long-term prophylaxis in vWD is obvious: prophylaxis has been successfully used in hemophilia, and joint hemorrhages with development of hemophilic arthropathy can occur, especially in type 3 vWD.\n'
p12789
sg4
(lp12790
(dp12791
g7
I43
sg8
VP04275
p12792
sg10
I3
sg11
VvWD
p12793
sg13
I1
sa(dp12794
g7
I203
sg8
VP04275
p12795
sg10
I10
sg11
Vtype 3 vWD
p12796
sg13
I3
sasg17
(lp12797
(dp12798
g7
I155
sg20
VC0263725
p12799
sg10
I22
sg11
Vhemophilic arthropathy
p12800
sg13
I2
sa(dp12801
g7
I123
sg20
VC0019080
p12802
sg10
I11
sg11
Vhemorrhages
p12803
sg13
I1
sa(dp12804
g7
I101
sg20
VC0684275
p12805
sg10
I10
sg11
Vhemophilia
p12806
sg13
I1
sa(dp12807
g7
I203
sg20
VC1264041
p12808
sg10
I10
sg11
Vtype 3 vWD
p12809
sg13
I3
sasa(dp12810
g2
S'The arthropathy results from recurrent bleeding into a joint, with the ankle and hip being the joints most often affected, particularly in patients with type 3 vWD.\n'
p12811
sg4
(lp12812
sg17
(lp12813
(dp12814
g7
I4
sg20
VC0022408
p12815
sg10
I11
sg11
Varthropathy
p12816
sg13
I1
sa(dp12817
g7
I153
sg20
VC1264041
p12818
sg10
I10
sg11
Vtype 3 vWD
p12819
sg13
I3
sa(dp12820
g7
I39
sg20
VC0019080
p12821
sg10
I8
sg11
Vbleeding
p12822
sg13
I1
sasa(dp12823
g2
S'Here, we conducted a microarray analysis and found that miR-374c-5p was most down-regulated miRNA in TGFBeta1-treated cervical cancer cells compared to the expression in parental cell lines.\n'
p12824
sg4
(lp12825
(dp12826
g7
I56
sg8
g59
sg10
I11
sg11
VmiR-374c-5p
p12827
sg13
I1
sa(dp12828
g7
I101
sg8
VP01137
p12829
sg10
I8
sg11
VTGFBeta1
p12830
sg13
I1
sasg17
(lp12831
(dp12832
g7
I118
sg20
VC0302592
p12833
sg10
I15
sg11
Vcervical cancer
p12834
sg13
I2
sasa(dp12835
g2
S'Ectopic overexpression of miR-374c-5p inhibited cervical cancerl invasion and migration in TGFBeta1- treated cervical cancer cells.\n'
p12836
sg4
(lp12837
(dp12838
g7
I91
sg8
VP01137
p12839
sg10
I8
sg11
VTGFBeta1
p12840
sg13
I1
sa(dp12841
g7
I26
sg8
g59
sg10
I11
sg11
VmiR-374c-5p
p12842
sg13
I1
sasg17
(lp12843
(dp12844
g7
I48
sg20
VC0302592
p12845
sg10
I15
sg11
Vcervical cancer
p12846
sg13
I2
sa(dp12847
g7
I65
sg20
VC2699153
p12848
sg10
I8
sg11
Vinvasion
p12849
sg13
I1
sasa(dp12850
g2
S'In clinical cervical cancer samples, lower miR-374c-5p expression predicted poor patient survival and highe lymph node metastasis in cervical cancers.\n'
p12851
sg4
(lp12852
(dp12853
g7
I43
sg8
g59
sg10
I11
sg11
VmiR-374c-5p
p12854
sg13
I1
sasg17
(lp12855
(dp12856
g7
I108
sg20
VC0686619
p12857
sg10
I21
sg11
Vlymph node metastasis
p12858
sg13
I3
sa(dp12859
g7
I133
sg20
VC0007847
p12860
sg10
I16
sg11
Vcervical cancers
p12861
sg13
I2
sa(dp12862
g7
I12
sg20
VC0007847
p12863
sg10
I15
sg11
Vcervical cancer
p12864
sg13
I2
sasa(dp12865
g2
S'miR-374c-5p was negatively correlated with FOXC1, which was upregulated in cervical cancers with lymph node metastasis.\n'
p12866
sg4
(lp12867
(dp12868
g7
I43
sg8
g59
sg10
I5
sg11
VFOXC1
p12869
sg13
I1
sa(dp12870
g7
I0
sg8
g59
sg10
I11
sg11
VmiR-374c-5p
p12871
sg13
I1
sasg17
(lp12872
(dp12873
g7
I97
sg20
VC0686619
p12874
sg10
I21
sg11
Vlymph node metastasis
p12875
sg13
I3
sa(dp12876
g7
I75
sg20
VC0007847
p12877
sg10
I16
sg11
Vcervical cancers
p12878
sg13
I2
sasa(dp12879
g2
S'Taken together, our findings highlight the important role of miR-374c-5p in regulating cervical cancers metastasis by targeting FOXC1, suggesting that miR-374c-5p may represent a novel potential therapeutic target and prognostic marker in cervical cancers.\n'
p12880
sg4
(lp12881
(dp12882
g7
I128
sg8
g59
sg10
I5
sg11
VFOXC1
p12883
sg13
I1
sa(dp12884
g7
I61
sg8
g59
sg10
I11
sg11
VmiR-374c-5p
p12885
sg13
I1
sa(dp12886
g7
I61
sg8
g59
sg10
I11
sg11
VmiR-374c-5p
p12887
sg13
I1
sasg17
(lp12888
(dp12889
g7
I87
sg20
VC0007847
p12890
sg10
I16
sg11
Vcervical cancers
p12891
sg13
I2
sa(dp12892
g7
I104
sg20
VC0027627
p12893
sg10
I10
sg11
Vmetastasis
p12894
sg13
I1
sa(dp12895
g7
I87
sg20
VC0007847
p12896
sg10
I16
sg11
Vcervical cancers
p12897
sg13
I2
sasa(dp12898
g2
S'Our studies of a mouse model reveal that phospholipase CGamma1 (PLCGamma1) is the dominant signaling effector by which excessive activation of TrkB promotes epilepsy.\n'
p12899
sg4
(lp12900
(dp12901
g7
I143
sg8
g59
sg10
I4
sg11
VTrkB
p12902
sg13
I1
sa(dp12903
g7
I64
sg8
VP19174
p12904
sg10
I9
sg11
VPLCGamma1
p12905
sg13
I1
sa(dp12906
g7
I41
sg8
VP04054
p12907
sg10
I21
sg11
Vphospholipase CGamma1
p12908
sg13
I2
sasg17
(lp12909
(dp12910
g7
I157
sg20
VC0014544
p12911
sg10
I8
sg11
Vepilepsy
p12912
sg13
I1
sasa(dp12913
g2
S'These findings advance PLCGamma1 as a novel target for therapies aimed at preventing temporal lobe epilepsy induced by status epilepticus.\n'
p12914
sg4
(lp12915
sg17
(lp12916
(dp12917
g7
I119
sg20
VC0038220
p12918
sg10
I18
sg11
Vstatus epilepticus
p12919
sg13
I2
sa(dp12920
g7
I85
sg20
VC0014556
p12921
sg10
I22
sg11
Vtemporal lobe epilepsy
p12922
sg13
I3
sasa(dp12923
g2
S"Significantly, abnormal expression and activation of PLC-Gamma1 appears in various brain disorders such as epilepsy, depression, Huntington's disease and Alzheimer's disease.\n"
p12924
sg4
(lp12925
(dp12926
g7
I53
sg8
VP98160
p12927
sg10
I10
sg11
VPLC-Gamma1
p12928
sg13
I1
sasg17
(lp12929
(dp12930
g7
I154
sg20
VC1521724
p12931
sg10
I19
sg11
VAlzheimer's disease
p12932
sg13
I2
sa(dp12933
g7
I83
sg20
VC0006111
p12934
sg10
I15
sg11
Vbrain disorders
p12935
sg13
I2
sa(dp12936
g7
I107
sg20
VC0014544
p12937
sg10
I8
sg11
Vepilepsy
p12938
sg13
I1
sa(dp12939
g7
I129
sg20
VC0020179
p12940
sg10
I20
sg11
VHuntington's disease
p12941
sg13
I2
sa(dp12942
g7
I117
sg20
VC0011581
p12943
sg10
I10
sg11
Vdepression
p12944
sg13
I1
sasa(dp12945
g2
S'Here, we aimed to assess whether murine Gpx4, a crucial antioxidant enzyme that protects neurons from membrane damage and ferroptosis, is critical for the protection from neuronal inflammation in two distinct pathophysiologic diseases, namely metabolic dysfunction in diet-induced obesity or PD.\n'
p12946
sg4
(lp12947
(dp12948
g7
I40
sg8
VP36969
p12949
sg10
I4
sg11
VGpx4
p12950
sg13
I1
sasg17
(lp12951
(dp12952
g7
I281
sg20
VC0028754
p12953
sg10
I7
sg11
Vobesity
p12954
sg13
I1
sa(dp12955
g7
I180
sg20
VC0021368
p12956
sg10
I12
sg11
Vinflammation
p12957
sg13
I1
sasa(dp12958
g2
S'In this work, we studied the prognostic value of the expression of 9 proteins, Ki-67, p53, Bcl-2, PSA, HER2, E-cadherin, p21WAF1/Cip1, p27Kip1 and p16ink4a in prostate cancer.\n'
p12959
sg4
(lp12960
(dp12961
g7
I98
sg8
VP55786
p12962
sg10
I3
sg11
VPSA
p12963
sg13
I1
sa(dp12964
g7
I147
sg8
VP42771
p12965
sg10
I8
sg11
Vp16ink4a
p12966
sg13
I1
sa(dp12967
g7
I79
sg8
VP46013
p12968
sg10
I5
sg11
VKi-67
p12969
sg13
I1
sa(dp12970
g7
I86
sg8
VP42771
p12971
sg10
I3
sg11
Vp53
p12972
sg13
I1
sa(dp12973
g7
I135
sg8
VP46527
p12974
sg10
I7
sg11
Vp27Kip1
p12975
sg13
I1
sa(dp12976
g7
I129
sg8
VP38936
p12977
sg10
I4
sg11
VCip1
p12978
sg13
I1
sa(dp12979
g7
I109
sg8
VP12830
p12980
sg10
I10
sg11
VE-cadherin
p12981
sg13
I1
sa(dp12982
g7
I91
sg8
VP10415
p12983
sg10
I5
sg11
VBcl-2
p12984
sg13
I1
sa(dp12985
g7
I103
sg8
VP04626
p12986
sg10
I4
sg11
VHER2
p12987
sg13
I1
sasg17
(lp12988
(dp12989
g7
I159
sg20
VC0600139
p12990
sg10
I15
sg11
Vprostate cancer
p12991
sg13
I2
sa(dp12992
g7
I98
sg20
VC1519176
p12993
sg10
I3
sg11
VPSA
p12994
sg13
I1
sasa(dp12995
g2
S'The p53, Bcl-2, Ki-67 and p27Kip1 proteins may be useful additional prognostic markers for prostate cancer.\n'
p12996
sg4
(lp12997
(dp12998
g7
I4
sg8
VP42771
p12999
sg10
I3
sg11
Vp53
p13000
sg13
I1
sa(dp13001
g7
I26
sg8
VP46527
p13002
sg10
I16
sg11
Vp27Kip1 proteins
p13003
sg13
I2
sa(dp13004
g7
I9
sg8
VP10415
p13005
sg10
I5
sg11
VBcl-2
p13006
sg13
I1
sa(dp13007
g7
I16
sg8
VP46013
p13008
sg10
I5
sg11
VKi-67
p13009
sg13
I1
sasg17
(lp13010
(dp13011
g7
I91
sg20
VC0600139
p13012
sg10
I15
sg11
Vprostate cancer
p13013
sg13
I2
sasa(dp13014
g2
S'The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 (CDKN1B) and p16 (CDK2NA) was investigated.\n'
p13015
sg4
(lp13016
(dp13017
g7
I173
sg8
VP42771
p13018
sg10
I3
sg11
Vp16
p13019
sg13
I1
sa(dp13020
g7
I156
sg8
VP40305
p13021
sg10
I3
sg11
Vp27
p13022
sg13
I1
sa(dp13023
g7
I161
sg8
VP46527
p13024
sg10
I6
sg11
VCDKN1B
p13025
sg13
I1
sa(dp13026
g7
I31
sg8
g59
sg10
I6
sg11
VmiR-24
p13027
sg13
I1
sasg17
(lp13028
(dp13029
g7
I52
sg20
VC0600139
p13030
sg10
I15
sg11
Vprostate cancer
p13031
sg13
I2
sasa(dp13032
g2
S'Additional mechanistic studies of two biomarkers, phosphatase and tensin homolog (PTEN) and cyclin-dependent kinase inhibitor 1B (p27Kip1), in prostate cancer revealed that TFC treatment significantly upregulated the expression of PTEN and p27Kip1.\n'
p13033
sg4
(lp13034
(dp13035
g7
I82
sg8
VP60484
p13036
sg10
I4
sg11
VPTEN
p13037
sg13
I1
sa(dp13038
g7
I130
sg8
VP46527
p13039
sg10
I7
sg11
Vp27Kip1
p13040
sg13
I1
sa(dp13041
g7
I92
sg8
VP46527
p13042
sg10
I36
sg11
Vcyclin-dependent kinase inhibitor 1B
p13043
sg13
I4
sa(dp13044
g7
I130
sg8
VP46527
p13045
sg10
I7
sg11
Vp27Kip1
p13046
sg13
I1
sa(dp13047
g7
I50
sg8
VP60484
p13048
sg10
I30
sg11
Vphosphatase and tensin homolog
p13049
sg13
I4
sa(dp13050
g7
I82
sg8
VP60484
p13051
sg10
I4
sg11
VPTEN
p13052
sg13
I1
sasg17
(lp13053
(dp13054
g7
I143
sg20
VC0600139
p13055
sg10
I15
sg11
Vprostate cancer
p13056
sg13
I2
sasa(dp13057
g2
S'Dual labeling fluorescence in situ hybridization using probes for 12p13 (CDKN1B; p27) and centromere 12 as a reference was used to successfully analyze more than 3700 prostate cancers with clinical follow-up data assembled in a tissue microarray format.\n'
p13058
sg4
(lp13059
(dp13060
g7
I81
sg8
VP40305
p13061
sg10
I3
sg11
Vp27
p13062
sg13
I1
sa(dp13063
g7
I73
sg8
VP46527
p13064
sg10
I6
sg11
VCDKN1B
p13065
sg13
I1
sasg17
(lp13066
(dp13067
g7
I167
sg20
VC0376358
p13068
sg10
I16
sg11
Vprostate cancers
p13069
sg13
I2
sasa(dp13070
g2
S'In the present work hypomethylation of the DDX43 gene was detected in 15% (32/214) of primary acute myeloid leukemia (AML) using real-time quantitative methylation-specific PCR (RQ-MSP).\n'
p13071
sg4
(lp13072
(dp13073
g7
I43
sg8
g59
sg10
I10
sg11
VDDX43 gene
p13074
sg13
I2
sasg17
(lp13075
(dp13076
g7
I94
sg20
VC0023467
p13077
sg10
I22
sg11
Vacute myeloid leukemia
p13078
sg13
I3
sa(dp13079
g7
I118
sg20
VC0023467
p13080
sg10
I3
sg11
VAML
p13081
sg13
I1
sasa(dp13082
g2
S'In the present study, we investigated the methylation status of the DDX43 promoter in 87 Chinese patients with chronic myeloid leukemia (CML) using real-time quantitative methylation-specific polymerase chain reaction and examined the DDX43 transcript in 35 patients using real-time quantitative polymerase chain reaction.\n'
p13083
sg4
(lp13084
(dp13085
g7
I235
sg8
g59
sg10
I16
sg11
VDDX43 transcript
p13086
sg13
I2
sa(dp13087
g7
I68
sg8
g59
sg10
I14
sg11
VDDX43 promoter
p13088
sg13
I2
sasg17
(lp13089
(dp13090
g7
I111
sg20
VC0023473
p13091
sg10
I24
sg11
Vchronic myeloid leukemia
p13092
sg13
I3
sa(dp13093
g7
I137
sg20
VC0023473
p13094
sg10
I3
sg11
VCML
p13095
sg13
I1
sasa(dp13096
g2
S'The aim of this study was to investigate the expression status of the helicase antigen (HAGE) transcript and its clinical significance in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).\n'
p13097
sg4
(lp13098
(dp13099
g7
I70
sg8
g59
sg10
I16
sg11
Vhelicase antigen
p13100
sg13
I2
sa(dp13101
g7
I88
sg8
g59
sg10
I4
sg11
VHAGE
p13102
sg13
I1
sasg17
(lp13103
(dp13104
g7
I152
sg20
VC0023467
p13105
sg10
I22
sg11
Vacute myeloid leukemia
p13106
sg13
I3
sa(dp13107
g7
I176
sg20
VC0023467
p13108
sg10
I3
sg11
VAML
p13109
sg13
I1
sa(dp13110
g7
I185
sg20
VC0023473
p13111
sg10
I24
sg11
Vchronic myeloid leukemia
p13112
sg13
I3
sa(dp13113
g7
I211
sg20
VC0023473
p13114
sg10
I3
sg11
VCML
p13115
sg13
I1
sasa(dp13116
g2
S'HAGE cDNA expression was more frequently present among the patients with acute monoblastic leukemia (M(4) and M(5), 7 of 20, 35.0%), compared to the patients with acute non-monoblastic leukemia (M(1), M(2), M(3) and M(6), 4 of 54, 7.4%) (p = 0.007).\n'
p13117
sg4
(lp13118
sg17
(lp13119
(dp13120
g7
I79
sg20
VC1321422
p13121
sg10
I20
sg11
Vmonoblastic leukemia
p13122
sg13
I2
sa(dp13123
g7
I73
sg20
VC0023465
p13124
sg10
I26
sg11
Vacute monoblastic leukemia
p13125
sg13
I3
sasa(dp13126
g2
S'Here, we report the expression patterns of ADAM8, ADAM9, ADAM10, ADAM12, ADAM17 and ADAM19 in cultured human myoblasts and peripheral blood mononuclear cells (PBMCs) in vitro, as well as in biopsies from patients suffering from polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM) and non-inflammatory controls.\n'
p13127
sg4
(lp13128
(dp13129
g7
I50
sg8
g59
sg10
I5
sg11
VADAM9
p13130
sg13
I1
sa(dp13131
g7
I84
sg8
g59
sg10
I6
sg11
VADAM19
p13132
sg13
I1
sa(dp13133
g7
I43
sg8
VP78325
p13134
sg10
I5
sg11
VADAM8
p13135
sg13
I1
sa(dp13136
g7
I57
sg8
g59
sg10
I6
sg11
VADAM10
p13137
sg13
I1
sa(dp13138
g7
I73
sg8
VP78536
p13139
sg10
I6
sg11
VADAM17
p13140
sg13
I1
sa(dp13141
g7
I65
sg8
g59
sg10
I6
sg11
VADAM12
p13142
sg13
I1
sasg17
(lp13143
(dp13144
g7
I294
sg20
VC0238190
p13145
sg10
I3
sg11
VIBM
p13146
sg13
I1
sa(dp13147
g7
I264
sg20
VC0221056
p13148
sg10
I2
sg11
VDM
p13149
sg13
I1
sa(dp13150
g7
I228
sg20
VC0085655
p13151
sg10
I12
sg11
Vpolymyositis
p13152
sg13
I1
sa(dp13153
g7
I242
sg20
VC0085655
p13154
sg10
I2
sg11
VPM
p13155
sg13
I1
sa(dp13156
g7
I213
sg20
VC0683278
p13157
sg10
I9
sg11
Vsuffering
p13158
sg13
I1
sa(dp13159
g7
I247
sg20
VC0221056
p13160
sg10
I15
sg11
Vdermatomyositis
p13161
sg13
I1
sa(dp13162
g7
I269
sg20
VC0238190
p13163
sg10
I23
sg11
Vinclusion body myositis
p13164
sg13
I3
sasa(dp13165
g2
S'However, the neurotoxicity and mechanisms of TDBP-TAZTO have not yet been studied.\n'
p13166
sg4
(lp13167
(dp13168
g7
I45
sg8
g59
sg10
I10
sg11
VTDBP-TAZTO
p13169
sg13
I1
sasg17
(lp13170
sa(dp13171
g2
S'We hypothesize that TDBP-TAZTO could induce neurotoxicity in mouse hippocampal neurons and SH-SY5Y cells.\n'
p13172
sg4
(lp13173
(dp13174
g7
I20
sg8
g59
sg10
I4
sg11
VTDBP
p13175
sg13
I1
sasg17
(lp13176
sa(dp13177
g2
S'Our findings suggested that cell apoptosis and oxidative stress are important mechanisms in neurotoxicity induced by TDBP-TAZTO.\n'
p13178
sg4
(lp13179
(dp13180
g7
I117
sg8
g59
sg10
I10
sg11
VTDBP-TAZTO
p13181
sg13
I1
sasg17
(lp13182
(dp13183
g7
I47
sg20
VC0242606
p13184
sg10
I16
sg11
Voxidative stress
p13185
sg13
I2
sasa(dp13186
g2
S'However, the neurotoxicity of TDBP-TAZTO has not yet studied in rodents.\n'
p13187
sg4
(lp13188
(dp13189
g7
I30
sg8
g59
sg10
I10
sg11
VTDBP-TAZTO
p13190
sg13
I1
sasg17
(lp13191
sa(dp13192
g2
S'We hypothesize that TDBP-TAZTO could induce the neurotoxicity in rat hippocampal neurons.\n'
p13193
sg4
(lp13194
(dp13195
g7
I20
sg8
g59
sg10
I4
sg11
VTDBP
p13196
sg13
I1
sasg17
(lp13197
sa(dp13198
g2
S'Our findings suggested that TDBP-TAZTO induces significant hippocampal neurotoxicity, which provokes cognitive impairment and depression-like behaviors in adult rats.\n'
p13199
sg4
(lp13200
(dp13201
g7
I28
sg8
g59
sg10
I4
sg11
VTDBP
p13202
sg13
I1
sasg17
(lp13203
(dp13204
g7
I126
sg20
VC0011581
p13205
sg10
I10
sg11
Vdepression
p13206
sg13
I1
sa(dp13207
g7
I101
sg20
VC0338656
p13208
sg10
I20
sg11
Vcognitive impairment
p13209
sg13
I2
sasa(dp13210
g2
S'In addition, the top candidate lncRNA ENSG00000261777 shares an intron with DDX19, and interacts with IGF2 P1, indicating its involvement in prostate cancer.\n'
p13211
sg4
(lp13212
(dp13213
g7
I102
sg8
VP14222
p13214
sg10
I7
sg11
VIGF2 P1
p13215
sg13
I2
sa(dp13216
g7
I76
sg8
g59
sg10
I5
sg11
VDDX19
p13217
sg13
I1
sasg17
(lp13218
(dp13219
g7
I141
sg20
VC0600139
p13220
sg10
I15
sg11
Vprostate cancer
p13221
sg13
I2
sasa(dp13222
g2
S'The International Contact Dermatitis Research Group (ICDRG) in 1976 examined the incidence of sensitization to TDB P and found two positives among 1103 patients.\n'
p13223
sg4
(lp13224
sg17
(lp13225
(dp13226
g7
I18
sg20
VC0011616
p13227
sg10
I18
sg11
VContact Dermatitis
p13228
sg13
I2
sasa(dp13229
g2
S"We have previously shown that sera of AD and Down's syndrome patients contain Abs which bind specifically to the high molecular weight neurofilament protein (NF-H) of the purely cholinergic electromotor neurons of Torpedo.\n"
p13230
sg4
(lp13231
(dp13232
g7
I113
sg8
VP12036
p13233
sg10
I43
sg11
Vhigh molecular weight neurofilament protein
p13234
sg13
I5
sa(dp13235
g7
I158
sg8
VP12036
p13236
sg10
I4
sg11
VNF-H
p13237
sg13
I1
sasg17
(lp13238
(dp13239
g7
I45
sg20
VC0013080
p13240
sg10
I15
sg11
VDown's syndrome
p13241
sg13
I2
sasa(dp13242
g2
S'The analysis of sex ratios in different variants of trisomy 13 with respect to ascertainment (prenatal diagnosis, miscarriages, liveborn) also does not support an intrauterine selection against males as a cause of a female prevalence among carriers of homologous REA.\n'
p13243
sg4
(lp13244
sg17
(lp13245
(dp13246
g7
I114
sg20
VC0000786
p13247
sg10
I12
sg11
Vmiscarriages
p13248
sg13
I1
sa(dp13249
g7
I52
sg20
VC0152095
p13250
sg10
I10
sg11
Vtrisomy 13
p13251
sg13
I2
sasa(dp13252
g2
S'We have used 20 PCR-based DNA polymorphisms to determine whether trisomy 13 due to de novo rea(13q;13q) in six cases is caused by translocation (13q;13q) or isochromosome (13q;13q); to determine the parental origin of the rearrangements and the mechanisms of formation.\n'
p13253
sg4
(lp13254
sg17
(lp13255
(dp13256
g7
I130
sg20
VC0040715
p13257
sg10
I13
sg11
Vtranslocation
p13258
sg13
I1
sa(dp13259
g7
I65
sg20
VC0152095
p13260
sg10
I10
sg11
Vtrisomy 13
p13261
sg13
I2
sa(dp13262
g7
I157
sg20
VC0242621
p13263
sg10
I13
sg11
Visochromosome
p13264
sg13
I1
sasa(dp13265
g2
S'Nominal significance was shown for 12 SNPs from BDNF, DRD1, HTR1E, HTR2A, HTR3B, DAT1/SLC6A3, and TPH2 genes replicating reported associations with ADHD.\n'
p13266
sg4
(lp13267
(dp13268
g7
I86
sg8
g59
sg10
I6
sg11
VSLC6A3
p13269
sg13
I1
sa(dp13270
g7
I81
sg8
g59
sg10
I4
sg11
VDAT1
p13271
sg13
I1
sa(dp13272
g7
I98
sg8
VP48775
p13273
sg10
I10
sg11
VTPH2 genes
p13274
sg13
I2
sa(dp13275
g7
I74
sg8
g59
sg10
I5
sg11
VHTR3B
p13276
sg13
I1
sa(dp13277
g7
I67
sg8
VP28223
p13278
sg10
I5
sg11
VHTR2A
p13279
sg13
I1
sa(dp13280
g7
I60
sg8
VP28566
p13281
sg10
I5
sg11
VHTR1E
p13282
sg13
I1
sa(dp13283
g7
I54
sg8
VP21728
p13284
sg10
I4
sg11
VDRD1
p13285
sg13
I1
sa(dp13286
g7
I148
sg8
g59
sg10
I4
sg11
VADHD
p13287
sg13
I1
sasg17
(lp13288
(dp13289
g7
I148
sg20
VC1263846
p13290
sg10
I4
sg11
VADHD
p13291
sg13
I1
sasa(dp13292
g2
S'For overt aggressive impulsivity nominal significance was shown for 6 SNPs from BDNF, DRD4, HTR1E, PNMT, and TPH2 genes that have also been reported to be associated with ADHD.\n'
p13293
sg4
(lp13294
(dp13295
g7
I92
sg8
VP28566
p13296
sg10
I5
sg11
VHTR1E
p13297
sg13
I1
sa(dp13298
g7
I99
sg8
VP11086
p13299
sg10
I4
sg11
VPNMT
p13300
sg13
I1
sa(dp13301
g7
I109
sg8
VP48775
p13302
sg10
I10
sg11
VTPH2 genes
p13303
sg13
I2
sa(dp13304
g7
I171
sg8
g59
sg10
I4
sg11
VADHD
p13305
sg13
I1
sa(dp13306
g7
I86
sg8
VP21917
p13307
sg10
I4
sg11
VDRD4
p13308
sg13
I1
sasg17
(lp13309
(dp13310
g7
I10
sg20
VC0001807
p13311
sg10
I10
sg11
Vaggressive
p13312
sg13
I1
sa(dp13313
g7
I171
sg20
VC1263846
p13314
sg10
I4
sg11
VADHD
p13315
sg13
I1
sasa(dp13316
g2
S'Next-generation sequencing (NGS) was performed to capture and sequence all exons of 47 known retinal dystrophy-associated genes in two affected family members who had no mutations in CYP4V2.\n'
p13317
sg4
(lp13318
(dp13319
g7
I183
sg8
g59
sg10
I6
sg11
VCYP4V2
p13320
sg13
I1
sa(dp13321
g7
I93
sg8
VP55283
p13322
sg10
I34
sg11
Vretinal dystrophy-associated genes
p13323
sg13
I3
sasg17
(lp13324
(dp13325
g7
I93
sg20
VC0854723
p13326
sg10
I17
sg11
Vretinal dystrophy
p13327
sg13
I2
sasa(dp13328
g2
S'To describe a 42-year-old man, a known case of Bietti crystalline dystrophy who underwent surgery for unilateral full thickness macular hole.\n'
p13329
sg4
(lp13330
sg17
(lp13331
(dp13332
g7
I66
sg20
VC0333606
p13333
sg10
I9
sg11
Vdystrophy
p13334
sg13
I1
sa(dp13335
g7
I113
sg20
VC2733564
p13336
sg10
I27
sg11
Vfull thickness macular hole
p13337
sg13
I4
sasa(dp13338
g2
S'Macular hole can occur in Bietti crystalline dystrophy and the post-surgical outcome is good.\n'
p13339
sg4
(lp13340
sg17
(lp13341
(dp13342
g7
I0
sg20
VC0024441
p13343
sg10
I12
sg11
VMacular hole
p13344
sg13
I2
sa(dp13345
g7
I45
sg20
VC0333606
p13346
sg10
I9
sg11
Vdystrophy
p13347
sg13
I1
sasa(dp13348
g2
S'We compare the choroidal vascular area between Bietti crystalline dystrophy (BCD) patients with CYP4V2 mutations, retinitis pigmentosa (RP) patients with EYS mutations, and normal controls, and investigate the correlation between choroidal vascular area and associated parameters.\n'
p13349
sg4
(lp13350
(dp13351
g7
I96
sg8
g59
sg10
I16
sg11
VCYP4V2 mutations
p13352
sg13
I2
sasg17
(lp13353
(dp13354
g7
I47
sg20
VC1859486
p13355
sg10
I28
sg11
VBietti crystalline dystrophy
p13356
sg13
I3
sa(dp13357
g7
I114
sg20
VC0035334
p13358
sg10
I20
sg11
Vretinitis pigmentosa
p13359
sg13
I2
sa(dp13360
g7
I136
sg20
VC0035334
p13361
sg10
I2
sg11
VRP
p13362
sg13
I1
sa(dp13363
g7
I77
sg20
VC1859486
p13364
sg10
I3
sg11
VBCD
p13365
sg13
I1
sasa(dp13366
g2
S'B-scan layer-by-layer analysis and unique SD-OCT reflectivity patterns of the following retinal white lesions are reviewed in the order of their retinal layer localization: myelinated nerve fiber layer, cotton wool spot, exudates, edema residues, drusen, fundus albipunctatus, Stargardt disease, Bietti crystalline dystrophy, punctate inner choroidopathy (PIC), presumed ocular histoplasmosis syndrome (POHS), post-photocoagulation chorioretinal scarring, and osseous choristoma.\n'
p13367
sg4
(lp13368
sg17
(lp13369
(dp13370
g7
I460
sg20
VC1275276
p13371
sg10
I18
sg11
Vosseous choristoma
p13372
sg13
I2
sa(dp13373
g7
I255
sg20
VC0311338
p13374
sg10
I20
sg11
Vfundus albipunctatus
p13375
sg13
I2
sa(dp13376
g7
I277
sg20
VC0271093
p13377
sg10
I17
sg11
VStargardt disease
p13378
sg13
I2
sa(dp13379
g7
I356
sg20
VC0730321
p13380
sg10
I3
sg11
VPIC
p13381
sg13
I1
sa(dp13382
g7
I315
sg20
VC0333606
p13383
sg10
I9
sg11
Vdystrophy
p13384
sg13
I1
sa(dp13385
g7
I446
sg20
VC0008767
p13386
sg10
I8
sg11
Vscarring
p13387
sg13
I1
sa(dp13388
g7
I231
sg20
VC0013604
p13389
sg10
I5
sg11
Vedema
p13390
sg13
I1
sa(dp13391
g7
I247
sg20
VC1260959
p13392
sg10
I6
sg11
Vdrusen
p13393
sg13
I1
sa(dp13394
g7
I362
sg20
VC0339403
p13395
sg10
I39
sg11
Vpresumed ocular histoplasmosis syndrome
p13396
sg13
I4
sa(dp13397
g7
I403
sg20
VC0339403
p13398
sg10
I4
sg11
VPOHS
p13399
sg13
I1
sa(dp13400
g7
I326
sg20
VC0730321
p13401
sg10
I28
sg11
Vpunctate inner choroidopathy
p13402
sg13
I3
sasa(dp13403
g2
S'Eleven deleterious variants, six nonsense and five missense, were identified in seven genes: four LCA-associated genes (CEP290, IQCB1, NMNAT1, and RPGRIP1), one gene responsible for syndromic LCA (ALMS1), and two IRDs-related genes (CTNNA1 and CYP4V2).\n'
p13404
sg4
(lp13405
(dp13406
g7
I120
sg8
g59
sg10
I6
sg11
VCEP290
p13407
sg13
I1
sa(dp13408
g7
I244
sg8
g59
sg10
I6
sg11
VCYP4V2
p13409
sg13
I1
sa(dp13410
g7
I213
sg8
g59
sg10
I18
sg11
VIRDs-related genes
p13411
sg13
I2
sa(dp13412
g7
I128
sg8
g59
sg10
I5
sg11
VIQCB1
p13413
sg13
I1
sa(dp13414
g7
I197
sg8
g59
sg10
I5
sg11
VALMS1
p13415
sg13
I1
sa(dp13416
g7
I135
sg8
g59
sg10
I6
sg11
VNMNAT1
p13417
sg13
I1
sa(dp13418
g7
I147
sg8
g59
sg10
I7
sg11
VRPGRIP1
p13419
sg13
I1
sa(dp13420
g7
I233
sg8
VP35221
p13421
sg10
I6
sg11
VCTNNA1
p13422
sg13
I1
sasg17
(lp13423
(dp13424
g7
I98
sg20
VC0339527
p13425
sg10
I3
sg11
VLCA
p13426
sg13
I1
sa(dp13427
g7
I98
sg20
VC0339527
p13428
sg10
I3
sg11
VLCA
p13429
sg13
I1
sasa(dp13430
g2
S'The results of this study demonstrate that causative variants identified in the CTNNA1 and CYP4V2 genes are also associated with LCA.\n'
p13431
sg4
(lp13432
(dp13433
g7
I91
sg8
g59
sg10
I12
sg11
VCYP4V2 genes
p13434
sg13
I2
sa(dp13435
g7
I80
sg8
VP35221
p13436
sg10
I6
sg11
VCTNNA1
p13437
sg13
I1
sasg17
(lp13438
(dp13439
g7
I129
sg20
VC0339527
p13440
sg10
I3
sg11
VLCA
p13441
sg13
I1
sasa(dp13442
g2
S'The identification of mutations in the CTNNA1 and CYP4V2 genes requires further elucidation in larger cohorts with LCA.\n'
p13443
sg4
(lp13444
(dp13445
g7
I39
sg8
VP35221
p13446
sg10
I6
sg11
VCTNNA1
p13447
sg13
I1
sa(dp13448
g7
I50
sg8
g59
sg10
I12
sg11
VCYP4V2 genes
p13449
sg13
I2
sasg17
(lp13450
(dp13451
g7
I115
sg20
VC0339527
p13452
sg10
I3
sg11
VLCA
p13453
sg13
I1
sasa(dp13454
g2
S'Association of CNV has been reported in patients with fundus flavimaculatus, best dystrophy, gyrate atrophy, choroideremia, retinitis pigmentosa, adult-onset foveomacular vitelliform dystrophy, Sorsby macular dystrophy, Bietti crystalline dystrophy, and myotonic dystrophy-related macular dystrophy.\n'
p13455
sg4
(lp13456
sg17
(lp13457
(dp13458
g7
I82
sg20
VC0333606
p13459
sg10
I9
sg11
Vdystrophy
p13460
sg13
I1
sa(dp13461
g7
I54
sg20
VC0271093
p13462
sg10
I21
sg11
Vfundus flavimaculatus
p13463
sg13
I2
sa(dp13464
g7
I254
sg20
VC0027126
p13465
sg10
I18
sg11
Vmyotonic dystrophy
p13466
sg13
I2
sa(dp13467
g7
I171
sg20
VC0339510
p13468
sg10
I21
sg11
Vvitelliform dystrophy
p13469
sg13
I2
sa(dp13470
g7
I201
sg20
VC0242383
p13471
sg10
I17
sg11
Vmacular dystrophy
p13472
sg13
I2
sa(dp13473
g7
I109
sg20
VC0008525
p13474
sg10
I13
sg11
Vchoroideremia
p13475
sg13
I1
sa(dp13476
g7
I82
sg20
VC0333606
p13477
sg10
I9
sg11
Vdystrophy
p13478
sg13
I1
sa(dp13479
g7
I124
sg20
VC0035334
p13480
sg10
I20
sg11
Vretinitis pigmentosa
p13481
sg13
I2
sa(dp13482
g7
I93
sg20
VC0018425
p13483
sg10
I14
sg11
Vgyrate atrophy
p13484
sg13
I2
sa(dp13485
g7
I201
sg20
VC0242383
p13486
sg10
I17
sg11
Vmacular dystrophy
p13487
sg13
I2
sasa(dp13488
g2
S'To compare atrophy of the choroid and retina between Bietti crystalline dystrophy (BCD) patients and EYS-related retinitis pigmentosa (RP) patients with a similar degree of central visual field defects, age, and axial length (AL).\n'
p13489
sg4
(lp13490
sg17
(lp13491
(dp13492
g7
I83
sg20
VC1859486
p13493
sg10
I3
sg11
VBCD
p13494
sg13
I1
sa(dp13495
g7
I53
sg20
VC1859486
p13496
sg10
I28
sg11
VBietti crystalline dystrophy
p13497
sg13
I3
sa(dp13498
g7
I113
sg20
VC0035334
p13499
sg10
I20
sg11
Vretinitis pigmentosa
p13500
sg13
I2
sa(dp13501
g7
I11
sg20
VC0333641
p13502
sg10
I7
sg11
Vatrophy
p13503
sg13
I1
sa(dp13504
g7
I135
sg20
VC0035334
p13505
sg10
I2
sg11
VRP
p13506
sg13
I1
sasa(dp13507
g2
S'Bietti crystalline corneoretinal dystrophy (BCD) is an inherited eye disease that is most common in the Chinese.\n'
p13508
sg4
(lp13509
sg17
(lp13510
(dp13511
g7
I65
sg20
VC0015397
p13512
sg10
I11
sg11
Veye disease
p13513
sg13
I2
sa(dp13514
g7
I44
sg20
VC1859486
p13515
sg10
I3
sg11
VBCD
p13516
sg13
I1
sa(dp13517
g7
I0
sg20
VC1859486
p13518
sg10
I42
sg11
VBietti crystalline corneoretinal dystrophy
p13519
sg13
I4
sasa(dp13520
g2
S'In this study, 43 Chinese BCD families were recruited; most patients manifested the characteristic phenotype of BCD, with 2 families initially misdiagnosed with retinitis pigmentosa.\n'
p13521
sg4
(lp13522
sg17
(lp13523
(dp13524
g7
I161
sg20
VC0035334
p13525
sg10
I20
sg11
Vretinitis pigmentosa
p13526
sg13
I2
sa(dp13527
g7
I26
sg20
VC1859486
p13528
sg10
I3
sg11
VBCD
p13529
sg13
I1
sa(dp13530
g7
I26
sg20
VC1859486
p13531
sg10
I3
sg11
VBCD
p13532
sg13
I1
sasa(dp13533
g2
S'We hypothesize that HP-B-CD ameliorates liver cholesterol and intracellular cholesterol levels inside Kupffer cells (KCs).\n'
p13534
sg4
(lp13535
sg17
(lp13536
(dp13537
g7
I102
sg20
VC0022575
p13538
sg10
I13
sg11
VKupffer cells
p13539
sg13
I2
sa(dp13540
g7
I117
sg20
VC0022575
p13541
sg10
I3
sg11
VKCs
p13542
sg13
I1
sasa(dp13543
g2
S'In contrast to control injections, hyperlipidemic mice treated with HP-B-CD demonstrated a shift in intracellular cholesterol distribution towards cytoplasmic cholesteryl ester (CE) storage and a decrease in cholesterol crystallization inside KCs.\n'
p13544
sg4
(lp13545
sg17
(lp13546
(dp13547
g7
I243
sg20
VC0022575
p13548
sg10
I3
sg11
VKCs
p13549
sg13
I1
sasa(dp13550
g2
S'Secreted frizzled-related protein 2 (Sfrp2) is highly expressed in developing limbs and is associated with skeletal malformation such as Brachydactyly and Syndactyly.\n'
p13551
sg4
(lp13552
(dp13553
g7
I37
sg8
g59
sg10
I5
sg11
VSfrp2
p13554
sg13
I1
sa(dp13555
g7
I0
sg8
g59
sg10
I35
sg11
VSecreted frizzled-related protein 2
p13556
sg13
I4
sasg17
(lp13557
(dp13558
g7
I155
sg20
VC0039075
p13559
sg10
I10
sg11
VSyndactyly
p13560
sg13
I1
sa(dp13561
g7
I107
sg20
VC0795693
p13562
sg10
I21
sg11
Vskeletal malformation
p13563
sg13
I2
sa(dp13564
g7
I137
sg20
VC0221357
p13565
sg10
I13
sg11
VBrachydactyly
p13566
sg13
I1
sasa(dp13567
g2
S'Here, we show that inactivation of Sfrp2 results in subtle limb defects in mice with mesomelic shortening and consistent shortening of all autopodal elements that is clinically manifested as brachydactyly.\n'
p13568
sg4
(lp13569
(dp13570
g7
I35
sg8
g59
sg10
I5
sg11
VSfrp2
p13571
sg13
I1
sasg17
(lp13572
(dp13573
g7
I191
sg20
VC0221357
p13574
sg10
I13
sg11
Vbrachydactyly
p13575
sg13
I1
sa(dp13576
g7
I59
sg20
VC0740404
p13577
sg10
I12
sg11
Vlimb defects
p13578
sg13
I2
sa(dp13579
g7
I19
sg20
VC0544461
p13580
sg10
I12
sg11
Vinactivation
p13581
sg13
I1
sasa(dp13582
g2
S'Serum DHCR24 Abs from 395 HCV-positive patients, including 133 chronic hepatitis (CHC), 85 liver cirrhosis (LCC), and 177 HCC (HCC-C) patients; 232 hepatitis B virus (HBV)-positive patients, including 103 chronic hepatitis (CHB), 56 liver cirrhosis (LCB), and 73 HCC (HCC-B) patients; and 24 healthy controls, were measured using enzyme-linked immunosorbent assay.\n'
p13583
sg4
(lp13584
(dp13585
g7
I6
sg8
g59
sg10
I10
sg11
VDHCR24 Abs
p13586
sg13
I2
sasg17
(lp13587
(dp13588
g7
I91
sg20
VC0023890
p13589
sg10
I15
sg11
Vliver cirrhosis
p13590
sg13
I2
sa(dp13591
g7
I122
sg20
VC2239176
p13592
sg10
I3
sg11
VHCC
p13593
sg13
I1
sa(dp13594
g7
I167
sg20
VC0019163
p13595
sg10
I3
sg11
VHBV
p13596
sg13
I1
sa(dp13597
g7
I63
sg20
VC0019189
p13598
sg10
I17
sg11
Vchronic hepatitis
p13599
sg13
I2
sa(dp13600
g7
I122
sg20
VC2239176
p13601
sg10
I3
sg11
VHCC
p13602
sg13
I1
sa(dp13603
g7
I122
sg20
VC2239176
p13604
sg10
I3
sg11
VHCC
p13605
sg13
I1
sa(dp13606
g7
I91
sg20
VC0023890
p13607
sg10
I15
sg11
Vliver cirrhosis
p13608
sg13
I2
sa(dp13609
g7
I108
sg20
VC3281200
p13610
sg10
I3
sg11
VLCC
p13611
sg13
I1
sa(dp13612
g7
I122
sg20
VC2239176
p13613
sg10
I3
sg11
VHCC
p13614
sg13
I1
sa(dp13615
g7
I224
sg20
VC0151517
p13616
sg10
I3
sg11
VCHB
p13617
sg13
I1
sa(dp13618
g7
I82
sg20
VC0019189
p13619
sg10
I3
sg11
VCHC
p13620
sg13
I1
sa(dp13621
g7
I63
sg20
VC0019189
p13622
sg10
I17
sg11
Vchronic hepatitis
p13623
sg13
I2
sa(dp13624
g7
I148
sg20
VC0019163
p13625
sg10
I17
sg11
Vhepatitis B virus
p13626
sg13
I3
sasa(dp13627
g2
S'DHCR24 auto-antibody represents a potential noninvasive biomarker for HCV-related liver disease and may facilitate the diagnosis of PIVKA-II and AFP-negative HCC.\n'
p13628
sg4
(lp13629
(dp13630
g7
I145
sg8
VP02771
p13631
sg10
I3
sg11
VAFP
p13632
sg13
I1
sa(dp13633
g7
I0
sg8
g59
sg10
I6
sg11
VDHCR24
p13634
sg13
I1
sasg17
(lp13635
(dp13636
g7
I82
sg20
VC0023895
p13637
sg10
I13
sg11
Vliver disease
p13638
sg13
I2
sa(dp13639
g7
I158
sg20
VC2239176
p13640
sg10
I3
sg11
VHCC
p13641
sg13
I1
sasa(dp13642
g2
S'Secondly, we explore the interplay between cholesterol precursors (7-dehydrocholesterol and desmosterol) and the enzymes that act upon them (DHCR7 and DHCR24) in the context of liver disease.\n'
p13643
sg4
(lp13644
(dp13645
g7
I151
sg8
g59
sg10
I6
sg11
VDHCR24
p13646
sg13
I1
sa(dp13647
g7
I141
sg8
g59
sg10
I5
sg11
VDHCR7
p13648
sg13
I1
sasg17
(lp13649
(dp13650
g7
I177
sg20
VC0023895
p13651
sg10
I13
sg11
Vliver disease
p13652
sg13
I2
sasa(dp13653
g2
S'Here, we identify five significant miRNAs by a comprehensive analysis in esophageal cancer, and two of them (hsa-miR-100-5p and hsa-miR-133b) show better prognoses with significant difference for both 3-year and 5-year survival.\n'
p13654
sg4
(lp13655
(dp13656
g7
I128
sg8
g59
sg10
I12
sg11
Vhsa-miR-133b
p13657
sg13
I1
sa(dp13658
g7
I109
sg8
g59
sg10
I14
sg11
Vhsa-miR-100-5p
p13659
sg13
I1
sasg17
(lp13660
(dp13661
g7
I109
sg20
VC0393754
p13662
sg10
I3
sg11
Vhsa
p13663
sg13
I1
sa(dp13664
g7
I109
sg20
VC0393754
p13665
sg10
I3
sg11
Vhsa
p13666
sg13
I1
sa(dp13667
g7
I73
sg20
VC0014859
p13668
sg10
I17
sg11
Vesophageal cancer
p13669
sg13
I2
sasa(dp13670
g2
S'miR-100 has been reported to be significantly downregulated in a variety of cancers, including esophageal cancer.\n'
p13671
sg4
(lp13672
(dp13673
g7
I0
sg8
g59
sg10
I7
sg11
VmiR-100
p13674
sg13
I1
sasg17
(lp13675
(dp13676
g7
I95
sg20
VC0014859
p13677
sg10
I17
sg11
Vesophageal cancer
p13678
sg13
I2
sa(dp13679
g7
I76
sg20
VC0006826
p13680
sg10
I7
sg11
Vcancers
p13681
sg13
I1
sasa(dp13682
g2
S'However, the role of miR-100 in human esophageal cancer has not been fully elucidated.\n'
p13683
sg4
(lp13684
(dp13685
g7
I21
sg8
g59
sg10
I7
sg11
VmiR-100
p13686
sg13
I1
sasg17
(lp13687
(dp13688
g7
I38
sg20
VC0014859
p13689
sg10
I17
sg11
Vesophageal cancer
p13690
sg13
I2
sasa(dp13691
g2
S'We demonstrated that overexpression of miR-100 in esophageal cancer cells markedly inhibited cell proliferation, migration and invasion as well as tumor growth.\n'
p13692
sg4
(lp13693
(dp13694
g7
I39
sg8
g59
sg10
I7
sg11
VmiR-100
p13695
sg13
I1
sasg17
(lp13696
(dp13697
g7
I50
sg20
VC0014859
p13698
sg10
I17
sg11
Vesophageal cancer
p13699
sg13
I2
sa(dp13700
g7
I98
sg20
VC0334094
p13701
sg10
I13
sg11
Vproliferation
p13702
sg13
I1
sa(dp13703
g7
I147
sg20
VC0598934
p13704
sg10
I12
sg11
Vtumor growth
p13705
sg13
I2
sa(dp13706
g7
I127
sg20
VC2699153
p13707
sg10
I8
sg11
Vinvasion
p13708
sg13
I1
sasa(dp13709
g2
S'Our results indicated that miR-100 plays a tumor-suppressor role in esophageal cancer and suggest its potential application for esophageal cancer treatment.\n'
p13710
sg4
(lp13711
sg17
(lp13712
(dp13713
g7
I68
sg20
VC0014859
p13714
sg10
I17
sg11
Vesophageal cancer
p13715
sg13
I2
sa(dp13716
g7
I68
sg20
VC0014859
p13717
sg10
I17
sg11
Vesophageal cancer
p13718
sg13
I2
sa(dp13719
g7
I43
sg20
VC0027651
p13720
sg10
I5
sg11
Vtumor
p13721
sg13
I1
sasa(dp13722
g2
S'Age (odds ratio (OR) 0.980; p &lt; 0.001), advanced clinical tumor stage (cT3 vs. cTa, cTis, cT1; OR 3.367; p &lt; 0.001), presence of hydronephrosis (OR 1.844; p = 0.043) and advanced tumor stage T3 and/or N+ at CT imaging (OR 4.378; p &lt; 0.001) were independent predictors for pT3/4 and/or pN+ tumor stage.\n'
p13723
sg4
(lp13724
sg17
(lp13725
(dp13726
g7
I61
sg20
VC0027651
p13727
sg10
I5
sg11
Vtumor
p13728
sg13
I1
sa(dp13729
g7
I135
sg20
VC0020295
p13730
sg10
I14
sg11
Vhydronephrosis
p13731
sg13
I1
sa(dp13732
g7
I61
sg20
VC0027651
p13733
sg10
I5
sg11
Vtumor
p13734
sg13
I1
sa(dp13735
g7
I61
sg20
VC0027651
p13736
sg10
I5
sg11
Vtumor
p13737
sg13
I1
sasa(dp13738
g2
S'Tumor location (involvement of the vesical trigone), clinical T stage (&gt;= cT3) and the number of tumors (&gt;= 3), but not sex, tumor grade and histological features determined by transurethral resection of bladder tumor, tumor size, shape of tumor, concomitant presence of carcinoma in situ, preoperative intravesical therapy, number of transurethral resection of bladder tumor procedures or the presence of hydronephrosis were significantly associated with ureteral involvement in the univariate analysis.\n'
p13739
sg4
(lp13740
sg17
(lp13741
(dp13742
g7
I210
sg20
VC0005695
p13743
sg10
I13
sg11
Vbladder tumor
p13744
sg13
I2
sa(dp13745
g7
I277
sg20
VC0007099
p13746
sg10
I17
sg11
Vcarcinoma in situ
p13747
sg13
I3
sa(dp13748
g7
I100
sg20
VC0027651
p13749
sg10
I6
sg11
Vtumors
p13750
sg13
I1
sa(dp13751
g7
I412
sg20
VC0020295
p13752
sg10
I14
sg11
Vhydronephrosis
p13753
sg13
I1
sa(dp13754
g7
I100
sg20
VC0027651
p13755
sg10
I5
sg11
Vtumor
p13756
sg13
I1
sa(dp13757
g7
I100
sg20
VC0027651
p13758
sg10
I5
sg11
Vtumor
p13759
sg13
I1
sa(dp13760
g7
I100
sg20
VC0027651
p13761
sg10
I5
sg11
Vtumor
p13762
sg13
I1
sa(dp13763
g7
I210
sg20
VC0005695
p13764
sg10
I13
sg11
Vbladder tumor
p13765
sg13
I2
sa(dp13766
g7
I0
sg20
VC0027651
p13767
sg10
I5
sg11
VTumor
p13768
sg13
I1
sasa(dp13769
g2
S'Transgenic mice with cardiomyocyte-directed expression of the transcriptional repressor CREM-IbDeltaC-X (CREM-TG) represent an experimental model of atrial fibrillation (AF) that shows a gradual, age-dependent progression from atrial ectopy to persistent AF.\n'
p13770
sg4
(lp13771
sg17
(lp13772
(dp13773
g7
I227
sg20
VC0085611
p13774
sg10
I13
sg11
Vatrial ectopy
p13775
sg13
I2
sa(dp13776
g7
I170
sg20
VC0232197
p13777
sg10
I2
sg11
VAF
p13778
sg13
I1
sa(dp13779
g7
I149
sg20
VC0004238
p13780
sg10
I19
sg11
Vatrial fibrillation
p13781
sg13
I2
sa(dp13782
g7
I170
sg20
VC0232197
p13783
sg10
I2
sg11
VAF
p13784
sg13
I1
sasa(dp13785
g2
S'Reduced expression of genes regulated by the transcription factors CREB/CREM (cAMP response element-binding protein/modulator) is linked to atrial fibrillation (AF) susceptibility in patients.\n'
p13786
sg4
(lp13787
(dp13788
g7
I78
sg8
g59
sg10
I47
sg11
VcAMP response element-binding protein/modulator
p13789
sg13
I4
sa(dp13790
g7
I67
sg8
VP16220
p13791
sg10
I4
sg11
VCREB
p13792
sg13
I1
sasg17
(lp13793
(dp13794
g7
I140
sg20
VC0004238
p13795
sg10
I19
sg11
Vatrial fibrillation
p13796
sg13
I2
sa(dp13797
g7
I161
sg20
VC0004238
p13798
sg10
I2
sg11
VAF
p13799
sg13
I1
sasa(dp13800
g2
S'Moreover, these data highlight a previously undescribed role for 5-HT6 receptors to modulate basal GABA and stimulated glutamate transmission, as well as reveal a potential therapeutic role for this receptor in the treatment of some types of anxiety-related disorders (eg OCD).\n'
p13801
sg4
(lp13802
(dp13803
g7
I65
sg8
VP50406
p13804
sg10
I15
sg11
V5-HT6 receptors
p13805
sg13
I2
sasg17
(lp13806
(dp13807
g7
I272
sg20
VC0028768
p13808
sg10
I3
sg11
VOCD
p13809
sg13
I1
sasa(dp13810
g2
S'Most importantly, transfection of miR-146a in a neuroblastoma cell line caused the downregulation of IL-1 receptor-associated kinase 1 (Irak1) levels, suggesting that the identified defect of miR-146a in Rett syndrome mice brains might be responsible for the observed upregulation of Irak1 in this model of the human disease.\n'
p13811
sg4
(lp13812
(dp13813
g7
I34
sg8
g59
sg10
I8
sg11
VmiR-146a
p13814
sg13
I1
sa(dp13815
g7
I34
sg8
g59
sg10
I8
sg11
VmiR-146a
p13816
sg13
I1
sa(dp13817
g7
I101
sg8
g59
sg10
I33
sg11
VIL-1 receptor-associated kinase 1
p13818
sg13
I4
sa(dp13819
g7
I136
sg8
VP51617
p13820
sg10
I5
sg11
VIrak1
p13821
sg13
I1
sa(dp13822
g7
I136
sg8
VP51617
p13823
sg10
I5
sg11
VIrak1
p13824
sg13
I1
sasg17
(lp13825
(dp13826
g7
I204
sg20
VC0035372
p13827
sg10
I13
sg11
VRett syndrome
p13828
sg13
I2
sa(dp13829
g7
I48
sg20
VC0027819
p13830
sg10
I13
sg11
Vneuroblastoma
p13831
sg13
I1
sasa(dp13832
g2
S'Increased transcript levels of Irak1, Fxyd1, Reln, and Gtl2 may contribute to the neuronal dysfunction in MeCP2-deficient mice and individuals with Rett syndrome.\n'
p13833
sg4
(lp13834
(dp13835
g7
I55
sg8
g59
sg10
I4
sg11
VGtl2
p13836
sg13
I1
sa(dp13837
g7
I45
sg8
VP78509
p13838
sg10
I4
sg11
VReln
p13839
sg13
I1
sa(dp13840
g7
I31
sg8
VP51617
p13841
sg10
I5
sg11
VIrak1
p13842
sg13
I1
sa(dp13843
g7
I106
sg8
VP51608
p13844
sg10
I5
sg11
VMeCP2
p13845
sg13
I1
sa(dp13846
g7
I38
sg8
g59
sg10
I5
sg11
VFxyd1
p13847
sg13
I1
sasg17
(lp13848
(dp13849
g7
I148
sg20
VC0035372
p13850
sg10
I13
sg11
VRett syndrome
p13851
sg13
I2
sasa(dp13852
g2
S'The first patient, a 35 year-old man had a multisystemic disease, with clinical symptoms of bilateral cataract, sensori-neural hearing loss, myopathy, ataxia, cardiac arrhythmia, depression and short stature and carried a 7970 G&gt;T (E129X) nonsense mutation in COII.\n'
p13853
sg4
(lp13854
(dp13855
g7
I263
sg8
VP00403
p13856
sg10
I4
sg11
VCOII
p13857
sg13
I1
sasg17
(lp13858
(dp13859
g7
I151
sg20
VC0004134
p13860
sg10
I6
sg11
Vataxia
p13861
sg13
I1
sa(dp13862
g7
I102
sg20
VC0086543
p13863
sg10
I8
sg11
Vcataract
p13864
sg13
I1
sa(dp13865
g7
I194
sg20
VC0013336
p13866
sg10
I13
sg11
Vshort stature
p13867
sg13
I2
sa(dp13868
g7
I159
sg20
VC0003811
p13869
sg10
I18
sg11
Vcardiac arrhythmia
p13870
sg13
I2
sa(dp13871
g7
I242
sg20
VC0544885
p13872
sg10
I17
sg11
Vnonsense mutation
p13873
sg13
I2
sa(dp13874
g7
I179
sg20
VC0011581
p13875
sg10
I10
sg11
Vdepression
p13876
sg13
I1
sa(dp13877
g7
I141
sg20
VC0026848
p13878
sg10
I8
sg11
Vmyopathy
p13879
sg13
I1
sa(dp13880
g7
I120
sg20
VC0155550
p13881
sg10
I19
sg11
Vneural hearing loss
p13882
sg13
I3
sasa(dp13883
g2
S'Here we investigate the impact of LC degeneration in a mouse model of tauopathy by lesioning the LC of male and female P301S tau transgenic mice with the neurotoxin N-(2-chloroethyl)-N-ethyl-bromobenzylamine (DSP-4) starting at 2 months of age.\n'
p13884
sg4
(lp13885
(dp13886
g7
I119
sg8
VP49768
p13887
sg10
I9
sg11
VP301S tau
p13888
sg13
I2
sasg17
(lp13889
(dp13890
g7
I37
sg20
VC0011164
p13891
sg10
I12
sg11
Vdegeneration
p13892
sg13
I1
sa(dp13893
g7
I70
sg20
VC0949664
p13894
sg10
I9
sg11
Vtauopathy
p13895
sg13
I1
sasa(dp13896
g2
S'Additional noradrenergic depletion by injection of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) aggravated pain hypersensitivity in PD rats.\n'
p13897
sg4
(lp13898
sg17
(lp13899
(dp13900
g7
I120
sg20
VC0020517
p13901
sg10
I16
sg11
Vhypersensitivity
p13902
sg13
I1
sasa(dp13903
g2
S'We investigated for the first time the levels of non-protein-bound iron (NPBI), a pro-oxidant factor, and 4-hydroxynonenal protein adducts (4-HNE PAs), as a marker of lipid peroxidation-induced protein damage, in classic autism.\n'
p13904
sg4
(lp13905
sg17
(lp13906
(dp13907
g7
I221
sg20
VC0004352
p13908
sg10
I6
sg11
Vautism
p13909
sg13
I1
sasa(dp13910
g2
S'The patients were divided into two groups: Group A included 17 patients with and group B 42 patients without paraesophageal varices on presclerotherapy computer tomography.\n'
p13911
sg4
(lp13912
sg17
(lp13913
(dp13914
g7
I124
sg20
VC0042345
p13915
sg10
I7
sg11
Vvarices
p13916
sg13
I1
sa(dp13917
g7
I81
sg20
VC0348801
p13918
sg10
I7
sg11
Vgroup B
p13919
sg13
I2
sasa(dp13920
g2
S'Other studies suggest that monitoring of monocyte chemoattractant protein-1(MCP-1), interleukin (IL)-17, GATA-3 (the key transcription factor of type 2 T helper cells) and forkhead box P3 (FOXP3, the key transcription factor of regulatory T cells) mRNA level in urinary sediment may provide an early clue for detecting disease flare in lupus patients.\n'
p13921
sg4
(lp13922
(dp13923
g7
I189
sg8
g59
sg10
I5
sg11
VFOXP3
p13924
sg13
I1
sa(dp13925
g7
I105
sg8
VP23771
p13926
sg10
I6
sg11
VGATA-3
p13927
sg13
I1
sa(dp13928
g7
I172
sg8
g59
sg10
I15
sg11
Vforkhead box P3
p13929
sg13
I3
sa(dp13930
g7
I84
sg8
VP60568
p13931
sg10
I19
sg11
Vinterleukin (IL)-17
p13932
sg13
I2
sa(dp13933
g7
I41
sg8
VP13500
p13934
sg10
I34
sg11
Vmonocyte chemoattractant protein-1
p13935
sg13
I3
sa(dp13936
g7
I76
sg8
VP41597
p13937
sg10
I5
sg11
VMCP-1
p13938
sg13
I1
sasg17
(lp13939
(dp13940
g7
I336
sg20
VC0024131
p13941
sg10
I5
sg11
Vlupus
p13942
sg13
I1
sa(dp13943
g7
I327
sg20
VC1517205
p13944
sg10
I5
sg11
Vflare
p13945
sg13
I1
sasa(dp13946
g2
S'ILC-2 express GATA3, produce IL-4, IL-5, IL-13 and amphiregulin, protect against parasitic infections and are related to allergy and obesity immunopathology.\n'
p13947
sg4
(lp13948
(dp13949
g7
I0
sg8
g59
sg10
I5
sg11
VILC-2
p13950
sg13
I1
sa(dp13951
g7
I29
sg8
VP05112
p13952
sg10
I4
sg11
VIL-4
p13953
sg13
I1
sa(dp13954
g7
I41
sg8
VP35225
p13955
sg10
I5
sg11
VIL-13
p13956
sg13
I1
sa(dp13957
g7
I51
sg8
VP15514
p13958
sg10
I12
sg11
Vamphiregulin
p13959
sg13
I1
sa(dp13960
g7
I35
sg8
VP05113
p13961
sg10
I4
sg11
VIL-5
p13962
sg13
I1
sa(dp13963
g7
I14
sg8
VP23771
p13964
sg10
I5
sg11
VGATA3
p13965
sg13
I1
sasg17
(lp13966
(dp13967
g7
I121
sg20
VC0020517
p13968
sg10
I7
sg11
Vallergy
p13969
sg13
I1
sa(dp13970
g7
I141
sg20
VC1609432
p13971
sg10
I15
sg11
Vimmunopathology
p13972
sg13
I1
sa(dp13973
g7
I91
sg20
VC0021311
p13974
sg10
I10
sg11
Vinfections
p13975
sg13
I1
sa(dp13976
g7
I133
sg20
VC0028754
p13977
sg10
I7
sg11
Vobesity
p13978
sg13
I1
sasa(dp13979
g2
S'Previous animal studies have shown that administration of FGF21 ameliorates kidney function, morphological glomerular abnormalities, dyslipidemia, hyperglycemia, insulin resistance, oxidative stress and obesity.\n'
p13980
sg4
(lp13981
(dp13982
g7
I162
sg8
VP01308
p13983
sg10
I7
sg11
Vinsulin
p13984
sg13
I1
sa(dp13985
g7
I58
sg8
g59
sg10
I5
sg11
VFGF21
p13986
sg13
I1
sasg17
(lp13987
(dp13988
g7
I147
sg20
VC0020456
p13989
sg10
I13
sg11
Vhyperglycemia
p13990
sg13
I1
sa(dp13991
g7
I182
sg20
VC0242606
p13992
sg10
I16
sg11
Voxidative stress
p13993
sg13
I2
sa(dp13994
g7
I162
sg20
VC0021655
p13995
sg10
I18
sg11
Vinsulin resistance
p13996
sg13
I2
sa(dp13997
g7
I203
sg20
VC0028754
p13998
sg10
I7
sg11
Vobesity
p13999
sg13
I1
sa(dp14000
g7
I133
sg20
VC0242339
p14001
sg10
I12
sg11
Vdyslipidemia
p14002
sg13
I1
sasa(dp14003
g2
S'In recent clinical trials, an FGF21 analogue reduced insulin levels and body weight, and ameliorated dyslipidemia in patients with type 2 diabetes mellitus and obesity, all of which are well-known risk factors for kidney disease.\n'
p14004
sg4
(lp14005
(dp14006
g7
I53
sg8
VP01308
p14007
sg10
I7
sg11
Vinsulin
p14008
sg13
I1
sa(dp14009
g7
I30
sg8
g59
sg10
I5
sg11
VFGF21
p14010
sg13
I1
sasg17
(lp14011
(dp14012
g7
I160
sg20
VC0028754
p14013
sg10
I7
sg11
Vobesity
p14014
sg13
I1
sa(dp14015
g7
I131
sg20
VC0011860
p14016
sg10
I24
sg11
Vtype 2 diabetes mellitus
p14017
sg13
I4
sa(dp14018
g7
I101
sg20
VC0242339
p14019
sg10
I12
sg11
Vdyslipidemia
p14020
sg13
I1
sa(dp14021
g7
I214
sg20
VC0022658
p14022
sg10
I14
sg11
Vkidney disease
p14023
sg13
I2
sasa(dp14024
g2
S'FGF21 is a novel biomarker for non-alcoholic fatty liver disease (NAFLD) in humans and limits hepatotoxicity in mice.\n'
p14025
sg4
(lp14026
(dp14027
g7
I0
sg8
g59
sg10
I5
sg11
VFGF21
p14028
sg13
I1
sasg17
(lp14029
(dp14030
g7
I66
sg20
VC0400966
p14031
sg10
I5
sg11
VNAFLD
p14032
sg13
I1
sa(dp14033
g7
I31
sg20
VC0400966
p14034
sg10
I33
sg11
Vnon-alcoholic fatty liver disease
p14035
sg13
I4
sasa(dp14036
g2
S'Consistent with this, Fgf21 can rescue Dnmt3a-mediated insulin resistance, and DNA methylation at the FGF21 locus was elevated in human subjects with diabetes and correlated negatively with expression of FGF21 in human adipose tissue.\n'
p14037
sg4
(lp14038
(dp14039
g7
I102
sg8
g59
sg10
I11
sg11
VFGF21 locus
p14040
sg13
I2
sa(dp14041
g7
I102
sg8
g59
sg10
I5
sg11
VFGF21
p14042
sg13
I1
sa(dp14043
g7
I55
sg8
VP01308
p14044
sg10
I7
sg11
Vinsulin
p14045
sg13
I1
sa(dp14046
g7
I39
sg8
g59
sg10
I6
sg11
VDnmt3a
p14047
sg13
I1
sa(dp14048
g7
I22
sg8
g59
sg10
I5
sg11
VFgf21
p14049
sg13
I1
sasg17
(lp14050
(dp14051
g7
I55
sg20
VC0021655
p14052
sg10
I18
sg11
Vinsulin resistance
p14053
sg13
I2
sa(dp14054
g7
I150
sg20
VC0011849
p14055
sg10
I8
sg11
Vdiabetes
p14056
sg13
I1
sasa(dp14057
g2
S'MT can modulate various stress-induced signalling pathways of MAPKs, Wnt, NF-kB, PI3K, Sirt-1/AMPK and FGF21 signalling to alleviate diabetes and diabetic complications.\n'
p14058
sg4
(lp14059
(dp14060
g7
I81
sg8
VP42336
p14061
sg10
I4
sg11
VPI3K
p14062
sg13
I1
sa(dp14063
g7
I103
sg8
g59
sg10
I5
sg11
VFGF21
p14064
sg13
I1
sa(dp14065
g7
I94
sg8
VP54646
p14066
sg10
I4
sg11
VAMPK
p14067
sg13
I1
sasg17
(lp14068
(dp14069
g7
I133
sg20
VC0011849
p14070
sg10
I8
sg11
Vdiabetes
p14071
sg13
I1
sa(dp14072
g7
I146
sg20
VC0342257
p14073
sg10
I22
sg11
Vdiabetic complications
p14074
sg13
I2
sasa(dp14075
g2
S'Berberine acts in the liver to regulate lipid utilization and maintain whole-body energy metabolism, and berberine-mediated autophagy and FGF21 activation have the therapeutic potential for treating metabolic defects under nutrition overload, such as fatty liver diseases, type 2 diabetes and obesity.\n'
p14076
sg4
(lp14077
(dp14078
g7
I138
sg8
g59
sg10
I5
sg11
VFGF21
p14079
sg13
I1
sasg17
(lp14080
(dp14081
g7
I293
sg20
VC0028754
p14082
sg10
I7
sg11
Vobesity
p14083
sg13
I1
sa(dp14084
g7
I257
sg20
VC0023895
p14085
sg10
I14
sg11
Vliver diseases
p14086
sg13
I2
sa(dp14087
g7
I273
sg20
VC0011860
p14088
sg10
I15
sg11
Vtype 2 diabetes
p14089
sg13
I3
sasa(dp14090
g2
S'Fibroblast growth factor 21 (FGF-21) is mainly secreted by liver and has been reported to be involved in the pathogenesis of type 2 diabetes.\n'
p14091
sg4
(lp14092
(dp14093
g7
I0
sg8
g59
sg10
I27
sg11
VFibroblast growth factor 21
p14094
sg13
I4
sa(dp14095
g7
I29
sg8
g59
sg10
I6
sg11
VFGF-21
p14096
sg13
I1
sasg17
(lp14097
(dp14098
g7
I125
sg20
VC0011860
p14099
sg10
I15
sg11
Vtype 2 diabetes
p14100
sg13
I3
sa(dp14101
g7
I109
sg20
VC0699748
p14102
sg10
I12
sg11
Vpathogenesis
p14103
sg13
I1
sasa(dp14104
g2
S'Some prospective studies have shown a positive association between FGF-21 and diabetes risk.\n'
p14105
sg4
(lp14106
sg17
(lp14107
(dp14108
g7
I78
sg20
VC0011849
p14109
sg10
I8
sg11
Vdiabetes
p14110
sg13
I1
sasa(dp14111
g2
S'Therefore, we prospectively evaluated the sex-specific association between FGF-21 and diabetes in a Chinese population.\n'
p14112
sg4
(lp14113
sg17
(lp14114
(dp14115
g7
I86
sg20
VC0011849
p14116
sg10
I8
sg11
Vdiabetes
p14117
sg13
I1
sasa(dp14118
g2
S'Serum FGF-21 concentration was measured in a case-control study comprising of 251 incident diabetes cases and 251 age-sex-matched controls nested within a prospective population-based cohort, the Singapore Chinese Health Study.\n'
p14119
sg4
(lp14120
sg17
(lp14121
(dp14122
g7
I91
sg20
VC0011849
p14123
sg10
I8
sg11
Vdiabetes
p14124
sg13
I1
sasa(dp14125
g2
S'After adjustment for risk biomarkers of diabetes including lipids, liver enzymes and inflammatory marker, the OR of type 2 diabetes with per one unit increment in log FGF-21 concentration was 1.16 (95% CI 0.90-1.50).\n'
p14126
sg4
(lp14127
sg17
(lp14128
(dp14129
g7
I116
sg20
VC0011860
p14130
sg10
I15
sg11
Vtype 2 diabetes
p14131
sg13
I3
sa(dp14132
g7
I40
sg20
VC0011849
p14133
sg10
I8
sg11
Vdiabetes
p14134
sg13
I1
sasa(dp14135
g2
S'Higher serum FGF-21 level was associated with an increased risk of diabetes in Chinese women but not in men.\n'
p14136
sg4
(lp14137
(dp14138
g7
I7
sg8
g59
sg10
I12
sg11
Vserum FGF-21
p14139
sg13
I2
sasg17
(lp14140
(dp14141
g7
I67
sg20
VC0011849
p14142
sg10
I8
sg11
Vdiabetes
p14143
sg13
I1
sasa(dp14144
g2
S'The sex difference in the association between FGF-21 and diabetes risk deserves further investigation and replication in other populations.\n'
p14145
sg4
(lp14146
sg17
(lp14147
(dp14148
g7
I57
sg20
VC0011849
p14149
sg10
I8
sg11
Vdiabetes
p14150
sg13
I1
sasa(dp14151
g2
S'The aim of this study was to examine the combined and independent effects of hyperglycemia and hyperinsulinemia on total and bioactive FGF21 in the postprandial period in humans, and determine whether this effect is attenuated in conditions of altered insulin secretion and action.\n'
p14152
sg4
(lp14153
(dp14154
g7
I100
sg8
VP01308
p14155
sg10
I7
sg11
Vinsulin
p14156
sg13
I1
sa(dp14157
g7
I135
sg8
g59
sg10
I5
sg11
VFGF21
p14158
sg13
I1
sasg17
(lp14159
(dp14160
g7
I77
sg20
VC0020456
p14161
sg10
I13
sg11
Vhyperglycemia
p14162
sg13
I1
sa(dp14163
g7
I95
sg20
VC0020459
p14164
sg10
I16
sg11
Vhyperinsulinemia
p14165
sg13
I1
sasa(dp14166
g2
S'Circulating glucose, insulin, total and bioactive FGF21, and fibroblast activation protein were measured in adults with and without type 2 diabetes (T2D) following an oral glucose tolerance test (OGTT), and under a series of insulin and glucose clamp conditions and following high-fat diet in healthy adults.\n'
p14167
sg4
(lp14168
(dp14169
g7
I21
sg8
VP01308
p14170
sg10
I7
sg11
Vinsulin
p14171
sg13
I1
sa(dp14172
g7
I50
sg8
g59
sg10
I40
sg11
VFGF21, and fibroblast activation protein
p14173
sg13
I5
sa(dp14174
g7
I21
sg8
VP01308
p14175
sg10
I7
sg11
Vinsulin
p14176
sg13
I1
sasg17
(lp14177
(dp14178
g7
I132
sg20
VC0011860
p14179
sg10
I15
sg11
Vtype 2 diabetes
p14180
sg13
I3
sa(dp14181
g7
I149
sg20
VC0011860
p14182
sg10
I3
sg11
VT2D
p14183
sg13
I1
sa(dp14184
g7
I180
sg20
VC0020963
p14185
sg10
I9
sg11
Vtolerance
p14186
sg13
I1
sasa(dp14187
g2
S'Our study demonstrates that haploinsufficiency of DYRK1A results in a new recognizable syndrome, which should be considered in individuals with Angelman syndrome-like features and distinct facial features.\n'
p14188
sg4
(lp14189
(dp14190
g7
I50
sg8
g59
sg10
I6
sg11
VDYRK1A
p14191
sg13
I1
sasg17
(lp14192
(dp14193
g7
I144
sg20
VC0162635
p14194
sg10
I17
sg11
VAngelman syndrome
p14195
sg13
I2
sa(dp14196
g7
I87
sg20
VC0039082
p14197
sg10
I8
sg11
Vsyndrome
p14198
sg13
I1
sasa(dp14199
g2
S'The DYRK1A gene was studied by direct sequencing and quantitative PCR in a cohort of 105 patients with ID and at least two symptoms from the Angelman syndrome spectrum (microcephaly &lt; -2.5 SD, ataxic gait, seizures and speech delay).\n'
p14200
sg4
(lp14201
(dp14202
g7
I4
sg8
g59
sg10
I11
sg11
VDYRK1A gene
p14203
sg13
I2
sasg17
(lp14204
(dp14205
g7
I196
sg20
VC0751837
p14206
sg10
I11
sg11
Vataxic gait
p14207
sg13
I2
sa(dp14208
g7
I222
sg20
VC0241210
p14209
sg10
I12
sg11
Vspeech delay
p14210
sg13
I2
sa(dp14211
g7
I209
sg20
VC0036572
p14212
sg10
I8
sg11
Vseizures
p14213
sg13
I1
sa(dp14214
g7
I169
sg20
VC0025958
p14215
sg10
I12
sg11
Vmicrocephaly
p14216
sg13
I1
sa(dp14217
g7
I141
sg20
VC0162635
p14218
sg10
I17
sg11
VAngelman syndrome
p14219
sg13
I2
sasa(dp14220
g2
S'To determine the role of IRAK-M in host defense against bacterial pneumonia, IRAK-M-deficient (IRAK-M(-/-)) and normal wild-type (WT) mice were infected intranasally with Klebsiella pneumoniae.\n'
p14221
sg4
(lp14222
(dp14223
g7
I25
sg8
VP51617
p14224
sg10
I4
sg11
VIRAK
p14225
sg13
I1
sa(dp14226
g7
I25
sg8
g59
sg10
I6
sg11
VIRAK-M
p14227
sg13
I1
sa(dp14228
g7
I25
sg8
g59
sg10
I6
sg11
VIRAK-M
p14229
sg13
I1
sasg17
(lp14230
(dp14231
g7
I56
sg20
VC0004626
p14232
sg10
I19
sg11
Vbacterial pneumonia
p14233
sg13
I2
sasa(dp14234
g2
S'The prevalence of autistic traits consistent with a clinical diagnosis for an autism spectrum disorder (ASD) was 5.5 % (n = 3 MtF and n = 2 FtM) compared to reports of clinical diagnoses of 0.5-2.0 % in the general population.\n'
p14235
sg4
(lp14236
sg17
(lp14237
(dp14238
g7
I18
sg20
VC0004352
p14239
sg10
I8
sg11
Vautistic
p14240
sg13
I1
sa(dp14241
g7
I104
sg20
VC1510586
p14242
sg10
I3
sg11
VASD
p14243
sg13
I1
sa(dp14244
g7
I78
sg20
VC1510586
p14245
sg10
I24
sg11
Vautism spectrum disorder
p14246
sg13
I3
sasa(dp14247
g2
S'A total of 88 self-identified male-to-female transsexuals (MtF), 43 female-to-male transsexuals (FtM), 62 females with an eating disorder, 56 male controls, and 116 female controls completed the Eating Disorder Examination Questionnaire, Eating Disorder Inventory, Body Checking Questionnaire, Drive for Muscularity Scale, Rosenberg Self-Esteem Scale, and Beck Depression Inventory.\n'
p14248
sg4
(lp14249
sg17
(lp14250
(dp14251
g7
I195
sg20
VC0013473
p14252
sg10
I15
sg11
VEating Disorder
p14253
sg13
I2
sa(dp14254
g7
I122
sg20
VC0013473
p14255
sg10
I15
sg11
Veating disorder
p14256
sg13
I2
sa(dp14257
g7
I361
sg20
VC0011581
p14258
sg10
I10
sg11
VDepression
p14259
sg13
I1
sa(dp14260
g7
I195
sg20
VC0013473
p14261
sg10
I15
sg11
VEating Disorder
p14262
sg13
I2
sasa(dp14263
g2
S'It was: xA-E-E-A-P-R-R-V-K-L-S-Q-R-Q-M-Q-E-L-K-E-A-F-T-M-I-D-Q-D-R-D-G-F-I-G-M- E-D-L-K-D-M-F-S-S-L-G-R-V-P-P-D-D-E-L-N-A-M-L-K-E-C-P-G-Q-L-N-F-T- A-F-L-T-L-F-G-E-K-V-S-G-T-D-P-E-D-A-L-R-N-A-F-S-M-F-D-E-D-G-Q-G-F-I-P- E-D-Y-L-K-D-L-L-E-N-M-G-D-N-F-S-K-E-E-I-K-N-V-W-K-D-A-P-L-K-N-K-Q-F- N-Y-N-K-M-V-D-I-K-G-K-A-E-D-E-D.\n'
p14264
sg4
(lp14265
(dp14266
g7
I8
sg8
VP23942
p14267
sg10
I231
sg11
VxA-E-E-A-P-R-R-V-K-L-S-Q-R-Q-M-Q-E-L-K-E-A-F-T-M-I-D-Q-D-R-D-G-F-I-G-M- E-D-L-K-D-M-F-S-S-L-G-R-V-P-P-D-D-E-L-N-A-M-L-K-E-C-P-G-Q-L-N-F-T- A-F-L-T-L-F-G-E-K-V-S-G-T-D-P-E-D-A-L-R-N-A-F-S-M-F-D-E-D-G-Q-G-F-I-P- E-D-Y-L-K-D-L-L-E-N-M
p14268
sg13
I4
sasg17
(lp14269
sa(dp14270
g2
S'Two-dimensional speckle tracking (2-D ST) echocardiography, a new imaging modality with useful applications in several cardiac diseases, has been validated for subjects with myocardial infarction against cardiac magnetic resonance (CMR).\n'
p14271
sg4
(lp14272
sg17
(lp14273
(dp14274
g7
I174
sg20
VC0027051
p14275
sg10
I21
sg11
Vmyocardial infarction
p14276
sg13
I2
sa(dp14277
g7
I119
sg20
VC0018799
p14278
sg10
I16
sg11
Vcardiac diseases
p14279
sg13
I2
sasa(dp14280
g2
S'Neurodegenerative processes (viz., stroke, dementia, Parkinsonism, epilepsy, etc) uncover BPAg1-n, an alternatively spliced form of BPAg1-e that stabilizes the cytoskeleton of sensory neurons, generating autoantibodies that may subsequently lead to BP by cross-reacting with BPAg1-e. We present a patient with Parkinsonism who later developed blisters, erosions and crusts localized to the palms and soles, confirmed histopathologically as bullous pemphigoid.\n'
p14281
sg4
(lp14282
sg17
(lp14283
(dp14284
g7
I343
sg20
VC0005758
p14285
sg10
I8
sg11
Vblisters
p14286
sg13
I1
sa(dp14287
g7
I35
sg20
VC0038454
p14288
sg10
I6
sg11
Vstroke
p14289
sg13
I1
sa(dp14290
g7
I440
sg20
VC0030805
p14291
sg10
I18
sg11
Vbullous pemphigoid
p14292
sg13
I2
sa(dp14293
g7
I67
sg20
VC0014544
p14294
sg10
I8
sg11
Vepilepsy
p14295
sg13
I1
sa(dp14296
g7
I43
sg20
VC0497327
p14297
sg10
I8
sg11
Vdementia
p14298
sg13
I1
sa(dp14299
g7
I53
sg20
VC0242422
p14300
sg10
I12
sg11
VParkinsonism
p14301
sg13
I1
sa(dp14302
g7
I53
sg20
VC0242422
p14303
sg10
I12
sg11
VParkinsonism
p14304
sg13
I1
sa(dp14305
g7
I353
sg20
VC1959609
p14306
sg10
I8
sg11
Verosions
p14307
sg13
I1
sa(dp14308
g7
I366
sg20
VC0205204
p14309
sg10
I6
sg11
Vcrusts
p14310
sg13
I1
sasa(dp14311
g2
S'Recent studies have shown that an elevated ambulatory or home blood pressure (BP) in the absence of office BP-a phenomenon called masked hypertension-is associated with poor cardiovascular prognosis.\n'
p14312
sg4
(lp14313
sg17
(lp14314
(dp14315
g7
I137
sg20
VC0020538
p14316
sg10
I12
sg11
Vhypertension
p14317
sg13
I1
sasa(dp14318
g2
S'We have recently reported that vitreous levels of IL-4, IL-17A, IL-22, IL-31, and TNFAlfa are higher than the respective serum levels in proliferative diabetic retinopathy (PDR) patients, and that vitreous levels of these cytokines are higher in PDR than in other non-inflammatory vitreoretinal diseases or uveitis associated with sarcoidosis.\n'
p14319
sg4
(lp14320
(dp14321
g7
I50
sg8
VP05112
p14322
sg10
I4
sg11
VIL-4
p14323
sg13
I1
sa(dp14324
g7
I71
sg8
g59
sg10
I5
sg11
VIL-31
p14325
sg13
I1
sa(dp14326
g7
I64
sg8
g59
sg10
I5
sg11
VIL-22
p14327
sg13
I1
sasg17
(lp14328
(dp14329
g7
I307
sg20
VC0042164
p14330
sg10
I7
sg11
Vuveitis
p14331
sg13
I1
sa(dp14332
g7
I137
sg20
VC0154830
p14333
sg10
I34
sg11
Vproliferative diabetic retinopathy
p14334
sg13
I3
sa(dp14335
g7
I173
sg20
VC0154830
p14336
sg10
I3
sg11
VPDR
p14337
sg13
I1
sa(dp14338
g7
I173
sg20
VC0154830
p14339
sg10
I3
sg11
VPDR
p14340
sg13
I1
sa(dp14341
g7
I331
sg20
VC0036202
p14342
sg10
I11
sg11
Vsarcoidosis
p14343
sg13
I1
sasa(dp14344
g2
S'Using a cross-sectional patient study and a well-characterized murine model of DED, herein we investigated the immunoregulatory function of interleukin-22 (IL-22) in the pathogenesis of DED.\n'
p14345
sg4
(lp14346
(dp14347
g7
I79
sg8
g59
sg10
I3
sg11
VDED
p14348
sg13
I1
sa(dp14349
g7
I140
sg8
g59
sg10
I14
sg11
Vinterleukin-22
p14350
sg13
I1
sa(dp14351
g7
I156
sg8
g59
sg10
I5
sg11
VIL-22
p14352
sg13
I1
sasg17
(lp14353
(dp14354
g7
I170
sg20
VC0699748
p14355
sg10
I12
sg11
Vpathogenesis
p14356
sg13
I1
sasa(dp14357
g2
S'We found that IL-22 levels were elevated in lacrimal fluids of DED patients and inversely correlated with severity of disease.\n'
p14358
sg4
(lp14359
(dp14360
g7
I14
sg8
g59
sg10
I5
sg11
VIL-22
p14361
sg13
I1
sasg17
(lp14362
sa(dp14363
g2
S'Moreover, loss of function analyses using IL-22 knockout mice demonstrated that IL-22 is essential for suppression of ocular surface infiltration of Th17 cells and inhibition of DED induction.\n'
p14364
sg4
(lp14365
(dp14366
g7
I42
sg8
g59
sg10
I5
sg11
VIL-22
p14367
sg13
I1
sa(dp14368
g7
I178
sg8
g59
sg10
I3
sg11
VDED
p14369
sg13
I1
sa(dp14370
g7
I42
sg8
g59
sg10
I5
sg11
VIL-22
p14371
sg13
I1
sasg17
(lp14372
(dp14373
g7
I133
sg20
VC0332448
p14374
sg10
I12
sg11
Vinfiltration
p14375
sg13
I1
sa(dp14376
g7
I103
sg20
VC0221103
p14377
sg10
I11
sg11
Vsuppression
p14378
sg13
I1
sasa(dp14379
g2
S'Our novel findings elucidate immunoregulatory function of LG-derived IL-22 in inhibiting IL-17-mediated ocular surface epitheliopathy in DED thus making IL-22 a new relevant therapeutic target.\n'
p14380
sg4
(lp14381
(dp14382
g7
I69
sg8
g59
sg10
I5
sg11
VIL-22
p14383
sg13
I1
sa(dp14384
g7
I58
sg8
g59
sg10
I16
sg11
VLG-derived IL-22
p14385
sg13
I2
sasg17
(lp14386
sa(dp14387
g2
S'Recent studies have reported the increased number of IL-22 producing T cells in patients with autoimmune noninfectious uveitis; however, the correlation between IL-22 and uveitis remains unclear.\n'
p14388
sg4
(lp14389
(dp14390
g7
I53
sg8
g59
sg10
I5
sg11
VIL-22
p14391
sg13
I1
sa(dp14392
g7
I53
sg8
g59
sg10
I5
sg11
VIL-22
p14393
sg13
I1
sasg17
(lp14394
(dp14395
g7
I94
sg20
VC0443146
p14396
sg10
I10
sg11
Vautoimmune
p14397
sg13
I1
sa(dp14398
g7
I119
sg20
VC0042164
p14399
sg10
I7
sg11
Vuveitis
p14400
sg13
I1
sa(dp14401
g7
I119
sg20
VC0042164
p14402
sg10
I7
sg11
Vuveitis
p14403
sg13
I1
sasa(dp14404
g2
S'In this study, we aimed to determine the specific role of IL-22 and its receptor in the pathogenesis of uveitis.\n'
p14405
sg4
(lp14406
(dp14407
g7
I58
sg8
g59
sg10
I5
sg11
VIL-22
p14408
sg13
I1
sasg17
(lp14409
(dp14410
g7
I104
sg20
VC0042164
p14411
sg10
I7
sg11
Vuveitis
p14412
sg13
I1
sa(dp14413
g7
I88
sg20
VC0699748
p14414
sg10
I12
sg11
Vpathogenesis
p14415
sg13
I1
sasa(dp14416
g2
S'Serum concentration of IL-22 was significantly increased in uveitis patients.\n'
p14417
sg4
(lp14418
(dp14419
g7
I23
sg8
g59
sg10
I5
sg11
VIL-22
p14420
sg13
I1
sasg17
(lp14421
(dp14422
g7
I60
sg20
VC0042164
p14423
sg10
I7
sg11
Vuveitis
p14424
sg13
I1
sasa(dp14425
g2
S'Experimental animal models of uveitis induced by interphotoreceptor retinoid binding protein 1-20 (IRBP1-20) exhibited elevation of hyperplasia RPE and IL-22 production.\n'
p14426
sg4
(lp14427
(dp14428
g7
I152
sg8
g59
sg10
I5
sg11
VIL-22
p14429
sg13
I1
sa(dp14430
g7
I68
sg8
VP14222
p14431
sg10
I29
sg11
Vretinoid binding protein 1-20
p14432
sg13
I4
sa(dp14433
g7
I132
sg8
g59
sg10
I15
sg11
Vhyperplasia RPE
p14434
sg13
I2
sasg17
(lp14435
(dp14436
g7
I30
sg20
VC0042164
p14437
sg10
I7
sg11
Vuveitis
p14438
sg13
I1
sa(dp14439
g7
I132
sg20
VC0020507
p14440
sg10
I11
sg11
Vhyperplasia
p14441
sg13
I1
sasa(dp14442
g2
S'When CD4+ T cells from the uveitis patients were stimulated with IRBP1-20, the production of IL-22 definitely increased.\n'
p14443
sg4
(lp14444
(dp14445
g7
I93
sg8
g59
sg10
I5
sg11
VIL-22
p14446
sg13
I1
sa(dp14447
g7
I5
sg8
VP01730
p14448
sg10
I4
sg11
VCD4+
p14449
sg13
I1
sasg17
(lp14450
(dp14451
g7
I27
sg20
VC0042164
p14452
sg10
I7
sg11
Vuveitis
p14453
sg13
I1
sasa(dp14454
g2
S'In addition, we examine the regulatory role of cysteamine, which has an anti-inflammatory role in the cornea, in uveitis through the down-regulation of IL-22RAlfa expression.\n'
p14455
sg4
(lp14456
sg17
(lp14457
(dp14458
g7
I113
sg20
VC0042164
p14459
sg10
I7
sg11
Vuveitis
p14460
sg13
I1
sasa(dp14461
g2
S'Cysteamine effectively suppressed the IRBP1-20-induced IL-22RAlfa expression and prevented the development of IRBP1-20-induced uveitis in the experimental animal model.\n'
p14462
sg4
(lp14463
sg17
(lp14464
(dp14465
g7
I127
sg20
VC0042164
p14466
sg10
I7
sg11
Vuveitis
p14467
sg13
I1
sasa(dp14468
g2
S'These finding suggest that IL-22 and its receptor have a crucial role in the development and pathogenesis of uveitis by facilitating inflammatory cell infiltration, and that cysteamine may be a useful therapeutic drug in treating uveitis by down-regulating IL-22RAlfa expression in RPE.\n'
p14469
sg4
(lp14470
(dp14471
g7
I27
sg8
g59
sg10
I5
sg11
VIL-22
p14472
sg13
I1
sasg17
(lp14473
(dp14474
g7
I93
sg20
VC0699748
p14475
sg10
I12
sg11
Vpathogenesis
p14476
sg13
I1
sa(dp14477
g7
I109
sg20
VC0042164
p14478
sg10
I7
sg11
Vuveitis
p14479
sg13
I1
sa(dp14480
g7
I109
sg20
VC0042164
p14481
sg10
I7
sg11
Vuveitis
p14482
sg13
I1
sa(dp14483
g7
I133
sg20
VC0302158
p14484
sg10
I30
sg11
Vinflammatory cell infiltration
p14485
sg13
I3
sasa(dp14486
g2
S'The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)-1Beta, IL-6, IL-2, IFN-Gamma, IL-10, IL-12p40, IL-13, IL-17A, IL-5, TNF-Alfa, and TNF-Beta, and with ELISA to determine the levels of TGF-Beta1, IL-22, and IL-23.\n'
p14487
sg4
(lp14488
(dp14489
g7
I298
sg8
VP01375
p14490
sg10
I8
sg11
VTNF-Beta
p14491
sg13
I1
sa(dp14492
g7
I278
sg8
VP05113
p14493
sg10
I4
sg11
VIL-5
p14494
sg13
I1
sa(dp14495
g7
I361
sg8
g59
sg10
I5
sg11
VIL-22
p14496
sg13
I1
sa(dp14497
g7
I372
sg8
g59
sg10
I5
sg11
VIL-23
p14498
sg13
I1
sa(dp14499
g7
I284
sg8
VP01375
p14500
sg10
I8
sg11
VTNF-Alfa
p14501
sg13
I1
sa(dp14502
g7
I350
sg8
VP01137
p14503
sg10
I9
sg11
VTGF-Beta1
p14504
sg13
I1
sa(dp14505
g7
I235
sg8
VP01579
p14506
sg10
I9
sg11
VIFN-Gamma
p14507
sg13
I1
sa(dp14508
g7
I229
sg8
VP60568
p14509
sg10
I4
sg11
VIL-2
p14510
sg13
I1
sa(dp14511
g7
I223
sg8
VP05231
p14512
sg10
I4
sg11
VIL-6
p14513
sg13
I1
sa(dp14514
g7
I263
sg8
VP35225
p14515
sg10
I5
sg11
VIL-13
p14516
sg13
I1
sa(dp14517
g7
I199
sg8
VP60568
p14518
sg10
I22
sg11
Vinterleukin (IL)-1Beta
p14519
sg13
I2
sasg17
(lp14520
(dp14521
g7
I23
sg20
VC0036416
p14522
sg10
I9
sg11
Vscleritis
p14523
sg13
I1
sasa(dp14524
g2
S'Serum IL-22 levels from patients with active scleritis were correlated with type of scleritis (non-necrotizing and necrotizing), degree of inflammation (0-4+ :&lt;=2+ and &gt;2+), and associated systemic disease.\n'
p14525
sg4
(lp14526
(dp14527
g7
I0
sg8
g59
sg10
I11
sg11
VSerum IL-22
p14528
sg13
I2
sasg17
(lp14529
(dp14530
g7
I45
sg20
VC0036416
p14531
sg10
I9
sg11
Vscleritis
p14532
sg13
I1
sa(dp14533
g7
I139
sg20
VC0021368
p14534
sg10
I12
sg11
Vinflammation
p14535
sg13
I1
sa(dp14536
g7
I45
sg20
VC0036416
p14537
sg10
I9
sg11
Vscleritis
p14538
sg13
I1
sa(dp14539
g7
I195
sg20
VC0442893
p14540
sg10
I16
sg11
Vsystemic disease
p14541
sg13
I2
sasa(dp14542
g2
S'Serum levels of IL-22 were elevated in active scleritis patients compared to controls (6.41 +/- 1.52 pg/ml versus 1.93 +/- 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005).\n'
p14543
sg4
(lp14544
(dp14545
g7
I16
sg8
g59
sg10
I5
sg11
VIL-22
p14546
sg13
I1
sasg17
(lp14547
(dp14548
g7
I190
sg20
VC0687702
p14549
sg10
I9
sg11
Vremission
p14550
sg13
I1
sa(dp14551
g7
I46
sg20
VC0036416
p14552
sg10
I9
sg11
Vscleritis
p14553
sg13
I1
sa(dp14554
g7
I46
sg20
VC0036416
p14555
sg10
I9
sg11
Vscleritis
p14556
sg13
I1
sasa(dp14557
g2
S'In our study cohort, IL-22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission.\n'
p14558
sg4
(lp14559
(dp14560
g7
I21
sg8
g59
sg10
I5
sg11
VIL-22
p14561
sg13
I1
sasg17
(lp14562
(dp14563
g7
I78
sg20
VC0036416
p14564
sg10
I9
sg11
Vscleritis
p14565
sg13
I1
sa(dp14566
g7
I152
sg20
VC0687702
p14567
sg10
I9
sg11
Vremission
p14568
sg13
I1
sasa(dp14569
g2
S'Our results suggest that IL-22, a T helper (Th) 17- and Th22- derived cytokine, may play a critical role in the physiopathology of scleritis.\n'
p14570
sg4
(lp14571
(dp14572
g7
I25
sg8
g59
sg10
I5
sg11
VIL-22
p14573
sg13
I1
sasg17
(lp14574
(dp14575
g7
I131
sg20
VC0036416
p14576
sg10
I9
sg11
Vscleritis
p14577
sg13
I1
sasa(dp14578
g2
S'However, it is unclear whether and how non-proliferative diabetic retinopathy (NPDR) is affected by Interleukin-17A (IL-17A) and Interleukin-22 (IL-22), two well-known inflammatory factors, and irisin, a novel potential anti-inflammatory factor.\n'
p14579
sg4
(lp14580
(dp14581
g7
I145
sg8
g59
sg10
I5
sg11
VIL-22
p14582
sg13
I1
sa(dp14583
g7
I117
sg8
g59
sg10
I6
sg11
VIL-17A
p14584
sg13
I1
sa(dp14585
g7
I100
sg8
g59
sg10
I15
sg11
VInterleukin-17A
p14586
sg13
I1
sa(dp14587
g7
I129
sg8
g59
sg10
I14
sg11
VInterleukin-22
p14588
sg13
I1
sasg17
(lp14589
(dp14590
g7
I79
sg20
VC0004606
p14591
sg10
I4
sg11
VNPDR
p14592
sg13
I1
sa(dp14593
g7
I39
sg20
VC0004606
p14594
sg10
I38
sg11
Vnon-proliferative diabetic retinopathy
p14595
sg13
I3
sasa(dp14596
g2
S'To assess changes in the salivary expression of IL-1Alfa, IL-1Beta, IL-2, IL-6, IL-10, IL-17, and TNF in acute leukemia (AL) patients before and during chemotherapy, and its association with HSV infection, oral candidiasis (OC), and oral mucositis (OM) onset.\n'
p14597
sg4
(lp14598
(dp14599
g7
I98
sg8
VP01375
p14600
sg10
I3
sg11
VTNF
p14601
sg13
I1
sa(dp14602
g7
I74
sg8
VP05231
p14603
sg10
I4
sg11
VIL-6
p14604
sg13
I1
sa(dp14605
g7
I58
sg8
VP01584
p14606
sg10
I8
sg11
VIL-1Beta
p14607
sg13
I1
sa(dp14608
g7
I68
sg8
VP60568
p14609
sg10
I4
sg11
VIL-2
p14610
sg13
I1
sasg17
(lp14611
(dp14612
g7
I191
sg20
VC0019348
p14613
sg10
I13
sg11
VHSV infection
p14614
sg13
I2
sa(dp14615
g7
I105
sg20
VC0085669
p14616
sg10
I14
sg11
Vacute leukemia
p14617
sg13
I2
sa(dp14618
g7
I121
sg20
VC0085669
p14619
sg10
I2
sg11
VAL
p14620
sg13
I1
sa(dp14621
g7
I249
sg20
VC1568868
p14622
sg10
I2
sg11
VOM
p14623
sg13
I1
sa(dp14624
g7
I206
sg20
VC0006849
p14625
sg10
I16
sg11
Voral candidiasis
p14626
sg13
I2
sa(dp14627
g7
I224
sg20
VC0006849
p14628
sg10
I2
sg11
VOC
p14629
sg13
I1
sa(dp14630
g7
I233
sg20
VC1568868
p14631
sg10
I14
sg11
Voral mucositis
p14632
sg13
I2
sasa(dp14633
g2
S'Together, this study shows an association between clinical forms of oral candidiasis and the number of colonies of C. albicans in saliva, and that a systemic immune response characterized by the production of TNF-alpha and IFN-gamma is observed in patients with oral candidiasis.\n'
p14634
sg4
(lp14635
(dp14636
g7
I209
sg8
VP01375
p14637
sg10
I9
sg11
VTNF-alpha
p14638
sg13
I1
sa(dp14639
g7
I223
sg8
VP01579
p14640
sg10
I9
sg11
VIFN-gamma
p14641
sg13
I1
sasg17
(lp14642
(dp14643
g7
I68
sg20
VC0006849
p14644
sg10
I16
sg11
Voral candidiasis
p14645
sg13
I2
sa(dp14646
g7
I68
sg20
VC0006849
p14647
sg10
I16
sg11
Voral candidiasis
p14648
sg13
I2
sasa(dp14649
g2
S'However, the relationship between MCPIP1 and myocardial ischemia/reperfusion (I/R) injury remained illdefined.\n'
p14650
sg4
(lp14651
(dp14652
g7
I34
sg8
g59
sg10
I6
sg11
VMCPIP1
p14653
sg13
I1
sasg17
(lp14654
(dp14655
g7
I45
sg20
VC0151744
p14656
sg10
I19
sg11
Vmyocardial ischemia
p14657
sg13
I2
sasa(dp14658
g2
S'The present study seeks to determine whether monocyte chemotactic protein-induced protein 1 (MCPIP1), a recently identified modulator of inflammatory reactions, is involved in the cerebral neuroprotection conferred by minocycline treatment in the animal model of focal cerebral ischemia and to elucidate the mechanisms of minocycline-induced ischemic brain tolerance.\n'
p14659
sg4
(lp14660
(dp14661
g7
I93
sg8
g59
sg10
I6
sg11
VMCPIP1
p14662
sg13
I1
sa(dp14663
g7
I45
sg8
g59
sg10
I46
sg11
Vmonocyte chemotactic protein-induced protein 1
p14664
sg13
I5
sasg17
(lp14665
(dp14666
g7
I269
sg20
VC0917798
p14667
sg10
I17
sg11
Vcerebral ischemia
p14668
sg13
I2
sa(dp14669
g7
I357
sg20
VC0020963
p14670
sg10
I9
sg11
Vtolerance
p14671
sg13
I1
sasa(dp14672
g2
S'Focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) for 2 h in male C57BL/6 mice and MCPIP1 knockout mice followed by 24- or 48-h reperfusion.\n'
p14673
sg4
(lp14674
sg17
(lp14675
(dp14676
g7
I6
sg20
VC0917798
p14677
sg10
I17
sg11
Vcerebral ischemia
p14678
sg13
I2
sa(dp14679
g7
I73
sg20
VC0740391
p14680
sg10
I4
sg11
VMCAO
p14681
sg13
I1
sa(dp14682
g7
I39
sg20
VC0740391
p14683
sg10
I32
sg11
Vmiddle cerebral artery occlusion
p14684
sg13
I4
sasa(dp14685
g2
S'Our in vitro and in vivo studies demonstrate that MCPIP1 is an important mediator of minocycline-induced protection from brain ischemia.\n'
p14686
sg4
(lp14687
(dp14688
g7
I50
sg8
g59
sg10
I6
sg11
VMCPIP1
p14689
sg13
I1
sasg17
(lp14690
(dp14691
g7
I121
sg20
VC0007786
p14692
sg10
I14
sg11
Vbrain ischemia
p14693
sg13
I2
sasa(dp14694
g2
S'The objective of the present study was to investigate whether MCPIP exerts an inhibitory effect on the cardiac inflammatory response and adverse remodeling after myocardial infarction (MI).\n'
p14695
sg4
(lp14696
sg17
(lp14697
(dp14698
g7
I185
sg20
VC0027051
p14699
sg10
I2
sg11
VMI
p14700
sg13
I1
sa(dp14701
g7
I162
sg20
VC0027051
p14702
sg10
I21
sg11
Vmyocardial infarction
p14703
sg13
I2
sa(dp14704
g7
I111
sg20
VC1155266
p14705
sg10
I21
sg11
Vinflammatory response
p14706
sg13
I2
sasa(dp14707
g2
S'The diminishment in atherosclerosis in bone marrow MCPIP1(-/-) mice may be partially attributed to the slight decrease in their plasma lipids.\n'
p14708
sg4
(lp14709
sg17
(lp14710
(dp14711
g7
I20
sg20
VC0004153
p14712
sg10
I15
sg11
Vatherosclerosis
p14713
sg13
I1
sasa(dp14714
g2
S'The present study seeks to determine the involvement of monocyte chemotactic protein-induced protein 1 (MCPIP1), a recently identified novel modulator of inflammatory reactions, in the cerebral neuroprotection conferred by EA pretreatment in the animal model of focal cerebral ischemia and to elucidate the mechanisms of EA pretreatment-induced ischemic brain tolerance.\n'
p14715
sg4
(lp14716
(dp14717
g7
I56
sg8
g59
sg10
I46
sg11
Vmonocyte chemotactic protein-induced protein 1
p14718
sg13
I5
sa(dp14719
g7
I104
sg8
g59
sg10
I6
sg11
VMCPIP1
p14720
sg13
I1
sasg17
(lp14721
(dp14722
g7
I268
sg20
VC0917798
p14723
sg10
I17
sg11
Vcerebral ischemia
p14724
sg13
I2
sa(dp14725
g7
I360
sg20
VC0020963
p14726
sg10
I9
sg11
Vtolerance
p14727
sg13
I1
sasa(dp14728
g2
S'Twenty-four hours after the end of the last EA pretreatment, focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) for 90 minutes in male C57BL/6 mice and MCPIP1 knockout mice.\n'
p14729
sg4
(lp14730
sg17
(lp14731
(dp14732
g7
I134
sg20
VC0740391
p14733
sg10
I4
sg11
VMCAO
p14734
sg13
I1
sa(dp14735
g7
I100
sg20
VC0740391
p14736
sg10
I32
sg11
Vmiddle cerebral artery occlusion
p14737
sg13
I4
sa(dp14738
g7
I67
sg20
VC0917798
p14739
sg10
I17
sg11
Vcerebral ischemia
p14740
sg13
I2
sasa(dp14741
g2
S'Our data demonstrated that MCPIP1 deficiency caused significant lack of EA pretreatment-induced cerebral protective effects after MCAO compared with the control group and that MCPIP1 is involved in EA pretreatment-induced delayed brain ischemia tolerance.\n'
p14742
sg4
(lp14743
(dp14744
g7
I27
sg8
g59
sg10
I6
sg11
VMCPIP1
p14745
sg13
I1
sa(dp14746
g7
I27
sg8
g59
sg10
I6
sg11
VMCPIP1
p14747
sg13
I1
sasg17
(lp14748
(dp14749
g7
I230
sg20
VC0007786
p14750
sg10
I14
sg11
Vbrain ischemia
p14751
sg13
I2
sa(dp14752
g7
I245
sg20
VC0020963
p14753
sg10
I9
sg11
Vtolerance
p14754
sg13
I1
sasa(dp14755
g2
S'This study seeks to determine if monocyte chemotactic protein-induced protein 1 (MCPIP1), a recently identified CCCH Zn finger-containing protein, plays a role in focal brain ischemia and to elucidate the mechanisms of LPS-induced ischemic brain tolerance.\n'
p14756
sg4
(lp14757
(dp14758
g7
I81
sg8
g59
sg10
I6
sg11
VMCPIP1
p14759
sg13
I1
sa(dp14760
g7
I33
sg8
g59
sg10
I46
sg11
Vmonocyte chemotactic protein-induced protein 1
p14761
sg13
I5
sasg17
(lp14762
(dp14763
g7
I219
sg20
VC0175697
p14764
sg10
I3
sg11
VLPS
p14765
sg13
I1
sa(dp14766
g7
I246
sg20
VC0020963
p14767
sg10
I9
sg11
Vtolerance
p14768
sg13
I1
sa(dp14769
g7
I169
sg20
VC0007786
p14770
sg10
I14
sg11
Vbrain ischemia
p14771
sg13
I2
sasa(dp14772
g2
S'Mouse microglia was prepared from cortices of C57BL/6 mouse brain and primary human microglia was acquired from Clonexpress, Inc. Wild type and MCPIP1 knockout mice were treated with LPS (0.2 mg/kg) 24 hours before brain ischemia induced by transient middle cerebral artery occlusion (MCAO).\n'
p14773
sg4
(lp14774
sg17
(lp14775
(dp14776
g7
I215
sg20
VC0007786
p14777
sg10
I14
sg11
Vbrain ischemia
p14778
sg13
I2
sa(dp14779
g7
I285
sg20
VC0740391
p14780
sg10
I4
sg11
VMCAO
p14781
sg13
I1
sa(dp14782
g7
I183
sg20
VC0175697
p14783
sg10
I3
sg11
VLPS
p14784
sg13
I1
sa(dp14785
g7
I251
sg20
VC0740391
p14786
sg10
I32
sg11
Vmiddle cerebral artery occlusion
p14787
sg13
I4
sasa(dp14788
g2
S'Our data indicate that absence of MCPIP1 exacerbates ischemic brain damage by upregulation of proinflammatory cytokines and that MCPIP1 participates in LPS-induced ischemic stroke tolerance.\n'
p14789
sg4
(lp14790
(dp14791
g7
I34
sg8
g59
sg10
I6
sg11
VMCPIP1
p14792
sg13
I1
sa(dp14793
g7
I34
sg8
g59
sg10
I6
sg11
VMCPIP1
p14794
sg13
I1
sasg17
(lp14795
(dp14796
g7
I152
sg20
VC0175697
p14797
sg10
I3
sg11
VLPS
p14798
sg13
I1
sa(dp14799
g7
I164
sg20
VC3272363
p14800
sg10
I15
sg11
Vischemic stroke
p14801
sg13
I2
sa(dp14802
g7
I180
sg20
VC0020963
p14803
sg10
I9
sg11
Vtolerance
p14804
sg13
I1
sasa(dp14805
g2
S'By contrast, the IGFBP-rPs were distributed paraphyletically into two clades: IGFBP-rP1, 5, and 6 in one clade and the CCN family (IGFBP-rP2-4,7-9) in another.\n'
p14806
sg4
(lp14807
(dp14808
g7
I131
sg8
g59
sg10
I15
sg11
VIGFBP-rP2-4,7-9
p14809
sg13
I1
sa(dp14810
g7
I78
sg8
g59
sg10
I9
sg11
VIGFBP-rP1
p14811
sg13
I1
sa(dp14812
g7
I17
sg8
VP06401
p14813
sg10
I9
sg11
VIGFBP-rPs
p14814
sg13
I1
sa(dp14815
g7
I119
sg8
VP24864
p14816
sg10
I10
sg11
VCCN family
p14817
sg13
I2
sasg17
(lp14818
(dp14819
g7
I137
sg20
VC2681923
p14820
sg10
I3
sg11
VrP2
p14821
sg13
I1
sa(dp14822
g7
I84
sg20
VC0220701
p14823
sg10
I3
sg11
VrP1
p14824
sg13
I1
sasa(dp14825
g2
S'qPCR confirmed the upregulation of insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-rP1 (p = 0.029, p = 0.0002), while expression of IGFBP-5, -rP2 (CTGF), -rP4 (Cyr61), FOSL1, LOXL2, OAZ1 and CDK4 was not different between groups.\n'
p14826
sg4
(lp14827
(dp14828
g7
I197
sg8
VP54368
p14829
sg10
I4
sg11
VOAZ1
p14830
sg13
I1
sa(dp14831
g7
I175
sg8
g59
sg10
I5
sg11
VCyr61
p14832
sg13
I1
sa(dp14833
g7
I206
sg8
VP11802
p14834
sg10
I4
sg11
VCDK4
p14835
sg13
I1
sa(dp14836
g7
I190
sg8
g59
sg10
I5
sg11
VLOXL2
p14837
sg13
I1
sa(dp14838
g7
I162
sg8
VP29279
p14839
sg10
I4
sg11
VCTGF
p14840
sg13
I1
sa(dp14841
g7
I98
sg8
VP56715
p14842
sg10
I3
sg11
VrP1
p14843
sg13
I1
sa(dp14844
g7
I183
sg8
VP15407
p14845
sg10
I5
sg11
VFOSL1
p14846
sg13
I1
sa(dp14847
g7
I35
sg8
VP01308
p14848
sg10
I52
sg11
Vinsulin-like growth factor-binding protein (IGFBP)-3
p14849
sg13
I5
sa(dp14850
g7
I147
sg8
VP24593
p14851
sg10
I13
sg11
VIGFBP-5, -rP2
p14852
sg13
I2
sa(dp14853
g7
I170
sg8
VP29973
p14854
sg10
I3
sg11
VrP4
p14855
sg13
I1
sasg17
(lp14856
(dp14857
g7
I98
sg20
VC0220701
p14858
sg10
I3
sg11
VrP1
p14859
sg13
I1
sa(dp14860
g7
I170
sg20
VC3151001
p14861
sg10
I3
sg11
VrP4
p14862
sg13
I1
sa(dp14863
g7
I157
sg20
VC2681923
p14864
sg10
I3
sg11
VrP2
p14865
sg13
I1
sasa(dp14866
g2
S'Meta-analysis results indicated that, compared with normal protein diet, low-protein diet (LPD) supplemented with keto analogues (sLPD) could improve serum albumin (P &lt; 0.00001), hyperparathyroidism (P &lt; 0.00001) and hyperphosphatemia (P = 0.008).\n'
p14867
sg4
(lp14868
sg17
(lp14869
(dp14870
g7
I182
sg20
VC0020502
p14871
sg10
I19
sg11
Vhyperparathyroidism
p14872
sg13
I1
sa(dp14873
g7
I223
sg20
VC0085681
p14874
sg10
I17
sg11
Vhyperphosphatemia
p14875
sg13
I1
sasa(dp14876
g2
S'To understand whether these mediators are important in muscle wasting in cancer patients, levels of the phospho forms of PKR and eIF2alpha have been determined in rectus abdominus muscle of weight losing patients with oesophago-gastric cancer, in comparison with healthy controls.\n'
p14877
sg4
(lp14878
(dp14879
g7
I129
sg8
VP05198
p14880
sg10
I9
sg11
VeIF2alpha
p14881
sg13
I1
sa(dp14882
g7
I121
sg8
g59
sg10
I3
sg11
VPKR
p14883
sg13
I1
sasg17
(lp14884
(dp14885
g7
I228
sg20
VC0024623
p14886
sg10
I14
sg11
Vgastric cancer
p14887
sg13
I2
sa(dp14888
g7
I73
sg20
VC0006826
p14889
sg10
I6
sg11
Vcancer
p14890
sg13
I1
sa(dp14891
g7
I55
sg20
VC0026846
p14892
sg10
I14
sg11
Vmuscle wasting
p14893
sg13
I2
sasa(dp14894
g2
S'SPC24 is over-expressed in clinical lung adenocarcinoma samples, and high level of SPC24 is associated with advanced stages of lung tumors.\n'
p14895
sg4
(lp14896
(dp14897
g7
I0
sg8
g59
sg10
I5
sg11
VSPC24
p14898
sg13
I1
sa(dp14899
g7
I0
sg8
g59
sg10
I5
sg11
VSPC24
p14900
sg13
I1
sasg17
(lp14901
(dp14902
g7
I127
sg20
VC0024121
p14903
sg10
I11
sg11
Vlung tumors
p14904
sg13
I2
sa(dp14905
g7
I36
sg20
VC0152013
p14906
sg10
I19
sg11
Vlung adenocarcinoma
p14907
sg13
I2
sasa(dp14908
g2
S'To reveal the role of SPC24, an important component of kinetochore, in the tumorigenesis of lung cancer, we performed Oncomine and immunohistochemistry (IHC) analyses for SPC24 in human lung adenocarcinoma tumors.\n'
p14909
sg4
(lp14910
(dp14911
g7
I22
sg8
g59
sg10
I5
sg11
VSPC24
p14912
sg13
I1
sa(dp14913
g7
I22
sg8
g59
sg10
I5
sg11
VSPC24
p14914
sg13
I1
sasg17
(lp14915
(dp14916
g7
I75
sg20
VC0007621
p14917
sg10
I13
sg11
Vtumorigenesis
p14918
sg13
I1
sa(dp14919
g7
I92
sg20
VC0684249
p14920
sg10
I11
sg11
Vlung cancer
p14921
sg13
I2
sa(dp14922
g7
I206
sg20
VC0027651
p14923
sg10
I6
sg11
Vtumors
p14924
sg13
I1
sa(dp14925
g7
I186
sg20
VC0152013
p14926
sg10
I19
sg11
Vlung adenocarcinoma
p14927
sg13
I2
sasa(dp14928
g2
S'We knocked down SPC24 in two non-small cell lung cancer (NSCLC) cell lines, PC9 and A549, by siRNA and evaluated cell proliferation, apoptosis, and migration in the SPC24-deficient cells.\n'
p14929
sg4
(lp14930
(dp14931
g7
I16
sg8
g59
sg10
I5
sg11
VSPC24
p14932
sg13
I1
sa(dp14933
g7
I16
sg8
g59
sg10
I5
sg11
VSPC24
p14934
sg13
I1
sasg17
(lp14935
(dp14936
g7
I29
sg20
VC0007131
p14937
sg10
I26
sg11
Vnon-small cell lung cancer
p14938
sg13
I4
sa(dp14939
g7
I57
sg20
VC0007131
p14940
sg10
I5
sg11
VNSCLC
p14941
sg13
I1
sa(dp14942
g7
I118
sg20
VC0334094
p14943
sg10
I13
sg11
Vproliferation
p14944
sg13
I1
sasa(dp14945
g2
S'We further performed multiple Oncomine expression analyses for SPC24 in various lung cancer datasets with important clinical characteristics and risk factors, including survival, recurrence, and smoking status.\n'
p14946
sg4
(lp14947
(dp14948
g7
I63
sg8
g59
sg10
I5
sg11
VSPC24
p14949
sg13
I1
sasg17
(lp14950
(dp14951
g7
I179
sg20
VC1458156
p14952
sg10
I10
sg11
Vrecurrence
p14953
sg13
I1
sa(dp14954
g7
I80
sg20
VC0684249
p14955
sg10
I11
sg11
Vlung cancer
p14956
sg13
I2
sasa(dp14957
g2
S'SPC24 is a novel oncogene of lung cancer, and can serve as a promising prognostic biomarker to differentiate lung tumors that have various clinicopathological characteristics.\n'
p14958
sg4
(lp14959
(dp14960
g7
I0
sg8
g59
sg10
I5
sg11
VSPC24
p14961
sg13
I1
sasg17
(lp14962
(dp14963
g7
I29
sg20
VC0684249
p14964
sg10
I11
sg11
Vlung cancer
p14965
sg13
I2
sa(dp14966
g7
I109
sg20
VC0024121
p14967
sg10
I11
sg11
Vlung tumors
p14968
sg13
I2
sasa(dp14969
g2
S"Treatment with 3,3'-iminodipropionitrile, which induces aberrant phosphorylation of NF in the perikarya of neurons and causes neuropathy, induced oocyte degeneration with follicular atresia, phosphorylation of NF-H in oocytes, and ovarian gene expression of cyclin-dependent kinase 5, a candidate kinase of NF-H.\n"
p14970
sg4
(lp14971
(dp14972
g7
I210
sg8
VP12036
p14973
sg10
I4
sg11
VNF-H
p14974
sg13
I1
sa(dp14975
g7
I210
sg8
VP12036
p14976
sg10
I4
sg11
VNF-H
p14977
sg13
I1
sa(dp14978
g7
I258
sg8
g59
sg10
I25
sg11
Vcyclin-dependent kinase 5
p14979
sg13
I3
sasg17
(lp14980
(dp14981
g7
I153
sg20
VC0011164
p14982
sg10
I12
sg11
Vdegeneration
p14983
sg13
I1
sa(dp14984
g7
I126
sg20
VC0442874
p14985
sg10
I10
sg11
Vneuropathy
p14986
sg13
I1
sa(dp14987
g7
I182
sg20
VC0243066
p14988
sg10
I7
sg11
Vatresia
p14989
sg13
I1
sasa(dp14990
g2
S'To explore the role of cyclin dependent kinase 5 (CDK5) in 2, 5-hexanedione (HD)-induced neuropathy.\n'
p14991
sg4
(lp14992
(dp14993
g7
I23
sg8
VP12004
p14994
sg10
I25
sg11
Vcyclin dependent kinase 5
p14995
sg13
I4
sa(dp14996
g7
I50
sg8
g59
sg10
I4
sg11
VCDK5
p14997
sg13
I1
sasg17
(lp14998
(dp14999
g7
I89
sg20
VC0442874
p15000
sg10
I10
sg11
Vneuropathy
p15001
sg13
I1
sasa(dp15002
g2
S'HD can induce significant changes of CDK5 and its activators p35, p25 in nerve tissues, which may be related to the neuropathy induced by HD.\n'
p15003
sg4
(lp15004
(dp15005
g7
I37
sg8
g59
sg10
I4
sg11
VCDK5
p15006
sg13
I1
sa(dp15007
g7
I66
sg8
VP80188
p15008
sg10
I3
sg11
Vp25
p15009
sg13
I1
sa(dp15010
g7
I61
sg8
VP51948
p15011
sg10
I3
sg11
Vp35
p15012
sg13
I1
sasg17
(lp15013
(dp15014
g7
I116
sg20
VC0442874
p15015
sg10
I10
sg11
Vneuropathy
p15016
sg13
I1
sasa(dp15017
g2
S"To investigate the mechanisms of the neuropathy induced by HD, the contents and activities of cyclin-dependent kinase 5 (CDK5) and activators (p35 precursor, p35 and p25) in rats' cerebrum cortex (CC), spinal cord (SC) and sciatic nerve (SN) were determined.\n"
p15018
sg4
(lp15019
(dp15020
g7
I166
sg8
VP80188
p15021
sg10
I3
sg11
Vp25
p15022
sg13
I1
sa(dp15023
g7
I94
sg8
g59
sg10
I25
sg11
Vcyclin-dependent kinase 5
p15024
sg13
I3
sa(dp15025
g7
I121
sg8
g59
sg10
I4
sg11
VCDK5
p15026
sg13
I1
sa(dp15027
g7
I143
sg8
VP51948
p15028
sg10
I13
sg11
Vp35 precursor
p15029
sg13
I2
sa(dp15030
g7
I143
sg8
VP51948
p15031
sg10
I3
sg11
Vp35
p15032
sg13
I1
sasg17
(lp15033
(dp15034
g7
I209
sg20
VC0035334
p15035
sg10
I4
sg11
Vcord
p15036
sg13
I1
sa(dp15037
g7
I37
sg20
VC0442874
p15038
sg10
I10
sg11
Vneuropathy
p15039
sg13
I1
sasa(dp15040
g2
S'The inconsistent changes of CDK5 activities in CNS and PNS might delegate the different mechanisms of HD-induced peripheral neuropathy.\n'
p15041
sg4
(lp15042
(dp15043
g7
I28
sg8
g59
sg10
I4
sg11
VCDK5
p15044
sg13
I1
sasg17
(lp15045
(dp15046
g7
I113
sg20
VC0031117
p15047
sg10
I21
sg11
Vperipheral neuropathy
p15048
sg13
I2
sasa(dp15049
g2
S'In the past decade, a growing number of regulatory non-coding RNAs (ncRNAs) including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have been identified to be strongly associated with schizophrenia.\n'
p15050
sg4
(lp15051
sg17
(lp15052
(dp15053
g7
I192
sg20
VC0036341
p15054
sg10
I13
sg11
Vschizophrenia
p15055
sg13
I1
sasa(dp15056
g2
S'However, the studies of these ncRNAs in the pathophysiology of schizophrenia and the reverting of their genetic defects in restoration of the normal phenotype have been hampered by insufficient technology to manipulate these ncRNA genes effectively as well as a lack of appropriate animal models.\n'
p15057
sg4
(lp15058
sg17
(lp15059
(dp15060
g7
I30
sg20
VC1857299
p15061
sg10
I5
sg11
VncRNA
p15062
sg13
I1
sa(dp15063
g7
I63
sg20
VC0036341
p15064
sg10
I13
sg11
Vschizophrenia
p15065
sg13
I1
sasa(dp15066
g2
S'In this review article, we mainly focus on the schizophrenia-related ncRNAs and the use of CRISPR/Cas9-mediated editing on the non-coding regions of the genomic DNA in proving causal relationship between the genetic defects and the pathophysiology of schizophrenia.\n'
p15067
sg4
(lp15068
sg17
(lp15069
(dp15070
g7
I47
sg20
VC0036341
p15071
sg10
I13
sg11
Vschizophrenia
p15072
sg13
I1
sa(dp15073
g7
I47
sg20
VC0036341
p15074
sg10
I13
sg11
Vschizophrenia
p15075
sg13
I1
sasa(dp15076
g2
S'This review describes the application of the powerful and feasible CRISPR/Cas9 technology to manipulate schizophrenia-associated ncRNA genes.\n'
p15077
sg4
(lp15078
sg17
(lp15079
(dp15080
g7
I129
sg20
VC1857299
p15081
sg10
I5
sg11
VncRNA
p15082
sg13
I1
sa(dp15083
g7
I104
sg20
VC0036341
p15084
sg10
I13
sg11
Vschizophrenia
p15085
sg13
I1
sasa(dp15086
g2
S'In contrast to reports on ncRNAs in affective disorders, schizophrenia and anxiety disorders, manuscripts on ncRNAs in posttraumatic stress disorder (PTSD) and associated animal models are scarce.\n'
p15087
sg4
(lp15088
sg17
(lp15089
(dp15090
g7
I36
sg20
VC0525045
p15091
sg10
I19
sg11
Vaffective disorders
p15092
sg13
I2
sa(dp15093
g7
I119
sg20
VC0038436
p15094
sg10
I29
sg11
Vposttraumatic stress disorder
p15095
sg13
I3
sa(dp15096
g7
I150
sg20
VC0038436
p15097
sg10
I4
sg11
VPTSD
p15098
sg13
I1
sa(dp15099
g7
I57
sg20
VC0036341
p15100
sg10
I13
sg11
Vschizophrenia
p15101
sg13
I1
sa(dp15102
g7
I75
sg20
VC0003469
p15103
sg10
I17
sg11
Vanxiety disorders
p15104
sg13
I2
sasa(dp15105
g2
S'A novel class of ncRNA-derived small RNAs, shown to be strongly induced during an early phase of learning in mouse, is also expressed in man, and at least one representative (SNORD85) was strongly down-regulated in schizophrenia synaptosomes.\n'
p15106
sg4
(lp15107
sg17
(lp15108
(dp15109
g7
I215
sg20
VC0036341
p15110
sg10
I13
sg11
Vschizophrenia
p15111
sg13
I1
sa(dp15112
g7
I17
sg20
VC1857299
p15113
sg10
I5
sg11
VncRNA
p15114
sg13
I1
sasa(dp15115
g2
S'We then discuss the possibility that ncRNA regulation of schizophrenia risk genes may underlie the diverse findings of genetic linkage studies including that protein-altering gene polymorphisms are not generally found in schizophrenia.\n'
p15116
sg4
(lp15117
sg17
(lp15118
(dp15119
g7
I57
sg20
VC0036341
p15120
sg10
I13
sg11
Vschizophrenia
p15121
sg13
I1
sa(dp15122
g7
I37
sg20
VC1857299
p15123
sg10
I5
sg11
VncRNA
p15124
sg13
I1
sa(dp15125
g7
I57
sg20
VC0036341
p15126
sg10
I13
sg11
Vschizophrenia
p15127
sg13
I1
sasa(dp15128
g2
S'Despite the strength of the association of multiple sclerosis (MS) and human leukocyte antigen (HLA)-DR2, other genetic elements could have a role in the pathophysiology of MS. We investigated possible associations with polymorphic susceptibility genes located within the HLA complex, i.e., heat-shock protein (HSP)70-1, HSP70-2, and HSP70-hom in Japanese patients with MS.\n'
p15129
sg4
(lp15130
(dp15131
g7
I321
sg8
VP54652
p15132
sg10
I7
sg11
VHSP70-2
p15133
sg13
I1
sa(dp15134
g7
I291
sg8
g59
sg10
I28
sg11
Vheat-shock protein (HSP)70-1
p15135
sg13
I3
sa(dp15136
g7
I334
sg8
VP08107
p15137
sg10
I9
sg11
VHSP70-hom
p15138
sg13
I1
sa(dp15139
g7
I71
sg8
VP05534
p15140
sg10
I23
sg11
Vhuman leukocyte antigen
p15141
sg13
I3
sa(dp15142
g7
I96
sg8
VP30486
p15143
sg10
I3
sg11
VHLA
p15144
sg13
I1
sa(dp15145
g7
I96
sg8
VP30486
p15146
sg10
I3
sg11
VHLA
p15147
sg13
I1
sasg17
(lp15148
(dp15149
g7
I291
sg20
VC0034152
p15150
sg10
I18
sg11
Vheat-shock protein
p15151
sg13
I2
sa(dp15152
g7
I63
sg20
VC0036429
p15153
sg10
I2
sg11
VMS
p15154
sg13
I1
sa(dp15155
g7
I63
sg20
VC0036429
p15156
sg10
I2
sg11
VMS
p15157
sg13
I1
sa(dp15158
g7
I43
sg20
VC0026769
p15159
sg10
I18
sg11
Vmultiple sclerosis
p15160
sg13
I2
sa(dp15161
g7
I311
sg20
VC0034152
p15162
sg10
I3
sg11
VHSP
p15163
sg13
I1
sasa(dp15164
g2
S'The mRNA expression levels of c2orf68 were examined in 30 pairs of human colorectal adenocarcinoma tissues and adjacent normal colorectal tissues by qRT-PCR.\n'
p15165
sg4
(lp15166
(dp15167
g7
I30
sg8
g59
sg10
I7
sg11
Vc2orf68
p15168
sg13
I1
sasg17
(lp15169
(dp15170
g7
I73
sg20
VC1319315
p15171
sg10
I25
sg11
Vcolorectal adenocarcinoma
p15172
sg13
I2
sasa(dp15173
g2
S'The present study aimed to evaluate the expression of NM_001013649.3 in human colorectal adenocarcinoma tissue and its correlation with clinicopathological aspects of the disease.\n'
p15174
sg4
(lp15175
sg17
(lp15176
(dp15177
g7
I78
sg20
VC1319315
p15178
sg10
I25
sg11
Vcolorectal adenocarcinoma
p15179
sg13
I2
sasa(dp15180
g2
S'Reverse transcription quantitative real-time PCR was used to assess the expression levels of NM_001013649.3 in cancer and adjacent normal colorectal tissues from 30 patients with colorectal adenocarcinoma.\n'
p15181
sg4
(lp15182
sg17
(lp15183
(dp15184
g7
I111
sg20
VC0006826
p15185
sg10
I6
sg11
Vcancer
p15186
sg13
I1
sa(dp15187
g7
I179
sg20
VC1319315
p15188
sg10
I25
sg11
Vcolorectal adenocarcinoma
p15189
sg13
I2
sasa(dp15190
g2
S'The mRNA levels of NM_001013649.3 are significantly down-regulated in colorectal adenocarcinoma tissue, and this down-regulation is most likely correlated with the differentiation status of the cancer, indicating that NM_001013649.3 is potentially involved in the pathogenesis of colorectal adenocarcinoma.\n'
p15191
sg4
(lp15192
sg17
(lp15193
(dp15194
g7
I264
sg20
VC0699748
p15195
sg10
I12
sg11
Vpathogenesis
p15196
sg13
I1
sa(dp15197
g7
I70
sg20
VC1319315
p15198
sg10
I25
sg11
Vcolorectal adenocarcinoma
p15199
sg13
I2
sa(dp15200
g7
I194
sg20
VC0006826
p15201
sg10
I6
sg11
Vcancer
p15202
sg13
I1
sa(dp15203
g7
I70
sg20
VC1319315
p15204
sg10
I25
sg11
Vcolorectal adenocarcinoma
p15205
sg13
I2
sasa(dp15206
g2
S'We investigated the localization of pituitary homeo box 1 (Ptx1) protein in five human non-neoplastic pituitaries and 73 of all types of pituitary adenomas using immunohistochemistry, and the expression of Ptx1 messenger RNA (mRNA) in 18 representative pituitary adenomas using the reverse transcriptase polymerase chain reaction (RT-PCR) technique.\n'
p15207
sg4
(lp15208
(dp15209
g7
I282
sg8
VP63136
p15210
sg10
I21
sg11
Vreverse transcriptase
p15211
sg13
I2
sa(dp15212
g7
I59
sg8
VP78337
p15213
sg10
I4
sg11
VPtx1
p15214
sg13
I1
sa(dp15215
g7
I206
sg8
VP78337
p15216
sg10
I18
sg11
VPtx1 messenger RNA
p15217
sg13
I3
sa(dp15218
g7
I36
sg8
VP78337
p15219
sg10
I21
sg11
Vpituitary homeo box 1
p15220
sg13
I4
sasg17
(lp15221
(dp15222
g7
I137
sg20
VC0032000
p15223
sg10
I18
sg11
Vpituitary adenomas
p15224
sg13
I2
sa(dp15225
g7
I137
sg20
VC0032000
p15226
sg10
I18
sg11
Vpituitary adenomas
p15227
sg13
I2
sasa(dp15228
g2
S'Ptx1 was detected in 10/14 (71.4%) of growth hormone (GH)-secreting adenomas, 12/12 (100%) of prolactin (PRL)-secreting adenomas, 18/20 (90%) of adrenocorticotropic hormone (ACTH)-secreting adenomas, 6/7 (85.7%) of thyroid-stimulating hormone (TSH)-secreting adenomas, and 17/20 (85%) of clinically non-functioning adenomas, including 9/10 (90%) of gonadotropin-subunit-positive adenomas.\n'
p15229
sg4
(lp15230
(dp15231
g7
I94
sg8
VP01236
p15232
sg10
I9
sg11
Vprolactin
p15233
sg13
I1
sa(dp15234
g7
I0
sg8
VP78337
p15235
sg10
I4
sg11
VPtx1
p15236
sg13
I1
sa(dp15237
g7
I244
sg8
VP01222
p15238
sg10
I3
sg11
VTSH
p15239
sg13
I1
sa(dp15240
g7
I105
sg8
VP01236
p15241
sg10
I3
sg11
VPRL
p15242
sg13
I1
sa(dp15243
g7
I215
sg8
VP01222
p15244
sg10
I27
sg11
Vthyroid-stimulating hormone
p15245
sg13
I2
sa(dp15246
g7
I54
sg8
VP01242
p15247
sg10
I2
sg11
VGH
p15248
sg13
I1
sa(dp15249
g7
I174
sg8
VP01189
p15250
sg10
I4
sg11
VACTH
p15251
sg13
I1
sa(dp15252
g7
I145
sg8
VP01189
p15253
sg10
I27
sg11
Vadrenocorticotropic hormone
p15254
sg13
I2
sa(dp15255
g7
I38
sg8
VP01242
p15256
sg10
I14
sg11
Vgrowth hormone
p15257
sg13
I2
sasg17
(lp15258
(dp15259
g7
I68
sg20
VC0001430
p15260
sg10
I8
sg11
Vadenomas
p15261
sg13
I1
sa(dp15262
g7
I68
sg20
VC0001430
p15263
sg10
I8
sg11
Vadenomas
p15264
sg13
I1
sa(dp15265
g7
I68
sg20
VC0001430
p15266
sg10
I8
sg11
Vadenomas
p15267
sg13
I1
sa(dp15268
g7
I68
sg20
VC0001430
p15269
sg10
I8
sg11
Vadenomas
p15270
sg13
I1
sa(dp15271
g7
I68
sg20
VC0001430
p15272
sg10
I8
sg11
Vadenomas
p15273
sg13
I1
sa(dp15274
g7
I68
sg20
VC0001430
p15275
sg10
I8
sg11
Vadenomas
p15276
sg13
I1
sasa(dp15277
g2
S'Thus, there was no relationship between Ptx1 expression and a particular type of pituitary adenomas.\n'
p15278
sg4
(lp15279
(dp15280
g7
I40
sg8
VP78337
p15281
sg10
I4
sg11
VPtx1
p15282
sg13
I1
sasg17
(lp15283
(dp15284
g7
I81
sg20
VC0032000
p15285
sg10
I18
sg11
Vpituitary adenomas
p15286
sg13
I2
sasa(dp15287
g2
S'By RT-PCR analysis, Ptx1 mRNA was expressed in all 18 cases of pituitary adenomas, including two cases negative for Ptx1 protein by immunohistochemistry.\n'
p15288
sg4
(lp15289
(dp15290
g7
I20
sg8
VP78337
p15291
sg10
I9
sg11
VPtx1 mRNA
p15292
sg13
I2
sa(dp15293
g7
I116
sg8
g59
sg10
I12
sg11
VPtx1 protein
p15294
sg13
I2
sasg17
(lp15295
(dp15296
g7
I63
sg20
VC0032000
p15297
sg10
I18
sg11
Vpituitary adenomas
p15298
sg13
I2
sasa(dp15299
g2
S'Clusters defining naive (NKG2A(+)CD57(-)NKG2C(-)) NK cell repertoires in the donor were associated with decreased risk for relapse in recipients with acute myeloid leukemia and myelodysplastic syndrome (hazard ratio [HR], 0.09; 95% confidence interval [CI]: 0.03-0.27; p &lt; 0.001).\n'
p15300
sg4
(lp15301
(dp15302
g7
I25
sg8
VP26715
p15303
sg10
I20
sg11
VNKG2A(+)CD57(-)NKG2C
p15304
sg13
I1
sasg17
(lp15305
(dp15306
g7
I150
sg20
VC0023467
p15307
sg10
I22
sg11
Vacute myeloid leukemia
p15308
sg13
I3
sa(dp15309
g7
I123
sg20
VC0277556
p15310
sg10
I7
sg11
Vrelapse
p15311
sg13
I1
sa(dp15312
g7
I177
sg20
VC0033027
p15313
sg10
I24
sg11
Vmyelodysplastic syndrome
p15314
sg13
I2
sasa(dp15315
g2
S'To investigate the expression of acetyl coenzyme A synthetase short-chain family member 2 (ACSS2) in patients with colorectal cancer (CRC) and its biological role.\n'
p15316
sg4
(lp15317
(dp15318
g7
I33
sg8
g59
sg10
I64
sg11
Vacetyl coenzyme A synthetase short-chain family member 2 (ACSS2)
p15319
sg13
I9
sasg17
(lp15320
(dp15321
g7
I134
sg20
VC1527249
p15322
sg10
I3
sg11
VCRC
p15323
sg13
I1
sa(dp15324
g7
I115
sg20
VC1527249
p15325
sg10
I17
sg11
Vcolorectal cancer
p15326
sg13
I2
sasa(dp15327
g2
S'In addition, ACSS2 S659 phosphorylation positively correlates with AMPK activity in glioma specimens and grades of glioma malignancy.\n'
p15328
sg4
(lp15329
(dp15330
g7
I67
sg8
VP54646
p15331
sg10
I4
sg11
VAMPK
p15332
sg13
I1
sa(dp15333
g7
I13
sg8
g59
sg10
I10
sg11
VACSS2 S659
p15334
sg13
I2
sasg17
(lp15335
(dp15336
g7
I84
sg20
VC0017638
p15337
sg10
I6
sg11
Vglioma
p15338
sg13
I1
sa(dp15339
g7
I122
sg20
VC0006826
p15340
sg10
I10
sg11
Vmalignancy
p15341
sg13
I1
sa(dp15342
g7
I84
sg20
VC0017638
p15343
sg10
I6
sg11
Vglioma
p15344
sg13
I1
sasa(dp15345
g2
S'Although ACSS2 function in cancer cells has been elucidated, its essentiality in ruminant mammary lipogenesis is unknown.\n'
p15346
sg4
(lp15347
(dp15348
g7
I9
sg8
g59
sg10
I5
sg11
VACSS2
p15349
sg13
I1
sasg17
(lp15350
(dp15351
g7
I27
sg20
VC0006826
p15352
sg10
I6
sg11
Vcancer
p15353
sg13
I1
sasa(dp15354
g2
S'Moreover, acyl-CoA synthetase short-chain family member 2 (ACSS2), a direct SREBP2 target, provided a growth advantage to cancer cells under acidic pH.\n'
p15355
sg4
(lp15356
(dp15357
g7
I76
sg8
g59
sg10
I6
sg11
VSREBP2
p15358
sg13
I1
sa(dp15359
g7
I59
sg8
g59
sg10
I5
sg11
VACSS2
p15360
sg13
I1
sa(dp15361
g7
I10
sg8
g59
sg10
I47
sg11
Vacyl-CoA synthetase short-chain family member 2
p15362
sg13
I6
sasg17
(lp15363
(dp15364
g7
I15
sg20
VC2678439
p15365
sg10
I3
sg11
VCoA
p15366
sg13
I1
sa(dp15367
g7
I122
sg20
VC0006826
p15368
sg10
I6
sg11
Vcancer
p15369
sg13
I1
sasa(dp15370
g2
S'In vivo studies revealed that in addition to nucleo-cytoplasmic acetate assimilating enzyme ACSS2, mitochondrial ACSS1 was critical for melanoma tumor growth in mice.\n'
p15371
sg4
(lp15372
(dp15373
g7
I92
sg8
g59
sg10
I5
sg11
VACSS2
p15374
sg13
I1
sa(dp15375
g7
I99
sg8
g59
sg10
I19
sg11
Vmitochondrial ACSS1
p15376
sg13
I2
sasg17
(lp15377
(dp15378
g7
I136
sg20
VC0025202
p15379
sg10
I8
sg11
Vmelanoma
p15380
sg13
I1
sa(dp15381
g7
I145
sg20
VC0598934
p15382
sg10
I12
sg11
Vtumor growth
p15383
sg13
I2
sasa(dp15384
g2
S'KEGG enrichment analysis indicated upregulated DEGs were involved in Renin-angiotensin system (e.g., Agt, angiotensinogen) and Wnt signaling pathway (e.g., Dkk1), while downregulated DEGs participated in Basal cell carcinoma (e.g., Lef1).\n'
p15385
sg4
(lp15386
(dp15387
g7
I69
sg8
VP00797
p15388
sg10
I5
sg11
VRenin
p15389
sg13
I1
sa(dp15390
g7
I232
sg8
g59
sg10
I4
sg11
VLef1
p15391
sg13
I1
sa(dp15392
g7
I75
sg8
VP21549
p15393
sg10
I11
sg11
Vangiotensin
p15394
sg13
I1
sa(dp15395
g7
I156
sg8
g59
sg10
I4
sg11
VDkk1
p15396
sg13
I1
sa(dp15397
g7
I101
sg8
VP21549
p15398
sg10
I3
sg11
VAgt
p15399
sg13
I1
sa(dp15400
g7
I47
sg8
g59
sg10
I4
sg11
VDEGs
p15401
sg13
I1
sasg17
(lp15402
(dp15403
g7
I204
sg20
VC0007117
p15404
sg10
I20
sg11
VBasal cell carcinoma
p15405
sg13
I3
sasa(dp15406
g2
S'Concurrent with the inhibition of Wnt/Beta-catenin signaling, 1-benzyl-I3C strongly down regulated expression of the melanoma master regulator, Microphthalmia Associated Transcription Factor isoform-M (MITF-M) by inhibiting promoter activity through the consensus LEF-1/TCF DNA binding site.\n'
p15407
sg4
(lp15408
(dp15409
g7
I202
sg8
g59
sg10
I6
sg11
VMITF-M
p15410
sg13
I1
sa(dp15411
g7
I38
sg8
VP35222
p15412
sg10
I12
sg11
VBeta-catenin
p15413
sg13
I1
sa(dp15414
g7
I264
sg8
g59
sg10
I5
sg11
VLEF-1
p15415
sg13
I1
sa(dp15416
g7
I144
sg8
g59
sg10
I56
sg11
VMicrophthalmia Associated Transcription Factor isoform-M
p15417
sg13
I5
sa(dp15418
g7
I117
sg8
g59
sg10
I25
sg11
Vmelanoma master regulator
p15419
sg13
I3
sasg17
(lp15420
(dp15421
g7
I117
sg20
VC0025202
p15422
sg10
I8
sg11
Vmelanoma
p15423
sg13
I1
sa(dp15424
g7
I144
sg20
VC0026010
p15425
sg10
I14
sg11
VMicrophthalmia
p15426
sg13
I1
sasa(dp15427
g2
S'Lymphoid enhancer binding factor 1 (LEF-1) has recently been reported as a potential immunohistochemical (IHC) marker for basal cell adenoma (BCA) and other salivary gland tumors, which may contribute to an increased accuracy in differentiating basaloid salivary gland neoplasms.\n'
p15428
sg4
(lp15429
(dp15430
g7
I36
sg8
g59
sg10
I5
sg11
VLEF-1
p15431
sg13
I1
sa(dp15432
g7
I0
sg8
g59
sg10
I34
sg11
VLymphoid enhancer binding factor 1
p15433
sg13
I5
sasg17
(lp15434
(dp15435
g7
I142
sg20
VC0205646
p15436
sg10
I3
sg11
VBCA
p15437
sg13
I1
sa(dp15438
g7
I172
sg20
VC0027651
p15439
sg10
I6
sg11
Vtumors
p15440
sg13
I1
sa(dp15441
g7
I254
sg20
VC0036095
p15442
sg10
I24
sg11
Vsalivary gland neoplasms
p15443
sg13
I3
sa(dp15444
g7
I122
sg20
VC0205646
p15445
sg10
I18
sg11
Vbasal cell adenoma
p15446
sg13
I3
sasa(dp15447
g2
S'We evaluated the utility of LEF-1 in fine needle aspiration (FNA) and resection specimens to distinguish pleomorphic adenoma (PA), BCA, basal cell adenocarcinoma (BCAC), and adenoid cystic carcinoma (ACC) as well as in non-neoplastic salivary gland (NNSG).\n'
p15448
sg4
(lp15449
(dp15450
g7
I28
sg8
g59
sg10
I5
sg11
VLEF-1
p15451
sg13
I1
sasg17
(lp15452
(dp15453
g7
I126
sg20
VC0026277
p15454
sg10
I2
sg11
VPA
p15455
sg13
I1
sa(dp15456
g7
I174
sg20
VC0010606
p15457
sg10
I24
sg11
Vadenoid cystic carcinoma
p15458
sg13
I3
sa(dp15459
g7
I200
sg20
VC0175754
p15460
sg10
I3
sg11
VACC
p15461
sg13
I1
sa(dp15462
g7
I49
sg20
VC0700198
p15463
sg10
I10
sg11
Vaspiration
p15464
sg13
I1
sa(dp15465
g7
I163
sg20
VC2243086
p15466
sg10
I4
sg11
VBCAC
p15467
sg13
I1
sa(dp15468
g7
I105
sg20
VC0026277
p15469
sg10
I19
sg11
Vpleomorphic adenoma
p15470
sg13
I2
sa(dp15471
g7
I136
sg20
VC2243086
p15472
sg10
I25
sg11
Vbasal cell adenocarcinoma
p15473
sg13
I3
sasa(dp15474
g2
S'When comparing benign (PA and BCA) and the most common malignant basaloid salivary gland tumor (ACC), positive LEF-1 favors a benign neoplasm.\n'
p15475
sg4
(lp15476
(dp15477
g7
I111
sg8
g59
sg10
I5
sg11
VLEF-1
p15478
sg13
I1
sasg17
(lp15479
(dp15480
g7
I126
sg20
VC0086692
p15481
sg10
I15
sg11
Vbenign neoplasm
p15482
sg13
I2
sa(dp15483
g7
I96
sg20
VC0175754
p15484
sg10
I3
sg11
VACC
p15485
sg13
I1
sa(dp15486
g7
I74
sg20
VC0036095
p15487
sg10
I20
sg11
Vsalivary gland tumor
p15488
sg13
I3
sasa(dp15489
g2
S'Preclinical studies have demonstrated the potential of inhibitors that target WNT receptor complexes at the cell membrane or that block the interaction of Beta-catenin with lymphoid enhancer-binding factor 1 and the androgen receptor, in preventing prostate cancer progression.\n'
p15490
sg4
(lp15491
(dp15492
g7
I155
sg8
VP35222
p15493
sg10
I12
sg11
VBeta-catenin
p15494
sg13
I1
sa(dp15495
g7
I78
sg8
g59
sg10
I12
sg11
VWNT receptor
p15496
sg13
I2
sa(dp15497
g7
I216
sg8
VP10275
p15498
sg10
I17
sg11
Vandrogen receptor
p15499
sg13
I2
sa(dp15500
g7
I173
sg8
g59
sg10
I34
sg11
Vlymphoid enhancer-binding factor 1
p15501
sg13
I4
sasg17
(lp15502
(dp15503
g7
I258
sg20
VC0178874
p15504
sg10
I18
sg11
Vcancer progression
p15505
sg13
I2
sasa(dp15506
g2
S'Taken together, our data suggested that MALAT1-miR-503-PI3K/Akt/mTOR/Snail pathway plays critical roles in silica-induced pulmonary fibrosis.\n'
p15507
sg4
(lp15508
(dp15509
g7
I60
sg8
g59
sg10
I3
sg11
VAkt
p15510
sg13
I1
sa(dp15511
g7
I69
sg8
g59
sg10
I5
sg11
VSnail
p15512
sg13
I1
sa(dp15513
g7
I55
sg8
VP42336
p15514
sg10
I4
sg11
VPI3K
p15515
sg13
I1
sa(dp15516
g7
I40
sg8
g59
sg10
I14
sg11
VMALAT1-miR-503
p15517
sg13
I1
sa(dp15518
g7
I64
sg8
VP42345
p15519
sg10
I4
sg11
VmTOR
p15520
sg13
I1
sasg17
(lp15521
(dp15522
g7
I122
sg20
VC0034069
p15523
sg10
I18
sg11
Vpulmonary fibrosis
p15524
sg13
I2
sasa(dp15525
g2
S'We identified trihydroxyphenolic compounds as potent blockers of TGF-Beta1 responses (IC50 ~50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis.\n'
p15526
sg4
(lp15527
(dp15528
g7
I65
sg8
VP01137
p15529
sg10
I9
sg11
VTGF-Beta1
p15530
sg13
I1
sa(dp15531
g7
I100
sg8
g59
sg10
I6
sg11
VSnail1
p15532
sg13
I1
sasg17
(lp15533
(dp15534
g7
I164
sg20
VC0034069
p15535
sg10
I18
sg11
Vpulmonary fibrosis
p15536
sg13
I2
sa(dp15537
g7
I218
sg20
VC0027627
p15538
sg10
I10
sg11
Vmetastasis
p15539
sg13
I1
sa(dp15540
g7
I206
sg20
VC0684249
p15541
sg10
I11
sg11
Vlung cancer
p15542
sg13
I2
sasa(dp15543
g2
S'Metagenomic analysis revealed direct correlation among PPARGC1A, zinc-finger transcription factor snail homolog 1 (SNAI1), and metastatic lung disease.\n'
p15544
sg4
(lp15545
(dp15546
g7
I65
sg8
VP35398
p15547
sg10
I48
sg11
Vzinc-finger transcription factor snail homolog 1
p15548
sg13
I6
sa(dp15549
g7
I55
sg8
g59
sg10
I8
sg11
VPPARGC1A
p15550
sg13
I1
sa(dp15551
g7
I115
sg8
g59
sg10
I5
sg11
VSNAI1
p15552
sg13
I1
sasg17
(lp15553
(dp15554
g7
I138
sg20
VC0024115
p15555
sg10
I12
sg11
Vlung disease
p15556
sg13
I2
sasa(dp15557
g2
S'To discuss the abnormal expression of Wnt inhibitory factor (WIF1) in hepatocellular carcinoma cells and its regulating effect on the hepatocellular carcinoma invasion and metastasis factors of tissue inhibitor of matrix metalloproteinases-3 (TIMP-3) and caveolin-1.\n'
p15558
sg4
(lp15559
(dp15560
g7
I61
sg8
g59
sg10
I4
sg11
VWIF1
p15561
sg13
I1
sa(dp15562
g7
I38
sg8
g59
sg10
I21
sg11
VWnt inhibitory factor
p15563
sg13
I3
sa(dp15564
g7
I255
sg8
g59
sg10
I10
sg11
Vcaveolin-1
p15565
sg13
I1
sa(dp15566
g7
I194
sg8
VP35625
p15567
sg10
I47
sg11
Vtissue inhibitor of matrix metalloproteinases-3
p15568
sg13
I5
sa(dp15569
g7
I243
sg8
VP35625
p15570
sg10
I6
sg11
VTIMP-3
p15571
sg13
I1
sasg17
(lp15572
(dp15573
g7
I70
sg20
VC1512411
p15574
sg10
I24
sg11
Vhepatocellular carcinoma
p15575
sg13
I2
sa(dp15576
g7
I172
sg20
VC0027627
p15577
sg10
I10
sg11
Vmetastasis
p15578
sg13
I1
sa(dp15579
g7
I159
sg20
VC2699153
p15580
sg10
I8
sg11
Vinvasion
p15581
sg13
I1
sa(dp15582
g7
I70
sg20
VC1512411
p15583
sg10
I24
sg11
Vhepatocellular carcinoma
p15584
sg13
I2
sasa(dp15585
g2
S'RT-PCR and Western blot were employed to detect the expression of WIF1 in six hepatocellular carcinoma cell lines of HepG2, Hep3B, Huh7, PLC/PRF/5, SMMC-7721 and MHCC97 and the immortalized human liver cell line THLE-3.\n'
p15586
sg4
(lp15587
(dp15588
g7
I141
sg8
g59
sg10
I3
sg11
VPRF
p15589
sg13
I1
sa(dp15590
g7
I66
sg8
g59
sg10
I4
sg11
VWIF1
p15591
sg13
I1
sa(dp15592
g7
I137
sg8
VP98160
p15593
sg10
I3
sg11
VPLC
p15594
sg13
I1
sasg17
(lp15595
(dp15596
g7
I78
sg20
VC1512411
p15597
sg10
I24
sg11
Vhepatocellular carcinoma
p15598
sg13
I2
sasa(dp15599
g2
S'Besides, Lipofectamine 2000 was employed to transfect the eukaryotic expression vector pcDNA3.1-WIF1 and blank plasmid pcDNA3.1 into hepatocellular carcinoma cell lines.\n'
p15600
sg4
(lp15601
(dp15602
g7
I87
sg8
g59
sg10
I13
sg11
VpcDNA3.1-WIF1
p15603
sg13
I1
sasg17
(lp15604
(dp15605
g7
I133
sg20
VC1512411
p15606
sg10
I24
sg11
Vhepatocellular carcinoma
p15607
sg13
I2
sasa(dp15608
g2
S'Transwell assay was used to detect the effect of WIF1 on the invasion ability of hepatocellular carcinoma cells; Western blot was used to detect the effect of WIF1 on the expression of TIMP-3 and caveolin-1 in hepatocellular carcinoma cells, it also discussed the effect on the expression of Beta-catenin.\n'
p15609
sg4
(lp15610
(dp15611
g7
I49
sg8
g59
sg10
I4
sg11
VWIF1
p15612
sg13
I1
sa(dp15613
g7
I292
sg8
VP35222
p15614
sg10
I12
sg11
VBeta-catenin
p15615
sg13
I1
sa(dp15616
g7
I49
sg8
g59
sg10
I4
sg11
VWIF1
p15617
sg13
I1
sa(dp15618
g7
I185
sg8
VP35625
p15619
sg10
I6
sg11
VTIMP-3
p15620
sg13
I1
sa(dp15621
g7
I196
sg8
g59
sg10
I10
sg11
Vcaveolin-1
p15622
sg13
I1
sasg17
(lp15623
(dp15624
g7
I81
sg20
VC1512411
p15625
sg10
I24
sg11
Vhepatocellular carcinoma
p15626
sg13
I2
sa(dp15627
g7
I81
sg20
VC1512411
p15628
sg10
I24
sg11
Vhepatocellular carcinoma
p15629
sg13
I2
sa(dp15630
g7
I61
sg20
VC2699153
p15631
sg10
I8
sg11
Vinvasion
p15632
sg13
I1
sasa(dp15633
g2
S'The expression of WIF1 in hepatocellular carcinoma cell lines was lower than that in the normal liver cell lines (P &lt; 0.01); while there was basically no expression of WIF1 in the human highly metastatic cell line MHCC-97 and moderate expression in HepG2 and SMMC-7721.\n'
p15634
sg4
(lp15635
(dp15636
g7
I18
sg8
g59
sg10
I4
sg11
VWIF1
p15637
sg13
I1
sa(dp15638
g7
I18
sg8
g59
sg10
I4
sg11
VWIF1
p15639
sg13
I1
sasg17
(lp15640
(dp15641
g7
I26
sg20
VC1512411
p15642
sg10
I24
sg11
Vhepatocellular carcinoma
p15643
sg13
I2
sasa(dp15644
g2
S'After transfecting the eukaryotic expression vector pcDNA3.1-WIF1 and blank plasmid pcDNA3.1 into hepatocellular carcinoma cell lines, compared with the blank plasmid group, the cell viability and invasion ability in the WIF1 group were all reduced (P &lt; 0.01), the expression of TIMP-3, caveolin-1 and mRNA were all down-regulated (P &lt; 0.01), and the expression of Beta-catenin was decreased (P &lt; 0.01).\n'
p15645
sg4
(lp15646
(dp15647
g7
I290
sg8
g59
sg10
I10
sg11
Vcaveolin-1
p15648
sg13
I1
sa(dp15649
g7
I371
sg8
VP35222
p15650
sg10
I12
sg11
VBeta-catenin
p15651
sg13
I1
sa(dp15652
g7
I52
sg8
g59
sg10
I13
sg11
VpcDNA3.1-WIF1
p15653
sg13
I1
sa(dp15654
g7
I282
sg8
VP35625
p15655
sg10
I6
sg11
VTIMP-3
p15656
sg13
I1
sa(dp15657
g7
I221
sg8
VP00390
p15658
sg10
I10
sg11
VWIF1 group
p15659
sg13
I2
sasg17
(lp15660
(dp15661
g7
I98
sg20
VC1512411
p15662
sg10
I24
sg11
Vhepatocellular carcinoma
p15663
sg13
I2
sa(dp15664
g7
I197
sg20
VC2699153
p15665
sg10
I8
sg11
Vinvasion
p15666
sg13
I1
sasa(dp15667
g2
S'Because of down-regulation or missing of expression of WIF1 in hepatocellular carcinoma cell lines, the up-regulation of WIF1 expression can significantly inhibit the invasion and metastasis of HepG2 and SMMC-7721 of hepatocellular carcinoma cell lines, which are related to the up-regulated expression of TIMP-3 and down-regulated expression of caveolin-1 and may be realized through the Wnt/Beta-catenin signaling pathway.\n'
p15668
sg4
(lp15669
(dp15670
g7
I55
sg8
g59
sg10
I4
sg11
VWIF1
p15671
sg13
I1
sa(dp15672
g7
I55
sg8
g59
sg10
I4
sg11
VWIF1
p15673
sg13
I1
sa(dp15674
g7
I346
sg8
g59
sg10
I10
sg11
Vcaveolin-1
p15675
sg13
I1
sa(dp15676
g7
I306
sg8
VP35625
p15677
sg10
I6
sg11
VTIMP-3
p15678
sg13
I1
sasg17
(lp15679
(dp15680
g7
I63
sg20
VC1512411
p15681
sg10
I24
sg11
Vhepatocellular carcinoma
p15682
sg13
I2
sa(dp15683
g7
I167
sg20
VC2699153
p15684
sg10
I8
sg11
Vinvasion
p15685
sg13
I1
sa(dp15686
g7
I63
sg20
VC1512411
p15687
sg10
I24
sg11
Vhepatocellular carcinoma
p15688
sg13
I2
sa(dp15689
g7
I180
sg20
VC0027627
p15690
sg10
I10
sg11
Vmetastasis
p15691
sg13
I1
sasa(dp15692
g2
S'The aim of the present study was to investigate the effect of anti-estrogen treatment (fulvestrant) on the biological activity of hepatocellular carcinoma (HCC), involving the estrogen receptor Alfa (ERAlfa) and Wnt pathways, and to evaluate whether ERAlfa and Wnt inhibitory factor-1 (WIF1) could be biomarkers for anti-estrogen clinical therapy.\n'
p15693
sg4
(lp15694
(dp15695
g7
I176
sg8
VP03372
p15696
sg10
I31
sg11
Vestrogen receptor Alfa (ERAlfa)
p15697
sg13
I4
sa(dp15698
g7
I261
sg8
g59
sg10
I23
sg11
VWnt inhibitory factor-1
p15699
sg13
I3
sa(dp15700
g7
I286
sg8
g59
sg10
I4
sg11
VWIF1
p15701
sg13
I1
sasg17
(lp15702
(dp15703
g7
I156
sg20
VC2239176
p15704
sg10
I3
sg11
VHCC
p15705
sg13
I1
sa(dp15706
g7
I130
sg20
VC2239176
p15707
sg10
I24
sg11
Vhepatocellular carcinoma
p15708
sg13
I2
sasa(dp15709
g2
S'Recently, Wnt inhibitory factor-1 (WIF-1) was found to be epigenetically inactivated in several solid tumors, but the biological and clinical relevance of WIF-1 methylation and expression status in hepatocellular carcinoma (HCC) are still unclear.\n'
p15710
sg4
(lp15711
(dp15712
g7
I10
sg8
g59
sg10
I23
sg11
VWnt inhibitory factor-1
p15713
sg13
I3
sa(dp15714
g7
I35
sg8
g59
sg10
I5
sg11
VWIF-1
p15715
sg13
I1
sa(dp15716
g7
I35
sg8
g59
sg10
I5
sg11
VWIF-1
p15717
sg13
I1
sasg17
(lp15718
(dp15719
g7
I224
sg20
VC2239176
p15720
sg10
I3
sg11
VHCC
p15721
sg13
I1
sa(dp15722
g7
I198
sg20
VC2239176
p15723
sg10
I24
sg11
Vhepatocellular carcinoma
p15724
sg13
I2
sa(dp15725
g7
I96
sg20
VC0280100
p15726
sg10
I12
sg11
Vsolid tumors
p15727
sg13
I2
sasa(dp15728
g2
S'To examine the expression profile and promoter methylation status of WIF-1 in hepatocellular carcinoma (HCC) and identify the possible relationship between the WIF-1 expression pattern and promoter methylation status.\n'
p15729
sg4
(lp15730
sg17
(lp15731
(dp15732
g7
I104
sg20
VC2239176
p15733
sg10
I3
sg11
VHCC
p15734
sg13
I1
sa(dp15735
g7
I78
sg20
VC2239176
p15736
sg10
I24
sg11
Vhepatocellular carcinoma
p15737
sg13
I2
sasa(dp15738
g2
S'Treatment of established hepatocellular carcinoma tumors with Ad-WIF1-Fc and/or Ad-sFRP1-Fc resulted in significant inhibition of tumor growth and prolonged animal survival.\n'
p15739
sg4
(lp15740
(dp15741
g7
I65
sg8
g59
sg10
I4
sg11
VWIF1
p15742
sg13
I1
sa(dp15743
g7
I83
sg8
g59
sg10
I5
sg11
VsFRP1
p15744
sg13
I1
sasg17
(lp15745
(dp15746
g7
I25
sg20
VC1512411
p15747
sg10
I24
sg11
Vhepatocellular carcinoma
p15748
sg13
I2
sa(dp15749
g7
I130
sg20
VC0598934
p15750
sg10
I12
sg11
Vtumor growth
p15751
sg13
I2
sa(dp15752
g7
I50
sg20
VC0027651
p15753
sg10
I6
sg11
Vtumors
p15754
sg13
I1
sasa(dp15755
g2
S'To investigate the promoter methylation status and mRNA expression of DKK-3 and WIF-1 gene in hepatocellular carcinoma (HCC).\n'
p15756
sg4
(lp15757
(dp15758
g7
I70
sg8
g59
sg10
I5
sg11
VDKK-3
p15759
sg13
I1
sasg17
(lp15760
(dp15761
g7
I120
sg20
VC2239176
p15762
sg10
I3
sg11
VHCC
p15763
sg13
I1
sa(dp15764
g7
I94
sg20
VC2239176
p15765
sg10
I24
sg11
Vhepatocellular carcinoma
p15766
sg13
I2
sasa(dp15767
g2
S'Differential high-throughput drug screening of c.1380delA CDH1 SB.mhdgc-1 versus sporadic gastric cancer cells identified several compound classes with enriched activity in c.1380 CDH1 SB.mhdgc-1 cells including mTOR (Mammalian Target Of Rapamycin), MEK (Mitogen-Activated Protein Kinase), c-Src kinase, FAK (Focal Adhesion Kinase), PKC (Protein Kinase C), or TOPO2 (Topoisomerase II) inhibitors.\n'
p15768
sg4
(lp15769
(dp15770
g7
I218
sg8
VP42345
p15771
sg10
I29
sg11
VMammalian Target Of Rapamycin
p15772
sg13
I4
sa(dp15773
g7
I250
sg8
VP45985
p15774
sg10
I3
sg11
VMEK
p15775
sg13
I1
sa(dp15776
g7
I333
sg8
VP17252
p15777
sg10
I3
sg11
VPKC
p15778
sg13
I1
sa(dp15779
g7
I290
sg8
VP41240
p15780
sg10
I12
sg11
Vc-Src kinase
p15781
sg13
I2
sa(dp15782
g7
I309
sg8
g59
sg10
I21
sg11
VFocal Adhesion Kinase
p15783
sg13
I3
sa(dp15784
g7
I338
sg8
VP17252
p15785
sg10
I16
sg11
VProtein Kinase C
p15786
sg13
I3
sa(dp15787
g7
I212
sg8
VP42345
p15788
sg10
I4
sg11
VmTOR
p15789
sg13
I1
sa(dp15790
g7
I58
sg8
VP12830
p15791
sg10
I15
sg11
VCDH1 SB.mhdgc-1
p15792
sg13
I2
sa(dp15793
g7
I304
sg8
g59
sg10
I3
sg11
VFAK
p15794
sg13
I1
sa(dp15795
g7
I255
sg8
VP45985
p15796
sg10
I32
sg11
VMitogen-Activated Protein Kinase
p15797
sg13
I3
sa(dp15798
g7
I173
sg8
VP12830
p15799
sg10
I11
sg11
Vc.1380 CDH1
p15800
sg13
I2
sasg17
(lp15801
(dp15802
g7
I315
sg20
VC0001511
p15803
sg10
I8
sg11
VAdhesion
p15804
sg13
I1
sa(dp15805
g7
I333
sg20
VC1868682
p15806
sg10
I3
sg11
VPKC
p15807
sg13
I1
sa(dp15808
g7
I338
sg20
VC1868682
p15809
sg10
I16
sg11
VProtein Kinase C
p15810
sg13
I3
sa(dp15811
g7
I90
sg20
VC0024623
p15812
sg10
I14
sg11
Vgastric cancer
p15813
sg13
I2
sasa(dp15814
g2
S'The objective of this study was to validate the Korean version of the Quality of Life-Cancer Survivors (QOL-CS-K) in a sample of lymphoma survivors.\n'
p15815
sg4
(lp15816
sg17
(lp15817
(dp15818
g7
I86
sg20
VC0006826
p15819
sg10
I6
sg11
VCancer
p15820
sg13
I1
sa(dp15821
g7
I129
sg20
VC0024299
p15822
sg10
I8
sg11
Vlymphoma
p15823
sg13
I1
sasa(dp15824
g2
S'The QOL-CS-K is a reliable and valid scale for measuring the QOL in long-term lymphoma survivors.\n'
p15825
sg4
(lp15826
sg17
(lp15827
(dp15828
g7
I78
sg20
VC0024299
p15829
sg10
I8
sg11
Vlymphoma
p15830
sg13
I1
sasa(dp15831
g2
S'In particular, we focused on understanding the implications of the novel interaction between these two pathways in primary pancreatic ductal adenocarcinoma tumor cells and provide the first evidence that this mechanism has implications for overcoming the resistance against experimental drugs targeting Ref-1 activity, with clear translational implications.\n'
p15832
sg4
(lp15833
(dp15834
g7
I303
sg8
VP27695
p15835
sg10
I5
sg11
VRef-1
p15836
sg13
I1
sasg17
(lp15837
(dp15838
g7
I156
sg20
VC0027651
p15839
sg10
I5
sg11
Vtumor
p15840
sg13
I1
sa(dp15841
g7
I123
sg20
VC1335302
p15842
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p15843
sg13
I3
sasa(dp15844
g2
S"The second phosphotyrosine binding domain (PTB2) of the human scaffolding protein FE65 interacts with the C-terminal part of the Amyloid Precursor Protein (APP) involved in Alzheimer's disease.\n"
p15845
sg4
(lp15846
(dp15847
g7
I56
sg8
g59
sg10
I30
sg11
Vhuman scaffolding protein FE65
p15848
sg13
I4
sa(dp15849
g7
I129
sg8
VP17342
p15850
sg10
I25
sg11
VAmyloid Precursor Protein
p15851
sg13
I3
sa(dp15852
g7
I156
sg8
g59
sg10
I3
sg11
VAPP
p15853
sg13
I1
sa(dp15854
g7
I43
sg8
VP26599
p15855
sg10
I4
sg11
VPTB2
p15856
sg13
I1
sasg17
(lp15857
(dp15858
g7
I173
sg20
VC1521724
p15859
sg10
I19
sg11
VAlzheimer's disease
p15860
sg13
I2
sa(dp15861
g7
I129
sg20
VC0011560
p15862
sg10
I7
sg11
VAmyloid
p15863
sg13
I1
sasa(dp15864
g2
S"Through the PTB2 domain, they all interact with the Alzheimer's disease amyloid precursor protein (APP) intracellular domain (AICD) and can alter APP processing.\n"
p15865
sg4
(lp15866
(dp15867
g7
I99
sg8
g59
sg10
I3
sg11
VAPP
p15868
sg13
I1
sa(dp15869
g7
I72
sg8
VP17342
p15870
sg10
I25
sg11
Vamyloid precursor protein
p15871
sg13
I3
sa(dp15872
g7
I99
sg8
g59
sg10
I3
sg11
VAPP
p15873
sg13
I1
sa(dp15874
g7
I12
sg8
VP26599
p15875
sg10
I11
sg11
VPTB2 domain
p15876
sg13
I2
sasg17
(lp15877
(dp15878
g7
I52
sg20
VC1521724
p15879
sg10
I19
sg11
VAlzheimer's disease
p15880
sg13
I2
sa(dp15881
g7
I72
sg20
VC0011560
p15882
sg10
I7
sg11
Vamyloid
p15883
sg13
I1
sasa(dp15884
g2
S'In this report we present two cases with inferior myocardial infarction that was likely caused by thrombotic occlusion of CAEs.\n'
p15885
sg4
(lp15886
sg17
(lp15887
(dp15888
g7
I41
sg20
VC0340305
p15889
sg10
I30
sg11
Vinferior myocardial infarction
p15890
sg13
I3
sa(dp15891
g7
I98
sg20
VC2883038
p15892
sg10
I20
sg11
Vthrombotic occlusion
p15893
sg13
I2
sasa(dp15894
g2
S'Autoantibodies were measured against glutamic acid decarboxylase-65 (GAD65), a CNS autoantigen proposed to be associated with autism and against Ro52, glial fibrillary acidic protein, tyrosine hydroxylase, aquaporin-4, and gamma-enolase, the mouse mammary tumor virus and the xenotropic murine leukemia virus.\n'
p15895
sg4
(lp15896
(dp15897
g7
I151
sg8
VP05230
p15898
sg10
I53
sg11
Vglial fibrillary acidic protein, tyrosine hydroxylase
p15899
sg13
I6
sa(dp15900
g7
I145
sg8
VP19474
p15901
sg10
I4
sg11
VRo52
p15902
sg13
I1
sa(dp15903
g7
I69
sg8
g59
sg10
I5
sg11
VGAD65
p15904
sg13
I1
sa(dp15905
g7
I37
sg8
g59
sg10
I30
sg11
Vglutamic acid decarboxylase-65
p15906
sg13
I3
sa(dp15907
g7
I206
sg8
VP55087
p15908
sg10
I30
sg11
Vaquaporin-4, and gamma-enolase
p15909
sg13
I3
sasg17
(lp15910
(dp15911
g7
I294
sg20
VC0023418
p15912
sg10
I8
sg11
Vleukemia
p15913
sg13
I1
sa(dp15914
g7
I248
sg20
VC1458155
p15915
sg10
I13
sg11
Vmammary tumor
p15916
sg13
I2
sa(dp15917
g7
I126
sg20
VC0004352
p15918
sg10
I6
sg11
Vautism
p15919
sg13
I1
sasa(dp15920
g2
S'To determine circulating soluble vascular adhesion protein-1 (sVAP-1) levels and their clinical associations in patients with systemic sclerosis (SSc).\n'
p15921
sg4
(lp15922
(dp15923
g7
I33
sg8
g59
sg10
I27
sg11
Vvascular adhesion protein-1
p15924
sg13
I3
sasg17
(lp15925
(dp15926
g7
I126
sg20
VC0036421
p15927
sg10
I18
sg11
Vsystemic sclerosis
p15928
sg13
I2
sa(dp15929
g7
I42
sg20
VC0001511
p15930
sg10
I8
sg11
Vadhesion
p15931
sg13
I1
sa(dp15932
g7
I146
sg20
VC0036421
p15933
sg10
I3
sg11
VSSc
p15934
sg13
I1
sasa(dp15935
g2
S'Serum VAP-1 levels were examined by enzyme-linked immunosorbent assay in 71 SSc patients, 13 systemic lupus erythematosus patients and 50 healthy individuals.\n'
p15936
sg4
(lp15937
(dp15938
g7
I6
sg8
g59
sg10
I5
sg11
VVAP-1
p15939
sg13
I1
sasg17
(lp15940
(dp15941
g7
I93
sg20
VC0024141
p15942
sg10
I28
sg11
Vsystemic lupus erythematosus
p15943
sg13
I3
sasa(dp15944
g2
S'Serum sVAP-1 levels were significantly elevated in SSc patients (617.2 +/- 338.7 ng/mL) compared with healthy individuals (320.2 +/- 144.2 ng/mL; P &lt; 0.001) and patients with systemic lupus erythematosus (329.0 +/- 176.1 ng/mL; P &lt; 0.001).\n'
p15945
sg4
(lp15946
sg17
(lp15947
(dp15948
g7
I178
sg20
VC0024141
p15949
sg10
I28
sg11
Vsystemic lupus erythematosus
p15950
sg13
I3
sasa(dp15951
g2
S'We have used single and multiple site-directed mutagenesis, and molecular modeling, to identify critical residues in the DNA binding site of MAb 2C10, an IgG anti-dsDNA autoantibody from an MRL/lpr lupus mouse.\n'
p15952
sg4
(lp15953
sg17
(lp15954
(dp15955
g7
I198
sg20
VC0024131
p15956
sg10
I5
sg11
Vlupus
p15957
sg13
I1
sasa(dp15958
g2
S'Antibodies H241 and 2C10 are lupus mouse IgG autoantibodies that bind native DNA.\n'
p15959
sg4
(lp15960
sg17
(lp15961
(dp15962
g7
I29
sg20
VC0024131
p15963
sg10
I5
sg11
Vlupus
p15964
sg13
I1
sasa(dp15965
g2
S'Nucleic acid specificity was tested for two monoclonal anti-double-stranded DNA autoantibodies, 2C10 and H241, derived from two lupus-prone MRL/Mp-lpr/lpr mice.\n'
p15966
sg4
(lp15967
(dp15968
g7
I147
sg8
g59
sg10
I3
sg11
Vlpr
p15969
sg13
I1
sa(dp15970
g7
I147
sg8
g59
sg10
I3
sg11
Vlpr
p15971
sg13
I1
sasg17
(lp15972
(dp15973
g7
I128
sg20
VC0024131
p15974
sg10
I5
sg11
Vlupus
p15975
sg13
I1
sasa(dp15976
g2
S'VAP-1 was expressed on sinusoidal and vascular endothelium in non-inflamed liver and in inflamed liver from patients with either allograft rejection or primary biliary cirrhosis.\n'
p15977
sg4
(lp15978
(dp15979
g7
I0
sg8
g59
sg10
I5
sg11
VVAP-1
p15980
sg13
I1
sasg17
(lp15981
(dp15982
g7
I152
sg20
VC0008312
p15983
sg10
I25
sg11
Vprimary biliary cirrhosis
p15984
sg13
I3
sasa(dp15985
g2
S'Aims-To investigate the ability of circulating IgG autoanti-IgE antibodies from atopic rhinitis patients to block the binding of IgE to its low affinity receptor (FcepsilonRII), also termed CD23.Methods-This involved the use of a well validated flow cytometric method to detect inhibition of FITC labelled IgE binding to human B cells expressing CD23 (RPMI 8866 cell line).Results-Taking inhibition values greater than 20% as being significant, 15 out of 20 IgG anti-IgE containing sera inhibited the binding of IgE-FITC to the RPMI 8866 cells.\n'
p15986
sg4
(lp15987
(dp15988
g7
I47
sg8
VP01854
p15989
sg10
I27
sg11
VIgG autoanti-IgE antibodies
p15990
sg13
I3
sa(dp15991
g7
I512
sg8
VP01854
p15992
sg10
I8
sg11
VIgE-FITC
p15993
sg13
I1
sa(dp15994
g7
I153
sg8
g59
sg10
I23
sg11
Vreceptor (FcepsilonRII)
p15995
sg13
I2
sa(dp15996
g7
I60
sg8
VP01854
p15997
sg10
I3
sg11
VIgE
p15998
sg13
I1
sa(dp15999
g7
I190
sg8
VP06734
p16000
sg10
I4
sg11
VCD23
p16001
sg13
I1
sa(dp16002
g7
I60
sg8
VP01854
p16003
sg10
I3
sg11
VIgE
p16004
sg13
I1
sa(dp16005
g7
I190
sg8
VP06734
p16006
sg10
I4
sg11
VCD23
p16007
sg13
I1
sa(dp16008
g7
I455
sg8
VP01854
p16009
sg10
I15
sg11
V20 IgG anti-IgE
p16010
sg13
I3
sasg17
(lp16011
(dp16012
g7
I80
sg20
VC0002103
p16013
sg10
I15
sg11
Vatopic rhinitis
p16014
sg13
I2
sa(dp16015
g7
I60
sg20
VC0270850
p16016
sg10
I3
sg11
VIgE
p16017
sg13
I1
sa(dp16018
g7
I60
sg20
VC0270850
p16019
sg10
I3
sg11
VIgE
p16020
sg13
I1
sa(dp16021
g7
I60
sg20
VC0270850
p16022
sg10
I3
sg11
VIgE
p16023
sg13
I1
sa(dp16024
g7
I60
sg20
VC0270850
p16025
sg10
I3
sg11
VIgE
p16026
sg13
I1
sa(dp16027
g7
I60
sg20
VC0270850
p16028
sg10
I3
sg11
VIgE
p16029
sg13
I1
sasa(dp16030
g2
S'In this study, we aim to investigate whether miR-338* (miR-338-5p), which has been found to be associated with tumor progression, is associated with pathological process of pulmonary fibrosis.\n'
p16031
sg4
(lp16032
(dp16033
g7
I55
sg8
g59
sg10
I10
sg11
VmiR-338-5p
p16034
sg13
I1
sa(dp16035
g7
I45
sg8
g59
sg10
I8
sg11
VmiR-338*
p16036
sg13
I1
sasg17
(lp16037
(dp16038
g7
I149
sg20
VC0030660
p16039
sg10
I20
sg11
Vpathological process
p16040
sg13
I2
sa(dp16041
g7
I173
sg20
VC0034069
p16042
sg10
I18
sg11
Vpulmonary fibrosis
p16043
sg13
I2
sa(dp16044
g7
I111
sg20
VC0178874
p16045
sg10
I17
sg11
Vtumor progression
p16046
sg13
I2
sasa(dp16047
g2
S'Exploratory immunohistochemical analysis of HLA-DRA and BTNL2 expression in papulopustular rosacea lesions from six individuals, including one with the rs763035 variant, revealed staining in the perifollicular inflammatory infiltrate of rosacea for both proteins.\n'
p16048
sg4
(lp16049
(dp16050
g7
I44
sg8
VP01903
p16051
sg10
I7
sg11
VHLA-DRA
p16052
sg13
I1
sa(dp16053
g7
I152
sg8
VP26640
p16054
sg10
I16
sg11
Vrs763035 variant
p16055
sg13
I2
sasg17
(lp16056
(dp16057
g7
I223
sg20
VC0332448
p16058
sg10
I10
sg11
Vinfiltrate
p16059
sg13
I1
sa(dp16060
g7
I76
sg20
VC1449853
p16061
sg10
I22
sg11
Vpapulopustular rosacea
p16062
sg13
I2
sa(dp16063
g7
I91
sg20
VC0035854
p16064
sg10
I7
sg11
Vrosacea
p16065
sg13
I1
sasa(dp16066
g2
S'We have earlier reported that diverse collagen vascular diseases, including arthritis, arteritis, thrombosis, myocarditis, myositis, sialo-/dacryoadenitis and dermatitis develop with the advent of autoantibodies in transgenic rats carrying the LTR-env-pX gene of human T lymphocyte virus type I (LTR-env-pX rats).\n'
p16067
sg4
(lp16068
(dp16069
g7
I244
sg8
g59
sg10
I15
sg11
VLTR-env-pX gene
p16070
sg13
I2
sa(dp16071
g7
I248
sg8
g59
sg10
I3
sg11
Venv
p16072
sg13
I1
sasg17
(lp16073
(dp16074
g7
I110
sg20
VC0027059
p16075
sg10
I11
sg11
Vmyocarditis
p16076
sg13
I1
sa(dp16077
g7
I87
sg20
VC0003860
p16078
sg10
I9
sg11
Varteritis
p16079
sg13
I1
sa(dp16080
g7
I140
sg20
VC0155223
p16081
sg10
I14
sg11
Vdacryoadenitis
p16082
sg13
I1
sa(dp16083
g7
I159
sg20
VC0011603
p16084
sg10
I10
sg11
Vdermatitis
p16085
sg13
I1
sa(dp16086
g7
I98
sg20
VC0040053
p16087
sg10
I10
sg11
Vthrombosis
p16088
sg13
I1
sa(dp16089
g7
I76
sg20
VC0003864
p16090
sg10
I9
sg11
Varthritis
p16091
sg13
I1
sa(dp16092
g7
I123
sg20
VC0027121
p16093
sg10
I8
sg11
Vmyositis
p16094
sg13
I1
sa(dp16095
g7
I38
sg20
VC0262428
p16096
sg10
I26
sg11
Vcollagen vascular diseases
p16097
sg13
I3
sasa(dp16098
g2
S'Child fat mass and fat mass distribution did not differ between the intervention and control group (MD 2.10, 95% CI -0.48 to 4.68; one trial, 115 participants, MD -0.50, 95% CI -1.69 to 0.69; one trial, 165 participants, respectively).One study (117 infants) reported a significant difference in infant allergy at short-term follow-up (risk ratio (RR) 0.13, 95% CI 0.02 to 0.95), but not at medium-term follow-up (RR 0.52, 95% CI 0.17 to 1.59).We found no significant difference in two trials evaluating postpartum depression.\n'
p16099
sg4
(lp16100
sg17
(lp16101
(dp16102
g7
I504
sg20
VC0221074
p16103
sg10
I21
sg11
Vpostpartum depression
p16104
sg13
I2
sa(dp16105
g7
I303
sg20
VC0020517
p16106
sg10
I7
sg11
Vallergy
p16107
sg13
I1
sasa(dp16108
g2
S'The harmonic force field was used to calculate vibrational corrections to the rotational constants of both species and thus the zero-point average structures for both species were derived; AsH2: rz(AsH) = 1.53436(15) Aa, thetaz(HAsH) = 90.695(20) degrees, and AsD2: rz(AsD) = 1.52902(13) Aa, thetaz(DAsD) = 90.722(17) degrees, where the errors in parentheses are due to residual inertial defects of the corrected moments of inertia.\n'
p16109
sg4
(lp16110
(dp16111
g7
I260
sg8
VP43694
p16112
sg10
I4
sg11
VAsD2
p16113
sg13
I1
sasg17
(lp16114
(dp16115
g7
I228
sg20
VC0024809
p16116
sg10
I4
sg11
VHAsH
p16117
sg13
I1
sa(dp16118
g7
I260
sg20
VC1842778
p16119
sg10
I4
sg11
VAsD2
p16120
sg13
I1
sa(dp16121
g7
I189
sg20
VC0205700
p16122
sg10
I3
sg11
VAsH
p16123
sg13
I1
sa(dp16124
g7
I260
sg20
VC1510586
p16125
sg10
I3
sg11
VAsD
p16126
sg13
I1
sasa(dp16127
g2
S'From the difference between the rz structures for AsH2 and AsD2 the re structure of AsH2 is estimated to be re(AsH) = 1.5158(6) Aa, thetae(HAsH) = 90.79(8) degrees.\n'
p16128
sg4
(lp16129
(dp16130
g7
I50
sg8
g59
sg10
I4
sg11
VAsH2
p16131
sg13
I1
sa(dp16132
g7
I59
sg8
VP43694
p16133
sg10
I4
sg11
VAsD2
p16134
sg13
I1
sa(dp16135
g7
I50
sg8
g59
sg10
I4
sg11
VAsH2
p16136
sg13
I1
sasg17
(lp16137
(dp16138
g7
I59
sg20
VC1842778
p16139
sg10
I4
sg11
VAsD2
p16140
sg13
I1
sa(dp16141
g7
I50
sg20
VC0205700
p16142
sg10
I3
sg11
VAsH
p16143
sg13
I1
sa(dp16144
g7
I139
sg20
VC0024809
p16145
sg10
I4
sg11
VHAsH
p16146
sg13
I1
sasa(dp16147
g2
S'To study the possible role of T cells bearing the gamma delta T cell receptor (TCR) heterodimer in the pathogenesis of autoimmune chronic active hepatitis (AI-CAH) and primary sclerosing cholangitis (PSC) in children, we measured levels of gamma delta+ T cells in the peripheral blood, assessed the proportion of cells bearing the disulphide-linked (BB3+) and non-disulphide-linked (A13+) subtypes of the receptor, and studied the co-expression of TCR-gamma delta and the activation markers HLA-DR and IL-2 receptor (IL-2R), and the memory cell marker CD45RO.\n'
p16148
sg4
(lp16149
(dp16150
g7
I502
sg8
VP60568
p16151
sg10
I13
sg11
VIL-2 receptor
p16152
sg13
I2
sa(dp16153
g7
I517
sg8
VP01589
p16154
sg10
I5
sg11
VIL-2R
p16155
sg13
I1
sa(dp16156
g7
I50
sg8
VP28072
p16157
sg10
I27
sg11
Vgamma delta T cell receptor
p16158
sg13
I5
sa(dp16159
g7
I491
sg8
VP30486
p16160
sg10
I6
sg11
VHLA-DR
p16161
sg13
I1
sa(dp16162
g7
I448
sg8
VP28072
p16163
sg10
I15
sg11
VTCR-gamma delta
p16164
sg13
I2
sasg17
(lp16165
(dp16166
g7
I168
sg20
VC0566602
p16167
sg10
I30
sg11
Vprimary sclerosing cholangitis
p16168
sg13
I3
sa(dp16169
g7
I119
sg20
VC0241910
p16170
sg10
I35
sg11
Vautoimmune chronic active hepatitis
p16171
sg13
I4
sa(dp16172
g7
I200
sg20
VC0566602
p16173
sg10
I3
sg11
VPSC
p16174
sg13
I1
sa(dp16175
g7
I156
sg20
VC0241910
p16176
sg10
I6
sg11
VAI-CAH
p16177
sg13
I1
sa(dp16178
g7
I103
sg20
VC0699748
p16179
sg10
I12
sg11
Vpathogenesis
p16180
sg13
I1
sasa(dp16181
g2
S'The RPH3AL, which is located at 17p13, has been identified from a candidate 17p13 medulloblastoma tumor suppressor locus.\n'
p16182
sg4
(lp16183
(dp16184
g7
I4
sg8
g59
sg10
I6
sg11
VRPH3AL
p16185
sg13
I1
sasg17
(lp16186
(dp16187
g7
I98
sg20
VC0027651
p16188
sg10
I5
sg11
Vtumor
p16189
sg13
I1
sa(dp16190
g7
I82
sg20
VC0025149
p16191
sg10
I15
sg11
Vmedulloblastoma
p16192
sg13
I1
sasa(dp16193
g2
S'We determined the exon-intron boundaries of RPH3AL and screened the coding region for mutations by direct sequencing in DNA extracted from 33 tumor samples with allelic loss of 17p13, including 10 medulloblastoma, 14 follicular thyroid cancer (FTC), and 9 ovarian cancer specimens.\n'
p16194
sg4
(lp16195
(dp16196
g7
I44
sg8
g59
sg10
I6
sg11
VRPH3AL
p16197
sg13
I1
sasg17
(lp16198
(dp16199
g7
I244
sg20
VC0206682
p16200
sg10
I3
sg11
VFTC
p16201
sg13
I1
sa(dp16202
g7
I256
sg20
VC1140680
p16203
sg10
I14
sg11
Vovarian cancer
p16204
sg13
I2
sa(dp16205
g7
I217
sg20
VC0206682
p16206
sg10
I25
sg11
Vfollicular thyroid cancer
p16207
sg13
I3
sa(dp16208
g7
I197
sg20
VC0025149
p16209
sg10
I15
sg11
Vmedulloblastoma
p16210
sg13
I1
sa(dp16211
g7
I142
sg20
VC0027651
p16212
sg10
I5
sg11
Vtumor
p16213
sg13
I1
sasa(dp16214
g2
S'Thus, despite its location in a homozygously deleted 17p13.3 locus, it is unlikely that RPH3AL is a gene involved in the oncogenesis of medulloblastoma, FTC, or ovarian cancer.\n'
p16215
sg4
(lp16216
(dp16217
g7
I88
sg8
g59
sg10
I6
sg11
VRPH3AL
p16218
sg13
I1
sasg17
(lp16219
(dp16220
g7
I136
sg20
VC0025149
p16221
sg10
I15
sg11
Vmedulloblastoma
p16222
sg13
I1
sa(dp16223
g7
I121
sg20
VC0007621
p16224
sg10
I11
sg11
Voncogenesis
p16225
sg13
I1
sa(dp16226
g7
I161
sg20
VC1140680
p16227
sg10
I14
sg11
Vovarian cancer
p16228
sg13
I2
sa(dp16229
g7
I153
sg20
VC0206682
p16230
sg10
I3
sg11
VFTC
p16231
sg13
I1
sasa(dp16232
g2
S'This finding supports the hypothesis that the decrease in CD28 expression, by CD8+ cells, is an event that takes place outside the spleen during human schistosomiasis infection.\n'
p16233
sg4
(lp16234
(dp16235
g7
I78
sg8
VP01732
p16236
sg10
I4
sg11
VCD8+
p16237
sg13
I1
sa(dp16238
g7
I58
sg8
VP33681
p16239
sg10
I4
sg11
VCD28
p16240
sg13
I1
sasg17
(lp16241
(dp16242
g7
I151
sg20
VC0036323
p16243
sg10
I15
sg11
Vschistosomiasis
p16244
sg13
I1
sa(dp16245
g7
I167
sg20
VC0009450
p16246
sg10
I9
sg11
Vinfection
p16247
sg13
I1
sasa(dp16248
g2
S'The current study has compared the activation status and the expression of the CD28 molecule on circulating CD4+ and CD8+ lymphocytes from patients with different clinical forms of schistosomiasis.\n'
p16249
sg4
(lp16250
(dp16251
g7
I79
sg8
VP33681
p16252
sg10
I13
sg11
VCD28 molecule
p16253
sg13
I2
sa(dp16254
g7
I117
sg8
VP01732
p16255
sg10
I4
sg11
VCD8+
p16256
sg13
I1
sa(dp16257
g7
I108
sg8
VP01730
p16258
sg10
I4
sg11
VCD4+
p16259
sg13
I1
sasg17
(lp16260
(dp16261
g7
I181
sg20
VC0036323
p16262
sg10
I15
sg11
Vschistosomiasis
p16263
sg13
I1
sasa(dp16264
g2
S'These findings of a different percentage of circulating CD8+ CD28+ cells might explain the different in vitro cellular reactivity of asymptomatic and hepatosplenic patients and the defects in the cytokine secretion patterns reported in individuals with hepatosplenic schistosomiasis.\n'
p16265
sg4
(lp16266
(dp16267
g7
I56
sg8
VP01732
p16268
sg10
I4
sg11
VCD8+
p16269
sg13
I1
sa(dp16270
g7
I61
sg8
VP33681
p16271
sg10
I5
sg11
VCD28+
p16272
sg13
I1
sasg17
(lp16273
(dp16274
g7
I253
sg20
VC0343968
p16275
sg10
I29
sg11
Vhepatosplenic schistosomiasis
p16276
sg13
I2
sasa(dp16277
g2
S'In Case 2, a 44-year-old Malay lady presented to our clinic with a progressive central scotoma in her right eye that she experienced since past 1 month.\n'
p16278
sg4
(lp16279
sg17
(lp16280
sa(dp16281
g2
S'This study reports the characterization of a novel human gene, chromosome 3 open reading frame 6 (C3orf6), mapped to chromosome 3q28, within the critical region of hereditary spastic paraplegia SPG14 locus.\n'
p16282
sg4
(lp16283
(dp16284
g7
I63
sg8
g59
sg10
I33
sg11
Vchromosome 3 open reading frame 6
p16285
sg13
I6
sa(dp16286
g7
I98
sg8
g59
sg10
I6
sg11
VC3orf6
p16287
sg13
I1
sasg17
(lp16288
(dp16289
g7
I194
sg20
VC1854568
p16290
sg10
I5
sg11
VSPG14
p16291
sg13
I1
sa(dp16292
g7
I164
sg20
VC0037773
p16293
sg10
I29
sg11
Vhereditary spastic paraplegia
p16294
sg13
I3
sasa(dp16295
g2
S'The involvement of C3orf6 in the spastic paraplegia was investigated by sequencing all coding exons and flanking sequences in the SPG14 family, excluding the presence of causative mutations.\n'
p16296
sg4
(lp16297
(dp16298
g7
I19
sg8
g59
sg10
I6
sg11
VC3orf6
p16299
sg13
I1
sasg17
(lp16300
(dp16301
g7
I130
sg20
VC1854568
p16302
sg10
I5
sg11
VSPG14
p16303
sg13
I1
sa(dp16304
g7
I33
sg20
VC0037772
p16305
sg10
I18
sg11
Vspastic paraplegia
p16306
sg13
I2
sasa(dp16307
g2
S'A retrospective study Tertiary referral center In this study, 13 patients who developed facial paralysis due to temporal bone trauma and undergone decompression by using MCF approach in Department of Otorhinolaryngology of Izmir Katip Celebi University Research and Training Hospital between January 1993 and December 2012 were presented retrospectively.\n'
p16308
sg4
(lp16309
sg17
(lp16310
(dp16311
g7
I88
sg20
VC0015469
p16312
sg10
I16
sg11
Vfacial paralysis
p16313
sg13
I2
sasa(dp16314
g2
S'Its human ortholog, TFAP-2beta, causes Char disease and has also been linked to sleep disorders.\n'
p16315
sg4
(lp16316
sg17
(lp16317
(dp16318
g7
I80
sg20
VC0851578
p16319
sg10
I15
sg11
Vsleep disorders
p16320
sg13
I2
sa(dp16321
g7
I39
sg20
VC1868570
p16322
sg10
I4
sg11
VChar
p16323
sg13
I1
sasa(dp16324
g2
S'In vivo lentivirus-mediated RNA interference of AP-2Alfa reversed the inhibitory effects of aspirin on atherosclerosis in Apoe-/- mice.\n'
p16325
sg4
(lp16326
sg17
(lp16327
(dp16328
g7
I103
sg20
VC0004153
p16329
sg10
I15
sg11
Vatherosclerosis
p16330
sg13
I1
sasa(dp16331
g2
S'Aspirin activates AP-2Alfa to upregulate IkBAlfa gene expression, resulting in attenuations of plaque development and instability in atherosclerosis.\n'
p16332
sg4
(lp16333
(dp16334
g7
I0
sg8
g59
sg10
I7
sg11
VAspirin
p16335
sg13
I1
sasg17
(lp16336
(dp16337
g7
I133
sg20
VC0004153
p16338
sg10
I15
sg11
Vatherosclerosis
p16339
sg13
I1
sa(dp16340
g7
I95
sg20
VC0011389
p16341
sg10
I6
sg11
Vplaque
p16342
sg13
I1
sasa(dp16343
g2
S'Mutations in human AP-2 TF have been linked with bronchio-occular-facial syndrome and Char Syndrome, congenital birth defects characterized by craniofacial deformities and patent ductus arteriosus, respectively.\n'
p16344
sg4
(lp16345
(dp16346
g7
I19
sg8
VP05549
p16347
sg10
I7
sg11
VAP-2 TF
p16348
sg13
I2
sasg17
(lp16349
(dp16350
g7
I86
sg20
VC1868570
p16351
sg10
I13
sg11
VChar Syndrome
p16352
sg13
I2
sa(dp16353
g7
I73
sg20
VC0039082
p16354
sg10
I8
sg11
Vsyndrome
p16355
sg13
I1
sa(dp16356
g7
I112
sg20
VC0000768
p16357
sg10
I13
sg11
Vbirth defects
p16358
sg13
I2
sa(dp16359
g7
I172
sg20
VC0013274
p16360
sg10
I24
sg11
Vpatent ductus arteriosus
p16361
sg13
I3
sa(dp16362
g7
I156
sg20
VC0000768
p16363
sg10
I11
sg11
Vdeformities
p16364
sg13
I1
sasa(dp16365
g2
S'It is still an open question whether AP-2Gamma expression may be influenced by preeclampsia, which is a serious pregnancy complication, or by smoking, which has deleterious effects on trophoblastic development.\n'
p16366
sg4
(lp16367
(dp16368
g7
I37
sg8
g59
sg10
I9
sg11
VAP-2Gamma
p16369
sg13
I1
sasg17
(lp16370
(dp16371
g7
I79
sg20
VC0032914
p16372
sg10
I12
sg11
Vpreeclampsia
p16373
sg13
I1
sa(dp16374
g7
I112
sg20
VC0032962
p16375
sg10
I22
sg11
Vpregnancy complication
p16376
sg13
I2
sasa(dp16377
g2
S'Thus, the expression of AP-2Gamma was studied in trophoblastic epithelium and endothelium of placentas from patients with preeclampsia (n = 43) and smokers (n = 45) as well as placentas of healthy pregnant women (control group, n = 26) between gestational ages 23 and 43 weeks.\n'
p16378
sg4
(lp16379
(dp16380
g7
I24
sg8
g59
sg10
I9
sg11
VAP-2Gamma
p16381
sg13
I1
sasg17
(lp16382
(dp16383
g7
I122
sg20
VC0032914
p16384
sg10
I12
sg11
Vpreeclampsia
p16385
sg13
I1
sasa(dp16386
g2
S'A correlation between increased trophoblastic and endothelial AP-2Gamma expression in patients with preeclampsia and reduced trophoblastic invasion and migration in preeclampsia has to be discussed.\n'
p16387
sg4
(lp16388
(dp16389
g7
I62
sg8
g59
sg10
I9
sg11
VAP-2Gamma
p16390
sg13
I1
sasg17
(lp16391
(dp16392
g7
I139
sg20
VC2699153
p16393
sg10
I8
sg11
Vinvasion
p16394
sg13
I1
sa(dp16395
g7
I100
sg20
VC0032914
p16396
sg10
I12
sg11
Vpreeclampsia
p16397
sg13
I1
sa(dp16398
g7
I100
sg20
VC0032914
p16399
sg10
I12
sg11
Vpreeclampsia
p16400
sg13
I1
sasa(dp16401
g2
S'Furthermore, increased AP-2Gamma expression may play a protective role in preeclampsia, protecting from raised blood pressure.\n'
p16402
sg4
(lp16403
(dp16404
g7
I23
sg8
g59
sg10
I9
sg11
VAP-2Gamma
p16405
sg13
I1
sasg17
(lp16406
(dp16407
g7
I74
sg20
VC0032914
p16408
sg10
I12
sg11
Vpreeclampsia
p16409
sg13
I1
sasa(dp16410
g2
S'Evaluation of dysmorphology by chromosome microarray (CMA) identified a 4.4 Mb deletion at chromosome 6p24 that included both TFAP2A and DSP, encoding desmoplakin, an additional component of the cardiac desmosome implicated in ARVD/C.\n'
p16411
sg4
(lp16412
(dp16413
g7
I137
sg8
VP15924
p16414
sg10
I3
sg11
VDSP
p16415
sg13
I1
sa(dp16416
g7
I126
sg8
VP05549
p16417
sg10
I6
sg11
VTFAP2A
p16418
sg13
I1
sa(dp16419
g7
I151
sg8
VP15924
p16420
sg10
I11
sg11
Vdesmoplakin
p16421
sg13
I1
sasg17
(lp16422
sa(dp16423
g2
S'Mutations in transcription factor TFAP2B cause Char syndrome, a human disorder characterized by PDA, facial dysmorphysm and hand anomalies.\n'
p16424
sg4
(lp16425
(dp16426
g7
I34
sg8
g59
sg10
I6
sg11
VTFAP2B
p16427
sg13
I1
sasg17
(lp16428
(dp16429
g7
I96
sg20
VC0013274
p16430
sg10
I3
sg11
VPDA
p16431
sg13
I1
sa(dp16432
g7
I47
sg20
VC1868570
p16433
sg10
I13
sg11
VChar syndrome
p16434
sg13
I2
sasa.